<SEC-DOCUMENT>0001213900-25-026371.txt : 20250331
<SEC-HEADER>0001213900-25-026371.hdr.sgml : 20250331
<ACCEPTANCE-DATETIME>20250331170042
ACCESSION NUMBER:		0001213900-25-026371
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		89
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250331
DATE AS OF CHANGE:		20250331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		25794642

	BUSINESS ADDRESS:	
		STREET 1:		100 PARK AVE., 23RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		(646) 677-3870

	MAIL ADDRESS:	
		STREET 1:		100 PARK AVE., 23RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ea0232395-10k_actinium.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 31 20:27:50 UTC 2025 -->
<html xmlns:atnm="http://www.actiniumpharma.com/20241231" xmlns:compsci="http://compsciresources.com" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt; width: 100%"><div style="margin: 0pt; font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNITED
STATES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Washington,
D.C. 20549</b></span></p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
<ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-14944">10-K</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark
One)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="ixv-14945">&#9746;</ix:nonNumeric>
Annual Report Pursuant To Section 13 or 15(d) Of The Securities Exchange Act Of 1934</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended<b>&#160;<ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-14946"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-14947">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-14948">2024</ix:nonNumeric></ix:nonNumeric></b></span></p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="ixv-14949">&#9744;</ix:nonNumeric>
Transition Report Pursuant To Section 13 or 15(d) Of The Securities Exchange Act Of 1934</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the transition period from _____ to _____</span></p><div>

</div><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COMMISSION
FILE NUMBER: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-14950">001-36374</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-82"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ACTINIUM
PHARMACEUTICALS, INC.</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-95"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber" id="ixv-101"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>74-2963609</b></span></ix:nonNumeric></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation or organization)</span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification No.)</span></p></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-122"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>100
Park Ave., 23<sup>rd</sup> Floor</b></span></ix:nonNumeric></p><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-14951">New
York</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressStateOrProvince" id="ixv-14952">NY</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-14953">10017</ix:nonNumeric></b></span></p><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices) (Zip Code)</span></p><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-14954">(646)</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-14955">677-3870</ix:nonNumeric></b></span></p><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
telephone number, including area code</span></p><div>

</div><p style="margin: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section&#160;12(b) of the Act:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading symbol</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of exchange on which registered</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-171"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common stock, par value $0.001</b></span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-177"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ATNM</b></span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:SecurityExchangeName" id="ixv-14956">NYSE</ix:nonNumeric> American</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
registered pursuant to Section&#160;12(g) of the Act: None</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&#160;&#9744;&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-14957">No</ix:nonNumeric>
&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&#160;&#9744;&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-14958">No</ix:nonNumeric>
&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-14959">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;No &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-14960">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;No &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions
of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging
growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-238"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness" id="ixv-245"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-255"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="ixv-14961">&#9744;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-14962">&#9744;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the act): Yes&#160;&#9744;&#160;&#160;No&#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-14963">&#9746;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of voting stock held by nonaffiliates of the registrant as of June&#160;30, 2024, the last business day of the
registrant&#8217;s most recently completed second fiscal quarter, based on the closing price of the common stock on the NYSE American
on June 28, 2024 was $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="dei:EntityPublicFloat" scale="0" unitRef="usd" id="ixv-14964">226,015,477</ix:nonFraction>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 28, 2025, <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-14965">31,195,891</ix:nonFraction> shares of common stock, $0.001 par value per share, were outstanding.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt; width: 100%"><div style="margin: 0pt; font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table&#160;of
Contents</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 80%"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</span></a></td>
    <td style="text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1B.&#160;</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved Staff Comments</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1C.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cybersecurity</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties</span></a></td>
    <td style="text-align: center">64</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</span></a></td>
    <td style="text-align: center">64</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures</span></a></td>
    <td style="text-align: center">64</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">Market for Registrant&#8217;s Common Equity, Related Stockholders Matters, and Issuer Purchases of Equity Securities</a></span></td>
    <td style="vertical-align: bottom; text-align: center">65</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reserved</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="text-align: center">66</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7A.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market&#160;Risk</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 8.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements and Supplementary Data</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9A.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="text-align: center">70</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9B.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</span></a></td>
    <td style="text-align: center">70</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9C</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</span></a></td>
    <td style="text-align: center">70</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Executive Officers and Corporate Governance</span></a></td>
    <td style="text-align: center">71</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Compensation</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships and Related Transactions, and Director Independence</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accountant Fees and Services</span></a></td>
    <td style="text-align: center">89</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits, Financial Statement Schedules</span></a></td>
    <td style="text-align: center">90</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2"><a href="#a_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature Page </span></a></td>
    <td style="text-align: center">95</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K (this &#8220;Report&#8221;) contains forward-looking statements that involve risks and uncertainties, principally
in the sections entitled &#8220;Description of Business,&#8221; &#8220;Risk Factors,&#8221; and &#8220;Management&#8217;s Discussion
and Analysis of Financial Condition and Results of Operations.&#8221; All statements other than statements of historical fact contained
in this Report, including statements regarding future events, our future financial performance, business strategy and plans and objectives
of management for future operations, are forward-looking statements. We have attempted to identify forward-looking statements by terminology
including &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221;
&#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221;
&#8220;should,&#8221; or &#8220;will&#8221; or the negative of these terms or other comparable terminology. Although we do not make forward-looking
statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. These statements are only predictions
and involve known and unknown risks, uncertainties and other factors, including the risks outlined under &#8220;Risk Factors&#8221; or
elsewhere in this Report, which may cause our or our industry&#8217;s actual results, levels of activity, performance or achievements
expressed or implied by these forward-looking statements. Moreover, we operate in a very competitive and rapidly changing environment.
New risks emerge from time to time and it is not possible for us to predict all risk factors, nor can we address the impact of all factors
on our business or the extent to which any factor, or combination of factors, may cause our actual results to differ materially from
those contained in any forward-looking statements. All forward-looking statements included in this document are based on information
available to us on the date hereof, and we assume no obligation to update any such forward-looking statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should not place undue reliance on any forward-looking statement, each of which applies only as of the date of this Report. Before you
invest in our securities, you should be aware that the occurrence of the events described in the section entitled &#8220;Risk Factors&#8221;
and elsewhere in this Report could negatively affect our business, operating results, financial condition and stock price. Except as
required by law, we undertake no obligation to update or revise publicly any of the forward-looking statements after the date of this
Report to conform our statements to actual results or changed expectations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 3; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
I</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
1. BUSINESS.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
of Our Business</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium Pharmaceuticals,
Inc. (&#8220;Actinium&#8221;, the &#8220;Company&#8221;, or &#8220;we&#8221;) is a pioneer in the development of targeted radiotherapies
intended to meaningfully improve outcomes for patients with advanced cancers including relapsed or refractory (&#8220;r/r&#8221;) disease
who have failed existing therapies. We are advancing a pipeline of differentiated clinical stage product candidates focused on validated
cancer targets. Our current pipeline is focused on indications in myeloid malignancies, solid tumors and conditioning for cell and gene
therapies that we believe have high unmet needs that are not addressed by currently available treatment options. Our goal is to create
a specialty radiopharmaceutical company with capabilities across radioisotope production, final drug product manufacturing, preclinical
research and development (&#8220;R&amp;D&#8221;) and clinical development. We are deploying our technologies and capabilities, which we
believe to be industry-leading, and intellectual property with approximately 230 issued and pending patents worldwide, to develop targeted
and next-generation radiotherapies.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Our Product Candidate Pipeline</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are advancing two clinical stage product candidates that are directed
against validated cancer targets. Actimab-A is our lead product candidate in development and is intended to address the significant unmet
medical needs of patients with myeloid malignancies including acute myeloid leukemia (&#8220;AML&#8221;) and myelodysplastic syndromes
(&#8220;MDS&#8221;). We are also evaluating Actimab-A&#8217;s potential to synergize with PD-1 immune checkpoint inhibitors (&#8220;ICIs&#8221;)
in solid tumor indications through the depletion of immune cells known as myeloid derived suppressor cells (&#8220;MDSCs&#8221;). Iomab-ACT
is a next-generation targeted conditioning agent we are developing with the intent to improve patient access to and outcomes with cellular
therapies such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle
cell disease (&#8220;SCD&#8221;). We are also developing ATNM-400, a novel preclinical, non-prostate specific-membrane antigen (&#8220;PSMA&#8221;)
targeting, first-in-class radiotherapy utilizing the Actinium-225 (&#8220;Ac-225&#8221;) radioisotope payload intended for patients with
prostate cancer directed against a novel radiotherapy target.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actimab-A is being developed
as a targeted radiotherapeutic to leverage the Actinium-225 (&#8220;Ac-225") isotope payload directed against CD33, a target expressed
ubiquitously in patients with AML, MDS and expressed in other myeloid malignancies. We are attempting to leverage the mutation-agnostic
ability of Ac-225 to establish Actimab-A as a backbone therapy in myeloid malignancies, which are extremely heterogenous and radiosensitive,
as a single agent or in combinations with chemotherapy, targeted agents, cellular therapy and immunotherapy. Actimab-A has been studied
in over 150 patients. We plan to initiate a Phase 2/3 trial with Actimab-A in combination with the chemotherapy regimen CLAG-M in patients
with r/r AML. In addition to our internal development efforts, we entered into a Cooperative Research and Development Agreement (&#8220;CRADA&#8221;)
with the National Cancer Institute (&#8220;NCI&#8221;) in February 2023 for the development of Actimab-A for AML and other myeloid malignancies.
The first clinical trial to be conducted under our CRADA with NCI will evaluate the triplet combination comprised of Actimab-A, Venetoclax
and ASTX-727, a novel oral HMA developed by Taiho Oncology, an Otsuka Holdings company, in frontline AML patients. Venetoclax in combination
with HMAs (Ven-HMA) is approved for patients with newly diagnosed AML. We believe this trial is supported by our Actimab-A + Venetoclax
combination trial that showed that combination was well-tolerated and showed supportive anti-leukemic activity. Additional clinical trial
concepts for Actimab-A have been submitted under the CRADA and are being reviewed. We anticipate that additional clinical trials with
Actimab-A will be initiated in 2025 including under the CRADA to leverage Actimab-A&#8217;s mutation agnostic mechanism.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March of 2025, we initiated
our Actimab-A solid tumor program that will combine Actimab-A with PD-1 checkpoint inhibitors. We initiated this program to evaluate if
Actimab-A can deplete CD33 expressing MDSCs and hence improve patient outcomes in combination with PD-1 ICIs such as KEYTRUDA<sup>&#174;</sup>&#160;and
OPDIVO<sup>&#174;</sup>. The Actimab-A solid tumor program is comprised of several controlled, head-to-head clinical trials that will evaluate
the combination of Actimab-A with KEYTRUDA<sup>&#174;</sup>&#160;versus KEYTRUDA<sup>&#174;</sup>&#160;alone, and Actimab-A with OPDIVO<sup>&#174;</sup>&#160;versus
OPDIVO<sup>&#174;</sup>&#160;alone. The initial tumors that are being targeted are Head and Neck Squamous Cell Carcinoma (&#8220;HNSCC&#8221;)
and Non-Small Cell Lung Cancer (&#8220;NSCLC&#8221;) with a separate trial for each indication.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ATNM-400 is our newest targeted
radiotherapy program that we are advancing for prostate cancer. Given the biology of the antigen targeted by ATNM-400 and the precise
and potent cell-killing of Ac-225, we believe ATNM-400 has the potential to address unmet needs in prostate cancer. We have generated
preclinical data with ATNM-400 showing selective tumor accumulation with minimal uptake in normal tissues. Our experiments also showed
dose-dependent cytotoxicity. We continue to study ATNM-400 with additional data expected from Pluvicto-resistant prostate cancer models.
Pluvicto (Lu-177-PSMA-617) is a prostate-specific membrane antigen (PSMA) directed targeted radiotherapy that uses the beta-particle emitting
radioisotope Lutetitium-177 (&#8220;Lu-177&#8221;) that is approved for patients with metastatic prostate cancer. ATNM-400 is differentiated
from Pluvicto as it targets a different marker than PSMA that has been shown to be overexpressed in patients with prostate cancer and
uses the alpha-particle emitter Ac-225, which is more potent than Lu-177 but has a shorter path length, which could result in fewer off-target
effects such as xerostomia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to ATNM-400, we
have active R&amp;D efforts leveraging our in-house preclinical development and translational research capabilities that are primarily
focused on supporting our ATNM-400 preclinical program, the Actimab-A and Iomab-ACT clinical programs and advancing several preclinical
programs for solid tumor indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Iomab-ACT is our next-generation
targeted conditioning agent directed against CD45, a target expressed widely across the hematopoietic system including normal nucleated
immune cells such as lymphocytes that is relevant to this program and uses the Iodine-131(&#8220;I-131") radioisotope payload. We
are developing Iomab-ACT for cell and gene therapies for both malignant and non-malignant hematologic indications. Iomab-ACT utilizes
non-myeloablative doses of I-131, to not fully deplete the patient&#8217;s bone marrow and immune system with the goal of improving patient
access and outcomes for potentially curative cell and gene therapies by replacing the need for the non-targeted, chemotherapy-based conditioning
regimens that are currently used. Iomab-ACT is currently being studied in three clinical trials. These trials include Iomab-ACT with a
commercial CAR-T therapy, Iomab-ACT prior to allogeneic BMT for patients with SCD, which could potentially inform a trial design with
gene therapy for SCD, and Iomab-ACT with a novel investigational CD19 CAR-T therapy.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
previously advanced our targeted conditioning program Iomab-B through the Phase 3 Study of Iomab-B in Elderly Relapsed and Refractory
AML (&#8220;SIERRA&#8221;) trial, a 153 patient, randomized multi-center trial conducted in the United States. and Canada. Iomab-B is
comprised of the anti-CD45 monoclonal antibody apamistamab with myeloablative doses of I-131 intended to enable patient access to bone
marrow transplant (&#8220;BMT&#8221;), the only potentially curative treatment option for patients with r/r AML. At this time, we are
seeking a strategic partner for Iomab-B to conduct an additional clinical trial based on feedback from the U.S. Food &amp; Drug Administration
(&#8220;FDA&#8221;) and are committed to establishing the best development path forward for Iomab-B in the U.S., while keeping internal
resources and strategic priorities in focus. As previously disclosed and noted above, Actinium also has a License Agreement with Immedica,
granting Immedica the exclusive product rights for commercialization of Iomab-B in certain countries in the European Economic Area, Middle
East and North Africa (&#8220;EUMENA&#8221;) region.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Actinium&#8217;s Approach to Targeted Radiotherapy
Development</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Radiation is a validated cancer
therapy that has been used to treat patients for over 100 years. It is used to treat over half of all patients diagnosed with cancer today.
Radiation therapy utilizes rays of energy to kill cancer cells and is commonly used in combination with other cancer treatment modalities.
Radiation therapy is primarily administered from outside of the body and therefore passes through normal healthy tissue and organs that
result in side effects and toxicities, which can be acute and/or chronic.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With our targeted radiotherapy
approach, we seek to address the limitations of external radiotherapy and achieve cellular level precision by leveraging the cancer cell
targeting ability of biologic molecules with the cancer cell killing ability of radioisotopes. In doing so, we seek to improve efficacy
outcomes, reduce toxicities and expand the use of radiation to cancer indications like blood cancers that cannot be addressed with externally
delivered radiation. In addition, we are also testing the use of targeted radiotherapies in solid tumor cancers where there are unmet
medical needs. Biological molecules have demonstrated high affinity for cancer cell identification and binding to biological markers on
the surface of cells known as antigens or ligands, which are the target receptors for our targeted radiotherapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Actinium&#8217;s Targeted Radiotherapies
</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="A diagram of a cell division  Description automatically generated" src="image_002.jpg" style="height: 212px; width: 572px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Alpha particles emitted by
as the element Ac-225 are the heaviest and have the highest charge, resulting in high amounts of linear energy transfer, which is capable
of producing double strand DNA breaks. However, alpha-particles travel short distances of just several microns and as a consequence do
not exert radiation outside of the body. Alpha particles can be stopped by an ordinary sheet of paper. Therefore, alpha particle-based
therapies do not require special shielding or that patients remain isolated following treatment. Beta particle-based therapies have a
longer pathlength but have lower amounts of linear energy transfer and at certain dose levels may require isolation or special handling.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Comparison of Radioisotope Pathlength</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img alt="A diagram of a paper and aluminum  AI-generated content may be incorrect." src="image_003.jpg" style="height: 170px; width: 445px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We focus on producing drug candidates that match a specific targeting
agent with the appropriate isotope for a desired indication. We employ an isotope-agnostic approach to targeted radiotherapy development.
Our development efforts are centered on validated targets that are known to have high expression on cancer cells compared to normal healthy
cells. We are advancing our clinical product candidates targeting CD33 and CD45 and have completed preclinical studies against other blood
cancer targets such as CD38, as well as various validated solid tumors targets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the cell-killing power of linear energy transfer delivered
via radiotherapeutics is unmatched by other technologies and that there are multiple indications where radiotherapeutics can succeed over
other approaches. However, radiotherapeutics must be delivered on a just-in-time basis, and commercial and supply chain barriers are higher
than with other types of medicines. Actinium&#8217;s strategy is to build a specialty radiotherapeutics company with the capabilities
to produce radioisotopes, manufacture radiotherapies, conduct preclinical research, clinical development and supply radiotherapies to
the point of care. We believe our strategy will enable us to build a successful company with the potential for high operating efficiencies.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our strategic priorities are to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Establish Actimab-A as a mutation agnostic,
backbone therapy for myeloid malignancies including patients with AML and high-risk MDS;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Establish Actimab-A as a pan solid tumor therapy
in combination with PD-1 inhibitors including KEYTRUDA<sup>&#174;</sup> and OPDIVO<sup>&#174;</sup> by depleting myeloid derived suppressor
cells;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Determine the potential of ATNM- as a viable
treatment for patients with prostate cancer;</i></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Establish Iomab-ACT as a universal targeted
conditioning agent for cell and gene therapies to improve patient access and outcomes;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Leverage our R&amp;D capabilities and clinical
development experience to further advance pipeline assets for cancer indications with high unmet needs; and</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Establish in-house manufacturing infrastructure
to support our planned later-stage clinical development and secure partnerships to enable the deployment of our proprietary Ac-225 cyclotron
manufacturing technology.</i></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market Opportunity for Our Targeted Radiotherapies
</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe our clinical programs
have the potential to address a significant number of patients with high unmet medical needs and therefore represent large potential market
opportunities. To our knowledge, Actimab-A, Iomab-ACT and ATNM-400 are first in class targeted radiotherapies for myeloid malignancies,
targeted conditioning for cell &amp; gene therapies and multiple solid tumors, respectively, with each discrete opportunity representing
a range of over 100,000 to several hundred thousand addressable patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Four Large &amp; Distinct Potential Market
Opportunities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_004.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Actimab</i>-<i>A Myeloid Malignancies Program
</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are focused on developing
our lead targeted radiotherapy Actimab-A for patients with AML and MDS, which are the most common myeloid malignancies in adults. AML
and certain MDS can progress rapidly, especially in patients with high-risk features such as certain genetic mutations. To our knowledge,
Actimab-A is the only CD33 targeted radiotherapy in development for patients with myeloid malignancies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Myeloid malignancies are a
group of cancers that affect blood-forming cells also referred to as hematopoietic cells in the bone marrow. These cells are from the
myeloid lineage and include white blood cells, red blood cells and platelets. Myeloid malignancies include AML, MDS, chronic myeloid leukemia
(&#8220;CML&#8221;) and myeloproliferative neoplasms (&#8220;MPNs&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe Actimab-A can be used in multiple treatment settings across
the myeloid patient journey. For patients with AML, we plan to develop Actimab-A for both fit and unfit patients in the frontline, relapsed
or refractory and maintenance settings either as a monotherapy or in combination with other treatments. For patients with MDS, we plan
to develop Actimab-A for patients who have high-risk disease and in the maintenance setting. In the United States and <span style="background-color: white">the
five largest countries in Western Europe (France, Germany, Italy, Spain and the United Kingdom, which we refer to as &#8220;EU5&#8221;)</span>,
we estimate the patient population across our target treatment settings in these diseases to be greater than 100,000 patients annually.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>U.S. and EU5 AML &amp; MDS Addressable Patient
Population</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><img alt="A graph of a number of people  Description automatically generated with medium confidence" src="image_005.jpg" style="height: 258px; width: 376px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AML is increasingly defined
by the presence of genetic mutations or cytogenetic abnormalities as well as prior therapy given the increased number of approved agents.
AML is a mutation rich disease that is genetically heterogeneous with identifiable mutations in over 95% of all patients. The most common
mutations for which there are approved therapies include fms-like tyrosine kinase 3 (&#8220;FLT3&#8221;), isocitrate dehydrogenase 1 &amp;
2 (&#8220;IDH1&#8221;) (&#8220;IDH2&#8221;), and nucleophosmin 1 (&#8220;NPM1&#8221;) &amp; KMT2A rearrangements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Various treatments are currently
approved or utilized for patients with AML and MDS including chemotherapies, targeted therapies, antibody drug conjugates (&#8220;ADCs&#8221;),
hypomethylating agents (&#8220;HMAs&#8221;) and BMT. Since 2017, twelve therapies have been approved for patients with AML. As part of
our development strategy, we have evaluated and expect to continue to evaluate Actimab-A in combination with these approved therapies
and other emerging treatment options or therapeutic modalities to leverage its mutation agnostic and potentially synergistic mechanism
of action. Given the ubiquitous expression of CD33, we believe Actimab-A has the potential to be a backbone therapy for myeloid malignancies.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Fewer approved treatment options
exist for patients with MDS, particularly high-risk patients. Treatments currently approved or utilized for high-risk patients include
chemotherapies, HMAs and IDH1 inhibitors. We intend to evaluate the potential utility of Actimab-A in MDS either as single agent or in
combination with other therapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Given the complexity and aggressiveness
of AML and High-risk MDS, these patients are often referred to and treated in comprehensive treatment centers for in-patient treatment
as opposed to community, outpatient-based care. As a result, we believe the majority of AML and High-risk MDS patients largely occurs
in a finite number of centers, which implies efficiencies from concentration of commercialization efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Actimab-A Solid Tumor Program </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe a large market
opportunity also exists for Actimab-A in solid tumor indications by depleting MDSCs to synergize with PD-1 checkpoint inhibitors and potentially
other immune checkpoint inhibitors. Several solid tumor indications have shown to have high expression of MDSCs including non-small cell
lung cancer (&#8220;NSCLC&#8221;), melanoma, renal cell carcinoma (&#8220;RCC&#8221;), colorectal cancer (&#8220;CRC), triple negative
breast cancer (&#8220;TNBC&#8221;), head &amp; neck squamous cell carcinoma (&#8220;HNSCC&#8221;), pancreatic cancer, glioblastoma (&#8220;GBM&#8221;)
prostate cancer and ovarian cancer. Cumulatively, over 600,000 patients are diagnosed with these cancers annually. PD-1 checkpoint inhibitors
are approved in a significant number of these indications and in 2024 generated sales totaling more than $45 billion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are planning to conduct our initial controlled, randomized clinical
trials in HNSCC and NSCLC in combination with the PD-1 checkpoint inhibitors KEYTRUDA<sup>&#174;</sup> and OPDIVO<sup>&#174;</sup>. These
two indications represent a potential addressable patient opportunity of over 250,000 patients. We expect to continue to evaluate additional
indications for potential future clinical trials assuming our initial efforts are successful.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>ATNM-400 Prostate Cancer Program </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;Prostate cancer is the
most common cancer in men, with approximately 1 in 8 men diagnosed with prostate cancer during their lifetime. According to the American
Cancer Society, an estimated 313,780 new cases of prostate cancer will be diagnosed in the United States in 2025. The global incidence
of prostate cancer is approximately 1.5 million new cases annually. Approximately 20% of prostate cancer cases are more aggressive forms
that progress to metastatic disease, which is associated with significantly worse survival outcomes. Radiotherapy is commonly used to
treat prostate cancer, and in 2022, the PSMA-targeting radiotherapy Pluvicto was approved by the FDA and the European Medicines Agency
(&#8220;EMA&#8221;) for the treatment of patients with metastatic castration-resistant prostate cancer. Pluvicto is marketed and sold
by Novartis and generated sales of $1.39 billion in 2024. ATNM-400 is differentiated from Pluvicto as it targets a different marker than
PSMA that has been shown to be overexpressed in patients with prostate cancer and uses the alpha-particle emitter Ac-225, which is more
potent than Lu-177 but has a shorter path length, which could result in fewer off-target effects such as xerostomia. </p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Iomab-ACT Cell &amp; Gene Therapy Conditioning
Program</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing Iomab-ACT as a targeted conditioning agent to prepare
patients for cellular therapies such as CAR-T or BMT and gene therapies. Our current clinical trials are focused on patients with blood
cancers and non-malignant blood disorders such as SCD. The first CAR-T therapies was approved in 2017 and currently, there are 6 approved
CAR-T therapies for patients with lymphomas, leukemia and multiple myeloma, which generated sales of over $4.0 billion in 2024. We estimate
that there are approximately 125,000 patients diagnosed with blood cancers that can be potentially treated with CAR-T therapies, which
are currently approved for r/r patients. SCD is a rare, debilitating and life-threatening blood disorder with significant unmet needs
that affects approximately 100,000 people in the U.S. Patients with SCD have a mutation that causes red blood cells to develop a crescent
or &#8220;sickle&#8221; shape, which restrict the flow in blood vessels and limit oxygen delivery to the body&#8217;s tissues, leading
to severe pain and organ damage called vaso-occlusive events (&#8220;VOEs&#8221;) or vaso-occlusive crises (&#8220;VOCs&#8221;).&#160;The
recurrence of these events or crises can lead to life-threatening disabilities and/or early death. An allogeneic BMT is a potentially
curative treatment option for patients with sickle cell disease, particularly in pediatric and adolescent patients who have had complications
such as strokes, acute chest crises or recurring pain crises due to their disease. In addition, there are two approved gene therapies
for patients with sickle cell disease, Casgevy (Vertex Pharmaceuticals, Inc. and CRISPR Therapeutics) and Lyfgenia (Bluebird Bio, Inc.).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Clinical Product Candidates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Actimab-A: Mutation Agnostic Mechanism of Action
with Backbone Therapy Potential in Myeloid Malignancies including AML and high-risk MDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actimab-A <i>(Ac-225-lintuzumab satetraxetan) </i>is our lead radiotherapeutic
product candidate in development for patients with myeloid malignancies. To our knowledge, Actimab-A is the only CD33 targeting radiotherapy
in clinical development. We are focused on developing Actimab-A as both a monotherapy and in combination with other treatment regimens
to leverage both the potential mechanistic synergies of radiation and its mutation agnostic cell killing ability. In addition to our internal
development efforts, we entered into a CRADA with the NCI in February 2023 for the development of Actimab-A for AML and other myeloid
malignancies.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to establish Actimab-A as a backbone therapy leveraging the
broad expression of CD33 in myeloid malignancies such as AML and MDS, which, like most blood cancers, are highly sensitive to radiation.
AML is a highly heterogenous, mutation rich cancer with over 70 identified driver genetic mutations. However, there are only approved
therapies for four mutations including FLT3, IDH1 &amp; IDH2, and NPM1. CD33 is expressed regardless of other mutations being present
The Ac-225 isotope payload that we utilize with Actimab-A emits potent alpha-particles with high linear energy that kill cells via double
strand DNA breaks for which there is no known resistance or repair mechanism.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b><i>Actimab-A&#8217;s Mechanistic
Synergy and Potential Combinations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt"><img alt="" src="image_006.jpg" style="height: 263px; width: 332px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our development strategy is
to exploit these properties of Actimab-A to address the unmet needs of patients with myeloid malignancies across the treatment journey
including the frontline, relapsed/refractory and maintenance settings. To accomplish this, we are leveraging our clinical development
experience, clinical data and preclinical work supporting Actimab-A&#8217;s mutation agnostic capabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Actimab-A Clinical Development Experience</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To our knowledge, Actimab-A
is one of the most studied alpha-particle based targeted radiotherapies in clinical development having been studied in over 150 patients
across multiple clinical trials. Actimab-A has been studied at multiple dose levels, different administration schedules and as a single
agent or in combination with chemotherapy and targeted agents in patients with AML in the front line and relapsed or refractory settings
with promising results to date.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Actimab-A Monotherapy Phase 2 Trial</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following multiple Phase 1
clinical trials, Actimab-A was studied in a 40-patient multi-center Phase 2 trial as a single agent in patients newly diagnosed with AML
age 60 and above who were ineligible for intensive chemotherapy. At the dose level of 2.0 &#956;Ci/kg, Actimab-A produced high overall response
rates (&#8220;ORR&#8221;) of 69% including Complete Remission (&#8220;CR&#8221;), Complete Remission with incomplete platelet recovery
(&#8220;CRp&#8221;) and Complete Remission with incomplete blood count recovery (&#8220;CRi&#8221;). Prolonged myelosuppression was the
most common adverse event and was expected as it is a known class effect of CD33 targeting therapies and given the advanced age of the
patients enrolled. The Actimab-A dose was adjusted to 1.5&#956;Ci/kg, which produced an ORR of 22%. Potent anti-leukemic effect was observed
at both dose levels. Of the patients treated with 1.5 &#956;Ci/kg of Actimab-A, the median age was 75 and over 50% of the patients had an
antecedent hematologic disorder including MDS, chronic myelomonocytic leukemia and myelofibrosis, which can compromise a patient&#8217;s
bone marrow function and ability to recover blood counts and proper function. This trial was conducted prior to the approval of many of
the targeted therapies that are routinely used in the treatment of patients with AML today. As a result of the prolonged myelosuppression
seen with doses of Ac-225 directed against CD33 expressing cells and the evolving AML treatment landscape, we adapted our development
strategy for Actimab-A to address the emerging unmet needs of patients in the era of precision medicines for AML.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b><i>Anti-Leukemic Activity
of Actimab-A Monotherapy</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_006a.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After completing the Phase
2 monotherapy trial, there was strong interest from trial investigators and other key opinion leaders to study Actimab-A in combination
with other treatment modalities to leverage its novel mutation agnostic radiotherapy mechanism. We evaluated several clinical trial concepts
and elected to pursue combination trials with Actimab-A with the salvage chemotherapy CLAG-M in patients with r/r AML and with the Bcl-2
inhibitor Venetoclax based on the potential for these combinations to address large segments of the AML patient population with high unmet
needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Actimab-A + Venetoclax Phase 1/2 Combination
Trial</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Venetoclax is an oral therapy
that works by attaching to and blocking the actions of the B-cell lymphoma-2 (&#8220;Bcl-2&#8221;) protein. Bcl-2 is overexpressed in
several blood cancers and prevents cancer cells from undergoing normal programmed cell death or apoptosis, which can help the cancer cells
overexpressing Bcl-2 live longer or increase resistance to chemotherapy. In November 2018, Venetoclax received accelerated approval from
the FDA in combination with the HMA azacitidine and decitabine or low-dose cytarabine for the treatment of newly diagnosed AML in patients
age 75 years or older or patients ineligible for intensive induction chemotherapy. Venetoclax was granted regular approval by the FDA
in October 2020.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Phase 1 portion of the
Actimab-A + Venetoclax trial enrolled 18 patients and was conducted at five clinical trial sites. Four dose levels of Actimab-A were evaluated
with the primary objective of evaluating the safety of the combination. Actimab-A + Venetoclax was well tolerated with an expected and
manageable adverse event profile with no early deaths observed. Efficacy was also evaluated with reduction in bone marrow blasts up to
93% reported.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Actimab-A + CLAG-M Phase 1b/2 Combination
Trial</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Medical College of Wisconsin
(&#8220;MCW&#8221;) was an active clinical trial site in the Phase 2 Actimab-A Monotherapy trial. MCW had previously conducted a study
evaluating salvage chemotherapies in patients with r/r AML including the regimens MEC, CLAG and CLAG-M. The results demonstrated that
CLAG-M produced superior outcomes based on rates of response and overall survival resulting in CLAG-M being the preferred salvage regimen
for patients with r/r AML. Based on MCWs experience with Actimab-A and CLAG-M, the team at MCW hypothesized that combining Actimab-A with
CLAG-M could improve patient outcomes compared to CLAG-M alone and lead to a clinical benefit by eliminating residual or resistant AML
blasts to produce higher rates of remissions and deep remissions including measurable residual disease (&#8220;MRD&#8221;) negativity.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MCW enrolled 26 adult patients
with high-risk r/r AML in the Phase 1b/2 trial of Actimab-A + CLAG-M with 23 patients evaluable for efficacy. Patients in the efficacy
cohort had a median age of 62 and 91.3% of patients being intermediate risk (13%) or adverse risk (78.3%) according to the 2017 ELN cytogenetic
risk classification. Additionally, 52.2% of patients had a TP53 mutation abnormality, 56.5% of patients had prior Venetoclax treatment
and 56.5% of patients had a prior allogeneic BMT with patients having a median of 2 lines of prior treatment (range: 1-5). This trial
evaluated four dose levels of Actimab-A in combination with CLAG-M ranging from 0.25 &#956;Ci/kg to 1.0 &#956;Ci/kg.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b><i>Patient Characteristics</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><img alt="" src="image_006b.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The results from this trial
were published in the peer-reviewed journal <i>Leukemia</i> in February 2025. In this publication, it was reported that Actimab-A + CLAG-M
had a tolerable safety profile with manageable toxicities and demonstrated promising efficacy supporting additional trials to further
evaluate the efficacy of the combination including survival outcomes. Based on the results of the study, it was determined that 0.75 &#956;Ci/kg
is the recommended Phase 2 dose (&#8220;RP2D&#8221;). In addition to a safety analysis, the results of 5 patients treated in a pharmacokinetic
expansion cohort at the RP2D were reported. Treatment-emergent adverse events (&#8220;TEAE&#8221;) were primarily hematologic and all
grade 3/4 TEAEs were hematologic. No patients discontinued treatment due to TEAEs and no early deaths were attributed to the Actimab-A
+ CLAG-M. The pharmacokinetic analysis evaluated radioactivity in whole blood and results showed that Actimab-A cleared rapidly with no
detectable radioactivity after a median of 24.5 hours. Importantly, no significant kidney or liver toxicity has been reported to date
and no incidences of veno-occlusive disease (&#8220;VOD&#8221;) reported.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The efficacy analysis of this
trial evaluated rates of CR, composite Complete Remission (&#8220;CRc&#8221;) which includes CR and Complete Remission with Incomplete
Count Recovery (&#8220;CRi&#8221;) and ORR which include CR, CRi and Morphologic Leukemia-Free State (&#8220;MLFS&#8221;), as well as
MRD negativity and survival outcomes. As listed in the table below, CR, CRc and ORR rates were reported for all patients as well as patients
treated at the RP2D, by number of lines or prior therapy and high-risk patients including those with a TP53 mutation and prior Venetoclax
treatment.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b><i>Rates of CR, CRc and
ORR with Actimab-A + CLAG-M</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt"><img alt="A table with numbers and symbols  Description automatically generated" src="image_007.jpg" style="height: 253px; width: 402px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In patients achieving a CRc,
MRD negativity was assessed including in patients in various high-risk subgroups. Across all patients, the MRD negativity rate was 75%
and was 100% in patients with prior Venetoclax treatment. In the ELN adverse risk patients and those with a TP53 mutation, MRD negativity
was 86% and 83%, respectively. We believe these high rates of MRD negativity support the rationale for conducting this study, which was
to determine if Actimab-A could deplete residual or resistant AML blasts to produce deep remissions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b><i>MRD Negativity Rates
in Evaluable Patients Achieving CRc</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><b><i><img alt="A screenshot of a graph  AI-generated content may be incorrect." src="image_008.jpg" style="height: 200px; width: 335px"/></i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Long-term survival outcomes
in the evaluable patients receiving Actimab-A + CLAG-M were also reported from this study from a 2-year follow-up. In the patients eligible
for a BMT, 60% of patients successfully received a BMT and had a median Overall Survival (&#8220;OS&#8221;) of 24 months. In patients
with one or two lines of prior salvage therapy, the median OS was 18.4 months. The median OS in patients with a TP53 mutation or prior
Venetoclax treatment was 9.6 months and 7.3 months, respectively. These survival outcomes compare favorably to outcomes reported in the
literature. In patients with prior Venetoclax treatment who then received intensive chemotherapy such as CLAG-M, OS has been reported
to be 2.4 - 4.6 months.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><i>Overall Survival Outcomes
with Actimab-A + CLAG-M</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><img alt="" src="image_009.jpg" style="height: 174px; width: 510px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the positive findings
from this trial, we plan to evaluate Actimab-A + CLAG-M will be evaluated in a pivotal Phase 2/3 trial in patients with r/r AML.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Actimab-A + CLAG-M Pivotal Phase 2/3 Trial</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have aligned with the FDA
on an operationally seamless, randomized pivotal Phase 2/3 trial to compare Actimab-A + CLAG-M to CLAG-M alone in patients with r/r AML.
Based on our interactions with the FDA, this trial will first complete a Phase 2 portion where the Actimab-A dose will be optimized in
combination with CLAG-M. We expect the Phase 2 portion of this trial to be initiated in 2025. Once the optimized Actimab-A dose is determined,
we expect the trial will seamlessly advance to the Phase 3 portion of the study, which is expected to reduce time and resources required
compared to separate Phase 2 and Phase 3 studies.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Actimab-A + CLAG-M Pivotal Phase 2/3 Trial
Design</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><img alt="A blue arrow with white text  Description automatically generated" src="image_010.jpg" style="height: 170px; width: 523px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The primary endpoint of the
Phase 3 trial will be Overall Survival. Event-Free Survival (&#8220;EFS&#8221;) and other efficacy measures as well as safety also being
evaluated. We are actively seeking potential strategic partners or collaborators to advance this trial.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Actimab-A NCI CRADA Trials</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2023, we entered into a
CRADA with NCI to develop Actimab-A for the treatment of patients with AML and other hematologic malignancies. The NCI will serve as the
regulatory sponsor for any clinical trials mutually approved by both parties to study Actimab-A, and the CRADA will provide extensive
support for and accelerate the development of Actimab-A alone or in combination with chemotherapy, immunotherapy, targeted agents and
other novel combinations. The CRADA studies will be overseen by the NCI in collaboration with Actinium&#8217;s clinical development team,
where we have the right to review and approve all protocols and have full rights to all data. The NCI CRADA provides for us to supply
Actimab-A and for NCI to cover all clinical trial execution and development expenses, which we believe will be a cost-efficient approach
as opposed to a Company sponsored trial and will therefore spare our balance sheet. The NCI Cancer Therapy Evaluation Program (&#8220;CTEP&#8221;),
which sponsors approximately two thirds of all combination cancer studies, will accept Letters of Intent (&#8220;LOIs&#8221;) or concepts
for Phase 1, 2 or 3 studies of Actimab-A in AML and other hematological malignancies.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2024, the NCI announced
that its myeloMATCH program was officially open to patient enrollment across the U.S. and Canda. MyeloMATCH is a portfolio of clinical
trials to test precision medicine treatments for adults with AML or MDS being designed and led by four leading cancer research organizations
including the Alliance for Clinical Trials in Oncology, Canadian Cancer Trials Group, ECOG-ACRIN Cancer Research Group, and SWOG Cancer
Research Network in collaboration with the NCI National Clinical Trials Network (&#8220;NCTN&#8221;). Collectively, the myeloMATCH program
expects to open trials at hundreds of cancer care sites across the U.S. and Canada with the goal of enrolling 5,000 or more patients over
the next several years. Under our CRADA with the NCI, Actimab-A is part of the myeloMATCH program and may be included in future clinical
trials.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Actimab-A, Venetoclax &amp; ASTX-727 &#8211;
Frontline AML Triplet Phase 1b Combination Trial</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2025, we announced
the initiation of the first clinical trial to be conducted under our CRADA by NCI. The trial will evaluate the triplet combination comprised
of Actimab-A, Venetoclax and ASTX-727, a novel oral HMA developed by Taiho Oncology, an Otsuka Holdings company, in frontline AML patients.
Venetoclax in combination with HMAs (Ven-HMA) is approved for patients with newly diagnosed AML. We believe this trial is supported by
our Actimab-A + Venetoclax combination trial that showed that combination was well-tolerated and showed supportive anti-leukemic activity.
The frontline AML triplet trial is expected to enroll up to 48 patients who are newly diagnosed with AML that are age 75 and above and
not eligible for intensive chemotherapy. The trial will evaluate various dose levels of Actimab-A along with dosing regimens. We expect
initial clinical data to be generated from this trial in second half of 2025.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Triplet Combination Trial Design with Venetoclax,
HMA &amp; Actimab-A Backbone </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_011.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additional clinical trial concepts for Actimab-A
have been submitted under the CRADA and are being reviewed. We anticipate that additional clinical trials with Actimab-A will be initiated
in 2025 including under the CRADA to leverage Actimab-A&#8217;s mutation agnostic mechanism.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Broad Development Strategy for Actimab-A</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_012.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Data Supporting Actimab-A&#8217;s Mutation Agnostic Profile</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To leverage Actimab-A&#8217;s
mutation agnostic capabilities and support its broad development, we have conducted preclinical experiments studying Actimab-A in combination
with targeted agents including Bcl-2 inhibitors, FLT-3 inhibitors, IDH inhibitors and menin inhibitors for NPM1 and KMT2A AML, chemotherapies
such as CLAG-M and in cell lines expressing TP53 mutations. The table below outlines the expression rates of these targets in patients
with AML.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_013.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Actimab-A Combination Data with Menin Inhibitors</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2024, we presented
the first-ever preclinical data demonstrating the combination of Actimab-A with leading menin inhibitors resulted in anti-tumor control
and potent leukemia cell killing in AML models at the 2024 European Hematology Association (&#8220;EHA&#8221;) Congress. We studied Actimab-A
in combination with the leading menin inhibitors, revumenib (Syndax Pharmaceuticals, Inc.) and ziftomenib (Kura Oncology, Inc.), which
are being developed for patients with KMT2A rearrangements and NPM1 mutations, which are present in approximately 10% and 30% of AML patients,
respectively. Actimab-A as a single agent showed potent in vitro AML cell killing activity in both MV-4-11 and MOLM-13 KMT2A mutant cell
lines, compared to the non-radio conjugated CD33 antibody lintuzumab (p&lt;0.0001) and the combination of Actimab-A with leading menin
inhibitors triggered an acute increase in AML necrosis and cell death in vivo relative to single agent therapy within 72 hours of dosing.
Actimab-A enhanced AML cell death when combined with both revumenib and ziftomenib at all dose levels in difficult to treat KMT2A mutant
AML. Anti-tumor effect was significantly potentiated and prolonged when combining Actimab-A with a leading menin inhibitor compared to
monotherapies in xenograft leukemia models in vivo (p&lt;0.0024 Actimab-A + menin).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b><i>Enhanced Tumor Control
with Actimab-A + Menin Inhibitor Revumenib </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt"><img alt="A graph of a patient's tumor  AI-generated content may be incorrect." src="image_014.jpg" style="height: 225px; width: 379px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Actimab-A Combination Data with FLT3 Inhibitors</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have also evaluated Actimab-A
in combination with FLT3 inhibitors such as gilteritinib (Astellas Pharma, Inc.) and midostaurin (Novartis Pharmaceuticals, Inc.). FLT3
is one of the most commonly mutated genes in AML and is associated with aggressive disease with poor outcomes. Actimab-A was shown to
have single-agent activity against FLT3 mutant AML cell lines, supporting its mutation-agnostic mechanism, and enhanced the anti-leukemic
activity of the FLT3 inhibition in vitro. We will continue to evaluate the potential of Actimab-A in combination with FLT3 inhibitors.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b><i>Synergistic Anti-Leukemic
Effect with FLT3 Inhibitors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt"><img alt="A comparison of different colored and black bars  AI-generated content may be incorrect." src="image_015.jpg" style="height: 255px; width: 467px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We expect to present additional data supporting
Actimab-A&#8217;s mutation agnostic capabilities and backbone potential at future scientific and medical conferences. In addition, we
will continue to explore potential clinical trials under our CRADA with NCI, investigator-initiated trials or under our sponsorship.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Actimab-A Solid Tumor Program: Potential Pan Solid Tumor Therapy
in Combination with PD-1 Checkpoint Inhibitors Including KEYTRUDA<sup>&#174;</sup> and OPDIVO<sup>&#174;</sup> by Depleting Myeloid Derived
Suppressor Cells </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Given the significant number
of patients treated with PD-1 ICIs, there is extensive data in the medical literature on outcomes in these patients. PD-1 ICIs have significantly
improved patient outcomes across several solid tumor indications, however, not all patients have robust or durable responses. Multiple
therapeutic modalities have been studied in combination with PD-1 ICIs in attempt to improve patient outcomes, but few combinations have
produced a sufficient enough clinical benefit to have been approved. To our knowledge, our Actimab-A solid tumor program is the only CD33
targeted radiotherapy being evaluated in combination with PD-1 ICIs. The rationale for studying Actimab-A in combination with either KEYTRUDA<sup>&#174;&#160;</sup>or
OPDIVO<sup>&#174;&#160;</sup>is based on the premise that depleting MDSCs with Actimab-A will improve the efficacy of these drugs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">MDSCs are immune-suppressive cells that help tumors
evade immune detection and promote disease progression. They are overexpressed in the tumor microenvironment in several different solid
tumors and associated with poor outcomes. They work by multiple mechanisms but most relevant to PD-1 inhibitors which work by keeping
T-cells active is that MDSCs prevent T-cells from recognizing and attacking cancer cells.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>MDSCs Immunosuppressive Effects</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><img alt="" src="image_016.jpg" style="height: 256px; width: 296px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Studies have shown that MDSCs are overexpressed
in patients with cancers. For instance, a study by Bronte et al., in patients with NSCLC receiving ICIs evaluated the role of immune cells
on patient outcomes. In this study, MDSCs were the only immune cell subtype to show a statistically significant association with tumor
response. The median level of MDSCs was determined to be 1.9% with patients above that level being classified as &#8220;High-MDSC&#8221;
and patients below that level being classified as &#8220;Low-MDSC&#8221;. In this study, only Low-MDSC patients had a clinical response
with no responses observed in High-MDSC patients and over 80% of High-MDSC patients having progressive disease. In addition, Low-MDSC
patients had a statistically significantly improvement in progression-free survival (&#8220;PFS&#8221;) of 8.39 months compared to 1.94
months in High-MDSC patients and OS of 15.15 months compared to 3.03 months in High-MDSC patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><img alt="" src="image_017.jpg" style="height: 194px; width: 532px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There is considerable preclinical scientific evidence
in the literature that depleting MDSCs could be a viable strategy in improving the outcomes of PD-1 directed immunotherapy, however, there
have been no viable clinical approaches that have been tried successfully to our knowledge.&#160; MDSCs are known to express the CD33
antigen which is the target of Actimab-A.&#160; Actinium has also generated published and unpublished preclinical data showing that Actimab-A
can selectively deplete MDSCs in solid tumors.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b><i>Actimab-A Depletes MDSCs
in In Vivo Preclinical Models</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt"><img alt="" src="image_018.jpg" style="height: 198px; width: 437px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe there is strong
scientific rationale supporting the potential for Actimab-A to deplete CD33 expressing MDSCs and hence improve patient outcomes with PD-1
ICIs such as KEYTRUDA<sup>&#174;</sup>&#160;and OPDIVO<sup>&#174;</sup>. Our Actimab-A solid tumor program is expected to be comprised of
several controlled, head-to-head clinical trials that will evaluate the combination of Actimab-A with KEYTRUDA<sup>&#174;</sup>&#160;versus
KEYTRUDA<sup>&#174;</sup>&#160;alone, and Actimab-A with OPDIVO<sup>&#174;</sup>&#160;versus OPDIVO<sup>&#174;</sup>&#160;alone. The initial
tumors that are being targeted are HSNCC and NSCLC with a separate trial for each indication.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt"><img alt="" src="image_019.jpg" style="height: 170px; width: 589px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The patient population for
these trials will be adults with PD-L1 expression and locally advanced metastatic HNSCC or NSCLC randomized to either Actimab-A alone
or Actimab-A with a specific checkpoint inhibitor. The objective of each trial would be to evaluate the safety and tolerability as well
as following endpoints including ORR, PFS and OS. Further, the following biomarker data would be collected including the pattern of depletion
of CD33+ MDSCs and T-cell activity in peripheral blood. We expect to present initial proof of concept clinical data from the first of
these trials in the second half of 2025 as well as provide an update on the outlook for the rest of the trials for the Actimab-A solid
tumor program.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ATNM-400 Program: Potential Novel, First-in-Class Ac-225 Prostate
Cancer Radiotherapy </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2025, we announced
ATNM-400, a novel, first-in-class Ac-225-based radiotherapy intended for patients with prostate cancer. We have generated preclinical
data with ATNM-400, which has been accepted for presentation at the American Association for Cancer Research (&#8220;AACR&#8221;) Annual
Meeting being held April 25 &#8211; 30, 2025. The abstract accepted for presentation highlighted the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">ATNM-400 selectively binds to prostate cancer cells, undergoes
rapid internalization, and induces dose-dependent cytotoxicity;</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">in prostate cancer xenograft mouse models, ATNM-400 accumulated
in tumors for up to 144 hours, while showing minimal uptake in normal tissues;</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">small animal SPECT/CT imaging with Indium-111-labeled antibody
confirmed selective tumor accumulation and clearance from healthy tissues; and</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a single dose of ATNM-400 achieved 68.5% tumor growth inhibition
at 20 &#181;Ci/kg and 99.8% at 40 &#181;Ci/kg, with all doses being well tolerated.</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We continue to study ATNM-400
and expect additional data from Pluvicto-resistant prostate cancer models to be presented at AACR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Iomab-ACT Program: Potential Universal Targeted Conditioning Agent
for Cell &amp; Gene Therapies to Improve Patient Access and Outcomes</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The opportunity exists for
better conditioning regimens in the area of cellular therapies beyond the non-targeted chemotherapy-based regimens that are used currently.
We are working on a next generation targeted conditioning program, Iomab-ACT, for the rapidly growing cell and gene therapy market, as
well as BMT conditioning for non-malignant hematologic indications such as SCD.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are studying Iomab-ACT
in collaboration with Memorial Sloan Kettering Cancer Center (&#8220;MSKCC&#8221;), for conditioning prior to CAR-T therapy for patients
with relapsed or refractory B-cell acute lymphoblastic leukemia (&#8220;B-ALL&#8221;) or diffuse large B-cell lymphoma (&#8220;DLBCL&#8221;).
This study funded by a NIH grant is the first study of its kind to use an ARC, with CAR-T therapy. At the 2024 Tandem Meetings | Transplantation
&amp; Cellular Therapy Meetings of ASTCT and CIBMTR, we presented results from the ongoing Phase 1 trial. No patients (0/4) developed
Immune Effector Cell-Associated Neurotoxicity Syndrome (&#8220;ICANS&#8221;) of any grade, a major safety measure of the study, as ICANS
is observed in 25% or more of patients with r/r B-ALL and DLBCL treated with various CAR T-cell products and negligible incidence of cytokine
release syndrome (&#8220;CRS&#8221;) as outlined in the table below.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b><i>Minimal CRS and ICANS
in Iomab-ACT Pilot Trial</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><img alt="A black and blue grid with white text  Description automatically generated" src="image_020.jpg" style="height: 180px; width: 495px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, Iomab-ACT demonstrated
transient depletion of peripheral blood lymphocytes and monocytes. Persistence of CAR T-cells up to 8 weeks and minimal non-hematologic
toxicities have been observed to date. These results prompted us to explore additional clinical trials with Iomab-ACT.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2024, we announced
FDA acceptance of an IND for a new Phase 1b/2 clinical trial that will study Iomab-ACT as targeted conditioning prior to patients receiving
an FDA approved commercial CAR-T therapy. This is an investigator sponsored trial conducted at the University of Texas Southwestern (&#8220;UTSW&#8221;).
To our knowledge, this will be the first trial to study a targeted radiotherapy conditioning agent with a commercial CAR-T therapy. Given
the robust clinical data that exists with commercial CAR-T therapies, we believe this trial may demonstrate the potential for Iomab-ACT
to improve outcomes over current chemotherapy conditioning regimens, which we are seeking to replace and provide patients better access
to CAR-T. This trial will enroll up to 30 patients and we expect to commence patient enrollment of this study in the first half of 2025
and generate proof of concept clinical data by year end 2025.&#160;The primary objectives are safety, tolerability and efficacy. Second
objectives will evaluate incidences of CRS and ICANS as well as the persistence and expansion of CAR-T cells, which has been associated
with improved efficacy and patient outcomes. If successful, we believe this Phase 1b/2 trial could support a pivotal trial, which could
be initiated as early as 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2024, we announced
a program for Iomab-ACT focused on providing patients with sickle cell disease broader access to cellular therapies including bone marrow
transplant and gene therapies. We also announced in July 2024 the FDA clearance of an IND for an investigator led clinical trial to study
Iomab-ACT as targeted conditioning prior to a BMT for patients with SCD in collaboration with Columbia University. Sickle cell disease
is a rare, debilitating and life-threatening blood disorder with significant unmet need that affects approximately 100,000 people in the
U.S. Patients with sickle cell disease have a mutation that causes red blood cells to develop a crescent or &#8220;sickle&#8221; shape,
which restrict the flow in blood vessels and limit oxygen delivery to the body&#8217;s tissues, leading to severe pain and organ damage
called vaso-occlusive events (&#8220;VOEs&#8221;) or vaso-occlusive crises (&#8220;VOCs&#8221;). The recurrence of these events or crises
can lead to life-threatening disabilities and/or early death. A BMT is a potentially curative treatment option for patients with sickle
cell disease, particularly in pediatric patients who have had complications such as strokes, acute chest crises or recurring pain crises
due to their disease. We expect patient enrollment for the Phase 1 trial to commence in the first half of 2025 and enroll up to 15 patients
with initial safety and efficacy results from the initial cohort of patients receiving Iomab-ACT prior to a BMT for their SCD in the second
half of 2025.If safety is demonstrated, the trial is expected to inform a clinical trial to evaluate Iomab-ACT as a targeted conditioning
agent prior to gene therapy for which there are two approved agents for patients with sickle cell disease, Casgevy (Vertex Pharmaceuticals,
Inc.) and Lyfgenia (Bluebird Bio, Inc.).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b><i>Iomab-ACT Clinical Trials
and Objectives </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_021.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We plan to continue
to develop Iomab-ACT based on early promising results, ultimately with the value proposition of improving overall access and outcomes
for patients who need cellular or gene therapies. We believe an opportunity exists for Iomab-ACT to potentially generate significant revenue,
if it can provide one or more clinical benefits related to lower CRS, less neurotoxicity, longer duration of response or a higher overall
success rate of cellular therapy due to benefits of targeted conditioning.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Iomab-B</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">In
February 2023, Actinium announced that the SIERRA trial met the primary endpoint with statistical significance, as 22% of patients (13/76)
on the Iomab-B arm achieved dCR compared to 0% of patients (0/77) on the control arm resulting in a p-value of &lt;0.0001. The SIERRA
trial met the secondary endpoint of Event-Free Survival (&#8220;EFS&#8221;) with a 78% reduction in the probability of an event (Hazard
Ratio=0.22, p&lt;0.0001 for both per protocol and ITT basis). EFS at 180 days for the Iomab-B arm was 28% compared to 0.2% for the control
arm. In the SIERRA trial, an event was defined as one of the following: a patient not achieving CR/CRp or crossing over, patient not
receiving BMT, a patient relapsing or death. The SIERRA trial did not, however, meet the secondary endpoint in achieving a statistically
significant improvement in OS in the intent to treat (&#8220;ITT&#8221;) population.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
August 5, 2024, Actinium announced that it concluded both its clinical and Chemistry, Manufacturing and Controls (&#8220;CMC&#8221;) interactions
with the FDA regarding the BLA pathway for Iomab-B based on the SIERRA trial results. As previously disclosed, we had received positive
feedback from the FDA regarding our CMC package for Iomab-B and were also assigned a BLA number. However, in the third quarter of 2024,
the FDA provided definitive feedback that the SIERRA trial alone is not adequate to support a BLA filing for Iomab-B, despite (a) the
SIERRA trial meeting the primary endpoint of dCR with statistical significance (p-value&lt;0.0001) and other positive secondary endpoints
including Event Free Survival (&#8220;EFS&#8221;) and safety, and (b) our presentation of several additional analyses from the SIERRA
study, including long-term follow-up demonstrating a trend towards improved overall survival and evidence of survival benefit in patients
with high-risk TP53 mutations, to support Iomab-B&#8217;s impact on overall survival. The FDA indicated that demonstrating an overall
survival benefit in a randomized head-to-head trial is necessary and has advised us to conduct a study to evaluate allogeneic BMT using
Iomab-B plus a reduced intensity conditioning regimen of fludarabine and total body irradiation (&#8220;Flu/TBI&#8221;) versus allogeneic
BMT using reduced intensity conditioning comprised of cyclophosphamide plus Flu/TBI. This proposed additional study differs from the SIERRA
trial, which allowed physician&#8217;s choice of salvage chemotherapies and heterogenous conditioning regimens in the control arm. Additionally,
the proposed new study will not allow patients to cross over from the control arm, which was allowed in the SIERRA trial and confounded
the overall survival analysis in the ITT patient population, as nearly 60% of patients crossed over from the control arm.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Actinium
continued interactions with the FDA in the third quarter of 2024 to further discuss the specifics of the additional head-to-head clinical
trial required by the FDA, including the patient population, which the FDA had suggested could include all adult AML patients. In the
fourth quarter of 2024, Actinium conducted a further meeting with the FDA. Based on this meeting, Actinium believes it has aligned with
the FDA on the patient population for a head-to-head Phase 3 clinical trial to further evaluate allogeneic BMT using Iomab-B plus a reduced
intensity conditioning regimen of Flu/TBI versus allogeneic BMT using reduced intensity conditioning comprised of cyclophosphamide plus
Flu/TBI in all adult patients aged 18 and above with active AML with blasts counts greater than 5% and less than 20%. This is a broader
patient population than the patients enrolled on the SIERRA trial, which only enrolled patients aged 55 and above. Further, the FDA now
requires that an additional dose optimization trial demonstrating safety and efficacy be completed to calculate the dose of Iomab-B based
on absorbed dose by the bone marrow, rather than the maximum tolerable dose of 24 Gy of radiation to the liver as was done in the SIERRA
trial based on several interactions we had with the FDA before starting the SIERRA trial. We are actively seeking a strategic partner
for Iomab-B in the U.S. to advance the head-to-head clinical trial or other clinical development activity for Iomab-B.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 7, 2022, we entered
into a License Agreement with Immedica Pharma AB (&#8220;Immedica&#8221;), pursuant to which Immedica licensed the exclusive product rights
for commercialization of Iomab-B in certain countries in the EUMENA region. Upon signing, we were entitled to an upfront, non-refundable
payment of $35.0 million from Immedica, which was received in May 2022. Under the terms of the License Agreement, we are eligible to receive
certain regulatory and commercial milestone payments and royalties on net sales of the product in certain countries that may result from
the License Agreement. Immedica is responsible for regulatory submissions in the EUMENA region, and we continue to retain commercialization
rights in the U.S. and rest of the world.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>&#160;</i></b></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>R&amp;D and Platform Technology</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our R&amp;D capabilities have
the potential to yield differentiated, high-value targeted radiotherapy programs that demonstrate our experience across multiple validated
cancer targets and isotopes and cover broad areas of focus leveraging our clinical development experience across hematology, targeted
conditioning, solid tumors, and next generation radiotherapies. We have internal R&amp;D capabilities with our research laboratory capable
of executing in vitro and in vivo experiments and translational research. We are working on several preclinical programs which include
novel approaches to validated cancer targets, as well as novel targets that we believe show immense potential for radiotherapeutic approaches.
Preclinical pharmacology studies with our targeted radiotherapeutics, such as HER2, CD33 and CD38, have shown strong improvement in tumor
growth inhibition in various preclinical tumor models.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We currently believe that our targeted radiotherapies,
which utilize biologic molecules, are less likely than small molecules to face pricing pressure and negotiation from IRA, given that small
molecules are at risk for pricing negotiations seven years after approval compared to eleven years for biologics with negotiated prices
taking effect two years after selection. Further, a drug or biological product that has an orphan drug designation, which our Actimab-A
and Iomab-B programs both have, for only one rare disease or condition will be excluded from the IRA's price negotiations requirements
until such time the biological products has designations for more than one rare disease or condition, or if is approved for an indication
that is not within that single designated rare disease or condition, unless such additional designation or such disqualifying approvals
are withdrawn by the time CMS evaluates the drug for selection for negotiation. In addition, regulatory barriers for generic large molecule
biologic based targeted radiotherapies are much higher than for small molecule radioligands such as those under development or approved,
namely, Pluvicto<sup>&#174;</sup>, Lutathera<sup>&#174;</sup>, and Xofigo<sup>&#174;</sup>. Generic versions of certain radiopharmaceuticals
utilizing peptides, which are considered small molecules, have been submitted to the FDA via the ANDA pathway. To our knowledge, only
the biosimilar approach pertains to large molecule biologic-based radiotherapies filed under 351(k) BLA pathway. The regulatory pathway
for a biosimilar is much more comprehensive than the pathway for generics, and it has not been proven that biosimilars are interchangeable
with the innovator&#8217;s large molecule biologic targeted radiotherapy. In addition, we are not aware of any regulations that would
require us to provide Actimab-A or Iomab-ACT, including their respective mAbs, lintuzumab and apamistamab, to any third party or potential
competitor. Despite the above, we are aware that one or more of the policies or regulations that afford our pipeline candidates
market protections may change in the future and that one or more of pour product candidates may be disadvantaged by such change.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We seek to expand our capabilities
and technologies across therapeutic modalities, linker technologies and in vivo cancer models, and build visibility through presentations
at key conferences and publications in journals of high impact. Our R&amp;D efforts are centered on the advancement of key programs with
a robust &#8220;fast-to-clinic&#8221; approach. Underpinning our development programs is our expanded patent portfolio of approximately
230 issued patents and pending patent applications worldwide.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Proprietary Ac-225 Cyclotron Manufacturing
Technology</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With
our in-depth, long-term experience in clinical development of Ac-225 based radiopharmaceuticals, we have developed an end-to-end technology
solution for producing Ac-225 that has demonstrated radiochemical and radionuclidic purity identical to current gold standard methods.
This patented technology has been used to produce Ac-225 in a cyclotron that is essentially identical to that derived from a Th-229 generator
and has the potential to be a lower-cost, commercially scalable higher-yielding approach. Importantly, the Ac-225 material produced by
our proprietary method contains no long-lived contaminants and less than 0.001% Actinium-227 (&#8220;Ac-227&#8221;). Using the cyclotron-produced
Ac-225 technology may allow for large commercial scale production with estimated cost of goods sold including capital expenditures and
operational costs for a single cyclotron facility to be several times less expensive than the price of currently available Ac-225 material.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Demonstrated Radiochemical Equivalence</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_022.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Blue</b>: Actinium&#8217;s cyclotron-produced
Ac-225<b><br/>
Red</b>: Ac-225 from a Th-229 generator</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our extensive know-how related to this production
technology is supported by five issued patents in the U.S. and 49 patents internationally and covers:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">End-to-end solution including processing and recycling of Radium-226 starting material</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Production of up to 100 mCi of Ac-225 per production cycle</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Utilization of a medium energy cyclotron</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Expected cost 10 to 20 times lower than currently available material</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Radiochemical purity &gt; 99%</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Radioisotopic purity 99.8% with no long-lived contaminants and &lt;0.001% Ac-227</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With our Ac-2225 based Actimab-A
and ATNM-400 programs and the rapidly increasing number of Ac-225 based programs in development, we believe that we are well positioned
to leverage this technology to produce Ac-225 to address the growing clinical and potential commercial demand.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Manufacturing and Supply Chain</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium has established significant
manufacturing and supply chain expertise having delivered over 500 doses for 18 clinical trials at 45 large cancer hospitals and have
never missed a dose.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe this experience
provides us with insights that are highly relevant to the unique manufacturing and distribution requirements of radiotherapeutics. Due
to the short half-life of radioisotopes, our finished drug products are shipped &#8220;hot&#8221; and must be administered within days.
Actinium has established core competencies in the process of manufacturing radiotherapeutics, coordinating with the hospital&#8217;s care
team, and delivering &#8220;just-in-time&#8221; doses.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We plan to establish our own
manufacturing capabilities and intend to commence the build-out of a facility in the second quarter of 2025. We believe that having in-house
manufacturing will provide enhanced control, flexibility and scalability to serve our current and planned clinical trials and R&amp;D
efforts as well as potential future activity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Isotope supply is critical
for the manufacturing of radiotherapeutics, and we have engaged several sources for the procurement of alpha (e.g., Ac-225) and beta (e.g.,
I-131 and Lu-177) emitters. We also have multiple isotope supply agreements and qualified vendors in place to supply isotopes for our
active and planned clinical trials. In March 2025, we announced that we entered into&#160;Ac-225 supply agreement with Eckert &amp; Ziegler,
a leading specialist in isotope-related components for nuclear medicine and radiation therapy, to support our comprehensive development
including U.S. and international clinical trials.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium has commercial agreements
with Contract Development and Manufacturing Organizations (&#8220;CDMOs&#8221;) with significant experience in mAb and final radio-labeled
drug products. Our finished drug product CDMOs are located in the U.S. and have experience in the international supply of radiotherapies.
We have scaled deliberately for manufacturing flexibility&#160;and are currently qualifying additional CDMOs to ensure readily available
drug product upon FDA approval and the ability to ramp up rapidly to meet commercial demand.<b>&#160;</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have established an actively managed end-to-end
supply chain that encompasses isotope sourcing through drug administration at the point of care to execute our clinical trials. Our end-to-end
supply chain did not miss a patient dose in our international, 24-site SIERRA Phase 3 clinical trial including 40 additional patients
that crossed over from the control arm to receive Iomab-B. We believe we have a thorough understanding and working knowledge of the intricacies
required to manufacture and distribute radiotherapies. Through our clinical experience with Iomab-B and Actimab-A, we have developed a
wealth of proprietary knowledge to enable coordination between Actinium and all key stakeholders including, but not limited to hematologists/oncologists,
infusion center and in patient rooms, nuclear medicine and radiology, hot labs and radio-pharmacies, and radiation safety committees,
among others.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Intellectual Property</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;Our proprietary technology platform is supported by IP, know-how
and trade secrets that cover the generation, development, methods of use and manufacture of targeted radiotherapies and their select components.
Our IP covers various methods of use in multiple diseases, including indication, dose and scheduling, radionuclide warhead, and therapeutic
combinations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 2025, our patent
portfolio is comprised of approximately 230 issued patents and pending patent applications worldwide, which we believe constitutes a valuable
business asset. Our IP includes 47 patent families, including key patents that relate primarily to our radiotherapeutic candidates. Our
patent portfolio includes 15 issued patents and 52 pending patent applications in the U.S., and 166 that are issued or pending internationally.
The effective lives of the issued patents in our portfolio, or patents that may issue from the pending applications in our portfolio,
ranges from expirations between 2024 and 2043.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;For our Iomab-B product candidate, we have four issued patents
in the U.S. and issued patents in Canada, Europe and Japan that relate to the composition. The basic patent terms of these patents expire
in 2036 and 2037. Related patent applications are also currently pending in the U.S. and internationally. In addition, we own both U.S.
and international pending patent applications that relate to the use of Iomab-B or Iomab-ACT in the treatment of cancers and non-malignant
conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our patents also cover key areas of our business such as manufacturing
key components of our product candidate, Actimab-A, including Ac-225 in a cyclotron. We have expertise in utilizing the alpha emitting
isotope Ac-225 including clinical experience in treating approximately 150 patients with our alpha-emitter-based therapies, &#8220;gold
standard&#8221; linker technology and 5 issued patents in the U.S. and 49 patents internationally related to the manufacturing of Ac-225
in a cyclotron, which we believe has the potential to produce higher quantities of Ac-225 than currently utilized methods. In addition,
we also own U.S. and international patents and pending patent applications that relate to the manufacturing of Actimab-A and its use in
the treatment of cancers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biopharmaceutical industry
is extremely competitive and rapidly evolving, particularly in the fields of oncology, hematology and cell and gene therapy. Our competition
is likely to come from larger pharmaceutical companies, biotechnology companies, academia, and other public and private entities that
focus on three broad areas relevant to our pipeline candidates &#8211; hematology/oncology agents, conditioning agents and radiopharmaceuticals.
In addition, in markets where we are going after a target, companies with research programs and capabilities in our disease area focus
may also be competing with our programs and pipeline. Additionally, our competition may have more resources than we do and more experience
in drug development.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In myeloid malignancies, specifically
AML, there are a significant number of programs in preclinical and clinical development. In addition, there are 12 approved products including
small molecules and targeted therapies. However, to our knowledge, our Actimab-A program is the only Ac-225 based targeted radiotherapy
in clinical development for AML and myeloid malignancies. In addition, Actimab-A is potentially synergistic with a majority of the approved
AML therapies. AML assets primarily consist of agents targeting specific AML mutations, immunotherapies, or cell cycle modulators, which
largely address finite segments of the population and do not have the broad potential for utilization like Actimab-A. Early clinical and
preclinical stage assets consist of more cell therapy and immune cell engagers, and the potential success of these modalities in AML remain
uncertain. Our strategy is to develop Actimab-A in combination with other products, and agents in the development pipeline have the potential
for synergies in combination with Actimab-A.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In conditioning, agents currently
used for myeloablation prior to a BMT, lymphodepletion prior to CAR-T and other adoptive cell therapies and reduced intensity conditioning
for gene therapy are largely generic, non-targeted chemotherapeutic agents. Jasper Therapeutics and Magenta Therapeutics ceased development
of their antibody and antibody-drug conjugate or ADC conditioning programs for BMT in malignant diseases. Certain companies such as Vertex
Pharmaceuticals (&#8220;Vertex&#8221;), Gilead Sciences (&#8220;Gilead&#8221;) and Allogene Therapeutics (&#8220;Allogene") have
or continue to explore non-chemotherapy conditioning with ADCs and antibodies for their in-house, proprietary cellular therapy programs.
For example, Vertex in-licensed ADC technology from ImmunoGen Inc. (acquisition by AbbVie announced in November 2023) and had a collaboration
with Molecular Templates, Inc. (ceased operations in 2024) to develop targeted conditioning agents, which was subsequently terminated.
Allogene is using its own proprietary anti-CD52 monoclonal antibody for use as a lymphodepletion agent in conjunction with CAR-T therapies.
Telix Pharmaceuticals has announced plans for a conditioning program based on a CD66 radiotherapeutic approach in systemic amyloid light-chain
amyloidosis (&#8220;SALA&#8221;) via an early-stage investigator-sponsored trial. Molecular Partners is developing a switch-DARPin targeting
cKIT&#215;CD16a&#215;CD47 as a conditioning regiment in AML, but this asset is in early preclinical studies. Without exception, all
these companies have either preclinical or early-stage programs that are, for the most part, solely focused on their proprietary programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Several companies are focused
on developing radiotherapies for solid tumors, with a majority of radiotherapy programs focused on PSMA or prostate-specific membrane
antigen in prostate cancer, neuroendocrine tumors or fibroblast activation&#160;protein (&#8220;FAP&#8221;). Companies with radiotherapeutics
in development include, but not limited to: Abdera Therapeutics, Aktis Oncology, Alpha-9 Theranostics, Ariceum Therapeutics, ARTbio, Bayer
AG, Clarity Pharmaceuticals, Cellectar Biosciences, Convergent Therapeutics, CuraSight, Curium Pharma, Full-Life Technologies, Fusion
Pharmaceuticals, Inc., Johnson &amp; Johnson, Lantheus Holdings, Inc., Mariana Oncology (acquired by Novartis AG in May 2024) ), Molecular
Partners, Monopar Therapeutics, Novartis AG, Orano Med, Perspective Therapeutics, Point Biopharma, Inc. (acquired by Lilly in December
2023), RadioMedix, Inc., Radiopharm Theranostics, Radionetics Oncology, Ratio Therapeutics, RayzeBio, Inc. (acquired by Bristol Myers
Squibb in February 2024), Q BioMed, Inc., Scintomics, Telix, and Y-mAbs Therapeutics, Inc. None of these or other companies that we are aware of appears to be pursuing a development program directed against
our biological target.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regulatory
Compliance</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development activities are all subject to stringent regulation, primarily by the FDA in the U.S. under the Federal Food,
Drug, and Cosmetic Act (the &#8220;FDCA&#8221;) and its implementing regulations, and the Public Health Service Act (&#8220;PHSA&#8221;)
and its implementing regulations, and by comparable authorities under similar laws and regulations in other countries. This includes
research and development, testing, and oversight of suppliers and contract manufacturers involved in the production of our product candidates
we are developing, as well as the design, manufacturing, safety, efficacy, handling, labeling, storage, record-keeping, advertising,
promotion and marketing. If, for any reason, we do not comply with applicable requirements, such noncompliance can result in adverse
consequences, including delays in approval of, or even the refusal to approve product licenses or other applications, the suspension
or termination of clinical investigations, the revocation of approvals previously granted, as well as fines, criminal prosecution, recall
or seizure of products, injunctions against shipping products and suspension of production and/or refusals of government contracts.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>FDA
Review Process and Product Approval</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates are regulated as biologics and must be approved by the FDA before they may be marketed in the U.S. This process generally
involves the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion of preclinical
    studies in accordance with the FDA&#8217;s current Good Laboratory Practices (&#8220;GLP&#8221;) requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of
    an IND, which must become effective before human clinical trials may begin and must be updated annually;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval by an independent
    Institutional Review Board (&#8220;IRB&#8221;) ethics committee at each clinical site before the trial is initiated;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance of adequate
    and well-controlled clinical trials to establish the safety, purity and potency of the proposed biologic, and its safety and efficacy
    for each indication, in accordance with good clinical practice (&#8220;GCP&#8221;);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of
    a BLA for a new biologic, after completion of all pivotal clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a determination by the
    FDA within 60 days of its receipt of a BLA to file the application for review;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory completion
    of an FDA pre-approval inspection of the manufacturing facilities to assess compliance with applicable current Good Manufacturing
    Practice (&#8220;cGMP&#8221;) regulations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential FDA audit of
    the clinical trial sites that generated the data in support of the BLA; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA review and approval
    of a BLA for a new biologic, prior to any commercial marketing or sale of the product in the U.S.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials generally are conducted in three sequential phases, although they may overlap or be combined.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 1 studies are designed
    to evaluate the safety, dosage tolerance, metabolism and pharmacologic actions of the investigational product in humans, the side
    effects associated with increasing doses, and if possible, to gain early evidence on effectiveness</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 2 studies are conducted
    to preliminarily or further evaluate the effectiveness of the investigational product for a particular indication(s) in patients
    with the disease or condition under study, to determine dosage tolerance and optimal dosage, and to identify possible adverse side
    effects and safety risks associated with the product</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 3 clinical trials
    generally involve a large number of patients at multiple sites designed to provide the data required to demonstrate the effectiveness
    of the product for its intended use, safety and to establish the benefit-risk relationship of the product and provide an adequate
    basis for product labeling</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of the preclinical and clinical testing, along with information regarding the manufacturing of the product and proposed product
labeling, are evaluated and, if determined appropriate, submitted to the FDA through a BLA. Once the BLA submission has been accepted
for filing, the FDA&#8217;s standard goal is to review applications within ten months of the filing date or, if the application relates
to a drug that treats a serious condition and would provide a significant improvement in safety or effectiveness qualifying for Priority
Review, six months from the filing date. The review process is often significantly extended by FDA requests for additional information
or clarification.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA offers certain programs, such as Breakthrough Designation (&#8220;BTD&#8221;) and Fast Track designation, designed to expedite the
development and review of applications for products intended for the treatment of a serious or life-threatening disease or condition.
For BTD, preliminary clinical evidence of the product indicates that it may demonstrate substantial improvement over existing therapies
on one or more clinically significant endpoints. The FDA may initiate review of sections of a BLA before the application is complete,
and the product may be eligible for accelerated approval. However, receipt of BTD or Fast Track designation does not ensure that a product
will be developed or approved on an expedited basis, or at all.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA reviews the BLA to determine, among other things, whether the proposed product is safe, pure and potent, which includes determining
whether it is effective for its intended use, and whether the product is being manufactured in accordance with cGMP, to assure and preserve
the product&#8217;s identity, strength, quality, potency and purity. The FDA may refer an application to an advisory committee for review,
evaluation and recommendation as to whether the application should be approved, and applications for new molecular entities and original
BLAs are generally discussed at advisory committee meetings unless the FDA determines that this type of consultation is not needed under
the circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the FDA evaluates the BLA and conducts inspections of manufacturing facilities, it may issue an approval letter or a complete response
letter (&#8220;CRL&#8221;). An approval letter authorizes commercial marketing of the biologic with specific prescribing information
for specific indications. A CRL indicates that the review cycle of the application is complete, but the FDA cannot grant approval. A
CRL may require additional inspections, and/or other significant, expensive and time-consuming requirements related to clinical trials,
preclinical studies or manufacturing. The FDA could approve the BLA with a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;)
to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted
distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things,
changes to proposed labeling, development of adequate controls and specifications, or a commitment to conduct one or more post-market
studies or clinical trials. Such post-market testing may include Phase 4 clinical trials and surveillance to further assess and monitor
the product&#8217;s safety and effectiveness after commercialization.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>


</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Post-Approval
Requirements</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
products manufactured or distributed by us or on our behalf pursuant to FDA approvals are subject to continuing regulation by the FDA
and certain state agencies, including requirements for record-keeping, reporting of adverse experiences with the biologic, submitting
biological product deviation reports to notify the FDA of unanticipated changes in distributed products, establishment registration,
compliance with cGMP standards, and certain state licensing requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
any significant change in the approved product or in how it is manufactured, including changes in formulation or the site of manufacture,
generally require prior FDA approval. The packaging and labeling of all products developed by us are also subject to FDA approval and
ongoing regulation. Noncompliance with any regulatory requirements can result in, among other things, issuance of warning letters, civil
and criminal penalties, seizures, and injunctive action. Accordingly, manufacturers must continue to maintain compliance with cGMP and
other aspects of regulatory compliance. The commercial distribution of prescription drugs is subject to the Drug Supply Chain Security
Act (&#8220;DSCSA&#8221;), which regulates the distribution of the products at the federal level and sets certain standards for federal
or state registration and compliance of entities in the supply chain.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DSCSA preempts certain previously enacted state laws and the pedigree requirements of the Prescription Drug Marketing Act (&#8220;PDMA&#8221;).
Trading partners within the drug supply chain must now ensure certain product tracing requirements are met, and are required to exchange
transaction information, transaction history, and transaction statements. Product identifier information (an aspect of the product tracing
scheme) is also now required. The DSCSA requirements, development of standards, and the system for product tracing have been and will
continue to be phased in over a period of years through 2023. In addition to new legislation, FDA regulations, guidance documents, and
policies are often revised or reinterpreted by the agency in ways that may significantly affect our business and our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Orphan
Drug Act</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have received Orphan Drug designation for Iomab-B and Actimab-A for patients with AML. Under the Orphan Drug Act, FDA may grant Orphan
Drug designation to drugs intended to treat a rare disease or condition, which is generally defined as a disease or condition that affects
fewer than 200,000 individuals in the U.S. Orphan Drug designation must be requested before submitting a BLA. In the U.S., Orphan Drug
designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages,
and user-fee waivers. Orphan Drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and
approval process. The first BLA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with
FDA Orphan Drug designation is entitled to a seven-year exclusive marketing period in the U.S. for that product, for that indication.
During the seven-year exclusivity period, FDA may not approve any other applications to market the same drug for the same orphan indication,
except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or where the manufacturer
of the approved product cannot assure sufficient quantities. As a result, there can be no assurance that our competitors will not receive
approval of drugs or biologics that have a different active ingredient for treatment of the diseases for which our products and product
candidates are targeted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pediatric
Information</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Pediatric Research Equity Act (&#8220;PREA&#8221;), certain BLAs must contain data to assess the safety and efficacy of the drug
or biologic for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric
subpopulation for which the product is safe and effective. The Food and Drug Administration Safety and Innovation Act (&#8220;FDASIA&#8221;),
amended the FDCA to require that a sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient,
new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan (&#8220;PSP&#8221;)
within 60 days of an end of Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase
3 or Phase 2/3 study. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct or
a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial
waiver. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. A sponsor can submit amendments to an
initial PSP if changes to the pediatric plan need to be considered based on preclinical data collected, early phase clinical trials as
well as other clinical development programs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
Regulation</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to regulations in the U.S., we are subject to foreign regulations governing clinical trials and commercial sales and distribution
of our product candidates, and products being marketed outside of the U.S. We must obtain approval by the comparable regulatory authorities
of foreign countries before we can commence clinical trials or marketing of our products in those countries. The approval process varies
from country to country, and the time may be longer or shorter than required by the FDA for BLA licensure. The requirements governing
the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country. As in the U.S., we
are subject to post-approval regulatory requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Regulatory Considerations</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also subject to regulation under the Occupational Safety and Health Act, the Toxic Substances Control Act, the Resource Conservation
and Recovery Act, The Clean Air Act, and other current and potential future federal, state, or local regulations. Our research and development
activities involve the controlled use of hazardous materials, chemicals, biological materials and various radioactive compounds. We believe
that our procedures comply with the standards prescribed by state and federal regulations; however, the risk of injury or accidental
contamination cannot be completely eliminated. We may also be subject to healthcare regulation and enforcement by the federal government
and the states and foreign governments where we may market our products and product candidates, if approved. These laws and regulations
include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, data privacy and security, aggregate spend
reporting, and product price advertising.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Anti-Kickback Statute, which prohibits, among other things, persons and entities including pharmaceutical manufacturers from
knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, overtly or covertly, in case
or in kind, to induce or reward, or in return for, or either the referral of an individual for, or the purchase, lease or order or recommendation
of an item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs.
The failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the
conduct per se illegal under the federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case
basis based on a cumulative review of all of its facts and circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Patient Protection and Affordable Care Act of 2010, as amended (&#8220;ACA&#8221;) codified as law that a claim including items
or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the
federal civil False Claims Act (&#8220;FCA&#8221;). The FCA prohibits individuals or entities from, among other things, knowingly presenting
or causing the presentation of a claims for payment to, or approval by, the federal government that are false, fictitious or fraudulent,
or knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim to avoid,
decrease or conceal an obligation to pay money to the federal government. Our activities relating to the reporting of wholesaler or estimated
retail prices for products we may commercialize in the future, the reporting of prices used to calculate Medicaid rebate information
and other information affecting federal, state and third-party reimbursement for products we may commercialize in the future, and the
sale and marketing of products we may commercialize in the future, will be subject to scrutiny under the FCA. State statutes and regulations
equivalent or substantially similar to the federal laws may extend to items and services reimbursed by commercial insurers and/or by
patients directly. State law equivalents to the Anti-Kickback Statute and False Claims Act may not have adopted exceptions and safe harbors
available at the federal level and therefore, may implicate a broader range of activities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) imposes criminal and civil liability for knowingly
and willfully executing, or attempting to execute, a scheme to defraud or obtain, by any means of false or fraudulent pretenses, representations
or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party
payors, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially
false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. The
federal physician payment transparency requirements, sometimes referred to as the &#8220;Physician Payments Sunshine Act,&#8221; created
under the ACA, and its implementing regulations, which requires applicable manufacturers of covered drugs, devices, biologics and medical
supplies for which payment is available under Medicare, Medicaid or the State Children&#8217;s Health Insurance Program (with certain
exceptions) to annually report to the Department of Health and Human Services (&#8220;HHS&#8221;), information related to certain payments
or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of,
or designated on behalf of, the physicians and teaching hospitals, as well as ownership and investment interests held by physicians and
their immediate family members. Under recent legislation, the Sunshine Act will extend to payments and transfers of value to physician
assistants, nurse practitioners, and other mid-level healthcare providers. The Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;)
has the potential to impose penalties for violations of the Sunshine Act, depending on the circumstances, and payments reported under
the Sunshine Act also have the potential to draw scrutiny on payments to and relationships with physicians and teaching hospitals, which
may have implications under the Anti-Kickback Statute and other healthcare laws.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also be subject to data privacy and security regulation by both the federal government and the state governments in which we conduct
our business. HIPAA, as amended by the Health Information Technology and Clinical Health Act of 2009 (&#8220;HITECH&#8221;) and their
respective implementing regulations, imposes, among other things, obligations, including mandatory contractual terms with respect to
safeguarding the privacy, security and transmission of individually identifiable health information held by certain healthcare providers,
health plans and healthcare clearinghouses, known as covered entities, and business associates. The HHS Office of Civil Rights (&#8220;OCR&#8221;)
has increased its focus on compliance and continues to train state attorneys general for enforcement purposes. Even where HIPAA does
not apply, according to the U.S. Federal Trade Commission (&#8220;FTC&#8221;), failing to take appropriate steps to keep consumers&#8217;
personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal
Trade Commission Act (&#8220;FTCA&#8221;), 15 U.S. Code &#167;45(a). Medical data is considered sensitive data that merits stronger safeguards.
There are numerous other laws and legislative and regulatory initiatives at the federal and state levels addressing privacy and security
concerns, and some state privacy laws apply in broader circumstances than HIPAA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), which prohibits corporations and individuals from engaging
in certain activities to obtain or retain business or to influence a person working in an official capacity. Our present and future business
has been and will continue to be subject to various other laws and regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Human
Capital</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 28, 2025, we had 37 full-time employees, 22 of whom have Ph.D. or M.D. degrees and 22 of whom are engaged in research and development
and clinical development activities. We believe that we have been successful to date in attracting skilled and experienced personnel
despite the competitive hiring marketing in the industry. Our employees are not covered by a collective bargaining agreement, and we
believe that our relationship with our employees is excellent. We continue to engage external consultants on an as-needed basis to temporarily
supplement existing staff.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated under the laws of the State of Delaware in 2013. Our principal executive offices are located at 100 Park Avenue, New
York, NY 10017, and our telephone number is (646) 677-3870. Our website address is www.actiniumpharma.com. The information contained
on our website or that can be accessed through our website is not considered part of this report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
make available free of charge through our website our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on
Form 8-K, and any such amendments to those reports as soon as reasonably practicable after we electronically file such material with
or furnish such material to the Securities and Exchange Commission (&#8220;SEC&#8221;). The SEC maintains a website at http://www.sec.gov
that contains reports, proxy and information statements and other information regarding companies that file electronically with the SEC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
1A. RISK FACTORS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>In
analyzing our company, you should consider carefully the following risk factors, together with all of the other information included
in this Annual Report on Form&#160;10-K. Factors that could cause or contribute to differences in our actual results include those discussed
in the following subsection, as well as those discussed below in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition
and Results of Operations&#8221; and elsewhere throughout this Annual Report on Form&#160;10-K. The following are material factors that
make an investment in our company speculative or risky. The risks and uncertainties described below are not the only ones we face. Additional
risks not currently known to us or other factors not perceived by us to present significant risks to our business at this time also may
impair our business operations.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Risk Factors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are providing the following summary of the risk factors contained in this Annual Report on Form 10-K to enhance the readability and accessibility
of our risk factor disclosures. We encourage you to carefully review the full risk factors contained in this Annual Report on Form 10-K
in their entirety for additional information regarding the material factors that make an investment in our securities speculative or
risky. These risks and uncertainties include, but are not limited to, the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are a clinical-stage
    company and have generated no revenue from commercial sales to date;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have incurred net losses
    in every year since our inception and anticipate that we will continue to incur net losses in the future;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail to obtain additional
    financing, we will be unable to continue or complete our product development or product commercialization and you will likely lose
    your entire investment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are highly dependent on the clinical, regulatory and commercial success of Iomab-B, Actimab-A, Iomab-ACT and other pipeline candidates
    which we may never achieve;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We continuously evaluate
    our business strategy and may modify our strategy as necessary to respond to developments in our business and other factors, and
    any such modification, if not successful, could have a material adverse effect on our business, financial condition, and results
    of operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business could be adversely
    affected by the effects of future health epidemics;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business is subject
    to cybersecurity risk;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have not demonstrated
    that any of our products are safe and effective for any indication and will continue to expend substantial time and resources on
    clinical development before any of our current or future product candidates will be eligible for FDA approval, if ever;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our clinical trials may
    fail to demonstrate adequately the efficacy and safety of our product candidates, which would prevent or delay regulatory approval
    and commercialization;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary, Interim, and
    &#8220;top-line&#8221; data from our clinical trials that we announce or publish from time to time may change as more patient data
    become available and are subject to audit and verification procedures that could result in material changes in the final data.;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">Healthcare legislative reform measures intended to increase
pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the federal regulation of the U.S. healthcare
system could have a material adverse effect our business, future revenue, if any, and results of operations;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in the healthcare industry and in healthcare spending could adversely affect our grant funded clinical programs, business, financial
condition and results of operations</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may rely on third parties
    to conduct certain aspects of our clinical trials. If these third parties do not successfully carry out their contractual duties
    or meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize
    our product candidates;</span></td></tr>
</table><div>

</div><p style="margin: 0pt">&#160;</p><div>

</div><p style="margin: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently depend on
    single third-party manufacturers to produce our pre-clinical and clinical trial drug supplies. Any disruption in the operations of
    our current third-party manufacturers, or other third-party manufacturers we may engage in the future, could adversely affect our
    business and results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our product candidates
    may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory
    approval, limit their commercial potential, or result in significant negative consequences;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our patent position is
    highly uncertain and involves complex legal and factual questions.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The use of hazardous materials,
    including radioactive and biological materials, in our research and development efforts imposes certain compliance costs on us and
    may subject us to liability for claims arising from the use or misuse of these materials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are highly dependent
    on our key personnel, and the demand for&#160;talent in the biotechnology industry is highly competitive; if we are not successful
    in attracting and retaining highly qualified personnel, we may not be able to successfully implement or execute our business strategy;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain provisions of our
    Certificate of Incorporation and Bylaws and Delaware law make it more difficult for a third party to acquire us and make a takeover
    more difficult to complete, even if such a transaction were in our stockholders&#8217; interest; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to utilize
    our net operating loss carryforwards and certain other tax attributes may be limited.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a clinical-stage company and have generated no revenue from commercial sales to date. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company with a limited operating history. We have no products approved for commercial sale and
have not generated any revenue from product sales to date. We will encounter risks and difficulties frequently experienced by early-stage
companies in rapidly evolving fields. If we do not address these risks successfully, our business will suffer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not profitable and have incurred losses in each period since our inception. As of December 31, 2024 and December 31, 2023, we had
an accumulated deficit of $375.8 million and $337.6 million, respectively. We reported a net loss of $38.2 million and $48.8 million
for the years ended December 31, 2024 and 2023, respectively. We expect to continue to operate at a net loss as we continue our research
and development efforts, continue to conduct clinical trials and develop manufacturing, sales, marketing and distribution capabilities.
There can be no assurance that the products under development by us will be approved for sale in the United States or elsewhere. Furthermore,
there can be no assurance that if such products are approved, they will be successfully commercialized, which would have an adverse effect
on our business prospects, financial condition and results of operation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to obtain additional financing, we will be unable to continue or complete our product development and you will likely lose your
entire investment.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of filing this report, we expect that our existing resources will be sufficient to fund our planned operations for more than
12 months following the date of this report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business or operations may change in a manner that would consume available funds more rapidly than anticipated and substantial additional
funding may be required to maintain operations, fund expansion, develop new or enhanced products, acquire complementary products, business
or technologies or otherwise respond to competitive pressures and opportunities, such as a change in the regulatory environment or a
change in preferred cancer treatment modalities. However, we may not be able to secure funding when we need it or on favorable terms
or indeed on any terms. In addition, from time to time, we may not be able to secure enough capital in a timely enough manner which may
cause the generation of a going-concern opinion from our auditors which can and may impair our stock market valuation and also our ability
to finance on favorable terms or indeed on any terms.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable
for our common stock. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per
share that is equal to or greater than the price per share paid by investors, and investors purchasing shares or other securities in
the future could have rights superior to existing stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we cannot raise adequate funds to satisfy our capital requirements, we will have to delay, scale back or eliminate our research and development
activities, clinical studies, or future operations. We may also be required to obtain funds through arrangements with collaborators,
which arrangements may require us to relinquish rights to certain technologies or products that we otherwise would not consider relinquishing,
including rights to future product candidates or certain major geographic markets. We may further have to license our technology to others.
This could result in sharing revenues which we might otherwise have retained for ourselves. Any of these actions may harm our business,
financial condition, and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of funding we will need depends on many factors, including the progress, timing and scope of our product development programs;
the progress, timing and scope of our preclinical studies and clinical trials; the time and cost necessary to obtain regulatory approvals;
the time and cost necessary to further develop manufacturing processes and arrange for contract manufacturing; our ability to enter into
and maintain collaborative, licensing and other commercial relationships; and our partners&#8217; commitment of time and resources to
the development and commercialization of our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have limited access to the capital markets and even if we can raise additional funding, we may be required to do so on unfavorable terms.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited access to the capital markets to raise funds. The capital markets have been unpredictable in the recent past for development
stage radiopharmaceutical and other biotechnology companies and unprofitable companies such as ours. In addition, it is generally difficult
for development-stage companies to raise capital under current market conditions. The amount of capital that a company such as ours is
able to raise often depends on variables that are beyond our control. As a result, we may not be able to secure financing on terms attractive
to us, or at all. If we are able to consummate a financing arrangement, the amount raised may not be sufficient to meet our future needs.
If adequate funds are not available on acceptable terms, or at all, our business, including our technology licenses, results of operations,
financial condition and our continued viability will be materially adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are highly dependent on the clinical, regulatory and commercial success of Actimab-A, Iomab-ACT and other pipeline candidates
which we may never achieve </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the drug candidates we are developing, or have developed, have received regulatory approval. Based on the current status of our pipeline
candidates, it will likely take several years or additional clinical studies before we can seek approval for any drug candidate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Actimab-A drug candidate
was studied in a Phase 2 clinical trial as a monotherapy and we are now studying it in combination with other therapies. We have aligned
with the FDA on an operationally seamless Phase 2/3 trial that is intended to support a BLA filing. There can be no assurance that the
Phase 2 portion of the trial will be successful and support advancing to the Phase 3 portion of the trial. In addition, our Iomab-ACT
drug candidate has only been studied in a limited number of human subjects in a Phase 1 trial with a novel CAR-T therapy. While the initial
results from this trial were encouraging, there can be no assurance that future results with Iomab-ACT from the commercial CAR-T trial
at UTSW or sickle cell conditioning trial at Columbia will be positive.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
for Iomab-B in particular, as previously disclosed, we completed the pivotal Phase 3 SIERRA trial (Study of Iomab-B in Elderly Relapsed
or Refractory AML) and presented the trial results in February 2023, which were expected to support a BLA filing. The SIERRA trial met
the primary endpoint of dCR with statistical significance (p-value&lt;0.0001) but did not meet the secondary endpoint in achieving a
statistically significant improvement in overall survival in the intent to treat population. On August 5, 2024, we announced that the
FDA determined that the SIERRA trial alone is not adequate to support a BLA filing and is requiring an additional randomized head-to-head
clinical trial to demonstrate an overall survival benefit in an intent to treat population. Further, the FDA is also requiring an additional
dose optimization trial to calculate the dose of Iomab-B based on absorbed dose by the bone marrow, rather than the maximum tolerable
dose of 24 Gy of radiation to the liver as was done in the SIERRA trial based on several interactions with the FDA prior to the start
of the SIERRA trial. Based on this revised approach now required by the FDA, the safety and efficacy data generated from all Iomab-B
studies, including the SIERRA trial, are inadequate to seek regulatory approval for Iomab-B, as dosing based on maximum tolerable dose
of 24 Gy to the liver will lead to variable doses to the bone marrow (the target organ), result in underdosing or overdosing of patients
and translate to a global patient safety risk. We are seeking a strategic partner for the U.S. in order to conduct the additional studies
required by the FDA; however, we may not be successful in our efforts to find such a partner, or the trials and studies may not be successful.
Further, there are no assurances that we can satisfy all of the FDA&#8217;s requests, and there could be additional regulatory hurdles
that may result in either non-acceptance or non-approval of a future BLA filing. The U.S. commercial opportunity for Iomab-B may thus
never be realized.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As previously disclosed and noted above, Actinium has licensed to Immedica
the exclusive product rights for commercialization of Iomab-B in the EUMENA region. We are evaluating the impact of the FDA&#8217;s 2024
determination of the SIERRA trial results in the context of global regulatory submissions for Iomab-B. At this time, filings for regulatory
approval, obtaining regulatory approvals, and successful commercialization of Iomab-B in the EUMENA region and on a global basis are highly
uncertain and may never be realized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unable to establish sales, marketing and commercial supply capabilities.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have, nor have we ever had, commercial sales and marketing capabilities. If any of our product candidates ultimately
become approved and we do not secure a commercial partner, we would have to build and establish these capabilities in order to commercialize
our approved product candidates. The process of establishing commercial capabilities will be expensive and time consuming. Even if we
are successful in building sales and marketing capabilities, we may not be successful in commercializing any of our product candidates.
Any delays in commercialization or failure to successfully commercialize any product candidate may have material adverse impacts on our
business and ability to continue operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business could be adversely affected by the effects of future health epidemics.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business could be adversely impacted by the effects of future pandemics, epidemics or infectious disease outbreaks. The full impact of
such an event cannot be predicted at this time, and could depend on numerous factors, including vaccination rates among the population
and the response by governmental bodies and regulators. Given the ongoing and dynamic nature of the circumstances, it is difficult to
predict the impact of a future pandemic on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
future pandemic could adversely affect our clinical trial operations, including our ability to conduct the trials on the expected timelines
and recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure
to a future pandemic if their geography is impacted by the pandemic. Further, future pandemics could result in delays in our clinical
trials due to prioritization of hospital resources toward the pandemic, restrictions in travel, potential unwillingness of patients to
enroll in trials, or the inability of patients to comply with clinical trial protocols if quarantines or travel restrictions are implemented
that impede patient movement or interrupt healthcare services. In addition, we rely on independent clinical investigators, contract research
organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical
studies and clinical trials, and a future pandemic may affect their ability to devote sufficient time and resources to our programs or
to travel to sites to perform work for us, which may result in delays or hinder our ability to collect data from our clinical trials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
a future pandemic may result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions
with IRB&#8217;s or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and contractors
due to limitations in employee resources or forced furlough of government employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business is subject to cybersecurity risks.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are increasingly dependent on information technologies and services. Threats to information technology systems associated
with cybersecurity risks and cyber incidents or attacks continue to grow, and include, among other things, storms and natural disasters,
terrorist attacks, utility outages, theft, viruses, phishing, malware, design defects, human error, and complications encountered as
existing systems are maintained, repaired, replaced, or upgraded. Risks associated with these threats include, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">theft or misappropriation
    of funds;</span></td></tr>
</table><div>

</div><p style="margin: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss, corruption, or misappropriation
    of intellectual property, or other proprietary, confidential or personally identifiable information (including supplier, clinical
    data or employee data);</span></td></tr>
</table><div>

</div><p style="margin: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruption or impairment
    of our and our business operations and safety procedures;</span></td></tr>
</table><div>

</div><p style="margin: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">damage to our reputation
    with our potential partners, patients and the market;</span></td></tr>
</table><div>

</div><p style="margin: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exposure to litigation;</span></td></tr>
</table><div>

</div><p style="margin: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased costs to prevent,
    respond to or mitigate cybersecurity events.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we utilize various procedures and controls to mitigate our exposure to such risk, cybersecurity attacks and other cyber events are evolving
and unpredictable. Moreover, we have no control over the information technology systems of third parties conducting our clinical trials,
our suppliers, and others with which our systems may connect and communicate. As a result, the occurrence of a cyber incident could go
unnoticed for a period time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have cybersecurity insurance coverage in the event we become subject to various cybersecurity attacks, however, we cannot ensure that
it will be sufficient to cover any particular losses we may experience as a result of such cyberattacks. Any cyber incident could have
a material adverse effect on our business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Regulation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
FDA, EMA or comparable foreign regulatory authorities may disagree with our regulatory plans and we may fail to obtain regulatory approval
of our product candidates.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products are subject to rigorous regulation by the FDA, EMA and numerous other federal, state and foreign governmental authorities. The
process of seeking regulatory approval to market an antibody radiation-conjugate product is expensive and time-consuming, and, notwithstanding
the effort and expense incurred, approval is never guaranteed. If we are not successful in obtaining timely approval of our products
from the regulators, we may never be able to generate significant revenue and may be forced to cease operations. In particular, the FDA
permits commercial distribution of a new antibody radiation-conjugate product only after a BLA for the product has received FDA approval.
The BLA process is costly, lengthy and inherently uncertain. Any BLA filed by us will have to be supported by extensive data, including,
but not limited to, technical, preclinical, clinical trial, chemistry, manufacturing and controls and labeling data, to demonstrate to
the FDA&#8217;s satisfaction the safety and efficacy of the product for its intended use. The lengthy approval process as well as the
unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates,
which would significantly harm our business, results of operations and prospects. In addition, even if we were to obtain approval, regulatory
authorities may approve any of our product candidates for fewer or more limited indications than we request, may not obtain the price
we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may
approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization
of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">For instance, as for Iomab-B, despite the Phase SIERRA 3 trial meeting
the primary endpoint of durable Complete Remission (dCR) with statistical significance (p-value&lt;0.0001), the FDA has determined that
demonstrating an overall survival benefit in a randomized head-to-head trial is required for a BLA filing. In addition, the FDA is also
requiring that an additional dose optimization trial demonstrating safety and efficacy be completed to calculate the dose of Iomab-B based
on absorbed dose by the bone marrow, rather than the maximum tolerable dose of 24 Gy of radiation to the liver as was done in the SIERRA
trial based on several interactions we had with the FDA before starting the SIERRA trial. The head-to-head Phase 3 trial will evaluate
allogeneic bone marrow transplant (BMT) using Iomab-B plus a reduced intensity conditioning regimen of fludarabine and total body irradiation
(Flu/TBI) versus allogeneic BMT using reduced intensity conditioning comprised of cyclophosphamide plus Flu/TBI. This is different from
the SIERRA trial, which allowed physician&#8217;s choice of salvage therapies and heterogenous conditioning regimens in the control arm.
However, there are no assurances that the additional trials will be successful or that we can satisfy all of the FDA&#8217;s requests.
There could also be additional regulatory hurdles that may result in either non-acceptance or non-approval of a future BLA filing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As previously disclosed and noted above, Actinium has licensed to Immedica
the exclusive product rights for commercialization of Iomab-B in the EUMENA region. We are evaluating the impact of the FDA&#8217;s 2024
determination of the SIERRA trials results referred to above in the context of global regulatory submission for Iomab-B. At this time,
filings for regulatory approval, obtaining regulatory approvals, and successful commercialization of Iomab-B in the EUMENA region and
on a global basis are highly uncertain and may never be realized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also evaluating Iomab-ACT, which uses a lower dose I-131 for conditioning prior to cellular therapies such as CAR-T and gene therapies.
We are currently studying Iomab-ACT in three clinical trials including two investigator sponsored studies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Actimab-A (lintuzumab-Ac-225)
product candidate has also been studied in several Phase 1 and 2 trials under our sponsorship and investigator-initiated trials in patients
with r/r AML and we plan to continue to study Actimab-A in clinical trials. Actimab-A is also being developed under a cooperative research
and development agreement (CRADA) with the National Cancer Institute (NCI) and we expect clinical trials to be initiated that will study
Actimab-A as a single agent or in combination with other therapies. Product candidates utilizing the lintuzumab antibody would require
BLA approval before they can be marketed in the United States. We are in the early stages of evaluating other product candidates consisting
of conjugates of Ac-225 with human or humanized antibodies for pre-clinical and clinical development in other types of cancer. The FDA
may not approve these products for the indications that are necessary or desirable for successful commercialization. The FDA may fail
to approve any BLA we submit for new product candidates or for new intended uses or indications for approved products or future product
candidates. Failure to obtain FDA approval for our products in the proposed indications would have a material adverse effect on our business
prospects, financial condition and results of operations.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
approval process in the United States and in other countries could result in unexpected and significant costs for us and consume management&#8217;s
time and other resources. The FDA, EMA and other foreign regulatory agencies could ask us to supplement our submissions, collect non-clinical
data, conduct additional clinical trials or engage in other time-consuming actions, or it could simply deny our applications. In addition,
even if we obtain approval to market our products in the United States or in other countries, the approval could be revoked, or other
restrictions imposed if post-market data demonstrates safety issues or lack of effectiveness. We cannot predict with certainty how, or
when, the FDA, EMA or other regulatory authorities will act. If we are unable to obtain the necessary regulatory approvals, our financial
condition and cash flow may be materially adversely affected, and our ability to grow domestically and internationally may be limited.
Additionally, even if we obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited
indications that we request. The Company&#8217;s products may not be approved for the specific indications that are most necessary or
desirable for successful commercialization or profitability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have not demonstrated that any of our products are safe and effective for any indication and will continue to expend substantial time
and resources on clinical development before any of our current or future product candidates will be eligible for FDA approval, if ever.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that a substantial portion of our efforts and expenditures over the next few years will be devoted to development of our existing
and contemplated biological product candidates. Accordingly, our business currently depends heavily on the successful development, FDA
approval, and commercialization of such candidates, which may never receive FDA approval or be successfully commercialized even if FDA
approval is received. The research, testing, manufacturing, labeling, approval, sale, marketing, and distribution of our biological product
candidates are, and will remain, subject to extensive regulation by the FDA and other regulatory authorities in the United States and
other countries, as applicable. We are currently not permitted to market any of our current or future product candidates in the United
States until we receive FDA approval (of each) via the BLA process. To date, we have three product candidates in clinical development
and have not-yet submitted a BLA for any of our candidates and, for many such candidates, do not expect to be in a position to do so
for the foreseeable future, as there are numerous developmental steps that must be completed before we can prepare and submit a BLA.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates pharmaceutical and biological product candidates under the FDCA and the Public Health Service Act
(&#8220;PHSA&#8221;), as well as their respective implementing regulations. Such products and product candidates are also subject to
other federal, state, and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance
with appropriate federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial
resources. The process required by the FDA before a drug or biological product may be marketed in the United States generally involves
the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion of preclinical
    laboratory tests and animal studies in accordance with FDA&#8217;s good laboratory practices (&#8220;GLPs&#8221;) and applicable
    requirements for the humane use of laboratory animals or other applicable regulations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of
    an Investigational New Drug (&#8220;IND&#8221;), which must become effective before human clinical trials in the United States may
    begin;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance of adequate
    and well-controlled human clinical trials in accordance with FDA&#8217;s IND regulations, good clinical practices (&#8220;GCPs&#8221;),
    and any additional requirements for the protection of human research subjects and their health information, to establish the safety
    and efficacy of the proposed biological product for its intended use;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of
    a BLA for marketing approval that meets applicable requirements to ensure the continued safety, purity, and potency of the product
    that is the subject of the BLA based on results of preclinical testing and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory completion
    of an FDA inspection of the manufacturing facility or facilities where the biological product is produced, to assess compliance with
    current good manufacturing practices (&#8220;cGMPs&#8221;) and assure that the facilities, methods and controls are adequate to preserve
    the biological product&#8217;s identity, strength, quality and purity;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential FDA audit of
    the nonclinical study and clinical trial sites that generated the data in support of the BLA; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA review and approval,
    or denial, of the BLA.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
testing any biological product candidate in humans, the product candidate enters the preclinical testing stage. Preclinical tests include
laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity
of the product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs.
The clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data,
any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may
continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises
concerns or questions regarding the proposed clinical trials and places the trial on a clinical hold within that 30-day time period.
In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also
impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns or non-compliance.
If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA.
Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin or that, for those
that have already commenced under an active IND, that issues will not arise that suspend or terminate such trials.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical trials
involve the administration of the biological product candidate to healthy volunteers or patients under the supervision of qualified investigators,
generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials are conducted under protocols detailing,
among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters
to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events
should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must
be conducted and monitored in accordance with the FDA&#8217;s regulations composing the GCP requirements, including the requirement that
all research subjects provide informed consent. Further, each clinical trial must be reviewed and approved by an independent institutional
review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting
the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical
trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed
consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until
completed. Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 1. The biological
    product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening
    diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human
    testing is often conducted in subjects.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 2. The biological
    product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate
    the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 3. Clinical trials
    are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically
    dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product
    and provide an adequate basis for product labeling.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-approval
clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical
trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for
long-term safety follow-up.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the completion of clinical trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the
biological product. The BLA must include results of product development, laboratory and animal studies, human trials, information on
the manufacture and composition of the product, proposed labeling and other relevant information. The FDA may grant deferrals for submission
of data, or full or partial waivers. The testing and approval processes require substantial time and effort and there can be no assurance
that the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all. Before
approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless
it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent
production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or
more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements.
To assure cGMP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training,
record keeping, production, and quality control.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria
for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently
than we interpret the same data. We cannot predict with any certainty if or when we might submit a BLA for regulatory approval for our
product candidates or whether any such BLA will be approved by the FDA. Human clinical trials are very expensive and difficult to design
and implement, in part because they are subject to rigorous regulatory requirements. For example, the FDA may not agree with our proposed
endpoints for any clinical trial we propose, which may delay the commencement of our clinical trials. The clinical trial process is also
lengthy and requires substantial time and effort.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the clinical trials we need to conduct to be in a position to submit BLAs for our product candidates currently in-development
will take, at least, several years to complete. Moreover, failure can occur at any stage of the trials, and we could encounter problems
that cause us to abandon or repeat clinical trials. Also, the results of early preclinical and clinical testing may not be predictive
of the results of subsequent clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks
in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier studies,
and preclinical and clinical data are often susceptible to multiple interpretations and analyses. Many companies that have believed their
product candidates performed satisfactorily in preclinical studies and clinical trials have, nonetheless, failed to obtain marketing
approval of their products. Success in preclinical testing and early clinical trials does not ensure that later clinical trials, which
involve many more subjects, and the results of later clinical trials may not replicate the results of prior clinical trials and preclinical
testing. Any failure or substantial delay in our product development plans may have a material adverse effect on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may encounter substantial delays in our clinical trials or may not be able to conduct our trials on the timelines we expect.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict whether we will encounter problems with any of our ongoing or planned clinical trials that will cause us or regulatory
authorities to delay, suspend, or discontinue clinical trials or to delay the analysis of data from ongoing clinical trials. Any of the
following could delay or disrupt the clinical development of our product candidates and potentially cause our product candidates to fail
to receive regulatory approval:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 19.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions imposed on us
    by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in receiving, or
    the inability to obtain, required approvals from IRBs or other reviewing entities at clinical sites selected for participation in
    our clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in enrolling patients
    into clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a lower than anticipated
    retention rate of patients in clinical trials;</span></td></tr>
</table><div>

</div><p style="margin: 0pt">&#160;</p><div>

</div><p style="margin: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the need to repeat or discontinue
    clinical trials as a result of inconclusive or negative results or unforeseen complications in testing or because the results of
    later trials may not confirm positive results from earlier preclinical studies or clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequate supply, delays
    in distribution, deficient quality of, or inability to purchase or manufacture drug product, comparator drugs or other materials
    necessary to conduct our clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable FDA or other
    foreign regulatory inspection and review of a clinical trial site or records of any clinical or preclinical investigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">serious and unexpected
    drug-related side effects experienced by participants in our clinical trials, which may occur even if they were not observed in earlier
    trials or only observed in a limited number of participants;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a finding that the trial
    participants are being exposed to unacceptable health risks;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the placement by the FDA
    or a foreign regulatory authority of a clinical hold on a trial; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in obtaining regulatory
    agency authorization for the conduct of our clinical trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may suspend, or the FDA or other applicable regulatory authorities may require us to suspend, clinical trials of a product candidate
at any time if we or they believe the patients participating in such clinical trials, or in independent third-party clinical trials for
drugs based on similar technologies, are being exposed to unacceptable health risks including but not limited to unacceptable or suboptimal
factors related to toxicity, clinical efficacy, imbalances in safety and efficacy profiles or for other reasons.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further, individuals
involved with our clinical trials may serve as consultants to us from time to time and receive stock options or cash compensation in
connection with such services. If these relationships and any related compensation to the clinical investigator carrying out the study
result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected interpretation
of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical
trial itself may be jeopardized. The delay, suspension or discontinuation of any of our clinical trials, or a delay in the analysis of
clinical data for our product candidates, for any of the foregoing reasons, could adversely affect our efforts to obtain regulatory approval
for and to commercialize our product candidates, increase our operating expenses and have a material adverse effect on our financial
results.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials may also be delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended
or terminated by us, the FDA, the IRBs at the sites where the IRBs are overseeing a trial, or a data safety monitoring board, or DSMB
(Data Safety Monitoring Board)/DMC (Data Monitoring Committee), overseeing the clinical trial at issue, or other regulatory authorities
due to a number of factors, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 19.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to conduct the
    clinical trial in accordance with regulatory requirements or our clinical protocols;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inspection of the clinical
    trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">varying interpretation
    of data by the FDA or similar foreign regulatory authorities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to achieve primary
    or secondary endpoints or other failure to demonstrate efficacy;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen safety issues;
    or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack of adequate funding
    to continue the clinical trial.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Modifications
to our product candidates may require federal approvals.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
BLA application is the vehicle through which the company may formally propose that the FDA approve a new pharmaceutical for sale and
marketing in the United States. Once a particular product candidate receives FDA approval, expanded uses or uses in new indications of
our products may require additional human clinical trials and new regulatory approvals, including additional IND and BLA submissions
and premarket approvals before we can begin clinical development, and/or prior to marketing and sales. If the FDA requires new approvals
for a particular use or indication, we may be required to conduct additional clinical studies, which would require additional expenditures
and harm our operating results. If the products are already being used for these new indications, we may also be subject to significant
enforcement actions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conducting
clinical trials and obtaining approvals is a time-consuming process, and delays in obtaining required future approvals could adversely
affect our ability to introduce new or enhanced products in a timely manner, which in turn would have an adverse effect on our business
prospects, financial condition and results of operation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
trials necessary to support approval of our product candidates are time-consuming and expensive. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initiating
and completing clinical trials necessary to support FDA approval of a BLA for Iomab-B, Actimab-A, and other product candidates, is a
time-consuming and expensive process, and the outcome is inherently uncertain. Moreover, the results of early clinical trials are not
necessarily predictive of future results, and any product candidate we advance into clinical trials may not have favorable results in
later clinical trials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">For instance, we worked with
the FDA to develop the SIERRA clinical trial to test the safety and efficacy of Iomab-B in patients with r/r AML who are aged 55 and above
prior to a BMT. Even though the SIERRA trial met the primary endpoint of dCR with statistical significance (p-value&lt;0.0001), the FDA
has determined that the analyses from the SIERRA trial do not support a BLA filing for Iomab-B. The FDA now requires an additional head-to-head
Phase 3 clinical study. We have further discussed the specifics of this additional clinical trial with the FDA. Based on these discussions,
Actinium believes it has aligned with the FDA on the patient population for this additional clinical trial, which can include all adult
patients aged 18 and above with active AML with blasts counts greater than 5% and less than 20%. This is a broader patient population
than the patients enrolled on the SIERRA trial, which only enrolled patients aged 55 and above. Further, the FDA is also requiring that
an additional dose optimization trial demonstrating safety and efficacy be completed to calculate the dose of Iomab-B based on absorbed
dose by the bone marrow, rather than the maximum tolerable dose of 24 Gy of radiation to the liver as was done in the SIERRA trial based
on several interactions we had with the FDA before starting the SIERRA trial. We are seeking a strategic partner for Iomab-B in the U.S.
to advance these additional trials. Even if we are able to secure a partner, there are no assurances that the additional trials will be
successful or that we can satisfy all of the FDA&#8217;s requests. There could also be additional regulatory hurdles that may result in
either non-acceptance or non-approval of a future BLA.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preliminary,
Interim, and &#8220;top-line&#8221; data from our clinical trials that we announce or publish from time to time may change as more patient
data become available and are subject to audit and verification procedures that could result in material changes in the final data.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may publicly disclose preliminary, interim, and top-line data from our clinical trials, which is based on a preliminary
analysis of then-available data, and the results and related findings and conclusions are subject to change as more patient data become
available or following a more comprehensive review of the data related to the particular study or trial. We may also make assumptions,
estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully
and carefully evaluate all data. Our clinical trials may be open label studies and certain of our clinical development and or operations
staff may review interim or preliminary safety or efficacy data during routine data collection, cleaning and analysis from time to time.
Interim or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations
may qualify such results once additional data have been received and fully evaluated. Preliminary, interim or top-line data also remain
subject to audit and verification procedures that may result in the final data being materially different from the top-line, interim
or preliminary data we previously published. As a result, top-line, interim and preliminary data should be viewed with caution until
the final data are available.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that
we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues
and more patient data become available. Adverse differences between interim data and final data could significantly harm our business
prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, or analyses
or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability
or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose
to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others
may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the interim, top-line or preliminary data that we report differ from final results, or if others, including regulatory authorities, disagree
with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could
harm our business, operating results, prospects or financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
clinical trials may fail to demonstrate adequately the efficacy and safety of our product candidates, which would prevent or delay regulatory
approval and commercialization.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if our clinical trials are completed as planned, we cannot be certain that their results will support our product candidate claims or
that the FDA or foreign authorities will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical
trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the
results of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates are
safe and effective for the proposed indicated uses. If FDA concludes that the clinical trials for Actimab-A, Iomab-ACT, or any
other product candidate for which we might seek approval, have failed to demonstrate safety and effectiveness, we would not receive FDA
approval to market that product candidate in the United States for the indications sought. In addition, such an outcome could cause us
to abandon the product candidate and might delay the development of others. Any delay or termination of our clinical trials will delay
or preclude the filing of any submissions with the FDA and, ultimately, our ability to commercialize our product candidates and generate
revenues. It is also possible that patients enrolled in clinical trials will experience adverse side effects that are not currently part
of a product candidate&#8217;s profile.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
intellectual property related to antibodies we have licensed has expired or likely expired.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key patents related to the humanized antibody, lintuzumab, which we use in our Actimab-A product candidate have expired. It is generally
possible that others may be eventually able to use an antibody with the same sequence, and we will then need to rely on additional patent
protection covering alpha particle drug products comprising Ac-225. Our final drug construct, Actimab-A, consists of the lintuzumab antibody
labeled with the isotope Ac-225. We currently own issued and pending patents relating to methods of manufacturing Actimab-A, methods
of treatment using Actimab-A and production of the Ac-225 isotope. In addition, we possess trade secrets and know how related to the
manufacturing and use of isotopes. Any competing product based on the lintuzumab antibody is likely to require several years of development
before achieving our product candidate&#8217;s current status and may be subject to significant regulatory hurdles but such development
by others is nevertheless a possibility that could negatively impact our business in the future. We own 4 issued U.S. patents, 2 issued
Canadian patents, 1 issued European patent (validated as a national patent in several countries) and 1 issued Japanese patent that relate
to the composition of our Iomab-B product candidate. Patent applications relating to Iomab-B are also pending in the U.S. and internationally.
We have and may continue to file patents related to Iomab-B that can provide barriers to entry but there is no certainty that these patents
will be granted or such granting thereof will adequately prevent others from seeking to replicate and use the apamistamab antibody or
the construct. Our patent portfolio includes pending applications related to radioimmunoconjugate composition, formulation administration,
and methods of use in treating solid or liquid cancers. This subject matter includes composition, administration, and methods of treatment
for our product candidates Actimab-A and Iomab-B. Any competing product based on the antibody used in Iomab-B is likely to require several
years of development before achieving our product candidate&#8217;s current status and may be subject to significant regulatory hurdles.
Further, if approved, Iomab-B would be entitled to 12 years of market exclusivity in the U.S. and 10 years in Europe, during which time
no generic biologic or biosimilar referencing Iomab-B can be granted marketing approval.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Actimab-A program clinical trials are
testing the same drug construct. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Actimab-A program is
comprised of several clinical trials conducted under the CRADA with NCI, Actinium sponsored trials, investigator-initiated trials in
AML and other myeloid indications and solid tumors that will study the same drug construct consisting of lintuzumab-Ac-225. Negative
results from any of these trials could negatively impact our ability to enroll or complete our other trials studying lintzumab-Ac-225,
including future studies conducted under our CRADA with the NCI. Additionally, negative outcomes including safety concerns, may result
in the FDA requiring amendment to certain clinical trials, placing a clinical hold on certain or all clinical trials or discontinuing
other trials utilizing lintuzumab-Ac-225.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We are currently developing, and in the future may develop, product
candidates in combination with other therapies and that may expose us to additional risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are currently developing, and may develop future
product candidates, for use in combination with one or more currently approved therapies. For example, Actimab-A is expected to be tested
in combination with KEYTRUDA<sup>&#174;</sup> and OPDIVO<sup>&#174;</sup> for treating HNSCC and NSCLC. If any of the approved therapies
we currently or may, in the future, use in combination with a current or future product candidate is found defective, removed from the
market, or otherwise becomes unavailable, our clinical trials may face significant delays, be suspended, or terminated. Any such events
would likely have a material impact on our operations and the development of the affected product candidate(s) and may ultimately prevent
the approval of such product candidate or render continued development efforts too costly to proceed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Even if a current or future product candidate were
to receive FDA approval to be commercialized in the U.S. for use in combination with one or more existing therapies, we would continue
to be subject to the risk that the FDA or similar foreign regulatory authorities could revoke approval of the therapy used in combination
with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with any such existing therapies. This
could result in our own products being removed from the market or cause material delays in, or the suspension or discontinuation, of our
production and/or distribution of the applicable product, as our ability to market any such product will be limited to the extent specified
in the FDA&#8217;s approval, if granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unable to obtain a sufficient supply of isotopes to support clinical development or at commercial scale.&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Iodine-131
is a key component of our Iomab-B drug candidate. We source medical grade I-131 from multiple suppliers, including two leading global
manufacturers. Currently, we believe there is sufficient supply of I-131 to support additional trials we may undertake utilizing I-131
and for future commercialization of potential I-131 based products. We continually evaluate I-131 manufacturers and suppliers. While
we consider I-131 to be commoditized and obtainable through several suppliers, there can be no guarantee that we will be able to secure
I-131 or obtain I-131 on terms that are acceptable to us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium-225 is a key component of our Actimab-A product candidate, technology
platform, preclinical R&amp;D programs and other drug candidates that we might consider for development with the Ac-225 payload. We have
secured multiple suppliers that are expected to provide cGMP Ac-225 for our planned clinical trials. There are adequate quantities of
Ac-225 available today to meet our current needs via our present supplier, the Department of Energy (&#8220;DOE&#8221;), who has been
our primary supplier of Ac-225 historically. The Ac-225 currently supplied for our clinical trials from the DOE is derived from the natural
decay of thorium-229 from so-called &#8216;thorium-cows&#8217; and is able to produce sufficient quantities that are several multiples
of the amount of Ac-225 we require to supply our clinical programs through to early commercialization phase. The DOE is also producing
Ac-225 from a recently developed alternative route for Ac-225 production via a linear accelerator that is currently being evaluated by
us. Initial preclinical and modelling results have indicated that the linear accelerator sourced Ac-225 does not impact labelling efficiency
and expected distribution. In accordance with representations made by the DOE, the capacity of Ac-225 from this route is expected to
be sufficient to supply all of Actinium&#8217;s pipeline and commercial Ac-225 needs and support new program expansion by not just Actinium
but also other companies that are developing Ac-225 based products. Additional routes of Ac-225 production are being pursued by the DOE
including the generation of new thorium cows and production via a cyclotron. The cyclotron production method for Ac-225 production leverages
Actinium&#8217;s proprietary technology and know-how and presents an additional path towards production of high-quality Ac-225 at a scale
that would be able to satisfy commercial needs. In addition, we are aware of at least ten other government and non-government entities
globally including the U.S., Canada, Russia, Belgium, France and Japan that have, or expect to have ability to supply Ac-225 or equipment
for its production within the timeframes relevant to the potential first commercial approval of our Ac-225-based drug candidate.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
contract for supply of this isotope from the DOE must be renewed yearly, and we renewed our contract to extend through the end of 2025.
While we expect this contract will continue to be renewed at the end of its term as it has since 2009, there can be no assurance that
the DOE will renew the contract or that change its policies that allow for the sale of isotope to us. There can be no assurance that
the DOE or our other suppliers will be able to supply all of the quantities of Ac-225 we request in the future. Failure to acquire sufficient
quantities of medical grade Ac-225 would make it impossible to effectively complete clinical trials and to commercialize any Ac-225 based
drug candidates that we may develop and would materially harm our business.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to conduct clinical trials to advance our drug candidates is dependent on our ability to obtain the radioisotopes I-131, Ac-225
and other isotopes we may choose to utilize in the future. Currently, we are dependent on third party manufacturers and suppliers for
our isotopes. These suppliers may not perform their contracted services or may breach or terminate their agreements with us. Our suppliers
are subject to regulations and standards that are overseen by regulatory and government agencies and we have no control over our suppliers&#8217;
compliance to these standards. Failure to comply with regulations and standards may result in their inability to supply isotopes and
could result in delays in our clinical trials, which could have a negative impact on our business. We have developed intellectual property,
know-how and trade secrets related to the manufacturing process of Ac-225. While we have manufactured medical grade Ac-225 of a purity
compared to the cyclotron sourced material in the past, this activity was terminated due to operating cost reasons, and we currently
do not have experience in manufacturing medical grade Ac-225 and may not obtain the resources necessary to establish our own manufacturing
capabilities in the future. Our inability to build out and establish our own manufacturing facilities would require us to continue to
rely on third party suppliers as we currently do. However, based on our current third-party suppliers and potential future suppliers
of Ac-225 we expect to have adequate isotope supply to support our current ongoing clinical trials, current and planned preclinical R&amp;D
activities and commercialization should our drug candidates receive regulatory approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise
adversely affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timely completion of clinical trials in accordance with their protocols depends on our ability to enroll a sufficient number of patients
who remain in the trial until its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety
of reasons, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size and nature of
    the patient population;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the patient eligibility
    criteria defined in the protocol;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size of the study population
    required for analysis of the trial&#8217;s primary endpoints;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the proximity of patients
    to trial sites;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the design of the trial;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to recruit
    clinical trial investigators with the appropriate competencies and expertise;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing clinical trials
    for similar or alternate therapeutic treatments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinician&#8217;s and patients&#8217;
    perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available
    therapies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and
    maintain patient consents; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the risk that patients
    enrolled in clinical trials will not complete a clinical trial.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, refractory patients, which several of our trials have or are expected to enroll, participating in clinical trials are seriously
and often terminally ill and therefore may not complete the clinical trial due to reasons including comorbid conditions or occurrence
of adverse medical events related or unrelated to the investigational products, or death. Even if we are able to enroll a sufficient
number of patients in our clinical trials, delays in patient enrollment will result in increased costs or affect the timing of our planned
trials, which could adversely affect our ability to advance the development of our product candidates.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>FDA
may take actions that would prolong, delay, suspend, or terminate clinical trials of our product candidates, which may delay or prevent
us from commercializing our product candidates on a timely basis.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that the data generated in our clinical trials will be acceptable to FDA or that if future modifications during the
trial are necessary, that any such modifications will be acceptable to FDA. Certain modifications to a clinical trial protocol made during
the course of the clinical trial have to be submitted to the FDA. This could result in the delay or halt of a clinical trial while the
modification is evaluated. In addition, depending on the quantity and nature of the changes made, FDA could take the position that some
or all of the data generated by the clinical trial is not usable because the same protocol was not used throughout the trial. This might
require the enrollment of additional subjects, which could result in the extension of the clinical trial and the FDA delaying approval
of a product candidate. If the FDA believes that its prior approval is required for a particular modification, it can delay or halt a
clinical trial while it evaluates additional information regarding the change.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delay or termination of our current or future clinical trials as a result of the risks summarized above, including delays in obtaining
or maintaining required approvals from IRBs, delays in patient enrollment, the failure of patients to continue to participate in a clinical
trial, and delays or termination of clinical trials as a result of protocol modifications or adverse events during the trials, may cause
an increase in costs and delays in the filing of any submissions with the FDA, delay the approval and commercialization of our product
candidates or result in the failure of the clinical trial, which could adversely affect our business, operating results and prospects.
Lengthy delays in obtaining regulatory approval for Iomab-B or completion of our ongoing or planned clinical trials would adversely affect
our business and prospects and could cause us to cease operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have obtained orphan drug designation from FDA for two of our current product candidates and intend to pursue such designation for other
candidates and indications in the future, but we may be unable to obtain such designations or to maintain the benefits associated with
any orphan drug designations we have received or may receive in the future.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have received orphan drug
designation for Actimab-A and Iomab-B for treatment of AML in both the United States and the EU. Under the Orphan Drug Act, the FDA may
grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects
fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States, there is no
reasonable expectation that the cost of developing and making available a drug or biologic for this type of disease or condition will
be recovered from sales in the United States for that drug or biologic. Similarly, the EMA grants orphan drug designation to promote the
development of products that are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating
condition affecting not more than five in 10,000 persons in the EU.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orphan drug designation neither shortens
the development time or regulatory review time of a drug or biologic nor gives the drug or biologic any advantage in the regulatory review
or approval process. In the United States, orphan drug designation entitles a party to financial incentives, such as opportunities for
grant funding towards clinical trial costs, tax advantages, and application fee waivers. In addition, if a product candidate receives
the first FDA approval for the indication for which it has orphan designation, such product is entitled, upon approval, to seven years
of orphan-drug exclusivity, during which the FDA may not approve any other application to market the same drug for the same indication,
unless a subsequently approved product is clinically superior to orphan drug or where the manufacturer is unable to assure sufficient
product quantity in the applicable patient population. In the EU, orphan drug designation entitles a party to financial incentives such
as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This period may
be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently
profitable not to justify maintenance of market exclusivity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain (or have obtained) orphan drug designation for certain product candidates, we may not be the first to obtain marketing approval
for such candidates for the applicable indications due to the uncertainties inherent in the development of novel biologic products, and,
an orphan drug candidate may not receive orphan-drug exclusivity upon approval if such candidate is approved for a use that is broader
than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost
if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient
quantities of the product to meet the needs of patients with the rare disease or condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finally,
even if we successfully obtain orphan-drug exclusivity for an orphan drug candidate upon approval, such exclusivity may not effectively
protect the product from competition because (i) different drugs with different active moieties can be approved for the same condition;
and (ii) the FDA or EMA can also subsequently approve a subsequent product with the same active moiety and for the same indication as
the orphan drug if the later-approved drug if deemed clinically superior to the orphan drug.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory
review.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product
candidate. The FDA may also require a REMS in order to approve our product candidates, which could entail requirements for a medication
guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries
and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates,
the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export
and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include
submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and
GCPs for any clinical trials that we conduct post-approval. In addition, the FDA could require us to conduct another study to obtain
additional safety or biomarker information. Later discovery of previously unknown problems with our product candidates, including adverse
events of unanticipated severity or frequency, or with our third-party suppliers or manufacturing processes, or failure to comply with
regulatory requirements, may result in, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on the marketing
    or manufacturing of our product candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines, warning letters
    or holds on clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal by the FDA to approve
    pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product seizure or detention,
    or refusal to permit the import or export of our product candidates; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions or the imposition
    of civil or criminal penalties.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could
prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government
regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or
unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain
regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Coverage
and reimbursement may be limited or unavailable in certain market segments for our product candidates which could limit our sales of
our product candidates, if approved.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commercial success of our product candidates in both domestic and international markets will be substantially dependent on whether third-party
coverage and reimbursement is available for patients that use our products. However, the availability of insurance coverage and reimbursement
for newly approved cancer therapies is uncertain, and therefore, third-party coverage may be particularly difficult to obtain even if
our products are approved by the FDA as safe and efficacious. Patients using existing approved therapies are generally reimbursed all
or part of the product cost by Medicare or other third-party payors. Medicare, Medicaid, health maintenance organizations and other third-party
payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new drugs,
and, as a result, they may not cover or provide adequate payment for these products. Submission of applications for reimbursement approval
generally does not occur prior to the filing of a BLA for that product and may not be granted until many months after BLA approval. In
order to obtain coverage and reimbursement for these products, we or our commercialization partners may have to agree to a net sales
price lower than the net sales price we might charge in other sales channels. The continuing efforts of government and third-party payors
to contain or reduce the costs of healthcare may limit our revenue. Initial dependence on the commercial success of our products may
make our revenues particularly susceptible to any cost containment or reduction efforts.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
legislative reform measures intended to increase pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise,
affect the federal regulation of the U.S. healthcare system could have a material adverse effect our business, future revenue, if any,
and results of operations.</i>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, there have been a number of legislative and regulatory initiatives focused on containing the cost of healthcare. The
Affordable Care Act, for example, substantially changed the way healthcare is financed by both governmental and private insurers. The
Affordable Care Act contains a number of provisions that could impact our business and operations, primarily, once we obtain FDA approval
to commercialize one of our product candidates in the United States, if ever, and may also affect our operations in ways we cannot currently
predict. Affordable Care Act provisions that may affect our business include, among others, those governing enrollment in federal healthcare
programs, reimbursement changes, rules regarding prescription drug benefits under health insurance exchanges, expansion of the 340B program,
expansion of state Medicaid programs, fees and increased discount and rebate obligations, transparency and reporting requirements, and
fraud and abuse enforcement. Such changes may impact existing government healthcare programs, industry competition, formulary composition,
and may result in the development of new programs, including Medicare payment for performance initiatives, health technology assessments,
and improvements to the physician quality reporting system and feedback program.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been significant
judicial, administrative, executive, and legislative initiatives to modify, limit, replace, or repeal the Affordable Care Act since its
enactment. For example, during his first term, former President Trump issued several Executive Orders and other directives designed to
delay the implementation of certain provisions of the Affordable Care Act or otherwise circumvent some of the requirements for health
insurance mandated by the Affordable Care Act. Concurrently, Congress considered legislation that would repeal or replace all or part
of the Affordable Care Act. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation
the Affordable Care Act have been passed. For example, the Tax Cuts and Jobs Act of 2017 eliminated the Affordable Care Act provision
requiring individuals to purchase and maintain health coverage, or the &#8220;individual mandate,&#8221; by reducing the associated penalty
to zero, beginning in 2019. In December 2018, a district court in Texas held that the individual mandate is unconstitutional and that
the rest of the Affordable Care Act is, therefore, invalid. On appeal, the Fifth Circuit Court of Appeals affirmed the holding on the
individual mandate but remanded the case back to the lower court to reassess whether and how such holding affects the validity of the
rest of the Affordable Care Act. The Fifth Circuit&#8217;s decision on the individual mandate was appealed to the U.S. Supreme Court.
On June 17, 2021, the Supreme Court held that the plaintiffs (comprised of the state of Texas, as well as numerous other states and certain
individuals) did not have standing to challenge the constitutionality of the Affordable Care Act&#8217;s individual mandate and, accordingly,
vacated the Fifth Circuit&#8217;s decision and instructed the district court to dismiss the case. As a result, the Affordable Care Act
remained in effect in its then-current form; however, we cannot predict what additional challenges may arise in the future, the outcome
thereof, or the impact any such actions may have on our business. This uncertainty has become even greater given the new Trump administration
and its proposed agenda.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the Affordable Care Act, there have been numerous other Congressional initiatives and proposed and enacted federal and state
legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer
patient programs, and reform government program reimbursement methodologies for drug products. Pharmaceutical product prices have been
the focus of increased scrutiny by the government, including certain state attorneys general, members of Congress and the United States
Department of Justice. State or federal healthcare reform measures or other social or political pressure to lower the cost of pharmaceutical
products could have a material adverse impact on our business, results of operations and financial condition.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Biden administration also
introduced various measures in 2021 focusing on healthcare and drug pricing, in particular. For example, on January 28, 2021, former President
Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through
the Affordable Care Act marketplace, which began on February 15, 2021, and remained open through August 15, 2021. The executive order
also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare,
including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements and policies that
create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. On the legislative
front, the American Rescue Plan Act of 2021 was signed into law on March 11, 2021, which, in relevant part, eliminates the statutory Medicaid
drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source drugs and innovator multiple source
drugs, which began on January 1, 2024. And, in July 2021, the Biden administration released an executive order entitled, &#8220;Promoting
Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response, on September 9, 2021, HHS
released a &#8220;Comprehensive Plan for Addressing High Drug Prices&#8221; that outlines principles for drug pricing reform and sets
out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to
advance these principles.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">More recently, on August 16,
2022, former President Biden signed into law the&#160;Inflation&#160;Reduction&#160;Act&#160;of 2022 (the &#8220;IRA&#8221;), which, among
other provisions, included several measures intended to lower the cost of prescription drugs and related healthcare reforms. Specifically,
the IRA authorizes and directs the Department of Health and Human Services (the &#8220;DHHS&#8221;) to set drug price caps for certain
high-cost Medicare Part B and Part D qualified drugs, with the initial list of drugs announced on August 29, 2023, and the first year
of maximum price applicability to begin in 2026. The IRA further authorizes the DHHS to penalize pharmaceutical manufacturers that increase
the price of certain Medicare Part B and Part D drugs faster than the rate of inflation. Finally, the IRA creates significant changes
to the Medicare Part D benefit design by capping Part D beneficiaries&#8217; annual out-of-pocket spending at $2,000 beginning in 2025.
Additional legislative and regulatory changes could be made to governmental health programs that could significantly impact pharmaceutical
companies and the success of our product candidates. At the state level, legislatures have increasingly passed legislation and implemented
regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts,
restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage
importation from other countries and bulk purchasing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Changes in the healthcare
industry and in healthcare spending could adversely affect our grant funded clinical programs, business, financial condition and results
of operations. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business and research
efforts rely, in part, on funding and support from U.S. government agencies such as the National Institutes of Health (&#8220;NIH&#8221;),
National Cancer Institute (&#8220;NCI&#8221;) and the Department of Health and Human Services (&#8220;HHS&#8221;). Government funding
for these programs is subject to annual budgetary decisions, which can be unpredictable and influenced by shifting political and economic
priorities. Reductions in government support for cancer research or other healthcare initiatives could limit grants, contracts, or other
financial resources that we or our research collaborators depend on, potentially delaying our clinical programs and increasing our reliance
on alternative funding sources. For instance, we have a CRADA with the NCI for the development of Actimab-A. While we have been informed
that the funding for our CRADA is not expected to be impacted, there can be no assurances that this will remain the case and any reduction
or elimination of funding can have a material adverse impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, with the change
in presidential administration that recently occurred in the United States, government spending programs have become even more difficult
to predict and may be subject to greater risk. Considerable uncertainty exists regarding how future budget and program decisions will
unfold, including the spending priorities of the new U.S. presidential administration and Congress and what challenges budget reductions
may present for our industry generally or for our company. In particular, President Trump recently attempted to place a widespread freeze
on most federal grants and loans. Any freeze on government support for our products, programs, or studies could significantly impair our
research and development activities, business, and operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Disruptions at
the FDA, the SEC and other government agencies or comparable regulatory authorities caused by funding shortages or global health concerns,
in addition to substantial uncertainty regarding the new Administration&#8217;s initiatives and how these might impact the FDA, its implementation
of laws, regulations, policies and guidance, and its personnel, could hinder government agencies&#8217; ability to hire and retain key
leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner,
or otherwise prevent those agencies from performing normal business functions on which our business operations rely, including timely
reviews, which could negatively impact our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The ability of the FDA
or comparable foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government
budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and
policy changes that may otherwise affect the FDA&#8217;s or comparable foreign regulatory authorities&#8217; ability to perform routine
functions. In addition, government funding of the SEC and other government agencies or comparable foreign regulatory authorities on which
our operations may rely, including those that fund research and development activities, is subject to the political process, which is
inherently fluid and unpredictable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Disruptions at the FDA
and other agencies, including substantial leadership, personnel, and policy changes, may also slow the time necessary for new drugs to
be reviewed and/or approved by necessary government agencies, which would harm our business. Changes in FDA staffing could result in delays
in the FDA&#8217;s responsiveness or in its ability to review submissions or applications, issue regulations or guidance, or implement
or enforce regulatory requirements in a timely fashion or at all. Similar consequences would also result in the event of another significant
shutdown of the federal government. For example, over the last several years, the U.S. government has shut down several times and certain
regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government
shutdown occurs, or if geopolitical or global health concerns prevent the FDA or other regulatory authorities from conducting their regular
inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process
our regulatory submissions, which could materially adversely affect our business, financial condition, results of operations and prospects.
Such changes could significantly impact the ability of the FDA to timely review and take action on our regulatory submissions, which could
have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns or substantial
leadership, personnel, and policy changes could impact our ability to access the public markets and obtain necessary capital in order
to properly capitalize and continue our operations. If the FDA is constrained in its ability to engage in oversight and implementation
activities in the normal course, our business may be negatively impacted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">With the change in the
U.S. Presidential Administration in 2025, there is substantial uncertainty as to whether and how the new administration will seek to modify
or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over our product candidates. This uncertainty
could present new challenges and/or opportunities as we navigate development of our product candidates. Some of these efforts have manifested
to date in the form of personnel measures that could impact the FDA&#8217;s ability to hire and/or retain key personnel, which could result
in delays or limitations on our ability to obtain guidance from the FDA on our product candidates in development and obtain the requisite
regulatory approvals in the future. Moreover, the new Administration has proposed action to freeze or reduce the budget of the National
Institutes of Health, or NIH, as related to its funding for medical research, which could decrease the ability of facilities that rely
on NIH funding to enroll and conduct clinical trials or increase the costs to us of conducting clinical trials. There remains general
uncertainty regarding future activities. The new Administration&#160;could issue or promulgate executive orders, regulations, policies
or guidance that adversely affect us or create a more challenging or costly environment to pursue the development of new therapeutic products.
Alternatively, state governments may attempt to address or react to changes at the federal level with changes to their own regulatory
frameworks in a manner that is adverse to our operations. If we become negatively impacted by future governmental orders, regulations,
policies or guidance as a result of the new Administration, there could be a material adverse effect on us and our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
relationships with customers, health care professionals and third-party payors may be subject to applicable healthcare laws, which could
expose us to penalties, including administrative, civil or criminal penalties, damages, fines, imprisonment, exclusion from participation
in federal healthcare programs such as Medicare and Medicaid, reputational harm, the curtailment or restructuring of our operations and
diminished future profits and earnings.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
professionals and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which
we obtain marketing approval. Our current and future arrangements with customers, healthcare professionals and third-party payors may
expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial
arrangements and relationships through which we conduct research, market, sell and distribute any products for which we obtain marketing
approval. Federal and state healthcare laws and regulations that may affect our operations, directly or indirectly, include the following,
among others:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Anti-Kickback
    Statute, which prohibits persons and entities from, among other things, knowingly and willfully soliciting, offering, receiving or
    providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for,
    or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made under federal
    and state healthcare programs such as Medicare and Medicaid;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal false claims
    laws, including civil whistleblower or qui tam actions under the federal False Claims Act, which impose criminal and civil penalties
    against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government,
    claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money
    to the federal government;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Health Insurance
    Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health
    Act of 2009, or HITECH, which imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare
    benefit program or making false statements relating to healthcare matters and also imposes obligations, including mandatory contractual
    terms, on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, and their respective
    business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of the
    covered entity as well as their covered subcontractors, with respect to safeguarding the privacy, security and transmission of individually
    identifiable health information;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Civil Monetary
    Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program
    beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider,
    practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Physician Payments
    Sunshine Act, created under the Affordable Care Act, and its implementing regulations, which requires certain manufacturers of drugs,
    devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health
    Insurance Program (with certain exceptions) to report annually information related to certain payments or other transfers of value
    provided to physicians and any ownership and investment interests held by physicians or their immediate family members. Beginning
    in 2022, applicable manufacturers also will be required to report such information regarding payments and other transfers of value
    to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse
    anesthetists and certified nurse midwives during the previous year; and</span></td></tr>
</table><div>

</div><p style="margin: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous state laws and
    regulations, including (among others) state anti-kickback and false claims laws, which may apply to our business practices, including,
    but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed
    by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical
    industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the United States federal government,
    or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations
    that require drug manufacturers to file reports relating to pricing and marketing information and that require tracking gifts and
    other remuneration and items of value provided to healthcare professionals and entities; state and local laws that require the registration
    of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances,
    many of which differ from each other in significant ways and often are not preempted by federal law, thus complicating compliance
    efforts.</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to comply with applicable healthcare laws and regulations will involve substantial costs. Interpretations of standards of compliance
under these laws and regulations are rapidly changing and subject to varying interpretations and it is possible that governmental authorities
will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable
fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any
other laws that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion
from government funded healthcare programs, such as Medicare and Medicaid, reputational harm, imprisonment, additional reporting obligations
and oversight (if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with
these laws), and the curtailment or restructuring of our operations, any of which could diminish our future profits or earnings. If any
of the physicians or other providers or entities with whom we expect to do business are found to be not in compliance with applicable
laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Third-party
payors may not adequately reimburse customers for any product candidates that we may commercialize or promote, and may impose coverage
restrictions or limitations such as prior authorizations and step edits that affect their use.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement
for these products and related treatments will be available from government health programs, private health insurers, integrated delivery
networks and other third-party payors. Third-party payors decide which medications they will pay for and establish reimbursement levels.
A significant trend in the United States healthcare industry and elsewhere is cost containment. Government authorities and third-party
payors have attempted to control costs by limiting coverage and the amount of payment for particular medications. Increasingly, third-party
payors are requiring that drug companies provide predetermined discounts from list prices and are challenging the prices charged for
medical products. Coverage and reimbursement may not be available for any product that we commercialize and, if reimbursement is available,
the level of reimbursement may not be sufficient for commercial success. Coverage and reimbursement may impact the demand for, or the
price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement is not available or is available
only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
reimbursement approval for any product candidate for which we obtain marketing approval from any government or other third-party payor
is a time-consuming and costly process. There may be significant delays in obtaining coverage and adequate reimbursement for newly approved
products. Moreover, eligibility for coverage and reimbursement does not imply that any product will be paid for in all cases or at a
rate that covers our costs, including research, development, manufacture, sale and distribution. Even when a payor determines that a
product that we may commercialize or promote is eligible for reimbursement under its criteria, the payor may impose coverage limitations
that preclude payment for some uses that are approved by the FDA, or may impose restrictions, such as prior authorization requirements,
or may simply deny coverage altogether. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover
our costs and may not be made permanent. Coverage and reimbursement rates may vary according to the use of the drug and the medical circumstances
under which it is used may be based on reimbursement levels already set for lower cost products or procedures or may be incorporated
into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government
healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where
they may be sold at lower prices than in the United States. Furthermore, the Centers for Medicare and Medicaid Services frequently change
product descriptors, coverage policies, product and service codes, payment methodologies and reimbursement values. Commercial third-party
payors often rely upon Medicare coverage policies and payment limitations in setting their own reimbursement policies. Our inability
to promptly obtain and maintain coverage and profitable payment rates from both government-funded programs and private payors for any
approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed
to commercialize our approved products and our overall financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Third Parties</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties
or meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize
our product candidates.&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have the ability to independently conduct our clinical trials for our product candidates and we must rely on third parties, such
as contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct such trials. Our
reliance on these third parties for clinical development activities results in reduced control over these activities. Moreover, the FDA
requires us to comply with regulations and standards, commonly referred to as GCPs (good clinical practices), for conducting, recording
and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the trial participants
are adequately protected. Our reliance on third parties does not relieve us of these responsibilities and requirements. If we or any
of our third-party contractors fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed
unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving
our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will
determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product
produced under current good manufacturing practice, or cGMP, regulations. Our failure to comply with these regulations may require us
to repeat clinical trials, which would delay the regulatory approval process.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our consultants, contract research organizations and other similar entities with which we are working do not successfully carry out their
contractual duties, meet expected deadlines, or comply with applicable regulations, we may be required to replace them. Although we believe
that there are a number of other third-party contractors we could engage to continue these activities, we may not be able to enter into
arrangements with alternative third-party contractors or to do so on commercially reasonable terms, which may result in a delay of our
planned clinical trials and delayed development of our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our third-party contractors are not our employees, and except for remedies available to us under our agreements with such third-party
contractors, we cannot control whether or not they devote sufficient time and resources to our programs. If these third parties do not
successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, or if the quality or accuracy of
the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons,
our pre-clinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able
to obtain regulatory approval for, or successfully commercialize, our product candidates on a timely basis, if at all, and our business,
operating results and prospects would be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
protection against generic competition for our biologic drug candidates and reimbursement by CMS may be subject to future change</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not aware of any existing or pending regulations or legislation that pertains to generic radiopharmaceutical products such as our
 targeted radiotherapy product candidates. Our ARC product candidates are regulated by the FDA as biologic products, and we intend
to seek approval for these products pursuant to the BLA pathway. The Biologics Price Competition and Innovation Act of 2009, or BPCIA,
created an abbreviated pathway for the approval of biosimilar and interchangeable biologic products. The abbreviated regulatory pathway
establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar
as &#8220;interchangeable&#8221; based on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar
product cannot be approved by the FDA until 12 years after the original branded product was approved under a BLA and in Europe a biosimilar
product cannot be approved until 10 years after the original branded product was approved. The law is complex and as a result, its ultimate
impact, implementation, and meaning are subject to uncertainty. Even if a biosimilar gets approved for one of the antibodies that we
use, the final constructs of our drug candidates consist of an antibody, radioisotope and in some cases a linker and we are not aware
of any regulations that would require us to provide the final constructs or components to third parties or potential competitors. Therefore,
based on the current regulations, we do not believe that the final drug product of our candidates can be subject to competition from
a biosimilar as outlined in BPCIA for at least 12 years in the U.S. and 10 years in the EU. We are aware that generic versions of certain
radiopharmaceuticals utilizing peptides have been submitted to the FDA via the Abbreviated New Drug Application (&#8220;ANDA&#8221;)
pathway, however, those products are not covered under the BPCIA and therefore that generic pathway is not applicable to Iomab-B or Actimab-A.
We expect this would also apply to other biologic drug candidates we may seek to develop in the future based on the current provisions
of the BPCIA. Additionally, the Inflation Reduction Act (&#8220;IRA&#8221;) that was enacted in August 2022, states that reimbursement
by the Centers for Medicare&amp; Medicaid Services (&#8220;CMS&#8221;) for high-expenditure single-source biologic drugs, which we expect
Iomab-B and Actimab-A to be, can only be negotiated after at least 11 years following approval compared to 7 years for non-biologic drugs
with negotiated prices taking effect two years after selection. Therefore, we currently believe that our ARCs are less likely than small
molecules to face pricing pressure and negotiation from IRA. Further, a drug or biological product that has an orphan drug designation,
which Iomab-B and Actimab-A both have, for only one rare disease or condition will be excluded from the IRA&#8217;s price negotiations
requirements &#160;until such time the biological products has designations for more than one rare disease or condition, or if is approved
for an indication that is not within that single designated rare disease or condition, unless such additional designation or such disqualifying
approvals are withdrawn by the time CMS evaluates the drug for selection for negotiation. In August 2023, 10 initial drugs were identified
with negotiated prices expected to take effect starting in 2026. In 2027 and 2028, it is expected that CMS will establish negotiated
prices for 15 additional drugs in each respective year. We do not believe there is a high likelihood that Iomab-B or Actimab-A would
be identified by CMS for negotiated pricing under IRA but there is potential that IRA and other additional state and federal healthcare
reform measures will be adopted in the future and the implementation of cost-containment measures or other healthcare reforms may prevent
us from being able to generate revenue, attain profitability or successfully commercialize our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product candidates may never achieve market acceptance.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actimab-A, Iomab-ACT and Iomab-B
and future product candidates that we may develop may never gain market acceptance among physicians, patients and the medical community.
The degree of market acceptance of any of our products will depend on a number of factors, including the actual and perceived effectiveness
and reliability of the product; the results of any long-term clinical trials relating to use of the product; the availability, relative
cost and perceived advantages and disadvantages of alternative technologies; the degree to which treatments using the product are approved
for reimbursement by public and private insurers; the strength of our marketing and distribution infrastructure; and the level of education
and awareness among physicians and hospitals concerning the product.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that oncologists and other physicians will not widely adopt a product candidate unless they determine, based on experience, clinical
data, and published peer-reviewed journal articles, that the use of that product candidate provides an effective alternative to other
means of treating specific cancers. Patient studies or clinical experience may indicate that treatment with our product candidates does
not provide patients with sufficient benefits in extension of life or quality of life. We believe that recommendations and support for
the use of each product candidate from influential physicians will be essential for widespread market acceptance. Our product candidates
are still in the development stage, and it is premature to attempt to gain support from physicians at this time. We can provide no assurance
that such support will ever be obtained. If our product candidates do not receive such support from these physicians and from long-term
data, physicians may not use or continue to use, and hospitals may not purchase or continue to purchase, them.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Failure of Actimab-A or Iomab-ACT
or any of our other product candidates to significantly penetrate current or new markets would negatively impact our business financial
condition and results of operations.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to claims that our third-party service providers, consultants or current or former employees have wrongfully used or disclosed
confidential information of third parties.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed
at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent
contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217;
former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims,
litigation could result in substantial cost and be a distraction to our management and employees.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently depend on single third-party manufacturers to produce our pre-clinical and clinical trial drug supplies. Any disruption in
the operations of our current third-party manufacturers, or other third-party manufacturers we may engage in the future, could adversely
affect our business and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently operate manufacturing facilities for pre-clinical or clinical production of any of our product candidates. We rely on
third-party manufacturers to supply, store, and distribute pre-clinical and clinical supply of the components of our drug product candidates
including monoclonal antibodies, linkers and radioisotopes, as well as the final construct which comprises our drug product candidates.
We expect to continue to depend on third-party manufacturers for the foreseeable future. Any performance failure on the part of our existing
or future manufacturers could delay clinical development, cause us to suspend or terminate development or delay or prohibit regulatory
approval of our product candidates or commercialization of any approved products. Further avenues of disruption to our clinical or eventual
commercial supply may also occur due to the sale, acquisition, business reprioritization, bankruptcy or other unforeseen circumstances
that might occur at any of our suppliers or contract manufacturing partners including an inability to come to terms on renewal of existing
contracts or new contracts.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently rely on single manufacturers to manufacture our pre-clinical and clinical trial drug supplies. With a view to maintaining business
continuity we are evaluating alternatives and second and even third sources of supply or manufacturing for our core suppliers and manufacturing
partners, however there can be no assurances that we will be able to identify such suppliers or partners and assuming we did, that we
would be able to enter into contracts that are on favorable terms or on terms that will enable sufficient supply to ensure business continuity
and support our growth plans.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates require precise, high-quality manufacturing. Failure by our current contract manufacturer or other third-party manufacturers
we may engage in the future to achieve and maintain high manufacturing standards could result in patient injury or death, product recalls
or withdrawals, delays or failures in testing or delivery, cost overruns, or other problems that could seriously hurt our business. Contract
manufacturers may encounter difficulties involving production yields, quality control, and quality assurance. These manufacturers are
subject to ongoing periodic and unannounced inspections by the FDA and corresponding state and foreign agencies to ensure strict compliance
with cGMPs and other applicable government regulations and corresponding foreign standards; we do not have control over third-party manufacturers&#8217;
compliance with these regulations and standards.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We currently plan to build out a manufacturing facility in the future
to operate for the purposes of manufacturing our own products. We have never built, owned or operated a manufacturing facility. There
can be no assurances that we will be able to successfully accomplish this and in doing so we may experience delays, cost overruns, or
other problems that could seriously hurt our business. Even if we successfully build out our planned manufacturing facility, we may not
realize the expected benefits of these efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
depend on vendors with specialized operations, equipment and know-how to manufacture the respective components of our drug candidates.
We have entered into manufacturing and supply agreements with these third-parties, and in some instances, we have agreed that such vendor
be the exclusive manufacturer and supplier. If any of the third-parties we depend on encounter difficulties in their operations, fail
to comply with required regulations or breach their contractual obligations it may be difficult, or we may be unable to identify suitable
alternative third-party manufacturers. While we identify and evaluate third-party manufacturers from time to time, even if we do identify
suitable alternative third-parties, we may fail to reach agreement on contractual terms, it may be prohibitively expensive and there
can be no assurance that we can successfully complete technology transfer and development work necessary, or complete the necessary work
in a timely manner. Any of which could prevent us from commencing manufacturing with third-parties which could cause delays or suspension
of our clinical trials and pre-clinical work that may have a negative impact on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore, these third-party contractors,
whether foreign or domestic, may experience regulatory compliance difficulty, mechanical shutdowns, employee strikes, or any other unforeseeable
acts that may delay or limit production. Our inability to adequately establish, supervise and conduct (either ourselves or through third
parties) all aspects of the formulation and manufacturing processes, and the inability of third-party manufacturers to consistently supply
quality product when required would have a material adverse effect on our ability to develop or commercialize our products. We have faced
delays and risks associated with reliance on key third party manufacturers in the past and may be faced with such delays and risks in
the future. Any future manufacturing interruptions or related supply issues could have an adverse effect on our company, including delays
in clinical trials.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are successful in obtaining marketing approval from the FDA and/or other regulatory agencies for any of our product candidates, we
anticipate continued reliance on third-party manufacturers.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, our product candidates have been manufactured in small quantities for preclinical and clinical testing by third-party manufacturers.
If the FDA or other regulatory agencies approve any of our product candidates for commercial sale, we expect that we would continue to
rely, at least initially, on third-party specialized manufacturers to produce commercial quantities of approved products. These manufacturers
may not be able to successfully increase the manufacturing capacity for any approved product in a timely or economic manner, or at all.
Significant scale-up of manufacturing may require additional validation studies, which the FDA must review and approve. Scale-up for
commercial product may require financial commitment or investment by us, which we may not have sufficient capital for or may elect not
to undertake. If third party manufacturers are unable to successfully increase the manufacturing capacity for a product candidate, or
we are unable to establish our own manufacturing capabilities, the commercial launch of any approved products may be delayed or there
may be a shortage in supply, which in turn could have a material adverse effect on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant
to inspections that will be conducted after we submit a BLA to the FDA. We do not control the manufacturing process of, and are completely
dependent on, our contract manufacturing partners for compliance with cGMPs. If our contract manufacturers cannot successfully manufacture
material that conforms to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities, they
will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. If the FDA or a comparable foreign
regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval
in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain
regulatory approval for or market our product candidates, if approved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may have conflicts with our partners that could delay or prevent the development or commercialization of our product candidates.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may have conflicts with our partners, such as conflicts concerning the interpretation of preclinical or clinical data, pertaining to
the global patient safety profile or efficacy results of our products, the achievement of milestones, the interpretation of contractual
obligations, payments for services, development obligations or the ownership of intellectual property developed during our collaboration.
We may seek to amend, modify or terminate agreements with partners, suppliers or service providers related to Iomab-B, Actimab-A or Iomab-ACT
but there can be no assurance that we can do so successfully or negotiate terms that are favorable to us. Failure of which can increase
the risk of or result in litigation or alternative dispute resolution options taken against us. Further, we may exercise our decision-making
authority under certain circumstances pertaining to global patient safety related to our products, which our partners may disagree with
and may result in potential conflicts and public disclosure of our rationale and position. If any conflicts arise with any of our partners,
such partner may act in a manner that is adverse to our best interests. Any such disagreement could result in one or more of the following,
each of which could delay or prevent the development or commercialization of our product candidates, and in turn prevent us from generating
revenues: unwillingness on the part of a partner to pay us milestone payments or royalties we believe are due under a collaboration;
uncertainty regarding ownership of intellectual property rights arising from our collaborative activities, which could prevent us from
entering into additional collaborations; unwillingness by the partner to cooperate in the development or manufacture of the product,
including providing us with product data or materials; unwillingness on the part of a partner to keep us informed regarding the progress
of its development and commercialization activities or to permit public disclosure of the results of those activities; initiating litigation
or alternative dispute resolution options by either party to resolve the dispute; or attempts by either party to terminate the agreement.&#160;Litigation
or alternative dispute resolution options can be lengthy and expensive, require significant time and attention from our management and
are highly uncertain. There can be no assurance that if we pursue, or a partner pursues litigation or alternative dispute resolution
options, that we will prevail. Monetary and equitable damages awarded against us could have a material adverse effect on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
in the future we are unable to establish U.S. or global sales and marketing capabilities or enter into agreements with third parties
to sell and market our product candidates, we may not be successful in commercializing our product candidates if they are approved and
we may not be able to generate any revenue.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not have a marketing or sales team for the marketing, sales and distribution of any of our product candidates that may receive
regulatory approval. In order to commercialize any product candidates after approval, we must build on a territory-by-territory basis
marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these
services, and we may not be successful in doing so. If our product candidates receive regulatory approval, we may decide to establish
an internal sales or marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates,
which will be expensive and time-consuming and will require significant attention of our executive officers to manage. Any failure or
delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization
of any of our product candidates that we obtain approval to market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to the commercialization of all or certain of our product candidates, we may choose to collaborate, either globally or on a territory-by-territory
basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and
distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into or maintain such arrangements
when needed on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive
regulatory approval or any such commercialization may experience delays or limitations. If we are not successful in commercializing our
product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer
and we may incur significant additional losses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face significant competition from other biotechnology and pharmaceutical companies.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates face, and will continue to face, intense competition from large pharmaceutical and biotechnology companies, as well
as academic and research institutions. We compete in an industry that is characterized by (i) rapid technological change, (ii) evolving
industry standards, (iii) emerging competition and (iv) new product introductions. Our competitors have existing products and technologies
that will compete with our product candidates and technologies and may develop and commercialize additional products and technologies
that will compete with our product candidates and technologies. Because several competing companies and institutions have greater financial
resources than us, they may be able to (i) provide broader services and product lines, (ii) make greater investments in research and
development, or R&amp;D, and (iii) carry on broader R&amp;D initiatives. Our competitors also have greater development capabilities than
we do and have substantially greater experience in undertaking preclinical and clinical testing of product candidates, obtaining regulatory
approvals, and manufacturing and marketing pharmaceutical products. They also have greater name recognition and better access to customers
than us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their
regulatory approval, limit their commercial potential, or result in significant negative consequences. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undesirable
side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and
could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities.
The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in
potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.
Even if any of our product candidates receives marketing approval, as greater numbers of patients use a product following its approval,
an increase in the incidence of side effects or the incidence of other post-approval problems that were not seen or anticipated during
pre-approval clinical trials could result in a number of potentially significant negative consequences, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities
    may withdraw their approval of the product;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities
    may require the addition of labeling statements, such as warnings or contraindications;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to change
    the way the product is administered, conduct additional clinical trials or change the labeling of the product;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may elect, or we may
    be required, to recall or withdraw product from the market;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we could be sued and held
    liable for harm caused to patients; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reputation may suffer.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could substantially increase the costs and expenses of developing, commercializing and marketing any such product candidates
or could harm or prevent sales of any approved products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Intellectual Property</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend upon securing and protecting critical intellectual property.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are dependent on obtaining and maintaining patents, trade secrets, copyright and trademark protection of our technologies in the United
States and other jurisdictions, as well as successfully enforcing this intellectual property and defending this intellectual property
against third-party challenges. The degree of future protection of our proprietary rights is uncertain for product candidates that are
currently in the early stages of development because we cannot predict which of these product candidates will ultimately reach the commercial
market or whether the commercial versions of these product candidates will incorporate proprietary technologies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
patent position is highly uncertain and involves complex legal and factual questions.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
we cannot predict the breadth of claims that may be allowed or enforced under our patents or in third-party patents. For example, we
or our licensors might not have been the first to make the inventions covered by each of our pending patent applications and issued patents;
we or our licensors might not have been the first to file patent applications for these inventions; others may independently develop
similar or alternative technologies or duplicate any of our technologies; it is possible that none of our pending patent applications
or the pending patent applications of our licensors will result in issued patents; our issued patents and issued patents of our licensors
may not provide a basis for commercially viable technologies, or may not provide us with any competitive advantages, or may be challenged
and invalidated by third parties; and, we may not develop additional proprietary technologies that are patentable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the issuance of a patent, while presumed valid and enforceable, is not conclusive as to its validity or its enforceability and it may
not provide us with adequate proprietary protection or competitive advantages against competitors with similar products. Competitors
may also be able to design around our patents. Other parties may develop and obtain patent protection for more effective technologies,
designs or methods. We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or trade secrets by consultants,
vendors, former employees and current employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
rights are territorial, and patent protection extends only to those countries where we have issued patents. Filing, prosecuting and defending
patents on our products and product candidates in all countries and jurisdictions throughout the world would be prohibitively expensive,
and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States.
Many countries, however, do not protect intellectual property to the same extent as the U.S. or Europe, and their litigation processes
differ. Competitors may successfully challenge or avoid our patents, or manufacture products in countries where we have not applied for
patent protection. Changes in the patent laws in the U.S. or other countries may diminish the value of our patent rights. As a result
of these and other factors, the scope, validity, enforceability, and commercial value of our patent rights are uncertain and unpredictable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indeed,
several companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions.
The legal systems of some countries do not favor the enforcement of patents and other intellectual property rights, which could make
it difficult for us to stop the infringement, misappropriation or other violation of our intellectual property rights generally. Proceedings
to enforce our intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention
from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications
at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that are initiated,
and the damages or other remedies awarded, if any, may not be commercially meaningful.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent positions of pharmaceutical companies, including our patent position, involve complex legal and factual questions, and, therefore,
the issuance, scope, validity and enforceability of any patent claims that we may obtain cannot be predicted with certainty. Patents,
if issued, may be challenged, deemed unenforceable, invalidated, or circumvented. A third-party may submit prior art, or we may become
involved in opposition, derivation, reexamination, inter partes review, post-grant review, supplemental examination, or interference
proceedings challenging our patent rights or the patent rights of our licensors or development partners. The costs of defending or enforcing
our proprietary rights in these proceedings can be substantial, and the outcome can be uncertain. An adverse determination in any such
submission or proceeding could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology
or products and compete directly with us, or reduce our ability to manufacture or commercialize products. Furthermore, if the scope or
strength of protection provided by our patents and patent applications is threatened, it could discourage companies from collaborating
with us to license, develop or commercialize current or future products. The ownership of our proprietary rights could also be challenged.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, our owned and licensed patents may not be valid, and we may not be able to obtain and enforce patents and to maintain trade
secret protection for the full commercial extent of our technology. The extent to which we are unable to do so could materially harm
our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
or our licensors have applied for and will continue to apply for patents for certain products and methods. Such applications may not
result in the issuance of any patents, and any patents now held or that may be issued may not provide us with adequate protection from
competition. Furthermore, it is possible that patents issued or licensed to us may be challenged successfully. In that event, if we have
a preferred competitive position because of such patents, such preferred position would be lost. If we are unable to secure or to continue
to maintain a preferred position, we could become subject to competition from the sale of generic products. Failure to receive, inability
to protect, or expiration of our patents for medical use, manufacture, conjugation and labeling of Ac-225, the antibodies that we license
from third parties, or subsequent related filings, would adversely affect our business and operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
issued or licensed to us may be infringed by the products or processes of others. Our ability to enforce our patent rights depends on
our ability to detect infringement. It is difficult to detect infringers who do not advertise the components that are used in their products.
Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s
product, particularly in litigation in countries other than the U.S. that do not provide an extensive discovery procedure. Any litigation
to enforce or defend our patent rights, if any, even if we were to prevail, could be costly and time-consuming and would divert the attention
of our management and key personnel from our business operations. We may not prevail in any lawsuits that we initiate and the damages
or other remedies awarded if we were to prevail may not be commercially meaningful.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cost of enforcing our patent rights against infringers, if such enforcement is required, could be significant, and we may not have the
financial resources to fund such litigation. Further, such litigation can go on for years and the time demands could interfere with our
normal operations. There has been substantial litigation and other proceedings regarding patent and other intellectual property rights
in the pharmaceutical industry. We may become a party to patent litigation and other proceedings. The cost to us of any patent litigation,
even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the costs of such litigation more
effectively than we can because of their substantially greater financial resources. Litigation may also absorb significant management
time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unpatented trade secrets, improvements, confidential know-how and continuing technological innovation are important to our scientific
and commercial success. Although we attempt to and will continue to attempt to protect our proprietary information through reliance on
trade secret laws and the use of confidentiality agreements with our partners, collaborators, employees and consultants and other appropriate
means, these measures may not effectively prevent disclosure of our proprietary information, and, in any event, others may develop independently,
or obtain access to, the same or similar information. In addition, we cannot guarantee that we have executed these agreements with each
party that may have or have had access to our trade secrets. Furthermore, if the employees and consultants who are parties to these agreements
breach or violate the terms of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose
our trade secrets through such breaches or violations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of our patent rights are licensed to us by third parties. If we fail to comply with the terms of these license agreements, our rights
to those patents may be terminated, and we may be unable to conduct our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are found to be infringing patents or trade secrets owned by others, we may be forced to cease or alter our product development efforts,
obtain a license to continue the development or sale of our products, and/or pay damages.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not have identified all patents, published applications or published literature that affect our business either by blocking our ability
to commercialize our products, by preventing the patentability of one or more aspects of our products to us or our licensors, or by covering
the same or similar technologies that may affect our ability to market our products. For example, we (or our licensors) may not have
conducted a patent clearance search sufficient to identify potentially obstructing third party patent rights. Moreover, patent applications
in the United States are maintained in confidence for up to 18 months after their filing. In some cases, however, patent applications
remain confidential in the U.S. Patent and Trademark Office, or the USPTO, for the entire time prior to issuance as a U.S. patent. Patent
applications filed in countries outside of the United States are not typically published until at least 18 months from their first filing
date. Similarly, publication of discoveries in the scientific or patent literature often lags behind actual discoveries. We cannot be
certain that we or our licensors were the first to invent, or the first to file, patent applications covering our products and candidates.
We also may not know if our competitors filed patent applications for technology covered by our pending applications or if we were the
first to invent the technology that is the subject of our patent applications. Competitors may have filed patent applications or received
patents and may obtain additional patents and proprietary rights that block or compete with our patents.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
manufacturing processes and potential products may violate proprietary rights of patents that have been or may be granted to competitors,
universities or others, or the trade secrets of those persons and entities. As the pharmaceutical industry expands and more patents are
issued, the risk increases that our processes and potential products may give rise to claims that they infringe the patents or trade
secrets of others. These other persons could bring legal actions against us claiming damages and seeking to enjoin clinical testing,
manufacturing and marketing of the affected product or process. If any of these actions are successful, in addition to any potential
liability for damages, we could be required to obtain a license in order to continue to conduct clinical tests, manufacture or market
the affected product or use the affected process. Required licenses may not be available on acceptable terms, if at all, and the results
of litigation are uncertain. If we become involved in litigation or other proceedings, it could consume a substantial portion of our
financial resources and the efforts of our personnel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to infringement or other intellectual property claims against us, we may become a party to other patent litigation or proceedings
before regulatory agencies, including post-grant review, inter parties review, interference or re-examination proceedings filed with
the U.S. Patent and Trademark Office (or similar proceedings before corresponding tribunals in other jurisdictions) that challenge our
patent rights or the patent rights of our licensors. The costs and efforts of defending our patents or enforcing our proprietary rights
in post-issuance administrative proceedings can be substantial and the outcome can be uncertain. An adverse determination in these proceedings
could weaken or invalidate the patent claims that cover our technology, which adverse determination could harm our business significantly
and dissuade companies from collaborating with us or permit third parties to directly compete with the same technology.</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to protect and enforce our patents does not guarantee that we will secure the right to commercialize our potential products and
respective patents.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
patent is a limited monopoly right conferred upon an inventor, and his successors in title, in return for the making and disclosing of
a new and non-obvious invention. This monopoly is of limited duration but, while in force, allows the patent holder to prevent others
from making, using and/or selling its invention. While a patent gives the holder this right to exclude others, it is not a license to
commercialize an invention covered by the patent where other permissions may be required for commercialization to occur. For example,
a drug cannot be marketed without the appropriate authorization from the FDA, regardless of the existence of a patent covering the product.
Further, the invention, even if patented itself, cannot be commercialized if it infringes the valid patent rights of another party.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely on confidentiality agreements to protect our trade secrets. If these agreements are breached by our employees or other parties,
our trade secrets may become known to our competitors.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on trade secrets that we seek to protect through numerous measures, including non-compete and confidentiality agreements with our
employees and other parties. If these agreements are breached, our competitors may obtain and use our trade secrets to gain a competitive
advantage over us. Any remedies that may be available to us may not be adequate to protect our business or compensate us for the damaging
disclosure. In addition, we may have to expend resources to protect our interests from possible infringement by others. For instance,
we learned that a former employee, Qing Liang, Ph.D., who was employed by Actinium in the position of Vice President, Head of Radiation
Sciences, violated the non-compete provision of her employment agreement by working for a direct competitor. Additionally, while working
for the direct competitor, Dr. Liang continued to provide consulting services to Actinium. We also learned that Dr. Liang was providing
consulting services to another company, which was in violation of certain provisions of her post-employment consulting agreement with
Actinium. Dr. Liang, who had access to materials containing proprietary information and trade secrets, pursuant to actions taken by Actinium,
is no longer employed by the direct competitor. With the assistance of outside counsel and a forensic investigator, we identified that
Dr. Liang downloaded confidential information prior to her employment at Actinium ending. To aid in arbitration proceedings, we petitioned
and were granted a Stipulated Preliminary Injunction by the Supreme Court of the State of New York, New York County (Index No. 656841/2022)
on June 28, 2022 that ordered that Dr. Liang is enjoined from destroying or deleting any Actinium documents or information, is enjoined
from using, transmitting or transferring any Actinium Information other than to her counsel or Actinium&#8217;s counsel, ordered to return
Actinium information within 5 days of Stipulated Preliminary Injunction, ordered to disclose to Actinium under oath, all persons and
devices she transferred or disclosed Actinium Information, and ordered to allow a qualified forensic examiner selected by Actinium to
remove and permanently delete all Actinium Information from any electronic devices, systems, email accounts, or other electronic or physical
storage sites belonging to Dr. Liang. On April 25, 2023, a Final Award and Permanent Injunction was granted by the Supreme Court of the
State of New York, New York County (Case No. 01-22-0003-2375) that ordered that Dr. Liang is permanently enjoined from using, possessing,
transmitting or transferring any Actinium property, documents of business information.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of their
former employers.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
employees may have been previously employed at other companies in the industry, including our competitors or potential competitors. Although
we are not aware of any claims currently pending against us, we may be subject to claims that these employees or we have inadvertently
or otherwise used or disclosed trade secrets or other proprietary information of the former employers of our employees. Litigation may
be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in
substantial costs and be a distraction to management. If we fail in defending such claims, in addition to paying money claims, we may
lose valuable intellectual property rights or personnel. A loss of key personnel or their work product could hamper or prevent our ability
to commercialize product(s), which would materially adversely affect our commercial development efforts.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
and maintaining patent protection depends on compliance with various procedures and other requirements, and our patent protection could
be reduced or eliminated in case of non-compliance with these requirements.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the relevant
patent agencies in several stages over the lifetime of the patents and /or applications. The relevant patent agencies require compliance
with a number of procedural, documentary, fee payment and other provisions during the patent application process. In many cases, an inadvertent
lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations
in which the failure to comply with the relevant requirements can result in the abandonment or lapse of the patent or patent application,
resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able
to use our technologies and know-how which could have a material adverse effect on our business, prospects, financial condition and results
of operation.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may
not be able to successfully implement our business strategy. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future operations and successes depend in large part upon the continued service of key members of our senior management team whom we
are highly dependent upon to manage our business. If any member of our current senior management terminates his or her employment with
us and we are unable to find a suitable replacement quickly, the departure could have a material adverse effect on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the third quarter of 2024, our overall headcount was reduced by approximately twenty percent, with a majority of departures coming from
our clinical and CMC groups. As a result of these departures, we expect our personnel expenses to be reduced by approximately $3.7 million
in 2025, which may be offset by additional hires or consultants. We do not expect these departures to have a material impact on our operations
or ability to execute our operating plan and are actively seeking a strategic partner for Iomab-B in the U.S. to advance the additional
studies and trials required by the FDA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
overall tightening and increasingly competitive labor market has been observed in the U.S. employment market generally. Specific to the
biotechnology industry in which we operate, there is significant demand and competition for highly specialized talent that we require.
A sustained labor shortage or increased turnover rates within our employee base as a result of general macroeconomic factors of <i>force
majeure </i>events, or due to dynamics within our industry, could lead to increased costs, such as increased wage rates to attract and
retain employees, and could negatively affect our ability to efficiently conduct our clinical development, R&amp;D, business development
and potential regulatory and commercial activities. If we are unable to hire and retain employees capable of performing at a high-level,
or if mitigation measures we may take to respond to a decrease in labor availability, have unintended negative effects, our business
could be adversely affected. An overall labor shortage, lack of skilled labor, increased turnover or labor inflation, general macroeconomic
factors or as a result of biotechnology industry dynamics could have a material adverse impact on our operations, results of operations,
liquidity or cash flows.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future success also depends on our ability to identify, attract, hire, or engage, retain, and motivate other well-qualified managerial,
technical, clinical and regulatory personnel. This activity is likely to create additional demands on the time and attention of our senior
management personnel as they identify, hire, and train external and internal candidates to fill the sizable number of positions required
to execute our business plans, including submitting a BLA and building a commercial organization. The market for talent in our industry
is very competitive. Many of the other biopharmaceutical companies we compete against for qualified personnel have greater financial
and other resources, more favorable risk profiles and a longer operating history in the biopharmaceutical industry than we do. They also
may provide more diverse opportunities and better chances for career advancement. Some of these opportunities may be more appealing to
high-quality candidates than what we have to offer. There can be no assurance that such professionals will be available in the market,
or that we will be able to retain existing professionals or meet or continue to meet their compensation requirements. Furthermore, the
cost base in relation to such compensation, which may include equity compensation, may increase significantly, which could have a material
adverse effect on us. Failure to establish and maintain an effective management team and workforce could adversely affect our ability
to operate, grow and manage our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Managing
our growth as we expand operations may strain our resources.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to need to grow rapidly in order to support additional, larger, and potentially international, pivotal clinical trials of our
product candidates as well as potential commercial operations in the future, which will place a significant strain on our financial,
managerial and operational resources. In order to achieve and manage growth effectively, we must continue to improve and expand our operational
and financial management capabilities. Moreover, we will need to increase staffing and to train, motivate and manage our employees. All
of these activities will increase our expenses and may require us to raise additional capital sooner than expected. Failure to manage
growth effectively could materially harm our business, financial condition or results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
use of hazardous materials, including radioactive and biological materials, in our research and development efforts imposes certain compliance
costs on us and may subject us to liability for claims arising from the use or misuse of these materials.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research, development and manufacturing activities involve the controlled use of hazardous materials, including chemicals, radioactive
and biological materials, such as radioactive isotopes. We are subject to federal, state, local and foreign environmental laws and regulations
governing, among other matters, the handling, storage, use and disposal of these materials and some waste products. We cannot completely
eliminate the risk of contamination or injury from these materials, and we could be held liable for any damages that result, which could
exceed our financial resources. We currently maintain insurance coverage for injuries resulting from the hazardous materials we use;
however, future claims may exceed the amount of our coverage. Also, we do not have insurance coverage for pollution cleanup and removal.
Currently the costs of complying with such federal, state, local and foreign environmental regulations are not significant, and consist
primarily of waste disposal expenses. However, they could become expensive, and current or future environmental laws or regulations may
impair our research, development, production and commercialization efforts.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may undertake international operations, which will subject us to risks inherent with operations outside of the United States.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we do not have any international operations at this time, we intend to seek market clearances in foreign markets that we believe will
generate significant opportunities. However, even with the cooperation of a commercialization partner, conducting drug development in
foreign countries involves inherent risks, including, but not limited to difficulties in staffing, funding and managing foreign operations;
unexpected changes in regulatory requirements; export restrictions; tariffs and other trade barriers; difficulties in protecting, acquiring,
enforcing and litigating intellectual property rights; fluctuations in currency exchange rates; and potentially adverse tax consequences.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we were to experience any of the difficulties listed above, or any other difficulties, any international development activities and our
overall financial condition may suffer and cause us to reduce or discontinue our international development and registration efforts.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities,
and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to experience growth in the number of our employees and the scope of our operations, particularly in the areas of product candidate
development, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing, and distribution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not have a marketing or sales team for the marketing, sales and distribution of any of our product candidates that are potentially
able to obtain regulatory approval. In order to commercialize any product candidates, we must build on a territory-by-territory basis
marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these
services, and we may not be successful in doing so. If our product candidates receive regulatory approval, we intend to establish an
internal sales or marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates,
which will be expensive and time consuming and will require significant attention of our executive officers to manage. We will also have
to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. Any
failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization
of any of our product candidates that we obtain approval to market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To manage our anticipated future growth, we must continue to implement
and improve our managerial, operational, and financial systems, expand our facilities, and continue to recruit and train additional qualified
personnel. Due to our limited financial resources and the limited experience of our management team in managing a public company with
such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified
personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources.
Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
continuously evaluate our business strategy and may modify our strategy as necessary to respond to developments in our business and other
factors, and any such modification, if not successful, could have a material adverse effect on our business, financial condition, and
results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
continuously evaluate our business strategy and modify our plans as necessary to achieve our objectives in response to changing circumstances.
As part of such a process, we may delay, modify or discontinue the development of certain of our drug candidates and choose alternative
approaches if we believe such changes would be in our best interest. We may also expand or alter our research and development activities
from time to time and redirect allocation of our resources. We have implemented such changes in our business strategy and may continue
to do so in the future. There can be no assurances that any product development or other changes that we implement will be successful
or that, after implementation of any such changes, that we will not refocus our efforts on new or different objectives.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may expand our business through the acquisition of rights to new product candidates that could disrupt our business, harm our financial
condition and may also dilute current stockholders&#8217; ownership interests in our company.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business strategy includes expanding our products and capabilities, and we may seek acquisitions of product candidates, antibodies or
technologies to do so. Acquisitions involve numerous risks, including substantial cash expenditures; potentially dilutive issuance of
equity securities; incurrence of debt and contingent liabilities, some of which may be difficult or impossible to identify at the time
of acquisition; difficulties in assimilating acquired technologies or the operations of the acquired companies; diverting our management&#8217;s
attention away from other business concerns; risks of entering markets in which we have limited or no direct experience; and the potential
loss of our key employees or key employees of the acquired companies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
can make no assurances that any acquisition will result in short-term or long-term benefits to us. We may incorrectly judge the value
or worth of an acquired product, company or business. In addition, our future success would depend in part on our ability to manage the
rapid growth associated with some of these acquisitions. We cannot assure that we will be able to make the combination of our business
with that of acquired products, businesses or companies work or be successful. Furthermore, the development or expansion of our business
or any acquired products, business or companies may require a substantial capital investment by us. We may not have these necessary funds,
or they might not be available to us on acceptable terms or at all. We may also seek to raise funds by selling shares of our preferred
or common stock, which could dilute each current stockholder&#8217;s ownership interest in the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Ownership of Our Common Stock</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
sale of securities by us in any equity or debt financing could result in dilution to our existing stockholders and have a material adverse
effect on our earnings.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have financed our operations primarily through sales of stock and warrants. It is likely that during the next twelve months we will seek
to raise additional capital through the sales of stock and warrants in order to expand our level of operations to continue our research
and development efforts.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any sale of common stock by us in a future offering could result in dilution to our existing stockholders as
a direct result of our issuance of additional shares of our capital stock. In addition, our business strategy may include expansion through
internal growth or by establishing strategic relationships with targeted customers and vendors. In order to do so, or to finance the
cost of our other activities, we may issue additional equity securities that could dilute our stockholders&#8217; stock ownership. We
may also assume additional debt and incur impairment losses related to goodwill and other tangible assets if we acquire another company
and this could negatively impact our earnings and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b><i>Our
common stock is subject to price volatility which could lead to losses by stockholders and potential costly security litigation.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading volume of our common stock has been and may continue to be extremely limited and sporadic. We expect the market price of our
common stock to fluctuate substantially due to a variety of factors, including market perception of our ability to achieve our planned
growth, quarterly operating results of other companies in the same industry, trading volume in our common stock, changes in general conditions
in the economy and the financial markets or other developments affecting our competitors or us. This volatility has had a significant
effect on the market price of securities issued by many companies for reasons unrelated to their operating performance and could have
the same effect on our common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
trading price of our common stock may be highly volatile and could fluctuate in response to factors such as:</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated variations
    in our operating results;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of developments
    by us or our competitors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of IND and/or
    BLA approval, the completion and/or results of our clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory actions regarding
    our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by us or
    our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adoption of new accounting
    standards affecting our industry;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions or departures
    of key personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction of new products
    by us or our competitors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of our common stock
    or other securities in the open market;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inaccurate or unfavorable
    reports from securities or industry analysts; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other events or factors,
    many of which are beyond our control.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
stock market is subject to significant price and volume fluctuations. In the past, following periods of volatility in the market price
of a company&#8217;s securities, securities class action litigation has often been initiated against such a company. Litigation initiated
against us, whether or not successful, could result in substantial costs and diversion of our management&#8217;s attention and our resources,
which could harm our business and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not intend to pay dividends on our common stock, so any returns will be determined by the value of our common stock.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends on our common stock. For the foreseeable future, it is expected that earnings, if any,
generated from our operations will be used to finance the growth of our business, and that no dividends will be paid to holders of our
common stock. As a result, the success of an investment in our common stock will depend upon any future appreciation in its value. There
is no guarantee that our common stock will appreciate in value.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Certain
provisions of our Certificate of Incorporation and Bylaws and Delaware law make it more difficult for a third party to acquire us and
make a takeover more difficult to complete, even if such a transaction were in our stockholders&#8217; interest.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
of our certificate of incorporation and bylaws may delay or discourage transactions involving an actual or potential change in our control
or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions
that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price
of our stock. Among other things, the certificate of incorporation and bylaws:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide that the authorized
    number of directors may be changed by resolution of the board of directors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide that all vacancies,
    including newly-created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority
    of directors then in office, even if less than a quorum;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">divide the board of directors
    into three classes;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide that stockholders
    seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of
    stockholders must provide notice in writing in a timely manner, and meet specific requirements as to the form and content of a stockholder&#8217;s
    notice;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we are governed by Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a public Delaware
corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three
years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved
in a prescribed manner. A &#8220;business combination&#8221; includes mergers, asset sales or other transactions resulting in a financial
benefit to the stockholder. An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or
within three years, did own, 15% or more of the corporation&#8217;s outstanding voting stock. These provisions may have the effect of
delaying, deferring or preventing a change in our control.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
Risk Factors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face risks associated with litigation
and claims.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We are subject to certain legal proceedings, as further described under
&#8220;Legal Proceedings.&#8221; In addition, from time to time, we may become involved in various claims, disputes and legal or regulatory
proceedings that arise in the ordinary course of business and relate to contractual and other obligations. Due to the uncertainties of
litigation, we can give no assurance that we will prevail on any claims made against us in any such lawsuit. Also, we can give no assurance
that any other lawsuits or claims brought in the future will not have an adverse effect on our financial condition, liquidity, or operating
results. Adverse outcomes in some or all of these claims may result in significant monetary damages that could adversely affect our ability
to conduct our business.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compliance
with the reporting requirements of federal securities laws can be expensive.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the information and reporting requirements of the Exchange Act and other federal securities laws, and the compliance obligations
of the Sarbanes-Oxley Act. The costs of preparing and filing annual and quarterly reports and other information with the Securities and
Exchange Commission and furnishing audited reports to stockholders are substantial. In addition, we will incur substantial expenses in
connection with the preparation of registration statements and related documents with respect to any offerings of our common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to utilize our federal net operating loss and tax credit carryforwards may be limited under Sections 382 and 383 of the Internal
Revenue Code of 1986, as amended, or the Code.&#160;The limitations apply if we experience an &#8220;ownership change&#8221;, generally
defined as a greater than 50 percentage point change in the ownership of our equity by certain stockholders over a rolling three-year
period.&#160;Similar provisions of state tax law may also apply. We have not assessed whether such an ownership change has previously
occurred.&#160;If we have experienced an ownership change at any time since our formation, we may already be subject to limitations on
our ability to utilize our existing net operating losses and other tax attributes to offset taxable income. In addition, future changes
in our stock ownership, which may be outside of our control, may trigger an ownership change and, consequently, the limitations under
Sections 382 and 383 of the Code.&#160;As a result, if or when we earn net taxable income, our ability to use our pre-change net operating
loss carryforwards and other tax attributes to offset such taxable income may be subject to limitations, which could adversely affect
our future cash flows.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to establish and maintain adequate finance infrastructure and accounting systems and controls could impair our ability to comply with
the financial reporting and internal controls requirements for publicly traded companies.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we operate in an increasingly demanding regulatory environment, including with respect to more complex accounting rules.
Company responsibilities required by the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, include establishing and
maintaining corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. Effective
internal controls are necessary for us to produce reliable financial reports and are important to help prevent financial fraud.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compliance with Section 404 of the Sarbanes-Oxley Act requires that we incur substantial accounting expense and expend significant management
efforts. We complied with Section 404 at December 31, 2024 and 2023 and while our testing did not reveal any material weaknesses in our
internal controls, any material weaknesses in our internal controls in the future would be required us to remediate in a timely manner
so as to be able to comply with the requirements of Section 404 each year. If we are not able to comply with the requirements of Section
404 in a timely manner each year, we could be subject to sanctions or investigations by the SEC, NYSE American or other regulatory authorities
which would require additional financial and management resources and could adversely affect the market price of our common stock. Furthermore,
if we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, and investors
could lose confidence in our reported financial information.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the price of
our common stock and trading volume could decline.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about
us or our business. Multiple securities and industry analysts currently cover us. If one or more of the analysts downgrade our common
stock or publish inaccurate or unfavorable research about our business, the price of our common stock would likely decline. If one or
more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which
could cause the price of our common stock and trading volume to decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
amended and restated&#160;bylaws, as amended,&#160;designate the U.S.&#160;federal&#160;district courts as the&#160;exclusive forum&#160;for
the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated&#160;bylaws, as amended,&#160;provide that, unless we consent in writing to the selection of an alternative forum,
the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause
of action arising under the Securities Act of 1933, as amended. In addition, our amended and restated bylaws, as amended, state that
any person purchasing or otherwise acquiring any interest in our security shall be deemed to have notice of and to have consented to
such provision. Such choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds
favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits, if successful, might
benefit our stockholders. Stockholders who do bring a claim in the federal district courts of the United States of America could face
additional litigation costs in pursuing any such claim.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tariff policies and potential countermeasures
could increase our costs and disrupt our global supply chain, which could negatively impact the results of our operations. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">President Trump has increased,
and has indicated his willingness to continue to increase, the use of tariffs by the U.S. to accomplish certain U.S. policy goals. Such
tariffs and any countermeasures could increase the cost of raw materials and components necessary for our operations, disrupt our global
supply chain and create additional operational challenges. Further, it is possible that government policy changes and related uncertainty
about policy changes could increase market volatility. Because of these dynamics, we cannot predict the impact of any future changes to
the U.S.&#8217;s or other countries&#8217; trading relationships or the impact of new laws or regulations adopted by the U.S. or other
countries on our business. Such changes in tariffs and trade regulations could have a material adverse effect on our financial condition,
results of operations and cash flows.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
1B. UNRESOLVED STAFF COMMENTS.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
1C. CYBERSECURITY.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="ixv-5382"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates in the biotechnology sector and is subject to various cybersecurity risks that could adversely affect the Company&#8217;s
business, financial condition or results of operations, including intellectual property theft, fraud, extortion, harm to employees, collaborators
or vendors, violation of privacy laws and other litigations, legal and reputational risk.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_2" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company acknowledges that an actual or perceived
breach of its information assets could damage its reputation, interfere with the progress of clinical trials, or interfere with efforts
to pursue regulatory approvals for its product candidates. The Company also recognizes that an actual or perceived breach of its information
assets could impact the Company&#8217;s business strategy, operations, or financial condition, as well as subject Actinium to third&#8211;party
lawsuits, regulatory fines or other actions or liabilities, any of which could adversely affect the Company. For further information,
see &#8220;Risk Factors&#8212;Our business is subject to cybersecurity risks&#8221; in Item 1A of this Annual Report on Form 10&#8211;K.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_3" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actinium&#8217;s
Risk Management Strategy:</b></span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_4" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="ixv-5407"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the critical importance of developing, implementing, and maintaining robust cybersecurity measures to safeguard its
information systems and protect the confidentiality, integrity, and availability of its data. With that objective, the Company undertook
a focused cybersecurity assessment conducted by an independent cybersecurity advisory firm to better understand the current cybersecurity
threats and risks necessary to establish the foundation of a cybersecurity risk assessment framework appropriate for its current business
operations and needs. The Company has also engaged well-known and established technology suppliers to support its key technology processes
and operating technical security management activities including threat, vulnerability, and network security management.</span></p></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_5" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_4"><ix:continuation id="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has established an Incident Response Policy and recovery plans to address its response to a cybersecurity incident, and such
plans are tested and evaluated on a regular basis. This includes continuous security operation centers monitoring of the Company&#8217;s
systems and accounts.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_6" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company proactively mitigates its financial exposure to cybersecurity incidents by maintaining a cyber liability insurance policy. However,
the Company&#8217;s cyber liability insurance may be inadequate or may not be available in the future on acceptable terms, or at all.
In addition, the Company&#8217;s cyber liability insurance policy may not cover all claims made against the Company. Defending a suit,
regardless of its merit, could be costly and divert management&#8217;s attention from the Company&#8217;s business and operations.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_7" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" id="ixv-5430"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, Actinium has <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="ixv-14966">not</ix:nonNumeric> experienced any material cybersecurity incident that affected the Company&#8217;s operations or financial condition.</span></p></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_8" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Governance:</b></span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_9" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskBoardOfDirectorsOversightTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="ixv-5459"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on a multidisciplinary team including third-party service providers to assess how identified cybersecurity threats could impact
our business. <ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="ixv-14967"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="ixv-14968">The Company&#8217;s cybersecurity function is managed by the Company&#8217;s Chief Financial Officer, who assumes the overall
responsibility and accountability of the function and with select members of the Company&#8217;s management is collectively responsible
for the day&#8211;to&#8211;day assessment and management of cybersecurity risks, their prevention, mitigation, detection, and remediation.</ix:nonNumeric>
Our Chief Financial Officer and other members of management have undergone various briefings from our cybersecurity advisory firm to
prepare them to effectively assess and manage material risks from cybersecurity threats.</ix:nonNumeric> Additionally, members of the third-party service
providers have cybersecurity experience and/or certifications.</span></p></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_10" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_9"><ix:continuation id="_CybersecurityRiskBoardOfDirectorsOversightTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" id="ixv-14969">Company&#8217;s Board</ix:nonNumeric> is involved in overseeing our risk management processes and policies that may be implemented from time to time.
<ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="ixv-14970">The <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="ixv-14971">Audit</ix:nonNumeric> Committee will coordinate these activities through regular interactions with the Company&#8217;s management including but not
limited to: presentations regarding recent developments, potential risks associated with third parties, emerging trends, any relevant
findings or any incident that rises to the level of established thresholds.</ix:nonNumeric></span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risk factors discussed in this document should be considered together with information included elsewhere in the Annual Report on Form
10&#8211;K and should not be considered as the only risks to which the Company is exposed.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
2. PROPERTIES.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not own any real property.
We have leased offices at 100 Park Avenue, New York, NY effective June 1, 2022. The lease has a term of 5 years 2 months, with an expiration
date in 2027, and a current annual rate of $623 thousand. We are also responsible for certain other costs, such as insurance, taxes, utilities
and maintenance. We issued a letter of credit in connection with the lease and as of December 31, 2024, maintain a $324 thousand certified
deposit as collateral for the letter of credit.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We lease lab space and office space at Albert
Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY. The lease has a term of twelve months, expiring August 31, 2025, with
a current annual rate of $140 thousand.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
3. LEGAL PROCEEDINGS.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">From time to time, we may become involved in various lawsuits and legal
proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in
these or other matters may arise from time to time that may harm business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 27, 2025, a
putative class action complaint (the &#8220;Complaint&#8221;) was filed by alleged stockholder Nihil Kohil against the Company and
executives Sandesh Seth, Avinash Desai, Madhuri Vusirikala, and Sergio Giralt, styled&#160;<i>Kohil v. Actinium Pharmaceuticals,
Inc., et al</i>., Case No. 1:25-cv-02553 in the Southern District of New York, wherein, the Complaint alleges that the defendants
made material misrepresentations and omissions concerning the Iomab-B Phase 3 Sierra Trial and the plaintiff asserts claims against
all defendants pursuant to section 10(b) of the Securities Exchange Act (the &#8220;Exchange Act&#8221;) and Rule 10b-5 promulgated
thereunder, as well as additional claims against the individual defendants pursuant to Section 20(a) of the Exchange Act.&#160; The
Complaint purports to assert class action claims on behalf of all persons and entities that purchased or otherwise acquired Actinium
securities between October 31, 2022 and August 2, 2024.&#160; Plaintiff seeks unspecified damages.&#160; The defendants have not yet
responded to the complaint, and they intend to vigorously defend themselves against the plaintiff&#8217;s allegations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company and other defendants
intend to defend vigorously against such claims, however, there can be no assurances as to the outcome.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
4. MINE SAFETY DISCLOSURES.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
II</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDERS MATTERS, AND ISSUER PURCHASE OF EQUITY SECURITIES.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Information</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed for quotation on the NYSE American under the symbol &#8220;ATNM&#8221;.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Holders</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 28, 2025, there were 31,195,891 shares of common stock issued and outstanding, which were held by approximately 100 holders
of record. There are no shares of preferred stock outstanding.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends on our common stock. For the foreseeable future, it is expected that earnings, if any,
generated from our operations will be used to finance the growth of our business, and that no dividends will be paid to holders of our
common stock. The decision to pay dividends is at the discretion of our Board of Directors and depends upon our financial condition,
results of operations, capital requirements, and other factors that our Board of Directors deems relevant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Authorized for Issuance under Equity Compensation Plans</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have one equity compensation plan. The Company&#8217;s 2019 Amended and Restated Stock Plan, (the &#8220;2019 Plan&#8221;)
has an expiration date of October&#160;18, 2029 and the number of shares of our common stock authorized under the plan for grant to employees,
directors and consultants is 9,333,333 shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had two equity compensation plans that expired on September 9, 2023; the Company&#8217;s Amended and Restated 2013 Stock Plan and the
Company&#8217;s 2013 Equity Incentive Plan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table indicates shares of common stock authorized for issuance under our equity compensation plans as of December 31, 2024:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Plan category</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#160;of<br/> securities&#160;to<br/> be&#160;issued<br/> upon&#160;exercise<br/> of&#160;outstanding<br/> options and restricted stock units<br/> (1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> average<br/> exercise<br/> price&#160;of<br/> outstanding<br/> options <br/> (2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#160;of<br/> securities<br/> remaining<br/> available<br/> for&#160;future<br/> issuance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Equity compensation plans approved by security holders</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,437,413</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6.48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,322,664</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity compensation plans not approved by security holders</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,437,413</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6.48</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,322,664</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes shares issuable
    upon the conversion of outstanding restricted stock units (&#8220;RSUs&#8221;).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Weighted Average Exercise
    Price column does not include an amount for outstanding RSUs.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
6. RESERVED.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>The information and financial
data discussed below is derived from the audited consolidated financial statements of Actinium Pharmaceuticals, Inc. for its fiscal years
ended December 31, 2024 and 2023.&#160;The consolidated financial statements of Actinium Pharmaceuticals, Inc. were prepared and presented
in accordance with generally accepted accounting principles in the United States. The information and financial data discussed below
is only a summary and should be read in conjunction with the historical financial statements and related notes of Actinium Pharmaceuticals,
Inc. contained elsewhere in this&#160;Report. The financial statements contained elsewhere in this Report fully represent Actinium Pharmaceuticals,
Inc.&#8217;s financial condition and operations; however, they are not indicative of the Company&#8217;s future performance. See &#8220;Cautionary
Note Regarding Forward-Looking Statements&#8221; above for a discussion of forward-looking statements and the significance of such statements
in the context of this Report.&#160;See also &#8220;Risk Factors&#8221; in Part I, Item 1A of this Report for a discussion of risks and
uncertainties that could impact Actinium Pharmaceuticals, Inc.&#8217;s future financial condition, operations and performance.&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium Pharmaceuticals,
Inc. (&#8220;Actinium&#8221;, the &#8220;Company&#8221;, or &#8220;we&#8221;) is a pioneer in the development of targeted radiotherapies
intended to meaningfully improve outcomes for patients with relapsed or refractory cancer who have failed existing therapies. We operate
as a single operating segment focused on research, discovery, and clinical development of targeted radiotherapies.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations &#8211; Year Ended December 31, 2024 Compared to the Year Ended December 31, 2023</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth, for the periods indicated, data derived from our statements of operations:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Increase</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(amounts in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Decrease)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Other revenue</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">81</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(81</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Total revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">81</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(81</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Research and development, net of reimbursements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,045</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,670</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,625</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,076</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,331</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,255</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42,121</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,001</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,880</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Interest income &#8211; net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,878</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,102</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">776</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,878</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,102</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">776</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(38,243</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(48,818</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(10,575</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenues</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recorded no commercial revenues for the years ended December 31, 2024 and 2023, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
revenue</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
National Institutes of Health awarded us a Small Business Technology Transfer cost reimbursable grant to support a clinical collaboration
with Memorial Sloan Kettering Cancer Center, or MSK, to study Iomab-ACT, our CD45-targeting Antibody Radio-Conjugate, for targeted conditioning
to achieve lymphodepletion prior to administration of a CD19-targeted CAR T-cell therapy developed at MSK. We recognized other revenue
during the year ended December 31, 2023 of $0.1 million from this grant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 7, 2022, we entered into a License Agreement with Immedica, pursuant to which Immedica licensed the exclusive product rights for
commercialization of Iomab-B in certain countries in the EUMENA region. Upon signing, we were entitled to an upfront, non-refundable
payment of $35.0 million from Immedica, which was received in May 2022. Under the terms of the License Agreement, we are eligible to
receive certain regulatory and commercial milestone payments and royalties on net sales of the product in certain countries that may
result from the License Agreement. We continue to retain commercialization rights in the U.S. and rest of the world.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
contract liabilities are recorded within Other revenue deferred &#8211; current liability or Long-term license revenue deferred in our
condensed consolidated balance sheets depending on the short-term or long-term nature of the payments to be recognized. Our contract
liabilities primarily consist of advanced payments from licensees. Long-term license revenue deferred was $35.0 million at December 31,
2024 and December 31, 2023, resulting from the receipt from Immedica; this deferred revenue will be recognized upon the European Union&#8217;s
regulatory approval of Iomab-B or provision of definitive feedback that Iomab-B will not receive approval in the European Union.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Expenses, net of reimbursements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
decreased by $8.6 million to $30.0 million for the year ended December 31, 2024, compared to $38.7 million for the year ended December
31, 2023. This decrease was primarily due to CMC expenses declining by $12.0 million and consulting expenses declining by $1.7 million
due to lower CMC activity related to Iomab-B. These declines were partially offset by increased preclinical expenses of $5.0 million.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the third quarter of 2024, our overall headcount was reduced by approximately twenty percent, with a majority of these former employees
being from our clinical and CMC groups. As a result of these departures, we expect our personnel expenses to be reduced by approximately
$3.7 million in 2025, which may be offset by additional hires or consultants. We do not expect these departures to have a material impact
on our operations or ability to execute our operating plan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
and Administrative Expenses</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses decreased by $1.3 million to $12.1 million for the year ended December 31, 2024, compared to $13.3 million for the year ended
December 31, 2023. Lower expenses were primarily the result of lower consulting fees and legal fees of $1.6 million and lower compensation
expense of $0.6 million due to lower headcount, partially offset by higher non-cash compensation expense of $1.2 million.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Income</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income is comprised of net interest income in both reporting periods. Other income of $3.9 million for the year ended December 31, 2024
increased from $3.1 million for the year ended December 31, 2023 primarily due to higher average interest rates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
Loss</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss decreased by $10.6 million to $38.2 million for the year ended December 31, 2024, compared to $48.8 million for the year ended December
31, 2023 due to lower research and development expenses, lower general and administrative expenses and a higher level of other income.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
we have financed our operations primarily through sales of our common stock and common stock equivalents. The following tables sets forth
selected cash flow information for the periods indicated:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(amounts in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(33,072</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(47,335</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(153</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29,321</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,870</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net&#160;change in cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(3,762</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(32,618</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities for the year ended December 31, 2024 was $33.1 million, a decrease of $14.2 million from $47.3 million
in the prior-year period, primarily as a result of a lower net loss of $10.8 million and a decrease in net operating assets and liabilities of $2.2 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities was $11 thousand and $153 thousand for the years ended December 31, 2024 and December 31, 2023, respectively,
primarily due to the purchase of equipment for our laboratory space.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, we entered into the Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC, or JonesTrading,
pursuant to which we are able to sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of our common
stock. On June 28, 2022, we entered into an Amendment and Restated Capital on Demand&#8482; Sales Agreement, or the Amended Sales Agreement,
with JonesTrading and B. Riley Securities, Inc. (&#8220;B. Riley&#8221;). The Amended Sales Agreement modifies the original Capital on
Demand&#8482; Sales Agreement to include B. Riley as an additional sales agent thereunder. Shares of common stock were offered pursuant
to a shelf registration statement on Form S-3 (File No. 333-242322) filed with the SEC on August 7, 2020 (the &#8220;Prior Shelf Registration
Statement&#8221;). On August 11, 2023, we filed a registration statement on Form S-3 (File No. 333-273911), and amended on February 2,
2024, which was declared effective on February 5, 2024, to replace the Prior Shelf Registration Statement, including a base prospectus
which covers the offering, issuance and sale of up to $500 million of common stock, preferred stock, warrants, units and/or subscription
rights; and a sales agreement prospectus covering the offering, issuance and sale of up to a maximum aggregate offering price of $200
million of common stock that may be issued and sold under the Amended Sales Agreement. For the year ended December 31, 2024, we sold
3.5 million shares of common stock, resulting in gross proceeds of $29.9 million and net proceeds of $29.3 million. For the year ended
December 31, 2023, we sold 1.9 million shares of common stock, resulting in gross proceeds of $15.1 million and net proceeds of $14.6
million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into a lease for corporate office space effective June 1, 2022. The lease has a term of five years and two months, with an expiration
date in 2027, and current annual rent of $0.6 million. We are also responsible for certain other costs, such as insurance, utilities
and maintenance. We issued a letter of credit in connection with the lease and as of December 31, 2024 maintain a $0.3 million certified
deposit as collateral for the letter of credit.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will require additional funds to conduct clinical and non-clinical trials, achieve regulatory approvals, and, subject to such approvals,
commercially launch our product candidates, and will need to secure additional financing in the future to support our operations. As
of the date of filing this report, we expect that our existing resources will be more than sufficient to fund our planned operations
for more than 12 months following the date of this report. We base this belief on assumptions that are subject to change, and we may
be required to use our available cash and cash equivalent resources sooner than we currently expect. Our actual future capital requirements
will depend on many factors, including the progress and results of our ongoing clinical trials, the duration and cost of discovery and
preclinical development, laboratory testing and clinical trials for our pipeline candidates, the timing and outcome of regulatory review
of our product candidates, the costs involved in preparing, filing, prosecuting, maintaining, defending, and enforcing patent claims
and other intellectual property rights, the number and development requirements of other pipeline candidates that we pursue, and the
costs of commercialization activities, including product marketing, sales, and distribution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to operate at a net loss as we continue our research and development efforts, continue to conduct clinical trials
and develop manufacturing, sales, marketing and distribution capabilities. There can be no assurance that the products under development
by us will be approved for sale in the United States or elsewhere. Our ability to obtain additional capital may depend on prevailing
economic conditions and financial, business, and other factors beyond our control. Current economic conditions have been, and continue
to be, volatile. Continued instability in these market conditions may limit our ability to access the capital necessary to fund and grow
our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any off-balance sheet arrangements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Estimates</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management&#8217;s discussion
and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared
in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;). The preparation of these financial
statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure
of contingent assets and liabilities in our consolidated financial statements during the reporting periods. These items are monitored
and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base
our estimates on historical experience, known trends and events, and on various other factors that we believe are reasonable under the
circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not
readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known.
Actual results may differ materially from these estimates under different assumptions or conditions. The Company does not have any critical
accounting estimates.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Adopted Accounting Pronouncements </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2023, the Financial
Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU 2023-07, <i>Segment Reporting </i>(Topic 280), <i>Improvements
to Reportable Segment Disclosures</i>, which provides improvements to reportable segment disclosure requirements, primarily through enhanced
disclosures around segment expenses. ASU 2023-07 requires us to disclose significant segment expenses that are regularly provided to the
chief operating decision maker, or CODM, and included within each reported measure of segment profit or loss. ASU 2023-07 also requires
that we disclose an amount for other segment items by reportable segment, a description of their composition and provide all annual disclosures
about a reportable segment&#8217;s profit or loss and assets pursuant to Topic 280 during interim periods. We must also disclose the CODM&#8217;s
title and position, as well as certain information around the measures used by the CODM and an explanation of how the CODM uses the reported
measures in assessing segment performance and deciding how to allocate resources. For public entities with a single reportable segment,
such as us, the entity must provide all the disclosures required pursuant to ASU 2023-07 and all existing segment disclosures under Topic
280. The amendments of ASU 2023-07 are effective for annual periods beginning January 1, 2024, and effective for interim periods beginning
January 1, 2025. We adopted this standard effective January 1, 2024 and reported on it in this Annual Report on Form 10-K for the year
ended December 31, 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued Accounting Pronouncements </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, FASB issued ASU 2024-03, <i>Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures</i> (Subtopic
220-40), to improve the disaggregation of expenses within the consolidated statement of operations. The amendments in ASU 2024-03 require
disclosures in the notes to the consolidated financial statements and specified information about certain costs and expenses. The amendments
require that at each interim and annual reporting period an entity disclose (a) employee compensation, (b) depreciation, and (c) intangible
asset amortization included in each relevant expense caption; include certain amounts that are already required to be disclosed under
current GAAP in the same disclosure as the other disaggregation requirements; and disclose a qualitative description of the amounts remaining
in relevant expense captions that are not separately disaggregated quantitatively. The amendments in ASU 2024-03 are effective January
1, 2027 and effective for interim periods beginning January 1, 2028. We will evaluate the impact of ASU 2024-03 on our financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, FASB issued ASU 2023-09, <i>Income Taxes</i> (Topic 740): <i>Improvements to Income Tax Disclosures</i>, to enhance the
transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide improvements primarily related
to the rate reconciliation and income taxes paid information included in income tax disclosures. We will be required to disclose additional
information regarding reconciling items equal to or greater than five percent of the amount computed by multiplying pretax income (loss)
by the applicable statutory tax rate. Similarly, we will be required to disclose income taxes paid (net of refunds received) equal to
or greater than five percent of total income taxes paid (net of refunds received). The amendments in ASU 2023-09 are effective for fiscal
years beginning January 1, 2025, including interim periods. We will evaluate the impact of ASU 2023-09 on our financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Subsequent Events</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 27, 2025, a putative
class action complaint (the &#8220;Complaint&#8221;) was filed by alleged stockholder Nihil Kohil against the Company and executives Sandesh
Seth, Avinash Desai, Madhuri Vusirikala, and Sergio Giralt, styled&#160;<i>Kohil v. Actinium Pharmaceuticals, Inc., et al</i>., Case No.
1:25-cv-02553 in the Southern District of New York, wherein, the Complaint alleges that the defendants made material misrepresentations
and omissions concerning the Iomab-B Phase 3 Sierra Trial and the plaintiff asserts claims against all defendants pursuant to section
10(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and Rule 10b-5 promulgated thereunder, as well
as additional claims against the individual defendants pursuant to Section 20(a) of the Exchange Act.&#160; The Complaint purports to
assert class action claims on behalf of all persons and entities that purchased or otherwise acquired Actinium securities between October
31, 2022 and August 2, 2024.&#160; Plaintiff seeks unspecified damages.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The defendants have not yet
responded to the complaint, and they intend to vigorously defend themselves against the plaintiff&#8217;s allegations however, there can
be no assurances as to the outcome.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 31, 2025, our Board
of Directors of approved the cancellation of certain stock options to purchase 5,149,944 shares of common stock held by certain current
employees and directors that were initially granted under the Company&#8217;s Amended and Restated 2013 Stock Plan and 2019 Amended and
Restated Stock Plan. Such cancellation is subject to the consent of the applicable holder of the stock options, which the Company is expecting
to receive shortly following the filing of this Annual Report on Form 10-K. Our Compensation Committee intends to conduct an analysis
of our equity compensation plan and develop an equity compensation strategy that satisfies the purpose of the 2019 Plan to attract and
retain the best available personnel who can make meaningful contributions towards achieving the business objectives of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required
under this item.</span></p><div>


</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders and Board of Directors of</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals, Inc.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AuditorOpinionTextBlock-c0_cont_1" escape="true" name="dei:AuditorOpinionTextBlock" id="ixv-6423"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_AuditorOpinionTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Actinium Pharmaceuticals, Inc. (the &#8220;Company&#8221;) as of December
31, 2024 and 2023, and the related consolidated statements of operations, changes in stockholders&#8217; equity and cash flows for each
of the two years in the period ended December 31, 2024 and the related notes (collectively referred to as the &#8220;financial statements&#8221;).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024,
in conformity with accounting principles generally accepted in the United States of America.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matters</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical
audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be
communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and
(2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-6480">Marcum <span style="font-variant: small-caps">llp</span></ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum
<span style="font-variant: small-caps">llp</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2012<b>.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-6502"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Houston,
Texas</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2025</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 73; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actinium
Pharmaceuticals, Inc.<br/>
Consolidated Balance Sheets</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(amounts
in thousands, except share and per share data)&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Current Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-14972">72,904</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-14973">76,677</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-14974">1,602</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-14975">1,586</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 27pt">Total Current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-14976">74,506</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-14977">78,263</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Property and equipment, net of accumulated depreciation of $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-14978">891</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-14979">694</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-14980">364</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-14981">550</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Restricted cash &#8211; long term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd" id="ixv-14982">324</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd" id="ixv-14983">313</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-14984">1,685</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-14985">2,289</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Finance leases right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-14986">20</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-14987">30</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total Assets</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-14988">76,899</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-14989">81,445</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center; text-indent: -9pt; padding-left: 9pt">Liabilities and Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-14990">7,568</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-14991">7,953</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Operating leases current liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-14992">569</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-14993">530</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Finance leases current liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-14994">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-14995">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 27pt">Total Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-14996">8,148</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-14997">8,494</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Long-term license revenue deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-14998">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-14999">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Long-term operating lease obligations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-15000">984</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-15001">1,553</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Long-term finance lease obligations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-15002">9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-15003">19</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-15004">44,141</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-15005">45,066</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Commitments and contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Stockholders&#8217; Equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Preferred stock, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-15006"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-15007">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-15008"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-15009">50,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-15010"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-15011"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-15012"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-15013">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Common stock, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-15014"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-15015">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-15016"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-15017">1,000,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-15018"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-15019">31,195,891</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-15020"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-15021">27,634,213</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2024 and 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-15022">31</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-15023">28</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-15024">408,553</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-15025">373,934</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-15026">375,826</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-15027">337,583</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-15028">32,758</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-15029">36,379</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-15030">76,899</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-15031">81,445</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actinium
Pharmaceuticals, Inc.<br/>
Consolidated Statements of Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(amounts
in thousands, except share and per share data)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Revenue</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other Revenue</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-15032">81</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-15033">81</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Research and development, net of reimbursements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-15034">30,045</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-15035">38,670</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-15036">12,076</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-15037">13,331</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-15038">42,121</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-15039">52,001</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-15040">42,121</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-15041">51,920</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest income &#8211; net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-15042">3,878</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-15043">3,102</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-15044">3,878</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-15045">3,102</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net loss</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-15046">38,243</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-15047">48,818</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net loss per common share &#8211; basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-15048"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-15049">1.27</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c9" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-15050"><ix:nonFraction contextRef="c9" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-15051">1.83</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Weighted average common shares outstanding &#8211; basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-15052"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-15053">30,070,028</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-15054"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-15055">26,604,045</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;</b></span></p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actinium
Pharmaceuticals, Inc.<br/>
Consolidated Statements of Changes in Stockholders&#8217; Equity<br/>
For the Years Ended December 31, 2024 and 2023<br/>
</b>(amounts in thousands, except share amounts)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Paid-In</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Stockholders&#8217;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Equity</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, January 1, 2023</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-15056">25,674,823</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-15057">26</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-15058">355,220</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-15059">288,765</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-15060">66,481</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" unitRef="shares" id="ixv-15061">13,144</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-15062">3,842</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-15063">3,842</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Sale of common stock, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-15064">1,902,005</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-15065">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-15066">14,610</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-15067">14,612</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of common stock from exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-15068">44,241</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-15069">262</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-15070">262</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-15071">48,818</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-15072">48,818</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, December 31, 2023</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-15073">27,634,213</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-15074">28</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-15075">373,934</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-15076">337,583</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-15077">36,379</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" unitRef="shares" id="ixv-15078">13,394</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-15079">5,292</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-15080">5,292</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Sale of common stock, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-15081">3,538,136</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-15082">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-15083">29,252</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-15084">29,255</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of common stock from exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-15085">10,148</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-15086">75</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-15087">75</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-15088">38,243</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-15089">38,243</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance, December 31, 2024</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-15090">31,195,891</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-15091">31</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-15092">408,553</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-15093">375,826</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-15094">32,758</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span>&#160;</p><div>

</div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actinium
Pharmaceuticals, Inc.<br/>
Consolidated Statements of Cash Flows</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(amounts
in thousands)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cash Flows from Operating Activities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-15095">38,243</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-15096">48,818</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Adjustments to reconcile net loss to net cash used in/provided by operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-15097">5,292</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-15098">3,842</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Depreciation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-15099">197</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-15100">207</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Amortization of right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd" id="ixv-15101">614</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd" id="ixv-15102">583</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitRef="usd" id="ixv-15103">15</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" sign="-" unitRef="usd" id="ixv-15104">49</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-15105">387</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-15106">2,177</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="atnm:IncreaseDecreaseInOperatingLeaseRightofuseAssets" scale="3" sign="-" unitRef="usd" id="ixv-15107">527</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-15108">530</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-15109">494</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net Cash Used In
    Operating Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-15110">33,072</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-15111">47,335</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash Flows Used in Investing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Purchase of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-15112">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-15113">153</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net Cash Used In Investing Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-15114">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-15115">153</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash Flows from Financing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Payments on finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd" id="ixv-15116">9</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd" id="ixv-15117">4</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Proceeds from sales of shares of common stock, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-15118">29,255</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-15119">14,612</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Proceeds from the exercise of stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd" id="ixv-15120">75</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd" id="ixv-15121">262</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net Cash Provided By Financing Activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-15122">29,321</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-15123">14,870</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Net change in cash, cash equivalents and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-15124">3,762</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-15125">32,618</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cash, cash equivalents and restricted cash at beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-15126">76,990</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-15127">109,608</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Cash, cash equivalents and restricted cash at end of year</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-15128">73,228</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-15129">76,990</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Supplemental disclosures of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash paid for interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash paid for taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Supplemental disclosure of non-cash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Right-of-use assets obtained in exchange for lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="atnm:RightofuseAssetObtainedInExchangeForLeaseLiabilities" scale="3" unitRef="usd" id="ixv-15130">30</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="f_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actinium
Pharmaceuticals, Inc.<br/>
Notes to Consolidated Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="ixv-7917"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 - Description of Business and Summary of Significant Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="atnm:NatureOfBusinessPolicyPolicyTextBlock" id="ixv-7923"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nature
of Business - </b>Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing ARCs and other targeted radiotherapies to
deliver cancer-killing radiation with cellular level precision to treat patients with high unmet medical needs.</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ConsolidationPolicyTextBlock" id="ixv-7930"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principles
of Consolidation -</b> The consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly
owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:UseOfEstimates" id="ixv-7936"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Estimates in Financial Statement Presentation -</b> The preparation of these consolidated financial statements in conformity with
accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses
during the reporting period. Actual results could differ from those estimates.</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-7942"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Segment
Information </b>- The Company operates as a single operating and reportable segment for the purposes of assessing performance and allocating
resources. The Company&#8217;s chief operating decision maker is its Chief Executive Officer, who reviews total assets in the consolidated
balance sheets and net loss and its components in the consolidated statements of operations: research and development expenses, general and administrative expenses, and interest income, for the purposes of making operating decisions,
assessing financial performance, and allocating resources.&#160;All assets are in the United States.</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="ixv-7948"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
and Cash Equivalents and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months
or less to be cash equivalents. The Company holds most of its cash equivalents in a Money Market account comprised of U.S. Treasury notes.
Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="ixv-7954"><ix:continuation continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_2" id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
is a summary of cash, cash equivalents and restricted cash at December 31, 2024 and December 31, 2023:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_3" id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_2"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-15131">72,904</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-15132">76,677</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd" id="ixv-15133">324</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd" id="ixv-15134">313</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-15135">73,228</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-15136">76,990</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
cash relates to certificates of deposit held as collateral for letters of credit issued in connection with the Company&#8217;s leases
of corporate office spaces.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-8009"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property
and Equipment -</b> Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives
of <ix:nonNumeric contextRef="c26" continuedAt="_PropertyPlantAndEquipmentUsefulLife-c26_cont_1" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-15137">three</ix:nonNumeric> to <ix:nonNumeric contextRef="c27" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-15138">five<ix:continuation id="_PropertyPlantAndEquipmentUsefulLife-c26_cont_1"> years</ix:continuation></ix:nonNumeric>. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives
of <ix:nonNumeric contextRef="c28" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-15140">seven years</ix:nonNumeric>. When assets are retired, the cost and related accumulated depreciation are removed from the accounts, and any related
gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations when incurred. Capitalized lease
assets are recorded at the lesser of the present value of minimum lease payments or fair value and amortized over the estimated useful
life of the related property or term of the lease.</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-8015"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases
-</b> The Company has an operating lease for corporate office space and a finance lease for office equipment located at the corporate
office space. Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases
is recognized on a straight-line basis over the lease term.</span></p></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_2" id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-8035"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
Value Measurement - </b>Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability,
in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the
highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="ixv-8041"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue
Recognition </b>- The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, <i>Revenue From
Contracts With Customers</i> (&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of
promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods
or services. To determine revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps:
(i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction
price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue as the entity satisfies a performance obligation. The Company only applies the five-step model to contracts
when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers
to the customer.</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_2" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods
or services promised within each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services
that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. In
determining whether goods or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can
benefit from the good or service either on its own or together with other resources that are readily available to the customer (capable
of being distinct) and (ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct
in the context of the contract).</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_3" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company then determines the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange
for the promised goods or services for each performance obligation and recognizes the associated revenue as each performance obligation
is satisfied. The Company&#8217;s estimate of the transaction price for each contract includes all variable consideration to which it
expects to be entitled. Variable consideration includes payments in the form of collaboration milestone payments. If an arrangement includes
collaboration milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates
the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue
reversal would not occur, the associated milestone value is included in the transaction price.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
606 requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance
obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should
be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised
good or service separately to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated
to the respective performance obligation as each performance obligation is satisfied, either at a point in time or over time, and if
over time, recognition is based on the use of an output or input method.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="ixv-8063"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Collaborative
Arrangements</b> - The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain
transactions between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or
net basis, depending on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships.
The Company evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the
nature of the underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators,
the Company follows the guidance of ASC 606<i>.</i></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:GovernmentAssistancePolicyTextBlock" id="ixv-8070"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grant
Revenue - </b>The Company has a grant from a government-sponsored entity for research and development related activities that
provides for payments for reimbursed costs, which included overhead and general and administrative costs as well as an
administrative fee. The Company recognizes revenue from grants as it performed services under this arrangement. Associated expenses
are recognized when incurred as research and development expense. Revenue and related expenses are presented gross in the
consolidated statements of operations. There was no grant revenue for the year ended December 31, 2024.</span></p></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_3" id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="atnm_LicenseRevenuePolicyTextBlock-c0_cont_1" escape="true" name="atnm:LicenseRevenuePolicyTextBlock" id="ixv-8089"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
Revenue -</b> The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain
product in specified territories using the Company&#8217;s trademarks. The terms of this arrangement includes payment to the Company
for a combination of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments;
and royalties on net sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration
should be included in the transaction price.</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="atnm_LicenseRevenuePolicyTextBlock-c0_cont_2" id="atnm_LicenseRevenuePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Upfront
license fees</i>: If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance
obligations identified in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when
the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled
with other promises, the Company determines whether the combined performance obligation is satisfied over time or at a point in time.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="atnm_LicenseRevenuePolicyTextBlock-c0_cont_3" id="atnm_LicenseRevenuePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Development,
regulatory or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement
of certain development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered
probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it
is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.
Milestone payments that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered
probable of being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate
the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#8217;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="atnm_LicenseRevenuePolicyTextBlock-c0_cont_4" id="atnm_LicenseRevenuePolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales-based
milestone payments and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the
volume of sales, the Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based
milestones relate and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii)
when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="atnm_LicenseRevenuePolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upfront
payments and fees may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements or when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when
the uncertainty associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts
receivable when the Company&#8217;s right to consideration is unconditional.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-8119"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug
product, the costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to
facilities and equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development
costs.</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-8125"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share-Based
Payments -</b> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing
model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee
is required to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-8131"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income
Taxes -</b> The Company accounts for income taxes in accordance with ASC 740 <i>Income Taxes</i>, which requires the asset and liability
method to calculate deferred taxes. Deferred taxes are recognized based on the differences between the financial reporting and income
tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to
reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred
tax asset will be fully realized.</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
740 prescribes guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions. Tax positions
must meet a &#8220;more-likely-than-not&#8221; recognition threshold to be recognized. There were no tax positions for which it is considered
reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within the next year.
The Company recognizes interest related to unrecognized tax benefits in interest expense and penalties in operating expenses.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><ix:continuation id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-8159"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
Loss Per Common Share</b> - Basic loss per common share is computed by dividing the net loss available to common stockholders by the
weighted average number of common shares outstanding during the reporting period. For periods of net loss, diluted loss per share is
calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive.</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-8165"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2024 and 2023, the Company&#8217;s potentially dilutive shares, which include outstanding common stock options,
restricted stock units and warrants, have not been included in the computation of diluted net loss per share as the result would have
been anti-dilutive.&#160;</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-15141">5,137</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-15142">5,445</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-15143">300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-15144">305</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-15145">7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-15146">1,442</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-15147">5,444</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares" id="ixv-15148">7,192</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock" id="ixv-8225"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsequent
Events </b>- The Company&#8217;s management reviewed all material events through the date the consolidated financial statements were
issued for subsequent event disclosure consideration.&#160;</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-8231"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Adopted Accounting Pronouncements - </b>In November 2023, FASB issued ASU 2023-07, <i>Segment Reporting</i> (Topic 280), <i>Improvements
to Reportable Segment Disclosures</i>, which provides improvements to reportable segment disclosure requirements, primarily through enhanced
disclosures around segment expenses. ASU 2023-07 requires the Company to disclose significant segment expenses that are regularly provided
to the chief operating decision maker (&#8220;CODM&#8221;) and included within each reported measure of segment profit or loss. ASU 2023-07
also requires that the Company disclose an amount for other segment items by reportable segment, a description of their composition and
provide all annual disclosures about a reportable segment&#8217;s profit or loss and assets pursuant to Topic 280 during interim periods.
The Company must also disclose the CODM&#8217;s title and position, as well as certain information around the measures used by the CODM
and an explanation of how the CODM uses the reported measures in assessing segment performance and deciding how to allocate resources.
For public entities with a single reportable segment, the entity must provide all the disclosures required pursuant to ASU 2023-07 and
all existing segment disclosures under Topic 280. The amendments of ASU 2023-07 are effective for the Company for annual periods beginning
January 1, 2024, and effective for interim periods beginning January 1, 2025. The Company adopted this standard effective January 1,
2024 and reported on it in this Annual Report on Form 10-K for the year ended December 31, 2024.</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock-c0_cont_1" escape="true" name="atnm:RecentlyIssuedAccountingPronouncementsPolicyTextBlock" id="ixv-8239"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued Accounting Pronouncements - </b>In November 2024, FASB issued ASU 2024-03, <i>Income Statement-Reporting Comprehensive Income-Expense
Disaggregation Disclosures</i> (Subtopic 220-40), to improve the disaggregation of expenses within the consolidated statement of operations.
The amendments in ASU 2024-03 require disclosures, in the notes to the consolidated financial statements, specified information about
certain costs and expenses. The amendments require that at each interim and annual reporting period an entity disclose (a) employee compensation,
(b) depreciation, and (c) intangible asset amortization included in each relevant expense caption; include certain amounts that are already
required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; and disclose a qualitative
description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively. The amendments
in ASU 2024-03 are effective January 1, 2027, and effective for interim periods beginning January 1, 2028. The Company will evaluate
the impact of ASU 2024-03 on its financial statements.</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, FASB issued ASU 2023-09, <i>Income Taxes</i> (Topic 740): <i>Improvements to Income Tax Disclosures</i>, to enhance the
transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide improvements primarily related
to the rate reconciliation and income taxes paid information included in income tax disclosures. The Company will be required to disclose
additional information regarding reconciling items equal to or greater than five percent of the amount computed by multiplying pretax
income (loss) by the applicable statutory tax rate. Similarly, the Company will be required to disclose income taxes paid (net of refunds
received) equal to or greater than five percent of total income taxes paid (net of refunds received). The amendments in ASU 2023-09 are
effective January 1, 2025, including interim periods. The Company will evaluate the impact of ASU 2023-09 on its financial statements.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock" id="ixv-8266"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 - Prepaid Expenses and Other Current Assets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="ixv-8272"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets consisted of the following at December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid&#160;insurance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="3" unitRef="usd" id="ixv-15149">608</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="3" unitRef="usd" id="ixv-15150">614</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid&#160;clinical trial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" unitRef="usd" id="ixv-15151">637</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" unitRef="usd" id="ixv-15152">746</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-15153">357</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-15154">226</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-15155">1,602</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-15156">1,586</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-8338"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 - Property and Equipment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-8344"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consisted of the following at December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Lives</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center"><ix:nonNumeric contextRef="c35" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-15157">5</ix:nonNumeric> years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-15158">817</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-15159">806</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment&#160;and furniture</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c37" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-15160">3</ix:nonNumeric> - <ix:nonNumeric contextRef="c38" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-15161">7</ix:nonNumeric> years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-15162">438</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-15163">438</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-15164">891</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-15165">694</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-15166">364</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-15167">550</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="atnm:ScheduleOfDepreciationExpenseTableTextBlock" id="ixv-8420"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense consisted of the following for the years ended December 31, 2024 and 2023, respectively:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research&#160;and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-15168">161</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-15169">175</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-15170">36</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-15171">32</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total depreciation expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-15172">197</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-15173">207</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" id="ixv-8476"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 - Leases </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys
to the Company the right to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying
asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic
benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company
has elected to account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components
are recognized when the obligation is probable. The Company made an accounting policy election to exclude from balance sheet reporting
those leases with initial terms of 12 months or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use
assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842
requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily
determined, its incremental borrowing rate. As an implicit interest rate was not readily determinable in the Company&#8217;s leases,
the incremental borrowing rate was used based on the information available at commencement date in determining the present value of lease
payments.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_2" id="_LesseeOperatingLeasesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lease term for all of the Company&#8217;s leases includes the non-cancellable period of the lease plus any additional periods covered
by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option
to extend (or not to terminate) the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term
(and lease liability) for the Company&#8217;s leases as the reasonably certain threshold is not met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company has two leases which have been capitalized in accordance with ASC 842, one for corporate office space
and one for office equipment. The Company entered into a lease for corporate office space effective June 1, 2022. The lease has a term
of <ix:nonNumeric contextRef="c0" name="us-gaap:LesseeOperatingLeaseDescription" id="ixv-15174">5 years and 2 months</ix:nonNumeric>, with an expiration date on <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="us-gaap:LeaseExpirationDate1" id="ixv-15175">July 30, 2027</ix:nonNumeric> and current annual rent of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="6" unitRef="usd" id="ixv-15176">0.6</ix:nonFraction> million. The Company is also responsible
for certain other costs, such as insurance, utilities and maintenance. During the year ended December 31, 2023, the Company spent $<ix:nonFraction contextRef="c45" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LandImprovements" scale="6" unitRef="usd" id="ixv-15177">0.5</ix:nonFraction>
million on improvements at its corporate office space, which were included in the value of the operating right-to-use asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_LeaseCostTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LeaseCostTableTextBlock" id="ixv-8512"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of lease expense are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd" id="ixv-15178">691</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd" id="ixv-15179">691</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd" id="ixv-15180">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd" id="ixv-15181">3</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd" id="ixv-15182">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total finance lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd" id="ixv-15183">12</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd" id="ixv-15184">3</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
cash flow information related to leases are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cash flow information:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flow use from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd" id="ixv-15185">618</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd" id="ixv-15186">606</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" unitRef="usd" id="ixv-15187">11</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd" id="ixv-15188">9</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd" id="ixv-15189">4</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" unitRef="usd" id="ixv-15190">30</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
average remaining lease terms are as follows at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average remaining lease term:</td><td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 89%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-15191">2.6</ix:nonNumeric> years</td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Finance leases</td><td>&#160;</td> <td style="text-align: right"><ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-15192">2.0</ix:nonNumeric> years</td> <td>&#160;</td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the interest rate implicit in the leases was not readily determinable at the time that the leases were evaluated, the Company used its
incremental borrowing rate based on the information available in determining the present value of lease payments. The Company&#8217;s
incremental borrowing rate was based on the term of the lease, the economic environment of the lease and reflect the rate the Company
would have had to pay to borrow on a secured basis. <ix:continuation continuedAt="_LeaseCostTableTextBlock-c0_cont_2" id="_LeaseCostTableTextBlock-c0_cont_1">Below is information on the weighted average discount rates used at the time that
the leases were evaluated:</ix:continuation></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_LeaseCostTableTextBlock-c0_cont_2"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>Weighted average discount rates:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-15194">4.8</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-15195">6.2</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-8786"><ix:continuation id="_LesseeOperatingLeasesTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities
of lease liabilities are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating&#160;<br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance&#160;<br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-15196">630</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-15197">11</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd" id="ixv-15198">643</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd" id="ixv-15199">11</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" unitRef="usd" id="ixv-15200">380</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-15201">1,653</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-15202">22</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-15203">100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-15204">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-15205">1,553</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiability" scale="3" unitRef="usd" id="ixv-15206">20</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="atnm:OtherRevenueTextBlock" id="ixv-8868"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 - Other Revenue</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a grant from a government-sponsored entity for research and development related activities that provides for payments for
reimbursed costs, which includes overhead and general and administrative costs as well as an administrative fee. The Company recognized
revenue from grants as it performed services under this arrangement. Associated expenses are recognized when incurred as research and
development expense. Other revenue recognized from this grant during the year ended December 31, 2023 was $<ix:nonFraction contextRef="c9" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="6" unitRef="usd" id="ixv-15207">0.1</ix:nonFraction> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 7, 2022, the Company entered into a license and supply agreement (the &#8220;License Agreement&#8221;) with Immedica Pharma AB
(&#8220;Immedica&#8221;), pursuant to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab)
in the European Economic Area, Middle East and North Africa (&#8220;EUMENA&#8221;), including Algeria, Andorra, Bahrain, Cyprus, Egypt,
Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria,
Tunisia, Turkey, the United Arab Emirates, the United Kingdom, the Vatican City and Yemen. Upon signing, the Company was entitled to
an upfront, non-refundable payment of $<ix:nonFraction contextRef="c46" decimals="-6" format="ixt:num-dot-decimal" name="atnm:NonRefundablePaymentReceived" scale="6" unitRef="usd" id="ixv-15208">35</ix:nonFraction> million from Immedica, which was received in May 2022. Under the terms of the License Agreement,
the Company is eligible to receive certain regulatory and commercial milestone payments and royalties on net sales of the product in
certain countries that may result from the License Agreement. The Company continues to retain commercialization rights in the U.S. and
rest of the world.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s contract liabilities are recorded within Other revenue deferred &#8211; current liability or Long-term license revenue
deferred in its condensed consolidated balance sheets, depending on the short-term or long-term nature of the payments to be recognized.
The Company&#8217;s contract liabilities primarily consist of advanced payments from licensees. Long-term license revenue deferred was
$<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" unitRef="usd" id="ixv-15209"><ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" unitRef="usd" id="ixv-15210">35.0</ix:nonFraction></ix:nonFraction> million at December 31, 2024 and December 31, 2023; this deferred revenue will be recognized upon European Union&#8217;s regulatory
approval of Iomab-B or provision of definitive feedback that Iomab-B will not receive approval in the European Union.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-8888"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 - Commitments and Contingencies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;)
to build upon previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase
2 clinical trial with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed
by FHCRC. A milestone payment of $<ix:nonFraction contextRef="c47" decimals="-6" format="ixt:num-dot-decimal" name="atnm:PaymentOfMilestone" scale="6" unitRef="usd" id="ixv-15211">1</ix:nonFraction> million will be due to FHCRC upon FDA approval of the first drug utilizing the licensed antibody.
Upon commercial sale of the drug, royalty payments of <ix:nonFraction contextRef="c47" decimals="2" format="ixt:num-dot-decimal" name="atnm:RoyaltyPaymentsPercentage" scale="-2" unitRef="pure" id="ixv-15212">2</ix:nonFraction>% of net sales will be due to FHCRC.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="ixv-8900"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 - Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the Company entered into the Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC, &#8220;JonesTrading&#8221;,
pursuant to which the Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $<ix:nonFraction contextRef="c48" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" unitRef="usd" id="ixv-15213">200</ix:nonFraction> million of its common
stock. On June 28, 2022, the Company entered into an Amended and Restated Capital on Demand&#8482; Sales Agreement (the &#8220;A&amp;R
Sales Agreement&#8221;) with JonesTrading and B. Riley Securities, Inc. (&#8220;B. Riley&#8221;). The A&amp;R Sales Agreement modifies
the original Capital on Demand&#8482; Sales Agreement to include B. Riley Securities as an additional sales agent thereunder. Shares
of common stock were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-242322) filed with the SEC on August
7, 2020 (the &#8220;Prior Shelf Registration Statement&#8221;). On August 11, 2023, the Company filed a registration statement on Form
S-3 (File No. 333-273911), which registration statement was amended on February 2, 2024, and declared effective on February 5, 2024,
to replace the Prior Shelf Registration Statement, including a base prospectus which covers the offering, issuance and sale of up to
$<ix:nonFraction contextRef="c20" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="6" unitRef="usd" id="ixv-15214">500</ix:nonFraction> million of common stock, preferred stock, warrants, units and/or subscription rights; and a sales agreement prospectus covering
the offering, issuance and sale of up to a maximum aggregate offering price of $<ix:nonFraction contextRef="c20" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" unitRef="usd" id="ixv-15215">200</ix:nonFraction> million of common stock that may be issued and sold
under the Amended Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company sold <ix:nonFraction contextRef="c20" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" unitRef="shares" id="ixv-15216">3.5</ix:nonFraction> million shares of common stock, resulting in gross proceeds of $<ix:nonFraction contextRef="c20" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" unitRef="usd" id="ixv-15217">29.9</ix:nonFraction> million and
net proceeds of $<ix:nonFraction contextRef="c20" decimals="-5" format="ixt:num-dot-decimal" name="atnm:NetProceedsFromIssuanceOfCommonStock" scale="6" unitRef="usd" id="ixv-15218">29.3</ix:nonFraction> million. During the year ended December 31, 2023, the Company sold <ix:nonFraction contextRef="c14" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" unitRef="shares" id="ixv-15219">1.9</ix:nonFraction> million shares of common stock, resulting
in gross proceeds of $<ix:nonFraction contextRef="c14" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" unitRef="usd" id="ixv-15220">15.1</ix:nonFraction> million and net proceeds of $<ix:nonFraction contextRef="c14" decimals="-5" format="ixt:num-dot-decimal" name="atnm:NetProceedsFromIssuanceOfCommonStock" scale="6" unitRef="usd" id="ixv-15221">14.6</ix:nonFraction> million.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>




</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_2" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company presently has one equity compensation plan, the 2019 Amended and Restated Stock Plan, (the &#8220;2019 Plan&#8221;). The 2019
Plan has an expiration date of October&#160;18, 2029 and the number of shares of our common stock authorized under the plan for grant
to employees, directors and consultants is <ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-15222">9,333,333</ix:nonFraction> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had two equity compensation plans that expired on September 9, 2023; the Company&#8217;s Amended and Restated 2013 Stock Plan
and the Company&#8217;s 2013 Equity Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-8940"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
is a summary of stock option activity for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-indent: -9pt; padding-left: 9pt">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" unitRef="shares" id="ixv-15223">3,396</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15224">8.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c74" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-15225">8.85</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" unitRef="usd" id="ixv-15226">15,204</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -9pt; padding-left: 0.25in">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" unitRef="shares" id="ixv-15227">2,402</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15228">5.28</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 0.25in">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" unitRef="shares" id="ixv-15229">44</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15230">5.92</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" unitRef="shares" id="ixv-15231">309</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c9" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15232">8.30</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Outstanding, December 31, 2023</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" unitRef="shares" id="ixv-15233">5,445</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15234">6.80</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c9" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-15235">8.70</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" unitRef="usd" id="ixv-15236">373</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -9pt; padding-left: 0.25in">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" unitRef="shares" id="ixv-15237">154</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15238">5.47</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 0.25in">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" unitRef="shares" id="ixv-15239">10</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15240">7.39</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" unitRef="shares" id="ixv-15241">452</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15242">10.04</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Outstanding, December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" unitRef="shares" id="ixv-15243">5,137</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15244">6.48</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-15245">7.04</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Exercisable, December 31, 2024</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" unitRef="shares" id="ixv-15246">2,555</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15247">10.63</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-15248">7.84</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2024, the Company granted newly hired employees options to purchase <ix:nonFraction contextRef="c50" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" unitRef="shares" id="ixv-15249">0.2</ix:nonFraction> million shares of common stock with an exercise price ranging
from $<ix:nonFraction contextRef="c51" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15250">7.20</ix:nonFraction> to $<ix:nonFraction contextRef="c52" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15251">8.15</ix:nonFraction> per share, a term of <ix:nonNumeric contextRef="c53" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-15252">10</ix:nonNumeric> years, and a vesting period of <ix:nonNumeric contextRef="c53" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-15253">4</ix:nonNumeric> years.&#160;The options have an aggregated fair value of
$<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityFairValueDisclosure" scale="6" unitRef="usd" id="ixv-15254">0.6</ix:nonFraction> million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model
include: (1) discount rate range from <ix:nonFraction contextRef="c54" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" unitRef="pure" id="ixv-15255">4.19</ix:nonFraction>% to <ix:nonFraction contextRef="c55" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" unitRef="pure" id="ixv-15256">4.45</ix:nonFraction>% (2) expected life of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-15257">6</ix:nonNumeric> years, (3) expected volatility range from <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" unitRef="pure" id="ixv-15258">80.5</ix:nonFraction>% to <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" unitRef="pure" id="ixv-15259">90.5</ix:nonFraction>%,
and (4) <span style="-sec-ix-hidden: hidden-fact-51">zero</span> expected dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2023, the Company granted its employees and members of the Board of Directors options to purchase <ix:nonFraction contextRef="c56" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" unitRef="shares" id="ixv-15260">2.4</ix:nonFraction> million shares of common stock
with an exercise price ranging from $<ix:nonFraction contextRef="c57" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15261">5.00</ix:nonFraction> to $<ix:nonFraction contextRef="c58" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15262">11.60</ix:nonFraction> per share, a term of <ix:nonNumeric contextRef="c59" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-15263">10</ix:nonNumeric> years, and a vesting period from <ix:nonNumeric contextRef="c57" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-15264">4</ix:nonNumeric> to <ix:nonNumeric contextRef="c58" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-15265">4.2</ix:nonNumeric> years.&#160;The
options have an aggregated fair value of $<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityFairValueDisclosure" scale="6" unitRef="usd" id="ixv-15266">9.0</ix:nonFraction> million that was calculated using the Black-Scholes option-pricing model. Variables used
in the Black-Scholes option-pricing model include: (1) discount rate range from <ix:nonFraction contextRef="c60" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" unitRef="pure" id="ixv-15267">3.5</ix:nonFraction>% to <ix:nonFraction contextRef="c61" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" unitRef="pure" id="ixv-15268">4.82</ix:nonFraction>% (2) expected life of <ix:nonNumeric contextRef="c9" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-15269">6</ix:nonNumeric> years, (3) expected
volatility range from <ix:nonFraction contextRef="c9" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" unitRef="pure" id="ixv-15270">79.0</ix:nonFraction>% to <ix:nonFraction contextRef="c9" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" unitRef="pure" id="ixv-15271">81.6</ix:nonFraction>%, and (4) <ix:nonFraction contextRef="c9" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-15272">zero</ix:nonFraction> expected dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, options to purchase <ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" unitRef="shares" id="ixv-15273">0.5</ix:nonFraction> million and <ix:nonFraction contextRef="c9" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" unitRef="shares" id="ixv-15274">0.3</ix:nonFraction> million common shares were cancelled, respectively,
upon the termination of employment.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of all options
issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at December 31,
2024 was $<ix:nonFraction contextRef="c62" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" unitRef="usd" id="ixv-15275">9.1</ix:nonFraction> million related to unvested options, which is expected to be expensed over a weighted average of <ix:nonNumeric contextRef="c53" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-15276">2.6</ix:nonNumeric> years. During 2024
and 2023, the Company recorded total option expense of $<ix:nonFraction contextRef="c53" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-15277">4.6</ix:nonFraction> million and $<ix:nonFraction contextRef="c59" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-15278">3.2</ix:nonFraction> million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="ixv-9192"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
is a summary of restricted stock unit (&#8220;RSUs&#8221;) activity for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Grant Date Fair Value Per Share ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c75" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" unitRef="shares" id="ixv-15279">325</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c75" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-15280">5.96</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c65" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" unitRef="shares" id="ixv-15281">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c65" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-15282">8.31</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c65" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" unitRef="shares" id="ixv-15283">25</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c65" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-15284">7.31</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c76" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" unitRef="shares" id="ixv-15285">305</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c76" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-15286">5.89</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c63" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" unitRef="shares" id="ixv-15287">5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c63" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-15288">8.31</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c64" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" unitRef="shares" id="ixv-15289">300</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c64" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-15290">5.85</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
RSUs vest at the earliest of a change of control event, the termination of the recipient&#8217;s continuous service status for any reason
other than by the Company for cause and the third anniversary of the date of the grant. The fair value of the RSUs, $<ix:nonFraction contextRef="c63" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" unitRef="usd" id="ixv-15291">1.8</ix:nonFraction> million, was
determined based on the stock prices on the dates of the grants and each RSU grant is being recognized over its respective three-year
period. The unrecognized compensation expense at December 31, 2024 of $<ix:nonFraction contextRef="c64" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" unitRef="usd" id="ixv-15292">0.4</ix:nonFraction> million is expected to be expensed over a weighted average
of <ix:nonNumeric contextRef="c63" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-15293">0.6</ix:nonNumeric> years. During 2024 and 2023, the Company recorded compensation expense related to RSUs of $<ix:nonFraction contextRef="c63" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-15294">0.6</ix:nonFraction> million and $<ix:nonFraction contextRef="c65" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" unitRef="usd" id="ixv-15295">0.6</ix:nonFraction> million, respectively.<b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="ixv-9333"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
is a summary of warrant activities for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-indent: -9pt; padding-left: 9pt">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="3" unitRef="shares" id="ixv-15296">1,443</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c77" decimals="2" format="ixt:num-dot-decimal" name="atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15297">16.58</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c78" format="ixt-sec:duryear" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" id="ixv-15298">1.33</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" scale="3" unitRef="usd" id="ixv-15299">5</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -9pt; padding-left: 0.25in">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="3" unitRef="shares" id="ixv-15300">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15301">8.77</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c72" format="ixt-sec:duryear" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm" id="ixv-15302">10.00</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 0.25in">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" scale="3" unitRef="shares" id="ixv-15303">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15304">106.80</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Outstanding, December 31, 2023</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c79" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="3" unitRef="shares" id="ixv-15305">1,442</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c79" decimals="2" format="ixt:num-dot-decimal" name="atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15306">16.42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c72" format="ixt-sec:duryear" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" id="ixv-15307">0.34</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -9pt; padding-left: 0.25in">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 0.25in">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" scale="3" unitRef="shares" id="ixv-15308">1,435</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c71" decimals="2" format="ixt:num-dot-decimal" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15309">16.42</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Outstanding, December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="3" unitRef="shares" id="ixv-15310">7</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c80" decimals="2" format="ixt:num-dot-decimal" name="atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15311">17.33</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c71" format="ixt-sec:duryear" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" id="ixv-15312">4.46</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Exercisable, December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" scale="3" unitRef="shares" id="ixv-15313">7</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c80" decimals="2" format="ixt:num-dot-decimal" name="atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15314">17.77</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c71" format="ixt-sec:duryear" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" id="ixv-15315">4.25</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 23, 2024, warrants to purchase an aggregate of <ix:nonFraction contextRef="c66" decimals="-5" format="ixt:num-dot-decimal" name="atnm:ExpiredWarrant" scale="6" unitRef="shares" id="ixv-15316">1.4</ix:nonFraction> million shares of common stock expired. These warrants were issued on April
23, 2019, when the Company completed an underwritten offering of <ix:nonFraction contextRef="c67" decimals="-5" format="ixt:num-dot-decimal" name="atnm:WarrantExpiredUnderwrittenOfferingShares" scale="6" unitRef="shares" id="ixv-15317">1.4</ix:nonFraction> million shares of common stock and warrants to purchase <ix:nonFraction contextRef="c67" decimals="-5" format="ixt:num-dot-decimal" name="atnm:ExpiredWarrant" scale="6" unitRef="shares" id="ixv-15318">1.4</ix:nonFraction> million
shares of common stock at a price of $<ix:nonFraction contextRef="c68" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-15319">11.55</ix:nonFraction> per share and related warrant. The warrants were exercisable for a period of <ix:nonNumeric contextRef="c69" format="ixt-sec:duryear" name="atnm:WarrantExpiredTerm" id="ixv-15320">5</ix:nonNumeric> years at an
exercise price of $<ix:nonFraction contextRef="c70" decimals="2" format="ixt:num-dot-decimal" name="atnm:WarrantExpiredPricePerShare" scale="0" unitRef="usdPershares" id="ixv-15321">15.00</ix:nonFraction> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, the Company recorded stock-based compensation expense related to warrants of $<ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-15322">5</ix:nonFraction> thousand
and $<ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-15323">6</ix:nonFraction> thousand, respectively.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-9581"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 - Income Taxes </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-15324">Significant components of the Company&#8217;s deferred tax assets and
liabilities at December 31, 2024 and 2023 are as follows:</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Net operating losses carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-15325">47,875</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-15326">41,698</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" unitRef="usd" id="ixv-15327">8,217</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" unitRef="usd" id="ixv-15328">8,219</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" unitRef="usd" id="ixv-15329">1,572</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" unitRef="usd" id="ixv-15330">1,512</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Research and development/orphan drug credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" unitRef="usd" id="ixv-15331">23,296</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" unitRef="usd" id="ixv-15332">20,509</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Capitalized research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-15333">20,664</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-15334">18,684</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 0.25in">Others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" sign="-" unitRef="usd" id="ixv-15335">11</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" sign="-" unitRef="usd" id="ixv-15336">57</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-15337">101,613</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-15338">90,565</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Deferred tax assets, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has recorded a valuation allowance of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" unitRef="usd" id="ixv-15339">101.6</ix:nonFraction> million and $<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" unitRef="usd" id="ixv-15340">90.6</ix:nonFraction> million against its deferred tax assets at December 31, 2024 and
2023 respectively, because management determined that it is not more-likely-than not that those assets will be realized.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
federal income tax purposes, the Company has $<ix:nonFraction contextRef="c81" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" scale="6" unitRef="usd" id="ixv-15341">189.3</ix:nonFraction> million of unused net operating losses (&#8220;NOLs&#8221;) at December 31, 2024
available for carry forward to future years. NOLs of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" unitRef="usd" id="ixv-15342">104.8</ix:nonFraction> million generated prior to 2018 will begin to expire if unused beginning
in 2026 when approximately $<ix:nonFraction contextRef="c82" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" unitRef="usd" id="ixv-15343">3.9</ix:nonFraction> million in NOLs are due to expire. The Company&#8217;s largest NOLs will begin to expire in 2034 - 2037,
with each year in excess of $<ix:nonFraction contextRef="c83" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" unitRef="usd" id="ixv-15344">15</ix:nonFraction> million. NOLs generated in 2018 and later years of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IndefiniteLivedContractualRights" scale="6" unitRef="usd" id="ixv-15345">84.6</ix:nonFraction> million have an indefinite life, but will be
limited to <ix:nonFraction contextRef="c74" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" unitRef="pure" id="ixv-15346">80</ix:nonFraction>% of their value if used in a tax year ending after January 1, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
state income tax purposes, the Company has $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" scale="6" unitRef="usd" id="ixv-15347">327.8</ix:nonFraction> million of unused NOLs at December 31, 2024 available for carry forward to future years.
These NOLs will begin to expire in 2035 if unused.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has federal research and development tax credits of $<ix:nonFraction contextRef="c84" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" unitRef="usd" id="ixv-15348">6.7</ix:nonFraction> million at December 31, 2024, which will begin to expire in 2033 if
unused and orphan drug credits of $<ix:nonFraction contextRef="c85" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" unitRef="usd" id="ixv-15349">16.5</ix:nonFraction> million which will begin to expire in 2037 if unused.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
and state tax laws impose limitations on the utilization of net operating losses and credit carryforwards in the event of an ownership
change for tax purposes, as defined in Section 382 of the Internal Revenue Code. Accordingly, the Company&#8217;s ability to utilize
these carryforwards may be limited as a result of an ownership change which may have already happened or may happen in the future. Such
an ownership change could result in a limitation in the use of the net operating losses in future years and possibly a reduction of the
net operating losses available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tax Cuts and Jobs Act of 2017 (TCJA) has modified the IRC 174 expenses related to research and development for the tax years beginning
after December 31, 2021. Under the TCJA, the Company must now capitalize the expenditures related to research and development activities
and amortize them over five years for U.S. activities and 15 years for non-U.S. activities. Since this has been the Company's policy
since 2018, the current year capitalization of research and development costs in accordance with IRC 174 was $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" scale="6" unitRef="usd" id="ixv-15350">28.0</ix:nonFraction> million for a total
accumulated gross amount of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="atnm:AccumulatedGrossAmount" scale="6" unitRef="usd" id="ixv-15351">87.9</ix:nonFraction> million as of December 31, 2024.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-9731"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
difference between the income tax provision and the amount that would result if the U.S. Federal statutory rates were applied to pre-tax
losses for the year ended December 31, 2024 and 2023 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Federal statutory income taxes</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" sign="-" unitRef="usd" id="ixv-15352">8,031</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-15353">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" sign="-" unitRef="usd" id="ixv-15354">10,252</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c9" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-15355">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" sign="-" unitRef="usd" id="ixv-15356">1,275</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" unitRef="pure" id="ixv-15357">3.3</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" sign="-" unitRef="usd" id="ixv-15358">1,743</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c9" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" unitRef="pure" id="ixv-15359">3.6</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred true-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="atnm:IncomeTaxReconciliationDeferredTrueup" scale="3" sign="-" unitRef="usd" id="ixv-15360">259</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="atnm:EffectiveIncomeTaxReconciliationDeferredTrueUps" scale="-2" sign="-" unitRef="pure" id="ixv-15361">0.7</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="atnm:IncomeTaxReconciliationDeferredTrueup" scale="3" sign="-" unitRef="usd" id="ixv-15362">176</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="3" format="ixt:num-dot-decimal" name="atnm:EffectiveIncomeTaxReconciliationDeferredTrueUps" scale="-2" sign="-" unitRef="pure" id="ixv-15363">0.4</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development/orphan drug tax credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" unitRef="usd" id="ixv-15364">2,787</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" unitRef="pure" id="ixv-15365">7.3</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" unitRef="usd" id="ixv-15366">3,263</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c9" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" unitRef="pure" id="ixv-15367">6.7</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="3" unitRef="usd" id="ixv-15368">788</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" sign="-" unitRef="pure" id="ixv-15369">2.0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="3" unitRef="usd" id="ixv-15370">608</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" sign="-" unitRef="pure" id="ixv-15371">1.2</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-15372">11,046</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" sign="-" unitRef="pure" id="ixv-15373">28.9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-15374">14,474</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c9" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" sign="-" unitRef="pure" id="ixv-15375">29.7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Provision for income tax</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-&#160;&#160;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-&#160;&#160;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-&#160;&#160;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-&#160;&#160;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-9896"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Note 9  - Subsequent Events </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 27, 2025, a putative
class action complaint (the &#8220;Complaint&#8221;) was filed by alleged stockholder Nihil Kohil against the Company and executives Sandesh
Seth, Avinash Desai, Madhuri Vusirikala, and Sergio Giralt, styled&#160;<i>Kohil v. Actinium Pharmaceuticals, Inc., et al</i>., Case No.
1:25-cv-02553 in the Southern District of New York, wherein, the Complaint alleges that the defendants made material misrepresentations
and omissions concerning the Iomab-B Phase 3 Sierra Trial and the plaintiff asserts claims against all defendants pursuant to section
10(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and Rule 10b-5 promulgated thereunder, as well
as additional claims against the individual defendants pursuant to Section 20(a) of the Exchange Act.&#160; The Complaint purports to
assert class action claims on behalf of all persons and entities that purchased or otherwise acquired Actinium securities between October
31, 2022 and August 2, 2024.&#160; Plaintiff seeks unspecified damages.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The defendants have not yet
responded to the complaint, and they intend to vigorously defend themselves against the plaintiff&#8217;s allegations, however, there
can be no assurances as to the outcome.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 31, 2025, our Board
of Directors of approved the cancellation of certain stock options to purchase <ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares" id="ixv-15376">5,149,944</ix:nonFraction> shares of common stock held by certain current
employees and directors that were initially granted under the Company&#8217;s Amended and Restated 2013 Stock Plan and 2019 Amended and
Restated Stock Plan. FSuSuch cancellation is subject to the consent of the applicable holder of the stock options, which the Company is
expecting to receive shortly following the filing of this Annual Report on Form 10-K. Our Compensation Committee intends to conduct an
analysis of our equity compensation plan and develop an equity compensation strategy that satisfies the purpose of the 2019 Plan to attract
and retain the best available personnel who can make meaningful contributions towards achieving the business objectives of the Company.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
9A. CONTROLS AND PROCEDURES.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disclosure
controls and procedures.</i></b> The Company, under the supervision and with the participation of its management, including the Company&#8217;s
principal executive officer and principal financial and accounting officer, evaluated the effectiveness of the Company&#8217;s &#8220;disclosure
controls and procedures,&#8221; as such term is defined in Rule 13a-15(e) and 15d-15(e) under the Securities Act of 1934, as amended
(the &#8220;Exchange Act&#8221;), as of the end of the period covered by this Annual Report on Form 10-K. Based on that evaluation, the
Company&#8217;s principal executive officer and principal financial and accounting officer have concluded that the Company&#8217;s disclosure
controls and procedures are effective as of December 31, 2024 to ensure that information required to be disclosed by the Company in reports
that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in
Securities and Exchange Commission rules and forms, and includes controls and procedures designed to ensure that information required
to be disclosed by the Company in such reports is accumulated and communicated to the Company&#8217;s management, including the Company&#8217;s
principal executive officer and principal financial and accounting officer, as appropriate, to allow timely decisions regarding required
disclosure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Management&#8217;s
Annual Report on Internal Control Over Financial Reporting.</i>&#160;</b>The Company&#8217;s management is responsible for establishing
and maintaining adequate internal control over financial reporting. The Company&#8217;s internal control over financial reporting is
a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s internal control over financial reporting includes policies and procedures that (1)&#160;pertain to the maintenance of
records that, in reasonable detail, accurately and fairly reflect transactions and dispositions of assets; (2)&#160;provide reasonable
assurances that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted
accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of management and the
directors of the Company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition,
use or disposition of the Company&#8217;s assets that could have a material effect on our financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of
any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions,
or that the degree of compliance with the policies or procedures may deteriorate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2024. In making this assessment,
management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated
Framework (2013). Based on its assessment and those criteria, management concluded that as of December 31, 2024, the Company&#8217;s
internal control over financial reporting was effective.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K does not include an attestation report from our registered public accounting firm regarding internal control
over financial reporting. Our internal control over financial reporting was not subject to such attestation as we are a non-accelerated
filer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in internal controls over financial reporting</i>.</b> There were no changes in the Company&#8217;s internal controls over financial
reporting that occurred during the fourth quarter of the fiscal year covered by this Annual Report on Form 10-K that have materially
affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
9B. OTHER INFORMATION.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c87" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="ixv-15377"><ix:nonNumeric contextRef="c87" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="ixv-15378"><ix:nonNumeric contextRef="c87" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="ixv-15379"><ix:nonNumeric contextRef="c87" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="ixv-15380">None</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ITEM
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 88; Options: NewSection; Value: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
III</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors
and Executive Officers</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
names, positions and ages of our directors and executive officers as of March 28, 2025, are as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 7%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 62%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve O&#8217;Loughlin</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer (Principal Financial and Accounting
    Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June S.&#160;Almenoff, M.D., Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey W. Chell M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Nicholson, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lead Independent Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard I. Steinhart</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajit S. Shetty, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
hold office for a term consistent with classified board provisions of our Charter. For further information, see the section titled &#8220;&#8212;Corporate
Governance&#8212;Term of Office&#8221; below. Officers serve at the discretion of the Board of Directors.</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no other&#160;arrangements or understanding between any of our directors and any other persons pursuant to which they were selected
as a director.</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background
of Executive Officers and Directors</b></span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal occupations for the past five years (and, in some instances, for prior years) of each of our directors and executive officers
are as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sandesh
Seth, Chairman and Chief Executive Officer</b></span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.&#160;Sandesh
Seth has been our Chief Executive Officer since June&#160;2017. Mr.&#160;Seth has been a Director since March&#160;2012, our Chairman
of the Board since October&#160;2013, and served as Executive Chairman from August&#160;2014 to June&#160;2017.</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr.&#160;Seth has 25 plus&#160;years
of experience in investment banking (Laidlaw&amp; Co (UK) Ltd., Cowen&#160;&amp; Co.), equity research (Bear Stearns, Commonwealth Associates)
and in the pharma industry (Pfizer, Warner-Lambert, SmithKline in strategic planning, business development and R&amp;D project management).
Mr.&#160;Seth was chairman of Relmada Therapeutics Inc., a specialty pharma company focused on CNS therapeutics, which he helped co-found.
Mr.&#160;Seth has an MBA in Finance from New&#160;York University; an M.S. in the Pharmaceutical Sciences from the University of Oklahoma
Health Center and a B.Sc. in Chemistry from Bombay University. He has published several scientific articles and was awarded the University
Regents Award for Research Excellence at the University of Oklahoma. Mr.&#160;Seth was designated as Regulatory Affairs Certified by the
Regulatory Affairs Professionals Society which signifies proficiency with U.S.&#160;FDA regulations. He has several patents related to
the use of radiopharmaceuticals as conditioning agents for adoptive cell therapies and as therapeutic combinations.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 89; Value: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
Mr.&#160;Seth has served in various business executive-level positions over the course of his career, has significant investment banking
experience, has developed significant management, operational and leadership skills and is well accustomed to interfacing with investors,
analysts, auditors, C-level executives, and outside advisors, led us to conclude that Mr.&#160;Seth should serve as a director.</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Steve
O&#8217;Loughlin, Chief Financial Officer</b>&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve
O&#8217;Loughlin has been our Chief Financial Officer since August&#160;2020. Mr.&#160;O&#8217;Loughlin served as our Principal Financial
Officer from May&#160;2017 to August&#160;2020. Mr.&#160;O&#8217;Loughlin joined Actinium in October&#160;2015 as Vice President, Finance
and Corporate Development, with almost a decade of life sciences industry experience gained from previous positions in investment banking
and publicly traded life sciences companies. Prior to Actinium, from June&#160;2015 to October&#160;2015, Mr.&#160;O&#8217;Loughlin worked
at J.&#160;Streicher LLC as an investment banker, from August&#160;2012 to June&#160;2015 Mr.&#160;O&#8217;Loughlin held the position
of vice president, corporate finance and development and was a corporate officer at Protea Biosciences, Inc., a publicly traded life
sciences tools company. Previously, From June&#160;2010 to June&#160;2012, Mr.&#160;O&#8217;Loughlin held corporate development positions
with Caliber&#160;I.D., a publicly traded diagnostics company. Mr.&#160;O&#8217;Loughlin previously worked in investment banking at Jesup&#160;&amp;
Lamont where he focused on the biotechnology and life sciences industries. Mr.&#160;O&#8217;Loughlin has a B.S. in Business Administration
with a concentration in finance from Ramapo College of New Jersey.</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June
S.&#160;Almenoff, M.D., Ph.D., Director</b></span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.&#160;Almenoff
has been a Director of the Company since November&#160;2024 and is a member of our Nominating and Corporate Governance Committee. Dr.&#160;Almenoff
is an accomplished biopharma executive with 25&#160;years of senior leadership experience. She currently serves as a Board Director and
advisor to management of numerous biopharma companies. Dr.&#160;Almenoff served as President and Chief Medical Officer of Furiex Pharmaceuticals,
which was acquired by Actavis plc (now AbbVie) for $1.2B.&#160;Furiex developed eluxadoline (Viberzi<sup>&#174;</sup>), which was approved
both in the United&#160;States and Europe. She also served as Chief Medical Officer of RedHill Biopharma Ltd (Nasdaq: RDHL) leading a
team that was instrumental in positioning Talicia<sup>&#174;</sup> as a first-line therapy. Earlier in her career, Dr.&#160;Almenoff was
at GlaxoSmithKline (GSK) for 12&#160;years, where she held various positions of increasing responsibility. She was a Vice President in
the Clinical Safety Organization, chaired a PhRMA-FDA working group, and worked in the area of scientific licensing. Dr.&#160;Almenoff
also led the development of pioneering data analytics systems, which have been widely adopted by industry and regulators to minimize
clinical risk for both development and marketed drugs.</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.&#160;Almenoff
has strong expertise in translational medicine, clinical development, commercial strategy, and business development across many
therapeutic areas. Dr.&#160;Almenoff has led or contributed to numerous regulatory submissions, product approvals and launches. Dr.
Almenoff is currently a member of the investment advisory board of the Harrington Discovery Institute (a venture philanthropy) and
an Executive Venture Partner, part time, at 82 Venture Studios, which is affiliated with Alloy Ventures. She is a member of the
Board of Directors  of Avalo
Therapeutics, Inc. (Nasdaq: AVTX) and Tenax Therapeutics (Nasdaq: TENX). She previously served as a member of the board of
directors of TiGenix NV (formerly Nasdaq: TIG), which was acquired by Takeda, Brainstorm Cell Therapeutics (Nasdaq: BCLI), and OHR
Pharmaceutical (formerly Nasdaq: OHRP).</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.&#160;Almenoff
received her B.A. cum laude from Smith College and graduated with AOA honors from the M.D.-Ph.D. program at the Icahn (Mt. Sinai) School
of Medicine. She completed post-graduate medical training at Stanford University Medical Center and served on the faculty of Duke University
School of Medicine. She is an adjunct professor at Duke, a Fellow of the American College of Physicians (FACP) and has authored over
70&#160;publications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
Dr.&#160;Almenoff brings over 25&#160;years of drug development experience having served in executive-level leadership roles as Chief
Medical Officer where she contributed to the approval of novel therapies as well as business development activities and that she advises
and serves on the board of several biopharmaceutical companies led us to conclude that Dr.&#160;Almenoff should serve as a director.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 90; Value: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jeffrey
W. Chell, M.D., Director</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.&#160;Chell
has been a Director of the Company since April&#160;2018. Dr.&#160;Chell is also a member of our Audit Committee and Compensation Committee.
He has been the chief executive officer emeritus of the National Marrow Donor Program (&#8220;NMDP&#8221;) since 2017 having served as
its chief executive officer since 2000. Dr.&#160;Chell has led the NMDP through transformational growth as its Be The Match Registry
tripled to more than 12&#160;million donors, the number of transplants facilitated has grown fivefold to over 6,400 annually, and revenue
more than tripled to nearly $400&#160;million per year. He is also the co-founder and has served as executive director of the Center
For International Blood&#160;&amp; Marrow Transplant Research since 2004, a leading research program in the field contributing over 70&#160;research
publications per year in peer-reviewed journals. Dr.&#160;Chell serves as the President of the Jeff Gordon Children&#8217;s Foundation,
a non-profit that funds innovative research and therapy for pediatric cancer patients. He also currently serves as chair of CLR Insurance,
a captive insurance company domiciled in the Cayman Islands. From 2014 to 2016, Dr.&#160;Chell served as co-chair of Bone Marrow Donors
Worldwide during its IT transformation project, improving revenues and reducing costs.</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to joining the NMDP, he served as president, Allina Medical Clinics, a 450 physician multi-specialty medical group from 1994 to 1999.
Prior to that he practiced Internal Medicine in Minneapolis and in the U.S.&#160;Air Force Medical Corps.</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.&#160;Chell
received his M.D. from the University of Minnesota and his training in Internal Medicine at the University of Wisconsin, Madison. Dr.&#160;Chell
is a diplomate of the American Board of Internal Medicine, a member of the American Society of Hematology and a member of the American
Society of Blood and Marrow Transplantation.</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">He
has received multiple honors including the 2018 Public Service award of the American Society For Blood and Marrow Transplantation, 2017
Most Admired CEO by the Minneapolis/St. Paul Business Journal, 2010 Healthcare Executive of the Year by the Minneapolis/St, Paul Business
Journal, and the 2017 Bone Marrow Foundation Service Award.</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
Dr.&#160;Chell brings many&#160;years of experience with patient donor programs, knowledge of challenges related to bone marrow transplants,
leadership of organizations and experience working in medical groups to our Board, led us to conclude that Dr.&#160;Chell should serve
as a director.</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>David
Nicholson, Ph.D., Director</b>&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
Nicholson Ph.D., serves as our Lead Independent Director of our Board and has been a Director of the Company since 2008. Dr.&#160;Nicholson
is also a member of our Compensation Committee. Since March&#160;2015, Dr.&#160;Nicholson served as Executive Vice President and Chief
R&amp;D Officer of Allergan, which was acquired by Abbvie in May&#160;2020. In August&#160;2014, Dr.&#160;Nicholson joined Allergan (previously
known as Actavis plc and Forest Laboratories, Inc.) as senior vice president, Actavis Global Brands R&amp;D.&#160;From March&#160;2012
to August&#160;2014, Dr.&#160;Nicholson was on the executive committee of Bayer CropScience as head of research&#160;&amp; development
responsible for the integration of the company&#8217;s R&amp;D activities into one global organization. Dr.&#160;Nicholson graduated
in pharmacology, earning his B.Sc. from the University of Manchester (1975)&#160;and his Ph.D. from the University of Wales (1980). Between
1978 and 1988, Dr.&#160;Nicholson worked in the pharmaceutical industry for the British company Beecham-W&#252;lfing in Gronau, Germany.
The main emphasis of his activities as group leader in a multidisciplinary project group was the development of cardiovascular drugs.</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From&#160;1988-2007,
Dr.&#160;Nicholson held various positions of increasing seniority in the UK, the Netherlands and the U.S.&#160;with Organon, a business
unit of Akzo Nobel. Ultimately, he became executive vice president, research&#160;&amp; development, and member of the Organon Executive
Management Committee. He implemented change programs, leading to maximizing effectiveness in research&#160;&amp; development, ensuring
customer focus and the establishment of a competitive pipeline of innovative drugs. In 2007, Dr.&#160;Nicholson transferred to Schering-Plough,
Kenilworth, New Jersey as senior vice president, responsible for Global Project Management and Drug Safety. From 2009 to December&#160;2011,
he was vice president licensing and knowledge management at Merck in Rahway, New Jersey, reporting to the president of Merck R&amp;D.&#160;As
an integration team member, Dr.&#160;Nicholson played a role in the strategic mergers of Organon BioSciences, the human and animal health
business of Dutch chemical giant Akzo-Nobel, and Schering-Plough in 2007 as well as of Schering-Plough and Merck in 2009. Dr Nicholson
brings a wealth of experience having previously championed the breakthrough anti-PD1 cancer drug Keytruda<sup>&#174;</sup> (pembrolizumab)
all the way from its earliest research and into development, heralding a revolution in cancer therapy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 91; Value: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
Dr.&#160;Nicholson brings over 40&#160;years of pharmaceutical experience to our Board, having served in various pharmaceutical
research and development executive-level positions over the course of his career, that he presently serves on the Boards of Adverum
Biotechnologies, Rapalogix Health, Wild Biosciences and Volastra Therapeutics, and that Dr.&#160;Nicholson has developed significant
management and leadership skills relating to the pharmaceutical industry and is well accustomed to interfacing with investors,
analysts, auditors, outside advisors and governmental officials, led us to conclude that Dr.&#160;Nicholson should serve as a
director.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ajit
S. Shetty, Ph.D., Director</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Dr.&#160;Shetty
has been a Director of the Company since March&#160;2017. Dr.&#160;Shetty is also a member of our Audit Committee, Compensation Committee,
and Chairman of our Nominating and Corporate Governance Committee. Dr.&#160;Shetty joined Janssen Pharmaceutical, Inc. (&#8220;Janssen&#8221;)
in 1976 ultimately rising to the position of president in 1986 where he led the establishment of Janssen&#8217;s business in the U.S.&#160;From
1999 to 2008 he was managing director of Janssen, during this time the Janssen Group of companies&#8217; global sales grew from $1&#160;billion
to $8&#160;billion, and from 2004 until 2012 he was chairman of the board of directors. In Dr.&#160;Shetty&#8217;s most recent role at
Johnson&#160;&amp;&#160;Johnson he was head of Enterprise Supply Chain, where he reported to the chief executive officer and was responsible
for the transformation and optimization of Johnson&#160;&amp; Johnson&#8217;s supply chain. Dr.&#160;Shetty earned a Ph.D. in Metallurgy
and B.A.&#160;Natural Sciences from Trinity College, Cambridge University and a Master of Business Administration from Carnegie Mellon
University. In 2007, Dr.&#160;Shetty was bestowed the title of Baron by King Albert&#160;II of Belgium for his exceptional merits. In
addition, he was elected Manager of the Year in 2004 in Flanders and received a Life-Time Achievement Award in India in 2010. In 2016,
Dr.&#160;Shetty was named as chairperson of the Vlaams Instituut voor Biotechnologie (VIB), a Belgium based life sciences research institute
focused on translating scientific results into pharmaceutical, agricultural and industrial applications. Dr.&#160;Shetty has served as
a member of Agile Therapeutics, Inc.&#8217;s board of directors from February&#160;2016 until May&#160;2023. We believe Dr.&#160;Shetty&#8217;s
qualifications to sit on our Board include his extensive pharmaceutical experience leading commercial and supply chain operations and
his significant educational background.</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
Dr.&#160;Shetty has more than 30&#160;years of leadership and executive experience in the pharmaceutical industry, that he has significant
supply chain knowledge and that he has experience conducting business in the U.S.&#160;and Europe, led us to conclude that Dr.&#160;Shetty
should serve as a director.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Richard
I. Steinhart, Director</b></span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Mr.&#160;Steinhart has served
as our Director and Chairman of the Audit Committee since November&#160;2013. Mr.&#160;Steinhart is also a member of our Nominating and
Corporate Governance Committee. Since October&#160;2017 Mr.&#160;Steinhart has been the senior vice president and chief financial officer
of BioXcel Therapeutics, Inc. Since March&#160;2014, Mr.&#160;Steinhart has been a member of the board of directors of Atossa Genetics,
Inc. where he is chairman of the audit committee and a member of the compensation committee. From October&#160;2015 to April&#160;2017,
Mr.&#160;Steinhart was vice president and chief financial officer at Remedy Pharmaceuticals, a privately-held, clinical stage pharmaceutical
company that sold its only asset, CIRARA, to Biogen for $120M plus earn-outs. From January&#160;2014 through September&#160;2015 Mr.&#160;Steinhart
worked as a financial and strategic consultant to the biotechnology and medical device industries. Previously, Mr.&#160;Steinhart was
senior vice president, finance and chief financial officer at MELA Sciences, Inc. from April&#160;2012 until December&#160;2013, having
previously served as vice president, finance and chief financial officer, treasurer and secretary from April&#160;2006. From May&#160;1992
until joining MELA Sciences, Mr.&#160;Steinhart was a managing director of Forest Street Capital/SAE Ventures, a boutique investment
banking, venture capital, and management consulting firm focused on healthcare and technology companies. Prior to Forest Street Capital/SAE
Ventures, he was vice president and chief financial officer of Emisphere Technologies, Inc. Mr.&#160;Steinhart&#8217;s other experience
includes seven&#160;years at CW Group, Inc., a venture capital firm focused on medical technology and biopharmaceutical companies, where
he was a general partner and chief financial officer. Mr.&#160;Steinhart began his career at Price Waterhouse, now known as PricewaterhouseCoopers.
He holds BBA and MBA degrees from Pace University and is a Certified Public Accountant (inactive).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 92; Value: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
Mr.&#160;Steinhart brings more than 35&#160;years of financial experience to our Board, having served in various executive-level financial
positions over the course of his career, and that Mr.&#160;Steinhart is a certified public accountant (inactive), led us to conclude
that Mr.&#160;Steinhart should serve as a director and chair the Audit Committee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Governance</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors oversees our business affairs and monitors the performance of management. In accordance with our corporate governance
principles, our Board of Directors does not involve itself in day-to-day operations. The Directors keep themselves informed through discussions
with the Chairman and Chief Executive Officer and other key executives and by reading the reports and other materials that we send them
and by participating in Board of Directors and committee meetings.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Term
of Office</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors are divided into three classes, designated Class I, Class II and Class III. Class I shall consists of two directors, Class
II shall consist of one director, and Class III consists of one director. The term of office for each Class I director expires at 2026
Annual Meeting of Stockholders; the term of office for each Class II director expires at the 2027 Annual Meeting of stockholders; and
the term of office for each Class III director expires at the 2025 Annual Meeting of stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of each director is set forth below or until their successors are duly elected:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 34%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Term
    (from 2024 Annual Meeting)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Nicholson</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class I</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2 years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard Steinhart </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class I</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2 years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class II</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey W. Chell</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class II</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June S. Almenoff</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class III</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 year</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajit Shetty</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class III</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 year</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, each director shall serve until his successor is duly elected and qualified, or until his retirement, death, resignation
or removal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Director
Independence</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
use the definition of &#8220;independence&#8221; of the NYSE American stock exchange to make this determination. We are listed on the
NYSE American under the symbol &#8220;ATNM&#8221;. NYSE MKT corporate governance rule Sec. 803(A)(2) provides that an &#8220;independent
director&#8221; means a person other than an executive officer or employee of the company. No director qualifies as independent unless
the issuer&#8217;s board of directors affirmatively determines that the director does not have a relationship that would interfere with
the exercise of independent judgment in carrying out the responsibilities of a director. Under the NYSE American director independence
rules, June S. Almenoff, Jeffrey W. Chell, David Nicholson, Ajit S. Shetty, and Richard I. Steinhart are independent directors of the
Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chief
Executive Officer Compensation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 12, 2020, we and
Mr. Seth entered into an employment agreement whereby Mr. Seth would serve as Chairman and Chief Executive Officer until February 24,
2024, unless terminated earlier as set forth in the employment agreement. On November 1, 2023, our board of directors approved an amendment
to Mr. Seth&#8217;s employment agreement, pursuant to which the term of Mr. Seth&#8217;s employment was extended from February 21, 2024
to February 21, 2027, subject to the terms of the employment agreement.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the employment agreement, Mr. Seth is entitled to (i) a base salary, which will be determined by the Board and adjusted
to be competitively aligned to a range between the 25th and 75th percentile of the relevant market data of chief executive officer positions
of similarly situated publicly companies, (ii) a performance bonus with a target of 50% of his annual base salary as well as other multipliers
as determined by the Board and (iii) options to purchase shares of common stock of the Company as the Board may grant. For 2023, Mr.
Seth&#8217;s annual base salary was set at $705,000, and for 2024, his annual base salary was set at $733,200.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 93; Value: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
and if granted, options will have an exercise price equal to the closing price of the Company&#8217;s common stock on the date of the
approval, and 2% of the grant will vest each month from the grant date until fully vested, in accordance with the 2019 Plan. The options
will expire 10 years from the grant date, subject to Mr. Seth&#8217;s continuing service with the Company. Mr. Seth also receives the
standard benefits available to other similarly situated employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Mr. Seth&#8217;s employment as Chief Executive Officer or Chairman is terminated due to death or disability, Mr. Seth will be entitled
to earned, but unpaid, salary, benefits and the Pro-Rated Bonus (as defined below) for the year of termination. Upon termination of his
employment for Cause (as defined in the employment agreement), or his resignation without Good Reason (as defined in the employment agreement),
Mr. Seth will receive any accrued and unpaid base salary, the Pro-Rated Bonus and benefits through the date of termination.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we terminate Mr. Seth&#8217;s employment without Cause, or if Mr. Seth resigns for Good Reason other than in connection with a Change
in Control, Mr. Seth will be entitled to (i) a single lump sum payment equal to 24 months of his compensation, (ii) continued health
benefits for 24 months, (iii) immediate vesting of all outstanding equity awards granted to Mr. Seth, and (iv) a single lump sum payment
equal to his annual bonus subject to the achievement of the applicable goals, pro-rated based on the number of days in the Company&#8217;s
fiscal year through the date of termination (the &#8220;Pro-Rated Bonus&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if we terminate Mr. Seth&#8217;s employment without Cause or if Mr. Seth resigns for Good Reason, or if we fail to renew his
position as Chief Executive Officer and Chairman on February 24, 2027, in any case, within the 12-month period beginning on the date
of a Change in Control (as defined in the 2019 Plan), Mr. Seth will be entitled to (i) a single lump sum payment equal to 30 months of
his compensation, (ii) continued health benefits for 30 months, (iii) immediate vesting of all outstanding equity awards granted to Mr.
Seth, and (iv) a single lump sum payment equal to the Pro-Rated Bonus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chief
Financial Officer Compensation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 12, 2020, we entered into an employment agreement with Mr. O&#8217;Loughlin, pursuant to which he serves as Chief Financial Officer
of the Company. Under the terms of the employment agreement, Mr. O&#8217;Loughlin is entitled to (i) a base salary, which shall be determined
by the Board, (ii) a performance bonus, which may be up to 30% of the annual base salary based upon the achievement of certain objectives
such as the Board shall determine and (iii) options to purchase shares of common stock of the Company as the Board may grant. For 2023,
Mr. O&#8217;Loughlin&#8217;s annual base salary was set at $420,000, and for 2024, his annual base salary was set at $436,800.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
and if granted, options will have an exercise price equal to the closing price of the Company&#8217;s common stock on the date of the
approval, and 2% of the grant will vest each month from the grant date until fully vested, in accordance with the 2019 Plan. The options
will expire 10 years from the grant date, subject to Mr. O&#8217;Loughlin&#8217;s continuing service with the Company. Mr. Loughlin will
also receive the standard benefits available to other similarly situated employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if we terminate Mr. O&#8217;Loughlin&#8217;s employment without Cause (as defined in the employment agreement) or if Mr. O&#8217;Loughlin
resigns for Good Reason (as defined in the employment agreement), in either case, within the 12-month period beginning on the date of
a Change in Control, Mr. O&#8217;Loughlin will be entitled to (i) a single lump sum payment equal to his annual base salary, (ii) continued
health benefits for 12 months, and (iii) immediate vesting of all outstanding equity awards granted to Mr. O&#8217;Loughlin.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of Directors Meetings and Attendance </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">During 2024, our Board of
Directors held six meetings and acted by unanimous written consent on one occasion. Each director attended at least 75% of the aggregate
of the meetings of our Board and the committees of which he or she was a member during the year ended December&#160;31, 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committees
of the Board of Directors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has formed three standing committees: Audit, Compensation and Nominating and Corporate Governance. Actions taken by
our committees are reported to the full board. Each of our committees has a charter and each charter is posted on our website.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 34%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
    Committee</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation&#160;Committee</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nominating
    and Corporate<br/>
    Governance Committee</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard I. Steinhart*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Nicholson*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajit S. Shetty*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey W. Chell</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey W. Chell</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June S. Almenoff</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajit S. Shetty</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajit S. Shetty</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard I. Steinhart</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 27px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>*</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates committee chair</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
Committee</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Audit Committee, which currently consists of three independent directors, provides assistance to our Board in fulfilling its legal and
fiduciary obligations with respect to matters involving the accounting, financial reporting, internal control and compliance functions
of the Company. The Board has determined that Mr.&#160;Steinhart is an &#8220;audit committee financial expert&#8221; as defined in Item&#160;407(d)(5)(ii)
of Regulation S-K. Our Audit Committee employs an independent registered public accounting firm to audit the financial statements of
the Company and perform other assigned duties. Further, our Audit Committee provides general oversight with respect to the accounting
principles employed in financial reporting and the adequacy of our internal controls. The Audit Committee is also responsible for overseeing
the Company&#8217;s cybersecurity policies and procedures. In discharging its responsibilities, our Audit Committee may rely on the reports,
findings and representations of the Company&#8217;s auditors, legal counsel, and responsible officers. Our Board has determined that
all members of the Audit Committee are financially literate within the meaning of SEC rules and under the current listing standards of
the NYSE American. The Audit Committee met four times during 2024. Each member of the Audit Committee was present at all of the Audit
Committee meetings held during 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Committee</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Compensation Committee, which currently consists of three directors, establishes executive compensation policies consistent with the
Company&#8217;s objectives and stockholder interests. The Compensation Committee met one time during 2024. Each member of the Compensation
Committee was present at all committee meetings held in 2024. Our Compensation Committee also reviews the performance of our executive
officers and establishes, adjusts and awards compensation, including incentive-based compensation, as more fully discussed below. In
addition, our Compensation Committee generally is responsible for:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing and periodically
    reviewing our compensation philosophy and the adequacy of compensation plans and programs for our directors, executive officers and
    other employees;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing our compensation
    plans, including the establishment of performance goals under the Company&#8217;s incentive compensation arrangements and the review
    of performance against those goals in determining incentive award payouts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing our executive
    employment contracts, special retirement benefits, severance, change in control arrangements and/or similar plans;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acting as administrator
    of any company stock option plans; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing outside compensation
    consultants when engaged.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Compensation Committee periodically reviews the compensation paid to our non-employee directors and the principles upon which their compensation
is determined. The Compensation Committee also periodically reports to the Board on how our non-employee director compensation practices
compare with those of other similarly situated public corporations and, if the Compensation Committee deems it appropriate, recommends
changes to our director compensation practices to our Board for approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 95; Value: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
consulting firms retained by our Compensation Committee and management also will, if requested, provide assistance to the Compensation
Committee in making its compensation-related decisions. The Compensation Committee engaged StreeterWyatt Analytics LLC, or Streeter Wyatt
and paid consultant fees of $35,000 during the year ended December 31, 2024. Streeter Wyatt was instructed to provide support and analysis
to the Compensation Committee and their services included developing a peer group regarding executive and director compensation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nominating
and Corporate Governance Committee</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Nominating and Corporate Governance Committee, which currently consists of three directors, is charged with the responsibility of reviewing
our corporate governance policies and proposing potential director nominees to the Board for consideration. Our Board has determined
that each member of our Nominating and Corporate Governance Committee qualifies as an &#8220;independent&#8221; member of the Board as
defined by the rules and regulations of the SEC and the NYSE American.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Nominating and Corporate Governance Committee&#8217;s primary responsibilities and obligations include, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing the administration
    of our Code of Business Ethics and Conduct and related policies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">leading the search for
    and recommending individuals qualified to become members of the Board, and selecting director nominees to be presented for election
    by the shareholders at each annual meeting;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assessing the diversity
    of the Board and recommending any changes to the Board&#8217;s composition;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensuring, in cooperation
    with the Compensation Committee, that no agreements or arrangements are made with directors or relatives of directors for providing
    professional or consulting services to us or our affiliate or individual officer or one of their affiliated, without appropriate
    review and evaluation for conflicts of interest;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assessing the independence
    of directors annually and report to the Board;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending to the Board
    for its approval, the leadership structure of the Board, including whether the Board should have an executive or non-executive Chairman,
    whether the roles of Chairman and Chief Executive Officer should be combined, and whether a Lead Director of the Board should be
    appointed; provided that such structure shall be subject to the bylaws of the Company then in effect;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensuring that Board members
    do not serve on more than six other for-profit public company boards that have a class of securities registered under the Exchange
    Act in addition to the Board;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing the Board&#8217;s
    committee structure and to recommend to the Board for its approval directors to serve as members of each committee as well as recommendations
    for committee chairs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and recommending
    changes to procedures whereby shareholders may communicate with the Board;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><p style="margin-top: 0; margin-bottom: 0"></p>
                                                         <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                                         <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing recommendations
    received from shareholders for persons to be considered for nomination to the Board;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring compliance with
    our corporate governance guidelines;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing and implementing
    an annual self-evaluation of the Board, both individually and as a Board, and of its committees;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 96; Value: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Nominating and Corporate Governance Committee considers all qualified candidates identified by members of the Board, by senior management
and by stockholders. The Committee follows the same process and uses the same criteria for evaluating candidates proposed by stockholders,
members of the Board and members of senior management. When evaluating a candidate to serve on our Board, the members of our Nominating
and Corporate Governance Committee consider items such as experience in the biotechnology sector, experience with public companies, executive
managerial experience, operations and commercial experience, fundraising experience and contacts in the investment banking industry,
personal and skill set compatibility with current Board members, industry reputation, knowledge of our company generally, and independence.
The Nominating and Corporate Governance Committee met one time during 2024. Each member of the Nominating and Corporate Governance Committee
was present at all committee meetings held in 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Amended and Restated Bylaws, as amended (the &#8220;Bylaws&#8221;) contains provisions that address the process by which a stockholder
may nominate an individual to stand for election to the Board at our annual meetings. To recommend a nominee for election to the Board,
a stockholder must submit his or her recommendation to our Secretary at our corporate offices at 100 Park Avenue, 23rd Floor, New York,
New York 10017. Such nomination must satisfy the notice, information and consent requirements set forth in our Bylaws and must be received
by us prior to the date set forth under &#8220;Submission of Future Stockholder Proposals&#8221; below. A stockholder&#8217;s recommendation
must be accompanied by the information with respect to stockholder nominees as specified in our Bylaws, including among other things,
the name, age, address and occupation of the recommended person, the proposing stockholder&#8217;s name and address, the ownership interests
of the proposing stockholder and any beneficial owner on whose behalf the nomination is being made (including the number of shares beneficially
owned, any hedging, derivative, short or other economic interests and any rights to vote any shares) and any material monetary or other
relationships between the recommended person and the proposing stockholder and/or the beneficial owners, if any, on whose behalf the
nomination is being made.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
approach toward Board diversity takes into consideration the overall composition and diversity of the Board and areas of expertise that
director nominees may be able to offer, including business experience, knowledge, abilities, customer relationships and appropriate perspectives
on environmental, social and governance matters. The Board recognizes the importance of diversity and the value it can bring to the Board&#8217;s
overall advice and oversight. In 2023, the Nominating and Corporate Governance Committee together with the Chairman and CEO, formally
undertook a process, including engaging with executive search firms and our internal human resources department, to identify and evaluate
qualified candidates to address the Board&#8217;s diversity and composition. The Nominating and Corporate Governance met one time in
2024 to review the Board&#8217;s composition and diversity. Our entire Board was involved in the process to evaluate new potential directors,
which included reference checks and in-person meetings. In October 2024, we increased our Board to six members and effective November
2024, added Dr. June Almenoff as a Class III Director who also serves on our Nominating and Corporate Governance Committee. Generally,
we strive to assemble and maintain a Board that brings to us a variety of perspectives and skills derived from business and professional
experience as we may deem are in our and our stockholders&#8217; best interests. In doing so, we also consider candidates with appropriate
non-business backgrounds.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lead
Director</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2017, our Board of Directors created the position of Lead Director and designated David Nicholson, an existing independent
director, as our Lead Director. Pursuant to the charter of the Lead Director, the Lead Director shall be an independent,&#160;non-employee&#160;director
designated by our Board of Directors who shall serve in a lead capacity to coordinate the activities of the other&#160;non-employee&#160;directors,
interface with and advise management, and perform such other duties as are specified in the charter or as our Board of Directors may
determine.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family
Relationships</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our officers or directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 97; Value: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Involvement
in Certain Legal Proceedings</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
our knowledge, none of our current directors or executive officers has, during the past ten years:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">been convicted in a criminal
    proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">had any bankruptcy petition
    filed by or against the business or property of the person, or of any partnership, corporation or business association of which he
    or she was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that
    time;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">been subject to any order,
    judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state
    authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his or her involvement in any type of
    business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with
    persons engaged in any such activity;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">been found by a court of
    competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated a federal or
    state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: .5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">been the subject of, or
    a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended
    or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any
    federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance
    companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty
    or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire
    fraud or fraud in connection with any business entity; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">been the subject of, or
    a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined
    in Section 3(a)(26) of the Exchange Act), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act), or
    any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated
    with a member.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our directors or executive officers has been involved in any transactions with us or any of our directors, executive officers, affiliates
or associates which are required to be disclosed pursuant to the rules and regulations of the SEC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Ethics</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has adopted a code of ethics, (the &#8220;Code of Ethics&#8221;), a copy of which is attached as Exhibit 14.1 to the Form 8-K
filed on January 2, 2013.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insider
Trading Policy</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Code of Ethics includes the Company&#8217;s insider trading policy and procedures governing the purchase, sale, and/or
other dispositions of the Company's securities by directors, officers and employees that is designed to promote compliance with insider
trading laws, rules and regulations, as well as procedures designed to further the foregoing purposes. A copy of the insider trading
policy is included in Exhibit 14.1 to this Annual Report on Form 10-K. While the Company is not subject to the insider trading policy,
the Company does not trade in its securities when it is in possession of material nonpublic information other than pursuant to previously
<ix:nonNumeric contextRef="c87" format="ixt:fixed-true" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="ixv-15381">adopted</ix:nonNumeric> Rule 10b5-1 trading plans, if any.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
Discussion and Analysis</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Compensation Committee of our Board of Directors has the responsibility to review, determine and approve the compensation for our executive
officers. Further, our Compensation Committee oversees our overall compensation strategy, including compensation policies, plans and
programs that cover all employees. At our 2022 Annual Meeting of Stockholders, our Stockholders voted on an advisory basis to approve
the compensation of named executive officers. Of the votes cast (excluding abstentions and broker non-votes), 79.3% were cast in support
of the results of our compensation program. In light of this, in reviewing the executive compensation program for 2023 and 2024, our
Compensation Committee decided to retain the general overall program design, which ties a significant portion of the executives&#8217;
pay closely with our performance. In the future, our Compensation Committee will continue to consider the executive compensation program
in light of changing circumstances and stockholder feedback.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently employ two executive officers: (1) Sandesh Seth, our Chairman and Chief Executive Officer (who we refer to in this Compensation
Discussion and Analysis as our CEO) and (2) Steve O&#8217;Loughlin, our Chief Financial Officer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Compensation Discussion and Analysis sets forth a discussion of the compensation for our Named Executive Officers, or NEOs, as well as
a discussion of our philosophies underlying the compensation for our NEOs and our employees generally.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Objectives
of Our Compensation Program</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee&#8217;s philosophy seeks to align the interests of our stockholders, officers and employees by tying compensation
to individual and company performance, both directly in the form of salary or annual cash incentive payments, and indirectly in the form
of equity awards. The objectives of our compensation program enhance our ability to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract and retain qualified
    and talented individuals; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: .25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide reasonable and
    appropriate incentives and rewards to our team for building long-term value within our company, in each case in a manner comparable
    to companies similar to ours.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we strive to be competitive with other similarly situated companies in our industry. The process of developing pharmaceutical
products and bringing those products to market is a long-term proposition and outcomes may not be measurable for several years. Therefore,
in order to build long-term value for our company and its stockholders, and in order to achieve our business objectives, we believe that
we must compensate our officers and employees in a competitive and fair manner that reflects current company activities but also reflects
contributions to building long-term value.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
utilize the services of StreeterWyatt Analytics LLC to review compensation programs of peer companies in order to assist the Compensation
Committee in determining the compensation levels for our NEOs, as well as for other employees of our company. StreeterWyatt is a recognized
independent consulting company and services clients throughout the United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Elements
of Our Compensation Program and Why We Chose Each</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Main
Compensation Components</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
company-wide compensation program, including for our NEOs, is broken down into three main components: base salary, performance cash bonuses
and potential long-term compensation in the form of stock options or restricted stock unit awards. We believe these three components
constitute the minimum essential elements of a competitive compensation package in our industry.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Salary</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Base
salary is used to recognize the experience, skills, knowledge and responsibilities required of our NEOs as well as recognizing the competitive
nature of the biopharmaceutical industry. This is determined partially by evaluating our peer companies as well as the degree of responsibility
and experience levels of our NEOs and their overall contributions to our company. Base salary is one component of the compensation package
for NEOs; the other components being cash bonuses, annual equity grants, and company benefit programs. Base salary is determined in advance
whereas the other components of compensation are awarded in varying degrees following an assessment of the performance of a NEO. This
approach to compensation reflects the philosophy of our Board of Directors and its Compensation Committee to emphasize and reward, on
an annual basis, performance levels achieved by our NEOs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 99; Value: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Performance
Bonus Plan</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a performance bonus plan under which bonuses are paid to our NEOs based on achievement of company performance goals and objectives
established by the Compensation Committee and/or our Board of Directors as well as on individual performance. The bonus program is discretionary
and is intended to: (i) strengthen the connection between individual compensation and our company&#8217;s achievements; (ii) encourage
teamwork among all disciplines within our company; (iii) reinforce our pay-for-performance philosophy by awarding higher bonuses to higher
performing employees; and (iv) help ensure that our cash compensation is competitive. Depending on the cash position of the company,
the Compensation Committee and our Board of Directors have the discretion to not pay cash bonuses in order that we may conserve cash
and support ongoing development programs and commercialization efforts. Regardless of our cash position, we consistently grant annual
merit-based stock options to continue incentivizing both our senior management and our employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on their employment agreements, each NEO is assigned a target payout under the performance bonus plan, expressed as a percentage of base
salary for the year. Actual payouts under the performance bonus plan are based on the achievement of corporate performance goals and
an assessment of individual performance, each of which is separately weighted as a component of such officer&#8217;s target payout. For
the NEOs, the corporate goals receive the highest weighting in order to ensure that the bonus system for our management team is closely
tied to our corporate performance. Each employee also has specific individual goals and objectives as well that are tied to the overall
corporate goals. For employees, mid-year and end-of-year progress is reviewed with the employees&#8217; managers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Equity
Incentive Compensation</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
view long-term compensation, currently in the form of stock options generally vesting in annual increments over four years, as a tool
to align the interests of our NEOs and employees generally with the creation of stockholder value, to motivate our employees to achieve
and exceed corporate and individual objectives and to encourage them to remain employed by the company. While cash compensation is a
significant component of employees&#8217; overall compensation, the Compensation Committee and our Board of Directors (as well as our
NEOs) believe that the driving force of any employee working in a small biotechnology company should be strong equity participation.
We believe that this not only creates the potential for substantial longer-term corporate value but also serves to motivate employees
and retain their loyalty and commitment with appropriate personal compensation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Compensation</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the main components of compensation outlined above, we also have provided contractual severance and/or change in control
benefits to several employees including our CEO. The change in control benefits for all applicable persons have a &#8220;double trigger.&#8221;
A double-trigger means that the executive officers will receive the change in control benefits described in the agreements only if there
is both (1) a Change in Control of our company (as defined in the agreements) and (2) a termination by us of the applicable person&#8217;s
employment &#8220;without cause&#8221; or a resignation by the applicable persons for &#8220;good reason&#8221; (as defined in the agreements)
within a specified time period prior to or following the Change in Control. We believe this double trigger requirement creates the potential
to maximize stockholder value because it prevents an unintended windfall to management as no benefits are triggered solely in the event
of a Change in Control while providing appropriate incentives to act in furtherance of a change in control that may be in the best interests
of the stockholders. We believe these severances or change in control benefits are important elements of our compensation program that
assist us in retaining talented individuals at the executive and senior managerial levels and that these arrangements help to promote
stability and continuity of our executives and senior management team. Further, we believe that the interests of our stockholders will
be best served if the interests of these members of our management are aligned with theirs. We believe that providing change in control
benefits lessens or eliminates any potential reluctance of members of our management to pursue potential change in control transactions
that may be in the best interests of the stockholders. We also believe that it is important to provide severance benefits to members
of our management, to promote stability and focus on the job at hand.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 100; Value: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also provide benefits to the executive officers that are generally available to all regular full-time employees of our company, including
our medical and dental insurance, and a 401(k) plan. Further, we do not have deferred compensation plans, pension arrangements or post-retirement
health coverage for our executive officers or employees. All of our employees not specifically under contract are &#8220;at-will&#8221;
employees, which means that their employment can be terminated at any time for any reason by either us or the employee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Determination
of Compensation Amounts</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
number of factors impact the determination of compensation amounts for our NEOs, including the individual&#8217;s role in the company
and individual performance, length of service with the company, competition for talent, individual compensation package, assessments
of internal pay equity and industry data. Stock price performance has generally not been a factor in determining annual compensation
because the price of our common stock is subject to a variety of factors outside of our control.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Industry
Survey Data</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
collaboration with StreeterWyatt, we establish and maintain a list of peer companies to best assure ourselves that we are compensating
our executives on a fair and reasonable basis, as set forth above under the heading &#8220;Objectives of our Compensation Program.&#8221;
We also utilize StreeterWyatt-prepared data for below-executive level personnel, which data focuses on biotechnology companies that can
be considered peers in terms of numerous variables including phase of development, size, therapeutic and technological focus among others.
The availability of peer data is used by the Compensation Committee strictly as a guide in determining compensation levels with regard
to salaries, cash bonuses and performance related annual equity grants to all employees. However, the availability of this data does
not imply that the Compensation Committee is under any obligation to exactly follow peer companies in compensation matters.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Determination
of Base Salaries</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a guideline for NEO base salary, we perform formal benchmarks against respective comparable positions in our established peer group.
We adjust salaries based on our assessment of our NEOs&#8217; levels of responsibility, experience, overall compensation structure and
individual performance. The Compensation Committee is not obliged to raise salaries purely on the availability of data. Merit-based increases
to salaries of executive officers are based on our assessment of individual performance and the relationship to applicable salary ranges.
Cost of living adjustments may also be a part of that assessment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Performance
Bonus Plan</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently
with the beginning of each calendar year, preliminary corporate goals that reflect our business priorities for the coming year are prepared
by the CEO with input from the other executive officers. These goals are weighted by relative importance. The draft goals and proposed
weightings are presented to the Compensation Committee and the Board and discussed, revised as necessary, and then approved by our Board
of Directors. The Compensation Committee then reviews the final goals and their weightings to determine and confirm their appropriateness
for use as performance measurements for purposes of the bonus program. The goals and/or weightings may be re-visited during the year
and potentially restated in the event of significant changes in corporate strategy or the occurrence of significant corporate events.
Following the agreement of our Board on the corporate objectives, the goals are then shared with all employees in formal meetings and
are reviewed periodically throughout the year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Determination
of Equity Incentive Compensation</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
assist us in assessing the reasonableness of our equity grant amounts, we have reviewed StreeterWyatt supplied information. Such information
included equity data from a cross-section of similar companies in our industry.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>




</div><!-- Field: Page; Sequence: 101; Value: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Equity
Grant Practices</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
stock options and/or restricted stock units granted to the NEOs and other executives are approved by the Compensation Committee. Exercise
prices for options are set at the closing price of our common stock on the date of grant. Grants are generally made: (i) on the employee&#8217;s
start date and (ii) at board of director meetings held once each year and following annual performance reviews. However, grants have
been made at other times during the year. The size of year-end grants for each NEO is assessed against our internal equity guidelines.
Current market conditions for grants for comparable positions and internal equity may also be assessed. Also, grants may be made in connection
with promotions or job-related changes in responsibilities. In addition, on occasion, the Compensation Committee may make additional
special awards for extraordinary individual or company performance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensation
Setting Process</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annually,
at a meeting of our Board of Directors and the Compensation Committee, overall corporate performance and relative achievement of the
corporate goals for the prior year are assessed. The relative achievement of each goal is assessed and quantified and the summation of
the individual components results in a corporate goal rating, expressed as percentages. The Compensation Committee then approves the
final disbursement of salary increases, cash bonuses and option or restricted stock unit grants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee looks to the CEO&#8217;s performance assessments of the other NEOs and his recommendations regarding a performance
rating for each, as well as input from the other members of our Board of Directors. These recommendations may be adjusted by the Compensation
Committee prior to finalization. For the CEO, the Compensation Committee evaluates his performance, taking into consideration input from
the other members of our Board of Directors, and considers the achievement of overall corporate objectives by both the CEO specifically
and the company generally. The CEO is not present during the Compensation Committee&#8217;s deliberations regarding his compensation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee has the authority to directly engage, at our company&#8217;s expense, any compensation consultants or other advisors
(such as StreeterWyatt) that it deems necessary to determine the amount and form of employee, executive and director compensation. In
determining the amount and form of employee, executive and director compensation, the Compensation Committee has reviewed and discussed
historical salary information as well as salaries for similar positions at comparable companies. However, the availability of this data
does not imply that the Compensation Committee is under any obligation to follow peer companies&#8217; compensation practices.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
paid consultant fees to StreeterWyatt of $35,000 during the year ended December 31, 2024. NEOs may have indirect input in the compensation
results for other executive officers by virtue of their participation in the performance review and feedback process for the other executive
officers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
11. EXECUTIVE COMPENSATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information regarding the compensation earned during the years ended December 31, 2024 and 2023 for our named
executive officers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; border-bottom: Black 1.5pt solid; font-weight: bold">Name/Position</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bonus&#160;(1)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option<br/> Awards&#160;(2)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">All Other<br/> Compensation</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left">Sandesh Seth</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">733,200</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">440,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,173,200</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic; text-align: left">Chairman and Chief Executive Officer(3)</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">705,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,705,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Steve O&#8217;Loughlin</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">436,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">145,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">581,800</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic; text-align: left">Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">420,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">170,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">900,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,490,000</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 27px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The bonus disclosed in
    this column relates to performance in the prior year, but was determined and approved by the Board and was paid in the year disclosed.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 27px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The dollar amounts in this
    column represent the aggregate grant date fair value of all option awards granted during the indicated year. These amounts have been
    calculated in accordance with FASB ASC Topic 718, using the Black-Scholes option-pricing model. For a discussion of valuation assumptions,
    see Note 7 to our financial statements. These amounts do not necessarily correspond to the actual value that may be recognized from
    the option awards by the NEOs.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Narrative
Disclosure to Summary Compensation Table</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a discussion of the material terms of each named executive officer&#8217;s employment agreement or arrangement, refer to the sections
above titled &#8220;Directors, Executive Officers and Corporate Governance&#8212;Chief Executive Officer Compensation&#8221; and &#8220;Directors,
Executive Officers and Corporate Governance&#8212;Chief Financial Officer/Principal Financial Officer Compensation.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2023, Mr. Seth was granted an option to purchase 984,367 shares of common stock and Mr. O&#8217;Loughlin was granted an
option to purchase 253,123 shares of common stock. The options have an exercise price of $5.00 per share and expire on December 28, 2033.
Pursuant to the terms of the 2019 Stock Plan, 2% of the options will vest each month from the respective dates of grants until fully
vested.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Compensation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the compensation of our non-employee directors for the year ended December 31, 2024:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fees <br/> Earned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock<br/> Awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option<br/> Awards&#160;(1)(2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All Other <br/> Compensation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">June S. Almenoff (3)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,333</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">65,611</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">73,944</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Jeffrey W. Chell</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">62,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">62,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">David Nicholson</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">75,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">75,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Ajit J. Shetty</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">72,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">72,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Richard Steinhart</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">70,000</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dollar amounts in this column represent the aggregate grant date fair value of options granted during 2024. These amounts have been calculated
in accordance with FASB ASC Topic 718, using the Black-Scholes option-pricing model. For a discussion of valuation assumptions, see Note
7 to our financial statements. These amounts do not necessarily correspond to the actual value that may be recognized from the option
awards by the Directors.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, the aggregate number of option awards outstanding for each director was as follows: (i) for Dr. Almenoff, 50,000 (ii)
for Dr. Chell, 182,484, (iii) for Dr. Nicholson, 185,817, (iv) for Dr. Shetty, 182,484, and (v) for Mr. Steinhart, 185,817.</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.Almenoff
was appointed as a director, effective November 1, 2024.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
non-employee directors are paid an annual fee of $45,000 and in most years, receive stock option grants. Dr. Nicholson as Lead Director
receives an additional annual fee of $10,000. Board committee members receive the following compensation, in addition to their annual
fees:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">BOD Committee</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Chairman</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Member</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Audit</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Compensation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Nominating and Corporate Governance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,000</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 103; Value: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OUTSTANDING
EQUITY AWARDS AT FISCAL YEAR-END &#8211; 2024</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth all unexercised stock options and unvested restricted stock units that have been awarded to our named executives
by the Company that were outstanding as of December 31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option Awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock Awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold">Name (a)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Securities<br/> Underlying<br/> Unexercised<br/> Options<br/> (#)<br/> (Exercisable)<br/> (b)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Securities<br/> Underlying<br/> Unexercised<br/> Options<br/> (#)<br/> (Unexercisable)<br/> (c)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity<br/> Incentive<br/> Plan<br/> Awards:<br/> Number of<br/> Securities<br/> Underlying<br/> Unexercised<br/> Unearned<br/> Options<br/> (#)(d)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option<br/> Exercise<br/> Price<br/> ($) (e)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option<br/> Expiration<br/> Date<br/> (f)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#160;of <br/> Shares&#160;or<br/> Units&#160;of<br/> Stock&#160;That <br/> Have&#160;Not<br/> Vested <br/> (#) (g)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Market<br/> Value of<br/> Shares or<br/> Units of<br/> Stock<br/> That <br/> Have&#160;Not<br/> Vested <br/> ($) (h)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity<br/> Incentive<br/> Plan<br/> Awards:<br/> Number<br/> of<br/> Unearned<br/> Shares,<br/> Units or<br/> Other<br/> Rights<br/> That<br/> Have&#160;Not<br/> Vested&#160;<br/> (#) (i)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity<br/> Incentive<br/> Plan<br/> Awards:<br/> Market</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>or<br/> Payout</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value of<br/> Unearned<br/> Shares,<br/> Units or</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other<br/> Rights<br/> That<br/> Have Not<br/> Vested&#160;<br/> ($) (j)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: rgb(204,238,255); text-indent: -0.125in; padding-left: 0.125in; width: 11%; text-align: left">Sandesh Seth</td><td style="background-color: rgb(204,238,255); width: 1%">&#160;</td>
    <td style="background-color: rgb(204,238,255); width: 1%; text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); width: 7%; text-align: right">16,666</td><td style="background-color: rgb(204,238,255); width: 1%; text-align: left"><sup>(1)</sup>&#160;</td><td style="background-color: rgb(204,238,255); width: 1%">&#160;</td>
    <td style="background-color: rgb(204,238,255); width: 1%; text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); width: 7%; text-align: right">-</td><td style="background-color: rgb(204,238,255); width: 1%; text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); width: 1%">&#160;</td>
    <td style="background-color: rgb(204,238,255); width: 1%; text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); width: 7%; text-align: right">-</td><td style="background-color: rgb(204,238,255); width: 1%; text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); width: 1%">&#160;</td>
    <td style="background-color: rgb(204,238,255); width: 1%; text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); width: 7%; text-align: right">59.70</td><td style="background-color: rgb(204,238,255); width: 1%; text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); width: 1%">&#160;</td>
    <td style="background-color: rgb(204,238,255); width: 7%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/15/2026</span></td><td style="background-color: rgb(204,238,255); width: 1%; text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); width: 1%">&#160;</td>
    <td style="background-color: rgb(204,238,255); width: 1%; text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); width: 7%; text-align: right">-</td><td style="background-color: rgb(204,238,255); width: 1%; text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); width: 1%">&#160;</td>
    <td style="background-color: rgb(204,238,255); width: 1%; text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); width: 7%; text-align: right">-</td><td style="background-color: rgb(204,238,255); width: 1%; text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); width: 1%">&#160;</td>
    <td style="background-color: rgb(204,238,255); width: 1%; text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); width: 7%; text-align: right">-</td><td style="background-color: rgb(204,238,255); width: 1%; text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); width: 1%">&#160;</td>
    <td style="background-color: rgb(204,238,255); width: 1%; text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); width: 7%; text-align: right">-</td><td style="background-color: rgb(204,238,255); width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="background-color: rgb(204,238,255); text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">24,998</td><td style="background-color: rgb(204,238,255); text-align: left"><sup>(1)</sup>&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">41.70</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/14/2027</span></td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: rgb(204,238,255); text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">33,333</td><td style="background-color: rgb(204,238,255); text-align: left"><sup>(1)</sup>&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">23.497</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/13/2028</span></td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="background-color: rgb(204,238,255); text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">50,000</td><td style="background-color: rgb(204,238,255); text-align: left"><sup>(1)</sup>&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">6.96</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/12/2029</span></td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: rgb(204,238,255); text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">139,062</td><td style="background-color: rgb(204,238,255); text-align: left"><sup>(1)</sup>&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">9.55</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/12/2030</span></td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="background-color: rgb(204,238,255); text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">241,941</td><td style="background-color: rgb(204,238,255); text-align: left"><sup>(2)</sup>&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">68,241</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">6.07</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/01/2031</span></td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: rgb(204,238,255); text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">479,872</td><td style="background-color: rgb(204,238,255); text-align: left"><sup>(2)</sup>&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">347,494</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">4.96</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/01/2032</span></td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="background-color: rgb(204,238,255); text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">236,248</td><td style="background-color: rgb(204,238,255); text-align: left"><sup>(2)</sup>&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">748,119</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">5.00</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/28/2033</span></td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: rgb(204,238,255); text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left"><sup>&#160;</sup>&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">300,000</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">378,000</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left"><sup>&#160;</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: rgb(204,238,255); text-indent: -0.125in; padding-left: 0.125in; text-align: left">Steve O&#8217;Loughlin</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">3,333</td><td style="background-color: rgb(204,238,255); text-align: left"><sup>(1)</sup>&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">53.70</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/28/2025</span></td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="background-color: rgb(204,238,255); text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">1,666</td><td style="background-color: rgb(204,238,255); text-align: left"><sup>(1)</sup>&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">59.70</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/15/2026</span></td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: rgb(204,238,255); text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">3,333</td><td style="background-color: rgb(204,238,255); text-align: left"><sup>(1)</sup>&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">41.70</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/14/2027</span></td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="background-color: rgb(204,238,255); text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">8,833</td><td style="background-color: rgb(204,238,255); text-align: left"><sup>(1)</sup>&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">23.497</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/13/2028</span></td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: rgb(204,238,255); text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">13,333</td><td style="background-color: rgb(204,238,255); text-align: left"><sup>(1)</sup>&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">6.96</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/12/2029</span></td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="background-color: rgb(204,238,255); text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">59,066</td><td style="background-color: rgb(204,238,255); text-align: left"><sup>(1)</sup>&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">9.55</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/12/2030</span></td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: rgb(204,238,255); text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">83,821</td><td style="background-color: rgb(204,238,255); text-align: left"><sup>(2)</sup>&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">23,642</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">6.07</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/01/2031</span></td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="background-color: rgb(204,238,255); text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">148,734</td><td style="background-color: rgb(204,238,255); text-align: left"><sup>(2)</sup>&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">107,704</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">4.96</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/01/2032</span></td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="background-color: rgb(204,238,255); text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">60,749</td><td style="background-color: rgb(204,238,255); text-align: left"><sup>(2)</sup>&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">192,374</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">5.00</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/28/2033</span></td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255)">&#160;</td>
    <td style="background-color: rgb(204,238,255); text-align: left">&#160;</td><td style="background-color: rgb(204,238,255); text-align: right">-</td><td style="background-color: rgb(204,238,255); text-align: left">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fully
vested.</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Company&#8217;s 2019 Stock Plan, 2% of these options vest each month from the date of grant.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnification
of Directors and Officers</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
102(b)(7) of the Delaware General Corporation Law allows a corporation to provide in its certificate of incorporation that a director
of the corporation will not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary
duty as a director, except where the directors breached the duty of loyalty, failed to act in good faith, engaged in intentional misconduct
or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law
or obtained an improper personal benefit. Our certificate of incorporation provides for this limitation of liability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145 of the General Corporation Law of the State of Delaware provides that a Delaware corporation may indemnify any person who was, is
or is threatened to be made, party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative
or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was an officer,
director, employee or agent of such corporation or is or was serving at the request of such corporation as a director, officer employee
or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&#8217; fees), judgments, fines
and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided
such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation&#8217;s best
interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was illegal.
A Delaware corporation may indemnify any persons who are, or were, a party to any threatened, pending or completed action or suit by
or in the right of the corporation by reason of the fact that such person is or was a director, officer, employee or agent of another
corporation or enterprise. The indemnity may include expenses (including attorneys&#8217; fees) actually and reasonably incurred by such
person in connection with the defense or settlement of such action or suit, provided such person acted in good faith and in a manner
he or she reasonably believed to be in or not opposed to the corporation&#8217;s best interests, provided that no indemnification is
permitted without judicial approval if the officer, director, employee or agent is adjudged to be liable to the corporation. Where an
officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify
him or her against the expenses which such officer or directors has actually and reasonably incurred.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145 further authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee
or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another
corporation or enterprise, against any liability asserted against him and incurred by him in any such capacity, or arising out of his
or her status as such, whether or not the corporation would otherwise have the power to indemnify him under Section 145.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
bylaws provide that we will indemnify our directors and officers to the fullest extent authorized by the General Corporation Law of the
State of Delaware. Expenses (including attorneys&#8217; fees) incurred by an officer or director of the Corporation in defending any
civil, criminal, administrative or investigative action, suit or proceeding may be paid by the Company in advance of the final disposition
of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if
it shall ultimately be determined that such person is not entitled to be indemnified by the Company as authorized under Delaware law.&#160;&#160;Such
expenses (including attorneys&#8217; fees) incurred by former directors and officers or other employees and agents of the Company or
by persons serving at the request of the Company as directors, officers, employees or agents of another corporation, partnership, joint
venture, trust or other enterprise may be so paid upon such terms and conditions, if any, as the Company deems appropriate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indemnification rights set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter acquire
under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person&#8217;s official
capacity and as to action in another capacity while holding such office, and shall continue as to a person who has ceased to be a director,
officer, employee, or agent and shall inure to the benefit of the heirs, executors, and administrators of such person.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain a general liability insurance policy that covers liabilities of directors and officers of our corporation arising out of claims
based on acts or omissions in their capacities as directors or officers. We have also entered into Indemnification Agreements with our
executive officers and directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">At the present time, there is no pending litigation or proceeding involving
a director, officer, employee, or other agent of ours in which indemnification would be required or permitted and we are not aware of
any threatened litigation or proceeding that may result in a claim for such indemnification, in each case, except as set forth under &#8220;Legal
Proceedings.&#8221;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>Timing
of Certain Equity Awards </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any policies and practices on the timing of awards of stock options or other equity grants in relation to the disclosure
of material nonpublic information. The Company grants stock options based on timelines in the normal course of business independent of
the occurrence of these types of events (e.g., at pre-established dates, such as on an employee&#8217;s start date, at board of director
meetings held once each year and following annual performance reviews). During the last completed fiscal year, we did not grant equity
awards in anticipation of the release of material nonpublic information that is likely to result in changes to the price of our common
stock, and did not time the public release of such information based on award grant dates. During the last completed fiscal year, we
have not made awards to any named executive officer during the period beginning four business days before and ending one business day
after the filing of a period report on Form 10-Q or Form 10-K or the filing or furnishing of a current report on Form 8-K, and we have
not timed the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 105; Value: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the beneficial ownership of our common stock as of March 27, 2025 held by (i) each person known to us to be the
beneficial owner of more than five percent (5%) of any class of our voting shares; (ii) each director; (iii) each Named Executive Officer;
and (iv) all directors and executive officers as a group.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC, and generally includes voting power and/or investment power with respect
to the securities held.&#160;&#160;Shares of common stock subject to options and warrants currently exercisable or which may become exercisable
within 60 days of March 27, 2025, are deemed outstanding and beneficially owned by the person holding such options or warrants for purposes
of computing the number of shares and percentage beneficially owned by such person, but are not deemed outstanding for purposes of computing
the percentage beneficially owned by any other person.&#160;&#160;Except as indicated in the footnotes to this table, the persons or
entities named have sole voting and investment power with respect to all shares of our common stock shown as beneficially owned by them.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, the principal address of each of the persons below is c/o Actinium Pharmaceuticals, Inc., 100 Park Ave, 23<sup>rd
</sup>Floor, New York, NY 10017.<b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name of Beneficial Owner</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <br/> Shares of <br/> Common <br/> Stock <br/> Beneficially <br/> Owned</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership<sup>(a)</sup></b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Beneficial Owners of 5% or More of Our Common Stock</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">BlackRock, Inc.</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,691,914</td><td style="white-space: nowrap; width: 1%; text-align: left">(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.4</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">The Vanguard Group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,625,000</td><td style="white-space: nowrap; text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Named Executive Officers and Directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sandesh Seth</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,414,624</td><td style="white-space: nowrap; text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Steve O&#8217;Loughlin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">440,690</td><td style="white-space: nowrap; text-align: left">(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.4</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">June Almenoff, M.D. Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Jeffrey W. Chell, M.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109,379</td><td style="white-space: nowrap; text-align: left">(5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">David Nicholson, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112,212</td><td style="white-space: nowrap; text-align: left">(6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Ajit S. Shetty, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,136</td><td style="white-space: nowrap; text-align: left">(7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Richard I. Steinhart</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112,195</td><td style="white-space: nowrap; text-align: left">(8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">All Directors and Officers as a Group (7 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,304,617</td><td style="white-space: nowrap; text-align: left">(9)(10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.9</td><td style="text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 27px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">less than 1%</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on 31,195,891 shares
    of common stock outstanding as of March 27, 2025</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the Schedule 13G
    filed by BlackRock Inc. (&#8220;BlackRock&#8221;) as the parent holding company or control person of BlackRock Advisors, LLC, BlackRock
    Fund Advisors, BlackRock Institutional Trust Company, N.A., BlackRock Financial Management, Inc., and BlackRock Investment Management,
    LLC with the SEC on January 29, 2024, reporting beneficial ownership as of December 30, 2023. BlackRock is the beneficial owner of
    1,691,914 shares of common stock and has sole voting power and sole dispositive power over 1,691,914 shares of common stock. The
    address for each of the reporting persons is 50 Hudson Yards, New York, NY 10001.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the Schedule 13G/A
    filed by The Vanguard Group, Inc. (&#8220;Vanguard&#8221;) with the SEC on November 12, 2024, reporting beneficial ownership as of
    September 30, 2024. Vanguard is the beneficial owner of 1,625,000 shares of common stock and has shared voting power over 48,600
    shares of common stock, sole dispositive power over 1,567,507 shares of common stock and shares dispositive power over 57,493 shares
    of common stock. The address for Vanguard is 100 Vanguard Blvd. Malvern, PA 19355. </span></td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 5,381 shares of
    common stock and 1,414,624 shares of common stock underlying options that will have vested within 60 days of March 28, 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 1,183 shares of
    common stock and 439,507 shares of common stock underlying options that will have vested within 60 days of March 28, 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 109,379 shares
    of common stock underlying options that will have vested within 60 days of March 28, 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 333 shares of
    common stock and 111,879 shares of common stock underlying options that will have vested within 60 days of March 28, 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 757 shares of
    common stock and 109,379 shares of common stock underlying options that will have vested within 60 days of March 28, 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 316 shares of
    common stock and 111,879 shares of common stock underlying options that will have vested within 60 days of March 28, 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 7,970 shares of
    common stock and 2,296,647 shares of common stock underlying options that will have vested within 60 days of March 28, 2025.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;<b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="text-align: justify; font-size: 10pt"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">On March 31,
2025, our Board of Directors of approved the cancellation of certain stock options to purchase 5,149,944 shares of common stock held
by certain current employees and directors that were initially granted under the Company&#8217;s Amended and Restated 2013 Stock Plan
and 2019 Amended and Restated Stock Plan.&#160;</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 106 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transactions
with Related Persons</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
disclosures regarding our policies relating to director independence, refer to the section above titled &#8220;Directors, Executive Officers
and Corporate Governance&#8212;Corporate Governance&#8212;Director Independence.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Competition
Agreements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive officers have signed non-competition agreements, which provide that all inventions become the immediate property of us and
require invention assignments. The agreements provide that the executive officers will hold proprietary information in the strictest
confidence and not use the confidential information for any purpose not expressly authorized by us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below shows the aggregate fees billed for professional services for the audits and audit-related fees of the Company&#8217;s annual
financial statements included in Form 10-K for the years ending December 31, 2024 and 2023, respectively, by Marcum LLP (PCAOB ID Number
<ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-15382">688</ix:nonNumeric>).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Audit Fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">180,048</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">184,202</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Audit &#8211; Related Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,097</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,797</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">All Other Fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">225,145</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">225,999</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit
Fees.</i> This category includes the audit of our annual consolidated financial statements, reviews of our financial statements included
in our Form 10-K and Form 10-Qs and services that are normally provided by our independent registered public accounting firm in connection
with its engagements for those years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit-Related
Fees. </i>This category consists of assurance and related services by our independent registered public accounting firm that are reasonably
related to the performance of the audit or review of our financial statements and are not reported above under &#8220;Audit Fees.&#8221;
The services for the fees disclosed under this category include consents regarding equity issuances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-Approval
Policy</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2015, the Audit Committee adopted policies and procedures for the pre-approval of audit and non-audit services performed by the independent
registered public accountants pursuant to which the Audit Committee generally is required to pre-approve the audit and permissible non-audit
services performed by the independent registered public accountants in order to ensure that the provision of such services does not impair
the registered accountants&#8217; independence.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the services rendered by Marcum in 2024 were pre-approved by the Audit Committee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 107; Value: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
IV</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)(1)&#160;Financial
Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
documents listed below are filed as part of this Form&#160;10-K:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Page</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"><a href="#f_001">Report of Independent Registered Public Accounting Firm (Firm ID # 688)</a></td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">F-1</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#f_002">Consolidated Balance Sheets as of December 31, 2024, and December 31, 2023</a></td><td>&#160;</td>
    <td style="text-align: center">F-2</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><a href="#f_003">Consolidated Statements of Operations for the&#160;years ended December 31, 2024, and December 31, 2023</a></td><td>&#160;</td>
    <td style="text-align: center">F-3</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><a href="#f_004">Consolidated Statements of Changes in Stockholders&#8217; Equity for the years ended December 31, 2024, and December 31, 2023</a></td><td>&#160;</td>
    <td style="text-align: center">F-4</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><a href="#f_005">Consolidated Statements of Cash Flows for the&#160;years ended December 31, 2024, and December 31, 2023</a></td><td>&#160;</td>
    <td style="text-align: center">F-5</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><a href="#f_006">Notes&#160;to Consolidated Financial Statements</a></td><td>&#160;</td>
    <td style="text-align: center">F-6</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)(2)&#160;Consolidated
Financial Statement Schedules:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedules
not filed are omitted because of the absence of the conditions under which they are required or because the required information is included
in the consolidated financial statements or the notes thereto.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 108; Value: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    <br/>
    Number</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020020895/ea125182ex1-2_actinium.htm">Capital
    on Demand&#8482; Sales Agreement, dated August 7, 2020, by and between Actinium Pharmaceuticals, Inc. and JonesTrading Institutional
    Services LLC (incorporated by reference to Exhibit 1.2 to Registration Statement on Form S-3 filed on August 7, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390022035693/ea161465ex1-1_actinium.htm">Amended
    and Restated Capital on Demand&#8482; Sales Agreement, by and between Actinium Pharmaceuticals, Inc., JonesTrading Institutional
    Services LLC, and B. Riley Securities, Inc., dated June 28, 2022 (incorporated by reference to Exhibit 1.1 to Form 8 K filed on June
    29, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390013001911/f8k041113ex3i_actinium.htm">Certificate
    of Incorporation of Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Form 8-K filed
    with the SEC on April 17, 2013).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000604/fs12014ex3v_actinium.htm">Certificate
    of Amendment to Certificate of Incorporation filed January 7, 2014 (incorporated by reference to Exhibit 3.5 to Form S-1 filed on
    January 31, 2014).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000688/f8k020314ex3i_actinium.htm">Certificate
    of Amendment to Certificate of Incorporation filed February 3, 2014. (incorporated by reference to Exhibit 3.1 to Form 8-K filed
    on February&#160;7, 2014).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390015001553/f8k022615ex3i_actinium.htm">Certificate
    of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to Form 8-K filed on March 4, 2015).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018002270/f8k022618ex3-1_actinium.htm">Certificate
    of Amendment to Actinium&#8217;s Certificate of Incorporation, as amended, filed on February 26, 2018 (incorporated by reference
    to Exhibit 3.1 to Form 8-K filed on February 26, 2018).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/f10k2018ex3-7_actinium.htm">Certificate
    of Amendment to Actinium&#8217;s Certificate of Incorporation, as amended, filed on March 6, 2019 (incorporated by reference to Exhibit
    3.7 to Form 10-K filed on March 15, 2019).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015104/ea123121ex3-1_actiniumpharma.htm">Certificate
    of Amendment to Certificate of Incorporation, as amended, filed on June 16, 2020 (incorporated by reference to Exhibit 3.1 to Form
    8-K filed on June 16, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018010603/f10q0618ex3-1_actinium.htm">Amended
    and Restated Bylaws, dated August 8, 2018 (incorporated by reference to Exhibit 3.1 to Form 10-Q filed on August 9, 2018).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020011052/ea121342ex3-1_actinium.htm">Amendment
    to the Amended and Restated Bylaws, dated May 7, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on May 5, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000604/fs12014ex4viii_actinium.htm">Form
    of Common Stock Warrant, dated December 27, 2013 and January 10, 2014&#160;(incorporated by reference to Exhibit 4.8 to Form S-1
    filed on January&#160;31, 2014).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390019006723/f8k041819ex4-1_actinium.htm">Form
    of Warrant (incorporated by reference to Exhibit 4.1 to Form 8-K filed on April 18, 2019).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390021019297/f10k2020ex4-15_actinium.htm">Description
    of Securities (incorporated by reference to Exhibit 4.15 to Form 10-K filed on March 31, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390015001800/f10k2014ex10xlii_actinium.htm">Actinium
    Pharmaceuticals, Inc. Amended and Restated 2013 Stock Plan (incorporated by reference to Exhibit 10.42 to Form 10-K filed on March
    16, 2015).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390015005829/f10q0615ex10i_actinium.htm">First
    Amendment to Amended and Restated 2013 Stock Plan, effective August 6, 2015 (incorporated by reference to Exhibit 10.1 to Form 10-Q
    filed on August 7, 2015).</a></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 109; Value: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390015009512/f8k121515ex10i_actiniumpha.htm">Second
    Amendment to the 2013 Amended and Restated Stock Plan, effective as of December 15, 2015 (incorporated by reference to Exhibit 10.1
    to Form 8-K filed on December 16, 2015).</a></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390016011534/f10k2015ex10xxxxxvi_actinium.htm">Third
    Amendment to the 2013 Amended and Restated Stock Plan, effective as of December 22, 2015 (incorporated by reference to Exhibit 10.56
    to Form 10-K filed on March 11, 2016).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390016019421/f8k121316ex1i_actiniumpharma.htm">Fourth
    Amendment to the 2013 Amended and Restated Stock Plan, effective as of December 13, 2016 (incorporated by reference to Exhibit 1.1
    to Form 8-K filed on December 14, 2016).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002461/f10k2016ex10lix_actinium.htm">Fifth
    Amendment to the 2013 Amended and Restated Stock Plan, as amended (incorporated by reference to Exhibit 10.59 to Form 10-K filed
    on March 16, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002910/f8k032717ex10i_actinium.htm">Director
    Agreement, dated March 28, 2017, between Ajit S. Shetty and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit
    10.1 to Form 8-K filed on March 28, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002910/f8k032717ex10ii_actinium.htm">Indemnity
    Agreement, dated March 28, 2017, between Ajit S. Shetty and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit
    10.2 to Form 8-K filed on March 28, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017002910/f8k032717ex10iii_actinium.htm">Confidential
    Information and Invention Assignment Agreement, dated March 28, 2017, between Ajit S. Shetty and Actinium Pharmaceuticals, Inc. (incorporated
    by reference to Exhibit 10.3 to Form 8-K filed on March 28, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017004962/f8k050517ex10i_actinium.htm">Amendment
    to Amended and Restated Consulting Agreement, dated May 5, 2017, by and between Actinium Pharmaceuticals, Inc. and Sandesh Seth (incorporated
    by reference to Exhibit 10.1 to Form 8-K filed on May 11, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017005183/f10q0317ex10ii_actinium.htm">Employment
    Agreement, dated September 17, 2015, between Steve O&#8217;Loughlin and Actinium Pharmaceuticals, Inc. (incorporated by reference
    to Exhibit 10.2 to Form 10-Q filed on May 15, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390017005183/f10q0317ex10iii_actinium.htm">Indemnification
    Agreement, dated May 15, 2017, between Steve O&#8217;Loughlin and Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit
    10.3 to Form 10-Q filed on May 15, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018003091/f10k2017ex10-56_actinium.htm">Sixth
    Amendment to the 2013 Amended and Restated Stock Plan, as amended (incorporated by reference to Exhibit 10.56 to Form 10-K filed
    on March 16, 2018).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018005261/f8k042718ex10-1_actinium.htm">Director
    Agreement, dated April 27, 2018, by and between Actinium Pharmaceuticals, Inc. and Jeffrey W. Chell (incorporated by reference to
    Exhibit 10.1 to Form 8-K filed on May 1, 2018).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018005261/f8k042718ex10-2_actinium.htm">Indemnity
    Agreement, dated April 27, 2018, by and between Actinium Pharmaceuticals, Inc. and Jeffrey W. Chell (incorporated by reference to
    Exhibit 10.2 to Form 8-K filed on May 1, 2018).</a></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018005261/f8k042718ex10-3_actinium.htm">Confidential
    Information and Invention Assignment Agreement, dated April 27, 2018, by and between Actinium Pharmaceuticals, Inc. and Jeffrey W.
    Chell (incorporated by reference to Exhibit 10.3 to Form 8-K filed on May 1, 2018).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018010603/f10q0618ex10-1_actinium.htm">Employment
    Agreement, dated August 8, 2018, by and between Actinium Pharmaceuticals, Inc. and Sandesh Seth (incorporated by reference to Exhibit
    10.1 to Form 10-Q filed on August 9, 2018).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018010603/f10q0618ex10-2_actinium.htm">Employment
    Agreement, dated August 8, 2018, by and between Actinium Pharmaceuticals, Inc. and Steve O&#8217;Loughlin (incorporated by reference
    to Exhibit 10.2 to Form 10-Q filed on August 9, 2018).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/f10k2018ex10-39_actinium.htm">Seventh
    Amendment to the 2013 Amended and Restated Stock Plan, as amended (incorporated by reference to Exhibit 10.39 to Form 10-K filed
    on March 15, 2019).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015271/ea123189ex10-1_actinium.htm">Form
    of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to Form 8-K filed on June 18, 2020).</a></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020022334/f10q0620ex10-3_actinium.htm">Employment
    Agreement, dated August 12, 2020, by and between Actinium Pharmaceuticals, Inc. and Sandesh Seth (incorporated by reference to Exhibit
    10.3 to Form 10-Q filed on August 14, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020022334/f10q0620ex10-4_actinium.htm">Employment
    Agreement, dated August 12, 2020, by and between Actinium Pharmaceuticals, Inc. and Steve O&#8217;Loughlin (incorporated by reference
    to Exhibit 10.4 to Form 10-Q filed on August 14, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020038523/ea130223ex10-1_actiniumpharm.htm">Actinium
    Pharmaceuticals, Inc. 2019 Stock Plan (incorporated by reference to Exhibit&#160;10.1 to Form 8-K filed on November&#160;20, 2020).</a></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020038523/ea130223ex10-2_actiniumpharm.htm">First
    Amendment to the Actinium Pharmaceuticals, Inc. 2019 Plan (incorporated by reference to Exhibit&#160;10.2 to Form 8-K filed on November&#160;20,
    2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390021057769/ea150278ex10-1_actiniumph.htm">Second
    Amendment to the Actinium Pharmaceuticals, Inc. 2019 Plan (incorporated by reference to Exhibit&#160;10.1 to Form 8-K filed on November&#160;9,
    2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26+&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390022047496/f10q0622ex10-1_actinium.htm">Exclusive
    License and Supply Agreement, dated April 7, 2022, between Immedica Pharma AB and Actinium Pharmaceuticals, Inc. (incorporated by
    reference to Exhibit&#160;10.1 to Form 10-Q filed on August&#160;12, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390022047496/f10q0622ex10-2_actinium.htm">Sublease
    Agreement, dated April 28, 2022, between ABN AMRO HOLDINGS USA LLC and Actinium Pharmaceuticals, Inc. (incorporated by reference
    to Exhibit&#160;10.2 to Form 10-Q filed on August&#160;12, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390022049740/ea156670ex99-4_actiniumpha.htm">Third
    Amendment to the Actinium Pharmaceuticals, Inc. 2019 Stock Plan (incorporated by reference to Exhibit 99.4 to the Registration Statement
    on Form S-8 filed on August 19, 2022).</a></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390022084094/ea171085ex10-1_actinium.htm">Fourth
    Amendment to the Actinium Pharmaceuticals, Inc. 2019 Stock Plan (incorporated by reference to Exhibit&#160;10.1 to Form 8-K filed
    on December&#160;30, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390023082459/f10q0923ex10-1_actiniumphar.htm">Amendment
    to Employment Agreement, dated November 1, 2023, by and between Actinium Pharmaceuticals, Inc. and Sandesh Seth (incorporated by
    reference to Exhibit 10.1 to Form 10-Q filed on November 2, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000107878212003323/f8k122112_ex14z1.htm">Code
    of Ethics (incorporated by reference to Exhibit 14.1 to Form 8-K filed on January 2, 2013).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000107878212003323/f8k122112_ex14z1.htm">Actinium Pharmaceuticals, Inc. Insider Trading Policy and Procedures (included in Exhibit 14.1).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390015001800/f10k2014ex21i_actinium.htm">List
    of Subsidiaries (incorporated by reference to Exhibit 21.1 to Form 10-K filed on March 16, 2015).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"><a href="ea023239501ex23-1_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Marcum LLP.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea023239501ex31-1_actinium.htm">Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea023239501ex31-2_actinium.htm">Certification of Principal Financial and Accounting Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea023239501ex32-1_actinium.htm">Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea023239501ex32-2_actinium.htm">Certification of Principal Financial and Accounting Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>

<tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="text-align: justify; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390024028038/f10k2023ex97-1_act.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium Pharmaceuticals, Inc. Compensation Recovery Policy (incorporated by reference to Exhibit 97.1 to Form 10-K filed on March 29, 2024).</span></a></td></tr>

  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS&#160;**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH&#160;**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Schema
    Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL&#160;**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Calculation
    Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF&#160;**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Definition
    Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB **</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Label
    Linkbase Document </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE **</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Presentation
    Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive
    Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished herewith. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates a management
    contract or compensatory plan or arrangement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain of the schedules
    (and similar attachments) to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5) of Regulation S-K under
    the Securities Act of 1933, as amended, because they do not contain information material to an investment or voting decision and
    that information is not otherwise disclosed in the Exhibit or the disclosure document. The registrant hereby agrees to furnish a
    copy of all omitted schedules (or similar attachments) to the SEC upon its request.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Portions of this exhibit
    have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because they are
    both (i) not material and (ii) the type that the registrant treats as private or confidential. A copy of the omitted portions will
    be furnished to the SEC upon its request.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 112; Value: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
Registrant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: March 31, 2025</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ACTINIUM PHARMACEUTICALS, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Sandesh Seth</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer (Duly&#160;Authorized
    Officer,<br/>
    Principal Executive Officer) </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steve
    O&#8217;Loughlin</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve O&#8217;Loughlin</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer <br/>
    (Duly Authorized Officer, <br/>
    Principal Financial and Accounting Officer)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following person on behalf of the
Registrant and in the capacities and on the dates indicated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 42%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Sandesh
    Seth</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer) </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ June Almenoff</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June Almenoff</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jeffrey
    Chell</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey Chell</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ David
    Nicholson</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Nicholson</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Richard
    I. Steinhart</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard I. Steinhart</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ajit J.
    Shetty</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ajit J. Shetty</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 113; Options: Last --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c3" id="hidden-fact-0" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-3" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-4" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-5" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-6" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-7" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-9" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-10" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-11" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-12" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-13" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-14" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-15" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-16" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-17" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-18" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-19" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-20" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-21" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-22" name="atnm:IncreaseDecreaseInOperatingLeaseRightofuseAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-23" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-24" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-25" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-26" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-27" name="atnm:RightofuseAssetObtainedInExchangeForLeaseLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-28" name="us-gaap:FinanceLeaseInterestExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-29" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-30" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-31" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-32" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-33" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-34" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-35" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-36" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-37" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-38" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-39" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-40" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-41" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-42" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-43" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c79" id="hidden-fact-44" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c71" id="hidden-fact-45" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c71" id="hidden-fact-46" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c71" id="hidden-fact-47" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c71" id="hidden-fact-48" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-49" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-50" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-51" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-52" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-53" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-54" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-55" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-56" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-57" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-15443">0001388320</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-15444">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-15445">FY</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="atnm-20241231.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:RevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:RevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:OtherRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:OtherRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cag6xP4Bvdp8g7pkxO2j+7aQEDWhC9NBQFF3IfuNj97Zy5Njm69ABek+DMR6GhYBNXNfUSw9pdSojRWkVvG0IkfkbUoYTYhzGCrqxoey3ARlapHObX412U9q+qvt5kY2/4VnOGpvlOzMcwiMOPpDhkLwZEaXzFm8Q6A0TYhKRPatDA==] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2012-06-15</xbrli:startDate>
    <xbrli:endDate>2012-06-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-01</xbrli:startDate>
    <xbrli:endDate>2020-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atnm:TwoThousandNineteenAmendedAndRestatedStockPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-23</xbrli:startDate>
    <xbrli:endDate>2024-04-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-04-23</xbrli:startDate>
    <xbrli:endDate>2019-04-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-04-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-23</xbrli:startDate>
    <xbrli:endDate>2024-04-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-01-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-01-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">atnm:FederalIncomeTaxMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">atnm:ExpireIn2026Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2018Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">atnm:TaxYearTwoThousandThirtyThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">atnm:OrphanDrugCreditsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">atnm:TaxYearTwoThousandThirtySevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-31</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-10-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>ea023239501ex23-1_actinium.htm
<DESCRIPTION>CONSENT OF MARCUM LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the incorporation by reference in the Registration Statement on Pre-Effective Amendment No. 1 to Form S-3 (File No. 333-273911)
and on Forms S-8 (File Nos. 333-266996, 333-231391, 333-223741, 333-197283, 333-246746, and 333-278395) of our report dated March 31,
2025 relating to the consolidated financial statements of Actinium Pharmaceuticals, Inc. appearing in this Annual Report on Form 10-K
for the year ended December 31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Marcum LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Houston, Texas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 31, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ea023239501ex31-1_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER<BR>
PURSUANT TO 18U.S.C SECTION 1350 AS ADOPTED<BR>
PURSUANT TO SECTION 302 OF THE SARBANES-OXELY ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Sandesh Seth, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this report on Form 10-K of Actinium Pharmaceuticals,
Inc. for the fiscal year ended December 31, 2024.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I
are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&ndash;15(e)
and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&ndash;15(f) and 15d&ndash;15(f))
for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to
be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">c.</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d.</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting
that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an
annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over
financial reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I
have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report
financial information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant
role in the registrant&rsquo;s internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 60%; text-align: justify">Dated: March 31, 2025</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 5%; text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%; text-align: left"><FONT STYLE="font-size: 10pt">/s/ Sandesh Seth</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Sandesh Seth</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Chairman and Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">(Duly Authorized Officer, Principal Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ea023239501ex31-2_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING
OFFICER<BR>
PURSUANT TO 18 U.S.C SECTION 1350 AS ADOPTED<BR>
PURSUANT TO SECTION 302 OF THE SARBANES-OXELY ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Steve O&rsquo;Loughlin, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this report on Form 10-K of Actinium Pharmaceuticals,
Inc. for the fiscal year ended December 31, 2024.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I
are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&ndash;15(e)
and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&ndash;15(f) and 15d&ndash;15(f))
for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c.</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d.</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I
have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 60%; text-align: justify">Dated: March 31, 2025</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steve O&rsquo;Loughlin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve O&rsquo;Loughlin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Duly Authorized Officer, Principal Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ea023239501ex32-1_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER,<BR>
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED<BR>
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of Actinium Pharmaceuticals, Inc. a Delaware corporation (the &ldquo;Company&rdquo;), on Form 10-K
for the period ended December 31, 2024 as filed with the Securities and Exchange Commission (the &ldquo;Report&rdquo;), I, Sandesh Seth,
Chief Executive Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350),
that to my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d));
and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Company.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 60%">Dated: March 31, 2025</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Sandesh Seth</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Duly Authorized Officer, Principal Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>ea023239501ex32-2_actinium.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTIFICATION
OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER,<BR>
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED<BR>
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of Actinium Pharmaceuticals, Inc. a Delaware corporation (the &ldquo;Company&rdquo;), on Form 10-K
for the period ended December 31, 2024 as filed with the Securities and Exchange Commission (the &ldquo;Report&rdquo;), I, Steve O&rsquo;Loughlin,
Chief Financial Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350),
that to my knowledge:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d));
and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Company.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 60%">Dated: March 31, 2025</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steve O&rsquo;Loughlin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve O&rsquo;Loughlin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Duly Authorized Officer, Principal Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>atnm-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 31 20:27:49 UTC 2025 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2024" targetNamespace="http://www.actiniumpharma.com/20241231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:atnm="http://www.actiniumpharma.com/20241231" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20241231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20241231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20241231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20241231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet" id="atnm_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals" id="atnm_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement" id="atnm_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ShareholdersEquityType2or3" id="atnm_r_ShareholdersEquityType2or3">
        <link:definition>995304 - Statement - Consolidated Statements of Changes in Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ConsolidatedCashFlow" id="atnm_r_ConsolidatedCashFlow">
        <link:definition>995305 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" id="atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies">
        <link:definition>995306 - Disclosure - Description of Business and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/PrepaidExpensesandOtherCurrentAssets" id="atnm_r_PrepaidExpensesandOtherCurrentAssets">
        <link:definition>995307 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/PropertyandEquipment" id="atnm_r_PropertyandEquipment">
        <link:definition>995308 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/Leases" id="atnm_r_Leases">
        <link:definition>995309 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/OtherRevenue" id="atnm_r_OtherRevenue">
        <link:definition>995310 - Disclosure - Other Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/CommitmentsandContingencies" id="atnm_r_CommitmentsandContingencies">
        <link:definition>995311 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/Equity" id="atnm_r_Equity">
        <link:definition>995312 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/IncomeTaxes" id="atnm_r_IncomeTaxes">
        <link:definition>995313 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/SubsequentEvents" id="atnm_r_SubsequentEvents">
        <link:definition>995314 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy" id="atnm_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" id="atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>996001 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables" id="atnm_r_PrepaidExpensesandOtherCurrentAssetsTables">
        <link:definition>996002 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/PropertyandEquipmentTables" id="atnm_r_PropertyandEquipmentTables">
        <link:definition>996003 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/LeasesTables" id="atnm_r_LeasesTables">
        <link:definition>996004 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/EquityTables" id="atnm_r_EquityTables">
        <link:definition>996005 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/IncomeTaxesTables" id="atnm_r_IncomeTaxesTables">
        <link:definition>996006 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" id="atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996007 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable" id="atnm_r_ScheduleofCashCashEquivalentsandRestrictedCashTable">
        <link:definition>996008 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable" id="atnm_r_ScheduleofDilutedNetLossPerShareTable">
        <link:definition>996009 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" id="atnm_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsTable">
        <link:definition>996010 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cag6xP4Bvdp8g7pkxO2j+7aQEDWhC9NBQFF3IfuNj97Zy5Njm69ABek+DMR6GhYBNXNfUSw9pdSojRWkVvG0IkfkbUoYTYhzGCrqxoey3ARlapHObX412U9q+qvt5kY2/4VnOGpvlOzMcwiMOPpDhkLwWqS0JaKNvryhmpLJiZy+4A==] CSR-->
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable" id="atnm_r_ScheduleofPropertyandEquipmentTable">
        <link:definition>996011 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofDepreciationExpenseTable" id="atnm_r_ScheduleofDepreciationExpenseTable">
        <link:definition>996012 - Disclosure - Property and Equipment - Schedule of Depreciation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/LeasesDetails" id="atnm_r_LeasesDetails">
        <link:definition>996013 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable" id="atnm_r_ScheduleofComponentsofLeaseExpenseTable">
        <link:definition>996014 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" id="atnm_r_ScheduleofMaturitiesofLeaseLiabilitiesTable">
        <link:definition>996015 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/OtherRevenueDetails" id="atnm_r_OtherRevenueDetails">
        <link:definition>996016 - Disclosure - Other Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails" id="atnm_r_CommitmentsandContingenciesDetails">
        <link:definition>996017 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/EquityDetails" id="atnm_r_EquityDetails">
        <link:definition>996018 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable" id="atnm_r_ScheduleofStockOptionActivityTable">
        <link:definition>996019 - Disclosure - Equity - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable" id="atnm_r_ScheduleofRestrictedStockUnitActivityTable">
        <link:definition>996020 - Disclosure - Equity - Schedule of Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable" id="atnm_r_ScheduleofWarrantActivityTable">
        <link:definition>996021 - Disclosure - Equity - Schedule of Warrant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/IncomeTaxesDetails" id="atnm_r_IncomeTaxesDetails">
        <link:definition>996022 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable" id="atnm_r_ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable">
        <link:definition>996023 - Disclosure - Income Taxes - Schedule of Components of the Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable" id="atnm_r_ScheduleofUSFederalStatutoryRatesTable">
        <link:definition>996024 - Disclosure - Income Taxes - Schedule of U.S. Federal Statutory Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/SubsequentEventsDetails" id="atnm_r_SubsequentEventsDetails">
        <link:definition>996025 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.actiniumpharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd"/>
  <xs:element name="ScheduleOfDilutedNetLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfDilutedNetLossPerShareAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfPropertyAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfDepreciationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfDepreciationExpenseAbstract"/>
  <xs:element name="ScheduleOfRestrictedStockUnitActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfRestrictedStockUnitActivityAbstract"/>
  <xs:element name="ScheduleOfWarrantActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfWarrantActivityAbstract"/>
  <xs:element name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
  <xs:element name="NonCashActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_NonCashActivityAbstract"/>
  <xs:element name="RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
  <xs:element name="WeightedAverageRemainingLeaseTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_WeightedAverageRemainingLeaseTermAbstract"/>
  <xs:element name="WeightedAverageDiscountRatesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_WeightedAverageDiscountRatesAbstract"/>
  <xs:element name="IncreaseDecreaseInOperatingLeaseRightofuseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets"/>
  <xs:element name="RightofuseAssetObtainedInExchangeForLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities"/>
  <xs:element name="OtherRevenueTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OtherRevenueTextBlock"/>
  <xs:element name="NatureOfBusinessPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_NatureOfBusinessPolicyPolicyTextBlock"/>
  <xs:element name="LicenseRevenuePolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LicenseRevenuePolicyTextBlock"/>
  <xs:element name="RecentlyIssuedAccountingPronouncementsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
  <xs:element name="ScheduleOfDepreciationExpenseTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfDepreciationExpenseTableTextBlock"/>
  <xs:element name="PropertyandEquipmentScheduleofDepreciationExpenseDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_PropertyandEquipmentScheduleofDepreciationExpenseDetailsTable"/>
  <xs:element name="EquityScheduleofRestrictedStockUnitActivityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable"/>
  <xs:element name="ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable"/>
  <xs:element name="ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue"/>
  <xs:element name="IncomeTaxReconciliationDeferredTrueup" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_IncomeTaxReconciliationDeferredTrueup"/>
  <xs:element name="EffectiveIncomeTaxReconciliationDeferredTrueUps" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps"/>
  <xs:element name="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="LeasesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_LeasesDetailsTable"/>
  <xs:element name="NonRefundablePaymentReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_NonRefundablePaymentReceived"/>
  <xs:element name="PaymentOfMilestone" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_PaymentOfMilestone"/>
  <xs:element name="RoyaltyPaymentsPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_RoyaltyPaymentsPercentage"/>
  <xs:element name="EquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_EquityDetailsTable"/>
  <xs:element name="NetProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_NetProceedsFromIssuanceOfCommonStock"/>
  <xs:element name="ExpiredWarrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ExpiredWarrant"/>
  <xs:element name="WarrantExpiredUnderwrittenOfferingShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_WarrantExpiredUnderwrittenOfferingShares"/>
  <xs:element name="WarrantExpiredTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_WarrantExpiredTerm"/>
  <xs:element name="WarrantExpiredPricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="atnm_WarrantExpiredPricePerShare"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_IncomeTaxesDetailsTable"/>
  <xs:element name="AccumulatedGrossAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_AccumulatedGrossAmount"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_SubsequentEventsDetailsLineItems"/>
  <xs:element name="CapitalOnDemandSalesAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_CapitalOnDemandSalesAgreementMember"/>
  <xs:element name="ExpireIn2026Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ExpireIn2026Member"/>
  <xs:element name="FederalIncomeTaxMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_FederalIncomeTaxMember"/>
  <xs:element name="OrphanDrugCreditsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OrphanDrugCreditsMember"/>
  <xs:element name="OtherRevenueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OtherRevenueMember"/>
  <xs:element name="RevenueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_RevenueMember"/>
  <xs:element name="TaxYearTwoThousandThirtySevenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_TaxYearTwoThousandThirtySevenMember"/>
  <xs:element name="TaxYearTwoThousandThirtyThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_TaxYearTwoThousandThirtyThreeMember"/>
  <xs:element name="TwoThousandNineteenAmendedAndRestatedStockPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>atnm-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 31 20:27:49 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ConsolidatedBalanceSheet" roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ConsolidatedIncomeStatement" roleURI="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ConsolidatedCashFlow" roleURI="http://www.actiniumpharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofCashCashEquivalentsandRestrictedCashTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofComponentsofLeaseExpenseTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofMaturitiesofLeaseLiabilitiesTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofUSFederalStatutoryRatesTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable"/>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:href="atnm-20241231.xsd#atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cag6xP4Bvdp8g7pkxO2j+7aQEDWhC9NBQFF3IfuNj97Zy5Njm69ABek+DMR6GhYBNXNfUSw9pdSojRWkVvG0IkfkbUoYTYhzGCrqxoey3ARlapHObX412U9q+qvt5kY2/4VnOGpvlOzMcwiMOPpDhkLw27pOklpzyAB2YLReGtotIQ==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiability" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="7" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="atnm_IncomeTaxReconciliationDeferredTrueup" xlink:href="atnm-20241231.xsd#atnm_IncomeTaxReconciliationDeferredTrueup"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="atnm_IncomeTaxReconciliationDeferredTrueup" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps" xlink:href="atnm-20241231.xsd#atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>atnm-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 31 20:27:49 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ConsolidatedBalanceSheet" roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ConsolidatedIncomeStatement" roleURI="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ShareholdersEquityType2or3" roleURI="http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ConsolidatedCashFlow" roleURI="http://www.actiniumpharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies" roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_PrepaidExpensesandOtherCurrentAssets" roleURI="http://www.actiniumpharma.com/role/PrepaidExpensesandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_PropertyandEquipment" roleURI="http://www.actiniumpharma.com/role/PropertyandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_Leases" roleURI="http://www.actiniumpharma.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_OtherRevenue" roleURI="http://www.actiniumpharma.com/role/OtherRevenue"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_CommitmentsandContingencies" roleURI="http://www.actiniumpharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_Equity" roleURI="http://www.actiniumpharma.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_IncomeTaxes" roleURI="http://www.actiniumpharma.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_SubsequentEvents" roleURI="http://www.actiniumpharma.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_AccountingPoliciesByPolicy" roleURI="http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://www.actiniumpharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_PropertyandEquipmentTables" roleURI="http://www.actiniumpharma.com/role/PropertyandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_LeasesTables" roleURI="http://www.actiniumpharma.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_EquityTables" roleURI="http://www.actiniumpharma.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_IncomeTaxesTables" roleURI="http://www.actiniumpharma.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofCashCashEquivalentsandRestrictedCashTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofDilutedNetLossPerShareTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofDepreciationExpenseTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofDepreciationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofComponentsofLeaseExpenseTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofMaturitiesofLeaseLiabilitiesTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofStockOptionActivityTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofRestrictedStockUnitActivityTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofWarrantActivityTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofUSFederalStatutoryRatesTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_LeasesDetails" roleURI="http://www.actiniumpharma.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_OtherRevenueDetails" roleURI="http://www.actiniumpharma.com/role/OtherRevenueDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_CommitmentsandContingenciesDetails" roleURI="http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_EquityDetails" roleURI="http://www.actiniumpharma.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_IncomeTaxesDetails" roleURI="http://www.actiniumpharma.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_SubsequentEventsDetails" roleURI="http://www.actiniumpharma.com/role/SubsequentEventsDetails"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockValue" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockValue" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="22" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_RevenueMember" xlink:href="atnm-20241231.xsd#atnm_RevenueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="atnm_RevenueMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueMember" xlink:href="atnm-20241231.xsd#atnm_OtherRevenueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="atnm_OtherRevenueMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpenses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:href="atnm-20241231.xsd#atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InterestPaidNet" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities" xlink:href="atnm-20241231.xsd#atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/PropertyandEquipment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/OtherRevenue" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueTextBlock" xlink:href="atnm-20241231.xsd#atnm_OtherRevenueTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="atnm_OtherRevenueTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_NatureOfBusinessPolicyPolicyTextBlock" xlink:href="atnm-20241231.xsd#atnm_NatureOfBusinessPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_NatureOfBusinessPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LicenseRevenuePolicyTextBlock" xlink:href="atnm-20241231.xsd#atnm_LicenseRevenuePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_LicenseRevenuePolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:href="atnm-20241231.xsd#atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfDepreciationExpenseTableTextBlock" xlink:href="atnm-20241231.xsd#atnm_ScheduleOfDepreciationExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="atnm_ScheduleOfDepreciationExpenseTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/LeasesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofDepreciationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_PropertyandEquipmentScheduleofDepreciationExpenseDetailsTable" xlink:href="atnm-20241231.xsd#atnm_PropertyandEquipmentScheduleofDepreciationExpenseDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="atnm_PropertyandEquipmentScheduleofDepreciationExpenseDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_PropertyandEquipmentScheduleofDepreciationExpenseDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cag6xP4Bvdp8g7pkxO2j+7aQEDWhC9NBQFF3IfuNj97Zy5Njm69ABek+DMR6GhYBNXNfUSw9pdSojRWkVvG0IkfkbUoYTYhzGCrqxoey3ARlapHObX412U9q+qvt5kY2/4VnOGpvlOzMcwiMOPpDhkLwq4sOCCGg6EoVDqKT+JKrFA==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiability" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:href="atnm-20241231.xsd#atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_IncomeTaxReconciliationDeferredTrueup" xlink:href="atnm-20241231.xsd#atnm_IncomeTaxReconciliationDeferredTrueup"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="atnm_IncomeTaxReconciliationDeferredTrueup" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps" xlink:href="atnm-20241231.xsd#atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="atnm-20241231.xsd#atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsTable" xlink:href="atnm-20241231.xsd#atnm_LeasesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="atnm_LeasesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_LeasesDetailsTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateAndOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateAndOtherMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_CorporateAndOtherMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForRent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandImprovements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LandImprovements" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/OtherRevenueDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_OtherIncome" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_NonRefundablePaymentReceived" xlink:href="atnm-20241231.xsd#atnm_NonRefundablePaymentReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="atnm_NonRefundablePaymentReceived" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_PaymentOfMilestone" xlink:href="atnm-20241231.xsd#atnm_PaymentOfMilestone"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="atnm_PaymentOfMilestone" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_RoyaltyPaymentsPercentage" xlink:href="atnm-20241231.xsd#atnm_RoyaltyPaymentsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="atnm_RoyaltyPaymentsPercentage" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsTable" xlink:href="atnm-20241231.xsd#atnm_EquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atnm_EquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="srt_RangeAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember" xlink:href="atnm-20241231.xsd#atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_CapitalOnDemandSalesAgreementMember" xlink:href="atnm-20241231.xsd#atnm_CapitalOnDemandSalesAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="atnm_CapitalOnDemandSalesAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_NetProceedsFromIssuanceOfCommonStock" xlink:href="atnm-20241231.xsd#atnm_NetProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atnm_NetProceedsFromIssuanceOfCommonStock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquityFairValueDisclosure" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ExpiredWarrant" xlink:href="atnm-20241231.xsd#atnm_ExpiredWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atnm_ExpiredWarrant" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_WarrantExpiredUnderwrittenOfferingShares" xlink:href="atnm-20241231.xsd#atnm_WarrantExpiredUnderwrittenOfferingShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atnm_WarrantExpiredUnderwrittenOfferingShares" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_WarrantExpiredTerm" xlink:href="atnm-20241231.xsd#atnm_WarrantExpiredTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atnm_WarrantExpiredTerm" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_WarrantExpiredPricePerShare" xlink:href="atnm-20241231.xsd#atnm_WarrantExpiredPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="atnm_WarrantExpiredPricePerShare" order="26" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_IncomeTaxesDetailsTable" xlink:href="atnm-20241231.xsd#atnm_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="atnm_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_IncomeTaxesDetailsTable" xlink:to="us-gaap_TaxPeriodAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_IncomeTaxesDetailsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_FederalIncomeTaxMember" xlink:href="atnm-20241231.xsd#atnm_FederalIncomeTaxMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="atnm_FederalIncomeTaxMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_OrphanDrugCreditsMember" xlink:href="atnm-20241231.xsd#atnm_OrphanDrugCreditsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="atnm_OrphanDrugCreditsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ExpireIn2026Member" xlink:href="atnm-20241231.xsd#atnm_ExpireIn2026Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="atnm_ExpireIn2026Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxYear2018Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxYear2018Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxYear2018Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_TaxYearTwoThousandThirtyThreeMember" xlink:href="atnm-20241231.xsd#atnm_TaxYearTwoThousandThirtyThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="atnm_TaxYearTwoThousandThirtyThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_TaxYearTwoThousandThirtySevenMember" xlink:href="atnm-20241231.xsd#atnm_TaxYearTwoThousandThirtySevenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="atnm_TaxYearTwoThousandThirtySevenMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedContractualRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedContractualRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IndefiniteLivedContractualRights" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_AccumulatedGrossAmount" xlink:href="atnm-20241231.xsd#atnm_AccumulatedGrossAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="atnm_AccumulatedGrossAmount" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.actiniumpharma.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="atnm_SubsequentEventsDetailsLineItems" xlink:href="atnm-20241231.xsd#atnm_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_SubsequentEventsDetailsTable" xlink:href="atnm-20241231.xsd#atnm_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atnm_SubsequentEventsDetailsLineItems" xlink:to="atnm_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="0" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>atnm-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 31 20:27:49 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Used In Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Used In Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided By Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Restricted Cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAbstract_lbl" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Total prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $891 and $694</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Schedule of Components of Lease Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total finance lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Schedule of Maturities of Lease Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Operating leases payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Finance leases payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Other Revenue [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl0" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Schedule of Stock Option Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">RSUs Outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">RSUs Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Outstanding Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Outstanding Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Warrants Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Components of the Deferred Tax Assets and Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US">Schedule of U.S. Federal Statutory Rates [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Provision for income tax, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Less: accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash &#8211; long term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl0" xml:lang="en-US">Restricted cash &#8211; long-term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Finance leases right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating leases current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance leases current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term license revenue deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term operating lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term finance lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 1,000,000,000 shares authorized; 31,195,891 and 27,634,213 shares issued and outstanding at December 31, 2024 and 2023, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Number of shares of common stock authorized (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development, net of reimbursements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income &#8211; net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per common share &#8211; basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per common share &#8211; diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding &#8211; basic and diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding &#8211; diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Sale of common stock, net of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Sale of common stock, net of offering costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock from exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock from exercise of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Number of Options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Operating Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in/provided by operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:href="atnm-20241231.xsd#atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows Used in Investing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Financing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sales of shares of common stock, net of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from the exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosures of cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities" xlink:href="atnm-20241231.xsd#atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities" xlink:to="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payments on finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl0" xml:lang="en-US">Financing cash flow use from finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_RevenueMember" xlink:href="atnm-20241231.xsd#atnm_RevenueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_RevenueMember_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RevenueMember" xlink:to="atnm_RevenueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueMember" xlink:href="atnm-20241231.xsd#atnm_OtherRevenueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_OtherRevenueMember_lbl" xml:lang="en-US">Other Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueMember" xlink:to="atnm_OtherRevenueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Diluted Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid clinical trial expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfDepreciationExpenseTableTextBlock" xlink:href="atnm-20241231.xsd#atnm_ScheduleOfDepreciationExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ScheduleOfDepreciationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Depreciation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfDepreciationExpenseTableTextBlock" xlink:to="atnm_ScheduleOfDepreciationExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Total depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Lease Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract_lbl" xml:lang="en-US">Finance lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of right-to-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="atnm-20241231.xsd#atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flow use from operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US">Operating cash flow use from finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NonCashActivityAbstract" xlink:href="atnm-20241231.xsd#atnm_NonCashActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NonCashActivityAbstract_lbl" xml:lang="en-US">Non-cash activity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonCashActivityAbstract" xlink:to="atnm_NonCashActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:href="atnm-20241231.xsd#atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations, Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations, Finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:href="atnm-20241231.xsd#atnm_WeightedAverageRemainingLeaseTermAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl" xml:lang="en-US">Weighted average remaining lease term:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term, Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term, Finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageDiscountRatesAbstract" xlink:href="atnm-20241231.xsd#atnm_WeightedAverageDiscountRatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WeightedAverageDiscountRatesAbstract_lbl" xml:lang="en-US">Weighted average discount rates:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageDiscountRatesAbstract" xlink:to="atnm_WeightedAverageDiscountRatesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rates, Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rates, Finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturities of Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Operating Leases, 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Finance leases, 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Operating Leases, 2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Finance Leases, 2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Operating Leases, 2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Finance Leases, 2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Present value of finance lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueTextBlock" xlink:href="atnm-20241231.xsd#atnm_OtherRevenueTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_OtherRevenueTextBlock_lbl" xml:lang="en-US">Other revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueTextBlock" xlink:to="atnm_OtherRevenueTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years) Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Options Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Granted options to purchase shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Restricted Stock Unit Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">RSUs Outstanding, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">RSUs Outstanding, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years) Outstanding Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Warrants, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Warrants, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl" xml:lang="en-US">Number of Warrants, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of the Deferred Tax Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating losses carry forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development/orphan drug credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Capitalized research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0" xml:lang="en-US">Federal research and development tax credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of U.S. Federal Statutory Rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Operating Leases, imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Finance Leases, imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Options, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">RSUs Outstanding, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xml:lang="en-US">Cancelled stock option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Number of Warrants, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory income taxes, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_IncomeTaxReconciliationDeferredTrueup" xlink:href="atnm-20241231.xsd#atnm_IncomeTaxReconciliationDeferredTrueup"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="atnm_IncomeTaxReconciliationDeferredTrueup_lbl" xml:lang="en-US">Deferred true-up</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncomeTaxReconciliationDeferredTrueup" xlink:to="atnm_IncomeTaxReconciliationDeferredTrueup_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps" xlink:href="atnm-20241231.xsd#atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps_lbl" xml:lang="en-US">Deferred true-up, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps" xlink:to="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and development/orphan drug tax credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US">Research and development/orphan drug tax credit, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US">RSUs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Lab equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office equipment and furniture [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US">Tax Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Current annual rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandImprovements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandImprovements_lbl" xml:lang="en-US">Spent amount on improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandImprovements" xlink:to="us-gaap_LandImprovements_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NonRefundablePaymentReceived" xlink:href="atnm-20241231.xsd#atnm_NonRefundablePaymentReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NonRefundablePaymentReceived_lbl" xml:lang="en-US">Non-refundable payment received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonRefundablePaymentReceived" xlink:to="atnm_NonRefundablePaymentReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_PaymentOfMilestone" xlink:href="atnm-20241231.xsd#atnm_PaymentOfMilestone"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_PaymentOfMilestone_lbl" xml:lang="en-US">Milestone payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PaymentOfMilestone" xlink:to="atnm_PaymentOfMilestone_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_RoyaltyPaymentsPercentage" xlink:href="atnm-20241231.xsd#atnm_RoyaltyPaymentsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_RoyaltyPaymentsPercentage_lbl" xml:lang="en-US">Royalty payments, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RoyaltyPaymentsPercentage" xlink:to="atnm_RoyaltyPaymentsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Aggregate amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US">Base prospectus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Shares of common stock sold (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NetProceedsFromIssuanceOfCommonStock" xlink:href="atnm-20241231.xsd#atnm_NetProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NetProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetProceedsFromIssuanceOfCommonStock" xlink:to="atnm_NetProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityFairValueDisclosure_lbl" xml:lang="en-US">Option fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityFairValueDisclosure" xlink:to="us-gaap_EquityFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl" xml:lang="en-US">Discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected volatility minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected volatility maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Options to purchase common shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Fair value of RSUs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Unrecognized compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ExpiredWarrant" xlink:href="atnm-20241231.xsd#atnm_ExpiredWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ExpiredWarrant_lbl" xml:lang="en-US">Expired warrant (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ExpiredWarrant" xlink:to="atnm_ExpiredWarrant_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_WarrantExpiredUnderwrittenOfferingShares" xlink:href="atnm-20241231.xsd#atnm_WarrantExpiredUnderwrittenOfferingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WarrantExpiredUnderwrittenOfferingShares_lbl" xml:lang="en-US">Warrant expired underwritten offering shares (in Shares)</label>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cag6xP4Bvdp8g7pkxO2j+7aQEDWhC9NBQFF3IfuNj97Zy5Njm69ABek+DMR6GhYBNXNfUSw9pdSojRWkVvG0IkfkbUoYTYhzGCrqxoey3ARlapHObX412U9q+qvt5kY2/4VnOGpvlOzMcwiMOPpDhkLw3goUcPFzfX8endtoz+rZ7A==] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantExpiredUnderwrittenOfferingShares" xlink:to="atnm_WarrantExpiredUnderwrittenOfferingShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_WarrantExpiredTerm" xlink:href="atnm-20241231.xsd#atnm_WarrantExpiredTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WarrantExpiredTerm_lbl" xml:lang="en-US">Warrant expired term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantExpiredTerm" xlink:to="atnm_WarrantExpiredTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_WarrantExpiredPricePerShare" xlink:href="atnm-20241231.xsd#atnm_WarrantExpiredPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WarrantExpiredPricePerShare_lbl" xml:lang="en-US">Warrant expired price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantExpiredPricePerShare" xlink:to="atnm_WarrantExpiredPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl" xml:lang="en-US">Unused net operating losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedContractualRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedContractualRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedContractualRights_lbl" xml:lang="en-US">Indefinite life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedContractualRights" xlink:to="us-gaap_IndefiniteLivedContractualRights_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US">Net operating loss percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet_lbl" xml:lang="en-US">Research and development costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:to="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_AccumulatedGrossAmount" xlink:href="atnm-20241231.xsd#atnm_AccumulatedGrossAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_AccumulatedGrossAmount_lbl" xml:lang="en-US">Accumulated gross amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AccumulatedGrossAmount" xlink:to="atnm_AccumulatedGrossAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NatureOfBusinessPolicyPolicyTextBlock" xlink:href="atnm-20241231.xsd#atnm_NatureOfBusinessPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NatureOfBusinessPolicyPolicyTextBlock_lbl" xml:lang="en-US">Nature of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NatureOfBusinessPolicyPolicyTextBlock" xlink:to="atnm_NatureOfBusinessPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates in Financial Statement Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xml:lang="en-US">Collaborative Arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock_lbl" xml:lang="en-US">Grant Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LicenseRevenuePolicyTextBlock" xlink:href="atnm-20241231.xsd#atnm_LicenseRevenuePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LicenseRevenuePolicyTextBlock_lbl" xml:lang="en-US">License Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseRevenuePolicyTextBlock" xlink:to="atnm_LicenseRevenuePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:href="atnm-20241231.xsd#atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateAndOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateAndOtherMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateAndOtherMember_lbl" xml:lang="en-US">Corporate Office Space [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateAndOtherMember" xlink:to="us-gaap_CorporateAndOtherMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_CapitalOnDemandSalesAgreementMember" xlink:href="atnm-20241231.xsd#atnm_CapitalOnDemandSalesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_CapitalOnDemandSalesAgreementMember_lbl" xml:lang="en-US">Capital on Demand Sales Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalOnDemandSalesAgreementMember" xlink:to="atnm_CapitalOnDemandSalesAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember" xlink:href="atnm-20241231.xsd#atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember_lbl" xml:lang="en-US">2019 Amended and Restated Stock Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember" xlink:to="atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_FederalIncomeTaxMember" xlink:href="atnm-20241231.xsd#atnm_FederalIncomeTaxMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_FederalIncomeTaxMember_lbl" xml:lang="en-US">Federal income tax [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FederalIncomeTaxMember" xlink:to="atnm_FederalIncomeTaxMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ExpireIn2026Member" xlink:href="atnm-20241231.xsd#atnm_ExpireIn2026Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ExpireIn2026Member_lbl" xml:lang="en-US">Net operating losses due to expire in 2026 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ExpireIn2026Member" xlink:to="atnm_ExpireIn2026Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxYear2018Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxYear2018Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxYear2018Member_lbl" xml:lang="en-US">Net operating losses expire in 2034 - 2037 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxYear2018Member" xlink:to="us-gaap_TaxYear2018Member_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_TaxYearTwoThousandThirtyThreeMember" xlink:href="atnm-20241231.xsd#atnm_TaxYearTwoThousandThirtyThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_TaxYearTwoThousandThirtyThreeMember_lbl" xml:lang="en-US">Tax Year 2033 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_TaxYearTwoThousandThirtyThreeMember" xlink:to="atnm_TaxYearTwoThousandThirtyThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_OrphanDrugCreditsMember" xlink:href="atnm-20241231.xsd#atnm_OrphanDrugCreditsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_OrphanDrugCreditsMember_lbl" xml:lang="en-US">Orphan Drug Credits [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OrphanDrugCreditsMember" xlink:to="atnm_OrphanDrugCreditsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_TaxYearTwoThousandThirtySevenMember" xlink:href="atnm-20241231.xsd#atnm_TaxYearTwoThousandThirtySevenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_TaxYearTwoThousandThirtySevenMember_lbl" xml:lang="en-US">Tax Year 2037 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_TaxYearTwoThousandThirtySevenMember" xlink:to="atnm_TaxYearTwoThousandThirtySevenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Schedule of Diluted Net Loss Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Property and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Statement of Income Location, Balance [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_PropertyandEquipmentScheduleofDepreciationExpenseDetailsTable" xlink:href="atnm-20241231.xsd#atnm_PropertyandEquipmentScheduleofDepreciationExpenseDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_PropertyandEquipmentScheduleofDepreciationExpenseDetailsTable_lbl" xml:lang="en-US">Property and Equipment - Schedule of Depreciation Expense (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PropertyandEquipmentScheduleofDepreciationExpenseDetailsTable" xlink:to="atnm_PropertyandEquipmentScheduleofDepreciationExpenseDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems_lbl" xml:lang="en-US">Schedule of Depreciation Expense [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:href="atnm-20241231.xsd#atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable_lbl" xml:lang="en-US">Equity - Schedule of Restricted Stock Unit Activity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:to="atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Schedule of Restricted Stock Unit Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Schedule of Warrant Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="atnm-20241231.xsd#atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US">Segments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsTable" xlink:href="atnm-20241231.xsd#atnm_LeasesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesDetailsTable_lbl" xml:lang="en-US">Leases (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsTable" xlink:to="atnm_LeasesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Leases [Line Item]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsTable" xlink:href="atnm-20241231.xsd#atnm_EquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityDetailsTable_lbl" xml:lang="en-US">Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityDetailsTable" xlink:to="atnm_EquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodDomain_lbl" xml:lang="en-US">Tax Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_IncomeTaxesDetailsTable" xlink:href="atnm-20241231.xsd#atnm_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncomeTaxesDetailsTable" xlink:to="atnm_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xml:lang="en-US">Income Taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_SubsequentEventsDetailsTable" xlink:href="atnm-20241231.xsd#atnm_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SubsequentEventsDetailsTable" xlink:to="atnm_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_SubsequentEventsDetailsLineItems" xlink:href="atnm-20241231.xsd#atnm_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SubsequentEventsDetailsLineItems" xlink:to="atnm_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_AccumulatedGrossAmount_lbl0" xml:lang="en-US">Accumulated gross amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AccumulatedGrossAmount" xlink:to="atnm_AccumulatedGrossAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps_lbl0" xml:lang="en-US">Percentage of deferred true-up.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps" xlink:to="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ExpiredWarrant_lbl0" xml:lang="en-US">Shares of expired warrant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ExpiredWarrant" xlink:to="atnm_ExpiredWarrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_IncomeTaxReconciliationDeferredTrueup_lbl0" xml:lang="en-US">The amount of income tax reconciliation deferred true-up.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncomeTaxReconciliationDeferredTrueup" xlink:to="atnm_IncomeTaxReconciliationDeferredTrueup_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets_lbl0" xml:lang="en-US">Amount of lessee&apos;s right to use underlying asset under operating lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LicenseRevenuePolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for license revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseRevenuePolicyTextBlock" xlink:to="atnm_LicenseRevenuePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NatureOfBusinessPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for nature of business.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NatureOfBusinessPolicyPolicyTextBlock" xlink:to="atnm_NatureOfBusinessPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NetProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetProceedsFromIssuanceOfCommonStock" xlink:to="atnm_NetProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NonRefundablePaymentReceived_lbl0" xml:lang="en-US">Represents the amount of non-refundable payment received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonRefundablePaymentReceived" xlink:to="atnm_NonRefundablePaymentReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_OtherRevenueTextBlock_lbl0" xml:lang="en-US">The entire disclosure for other revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueTextBlock" xlink:to="atnm_OtherRevenueTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_PaymentOfMilestone_lbl0" xml:lang="en-US">Amount of  milestone payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PaymentOfMilestone" xlink:to="atnm_PaymentOfMilestone_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity&apos;s financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities_lbl0" xml:lang="en-US">Represents the amount of right-of-use assets obtained in exchange for lease liabilities which includes both operating and finance lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities" xlink:to="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_RoyaltyPaymentsPercentage_lbl0" xml:lang="en-US">percentage of royalty payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RoyaltyPaymentsPercentage" xlink:to="atnm_RoyaltyPaymentsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ScheduleOfDepreciationExpenseTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of depreciation expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfDepreciationExpenseTableTextBlock" xlink:to="atnm_ScheduleOfDepreciationExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl0" xml:lang="en-US">The number of share-based compensation arrangement by share-based payment award, non-options exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue_lbl0" xml:lang="en-US">Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of non options outstanding and currently exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted average remaining contractual term for vested portions of non options outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on non options exercised (or share units converted) into shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on non options exercised (or share units converted) into shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl0" xml:lang="en-US">The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted average remaining contractual term for vested portions of non options outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Amount by which the current fair value of the underlying stock exceeds the exercise price of non options outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted average remaining contractual term for portions of non options outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">The weighted average grant-date fair value of non-options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_WarrantExpiredPricePerShare_lbl0" xml:lang="en-US">Warrant expired price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantExpiredPricePerShare" xlink:to="atnm_WarrantExpiredPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_WarrantExpiredTerm_lbl0" xml:lang="en-US">Warrant expired term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantExpiredTerm" xlink:to="atnm_WarrantExpiredTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_WarrantExpiredUnderwrittenOfferingShares_lbl0" xml:lang="en-US">Warrant expired underwritten offering shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantExpiredUnderwrittenOfferingShares" xlink:to="atnm_WarrantExpiredUnderwrittenOfferingShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl0" xml:lang="en-US">Payments for Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensations Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Exercisable Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps_lbl1" xml:lang="en-US">Effective Income Tax Reconciliation Deferred True Ups</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps" xlink:to="atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl0" xml:lang="en-US">Right Of Use Assets Obtained In Exchange For Lease Obligations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="atnm_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WeightedAverageDiscountRatesAbstract_lbl0" xml:lang="en-US">Weighted Average Discount Rates Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageDiscountRatesAbstract" xlink:to="atnm_WeightedAverageDiscountRatesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets_lbl1" xml:lang="en-US">Increase Decrease In Operating Lease Rightofuse Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LicenseRevenuePolicyTextBlock_lbl1" xml:lang="en-US">License Revenue Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseRevenuePolicyTextBlock" xlink:to="atnm_LicenseRevenuePolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Shareholders&apos; Equity and Share-Based Payments [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl1" xml:lang="en-US">Restricted Cash, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NetProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US">Net Proceeds From Issuance Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NetProceedsFromIssuanceOfCommonStock" xlink:to="atnm_NetProceedsFromIssuanceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl0" xml:lang="en-US">Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl0" xml:lang="en-US">Investment Income, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfPropertyAndEquipmentAbstract" xlink:href="atnm-20241231.xsd#atnm_ScheduleOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="atnm_ScheduleOfPropertyAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfRestrictedStockUnitActivityAbstract" xlink:href="atnm-20241231.xsd#atnm_ScheduleOfRestrictedStockUnitActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfRestrictedStockUnitActivityAbstract_lbl" xml:lang="en-US">Schedule Of Restricted Stock Unit Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfRestrictedStockUnitActivityAbstract" xlink:to="atnm_ScheduleOfRestrictedStockUnitActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract_lbl0" xml:lang="en-US">Finance Lease, Liability [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WarrantExpiredTerm_lbl1" xml:lang="en-US">Warrant Expired Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantExpiredTerm" xlink:to="atnm_WarrantExpiredTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AccumulatedGrossAmount_lbl1" xml:lang="en-US">Accumulated Gross Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AccumulatedGrossAmount" xlink:to="atnm_AccumulatedGrossAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WarrantExpiredPricePerShare_lbl1" xml:lang="en-US">Warrant Expired Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantExpiredPricePerShare" xlink:to="atnm_WarrantExpiredPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl0" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl0" xml:lang="en-US">Prepaid Insurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedContractualRights_lbl0" xml:lang="en-US">Indefinite-Lived Contractual Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedContractualRights" xlink:to="us-gaap_IndefiniteLivedContractualRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_FederalIncomeTaxMember_lbl0" xml:lang="en-US">Federal Income Tax Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FederalIncomeTaxMember" xlink:to="atnm_FederalIncomeTaxMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl0" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl0" xml:lang="en-US">Machinery and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl0" xml:lang="en-US">Lease Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl1" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_PaymentOfMilestone_lbl1" xml:lang="en-US">Payment Of Milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PaymentOfMilestone" xlink:to="atnm_PaymentOfMilestone_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensations Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl0" xml:lang="en-US">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OrphanDrugCreditsMember_lbl0" xml:lang="en-US">Orphan Drug Credits Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OrphanDrugCreditsMember" xlink:to="atnm_OrphanDrugCreditsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl0" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl0" xml:lang="en-US">Lessee, Operating Lease, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl0" xml:lang="en-US">Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl1" xml:lang="en-US">Finance Lease, Principal Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NatureOfBusinessPolicyPolicyTextBlock_lbl1" xml:lang="en-US">Nature Of Business Policy Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NatureOfBusinessPolicyPolicyTextBlock" xlink:to="atnm_NatureOfBusinessPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NonCashActivityAbstract_lbl0" xml:lang="en-US">Non Cash Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonCashActivityAbstract" xlink:to="atnm_NonCashActivityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CapitalOnDemandSalesAgreementMember_lbl0" xml:lang="en-US">Capital On Demand Sales Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalOnDemandSalesAgreementMember" xlink:to="atnm_CapitalOnDemandSalesAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock_lbl0" xml:lang="en-US">Government Assistance [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet_lbl0" xml:lang="en-US">Research and Development Arrangement with Federal Government, Costs Incurred, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:to="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl0" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_TaxYearTwoThousandThirtySevenMember_lbl0" xml:lang="en-US">Tax Year Two Thousand Thirty Seven Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_TaxYearTwoThousandThirtySevenMember" xlink:to="atnm_TaxYearTwoThousandThirtySevenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OtherRevenueTextBlock_lbl1" xml:lang="en-US">Other Revenue Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueTextBlock" xlink:to="atnm_OtherRevenueTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxYear2018Member_lbl0" xml:lang="en-US">Tax Year 2018 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxYear2018Member" xlink:to="us-gaap_TaxYear2018Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_IncomeTaxReconciliationDeferredTrueup_lbl1" xml:lang="en-US">Income Tax Reconciliation Deferred Trueup</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncomeTaxReconciliationDeferredTrueup" xlink:to="atnm_IncomeTaxReconciliationDeferredTrueup_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl0" xml:lang="en-US">Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_TaxYearTwoThousandThirtyThreeMember_lbl0" xml:lang="en-US">Tax Year Two Thousand Thirty Three Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_TaxYearTwoThousandThirtyThreeMember" xlink:to="atnm_TaxYearTwoThousandThirtyThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RevenueMember_lbl0" xml:lang="en-US">Revenue Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RevenueMember" xlink:to="atnm_RevenueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities_lbl1" xml:lang="en-US">Rightofuse Asset Obtained In Exchange For Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities" xlink:to="atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ExpiredWarrant_lbl1" xml:lang="en-US">Expired Warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ExpiredWarrant" xlink:to="atnm_ExpiredWarrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ExpireIn2026Member_lbl0" xml:lang="en-US">Expire In2026 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ExpireIn2026Member" xlink:to="atnm_ExpireIn2026Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl0" xml:lang="en-US">Weighted Average Remaining Lease Term Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OtherRevenueMember_lbl0" xml:lang="en-US">Other Revenue Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueMember" xlink:to="atnm_OtherRevenueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RoyaltyPaymentsPercentage_lbl1" xml:lang="en-US">Royalty Payments Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RoyaltyPaymentsPercentage" xlink:to="atnm_RoyaltyPaymentsPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfDepreciationExpenseTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Depreciation Expense Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfDepreciationExpenseTableTextBlock" xlink:to="atnm_ScheduleOfDepreciationExpenseTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WarrantExpiredUnderwrittenOfferingShares_lbl1" xml:lang="en-US">Warrant Expired Underwritten Offering Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WarrantExpiredUnderwrittenOfferingShares" xlink:to="atnm_WarrantExpiredUnderwrittenOfferingShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl2" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember_lbl0" xml:lang="en-US">Two Thousand Nineteen Amended And Restated Stock Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember" xlink:to="atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfDepreciationExpenseAbstract" xlink:href="atnm-20241231.xsd#atnm_ScheduleOfDepreciationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfDepreciationExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Depreciation Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfDepreciationExpenseAbstract" xlink:to="atnm_ScheduleOfDepreciationExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0" xml:lang="en-US">Cash Paid For Amounts Included In The Measurement Of Lease Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl1" xml:lang="en-US">Recently Issued Accounting Pronouncements Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateAndOtherMember_lbl0" xml:lang="en-US">Corporate Segment and Other Operating Segment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateAndOtherMember" xlink:to="us-gaap_CorporateAndOtherMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl0" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl0" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandImprovements_lbl0" xml:lang="en-US">Land Improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandImprovements" xlink:to="us-gaap_LandImprovements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Finance Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NonRefundablePaymentReceived_lbl1" xml:lang="en-US">Non Refundable Payment Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonRefundablePaymentReceived" xlink:to="atnm_NonRefundablePaymentReceived_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl0" xml:lang="en-US">Other Current Assets [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl0" xml:lang="en-US">Deferred Tax Assets, Deferred Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfDilutedNetLossPerShareAbstract" xlink:href="atnm-20241231.xsd#atnm_ScheduleOfDilutedNetLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfDilutedNetLossPerShareAbstract_lbl" xml:lang="en-US">Schedule Of Diluted Net Loss Per Share Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfDilutedNetLossPerShareAbstract" xlink:to="atnm_ScheduleOfDilutedNetLossPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl0" xml:lang="en-US">Finance Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl0" xml:lang="en-US">Finance Lease, Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl0" xml:lang="en-US">Finance Lease, Interest Payment on Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityFairValueDisclosure_lbl0" xml:lang="en-US">Equity, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityFairValueDisclosure" xlink:to="us-gaap_EquityFairValueDisclosure_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWarrantActivityAbstract" xlink:href="atnm-20241231.xsd#atnm_ScheduleOfWarrantActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfWarrantActivityAbstract_lbl" xml:lang="en-US">Schedule Of Warrant Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWarrantActivityAbstract" xlink:to="atnm_ScheduleOfWarrantActivityAbstract_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>atnm-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 31 20:27:49 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ConsolidatedBalanceSheet" roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ConsolidatedIncomeStatement" roleURI="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ShareholdersEquityType2or3" roleURI="http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ConsolidatedCashFlow" roleURI="http://www.actiniumpharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies" roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_PrepaidExpensesandOtherCurrentAssets" roleURI="http://www.actiniumpharma.com/role/PrepaidExpensesandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_PropertyandEquipment" roleURI="http://www.actiniumpharma.com/role/PropertyandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_Leases" roleURI="http://www.actiniumpharma.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_OtherRevenue" roleURI="http://www.actiniumpharma.com/role/OtherRevenue"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_CommitmentsandContingencies" roleURI="http://www.actiniumpharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_Equity" roleURI="http://www.actiniumpharma.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_IncomeTaxes" roleURI="http://www.actiniumpharma.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_SubsequentEvents" roleURI="http://www.actiniumpharma.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_AccountingPoliciesByPolicy" roleURI="http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://www.actiniumpharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_PropertyandEquipmentTables" roleURI="http://www.actiniumpharma.com/role/PropertyandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_LeasesTables" roleURI="http://www.actiniumpharma.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_EquityTables" roleURI="http://www.actiniumpharma.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_IncomeTaxesTables" roleURI="http://www.actiniumpharma.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofCashCashEquivalentsandRestrictedCashTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofDilutedNetLossPerShareTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofDepreciationExpenseTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofDepreciationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofComponentsofLeaseExpenseTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofMaturitiesofLeaseLiabilitiesTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofStockOptionActivityTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofRestrictedStockUnitActivityTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofWarrantActivityTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_ScheduleofUSFederalStatutoryRatesTable" roleURI="http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_LeasesDetails" roleURI="http://www.actiniumpharma.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_OtherRevenueDetails" roleURI="http://www.actiniumpharma.com/role/OtherRevenueDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_CommitmentsandContingenciesDetails" roleURI="http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_EquityDetails" roleURI="http://www.actiniumpharma.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_IncomeTaxesDetails" roleURI="http://www.actiniumpharma.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20241231.xsd#atnm_r_SubsequentEventsDetails" roleURI="http://www.actiniumpharma.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#ai" roleURI="http://xbrl.sec.gov/dei/role/document/AuditInformation"/>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RevenueMember" xlink:href="atnm-20241231.xsd#atnm_RevenueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="RevenueMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherRevenueMember" xlink:href="atnm-20241231.xsd#atnm_OtherRevenueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="OtherRevenueMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:href="atnm-20241231.xsd#atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOperatingLeaseRightofuseAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightofuseAssetObtainedInExchangeForLeaseLiabilities" xlink:href="atnm-20241231.xsd#atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="RightofuseAssetObtainedInExchangeForLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/PropertyandEquipment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/OtherRevenue" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherRevenueTextBlock" xlink:href="atnm-20241231.xsd#atnm_OtherRevenueTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="OtherRevenueTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="NatureOfBusinessPolicyPolicyTextBlock" xlink:href="atnm-20241231.xsd#atnm_NatureOfBusinessPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NatureOfBusinessPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicenseRevenuePolicyTextBlock" xlink:href="atnm-20241231.xsd#atnm_LicenseRevenuePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LicenseRevenuePolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:href="atnm-20241231.xsd#atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RecentlyIssuedAccountingPronouncementsPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfDepreciationExpenseTableTextBlock" xlink:href="atnm-20241231.xsd#atnm_ScheduleOfDepreciationExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="ScheduleOfDepreciationExpenseTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/LeasesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfDilutedNetLossPerShareAbstract" xlink:href="atnm-20241231.xsd#atnm_ScheduleOfDilutedNetLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutedNetLossPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="atnm-20241231.xsd#atnm_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_EquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofDepreciationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfDepreciationExpenseAbstract" xlink:href="atnm-20241231.xsd#atnm_ScheduleOfDepreciationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentScheduleofDepreciationExpenseDetailsTable" xlink:href="atnm-20241231.xsd#atnm_PropertyandEquipmentScheduleofDepreciationExpenseDetailsTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDepreciationExpenseAbstract" xlink:to="PropertyandEquipmentScheduleofDepreciationExpenseDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentScheduleofDepreciationExpenseDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cag6xP4Bvdp8g7pkxO2j+7aQEDWhC9NBQFF3IfuNj97Zy5Njm69ABek+DMR6GhYBNXNfUSw9pdSojRWkVvG0IkfkbUoYTYhzGCrqxoey3ARlapHObX412U9q+qvt5kY2/4VnOGpvlOzMcwiMOPpDhkLwxVayxzMUOspkjhetP9ZLtA==] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentScheduleofDepreciationExpenseDetailsTable" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiability" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRestrictedStockUnitActivityAbstract" xlink:href="atnm-20241231.xsd#atnm_ScheduleOfRestrictedStockUnitActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:href="atnm-20241231.xsd#atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictedStockUnitActivityAbstract" xlink:to="EquityScheduleofRestrictedStockUnitActivityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofRestrictedStockUnitActivityDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantActivityAbstract" xlink:href="atnm-20241231.xsd#atnm_ScheduleOfWarrantActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantActivityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice" xlink:to="ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue" xlink:href="atnm-20241231.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxReconciliationDeferredTrueup" xlink:href="atnm-20241231.xsd#atnm_IncomeTaxReconciliationDeferredTrueup"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="IncomeTaxReconciliationDeferredTrueup" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="EffectiveIncomeTaxReconciliationDeferredTrueUps" xlink:href="atnm-20241231.xsd#atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxReconciliationDeferredTrueUps" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="atnm-20241231.xsd#atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsTable" xlink:href="atnm-20241231.xsd#atnm_LeasesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="LeasesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateAndOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateAndOtherMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_CorporateAndOtherMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForRent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandImprovements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LandImprovements" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/OtherRevenueDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_OtherIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonRefundablePaymentReceived" xlink:href="atnm-20241231.xsd#atnm_NonRefundablePaymentReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="NonRefundablePaymentReceived" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="PaymentOfMilestone" xlink:href="atnm-20241231.xsd#atnm_PaymentOfMilestone"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="PaymentOfMilestone" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyPaymentsPercentage" xlink:href="atnm-20241231.xsd#atnm_RoyaltyPaymentsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="RoyaltyPaymentsPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsTable" xlink:href="atnm-20241231.xsd#atnm_EquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="EquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CapitalOnDemandSalesAgreementMember" xlink:href="atnm-20241231.xsd#atnm_CapitalOnDemandSalesAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="CapitalOnDemandSalesAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandNineteenAmendedAndRestatedStockPlanMember" xlink:href="atnm-20241231.xsd#atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandNineteenAmendedAndRestatedStockPlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="srt_RangeAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_ClassOfStockLineItems" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceedsFromIssuanceOfCommonStock" xlink:href="atnm-20241231.xsd#atnm_NetProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="NetProceedsFromIssuanceOfCommonStock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquityFairValueDisclosure" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpiredWarrant" xlink:href="atnm-20241231.xsd#atnm_ExpiredWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ExpiredWarrant" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantExpiredUnderwrittenOfferingShares" xlink:href="atnm-20241231.xsd#atnm_WarrantExpiredUnderwrittenOfferingShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="WarrantExpiredUnderwrittenOfferingShares" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantExpiredTerm" xlink:href="atnm-20241231.xsd#atnm_WarrantExpiredTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="WarrantExpiredTerm" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantExpiredPricePerShare" xlink:href="atnm-20241231.xsd#atnm_WarrantExpiredPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="WarrantExpiredPricePerShare" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="atnm-20241231.xsd#atnm_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_TaxPeriodAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ExpireIn2026Member" xlink:href="atnm-20241231.xsd#atnm_ExpireIn2026Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="ExpireIn2026Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxYear2018Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxYear2018Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxYear2018Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxYearTwoThousandThirtyThreeMember" xlink:href="atnm-20241231.xsd#atnm_TaxYearTwoThousandThirtyThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="TaxYearTwoThousandThirtyThreeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxYearTwoThousandThirtySevenMember" xlink:href="atnm-20241231.xsd#atnm_TaxYearTwoThousandThirtySevenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="TaxYearTwoThousandThirtySevenMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FederalIncomeTaxMember" xlink:href="atnm-20241231.xsd#atnm_FederalIncomeTaxMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="FederalIncomeTaxMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OrphanDrugCreditsMember" xlink:href="atnm-20241231.xsd#atnm_OrphanDrugCreditsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="OrphanDrugCreditsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedContractualRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedContractualRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IndefiniteLivedContractualRights" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedGrossAmount" xlink:href="atnm-20241231.xsd#atnm_AccumulatedGrossAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="AccumulatedGrossAmount" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.actiniumpharma.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="atnm-20241231.xsd#atnm_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="atnm-20241231.xsd#atnm_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/Cover" xlink:type="extended"/>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/AuditInformation" xlink:type="extended"/>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $= GH# 2(  A$! Q$!_\0
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MF&H8*&(H89U_J^&A6QN+KTL1BJ^+KU8JI0P^'H8=?.7_  RK\(O^JE_^'O\
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MLU+QC'XN3QHOAB'7O#/BCQTUY9Q/X4N(O$]LT^ESQ:;<VB:G??%_Q)_X*/\
M[37Q1CT#XR7_ ,5/A;H^B:K^PY_P5E^)UA^SO\'O$GCOPSXE^'6I_!;P_H6D
M> M&_:!U#3_&\>OW?C/2;C0KS4-!\3>'X?AOK.@ZO=>+X=#M;<V=MJC?68?A
MSBZO4C%YO&%*=/GC5CC:E9\\E0G"A*E3P2G3K2IXFC4G[2<*%)5%&6)G53HO
MQJM'@ZG%M</X.4U+E<'@84URIU%*HIRQMI04J52,>2,JDW%M4HP_>+^EK_AE
M7X1?]5+_ /#W_&?_ .;RC_AE7X1?]5+_ /#W_&?Z_P#0^?YZ=*_,WX-_\% /
MBMXL^)?C.Q\1_$_]E3X/_"3X%WOA#X?>(?AS\6KCQM/^T%\3!<_LQ^%OC7=_
M%#P3JJ>,WFO["]U'Q"UOH7AU/!'BN^\0>&?#?B+56\32ZZ5M(_SY\9_\%2_V
MO/C-\%_C/:^$OC/\"? E[\//'W_!.7QUH'QN\ ^"M>T'1]5^%?[6?Q'U32M3
M\-ZUX?UWXK>*-2T'2M(&@Z5=:GK'B#5/"7B;6/!^KZIH^M^$_!6I7UG?Q98?
M(>+\17E2_M1THTWA%6K5,7B'3HK&R4:-W#+'&K-1G0J5*6&JXF488BGRSJSA
M7A1NKAN#:5-3_L'!3<E7]G"&"I<U1X=7G;FS!.$6XU(QG5A23E2E>,(RIRG_
M $<?\,J_"+_JIG_A[_C/_P#-[2?\,J_"+_JIG_A[_C/W_P"Y]_\ U=J_%+PM
M_P %"OCSIOC7Q9\&?"WC;X _#C5_%7[8/_!0O2I/CU^T5JWQ"\2_";3_  ]^
MS#J/@-=-\#^'=-O_ (F:;+IVO^-W\6R:U9:)IOC+3/"_@SP;HNK7/AOPGJ3C
MRH^/UO\ X+"?M@:SX%\;_''P?\/_ (%>#OAW\'_V:?V(?VA?'G@'QYH7CS4O
M%_BB;]I?XI>)OAQXF\/>#O%EEXNT&PTSPY<V>A'Q=X$\4ZSX4NKO^R[C1EO]
M(U!=7GDTYQX?XRG-1IYFG&?L^2=3,/8\WMWAH8=6E@II2Q%;$QHTH1J5)QE%
MO$QP<9TG43P_!BBW+(L'>/-S*&7\]O9^UE5=UC8MJE"DZDVXQBXNU)UW&:C^
M[W_#*OPB_P"JE_\ A[_C/_\ -Y1_PRK\(O\ JI?_ (>_XS__ #>5]&T5\=_;
M.;?]#+&?^#O_ +D>Y_JOPW_T(LK_ /"7_P"^#YR_X95^$7_53/\ P]_QG_\
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MBI0A'DDW.I3=*K&/]%8_8]_97!R/V?/A'_X0V@__ "'0?V/OV6#U_9\^$?\
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MAWQLU@_C/09H;?1HXY=%\7/I6F-XGTMU:QU]M.L&U6"[-G;F/@O^&/?V;_\
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M.8!N;$1_=C<<+R:YK_AGKX!?]$.^#_\ X;3P7_\ *2C_ (9Z^ 7_ $0[X/\
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M^%3H?_R=7)_\,]? +_HAWP?_ /#:>"__ )24?\,]? +_ *(=\'__  VG@O\
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MKX!?]$.^#_\ X;3P7_\ *2C_ (9Z^ 7_ $0[X/\ _AM/!?\ \I*+9)_-G/\
MX+RC_P"6A?BO_GWPO_X.XD_^9SK/^%D?#O\ Z'WP7_X5.A__ "=3)/B9\-X8
MWEE^(/@B**-2\DDGBO04CC0=6=VOPJJ.[,0!ZURW_#/7P"_Z(=\'_P#PVG@O
M_P"4E/C_ &?O@+$ZR1?!'X11R(0R21_#;P:CJPZ%6710RD=B""*+9)_-G/\
MX+RC_P"6_P"?H%^*_P#GWPO_ .#N)'^'U=7^]>JW/(/&_P 5[CXX1:E\)/V>
M]1DUE=:$VA_$#XTZ2K3>!_AOX=N,VVNIH'B$ :?XM^(EY8//8^'=(\/7%[!H
MU[<QZWKU[8V]@MO>?3?A[PKH'A;0-#\,:)IEM::-X<T?3-!TBT\I)/LNF:19
M0:?86^]U+OY-I;Q1[W)9MN6)))K8LK*STVU@L=.M+6PL;6)8;6SLK>*UM;:%
M!A(H+>!(X88D'"QQHJJ.  *LUGBL93G2I87"4IX;"49RJ\LZJJXC$8B<(TY8
MC$U81I0<U2BJ5&C1A&AAZ3G&'M)U:U:>^ RRM2Q%?,,RQ-/'9EB:5/#N5*@Z
M&"P>#I5)5H8+ 8>I4KU8TY5YRQ&)Q.)JU,7C<0J<ZOL:-##86D445\">!/\
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MSIMU;7%Q]%Z+X+^#]I^T=X;T?1O@K^SU%I?BOQ[XY\7>._"GQ \4_"PMX?\
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M0P=24X<2YE4AAHXW%O"TW)1S:-3$J$;8BI+!PJP]E*T)R:]H_2!_P5$_;V8
MK^TS\0F!Z$7ED0?H19X-!_X*B?M[#&?VF?B$,G S>60R3T _T/DGTK[+^(_[
M*G[+'Q#\9>-O$/B'XC^$_ASJ^D?#;P7JM]\//A[<?"OP=J/@NXU&Q^(%SK7B
M_P >6/A7Q)XN^%_B75=(E\/^%[.\T?X<ZMX6M-4T_7]-N[JPT76KE;:[P_ G
M[)_[%WA.^\)3>)?CEIEUX;^(/P0^(1\1^,=>O_"OB33])$WPW\(>($^)'@WP
MU9&SUO0_$'ASQ1K&L>%](T"^CU:YDNK$S)>27]EJ6GQ\*QO#+I*?]@T?:<BD
MZ,,AH5/>]FJKA&K' *%1JG=Q=.+55I*ESJ2J'KRROCM8B5)<7XGV"J2A'$U.
M+\91]Q5GAXU*F'J9PZM!.KRQJ1JU(O#Q<I5W3E"5%_*'_#T3]O8D@?M,_$(D
M8R/MEED9Z9'V/C/;-+_P]#_;W_Z.8^(?_@79?_(=>O:[^SW^S?HO@6&?QEK5
MT1X M/C5<VOA/PC\3/A2/%.MRZ?^T1X&\!>$8-6\?V'A2\G\40:GX%\0WWBZ
MPO)='N'CL;9IM$MK/1K>]BJ#QQ^Q7\#/#_PK^/WBWP?XQ\4_$"_^%/AOXU>(
M]-\6:1X\\ R^'M.U#P!\6?#W@?P;X,\0^$+#3;S7]7E\1>#]97Q?<>+-+U*R
MT:\>XMK?3HXXHI=V\:W#+<5+)<+#GK0HPD\EPCIRE4JPI0?M/JT8I-U:3EVY
M^6#K2A-+CGAN.XQG*'%&85%2PU7$U(1XIS/VT(4</5Q%5.@L?.HVEA\1&-MW
M2YJJPL*E-R\H_P"'H?[>_P#T<Q\0_P#P+LO_ )#I#_P5%_;U!P?VF?B$#P,&
M\L@<GH,?8^^#CUKMX?V4?@*UWX/@MO$/B'6[/5/AE<^,-!UFU^,GPCTVV^/W
MCA/AKH_BS_A6?@K2+JQDUOX3ZEI_BR^U7PM=ZQXQM];TVX.AR6*/%K]Y!9U[
M3IWP2_9E\.^"O'_@?3/$7PS\2W5CI7[4NDZ'XU\3Z_X0;Q#8:E_8/[/DOA&*
M\UJ"Y2QO=0\"ZSKWC32-%U[3;;^SM2N-,U_4=(@EA%U%$JE;AN"CR9'AJK<H
M)I9-@X<L)5)4G-MX2=N5PDY0:4U9P:C6C.C"J.&XWJ.7M>+,?0C&%1QD^*,S
MJN=2%"G7C2C&.94K^TC4BH55*5)W56+GAIT\34^7_P#AZ)^WL" ?VF?B$"<X
M'VRRR<=<#['SCOBE_P"'H?[>_P#T<Q\0_P#P+LO_ )#K[8B_8N_9<\))\0O!
M-EK,?CX^+?"/PS*"Z^+_ ,*+#QAX,U'3?VB)O"'C'Q'X*\8WEFNE'3V^'B1^
M.-0L'T4W>J>'(I/L\D6G7<=W'XIX0_8P_9-UB]\$6VH?':_O/"VM^,?"VE2_
M$ZR\=_#[2-+\8_VO\1_&'A;Q-X$T/PCJ%G/K/@WQ!X-\%Z%H_CJY\9>([J[\
M/WT.I&#[!#!>:=++E#&<+3C4G_8M!0A9QDLAPTG4@Z4JG,H1PG-%WA.$:<KS
MJ.+G24Z<:DJ.]7+/$"E.E3_UIQ;J5'*$XOB_'0C2J1KPH*+J3S%0J0:JTZDJ
MT+4J*FJ5=TJTZ$,5XE_P]#_;W_Z.8^(?_@79?_(='_#T/]O?_HYCXA_^!=E_
M\AU]!?!C]E+]D?6O"WP@^+GC'Q'=0Z5XD^,'@.TUGP%K?QE\%W.G-X!\2?$O
M7_ NHZ'XDN[30- UW2]7\/V>FZ-XBUZYCMX$&G:LIN#IVGWMK?)F^%/V-OV8
M/$&H>#O^$J^(>K^!+#Q)XU\,V6M7R_%+X;7EE9:EX@^*/BKPOXM^"NEZ;)IO
M]HZ3XD^&?@S2M,\6W'Q%UIY/#.K6T^U=-@M[VPFDTEB>&(3JQEDE!>Q=2,VL
MBPLOWE*4XU*<8QPSE-QY&[P4HRO:-VIN.,,%Q[4IX><.*L6WB8T9THOB[,8/
MV->%*5&M4G/'QITHS]K%<M1PG"S=114J:GX?_P /0_V]_P#HYCXA_P#@79?_
M "'1_P /0_V]_P#HYCXA_P#@79?_ "'7Q'XH;06\2:\/"UAJ.E^'(]6OH-$L
M-7U>#7]3M]/M[A[> 7VLVVF:-;:C<2B(SM<0:5918E$:1%4$CX5>Y')\GE&,
MO['RR/,D[2RW *2ND[22PLDFKV:3:332;M=_*3XFXFC*4?\ 67/I<LI1YH9[
MG#A+EE*/-!O'Q;C+EO%N,6XM-QBW9??/_#T/]O?_ *.8^(?_ (%V7_R'1_P]
M#_;W_P"CF/B'_P"!=E_\AU\#44_[&R?_ *%&5_\ AMP/_P R$_ZS\3?]%)Q!
M_P"'S-__ )XGWS_P]#_;W_Z.8^(?_@79?_(='_#T/]O?_HYCXA_^!=E_\AU\
M#44?V-D__0HRO_PVX'_YD#_6?B;_ **3B#_P^9O_ //$^^?^'H?[>_\ T<Q\
M0_\ P+LO_D.C_AZ'^WO_ -',?$/_ ,"[+_Y#KX&HH_L;)_\ H497_P"&W __
M #('^L_$W_12<0?^'S-__GB??/\ P]#_ &]_^CF/B'_X%V7_ ,AT?\/0_P!O
M?_HYCXA_^!=E_P#(=? U%']C9/\ ]"C*_P#PVX'_ .9 _P!9^)O^BDX@_P##
MYF__ ,\3](]"_P""FW[=MQ@W'[2/Q EY!^>\M.>2,'%H/3M7L^A?\%&/VT[C
M9Y_Q^\;RY"YWW<'<#T@'ZU^5/ASHO_ ?_0VKWWPYUC^B?R%<M?)\H5[95EB]
M,NP*Z+MA3T,-Q+Q(XQOQ%GSO??.LU??OF#/U!T+]OG]KFX5#/\;/%TI.<[[M
M?0>B#W_/Z5[/X?\ VV_VG[GR_M'Q:\2S;@<[[H\\CT(K\UO#GW(_Q_DM>^^&
M.D/T/\Q7E5LJRM*5LLRY:O; 8-=/+#'T6'XAS]K7/<Z>BWS?,GT7?',_1;0?
MVN_VA+G9Y_Q(UV7=C.ZZF_I(*]FT+]IWXUW+()_&VJ2C'.^YNN?E[XN >O-?
M OAOK&/8?IC_ !KWSPY]]/I_[+7DULMRY7ME^!6O3!X5='_U#GTF$SO.FHWS
MG-GZYGF#[=\8S[F\/_'[XHW.W[1XDNY<KD[[B]/IZ7@_QKO;;XV?$)SAM9F.
M"!S<:AZC_I^KY;\,?P_[O^%>EV?4_4?S%>15P&!5[8+!K?;"X==_^G)]#ALW
MS9O7-,R>^^88U_GBF>\6OQC\=/MW:H[<C.;C4><C//\ I_\ +%;]M\6O&3XW
M7V>,_P#'QJ?H/34*\.L^J_5?Y5TUIU'T/\A7F5L'@_\ H$PJWVP]!=?*DCZ#
M#9EF3:OF./>BWQN+?7SQ#/:K3XI>*V8;[E' )R&GU/GY3U_XF/Y8Q@\U] ^!
MO&\'B*UCMKIUCU*-0OS%5^T[5R<@!56X"@LRJ DZ*T\*KMG@MOCBS^_^)_\
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M1HTE+6G2<FY6E4@>F_2BBBOS,_=PHHHH **** "BBB@ HHHH **** "BBB@
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MQS_\(CPK_P#/!H_X?V_L/_\ 0(^.?_A$>%?_ )X-'^M7'/\ T1%3_P &8O\
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M<_\ PB/"O_SP:/\ A_;^P_\ ] CXY_\ A$>%?_G@T_\ 6KCG_HB*G_@S%_\
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M]F;XSLTB"-V/PN\7%GC'1')T7+(.RDE1Z5_59_P_M_8?_P"@1\<__"(\*_\
MSP:/^']O[#__ $"/CG_X1'A7_P">#1_K5QS_ -$34_\ !F+_ /EP?\0^\)?^
MCJT/_!.7?_,GF_O?=G\J1_8E_:M9VE;]F;XS&1E*M(?A;XN+LI7:59SHNXJ5
M^4@D@KQC'%(/V(_VK!G'[,GQE&8Q$<?"SQ;S$HP(C_Q)>8P  $/R@#@5_6/8
M_P#!=']BO4"H@TKXUC=T\SP;X57KCKCQ\WK78V/_  69_9$U @0:;\71DX_>
M>%?#"C]/'#5+XMXVC\7!4UZU,7_\N-(^'/A5/X?%&E*_:CEKOW_YAD?R'_\
M#%W[6HZ?LV_&W_PV7C'_ .4]'_#%W[6W_1MOQM_\-EXQ_P#E/7]D%C_P5B_9
M>U#;Y%A\3QNQCS/#OAI.N,=/&3>M=E8_\%*?V>-0*BWL_B""V,>9HWAU>OKC
MQ8W3OV]ZREQEQC'XN#;>M3%__+#HCX8>&<_A\3.;M:CEW_RE'\5O_#%W[6W_
M $;;\;?_  V7C'_Y3T?\,7?M;?\ 1MOQM_\ #9>,?_E/7]P5C^WE\$=0V^1;
M>,QNQCS--T!<9QUQXF;UKL;']KKX5ZAM\B#Q*-V,>9;:$O7&.GB%AW[9K)\<
M\5Q^+A*"]:N+_P#DSHCX3>'D_@\1JDK[6P^7?_*D?PF?\,7?M;?]&V_&W_PV
M7C'_ .4]'_#%W[6W_1MOQM_\-EXQ_P#E/7][47[1GP_FQLCUGGU71!_[G/QX
MJ_'\>_ \N-J:KSTS_8H_]S1K-\?<31WX5I+UK8O_ .2-X^#O DOA\0,1+TPV
M6_\ R!_ M_PQ=^UM_P!&V_&W_P -EXQ_^4]'_#%W[6W_ $;;\;?_  V7C'_Y
M3U_?Q'\:O!TF-JZCSZMH_KCG_B<&M2T^*GA:[E2)7N8R[*H>1]-<#+!?N6^H
MSS.1G.V**1V (16<JIREXB\0Q5Y<,T$E?>OC.F^S;_!_,WAX*<%U&E#CK%R;
M:2MA<MZM):M)+5K5M+JVE=K_ #\_^&+OVMO^C;?C;_X;+QC_ /*>C_AB[]K;
M_HVWXV_^&R\8_P#RGK_12CECFC26&1)8I45XY(V#HZ, RNC*2K*P((()!!R*
M?7#_ ,18S!:/)< FNGUK&_\ R!ZR^CMDK2:XGS=IJZ:P&5M-/5--5&FFFFFF
MTUJF?Y['A_\ 8V_:NB"^;^SK\9XNG^L^&WC!>C$GKHX[&O<- _9)_:;AV&7X
M"_%N+ 7/F?#WQ8O11ZZ0*_NWHK*?BICZE[Y/@5?MB<9^L3HI_1]R>FDEQ+FS
MMWP&6K\JA_%OH'[+_P"T1$J"7X*_$^(C.0_@7Q0N.!USI7L?R->W^'?V<OCM
M!Y7F_"3XB1X'._P9XD7&2/[VF#T-?ULT5R3\2<;.]\JP:O\ ]1&*_P#D3T*?
M@;E5-67$&9O1+7!9>MDETGY'\S/A_P" _P 8X2AE^&?CF+ YW^$_$*^ASSIO
M3@_ES7MN@?!OXHPLAE\!^+8^QW^&M=7'R]\Z=7[\T5RSX_Q<[_\ ";A5?_I_
MB7Y?RGI4O!_+J5K9WF$K=\)@5^4S\=O#OPP\?0!3-X4\0Q?+_'H6LJ?UT\5Z
M':_#OQFIRWAW60">^CZN.F/6PK]1J*Y)\:8J=_\ 8,,KW_Y?5WO?NCT*?A?@
M:>V;XU^N&PB_*1^;5KX!\6H5W:%JPP1G_B4ZMQP.O^@_6NBM?!'B<$9T;4AQ
MWTO51V'K8U^@=%<L^*L1/?!T%O\ \O:W7Y'?3\/L'3VS+%OUH8;])'P]9^"_
M$>]0=+OUW,!E].U-5&1C+,;+"@9Y). *^C? '@--$ACU+4X@VHNJM# X!^R^
MDL@QQ<D8*1Y86P.23.28_5**\W&9SB,73=)0A0C+2;IRG*4H_P MY6LG]JVL
MEHVE=/V\LX7P>75XXB56IBITTO91K0IQA3FMJG+"_/-+X.;2#]])RLXE%%%>
M.?3%6^M?MUE>60N;JS-Y:W%K]LL91!>VOVB%XOM-G.4D$-U!O\VWE*.(YE1R
MC 8/X:?L&V'Q2\)?MI>/?!7CS2OCKJ-G;>#?BA>Z3XY^+/Q#U#Q!KOB;1+7X
MA:)I>A^(O'FE:1\$_ WAF[U?5C!J>G>''U;XC^--1T#3](N8=%TZWT[5GOC^
MZM?AW_P3^T6VT_\ ;#^/D.IZ7"OCG2M:^.*>([T_#OX=1ZC:6VK_ !5L]3T>
MUU'XL:;\>?&GQ"\12W.CW&EW L?$/PR\/%(FM[:^GTA]-T_3[OZ7)96RKB2+
M4)1_L^BTFO?C*5?DC4C)*ZC'X9IR<9.<%R<UIKR\<KXO*VG)/ZS/5/W6E3YG
M%J]FWNG:Z2EK;0_<2OXY?^#@AF/[9/@!2Q*K^SSX/(4D[06\??%'<0,X!; R
M0,G SG Q_8U7\<O_  <$ _\ #97@$X.#^SQX. .#@D>/OBCD ]"1D9 Z9&>H
MKVO#3_DJ:7_8OS'_ --4#\P\=O\ DWV(_P"QUD?_ *DXL_"FOJW]C?XH?#'X
M)?%S4?BY\3#XGGD\$?#KQW/\.-)\'&&U\0ZG\4->T:3PQX:FT[7;NTO].\+W
M7A^WUG5/$EAXAU"QO8+#5=*T\BSN'<)3/V)M'\"^+?VG_@]\.OB/\./#GQ,\
M(_%#QMX>\ :II7B&^\2:>VD6^O:G;I-KVAW/AG6=&N%URUACDM[3^T'O=-"7
M,K36$LBQ,GV)I_[,WP#\>7OPR\3V^@:EX+\1_&;P%^U]XMT[X;^&+62^^$?@
MO1OV9-"^(FFVMREYXD\1:EX[U/Q/XJU;PWH^KJ[ZHVDZ7<KJCF!H#9V*_MN:
MX_"P]OEV,IXJ-*OA.:=;#NF^:E4=15*:M)U:7N8:M&I4E!P5.4E%N52*7\J\
M/Y1F%7ZIG.6U\OEB,)F')3PV,C77L\12C1=&M+FA'#U[5<=A9T*,*T:DJ\(.
M?+"A4;ZGQ5^U?^RQXGG^,7B[P;XKU?X5^.OC3!X!\;^.]5\;_ CPQ\<M7\1W
M%G\+M<\$_$7X/32:I!IVBVM_XA\;1:+\0F\5:=;Z+H6H7>J3WCRVE_HMM:S>
MB+^WG^SAJ=W:^*_%GB*?Q5X@_P"$(^!UKHNGZ[\(;&]D\%ZY\.OV6OC'\--?
MT.Z>XL)]*UZSF^,/B+POXGLIMESITMAJ,+F".'0C:P<]8_\ !.3X0^#O%"S:
MG>_$SQ'I&E:+\4=#U32OB?H5EX2T?QIKT?[(OB+X\>$_'?PIUG0+Q;O7O#/@
MK7[6TT[Q$]W'Y<EU#:M,(XKB2SJK_P .YO@/\.M:N])\7^*OBQ\4]5M?@=\9
M->'AWPSHMOI%QXB\:>!OA=X5\?:-X[^'.HV]M-IWB+PC.VOZAIUEX7FN]0U2
M>[TZPU._E?2[^2&V^5D^&*BC!5\UJ<L$Z5HJ565/V=&BZ2JN,9QA3IT<-'][
M6A&-.U-.G!UX0_08QX]IRE5>$X>H\]62Q'-.4</"O[7%8J.(>'C.=*=6K7Q.
M.J?N,+4G.O>M*-:I'"5:JZM^V1^RMXYN/#%SXHN8- UKPQ>^&]>T'Q#X<^"_
MAO1GM/%5]^S1;^&/B#<:U<Z-X<:\_LGQ#\<!=:EJ=[IMA>:U:[H==\,+II2&
M6V[CQ-^VW^QW=:!\3-&TC6 O@;6?B!\:/&LGPA'P(M+FQ^)EE\1?V>/"'@+P
MY86&L:F''PTU/2/BWI4_C34;NUG@DF33EU!KVZO9((9?D#]FKX%^$O$7P%\$
M>/=-_9KUC]K#QY\1_P!H/Q%\(?%7AO3_ !9XE\+M\*/".D>#M+US0[NWOO#5
MU;6'A/Q+XON]0U*]MO'?CY;OP?IMGH$]D+-Y5O&'IWPT_P"";'@OQYHWPI>^
M\>?$;0M5\<K\&O$NM^(XO#V@ZE\)I=!^,OQ5U+X:+\-_A_XUCNP_B;XM^ 19
M#6M>22'^S=1AM=5CALK.*TCNIM\1A>'L/4J0Q&(S*C#"5ZE&*5>G57/0FZU:
M4:$'/$T(QFG[.K5ITY3YU6P5[2J4^7!YAQIC:-"I@\%D6)JYAA*6)G*6$Q%"
M7LL92CA</"IBZT:6 Q4YTFG6H8>M5ITE3>&S5J].A7H?LE_M<_LE?L]>$;N&
MX^'OQ4T?4_BOXY\+>%_BUX:\.>.+?Q##%\'=#\%:SX=\17&MZ_XA\(6[>)M"
M\;ZOXTUK5[OX>:/:Z??:=<^&M#NX-?,HC2ORM\06>AZ=X@U_3_#&I2ZSX9L=
M;U:T\-ZQ/:2V$^J^'[>_N(M%U">QG)GLIKO35MIY;68F6"1VCD)92:_;#X4?
M\$[?V;]?\:_!G5=/\7?%;QIX=\5ZU\&=<U[P5XX\/^'M'@O_  )\6/$'Q-\!
MG2QJ7A367O\ _A*=/\2?#N?7(3;M!ITVE:E9:9YIO(+FX?A-'_X)K?#O6+W1
M-8_X2/\ :"MO#_C2Q^$%II7PVA^'6@3_ !T^'FL_%[Q_\1/ <?BKXH>&WOX[
M+3/A?X1E^'[>(-0U2!8+VZTKQ%H]NT]HV;V;NPN;Y%@\7C<1"OF*JXJ,9XCZ
MS"K-2G1J5(0A&%2:J0G1IPJ0C*4_9RH)Q=95%3A5\G'\-\79GEV5X2IA,E>'
MR^=2G@E@:F'HRA3Q-&C5K59U:-.5&I1Q5>M1K5(4Z:KPQ<HU(X5T)5JN'_'.
MO[>_^"('_)@/@?\ ['GXB?\ I\K^*3Q=H'_")^+?%?A3^U-/US_A%O$VO^&_
M[;TE_-TK6/["U6[TL:KILF6WV.H"U^U6K;FS#*GS-U/]K?\ P1 _Y,"\$?\
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M8;?(F^(OR]-_B/2VZ'C./#R].G;-=?8?\$V/V=M.*F"7QP=N,>9K>F-TQ_U
MAUQV]:_0*BLWQ+Q!+XLXQ[]:R_\ E1O'@7@Z'P\-91'TPK_^:#XLL?V#O@AI
M^WR)/%I"]GU/3&S]?^)*/SKL;+]D;X46 'V<^(./[][IKC Z<?V2/;OVKZBH
MK*6?YU+XLTQC]:J_^5F\>#^%H?#D&61],.__ )>SP.+]G'X>P@!#JWRX^]-I
MI.!U'_(+[^O7'%7X_@%X%BQM.IG P"7T[(.>O_(-_3I7MM%9O.<UEOF&*?K4
M7_R!O'A?AV/PY-@(V[46O_<IY%'\$_!D7W!J'7NVG'CKCG3?7OVK2M?A1X5M
M94E1+MBC!L,;)0V"#C=%8QR)GD;XY$D4'*.KA6'I=%92S/,9*TL;B&G?>IWW
MV@OS-XY#DL&G#+,'&UK6I=K-:.HUT6C37=/5..**."..&&-(HHD6...-0J1H
M@"JB*  JJH   P *DHHKAWU>K?4]9)))))))))*R26B22LDDDDDDDDK(****
M "BBB@ HHHH **** "BBB@ HHHH **** //_ (L:5+KOPL^)>B0>'](\6S:Q
M\/\ QEI4/A7Q!J\_A_0?$TNH>'=2M(_#^MZ];?Z3HFD:R\PT[4M7M_W^FV=S
M->1?O(5K^>[_ ()*^$#\/?VOOB+X/.D?"#P]/8?"G7&O/ /P&\3^"/C+X)^%
M<O\ PDOA?R=$U?XOQ:=XD^)5CK&M0GSK?PSXG^(T-O>KIMU<1>&Y3IRW-K_1
MQXC\/:+XN\/:]X4\2:?!J_AWQ/HVJ>'M?TJZW_9M3T76K&?3=5T^X\IXY/(O
M;&YGMI?+D1_+E;8ZMAA\B?LY_L-_#3]E'Q_XI\2_!#Q-XY\.^!/&/AG0O#NK
M_!S5]5MO%/@K3O\ A#Q-;>"+KPGJ>N6=UXS\.6_AC2;[5M&M]&C\27FD7EE?
MJ]U:-=6-I/'])E6:X?"9-GN7U9U%5S"E25""ISE1G.')%\]6->U*<8\SA?!S
M]HUR2Q="FW3GY>,P=2MCLOQ,(Q<,-.3J2YHJ<8RYFN6#IWG%NRE^_CR_$J-2
M24H_:E?QR?\ !P1_R>5X!_[-X\'?^I]\4J_L;K\!/^"NW_!,_P".'[6_Q-\!
M?&7X&/H&N:EI7@>T^'WB3PGK>M6GA^Y@MM*UW7M<TO6]+O-0\K3[N*9O$E]:
MZC;37=O<VYM;.6VCO$N)_LGH< X_!Y=Q)0Q&.Q%+"T)83&T?;5I<E*-2K2I^
MSC.=FH*3IRBI2M'FLFUS)GP7C%E&9YWP/B\'E."Q&88N&993BOJN%A[7$3HX
M?$UW6E3I*495'3C6A)PA>?)S2C&7))'\K/PB^$/C+XV^+I/!W@I=%@N;'0-=
M\7>(=>\4:S;^'?"7@_P?X8LS?^(?%GBO7[I9(=)T+2;;9Y]P(;BXFN)[:SL[
M6YN[F&!_55_9P_:/T;7_ !AX'^%5AJ?Q:L]7^&>G:_XOU?\ 9TUR[^(?@KQ-
M\*O$<JWMM'K]_P"'DMS<:/>7^EC[7X5\2Z=9ZD-1TU1/HIE@A:OT_P#@'_P2
MJ_X*!?!'Q7XEU2\^"G@+QYX/^('PZ\7?";XD>";WXM^&]!;Q+X#\:PVBZM9:
M?XAL+ZYO/#^LVEYIVFZKI.KPVMXEM?6$2W-E=VLDT#_4'P[_ &(_VPOA?<ZE
MI'A#]B'X:Z)\.K7Q-\'/B-X-\+:'^TW'HOB2W^*GP0@\11>&/&_Q&\=6F;OX
MCC7V\3W[>,-#_LGPU9:E';:7'82:8UF9)?U_'<5X*%:JL)F62XJBJ5%T85,9
M@E3G4O>JZM2=>G756G5C3=&E3I>QE3O7E7C5HQIS_FO*O#O-*N&PSS'(^*L!
MBI8C$QQ5:CE>:NM2HVY</##T:6$JX25"O0G6^M8BMB/K,*_+A:>#J8?$U*U+
M\2/"?PZ_X*$1>$=,UGP)X5_:NB\#^(_ $?A[1[[PJ?'T'A_6?AAIEEJNL6V@
MV1TZ[CMI_!]G8W&N7=AI(1;!$GU6.SMS)+=1-U^J?!K]OC0I/@YH-UX@^,;>
M$OBCH7PTTKX9>*-*\4_$76OAXEIXY\#ZU?>#/!$5[H]G?7-MJFG>#_$/B;19
M_"VF:/?/IEMJGB+1+&*YM[C44?\ <+0?@#_P4KTG4_"&KW?[./@B\N_#FL_
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M!JMQJ!\_4;KQ"UIJM_%*LUUJ&IO::E.L<KVUT8_Z,/#/[-__  40\,ZC\/\
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M!AE[TE*$8*7]E6<I*$U%1G*4^63@YM.:TCDN22:G&BF[NK=9EF;VE&HY<O\
M;EN52<6[P45=1E&,7R.G;?#^>V-B3X^^(5S]B_X0O<+G6[&07O\ PAPN1+]M
M"Z0@E_X3 W(/C/R_*_M4V]M]D_LX(P>K_P *WN/LGV3_ (6/\2\_V6=-^U_V
M_I_VL,?$_P#PDO\ :7F_V+M_M,1_\4V+@QF+_A&/^)?Y'VC-[7&_$/\ :D^
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M,-6\2PJZ/?ZO##=6\MG$IMV_@ _X;:_:\W;/^&J/V@=V<;?^%S_$+=GTV_\
M"1YS[8S3A^VO^U^20/VI?V@R5QD#XR_$/(SR,C_A(\C(Y&>M3_Q+GQ9R\O\
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M4/%2(T;ZEJ,,$]O)8QH86_@$_P"&U?VP?^CI/VA/_#R?$3_YHJ/^&U?VP?\
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MQ#K9ZCGKJ%:\?Q&\<E@#XL\2$>^OZT>X];^N.?AQQ'!W?$&6MIWTRN&]T^N
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MHRBXK]ER6APOG^74,RRRFZ^%KQM;Z_FZJT*D8Q53#XBG_;;E2KT6^6I"3O\
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MV_E;I:V@O^(H^$EK<V<6M;_<N)=K<N_^L-]M+WOUO?4_JLNOA_/<QWB+X_\
MB%;&\@\70B2VUNR1[0^*[R"[AGLRVDN(IO"@@-IX39@XTZTFGBN5OF<.ME_
M\[W<ET/&_CI ^J7NI_95U>S%JBWGAM?#HTU(SI98:99R*?$-G;ER\7B)FOFF
MD@Q:#^4D?\'#?[3;?=^#WP%;'7&G?$ XSG'3XA]\'\CZ4O\ Q$,_M._]$<^
M_P#X+/B#_P#/"I?ZE<=6MR8"UK?[SE&UK;_V7?;K>_6]]2O^(J>$U^;GSB]^
M:_U'B/?FYKV_U@M\6MK6Z6Y?=/ZKK7P#/;-9L?'GQ N?L;^$'*W.M6;K=_\
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M%Y[?X3_X)@?!'P?=^*=7\-_'._EUB_\ %'PP\5:!JFLG1O$:^'-5M_B-X?\
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M2Q\20:)XGDSX?\R^N],O],?3=3^4/^&!OVU>!_PRI\?<#D#_ (5-XXX/J/\
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M\OI4)8]U>&XPJ3PE++XTZ-2,%-QKU8U'**@Y?(]%?7'_  P/^VM_T:K\?O\
MPT_CC_Y1T?\ # _[:W_1JOQ^_P##3^./_E'7N_ZQ\.?]%%P__P"'[)/_ )\'
MRG^I7&O_ $1G&'_B)<4__0V?(]%?7'_# _[:W_1JOQ^_\-/XX_\ E'1_PP/^
MVM_T:K\?O_#3^./_ )1T?ZQ\.?\ 11</_P#A^R3_ .? ?ZE<:_\ 1&<8?^(E
MQ3_]#9\CT5]<?\,#_MK?]&J_'[_PT_CC_P"4='_# _[:W_1JOQ^_\-/XX_\
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MY\&>,/%W@V\N8+R\\(>*?$'A:ZO+;/V:[N/#^K7>DS75ODDB&X>T::,$DA'
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M6]G6_L>DG&FHU*DJU2GAL*J5#$5/K=J%51_37_B(@^*W_1MOP]_\+?Q)T_\
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M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_*7_ (+3,R_\$_\
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M["WB:\B$4NO6&DS7!5FMHKB(&0?J]_Q#Y_M'[43_ (7E\'_+CA:WCC^V>/\
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M-MX8I(I9I[ZV>6UBBBEBDDDE5$D1B&'PG^S5^U1\"?%/B/P/\%/AS\ ?C?\
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M5]'KB)351?2-\+547+::X^S/G7+-U(^]_;G-[M1N:U:4VY6;<N;^7&7]K?\
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M,>KZ+^T&N@ZO'X5U729;FT\'+ITOB6#Q-J2KH6D-%J^G)8JTEW7>Z+_P5/\
MV?\ 7-+U'5;3PI\66@\/:#\1_$?BP0>&]#OE\-:=\-M3\(:+>^?=V/B>XL-6
ME\2ZOX_\':;X1;0+O5+36+G6HRUU:VUM<W,;W_X*E_L_V_BW3/AWJ7AOXFZ)
M\1K_ ,0^*?"5YX*UK0]%M]6T'Q'X<\47'@:VL=7>S\0W]M);>(?&5K/HNEZC
MHDFLVMM#$^M:TVEZ,!>GW,ORK-,'B*DZ^0U\;&-*2E1FJ2]G*$H5X597=>U.
M+H6J_NTIX>=2"J4W5A*7!B<9A*].,:>84Z#<U:I'G?,FG3E!64/>?M+P]Y\M
M2,9.$E"27SO>?\%$?VD;>VGM=<^'GPV\(V?B@Z9J6A_$>\\/?$^X\)?"WPM>
M?%/X]?#*2X^)-DDTE_K.M:K<_";PPWA^?1I=$TRUU/Q_IJZI;7-A';2W_DW[
M/?\ P4._:?TQOA?8_$_PY+XST;QOX\^&WA/7]9U/PQJ4OQ#DO/$_PD^!6JR6
M?@WP+I,'@>:2QNO$?C;Q+J&L:U8:7XRN/#=S'(-7\+Z9H<%]J.D_:?@;_@IQ
MX!\7^%;:35_AMXV\ _$2Z_9TL/C]%X4\53:);Z/<PZSX4'B?1?#_ (?UYM1M
M;[QK'>+-9V<VM^$]!U.PTVYN1::P=,O4:W'&_$;]M?\ :N^$/BWX[67C?X/_
M  +U'PU\$/AS\+/B1>VW@_QYX_O_ !KKEG\8_'&K^"?"F@Z?IVI>#+#0SKFF
MWGAW5I->#:NNGL9]+32KR\$MTUO[=.@FL1@Y\*Y?1JRUY:V80HSJ6;PT)82I
M)5W.U:M05Z5>-%S2J.+G4GR<,JFM.O'-\34@M+T\-*<8Z*JU6BG34?<A4^.F
MYV;BFHQCS>)ZU_P4)_:2F/@CQKI?AGPWJ<MA9?%J]\:_"/P9X6^(;-X(N[/P
MUI(TWPQ\;=7U[PW<>;KGPCO)[_Q9XK;X<:Y876LZ3IVHVTN@:,LNCW%_VEI_
MP4C^/%IXF^'UCJ7P5T'Q1X>\6Z9\5K/0KKX>Z3XMU37OC!KO@35_'^G>%?%G
M@'P[=ZL->\(?"OX@V/A71M7T;Q-J&B_$*SM(M7N8-;U?1K8:-JFL^[WW_!5;
M]F/2O$%GX4UFV^(FD>)1'XNMO$NB7WAS3_[1\%>(?"6O>/?#,WACQ%;6NN74
MDFHZGK/PU\4VUC>Z$-9T.V1-)N=9U32[?6+20V==_P""H'P)\*IH[>*?"'Q5
MT.77?@WJ7QLT^PET7POJ.L+X=L/!<OQ$@T74M'T;Q?J.H:)XGU;P9&NKZ5IV
MM0:?;WLDJV,5ZTZR;,7AZDE"#X*OSPJJC^^G3E*$E.2=-TZD7-4W4@XU5[5N
MCR5'-U*D*BM5(IRDL]V<.?W(R2DK)J2E%\KFHRO!\B4^:*BHQE%_"?C#_@I;
M^U-XI^!=EJVG>#/"7PE\0^(8/$SZ1X_L_#?C+7X/%>K>']?^$%LGP]^'&C3Q
MZ_9:?\0+:T\=^+%UF7Q)<>)-+GL_ FM7%GI]A<'4H_#/]!]?GDG_  4M^ \5
MPECJGAOXJZ)J&E:[J>C?$6QU'PG8^?\ ">VL/B-H7PGMM=\;_9-=NE?2=8\<
M^)]"TO3/^$7;Q'J#VUS>:C=6-K::9>.GDOQ!_P""K'@_3O!D7B?X;?";QGXB
MD_X2'XO>&=:A\6W&C^&+[P7=_"OX4^+?B;-J/BKPE;:CJOC"QM;^'PK/9S:3
MJ&F:/X@M[87%];6%ZHLX[SBQV6X[,'0I8+AO^S%&M7DW&K!PJ?6'#V4)UJM6
MZC"-)NDI3E"2FI4(\E2#J[T,5A\-[2=?,_K3<*:2<)*4?9\W.XTX0M>3FE.T
M5).-JCYHM0_6>BOSQU+_ (*._"S0_AK>?%75/A[\7YO MOK]EX5TWQKIWA*S
M_P"$,\4:TFN:CX4\2W.DZ]J&N6<&B>'O"WBK1]1T?5=>\<CPKIZN+&XBGEMK
MZ*8?>OAW7;'Q1X?T/Q+I;;]-\0:1INM6#>=:7!-GJEG#>VV9["YO;&9O)G0-
M)9WEU:NP+6]S/$4E;YW$X#&8.,9XG#U*,)5*E&,I\G*ZM*,)5*=XU)VG"-2#
MG"2A*/,E**E>,?3I8BA6;C2JQG*,8S:5[J$W)1EK&-XR<9*+5T[-IM6;V#T/
ML,_E2TC=#]#_ "I:XS8**** "O\ .JUOP!\1/C=^T1X\\(^"-+NO&/CG7_&/
MQ U@6MQJNEZ?-=QZ9=ZMKNOZG?:OXAU#3=,MX[6R@O=2OKN_U"!-B32L[.3G
M_15K_/;\$?&*U^ _[4/COXCW?AVW\5QVC?&KPW%H5[;V%[IMW>>--!\2^%K*
M35].U..:PU31K6ZU2*XU;2KJ-XM2L(Y[-A^^K^G_ *-\\92I>(5;+J%/$9C3
MRK)W@J-6RA5Q'UK,72I3DYTVJ<YZS7M:<7R)N2M<_@[Z;5/+<1B/!S#9WBJV
M#R6MGW$JS3$4+NKA\']1R:->O2@J==.M"DN6FUAZLE[1QC%WL>&_$CX3_$;X
M1>);CPC\1?">H^'->MM-TK66MS)9:Q8W&C:Y;1W>C:OI^N:!=:IH6IZ7J<$L
M;66H:=J5U:3L3$DIE1D' M#.AN ]O<H;/B\5K>=6L\R"$?;%,8-KF5EB'GB/
M,A"#YN*_1;P/_P %#/%.E6?@W_A/_"6G^,IO#GQL\&^/+_P]I-AH'A#P%/\
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M"U)*7MHXEN4YX*+MA]<5%T8U)TZ_H-%%%?D)_204444 %%%% !1110 4444
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MBHJ?^(9B/_H8%_Q*MX0?]&=S_P#\2S,__GZ?A=_Q#J:G_P!'9Z?_ .&4N?\
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ME"WN#J$DMTB6OD2^:5,;8_1C0_VO?@#IGAWXJ77A[XH_&OP+XDL_@]I_P=^
M?A74O!U]XT\#:9I6J_#S6]'^)?BWQ3I6E>,_"VCWGQ0\8:MXI\1^&-,\7ZU8
M:SIGAW2M5U3Q3'H-YJ=S9067QI\#_CSHOPZ_9^_:%^$NMZCXN2]^*6O_ +.M
M[X:L=+NKV30H=*^&WQ$U+Q+X\M=0"WT$5I_:NA7HM8X8[9X]:E:2UO@(CN/9
M2SKBG$4,=4ADE/#5</F>3T,/0Q='-HSK8#'3_P"%&MI7C"K5RVC.E4E7PU5X
M-U5BL/.C_L\:^(VAC<TJ4Z\HX&-*=/$X.G3A6AC%*="N_P#:)Z5%&<\-"4).
M=.?L7-5:<H?NU4J?+XTO6F\/#Q<MAJ+>%#J[>'QXE$$YT(ZZEDNHMHPU0#[&
M=473W2^:Q\[[0+1EN#'Y1#5T&D^ /B'KT&@W6A^"_&&LVOBH^(U\,7.EZ#JU
M_!XB;P?9C4?%PT.6UMI4U0^%]/9;_P 0BR:8Z19L+B^\B(AJ_6"P_;0_9"U7
MXF^/O$WBWX>3VWAIOV@OB3X^^$FEZ+\)?!L>B^&?AU>_"Q/"?PTT+5O#$ M[
M,)I/B,W=]J-I9Q3:M#-/'J<>IM,'>/)\3?MJ_LUP?%WP%XB^''ACQ1X4^&G@
MKXD?MM^)],\,Z=X7L](BT3PY^T5\/K'P[X$TS1]'MM1EMK4V>M1W9UVR@G^S
MZ9:L)+:6Y1E4<_\ K1Q+.4J5/@S,Z518:>*57$55/"W>$=:E@54H5(U*F,C7
ME3P]:<80P_-&O&G%2A2J5,O[5S.3<(Y+BH2]DZO-4FG2UH\\*'-3DI2K*HXT
MYR2C3NJBBDU"4OR8\/Z/KWBR]ETWPMIFJ>(]1ATW4]9FL=$MKC4[N+2-$L)]
M4UC5)(+199$T_2M,MKG4-0NV406EE;S7,[I%&[B6XT#Q+::&WB:[T76[3PZF
MJ0Z(^N7=A>VNE)K-SIR:Q;Z4][/%' FH7&D21ZI!:,XFFT]TO(T:W=9#^L-Y
M^V;^REJ&K^(+N3X6V-C::7+\4M+^&9T3X3>$]"N=-\*^,OV4$^&NCV.M2Z6+
M275)T^.D8\8W<VL/J<]M%+/KD,OFSRV;=SJ7[<W[)GC3X@-XY^(NA>)O$E]<
M^)O#WBZPFNOA3X6GC\/76A_LS:9\+[+0=7L6N7M==TW3/B-8W6L)>:="E[)8
MW-G?6;6LEJ$A53BKB2,U)<%9M[%4HU)Q5>%7$<[BYNC3]FXT)-QG24IS]FJ%
M2%>GR8MQ@V2S7,E*_P#8F,]GRJ32J1E4YK<SA'E:IMVE%.4N7V<E4CRUFHM_
MC/I'A[Q/X@6XDT+0]=UF.TT[5M7N9=,T^^O8H-*T&V2]UW4I)8(GC%EHMG)'
M=ZK<;S'I]O)'-=-$DB,W/_:UV[_M*[,E=WG#;N R1NW8R!R1G('-?MSXF_;K
M_9 U6XU#1[7X>ZS)\(-%\?\ [5NN^$O@W#\.]"T#3KKPY\<O#O@D>$[:VUK3
M;U[CPO/IVLZ-XGTO5+59;I=.AUBTU.QGN8;."*'@O%7[9'[*UC+XHU;P#\-]
M)OO&=UX:UBP\(>*M7^ 7PWT/3M!L-6^/'@OQIX5\#MX.B?6-"N+OX7_"32?$
MW@F#X@7%M)J&NSZLME'OLU2ZJL/Q5Q%5DE5X(SFE[10=)/$T(1I<[@N3%U9\
MT(SIQJQGB'1ISI4U"I##RQLXU(T'3S7,9NTLCQL.;E<+U::4.;ETK3E=*4%-
M2J>SC*$4I*FZ\E)0_(@2N1D2.0>00YP1Z]:/,D_YZ/\ ]]-_C7J7QU\1>!/%
M_P :OBSXL^%^B_\ ".?#?Q-\0O%6O>!?#_\ 9\>E?V+X7U75KB\TG3!I<,DL
M.FK:6TRQ)8PRR0VB*L$3>6B@>55]IAZU2OA\/6G2K8:=:A0K3PU9KVV'G6HT
M:L\/6Y).'M:$ZDJ%7D;C[2C4Y6X\K?MTYRG3ISE&=.4Z=.<J<VN>G*<(3E3G
MRMKGIN3A*S:YH2L[6'^9)_ST?_OIO\:/,D_YZ/\ ]]-_C3**VN^[^]_YEW?=
M_>_\Q_F2?\]'_P"^F_QH\R3_ )Z/_P!]-_C3**+ON_O?^87?=_>_\Q_F2?\
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MFU443V*6?SX8FLYIU_J\L+>*FZ*Q"DJZ]BZ3HO2HJB?*XWC:W-SQY;GY'_\
M$-=^U]_T6C]F[_P>_$__ .=91_Q#7?M??]%H_9N_\'OQ/_\ G65XG_Q%!_ML
M?]$C_9X_\$7CG_YNJ/\ B*#_ &V/^B1_L\?^"+QS_P#-U7]%_P"M/T@/^?W"
M?_A'E'_R9U?\1VQ?_0;3_P##'#_Y>>V?\0UW[7W_ $6C]F[_ ,'OQ/\ _G64
M?\0UW[7W_1:/V;O_  >_$_\ ^=97B?\ Q%!?ML?]$C_9W_\ !#XY_'_F>O\
M]7O1_P 10?[;'_1(_P!GC_P1>.?_ )NJ/]:?I ?\_N$__"/*/_DP_P"([8O_
M *#:?_ACA_\ +SVS_B&N_:^_Z+1^S=_X/?B?_P#.LH_XAKOVOO\ HM'[-W_@
M]^)__P ZRO$_^(H+]MC_ *)'^SQ_X(O'/_S=>G^/M2?\107[;'_1(_V=_P#P
M0^.?Q_YGK_\ 5[T?ZT_2 _Y_<)_^$>4?_)A_Q';%_P#0;3_\,</_ )>>V_\
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M?_HZ6X_\--\#?_G:4?Z[^.W_ $,?#W_PT8K_ .3#_B8G,_\ GQ3_ /#7A_\
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MM*/]=_';_H8^'O\ X9\5_P#)A_Q,3F?_ #XI_P#AKP__ ,\C[A_XASOV_?\
MH(? OI_T435>O''_ ")_;G\J/^(<W]OS_H(_ L=?^:AZK^'_ #)_?^E?#W_#
M^7_@JO\ ]'2W'_AIO@;_ /.TH_X?R_\ !5?_ *.EN/\ PTWP-_\ G:4?Z[^.
M_P#T,?#W_P ,^*_^3#_B8G,_^?%/_P ->'_^>)]P?\0YW[?O_00^!?\ X<35
M?_F/H_XASOV_?^@A\"__  XFJ_\ S'U\/_\ #^7_ (*K_P#1TMQ_X:;X&_\
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MXN,W/VWM-9<]_>A5A*].K2G&%2C4A*E.G!P40HHHKSSJ"BBB@ HHHH ****
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M#WXF'X0ZKI/A6]\4>,+WXJZ/!X,\6?\ "1^-]%F\/W46M?"'Q*FE6^B/XO\
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MQ3U<ELDU?SS_ (+*?\HQ/VP_^R96W_J7^&:_A^_X)V:-^RMI_P */VE_BO\
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MM3T^O8=2ER9;"%-TY05/F<_BE*3YISP\Y.,N;WN1TZJ<*;IUJ<5.$OU\N/\
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M!7GD]."Y5.\IXR*Y'+D4[RH17(Y/E4K\KE[J?-[I_J9?\-R?L4_]'@_LM_\
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M/_1X/[+?_B0/PF_^:VC_ (;D_8I_Z/!_9;_\2!^$W_S6U_E%+J5F[%4O[9V
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MOGG",DN.\9)7CEF':O:ZKXEJ_+*5KJFU?EC*5KWY8RE:T6U_J8?\-R?L4_\
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M Q_M<?LQR ]"GQ[^%3 _3;XK.:_RA!?VS+&XO8"LTABB87,96653@QQD/AY
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MPDL5EN+K9BZ+<J]"I0ITZOLDKN=%492]I*%FY4VN:4;N%Y+EE^C<%^.%#/\
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M6[7S_%&&K8K)<53H14YQE0K.+E&-X4:O-4:<FE=1=TKINS2ULG_!'17Z:?\
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MO]!T\:=I%CINH-\B_P##NH<?\7A/.W_FGX[Y_P"IV[8I?^'=(SC_ (7">_\
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M/V:O^"@7[*7@:#P-J_QX^%/B?QWXWTWX9OX-^)&HVOPI^%.OZ1\0+S5OBO\
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4.G%SJ3G4FU"$4Y3G*4GJWLE__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #4 CP# 2(  A$! Q$!_\0
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M0$LTM$TV-84D,B!78%6(P<,#D#'& <8K3M=/M+*2:2V@6-YMOF$?Q;5"KGZ
M 4FX6T0)2ZEFBBBLBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *;*XBB>0@D*I8@>U.HH Y31M3US4+;3M6
MDN=/%E?/S:LI1HT.=NU\G<W'(P.]+_PG-F%OBUI./LL#7& Z,756VGH3@Y(X
M-:%OX4T>VO4N8[=\Q.TD432L8XG/5E0G /)Z#O4<?@[1HH)(5@E\MX&MMIF<
MA8RP8J,G@9':M^:FWJ=;E1;NU^A$?%T:^=$^FW:WJ7$=NML2FYVD4LISG &
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MGM4@:&!7$4&TLI3)<G -,AN!%F.0%H6.2!U4^H]_YUC//:;Q"Y=8-:Z;/O\
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MUSS1M%W-6/I4P-5HLD=#5A4;OQ7,S5#P:<!2  &G5 PHHHI %)12T#"BBB@
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M>->.M"M=.OS<65S&TF_B-'!D5L="!R/J>@Z5WFL>(KB:_&CZ0L\=V9A&]T8
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M1110 4AZTM(>M "T444 %%%% !VHH[44 %%%% !1110 4444 %%%% !1110
M48S110 4444 4=2TBRU6$QW4(8]F Y%>=ZU\-98F,VGMO4= O# >GY#'XFO4
MJ*UA6E#85M;H\/CBUC2I-CA^#SD8]?P_O5OV/B&52!,A'KQ_GWKTN>TM[E2)
MH4<'U%9DWAG39266(H3W'X_XUT?6(O=$N*>Z,JSUF*4#..??Z5JP74#@$*O/
MM3%\-6Z-E'_,59BTA(\?,./:LI2B]@44B9)TQQ@5()L]*$LU4#FI1"HK%M%#
M 2U2*I[TX #H*6E<88HHHI %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0]:6D/6@!:*** "BBB
M@ [44=J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*0]:6D/6@!:*** "BBB@ I,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T4
M4 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:
M,T44 &:,T44  -+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
H !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %&*** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" "J ;T# 2(  A$! Q$!_\0
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MVFC8?6F05/L5O_SQ3\J%LK?</W*=?2K>VE5#N% 'HNCDG2K?)Z(!5ZJ.C_\
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M#!J>(E )C&%;UI+/3TMAOE(51WJOI(>--^<$#.:T+.U744M&E9FG+.SJ3PZ
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M5/E\7Z=H.'NX[UQ-PODV[/T]<=.M1_\ "U="_P"??5?_  !>J0A?^%2>#?\
MH##_ ,")?_BJ/^%2>#?^@,/_  (E_P#BJ3_A:NA?\^^J_P#@"]'_  M70O\
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MX_XTT([2BN+_ .%FVG_0O>)?_!<?\:/^%FVG_0O>)?\ P7'_ !I@=I17%_\
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M]WTQ1NJ'?GFC?GO0!,3E>!W';W%;=<^&R1]1Q^-=!30@HHHI@%%%% !1110
M4444 %%%% !124M !129HS0 M%)3'GBBQYDB)GIN8"@+7)**0$$9'(-+0 45
M0UC6[#0+!KW5+@6]LK!2Y4GD]. ":Y__ (6MX-_Z#<?_ 'YE_P#B: .OHKD/
M^%K>#?\ H-Q_]^9?_B:/^%K>#?\ H-Q_]^9?_B: .OHKD/\ A:W@W_H-Q_\
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M/?WM1_\  V3_ !H Z[[);_\ /"+_ +X%<1&0 PP.';C;[FK/_"J/#W][4?\
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ME64\ADDMT9FY)H$U<\V\J7_GF_Y58AEGB'^K<_A7??V+I_\ S[)^M']BZ?\
M\^R?K3N)1L<0;N5N6A8D>JU7<RNP C? /0#I7?\ ]BZ?_P ^R?K1_8NG_P#/
MLGZTW)M6*;DU9L71O^05!_NU>ID4:1($C4*J] *?4@%%%% !1110 5Y5Y<OF
M2[8WQYC\X_VC7JM4GT>Q=BS6R$DY)H \W\J7_GF__?-'E2_\\W_*O1O[$T__
M )]4_6C^Q-/_ .?5/UI6 \X\J4G_ %3G\*7RI?\ GFX_"O1O[%T__GV3]:/[
M%T__ )]D_6BP'G/E2_\ /-_RH\J7^XWY5Z-_8NG_ //LGZT?V)I__/JGZT6
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $  @H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *8\L<>-\BKGIN.,T^L_5]%L=;M/L]["'
M.4<?>0^H-.-KZB=^AA^*/$ T_4=*2"?Y%E\ZXV-_RS^[@_\ ?3'_ (#73BY@
M) $\9S_MBO&+NWALKZXME>-UCE:,.%"[\''3Z\5V?@KPYITEK%J\J)+<!V")
ML 6$@D=.[=\^_%>A6P\(4U*_X;WU*E#E2DGO_7Y'<T445YP@HHHH **** "B
MBB@ HHHH **** "N _X6?;R:A=006!>*WG\LL9</(GR#<JXZEGX4]E)KOZB:
MUMWE65H(FD5MX<H"0V,9SZXXH XT_$ C0EOC90^<9VC,?VCY=JQ>:2&QR=OR
M@8^]Q4/_  L@^9M&FC&[>,S8/E[BNTC'^MR,[/3O79?V5I^5/V&W^48 \H8'
MS;NGUY^M2?8;0DG[+!DR>;GRQ]_^]]??K0!/1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 445#=W*6=G/<N"5B1G('? SBA:@345!9W*7ME!=("%FC5P#U&1G!J>AJP!1
M110 4444 %%%% !1110 4444 %(X8HP4[6(X)&<&EKD]?\-7NIZM/=6RV:![
M*2WW2DMO9L;2RXQ\I&0<GZ=Z -72O#>GZ79/;^6+AY5VSRS %I?7/M[5)I&B
MQ:+]JCMI7-O-)YB1/SY9P 0#UQP.M8MCX:N='UR2:QA@?3W@CMC%))N8H BY
MY7Y0 K$C)W%NU9LW@6^&GV,%G+:VURB3-/<HS#YY%;<JJ!]W+#'(QMZ'BK=2
M3O=[BY4COZ*RO#NFSZ5HT=K<&/>))'"1DE(E9RP12>2%! _"M6H&%%%% !11
M10 4444 %%%5=3O1IVF7-Z4W^1&S[=V-V!TS0!:HK'\.:Q/K>G/<W%G]D=92
M@B+[B%P",\<'!&1V-;% !117 3?\):-4D:U%^]N+HF&.?8H8$ '<P/"*=Q'!
M!SB@#OZ*\\\[Q=_8<=L$U#[9YS2;]J;]NS"ACTQYW4==E-(\<^:?^/C_ %_.
M-F/-W'I_TPVX]\T >BT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 17'G_ &>3[-Y?G[?D
M\W.W/OCG%<U->ZA?*;.\^SPLK*TT(1MQ (/!)P5)'7^M=57.WL=WJ&O2QV\9
M18(UB\^1?D3=\S8_O'A..G'/H=J35]27NKE>&]U"Q'V2S^SS,[L\4)1BX!))
MR<X"@GJ?YUTMMY_V:/[5Y?G[?G\K.W/MGG%85I'=Z=K\*7$9=9XVB^T1K\K8
M^9=P_A/WO8YX]!T5%5J^@+=V"BBBL2@HHHH **** "BBB@ HHHH *\_^*5_>
M6%IIS6=W/;EG<,8I"F>!UQ7H%>;_ !=_X\M,_P"NDG\EK:C_ !$<V*=J3L>=
M_P#"1:W_ -!>_P#_  )?_&MGPIKFK7'BK38IM3O)(WG4,CSL01GN":Y2MSP=
M_P C?I?_ %\+_.O0E%<KT/&ISESK7JCZ"HHHKR3Z(**** "BBB@ HHHH *R?
M%%O#=>%]3AG6 H;=S^_3<@(&02,'H<'H:UJQO%D<TGAB_P#(E\N1(B^26P0.
MH(7DY&>* ,SX=>1_PBP%N1M\YB1D94D X.(TY_#\:ZRN-^&8ME\*-':*4A2Y
M=1&5(V=,CEB>M=E0 445375]->01KJ%J7:0Q!1,N2XZKUZ^U %RBJ?\ :VG?
M95NOM]K]G9_+$OFKM+9QC.<9]J#JVG!BIO[4,)?((\U>)/[G7[WM0!<HHHH
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M1]!4445Y!](%%%% !1110 4444 %8/C"&YN- :*UOX;)VEC#22W!@#+NY3>
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M9[\8/F=.: /1:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO_UR7^5?-(^\/K7TM9?\>-O_ -<E_E48K9&F7[R^1/1117$>J%%%% 'GE_\
M\A"X_P"NC?SJO5B__P"0A<?]=&_G5>O46Q\]+=G7>%O^/"7_ *Z?T%;M87A;
M_CPE_P"NG]!6[7GU?C9[6'_A1"BBBLS<*Y;Q7_K[?_=/\ZZFN6\5_P"OM_\
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MK;8,Y+N$Z8SP<=,C\ZNW=I!?6DEK<H)(9!AU)ZBLJ?PCHES?B]EL5,XZ$,P
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M2!/,+[)!&?E7+#DCJ*YH>./$2Z*;^6VLXXI'412S)Y8;[Y95!?Y\!5YRN<G
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M>H;;4O#$-]-8MIMO;2PW/DJ%MLC[R!6) PH+% ,]P*ICQ+X>_LE=032(1*8
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E8:,LXL8?+\]_,D^8G<<8[^PK0J)2UT>@TNX4445!04444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $" 7@# 2(  A$! Q$!_\0
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MPG_Q-<Q11[.'9!S/N=/_ ,+%\7_]!ZX_[X3_ .)H_P"%B^+_ /H/7'_?"?\
MQ-<Q11[.'9!S/N=/_P +%\7_ /0>N/\ OA/_ (FC_A8OB_\ Z#UQ_P!\)_\
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M  KKPA_T +/_ +Y/^-=/11[2?=ARQ[',?\*Z\(?] "S_ .^3_C1_PKKPA_T
M+/\ [Y/^-=/11[2?=ARQ[',?\*Z\(?\ 0 L_^^3_ (T?\*Z\(?\ 0 L_^^3_
M (UT]%'M)]V'+'L<Q_PKKPA_T +/_OD_XT?\*Z\(?] "S_[Y/^-=/11[2?=A
MRQ[',?\ "NO"'_0 L_\ OD_XT?\ "NO"'_0 L_\ OD_XUT]%'M)]V'+'L<Q_
MPKKPA_T +/\ [Y/^-'_"NO"'_0 L_P#OD_XUT]%'M)]V'+'L<Q_PKKPA_P!
M"S_[Y/\ C1_PKKPA_P! "S_[Y/\ C73T4>TGW8<L>QS'_"NO"'_0 L_^^3_C
M1_PKKPA_T +/_OD_XUT]%'M)]V'+'L<Q_P *Z\(?] "S_P"^3_C1_P *Z\(?
M] "S_P"^3_C73T4>TGW8<L>QS'_"NO"'_0 L_P#OD_XT?\*Z\(?] "S_ .^3
M_C73T4>TGW8<L>QAZ;X.\.:1>+=V&CVL%PHPLBIDK],]*W***EMO<:26QEW'
MAO1+N=I[C2K225^6=HAD_6HO^$2\/?\ 0&LO^_(K9HI\TNY/LX=D8W_")>'O
M^@-9?]^11_PB7A[_ * UE_WY%;-%'-+N'LX=E]QC?\(EX>_Z UE_WY%'_")>
M'O\ H#67_?D5LT4<TNX>SAV7W&-_PB7A[_H#67_?D4?\(EX>_P"@-9?]^16S
M11S2[A[.'9?<8W_")>'O^@-9?]^11_PB7A[_ * UE_WY%;-%'-+N'LX=E]QC
M?\(EX>_Z UE_WY%'_")>'O\ H#67_?D5LT4<TNX>SAV7W&-_PB7A[_H#67_?
MD5+;>&]$L[A9[?2K2*5.5=8@"/I6I11S2[A[.'9!1114EA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.!T/OC%/\.F4V$HDGGG"RD(\ZL&*[1S\P!.3D^V<=J ->BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\8^.?_'YHO\ USE_
MFM>SUXQ\<_\ C\T7_KG+_-:Z,-_%1E5^!GDE%%%>N<9ZC\$/^1AU+_KT_P#9
MQ7N->'?!#_D8=2_Z]/\ V<5[C7DXK^(SLI?"%%%%<QJ%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!B^)]O]E*7D"A95;849Q)C)V[5()Z9_"IM!
M,?V&18UA3;*0RQ1L@!P#T/L0<^A%5O$QD:T2#[))<12MABD8/E_[1)=<>G!J
M7PU'Y6F,GE! )3@\;FX')P[<_4] * -BBBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *\8^.?_'YHO_7.7^:U[/7C'QS_ ./S
M1?\ KG+_ #6NC#?Q495?@9Y)1117KG&>H_!#_D8=2_Z]/_9Q7N->'?!#_D8=
M2_Z]/_9Q7N->3BOXC.RE\(4445S&H4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% '/>*7@GMA9S02RJJFYEV!2%C7@DACS][@>V>U:&C:9_95H\/F
M(Y>0R'RXA&HX X4=.F3[DU2U^.Q>ZMQ>Z;>W*R*T7F6V\@ ]58*0<''?TK0T
MI8%M"+:*YCCW'BX+[L\?WR3B@"]1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %>,?'/_ (_-%_ZYR_S6O9Z\8^.?_'YHO_7.
M7^:UT8;^*C*K\#/)****]<XSU'X(?\C#J7_7I_[.*]QKP[X(?\C#J7_7I_[.
M*]QKR<5_$9V4OA"BBBN8U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH H:O8R:A9"&-DRLBN4D!*2 '[K8[?X#K2:/8/I]K)'(8@9)6D$<((CC!Q
M\JY[<9^I-5O$TZVVE+,6E1TE5HVC<)A@#U)! '4=#Z5+H5Y]LLY&,LDI24KO
M=E.> >"H QS^!R.U &I1110 4444 %%%% !1110 4444 %%%% !1110 5E^(
M=<MO#>BSZK=QRR0PE0RQ %CN8*,9(]:U*XSXJ_\ ).M2_P!Z+_T8M7!*4DF3
M)V39C_\ "[/#W_/AJ?\ WQ'_ /%T?\+L\/?\^&I_]\1__%UX117I?5:9R^VD
M?0>E_%S0]6U6UT^"RU!9;F58D9T3:"QP,X;I7?U\M>"_^1VT3_K]B_\ 0A7U
M+7'B*<:;2B;TI.2U"BBBN8U"O&/CH0+S1<G'[N7^:U[/7">/=5TS2[VU.HS)
M'YL+!=Z$Y4$;@, YZCY3@-W(Q6]!VJ)F=17B?.^0>XXHW#U%=WJ.HZ)J-AHR
M1W,#+I^R::-HBI>-4C#)C& Q8-\H)!Y.>:O-XDT/SY3)>PRRXS/,(&Q<Q;IC
MY(^7J \0YP/EZ_+7I^T?8Y>5=RS\#R#XAU+!_P"77_V<5[C7F_PXU33;_4)8
M[.1)&2WW(JQE3;Q;85\LG R=ZN>,CG.>:](KS<0[U+G535HA1117.:!1110
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MZ]/_ &<5[C7DXK^(SLI?"%%%%<QJ%%%% !1110 4444 %%%% !1110 4444
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M]QKR<5_$9V4OA"BBBN8U"BBB@ HHHH **** "BBB@"O-?6=N^R:Z@C?KM>0
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M2-+D:2PT^"U=AM9H5V$CTXJ_Y">K_P#?9_QKBK5%4GS(WA'E5B2BH_(3U?\
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MU3(X4$^@S3K5&CM(4<898U!'OBJ&JK.MWI]S%:RW"P2L76(KN *,,_,1W(H
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.BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $' 4P# 2(  A$! Q$!_\0
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M,13=- ^V7_ _UO\ 4UO"<E&2_K<Y:L%[2G\_R-!,^6N[K@9IU%%<YV!1110
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M(<#)P_.[=W..F*K+\)XUTZVLUUF3;#-YQ)@)!8>7M8?/D$"/U(.X\=,>CT4
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M+/##Z5#9Z/HUHT<]I;VT\93S(I6^?=D<9STKU!)DNE:)XD<,I!5AE6SP0?\
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MZ<XZ30]4EU>*XDDMQ"()/(89/,J\2 >P;@'O@ULU#;6L%E;K;VT210IG:B#
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M5YSW.U;%C=1FH ]/5LTADM)B@&G"@!NVC;3Z7% # *=BEQ2T )2T44 %%%%
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M"XA1@X5]XR78]>_!I#.B$E3H]9ZM5F-J +R-4H-5HS5A: )!2TT4Z@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHJM>:A::>;<74PB^T3+!%D'YI&SA?QP:
M +-1SP1W-O+!,@>*5"CJ>C*1@BJUKK&G7A807<3%9WM\$X)D3[RC/4CVI3JV
MGBXB@-Y#YDQ98QO'S,I *YZ9!8<=: ,^?P=X?N9$DETR)F2(0CE@-@0H!C.#
MA69<]<&JEQX%TJZU]-4FWM&L80VA"^4V(S'EN,GY&(Y/IZ5NG4K$!B;VW 5_
M+8F5>&_NGGK[4V;5;"VBDDGNXHEC1W?S&VD*F=S8/.!@\T 4&\(Z"T$<+:<C
M)&KJN78G#$%LG.3RJG)Z$ CI2'PGH0N+6?\ LZ/S;7886W-P5)92>?F(+,<G
M)Y/K6G%?VLY01W$9,F?+&[!?'4KZCW%*+NV=W1;B)F1MK*'!*G&<'T.* ,2\
M\'Z#<Q2K_9MO'+(96,ZH/,W2!@Y)/7.X\'(]JH:?X+TC388@\;WD\<S3BXG/
MSEB5/., C*J<'/(SUKI&OK+9*_VRWVQ8\P^:N$STSSQFH9KNU1RCW5NK@@%6
ME4')Z#&>^* ,)O#&BHJ*NG1*(P@3!8%=C,RX.>Q=O^^C3['2;'2Q,+*W6'SF
M#R'<6+D# ))))P.*TIKB!#&#*A,K!4"G.XG..GT//L:JB^L3/-$+N#?"5$F9
M  I;( )Z9X/'6@"9!5F,54-W:1RK$;B(R-)Y>U6!(;!.#CIPIZ^E2QZEI_F^
M7]NMMWD^?_K5QY>=N[.<8SQF@#1CKB[^Q\=2ZSJS6UYLLG(%IY;(,)NCQC/(
M8 2YR,'(Z\8[:/! (((/((YS4RB@#S6^F\66.IV-A)<7TIDFVP^658&/[2V3
M*=N#F'9T(Q@YIUII'Q MM/00W7EW"PF)8FDC,2 6R@$ #KYP;_\ 57I8I: /
M.X;'Q^)]++WG[A-QF#,FY?G/$G)W?)@#&<'\ZBATWQ_%/IP&HY462^>T[HX%
MP4?>'QC(W%-NT' !Z=^AL?&VG7DC+,C6R\;'+I)NRVT A"2K$D<$ ]?0U=B\
M1Z+=&40ZE;OY6[?ANFT$D_3 )SWP<=* .&'AK7[KPUK\%];W4ES>S6TBI)>Q
MF20(B!_F V8W*?E; (X.,U4AT'QK8V4 LRUN5M%B\B*Z!6,"=F8!2V YC*\@
MX&" 1Q7>S>*-!B,P?5( 87"2 9)#'/& .>AZ>E,/B/2/LT]R]V(X(KC[.79&
MPS[0WRX'(P<Y'I0!QLNE^.)%)DU.<2>7M_<RQJI(M^#C'7SL9]L]C4NJ:+?W
M6O6M[=:2FIKY%NJ-]L\G[%*K9D; ZYR.5R?EQTKJ)_$6B0F7S-2@7R@"QY(Y
MP!@X^8Y9>!D\BGV>H6NH7%U%;,S-;% Y*$ [E##&>O!H \YU3P[XUU:PN(;Q
MUN&$TC1*)54<QRKE3GA3NC&#COQWKLO#%OX@M]1U!=79Y;0D&VD>52?O'Y0J
M] !CGC/IWKH5CJ=$Q0!-'5A:B1:F44 .%.I!2T %%%% !1110 4444 %%%%
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M[7[6>^\/ZA:VK.MQ+;ND91]C;B.,'M]:YJ]M/%R&S:R>X<M<F2;S)X\)&)
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MZOJ3ZQ.'M68_9T55VCYCMVD-G&W .0.:Z0+0 BK4@%(!3@*  4M%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+10 VC%.HQ
M0 W%&*=BB@!,4M%% !1110 4444 %)BEHH ;BC%.HH ;BC%.HH 3%+110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
+!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_006a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #2 8P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LOQ'KD/AO0+K5YX9)H[
M<*3'%C<Q+!0!GCJ16I6+XMT$^)_"][HPG$'VD(/,*[L .K'C(],4 4=/\>:-
M=1,+Z7^R[M+IK.2VNW4,LJXR,@D$?,O.<<U;G\:>&K8W FUNR0VTHAF!E&4<
MDC:??Y3Q[5SNL_#&QN;VSETN.UM[6.%X)[242;)%9PY;*.I+9'\1(/?I4A\!
M7EJ]M=Z=J-M'?6^I75XC36Y>-EGR"K $$D#&#GM[T =))XIT&&YNK>35K19;
M2,R3J9!^[48R3],C/ID51?Q_X95].":K#,NH7+6L,D1W+YBC)!/;L/JP]:YN
MX^%KS2ZT/MMNR7XN&BF>.0R0M,07&-^S;QV&3QZ5JR>"+E-8&I6=]!'(NL?V
MBL;P9788!"R<$<X!(/KCB@#1O/%@A\1/HUEI5[J$ENL;WDL&P);!_NYW$%B0
M"<#/'-0:%\0-!UK06U-KZWMS#&KW4)E#-!N. &QZD8HN/#6JP>*[O5])U2""
M#45B6^@GMS(28P0&C(88)4X.<^M8L7PXOK.PABL-92">+3HK+>L17?LG,IR0
M00&!*G!SSG- '3R>,_#4*6CR:W9(MX UN6E \P%MH(_'CZU(_BWP_'?W-B^K
MVBW-JC/-&9.8U7[Q/TR,UQT?PLD32'LFU.-F:PDM _DGY2]SYVX98GVZ^^:R
M+?P1K>K:GX@L+VT:VM;YK@I>2'(@S.LB",!\,'QEN%(QUS0!ZOIVI66K6:W=
MA<QW%NQ(#QG(R#@CV/M5JL3PMH;:!I+VTBVXFEF>>4P;]K,V,G+LS$\=2:VZ
M "BBB@ HHHH **** "BBB@#*AUF6X@CGBTB_:*10Z-F$9!Y!YDJ3^T[G_H#7
M_P#WU#_\<KS;XI.\?PWT$H[*=\7*G'_+(UR/PCFE?X@6P>5V'DR\%B?X:YI5
M^6HH6/9H94ZN#EBN>UKZ6[>9[O\ VG<_] 6__P"^H?\ XY1_:=S_ - 6_P#^
M^H?_ (Y6--/K+6%P(%U .UTY3*)O2,#"C)X(+X/^Z3SQ3[O4=9FN9K2*UN%A
MB=1+/ @W%<(3LSU.2>W;UKI/&-;^T[G_ * M_P#]]0__ !RD.I7)&#HM_C_>
MA_\ CE8DMSKZO'<0PSLMO)Y<L3C[Z'<2V!U(&P #OFI+#6-:O-'M+I+8/+(9
M?,40D;2/N(<D8![MST]Z -2*\>#/E:!>1Y.3L\@9_P#(E2?VG<_] 6__ .^H
M?_CE8:7GBA?,G-ONC<!0IA^90/XPN[KC^'/X]JTM,FUN6^B?446*)XGW11QC
M".&&,MDGIF@">369(%#SZ5?1QEE4N3$0N2 "<.3U/I6I6=KG_(*?_KI%_P"C
M%K1H **** *]]=K8V<ERZEE3&0"!U('?ZUB-XPM5DD7[+.RQMAF7!P.N>O3!
M'T/%=$RJZE64,#U!&:;Y48SB->?:@ 217B213E6 ((YX-+O'H?R-.Q@8%% #
M=X]#^1HWCT/Y&G44 -WCT/Y&C>/0_D:=10 W>/0_D:-X]#^1IU% #=X]#^1H
MWCT/Y&G44 -WCT/Y&C>/0_D:=10 W>/0_D:-X]#^1IU% #=X]#^1HWCT/Y&G
M44 -WCT/Y&C>/0_D:=10 W>/0_D:-X]#^1IU% #=X]#^1HWCT/Y&G44 -WCT
M/Y&C>/0_D:=10 W>/0_D:-X]#^1IU% #=X]#^1HWCT/Y&G44 -WCT/Y&C>/0
M_D:=10 W>/0_D:-X]#^1IU% #=X]#^1HWCT/Y&G44 -WCT/Y&C>/0_D:=10!
MAP:/IVM^&M,@U*SBNHD@C=4E7(!V 9_6GZ=X3T#2;Q;NPTJVM[A00)(TP0#U
MKG?%5W<V7P]TN6UN)()"(%W1L5.-AXK \":OJ5WXK@AN;^YFB,<A*22$@\>E
M=4,%STG6TT_0AXR<'[%-V?GIKY'K5%<Q/K5Y_9]P\4H,\-ZR86W;+QAONJ#Q
MN.0 >AI;_P 13B\GLK>)HS%(JRW'E-((E(4YP!@GYNF?>N4LZ:BN2EU_4HFC
MG2!Y((I/*N%\LCKN.\\9 "A#_P "J:T\47-WI5I>QV2/YYERJ,6QM&0G /S'
MWXX- '3T5R*^)=6 DF?3E-N0 C@/A3W<_+G9CVS[5IZ9JNHWE]$MS9+:P2Q.
MP5MQ<,K 8)Q@<$G% %G73C29"?\ GI%_Z,6M('-9VN?\@I_^ND7_ *,6M&@
MHHHH *YI?&=HP#?9+C;O*,>/EP>I&>G3FNEIGE1C_EFOITH CGO+>VMOM,\R
M1P\?.QXYZ543Q!I$DBQIJ%NSL0%4/R2:S_'''A.[^J?^A"O+M%;_ (GNG_\
M7S'_ .A"N_#X6-6FYM['/4K.$E$]QWKZG\J/,7U/Y4ZBN Z!OF+ZG\J/,7U/
MY4ZB@!OF+ZG\J/,7U/Y4ZB@!OF+ZG\J/,7U/Y4ZB@!OF+ZG\J/,7U/Y4ZB@!
MOF+ZG\J/,7U/Y4ZB@!OF+ZG\J/,7U/Y4ZB@!OF+ZG\J/,7U/Y4ZB@!OF+ZG\
MJ/,7U/Y4ZB@!OF+ZG\J/,7U/Y4ZB@!OF+ZG\J/,7U/Y4ZB@!OF+ZG\J/,7U/
MY4ZB@!OF+ZG\J/,7U/Y4ZB@!OF+ZG\J/,7U/Y4ZB@!OF+ZG\J/,7U/Y4ZB@!
MOF+ZG\J/,7U/Y4ZB@!OF+ZG\J/,7U/Y4ZB@#GQHUGK_A/3;2\WF(0Q2#8VTY
M"?\ UZ;I/@O2-%U!+ZT\_P Y5*C?)D8/7BM+^P=')S_9-C_X#I_A1_8.C_\
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M444 &11D444 &11D444 &11D444 &11D444 &11D444 &11D444 &11D444
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M<:W?#/\ R\2?^A&K_L[W^7FZ7_$7UKW;V/<3=VP )N(@#T.\<T+=6[9VSQ'
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M/_75?\:5KZT159KJ!0PRI,@&?I7R5?D_VC<\_P#+5OYUUGC+_D5/!W_7B_\
MZ'26+NF[;&D^'HQE"/M/B\O*_<^BDO;23.RZA;:,G;(#@4?;+7_GYA_[^"O
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MJ/X7?\?NO?\ 8(F_FM)N^:HR%?N)>IKQ6_\ ;_\ MU'2>,V_XJ27G_EG%_Z
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M?^+<0?\ 81;_ -%TWP8W_%56?/\ ?_\ 0&H;CX;P?]A(_P#HNH_!1SXLLO\
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M5,_-4Y!_ EZFO%G^_P#_ &ZCI_&[?\5/-C_GE%_Z+6I;1O\ BW=__P!?R?\
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MPZ_Y!WBCC_F'?^S"JEL?])B_WA7V60_[L_4_->*O^1B_1#?BA_R4/5?]Y/\
MT6M(/^22-_V&A_Z)I?BA_P E#U7_ 'D_]%K2#_DDC<#_ )#0_P#1-?(/XY_,
M_0:?^ZX?UA^3$^&7_)0])_WW_P#0&KFK[_C_ +C_ *Z-_.NE^&7_ "4/2?\
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M>5X(],<54BE4>,)H?,N!^Z#A=B["<8//WN@'MR:N:!8W&G:+;VMUY7GH#O\
M*8E22<Y' Q]  !4<6ES)X@EU M#Y; @#YR_W5'][:.GI0!!XL:)-(1YGG1%G
M0DP$!L9YY)&.,]_;O6U"08(R"Q!4<L,$\=_>LOQ)IEQJNDFWM602[PP+]/U!
M'YBM.!#';QQL0650"1[#WH PO"SP'^T4BDN7*7+!O.Q@<G&,'CCMP?;FC61#
M_P ))I/F&?=D[=D:E<Y&,D\_E4WA[1[G2FOFN9DD-Q,74(,;5R<#ISUZGGU)
MP*DO]+FN=8M;Q/**1!00[.",-DD '!XXY]: +>J[1I-T6+@")CE%!(P/0U!X
M?F%QHEO,))9-X)+2[<YSS]WC'TXJSJ5O)=Z9<V\14221LJENF2*@T/3Y=+T>
M"TGE666,'<ZC ))ST' _  4 9MD8O^$XU'$DOF&%/D,:;<<=_O?B< Y[XJ7Q
M:T*:5$\\EPB+<(28" W?/)(QQGO[=ZGBTJ2'Q'+J"F/RY4PW)W9XXQWZ>OX=
MZ9XGTJ[U?2EMK.2*.42!LR#(P ?8^OI0!KQX,"8+$%1RPP>G>L3PM-!+9SB&
M6[D\N78?M.WC P,;0 ..QY'>MN)"D"(V-RJ ?RK)\.Z5<:5#<)<&+,DF\"-B
M>W?@<_Y)- $.L26_]OZ5%()1,S$JZJI'!!QSSSZKT'7K6IJC1II5VTRNT8B8
ML$ZD8[51U'2KB[UNQO(_*\N#EBS$-U[<?U'OFKVIVTEYIEQ;1,BO*A4%\X&?
M7% %;PZT3:';O"SF-MQ&]54CYCQ\O'XC@]:S=.CMQXXU-UDN#.8@&5@-F/EZ
M=Q^(Y]\5L:18OINF16KNCLF<E%P.23P.W6JMGI$\'B&[U)Y8C',I5453N_AZ
MG/L>/RQS0!!XL:%--@>9[A%6X3)@(#8[\DC''Y]*W$P85^\1M'4<G\*R_$.E
MS:M8);P,BL'!W/T7@\XP<X]/U%::(RVZH2-P4 D9QG% &/X:N4NX+F2-YRBR
MF,)*%^0#I@KP?QY'0U#JP@/BG2_,,X?!V[(U*YSQDGGUSC\<5:\/Z5/I4%PD
M[1GS9-ZJG\/&.N!GUSC//.>M.O-+FN=;MKU6A\N(#(??NR"3QA@O?N#0!)X@
MV_V!>EVD0"/.Z+&X?3/'XFET(JVAVA26:52G#S8WMSWQQ^52:M:27^ESVL3(
MKR  %P2.HSG%+I5F^GZ9!:NZNT2X+*, \]A0!EZ=,#XMU.$3SD!5/E%$"#@<
M@CYL_7@^^*9XO6U:TLOM?G^6+I3B' /YDC\N_3!JW9:1/;Z_=ZC)+$4F!"HJ
MG=VQDYYZ?X5'XFTF\U:UMX[.2)'CE#L9/3';@\_KZ$4 ;7_+/J>GIS7/^$#;
MM87!@:8_OR&\Q%7!'IMXZ?B.AKH,'9M[XQ6+X8TF\TBSN(KR2)VDE+J8^@&!
M[#G_ "<T 17HM?\ A,+$R?:_.\OY-@7RQ][KQNYR>G P,]:N^(U1O#M\)"X0
MQ'.S&?UX'U[5#=:7<R^);6_C,?V>-,.&9LY&[D#I_%_/VJ[J]I)?:3<VT.SS
M)$PN\\9]_P#]1H ;H@@&BV@MO,\@1C9YGWL>_K]:S=(\G_A)=5VF?S >=R*%
M(X[CGKD<]NE:>CVDMCI%K:SLK2QH%8KT)_S^%5M.TV>UU:\N72$1RD[661V8
MY;/(/ 'TH J>+C;BVL_M#3*AG _=(K=O]K^G)[5T)X0]>GIFL?Q%I,^KP6\<
M#QH4DW%G[<=<=_T//!%:[*6C*C@D8H Y_P &^7_94XCDE?\ TA\^8B+@^@V\
M?GR.G&*;?K ?&^G;WF$HA8J%5=I//X^O0$#CIFKGA[2I]*M9HYFC/F2;PJ?P
M\8QG STSG'?G-)<Z3/-XC@U$/%Y4:A<'.X<'/;OD<9'XT 2^(MO_  C]Z7:1
M0(\YCQN'(]>!]>U3Z0\;Z1:M"TK1F,;3-]\CWHU>SDU#2Y[6)D5Y  "X)'4$
MY'TIVF6CV&F6]J[J[1)M+*" ?H#0!EZ/,C^(-4A6:X9HV^XZJ$&3G(QSG.>O
M;D4>)YDMTLG:6>/=-L+0JI."/]KZ#ISZ5/IND3V>L7]])+$RW).U44@CG(R<
M\\?_ %J9XDTJZU6"V2U:-6CF#$N>@[XX/^/H10!KS@-;2!MVTH0<#)Z>E8GA
M!U?1,K-<2_O&R9\$@\< @D$5MSHTEM)&A =D(!/3.*SM TR72;!K>5HV.\L"
MG3&![#'3I_/K0!7N[F-?%5G:AYTD>/>=JJ5?&[ .?F]>1QT!ZUNUB7.E74OB
MNUU%!!]EBA*ON<A]W.,#'3GIG!STX%;= !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
J444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_006b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006b.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $% 5P# 2(  A$! Q$!_\0
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M^E>@4@50Q8* 6ZD#K0 M%%% !1110 4444 %<IX]TM=4TBV1[74;CR9_-1;
M1LRN%8*65^"N375T4 <5J,5^ECX-74XT!2ZC%ZD( 02>2P4 #MOQC'&<5SEE
MX:DU7P_XG\S0KS2Y+BVV6VGQIY2%4#^6"P/[QV)RV>.@YKU=E5AAE!&<X(I:
M .-UF&\NO!<FDQ:1)+>1VENB-+$C(&?",5R3\R#)/'IUJ31M.ATKQLUAIT?E
MV-MH\,3JO3<)&V9_VMN[\ZZZD"J&+!0"W4@=: %HHHH *XSQ1_R%A_UR7^9K
MLZXSQ1_R%A_UR7^9JH[G/B/@.7\8:)JFL3:4=/L(KP6^AM)Y<_FA2V4X0HRC
MS,9P"<5:L=5\3#5=.TRUGN3IOV.!4FN;=A),IB/F.3L.) PZ%@!CD'-=EI\%
ME%I>FI/?RQ2301B-&NV4N=HX49Y_"KD=M92R2QQW\[O"<2JMXQ*'W&>/QI,T
MBWRK0\X\/2:]HFA*B2ZD(+?1DO6C%F)));F1Y P.X9)4 ';G/K[V+3Q)XEDM
MK?[;<W]K;_:+E%NH]-,LDFTIY*LFT<,I8Y &<=J[EWTF*2*.36"CR@-&K7Y!
M<'H0-W(IUU_9=BZI=ZL]NS#*B:^*$C\6I%7?8X,:AKNFWNI1-?:G%;R:K.TM
MP+(S-$GE@PA%VGY6.1QG&W'&<U;_ +7\7&TO]2NY)+1M/L+6Z>S\A0DC$%IE
MW$9SA<8!X)KMTL[60.4O;A@APY%VQVG&>>>."#5>XTG2=5MA:W,[7<$Z[Q$]
MTSK(H(.0,\C.* N^POA>ZO;_ $"WO[\D2W9:X2,J!Y<;$E$^H4KGWS6Q5$:7
M$  )[L = +A^/UI/[/@#A#=76XC(7[4^2/SIA=]B_15+^S(_^?B\_P# E_\
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M?_&F%WV+M%4O[,C_ .?B\_\  E_\:/[,C_Y^+S_P)?\ QH"[[%VBJ7]F1_\
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ME%DZK*&BC1<Y^91M(P.ISDD56DTGQ-<366MP"].IW>EW)#"?Y+>62176,@G
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MSQ_2GZ;X)UVWD9UT^*T?R[%'87ID,SQ3[Y9"3R-PYQW^M>D_VO8?\_"_D?\
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M<U4N=#^W?VMJ$+::EUJ4EI(D=W"6*1QH@>-CM..5., B@.:/<] -_9J8P;N
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ML'-'N7**I_VK9?\ /POY&C^U;+_GX7\C18.:/<N453_M6R_Y^%_(T?VK9?\
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M!(YXQSWJP?$^A@69.JVH%Y_Q[_O!^\YV\?CQ]>*YO5O#4&K'63)_:,9U(VS
MK;?ZIH.5/7D$]1Q6=+X)\R&TA6[OHH87$DD261VR2"7S-XR^03C!R3Z]:+!S
MHZ6T^('AFZB:1M4AM\2O%MG.PDJVTG![9[^]7?\ A+?#XMEN/[8M/):4PAO,
M&-XZC\,@_C7(R>#(Y8M4B>>^,=[!<0(/L(S$LLOFGG=\V#D=J;J_@>VU74[F
M^+WR//*[-&UH2FQHT1DP&&?N Y]\$&BP<Z.PN/%>A6T]Q;OJ=N;BW1WDA5LN
M B[F&/7'.*N:1JEMK6DVNI6;%K>YC$B;A@X/8^]<D?#-M]H\P+?A?M<MSM%K
MT$EOY&S.>PYS^%;FAL^D:'9:;)%>7!M85A$HM=FY5&!QD\X HL'.C>HJA_:8
M_P"?*]_[\T?VF/\ GRO?^_-.P<Z+]%4/[3'_ #Y7O_?FC^TQ_P ^5[_WYHL'
M.B_15#^TQ_SY7O\ WYH_M,?\^5[_ -^:+!SHOT50_M,?\^5[_P!^:/[3'_/E
M>_\ ?FBP<Z+]%4/[3'_/E>_]^:/[3'_/E>_]^:+!SHOT50_M,?\ /E>_]^:/
M[3'_ #Y7O_?FBP<Z+]%4/[3'_/E>_P#?FC^TQ_SY7O\ WYHL'.B_15#^TQ_S
MY7O_ 'YH_M,?\^5[_P!^:+!SHOT50_M,?\^5[_WYH_M,?\^5[_WYHL'.B_15
M#^TQ_P ^5[_WYH_M,?\ /E>_]^:+!SHOT50_M,?\^5[_ -^:/[3'_/E>_P#?
MFBP<Z+]%4/[3'_/E>_\ ?FC^TQ_SY7O_ 'YHL'.B_15#^TQ_SY7O_?FC^TQ_
MSY7O_?FBP<Z+]%4/[3'_ #Y7O_?FC^TQ_P ^5[_WYHL'.B_15#^TQ_SY7O\
MWYH_M,?\^5[_ -^:+!SHOT50_M,?\^5[_P!^:/[3'_/E>_\ ?FBP<Z+]<9XH
M_P"0L/\ KDO\S72?VF/^?*]_[\UROB*Y\[4P_D3I^[ Q(F#WIQW,,1).!++X
MS@T&ZT'2;FV/E7>GB07.["QN  JMQP&/&<]2*O:;XVTZ\TVVN)P\$TL5H[Q
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M=A&&9RH0%5*EN.Y'85K:%JRZUI:W8B,,@D>*6(G.QT8JPSWY%9\G@S3#):K
MT]M8V[K(-/@<+;NRMO5BN.N[G@C/&<U=\/:2VC:4+:619)Y)I)YG48#/(Y<X
M]N<4 :M%%% !7&>*/^0L/^N2_P S79UQGBC_ )"P_P"N2_S-5'<Y\1\ S4/&
M]OX8LM-MI=/N;H_V:+N1HGC4)&H )^=AD\]!DUK-XST9MJ07*RSDPAH<[602
ME=N[/ /S#CK52#PGIVK7.D:OJ$,%VL&FK EO/ KJ&)5MXST(QCIWJ2X\'1SR
M:BWVQE^VZC!?$",?)Y00!.O(/E]>V:EFT?A1>/BW0!]M_P")M;?Z$"UQ\WW
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6BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #] 9(# 2(  A$! Q$!_\0
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MJ)T*6GNK==$;4L57?-[[V?5^7F6?^$KU[_H)2_DO^%'_  E>O?\ 02E_)?\
M"L:BK]A2_E7W(Q^MXC^=_>_\S9_X2O7O^@E+^2_X4?\ "5Z]_P!!*7\E_P *
MQJ*/84OY5]R#ZW7_ )W][_S-G_A*]>_Z"4OY+_A1_P )7KW_ $$I?R7_  K&
MHH]A2_E7W(/K=?\ G?WO_,V?^$KU[_H)2_DO^%(?%>O8_P"0E+^2_P"%8](>
MAH]A2_E7W(/K>(_G?WO_ #.GUCQ-K4&KW446H2)&KX50%XX'M5+_ (2O7O\
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MT_[9<?\ /0_D*/[2J_RK\0_L&A_._N1Y=_8.L?\ 0+O/^_+4?V#K'_0+O/\
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MC_Z:K^1IQ:743396HJS]C_Z:K^1H^Q_]-5_(U7,A<K*U%6?L?_35?R-'V/\
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MG]U/^^:KT4<J#F98^UR?W4_[YH^UR?W4_P"^:KT4<J#F98^UR?W4_P"^:?\
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MV6?_ )YG\Q3_ +/-Y&WRSG?GJ/2K%._Y9_\  J'-CY$4OLL__/,_F*/LL_\
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MR7]?\:/+B_YY+^O^-5SBY&5+C_CX?ZU'6C)'&9&)B4G\:;Y<7_/)?U_QH4]
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M:QI0\>J^MDO816SV4DL*[86E!^554=SA03GG!->A6EI%86J6MG EO;Q\)%$
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MX?2VBN#JMN8I7:-"H9B67!9=H&01D9!'>K#:[I*ZC#I[7\*WDP'EPL2"^1D
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M09$8;<;3@< #'8UVE%',NP<IPL'P]T:WTM].BDNUM\QM#AD#6Y1PZ%&"Y)!
MY;=P,4M_X+B;PI?:3I]U*MQ/=B_2XNV\PBX$BR9; '!*_J:[FBCF78.4Y$^$
M-,>[^TR"9W.H/J+(S@H97B\I@1CE-O:EO/!^CW.D7FF6MNNF07B>7<-I\:1-
M(F""I.T\<GWKK:*.9=@Y3CKSP=:ZCID&F7NI:I/81HB26[3*%G5&RN_"@]@/
MEQD 9JUHFC2Z=?ZW?7,T<D^I7GG#RP0$C5%2->>X"Y/N:Z>BCF#E*%._Y9_\
M"J[11SARE"L;7_#=OXB-B;B[NX/L4WGQ"W9,&0=&8,K X[<<9KJ**.<.4Y35
MM#GOGT*>"[S<Z5>)/YMP,F5-K)(#M ^8JQ/ QD4RV\*1VNI:G?Q:QJOVC40O
MG-YL8VE>$*X3C X[@@\YKKJ*.8.4Y*S\)V=C(LL-[J7G&XDN9Y3<8:YD=-A,
MF  0!C:   0*S=6\"I>Z?J4<6H7$U[J2PV]S=WKAV%LC[BBA5 SC=VZGDUW]
M%+F78?*4, <*, < >@HJ_13YQ<I2?[YIM7Z*.<.4PM4TTZG;B$7][9CD,UI(
M%+ C!!R#_B.QK+O_  M'_9NA6FDF.U&BW<,]LLF678H*LI/7)5FY]:[&BCF#
ME.*O_ NEZM+</J=SJ%\9;=[9//G'[F-F#$)@#G*KR<GC%3V?A*TL[MKQ;_4G
MNI+@7%Q,TX!N&$?EJKA0 5"]  .0#7744<R[!RG!:OX(%]INJ)#J-S-J&HVZ
M63WE\^\QVV_+(H4 ="WU)&376HBQQK&@PB*%4>@ P*T**.8.4H4[_EG_ ,"J
M[11SARE"BK]%/G#E*%%7Z*.<.4Y_5=%M-9ET][LRE;&Y6ZCC5L(\B@[=XQR!
MG('K5?6=&EU'5M$U&WF2.73KAW<.#\\4D91U!'0\@CZ5U%%+F#E.2B\*P1W=
MQ?'4]4DU"6%8%O'F4R11AMP1/EQC/)R"3WJ&+P1I<5J]L9]0>*<W+7:M<D"[
M:==KM)@ $X'&,8[5V=%',NP<IY[>?#^!].DM;:]G=KE[6*ZFNV#-]E@?<(D"
L@ 'C&2.YR:[0G))]:O44<P<I0HJ_13YPY2A3D_UB_45=HI<X<H4445!9_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #( 4\# 2(  A$! Q$!_\0
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M8KAJ[GXD_P#'UI_^X_\ ,5PU?7Y=_NT?G^9^<9U_OU3Y?D@HHHKO/)"BBB@
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M^RA1BU9/6_\ F=?_ &-X/_Z#\WY#_P")H_L;P?\ ]!^;\A_\37(45V?5I_\
M/V7X?Y'F?7:7_/B/_DW^9U_]C>#_ /H/S?D/_B:/[&\'_P#0?F_(?_$UR%%'
MU:?_ #]E^'^0?7:7_/B/_DW^9U_]C>#_ /H/S?D/_B:/[&\'_P#0?F_(?_$U
MR%%'U:?_ #]E^'^0?7:7_/B/_DW^9U_]C>#_ /H/S?D/_B:/[&\'_P#0?F_(
M?_$UR%%'U:?_ #]E^'^0?7:7_/B/_DW^9U_]C>#_ /H/S?D/_B:/[&\'_P#0
M?F_(?_$UR%%'U:?_ #]E^'^0?7:7_/B/_DW^9U_]C>#_ /H/S?D/_B:/[&\'
M_P#0?F_(?_$UR%%'U:?_ #]E^'^0?7:7_/B/_DW^9U_]C>#_ /H/S?D/_B:/
M[&\'_P#0?F_(?_$UR%%'U:?_ #]E^'^0?7:7_/B/_DW^9U_]C>#_ /H/S?D/
M_B:/[&\'_P#0?F_(?_$UR%%'U:?_ #]E^'^0?7:7_/B/_DW^9U_]C>#_ /H/
MS?D/_B:/[&\'_P#0?F_(?_$UR%%'U:?_ #]E^'^0?7:7_/B/_DW^9U_]C>#_
M /H/S?D/_B:/[&\'_P#0?F_(?_$UR%%'U:?_ #]E^'^0?7:7_/B/_DW^9U_]
MC>#_ /H/S?D/_B:/[&\'_P#0?F_(?_$UR%%'U:?_ #]E^'^0?7:7_/B/_DW^
M9U_]C>#_ /H/S?D/_B:/[&\'_P#0?F_(?_$UR%%'U:?_ #]E^'^0?7:7_/B/
M_DW^9V,>A>$I9%C379B[D*HP.2?^ UL_\*XT[_G\N_\ QW_"O/\ 3?\ D*6?
M_7=/_0A7N5>7CZE;#.*C4;OZ?Y'OY31PV-C-SI15K;7_ ,SC/^%<:=_S^7?_
M ([_ (5V,:".-4!R% '-.HKR*N(JU;>TE>Q]%0PE##W]E&UPHKC?B;?WNG>$
M1-8WDEG(;N%'G1RFU"V&RP5BHQW"GZ5SOAWQE#I=]I@U?7I)K*XT^3;*SO.D
MD_GD</Y:$D+@<J/QZU@=1ZI17E_A#7?$ESXLL;'4Y)WLY!J$\4I7"R()@BHW
M'WD*MC_9<55@\<^((M3U^]6RO9+*YAEDTH7$'[D>2VTE-IW$,F9"#@G:<4 >
MM45Y7IOBWQ&)95AFCU.*^U5[&VN1;,J1MB(J^,_ZO9YIZGE>N#4T/C;Q/=RW
MT:VUE;LM]#:QAXV=[?=<>5\Z@C/R?,#D?3!!H ].HKS"\\=>(K&\UVT^SVUS
M)9@>2T,)V(OFJA>0[LJ0K%MI '!PQ )JMXDUGQ3J.B>'IK,77VJ=+N2>/2;D
M1><L8&U@S(PY'.WN3@'O0!ZQ17D+>-_$&G:=]H2Y@OE#6XDF,+$S9MHV/E(2
MH)+%LKD-Z G-=%X2U_6+OQ;J^G:@'2R6XN&LWE0[I@KJ"H/\(0$<$$G=G/%
M'=#_ %I_W1_6G4T?ZT_[H_K3J .4^(/_ "+:_P#7PG\C7EU>H_$'_D6U_P"O
MA/Y&O+J^JRK_ '?YL^!X@_WSY+]0HHHKU#P HHHH **** "BBB@ HHHH **[
M/PBI330XBD?SKY8SY$88XV\B3/2/GM[U;CM!_8R6ENS(CP3F62.%6@+J6SO)
MY'0 >G%<,\8HS<;;,]:GEKJ4U/FW5]C@:*[-%T^]@AN(U(;RI4A58 & " D
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M^+H^W^!_^@5>?F?_ (NN/HH^IQ_FE_X$P_M&?_/N'_@*.P^W^!_^@5>?F?\
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MN-0M;8+81R+;.C(-QD%P=S DE1LY^AH ]!HKS*SG\;EM/MKN+4MUPMB99E5
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M_(:O_P#KYD_]"->YD_QS]%^9\KQ+_#I^K_(IT445]$?&!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >D?#?_D%7G_7<?^@B
MNTKB_AO_ ,@J\_Z[C_T$5VE?'8__ 'F?K_D?I64?[E3]/U84445Q'IA1110
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7T>@HHH -H]!2T44 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "N ?X# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BL;Q-X@3PWI/V^2W:<&58PBMMZ]\X/I61'\0;-KC4D>
MRFCCL;8W!<L,N!CC'J2P Y/^(!V%%<;IOQ%T[4]=32XK>5"SLOG.ZA>.5/\
MP(<BDN/B5I%EK=UIM[%/ ;>4Q-+C<"=RA< <\[C_ -\&@#LZ*Y!/B/H9:3?Y
MZJ)/+C(3<TAP3D*.><<?ATI][X[M;82/#92SQ+;B9&#JK,2@?&T\@;3][IGC
MK0!UE%16MPEW:0W,9!26-9%(.1@C(YJ6@ HHHH **** "BBB@ HHHH ****
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MIFRS8! .#[GD >E)T<*G;V?]?>5'$X^4>;V^GJO\BU_PL74?^?2U_)O\:/\
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M\;4=&L;UUVM<6\<I7T+*#_6KE+Z_B?Y_R_R*_LC!?\^U^/\ F<7_ ,*YLO\
MG^F_[Y%'_"N;+_G^F_[Y%=I12^OXG^?\O\@_LC!?\^U^/^9Q?_"N;+_G^F_[
MY%'_  KFR_Y_IO\ OD5VE%'U_$_S_E_D']D8+_GVOQ_S.+_X5S9?\_TW_?(H
M_P"%<V7_ #_3?]\BNTHH^OXG^?\ +_(/[(P7_/M?C_F<7_PKFR_Y_IO^^11_
MPKFR_P"?Z;_OD5VE<%KOCJ]TJ\UNUACL)9;.2T6W0.2S"8L&W#(&X;>F5'/6
MCZ_B?Y_R_P @_LC!?\^U^/\ F6?^%<V7_/\ 3?\ ?(H_X5S9?\_TW_?(JKJG
MQ$^P^&M&U")+:2XO1$]Q@.T4*MLW#(&0QWC:#C/7M5S7?'CZ-JMU91Z/)=+;
MKEI1<(F3Y+S8P>?N1MSZX'?@^OXG^?\ +_(/[(P7_/M?C_F-_P"%<V7_ #_3
M?]\BC_A7-E_S_3?]\BK.E>.[+5-:>Q$'D0X?RYY)ER2K(I#IU3)D7;G[WY9Z
MNCZ_B?Y_R_R#^R,%_P ^U^/^9Q?_  KFR_Y_IO\ OD4?\*YLO^?Z;_OD5VE%
M'U_$_P _Y?Y!_9&"_P"?:_'_ #.+_P"%<V7_ #_3?]\BK^C>$[?0]22YBN9)
M&92F&4"NEJ-_]=%]3_*E+&UYIQE+1E0RS"4I*<()->O^9)1117&>D%%%% !1
M110!6?3K&62222SMW>7'F,T2DO@%1DXYX)'T)J:&&*WA2&&-(XD4*B(H"J!T
M  Z"GT4 9>GPQ3G4$EC21?MC'#J"/NK3/#YB\B^2$*JQWTRE5&-IW=,?K^-3
M:5_K-0_Z^V_]!6H=%9#?:TBE=RWN6 ZC,:=:M?"Q=235/#VE:U)')J%FL[Q@
MJC%F4@'MP17-ZMHNB^&=0T;4;6%;*-;S;/,96VA#&_WLG&,XKMZ;)&DJ;)$5
MU]&&123:,IT8RU25^YCKXO\ #C,%&MV)). /.6MJL'Q1I:7'AC4(;.QCDN'A
M*QJB*&)]JA7Q->A0/^$6UG@?W8__ (NBU]A>T<96G^"?_!.D[45S7_"4WW_0
MJ:U_WS%_\76AHNMKK!NHS975G/:NJ217 4,,J&!X)'0TK,M58MV7Z_Y&K111
M2- HHHH **** "BBB@"AJ?6R_P"OI/ZU)J7VK["YLG*S@KC"AN,C/!]LU#J\
MBQ1VLKYV)<H6(!.!SZ4[^VK#_GJ__?I_\*TY6XJR,.>,9RYG;8RX+CQ"DD27
M"!B=A)2,$#.=P)XY^GI[U#%JWB2.,";2?,?J2!C@+@C@]2W/T-;7]M6'_/5_
M^_3_ .%']M6'_/5_^_3_ .%+V<^Q7MJ?\R,N'5M?9$\S1@'()?Y\ >PK:L)+
MF6T22[C$<K_-Y8_@'H?>H/[:L.OFO_WZ?_"E_MJP_P">K_\ ?I_\*/9S[![:
MG_,B"\U:^MKIXH="O;F-<8ECDB"MQVW,#^E0?V[J7_0LZC_W]A_^+J]_;5A_
MSU?_ +]/_A1_;5A_SU?_ +]/_A4^RJ>?W&ZQ5!+5+[V4?[=U+_H6=1_[^P__
M !=:UG/+<VJ2S6TEM(V<Q2%2R\]]I(_6J_\ ;5A_SU?_ +]/_A2?VU8?\]G_
M ._3_P"%-4IKN3/$T9+2R^;_ %%T7_D#VW^[_4U?JAHH(T>VR"/DS@C'>K].
M?Q,SI?PX^B*D+V\MA%'*T3HT2AE8@@C'<4CP:?)8O9%(!:R*4:)<!2#U&!ZT
MZ.:&VTR.>>1(HDB4L[D  8'4FI4F@D>1$DC9HVV. 02IP#@^AP0?QHE:["-^
M5$1BL#.LYCMO.0863:NX#V-2.]O+&T<C1.C##*Q!!%)]KMOMC6?F+]H6,2E.
MX4G /Y@U-\N<<9J="M2KY&G?+^ZM?D78ORKPOH/;VI7CL)0PD2V<,P9@P4Y(
MX!/O5GY?:F&6%94B,D8D<$JA(RP'7 [XR*- U,NUT+0K*>YFAM;</=',NYMP
M;DMT)( R2<#N:N-;V#7:73"(S)'Y8;=_#D-C'3@@$>E)=ZI86,L45S<)&\OW
M ?XOF5?_ $)U'XU9FFAMX7FFD2.*,$N[$ */<TPU(S]D,)A/DF(@@H<;2/I4
M;V^GO:-:E(%@*LNQ,* &!!QCIU/3UI+C5M,M,_:+ZUBQ)Y1WRJ/GP#MY[X(.
M/>HX=;TFXM;BY@U"VE@ME+3/'(&$8 )YQTZ&@-2U$UM!"D,3QI&BA54,, #@
M"G^?%_SU3_OH4Y&1U#+@@C(XJE/K&F6TLT4U[ LD !E3<"R D $CJ!\P_.EH
M&I;\^+_GJG_?0H\^+_GJG_?0I^!Z"C ]!1H&HSSXO^>J?]]"CSXO^>J?]]"G
MX'H*,#T%&@:C//B_YZI_WT*//B_YZI_WT*?@>@HP/04:!J,\^+_GJG_?0JJ]
MGI4C2L]M9LTW$I,:DO\ [WKT'6KN!Z"JM_J5AI<22W]Y;VL;L$5YY @+'MDT
M:!J."V05E"P ,06  Y(QC/TP/RH=;*1F9UMV9NI(!SP1_(D?C2QWMG->36D=
MQ"]S JM+"K@O&&^Z6'49P<9J?Y?:C0-2KY&G[W?RK7<^W>=JY;;]W/KCMZ5/
MY\7_ #U3_OH4\ $9&*,#T%&@:C//B_YZI_WT*//B_P">J?\ ?0I^!Z"C ]!1
MH&HSSXO^>J?]]"F-+&\\05U)R> ?:IL#T%1N!YT7'<_RIJPG<EHHHJ2PHHHH
M **** ,6?Q'%!XHBT0VTIWQ;S< C:K89@N.O*HQS[#UI?#'B*#Q/I']HV\1B
MC,C(%+AC@="<="01P:FNO#^FWFJIJ<L+?;$C\M9$D9?ESGH#C/)&>N"1T-2Z
M5H]CHEJUMI\/E1,YD(+ELDX'4DG    [  4 ,TK_ %FH?]?;?^@K5*"Z@L_%
MNH03O%"US%#)$6<#S,;E( ZDYJ[I7^LU#_K[;_T%:K>)M*.HZ1.UM!&VHQ*'
MM9"BE@ZD,H!/0$C]:N%KV?43-JBJ6DWZZII5M> !3+&&90<[6[C\#5VI:L[,
M84444@"L'1_^1F\1?]=H/_1*UO5SESX<U(ZM>7UAX@FLQ=LK/$MM&XRJA1RW
ML*:,JE[II7M_D='17-_V%XA_Z&Z?_P  H?\ "C^PO$/_ $-T_P#X!0_X4[+N
M+VDOY'^'^9TE%<W_ &%XA_Z&Z?\ \ H?\*/["\0_]#=/_P" 4/\ A19=P]I+
M^1_A_F=)16)X3NKJ[\/Q2WMP;B<2S(TI4*6VR,H.!QT%;=)JQI"7-%2[A111
M2*$90PPP!'N*;Y4?]Q?R%/HH 9Y4?]Q?R%'E1_W%_(4^B@!GE)_='X4&&,]4
M%/HH C\B+^X*/(B_N"I** (_(B_N"C[/%_<%244 ( %  & *6BB@#+OM-76/
M#4FG/(8A<6X3>!DJ<#!QWK#N_!4VH227-W?1&ZE,DA*0D(DC")591NR-HB[G
MJW:NFM8W^R0_OG_U:]AZ?2IO+?\ Y[O^0_PJWHWJ91UBM#B+CX>2SM=M_:2
MS,&XA(,@$CO^\.[YC\^,C'W14T_P_2:W:,7[I+)/F695.]X3&J&,G.>J@YKL
M?+?_ )[O^0_PH\M_^>[_ )#_  HN^X[>1QA\ SO-!/+J[R3K;NDKE2-TK;\N
M &XR9.0>RBKFG^#$T[5+:\AFA @\P*GD_=#QQJ2ISP=R%O\ @9^M=/Y;_P#/
M=_R'^%'EO_SW?\A_A1?S';R.(LOA]<6R()=6$C+*9,B';U:%N!GC_4G\6]JO
MVO@U[?1=5T]KU";Z 0;TB*@8!'F,-QR[9^8\9P*ZCRW_ .>[_D/\*/+?_GN_
MY#_"B_F%O(YFW\(2Z?JK7]A>(&,DG[NY1I1Y;K&",EL[@8^N>AQBK-WX?F;P
M[K%A#,KS7DLT\>1M +-N"G^6:W?+?_GN_P"0_P */+?_ )[O^0_PI7\P^1R_
M_"%13W-S//<%?M1E:8(BECND5U!+9!V[2.G?C%0WW@VX$5X+&XC"S6AM1'@I
MYFX*N^3!VDJ%R-JBNN\M_P#GN_Y#_"CRW_Y[O^0_PIW\PMY#U&U0,YP,4M1^
M6_\ SW?\A_A1Y;_\]W_(?X5-AW?8DHJ/RW_Y[O\ D/\ "CRW_P">[_D/\*+!
M=]B2BH_+?_GN_P"0_P */+?_ )[O^0_PHL%WV)*P?%FB7GB#2EL+:YMXH7D!
MN8YXBZSQCK&<," 3C..HR.];7EO_ ,]W_(?X4>6__/=_R'^%%@N^QRD7@=H+
MK7[B/59V.L6;0,LB*?+=BYW @ D#>  3P!C/3&:WPQBB,AL[N&WW[@R"$[)%
M/DD(XW<INB8D=_,/OGO?+?\ Y[O^0_PH\M_^>[_D/\*+!=]C*\.:/<Z'8)8R
M74,UNBDHJ1%-C,[,P&6/R#<H5>P7J:V:C\M_^>[_ )#_  H\M_\ GN_Y#_"B
MP7?8DHJ/RW_Y[O\ D/\ "CRW_P">[_D/\*+!=]B2HW_UT7U/\J/+?_GN_P"0
M_P *8499XB9&;D\$#TII";?8GHHHJ2PHHHH **** "BLB\\06]GX@L](>&9I
M+E<^:H&R/.[:&YSSL;&!VYJ72-;M=:-]]E$FVSNFM6=A@.R@$E?4?-C/M0!C
MFX\117U^NE6%A/;_ &EB7N+EHVW87C 4\=*AO]<\6:58RWUYH^E_9H0&D\N\
M8MC/8;.M;^E?ZS4/^OMO_05JCXV_Y$S5/^N7]164TTFTSMP]2,IQIR@G=I=;
M[^H:&(K'6-7TI L8$JW42!-HV..<>H# BM^L#6;9K77--UB"%&DWBTG8N5)C
M<X&!T.&.:WZZ9ZVEW.%=@HHHK,84444 %%%% !1110!S\O@S2))I) +N+S'+
ME(;N1%!)R<*&P.:9_P (3I/_ #TU'_P/F_\ BJZ.BGS,R]C3_E1Q[Z-;Z)XH
MT+[%->8GDF219;J216 B8CAB>]=A5#5-&T_6H8XM0MA,D;;T&XKM.,9R".QK
M,_X07PW_ - [_P CR?\ Q5.Z>Y"A*#?(E;U_X<Z*BN=_X07PW_T#O_(\G_Q5
M'_""^&_^@=_Y'D_^*I:%WJ]E]_\ P#HJ*YW_ (07PW_T#O\ R/)_\55?2-+L
M]'\9W5K81&&!M/CD*;V8;O,89Y)[ 4[(7/--<R6OG_P#JJ***DV"BBB@ HHH
MH **** ,V\:X3PY)):S>5.EMO1]@?!"YZ'KTQ7)V^K^*9)@$GA:)+".>::>!
M4CC9XW;)P<Y#!!@ C&<\UV5K=PBTA!8_ZM?X3Z?2I?M<']X_]\G_  K1IW>A
MC&4>5:G$Q>*]3 T<AS*99I([A/*4^:JE@)$Q@E>!A@, <FI4\;:HD+2W&C1A
M?*,@\N5V.?*67G*#C#$'W%=C]K@_O'_OD_X4?:X/[Q_[Y/\ A19]BN9=SGM)
M\376J^(?LZPP+I[12M%)\V^0I(5R,C&",''O5+3_ !9JC0V/F62W*S1Q-)*&
M*L'E\TA0H7&%\L \YY%==]K@_O'_ +Y/^%1P26=M$(H%$<8)(5$( ).3V]2:
M5GV#F7<YW_A);T7^CI=+'8K=32QRP21L6($9*L"0,#=@=.<]:K:#XBU*]U"T
MBN)EDC>\G@RL8 D01!U8$<'!R./7!Y%=?]K@_O'_ +Y/^%1M)9O/'.R@RQ@J
MCE#E0<9QQWP/RHL^P<R[ENBH/M<']X_]\G_"C[7!_>/_ 'R?\*7*^Q7/'N3T
M5!]K@_O'_OD_X4?:X/[Q_P"^3_A1ROL'/'N3T5!]K@_O'_OD_P"%'VN#^\?^
M^3_A1ROL'/'N3T5!]K@_O'_OD_X4?:X/[Q_[Y/\ A1ROL'/'N3T5!]K@_O'_
M +Y/^%'VN#^\?^^3_A1ROL'/'N3UQWBS7=:TKQ#HUMIR02P7,B(\. 9),R*K
M<9R%5"S9&>1SQ75?:X/[Q_[Y/^%'VN#^\?\ OD_X4<K[!SQ[G)6?BRYO?B!_
M9B*YTUX5:V:.,$2@Q[S(Q/(7.5! QD8/)XH6_P 0=9<)/+X=4V[*K!(9G:4[
MA-M 4H!G,)SS_&O6N\^UP?WC_P!\G_"C[7!_>/\ WR?\*.5]@YX]S"\+>*?[
M>B=;B*&*;S&6)H'9XYU"HS%"RJ?E+A3QU!KI*@^UP?WC_P!\G_"C[7!_>/\
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M0'DR1$Y<!U!R#TVR-QZ@58\,:/=:-ILT-[+;37$MP\SR6\916S@ ;23C  7
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ME_\ GO)_X[_A1Y+_ //>3_QW_"E9=QW?8EHJ+R7_ .>\G_CO^%'DO_SWD_\
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MN@HHJ9-/96&@HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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-R?9PO>VH4444BS__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "J @L# 2(  A$! Q$!_\0
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M%9Z9>O%;W"74]W/,(UCA.T1IW<G!S]/:K]IX?TT&)+F6>4W=Y):V\D3 !0O
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M3GI72;'_ +C?E1L?^XWY4 >:W?PSO[G3K"Q.JV<L%OIGV I<P.ZQ/D_OHE#
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M\):O>:G87=OJ8C.HZ==O97+Q#"2LH!#@=MRLIQV)-=!7*>#?^0IXN_[#3?\
MHB&NKH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML_V19(-\:V\K!F@==P+*&&0001P/7(!M>'M2O=0M[@7Z61EAEV+-93B2*9<
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MZJ@#E_['\8?]#9:?^"D?_'*KWMIXGTZSDN[SQG8P6\0R\CZ4 JCIR?,KL**
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M_P!!37O_  ;3_P#Q5'_"!Z?_ -!37O\ P;3_ /Q5']K^,O\ H4['_P &X_\
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MNGHS7)D,N7;#&1=KG&<#<  <4 <])XPUZTNKR.ZTW3]EC):&<Q3N2T=PP4!
M5^\O).>#QC';+\0^/-1^QZE;VX@5)(+Q;:XM&DS$\2DC]X5",2 <[2=I]<5V
M.K0>'+*TN+_45A6&Z:!9'RS&9D;,04+RQ!Z #)]ZPX;'P#?1[O*1@UPUF()S
M,IBDG!S'Y38,8<$G& #0!?B\6RZ;?75CXB@2&:*.*9'L(Y;A660N "%4L"#&
MW.,'CZ5@:GXQEMO'GGK=W*Z59W,6G3PK"YA;S!\\K/MV@H[1+R> 'KK3%X?\
M%:;=:A(5LK9F3SYY7>0GHJ DDG S@#H,U'JJ^&M'T!].OTC6POWD3[.%>1KA
MI"6?"KEF)))XZ4 1>/KJYL_",TMI)<),;FUC_P!&?9(P:>-656R,$@D9R.M<
M3>:IJMM8^+&M+C6+".QTSYK;4;L2W"S$Y26,@MA-NX9W8)[ J:]$M9]%\4Z4
M8X66ZMH9D#QN&5HY(V5U#*<,&!"G!]O6J<R>%?$<VISR^1<R6,<FGWS$LI1.
M&>-NF1P#[<X[T 8-A;:Q)=W9M[K7=)THV3B>XUB9)&CDW*5>/+,5P@DR2<<J
M<<52WZC=?88X=2U:/1+_ %F**TDDG9;B2+[/*SL&/S"-G52N>>">A%=RZ:/X
MQ\-@-MO=)OXP>"RB1,Y'H>U5F\%Z#):?9GM9WB$RSKOO)F974%0RL7R.&(X/
M>@"KX?>YLO%&KZ&U]<7UI;P6]S$]R^^2(R&0-&6ZD?(&&>1N/;%=35#2M%T[
M1()(M.M5A65]\AW%FD;IEF8DL< #DU?H **** .3\&#;J7BU1PHUMR!]88B?
MUK+^)/\ K;#_ '7_ )BMOPI:7%KJ/B=YXF1)]6:6(GHZ^3$,C\01^%8GQ)_U
MMA_NO_,5VX#_ 'F'K_F>9FW^Y5/3]4<'1117V)^:FS9Z)#=VEJQNW2YN_,\E
M/*RF4[%LY&?I34\.:A)Y841%WQN029:/*EAN';(!(QG\Z@@UJ\MK-+:+R0(P
MX20Q NF[[V&ZC-3P:GJE])#;0QI/(N#M$(+2;5P"WKA<X/:N1^W3;NK>9Z,7
MA9)*SOIMWT]?/_*XU?#U_)'<2((V6$D'#?>(7<0..P]<4MCI$-Q;6TMQ=F W
M<QA@58]^2,9+<C RP'>KKR>)+E+J)[224' D!A#%#M X]#M JA97VIV.G^;#
M&#:I-\DDD(<1RXZJ2.#C%+FJRB_>5]-GY?YE.G0A--PE:SW3[_+IYZ.UR:+P
MQ>O)$K2VZ;V4,-^612^S<1Z;N*</#%U*0()H&!) =GVJQWE !]2*?_:>J26-
MC]DMF504@\X(&:60.7 W8SU(./:H)=<U2WG,4@CB>*0$Q^4!M8.7Z?[Q-2GB
M&]&BG'!Q6L96T[]OZ_301M N(T9I985 \LAP^4PY8=1SU4CI1)X=O8YKJ+?
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M](A-3BI+J5-2TNQUBQ>RU&TBNK9_O1RKD9'0^Q]ZP1\.?"P&!I\H ["]G_\
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MWZ['/Z99RWMWMA>!7C!DQ.>& Y(QCGCM3KBV^S6SXNK&8.X)$1W,.O3C@?\
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M'+%$)+B,PW&IZ<(Y9D"8;<D;*1S@ MS@=*QX= U>/5;V**QG6UUS4+F"^?&
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M9_*E];P?:17]GYDW>\?Z^1@^*+B*8V4:78N9$60NX*D\N2 =I(Z>]<]7?_\
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MUH Z+SX?^>J?]]"CSX?^>J?]]"N=_P"%=^#?^A:TS_P'6C_A7?@W_H6M,_\
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M_P!_U_QK/_X0SPM_T+6C?^ $7_Q-'_"&>%O^A:T;_P  (O\ XF@#0_M?3/\
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AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !_ =L# 2(  A$! Q$!_\0
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M(]BI_96G?\^%K_WY7_"C^RM._P"?"U_[\K_A5NBCFEW#DCV*G]E:=_SX6O\
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MGWP171UYYXF_Y&&Z_P" ?^@"NG#P4Y.,MCFQ,W3BI1W.XTK_ ) ]E_U[Q_\
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M9)6$FR5 LB'!+$($#;R-V=H'?J,UJ:3I"Z6;AS=7%S-<,K223$$G VC& ,#
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M-VD#Q2*[D(<-A2,#!RO7/'TKGHOARB:*M@]\ID\PNTZ0X8CR6BV]?]H'\,4
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MM<QO';6L#LJ$?.0!EFQVX' K2E*5*7.NAC7IPKP=.6S[?YG*?\(7KW_07_\
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M^>:?]\BCRH_^>:?]\BGT47 9Y4?_ #S3_OD4>5'_ ,\T_P"^13Z*+@,\J/\
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M.UA^IQ0!Z$SJI 9@-QP,GJ:6O,XM+\633QFZDNY&AD9G) PK_.%:,LQ!X(Z
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M@::>P4444#"J6H?ZZP_Z^1_Z U7:I:A_KK#_ *^1_P"@-50W(GL7:X*'Q-K
MU&]G)EFLK2]N(YX_L>V..WCW?,)?XFX''<G'%=[4$5G;0Q2Q1P(L<KL\BXX9
MF.6)^N:DLYO3O&4VHZA:62:--'+/\Y,DFU5CV[MV2N2<=L?C4FK^+'TZ[OK=
M;(F.V"(UQY@XDD4E/DZD9 !Y[U9BA\.Z)?1PV\,,=V<[5C!9QT!SW Y%#:+H
M;ZK>:S<&":63:CM(X*QE5*X],\GKZT 9=IXY,5C$^J6)@?R49W60%2S1;U'3
M@M@C'8XZYI#XZ^20W-E+9-#+'OC9@SE"2&.T@<<=1D>]:VH:/H]P(D>6""&"
M2&66,%0'\L_NPV>@! _E38+3PV=0N5A@MFG$I:<CD(ZX;GLOWLT 4I_%LUL+
M66ZLA;K-&\J(;A"'7:"N6_A//I],U#;^/3/(Z_V3(!;N%NF\X?N\R"/Y<@%N
M2#VXK630O#?DK"MK9E)LE!N!+9'\)SGMQCICBK,'A[2+9)$AL(564@OQG<0=
MPSZ\C- &G7GGB;_D8;K_ (!_Z *]#KSSQ-_R,-U_P#_T 5V83XWZ''C/X:]3
MN-*_Y ]E_P!>\?\ Z"*E2\MY+N6U29&N(E#/&#RH/0FHM*_Y ]E_U[Q_^@BK
M"PQ+,\RQH)7 #.%&6 Z9-<L_B9TQORJW]:#+NX%I93W)7<(HVDVCO@9Q7.V'
MCBPO+6SN)8GMEFB=YED/S0.I4;"!U)+#&.N1ZUT5W#'<6<\,K;8Y(V1SG& 1
M@US\_@K2I[F.\62>.5+9( Z2#!V%61R,8+#:.?2I++]AXCL=3U:33[4N[QP>
M:SE2 IW%2ISR&!'3WJI>^,M+MRJ03+/(9-F,E1@$AF!(Y /!Q5C2_#<&EZE)
M?I<SR7$R,LY<C$K%MVX@#@CIQVK-'P_TB-W8-(B99E"A1LW$LWS8R>3W- %U
M_%^E*BJMS&9V'"G<$)&"P#XP2 PJ"'QMI\UO"X5EE>;RVC?*[5WE"^2,$ CM
M6;'X*EFU&)&N2ND0EY(T27<7+ <].#D$GDCGBM'_ (0?3Y%5+BXNIXHR?*1V
M&$!8LP&!SDG\J -C3=9L-6\S[%.)#&%+#:00&&5//8CH:R['QC83QR/='[,/
M.=(P0Q.Q6V;VX^4%N*D\.Z/I>AK<1V5U'*<I&_* H%&%!V@<_7K3)?"%FX*I
M<W,:R!EG"L/WJ%R^T\<<D].Q- &KIFJV>L6IN;"4RP!B@?85!(ZXR!D>XXJ[
M532].ATG3+?3[<L8;= B;CDX%6Z (+S_ (\;C_KFW\JJC_D7!_UZ?^R5:O/^
M/&X_ZYM_*JH_Y%P?]>G_ +)6D=EZF<OB?H7+;_CUA_W!_*I:BMO^/6'_ '!_
M*I"0H))  ZDU#W+6QG:MJS::UM##:27=S<LRQQ(P7(52S$D\#@?K6/HOBI[^
MRUG5[J,1:;:G, P-Q0(&8GGJ2>G\ZUKB/2=>M%\XI-$DC!6#E"&7(;!!!]0<
M=J;;6&B7.F>3;16[65SMDV(?E?;C!QZ?*/RI#,+1O&=Q=V"136BW.KM.8_(@
M/EJ5*>8&R_0!>/<J:#XUN(KN5;C3I$599(XHE*EI,"'&3GY2#+6]>Z1H^H3-
M/<PQ-*R@&19"K87..01C&3^=1)HF@FX>06D2O&0N3E5!PN,#IT5.GH* ,P>-
MPJGS]*GA8B0(&F3#.CJCC.>Q<<]^U5]/\>_;+F69["1=.0Q(\N1F%V9U.1U8
M97L*Z"XT#1[K;'+:1ED9I%PQ#*68,6!!R#N53GVJE;:+X9M=7\F"WACO85\X
MIO;@9SN()P<%\Y/3- %#6?'$-I?:?]CDC>S/[V\=XV!$1;8-OH0QR<_PJ:T_
M$7B%M!FLW:W\VTD$KSN&&Y%1-W [YK0FLM-?[6\T<+?;(@LY8_ZQ ",'VP3^
M=5C!HNL6MN&6.XMX54PEB=I#+@8/\0*GWH ETG5FU%[J&:T>UNK5U66)F#8W
M*&!!'!X-:54=/L=/TN%DLU2-9'RS%RQ=NG+$DG@ ?A5BUNX+V 3V\@DC)(#
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MYYXF_P"1ANO^ ?\ H KT.O//$W_(PW7_  #_ - %=F$^-^AQXS^&O4[C2O\
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M#>C\:Z%*25NV,07<9_*;R_N;\;L8SM.<=:A3QSI$MV(4,QC$+RR2&)@(]N,
MC&<G<,>M5SH?AU]%N@9)IK**<F8KELNL8B(&!SP.W>LN"'PC)!&W]JS,'\R%
MCL\O@%1R HV[6"\\<T =,GBW2I)1"K7!F!Q)%]G?=%SC+C'RC)ZFHK7QAI\L
M5E]H$L$UV!L38S#)) 7<!C)V]*S--L=$NM<GBM=5OSJC+NNV(*-.@; !^4
M'@;<=ZN-X$TXS02I<72& QM'AE.UDSM()&1UZ#@T 6X?$T-_+:G2K::^MI93
M%+<1J0L)QGYL_D?0\5?U.:.W2WFE;;''+N8^@"L346BZ'::#;R6]D9! [;_+
M9L@-_$P]V/)]R3WJ75(4N$@AE&Z.27:P]058&C3J95;\CMN9W_"9Z#_S^_\
MD-O\*/\ A,]!_P"?W_R&W^%'_"%Z%_SYG_OXW^-'_"%Z%_SYG_OXW^->A_L7
M][\#S/\ A4_N?B'_  F>@_\ /[_Y#;_"FP:]8ZU/;"TDRT5W@J>"1L;!'M3O
M^$+T+_GS/_?QO\:(?#EGH\$LUC"6F$@E&3DX!^Z/PR/QI/ZI9\G-?SL5#^T.
M=>UY>7K:]S?HID4J3Q++$P9'&5([BGUP'K!1110 4444 %%%% !7GGB;_D8;
MK_@'_H KT)F5$9W8*JC))Z 5S-QX=&L3OJ#RM$9CD+C^$<+^@!KIPTU"3E+8
MY<3!SBHQW-K3CY2/9-PUN<*#W0_=/Y<?A5VJ]S:F9EEB?RYT^Z^,\>A'<55E
MU9+$ :C&8,\>8OSHWTQS^8K&W,[HVNHJSV-*BLG_ (2;1_\ G\_\A/\ X4?\
M)-H__/Y_Y"?_  I^RG_*P]K3_F1K45D_\)-H_P#S^?\ D)_\*/\ A)M'_P"?
MS_R$_P#A1[*?\K#VM/\ F1K45D_\)-H__/Y_Y"?_  H_X2;1_P#G\_\ (3_X
M4>RG_*P]K3_F1K45D_\ "3:/_P _G_D)_P#"C_A)M'_Y_/\ R$_^%'LI_P K
M#VM/^9&M163_ ,)-H_\ S^?^0G_PJ2+68KW(TY#<$=6/R*/KGG\A1[.:W0>T
M@]F3:BY, MHS^]N#Y:^P_B;\!_3UJV$4)LVC;C&.V*KVUJT;M/,_F7#C!8#
M4?W5'8?SJS4M]$4EU93TYBL)M7/[RW.PY[K_  G\1^N:N56N;8R.LT+^7<(,
M*V,@C^ZP[BJTNKQ66!J"&W)Z,/G4_3'/YBG9R=T3?E5F:5%9/_"3:1_S]_\
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F:O44<WD@Y?-E+['+<,#>RJZ Y$,:X3/OW;]![5=HHJ6VRDDC_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $O 90# 2(  A$! Q$!_\0
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MW=.T%]'()8(XRLC ME1C()/ /]WUK)MM"OM&L-"N;72O-EM[:2*Y@A*J^]U
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MO^%AZ]_SPTS_ +]R?_%T?\+#U[_GAIG_ '[D_P#BZ/[-Q/\ +^*#^V\%_/\
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M)_E_%"_MO!?S_@SU&F2PQ3ILEC21/[KJ"*\Q_P"%AZ]_SPTS_OW)_P#%T?\
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M!<_SK8MOAI,PS>:OC_9MX0/U;->AT5QSS'$2^U;T/2I9-@Z?V+^NIRUM\/=
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M<0R-:?V5'<W]JO38S89P/4<&M[PYXOTZPT[6-1U;50MF^KS1V\LA+#;@%5&
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M)Z.D][<7"+>27C#+W 5MH"A0J\<# KS;4O#^I1/X6TK4-,BU>[2UN&-G+=%
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M@5)10Y-[L$DM@HHHJ1A1110 4444 16_^K_&I:BM_P#5_C4M !1110 4444
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M2*FTQW!*CYV)YZY/![U7U/P?H7BO6X-8U$IJ4$%NT$-N2K0J2P+.,<[N .M
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MN,T :Q^'^J?VG(XU&U-C_;R:PBF-O,'&'0GIZ8I-.^'5]97EC.]_;L+9=0#
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MKF.,(01C^%0>G'XUF6WPPTJS\(G0(+NZ5?M@O?M#;6<R!LKN!&UE  &",8%
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MTYHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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2KN:* "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ## 8D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#KM6\5:U;Z
MQ>00WA6..9E5=HX -4_^$NU__G]?_OV/\*J:S(\/B2]EC.UTN693Z'-;NI:K
MJ$_AS2!YQ9[WS(YMJ+F0;L8Z>E?6>SIQC#W$[_Y7['Y[[:M.=6]62Y;[7[V[
M^:,S_A,-=_Y_C_WP/\*/^$PUW_G^/_? _P *TY_#FG>5&8UEB=;R*WE0SASA
MC@YP,*WMS4#Z3HXGU1TBNV@TT;73S!NE8L1D'' &*2GAGM#\%Y+]2I4\='>J
M_P#P)]F_P2=RG_PF&N_\_P ?^^!_A1_PF&N_\_Y_[X%:7_"-Z<)3-F86Z6,=
MR8Y90C%G)&"V. *<EAI-G9:UL5KA!;QNK"0$IN/W<X['OW%+GPW2%_DAJECE
M\55K?[3Z*YE_\)AKO_/\?^^!_A1_PF&N_P#/\?\ O@?X5AT5U_5Z/\B^Y'F_
M7<3_ ,_)?>S<_P"$PUW_ )_C_P!\#_"C_A,-=_Y_C_WP/\*PZ*/J]'^1?<@^
MNXG_ )^2^]FY_P )AKO_ #_'_O@?X4?\)AKO_/\ '_O@?X5AT4?5Z/\ (ON0
M?7<3_P _)?>S<_X3#7?^?X_]\#_"C_A,-=_Y_C_WP/\ "L.BCZO1_D7W(/KN
M)_Y^2^]FY_PF&N_\_P ?^^!_A5O3?%>M3W@22]++L<XVCJ%)%<Q5[2/^0@/^
MN<G_ *":BIAZ2@_=7W(UHXS$.I%.H]^[+P\8:[C_ (_C_P!\#_"C_A,-=_Y_
MC_WP/\*PQT%%7]7H_P B^Y&7UW$_\_)?>S='B_7CTOF/T0?X4'Q?KPZWS#ZH
M/\*M>$9%@M=8F:9H=D"GS40.R\]0#UH9K;7-<M;2>\N[Q)$*)(81&T;'O@=1
MZUS-4E.4735EUMY7[?J=\7B)4HR59WELK^=N]_P*G_"8:[_S_'_O@?X4?\)A
MKO\ S_'_ +X'^%7SX?TZ+4KZTD6[865GYKL& ,C\$E1CA:6#0=+G:*[Q<I:2
MV3W'E;QO4J<8SCD&ESX7?D_!>I7L\?>WM'_X$^CL_P 3/_X3#7?^?X_]\#_"
MC_A,-=_Y_C_WP/\ "K]GH>D7%E!=2M)%'>2.L6ZX4&%1QGI\YS3;+0-/N=-_
M=%[F]*R959@C @G!52/F'OFARPRWA^ E3QSM:H]5?XG_ %J4O^$PUW_G^/\
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MT:]6,>52=O4V]/\ $ES:"8S.\DGV7[/ XQE.01GU%4Y-:U&:=YGN6+O$83P
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M^;Q+:6]P;>;5;.*<'!C>5 P/I@FK U8FX^SBZB,^W?Y61NV^N.N/>J_M.?\
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M2IQG!].*GZXM/W:T\RO[)GK^^EKY+S_S9Y/]BN_^?6?_ +]FC[%=_P#/K/\
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M8%/_ )^/[E_F>2?8KO\ Y]9_^_9H^Q7?_/K/_P!^S7K?VZX_O_H*/MUQ_?\
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M7-R>$+?[9;/;W+0VL:P+)!L!+^22R$-U'+'/K72'DU2OU)=N@44450@HHHH
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MOFQ?\]1^1H\V+_GJ/R-%F%T.HIOFQ?\ /4?D:/-B_P">H_(T68712UVP?5=
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M1H\V+_GJ/R-59BNAU%-\V+_GJ/R-'FQ?\]1^1HLPNAU%-\V+_GJ/R-'FQ?\
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MS *_AC->M;6]#1AL8YQZ4K!<\MT+PC:G_A#OM.DG][%<_P!H>8I^?@%!+GJ
M>@/3'%5=+L8K2&U_X2;2;NZTY+&6WLH_L[2B*03/E=HY5BFS:WH.M>N;6]#1
MAQZT6"YB^%(+^V\)Z7#J>_[:ENHE#G+ ]@3Z@8!^E;%+M;THVMZ4Q"44NUO2
MC:WI3 2BEVMZ4;6]* $HI=K>E&UO2@!*<GWJ3:WI3D5MW2DP&44NUO2C:WI3
M 2BEVMZ4;6]* $HI=K>E&UO2@#F_'=O-=>#;V&WB>65FBPB+DG$BD\?2N<U#
M2K_P_P",])CM;66?05O)[^(QKN^RN8GWQX_NL3N7W)%>D;6]#1M8= :30[GG
M(TK6;L^'=-MQ';O KZO>37,+21F=R=L9 (RP+,>O\(K:\$6]_I-M?Z#?KN^P
M3EK:=(RL<D,GS@+DG[I++C/85UFUO0T;6]#18+C:*7:WI1M;TIB$HI=K>E&U
MO2@!**7:WI1M;TH 5NB_2FT]E;"\=J;M;TI )12[6]*-K>E,!**7:WI1M;TH
M 2N2^(.D?VGI%G)#%,UU%>11AX"0XAD8)*,C^$H3FNNVMZ4NUO0TF!Y/XET:
M:/7]6@DAE6-HH8](\C3S.415QMA<$")@W)SCL<U-964]GXUAECLIKJZ:_+3_
M &JT*31 KAI5N%.UH_1#GKBO4L,!@9HPV,<XI6'<;12[6]*-K>E4(2BEVMZ4
M;6]* $HI=K>E&UO2@!\/^N6K=585(E7(JU6<]S2.P4445!04444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
L !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #A 7L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M -*)*ZBN5^'4:0^"K:*-0D:7%TJJ.@ N) !754 %%%% !1110 4444 %%%%
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MC.U0 Q.3TX".?^ FNAK)F\-:5<7ZWCVH\Q4*!5.%P>IP.,D$CZ&M:@ HHHH
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AO%#V5PA8*&C8$DX
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MQ=7"S$G*E8]N!@<>_.3^-6*&K G<****0PHHHH **** "BBB@ HHHH ****
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M83+ LEG PMW$D0*#Y& (!'N 30!X>-*TH?%R+Q8WQ$T^6T1UD*23_OR N-F
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
8B@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image_015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #_ =,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKG%9'P_U"[U7P+I5[?3>==21MYDF,;B&89_2@#I:*** "BBB@ HHHH ****
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M,/\ DG&C?]<W_P#1C4 ==16%_;6H?V[_ &=_9+^7C=Y_F#&WIG%;M !1110
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MJ>B@+'.?\(7IIG$KRW3[,^6C2Y6,'L!6KI6E0:/9?9;9I#$&+#>V2,G-7J*
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MM<9'-;DJ1R1,DJJT9ZAAD5'##:QNS01PJQ !*  X_"A>8GY$]%&0.])D>HH
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M]!/7J5W_ ,><_P#US;^5>76__)O47_7$?^E% ',_Q_C7HOA#_DDL?_7M<?\
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M)7++QRWT'4UG>&/#US]LCU6[BMK91&J16]LVZ-U X?V.>:NZ;;WFJ(+/Q%:
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M XJ[XA\4KI96*V,,DN[8S,WRHQ' ..AS@_0&MC5-3M](TZ:]N2?*B'11DD]
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M!'TKNM.TRVTY9#!$L9E;>RCH">N/;/-6RB%U<JI9<X8CD4ZDM%8'J[A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
# ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>image_016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $  2@# 2(  A$! Q$!_\0
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MT94Y8<U9EE&*\!=S[J2O9$GVC!Q4ZD2#K6.\OS5;M+Q5;!&::EJ3.%E=%EH
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M+3Q)BJ@CG_YXR?\ ?!IXCF[Q2?\ ?)JK$ILM>90)/>H!'-_SRD_[Y-*(YO\
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M-:OK&"U@D6",["[$-O&SJ/3Y^N.W>CV<KV#F1V=%<-=^*=521D8VL7EB5&"
MY=TG5,J3VVG.,&KNHW.K7FKZ;]EO;W2X9KA[=X)+>)MX16;>"<\-@#KT[4>S
M8<R.LHKFM2\2SV.K7=LL4!6V@\Q869A-<'8S?NP!@@8P:Q/^$MU:ZBM9@([?
MS%Y$9616_?1+G/..'88S0J<F#DD>@45R6K^+Y]-\1-IT5FD\:0LS $B0L(V<
M #N#MQT_PJG=>*]0\B.6.ZT]HVMY')MB6W.K)@*3W 8Y'-"IR8.21W-%<;<>
M)]2:[DM4MTB:VNTMI7P<.S%B ,]1L"D]_FJ70_$U_?7.G6-Q';R3W$"W+2Q
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MON)/O6[Y^N?\^%G_ .!+?_$U,H+HQJIW3^XU:1F5%+,0J@9))P *S//UP_\
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E=[10NC*]P]UJ;J5^UL/*5A@B)1A?SY/XT5JT5,G=W+C'E5C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>image_017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #" A0# 2(  A$! Q$!_\0
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M;:;%M; N$:Y$<A'R;3N&<Y(S6;IQNM2U4>NALT5R*:3JBZI=%OM&TF4))'(
M&C*X1<EN"./X>",YJ.TT_5[>T0BUEVPW<4H7>%DD4 ALC<5[CN,U7L8_S"]J
M_P"4ZN:]MK>7RYIE1MC2?-Q\HZG-.EN8H(1+(^(R0 <$]3@?SKDIM&U&[M6$
MMNWF&"Z #2 X9G#(,Y]JV+JUN7\/VT%K#)%*K0YC+_,H##=DY],]Z'3@K:@J
MDG?0VJ*YFRTN]@U2VNF64$W-P9B9<CRSG9QG&,XJMK$-U=Z]>PVL4\DP@B,+
MI-L6%R3\Q&>>GH?UI*DG*W,#JM*]CKZ*Y1=-U;^UC)MD6?[2[F\,N8S"5.$V
M9]<=NV<U4_LG5S8SI#!<0RFW"2EKC=YTN\'>O/' //'7%-48_P R!U9?RG9S
M316\32S2+'&HRS,< 4^L76])\[PS-I]G$6( ,:%SDD-GJ3]>M4&M-3^V>7':
MS+ UY!.',HPD84!E/.<C'2IC3C)7N5*;3M8ZFBN+70+\VB[XYS,;6??^_/,N
M[]WW]/PJR=.U1M221HIC/YL3)<^?A(XP!O0KGD_>[<YJO8Q_F)]K+^4ZNBLG
MP_I\ECI^ZX5Q=2,QDWR%N-QV]\#@CI6M6,DD[)FL6VKL****DH***R_$CO'X
M<OWC9E<1$AE."*J,>:27<F3Y4V:E%8-]KL:6EL+&\M&,DJ123,X=8003EL'O
MC R16=+XDU1;:(PP0S23[XX&53M=T?!;K]TJ<CW%:QH39FZT$=?16+::E-J6
M@WMZ1LC82>1@$'8!C)]\@UREA>7TCZ5;//+MMIXF=BQ_>"4J5'OP6IQH.5[O
M84JZ5M-ST6BN&CGC6>2:&\D.I_VHT:PB<G<F_!!3.-N,\XIUC<M#JZM%=&ZE
ME>8*4G8.3@X66)N@'J,=JKZN[;D^W78[>BN/TF>S2.UN4U"9]4>&1YHVE9E9
M@N3Y@YV 'ITK3\.ZQ/J?GI<M&9(PC?NU&,,.Q#$$>G0U$Z+C=]BXU5*R[F[1
M7('Q/=M<7*PO;/&(I7B+C8%*L ,_-G\P/RH?Q+??8%=7@\P3.DFY5# !01@;
M]K>^&Z=J?U>8O;P.OHKE)O$UT'+QM;A4C@=870A[GS.NSGC'XTVZURXFM]1#
MSVHVK<(MJ PE78."2#WZ]NO!H6'F'MX'6T5RCZ]=#48K2"2'8Q$)!3E&\O=G
MELGGVQ[YJE;^)-0@L;!%D@F9K83-)(0-[%\;,EAR.YY.2.*%AYM"^L0.XHKD
M9-6N;O6+2-YXHE346B^S+D2;54\MSR#]/2M/7M5O-,E@6WB607 ,<8*DGS<C
M;GGH1N_*I=&5TNK*]K&S?8VZ*XJ37+S4/)N(PL(>.X$!PVX%(@2<9P?FSCCC
M%,CU34+:)[V.ZBF\K3X)) X)#DL01UX/J?45?U:7<GZQ$[BBLK7;^XL+&.6V
M,0=Y50^80.#G[N2 3[$UAKKUP;J.\>\1(#ISR;&B(4N'P<+G.>/R_.HA1E)7
M1<JL8NS.QHKC8];O[JYM%>ZBB5+X1.P  <%"P!PQ'J.O7'I4</B*ZM+.R(,*
MP%69^KO_ *UEZ%MV,>F>:OZM,CZQ$[:BN/BU"Z6\(EE^T,FIRHJ9(95",0.#
MT.. 14L?B.<Z>)GO;-I91$52.(DQ%S]UOFQ^9'O2>'ET&J\>IU=%<#=ZM=7M
MD]P\IC?[!,#Y38&5F50PP3SC^==!;ZM>R:Y_9;)'NCD=Y'"G!AV@H1SU)8 _
M0T2H22"->+9O4445SFX4444 %%%% !1110 4444 %%%% !1110 4444 -:.-
MRI=%8J<J2,X^E.HHH **** "BBB@"*ZN8[.UEN9B1%$I=B!G@5FGQ)IRB,N9
MD#@-\T3#8I. S>@)Z5?OK1+ZQGM'9E29"A*]0",5GW?AVVNKJ*X,KHR1K$PV
MJV]5.1U!P?<5K#V=O?,I\_V20>(+ FYP92ELKF1Q&=OR_>Y_SFFKXCT\Q22$
MS*5V81HF#OO^[M'4YJI?>&%E-[<13N]Q-#*B*P51EQCYB!E@.V>E/C\-(T :
MXNYWN@(MDWRYBV<J!Q@\D]>M:6HVO<B]6]K%AO$=@J1M^_9W+KY:PL74IC<"
M.Q&:?'K]C+=0V\322-*J."L9( ;[N?3^G>HX?#\$,L<QGE>93*SNV,R-( "3
MQZ 8Q4/_  B]OOLR;B4K:JBJ"JY^7IAL9&>X!I6H^8[U2[9:U97]RT$#L6 )
M4E" X!P2I[X-7]H#%L#)ZFLK3= M]+N6EAD9EP0B%5^4$Y/(&3^)Z5K5E/EO
M[FQI#FM[VX4445!84444 %%%% !1110 4444 %(RJZE64,IZ@C(-+10!4F6S
MMK:=C!'Y:KF1$C!)'T'6IPL)"85!M&4&/N_3TKDCX?U$-J*QPQJD\,J!F=6)
M+'(PV <>NZH)8BOB&. Q++<?VA%+YOS;U0*,KC'W1CKG'XUU>R3VD<WM6MXG
M8RRP6UJ[%1Y4:DE47/'L!5,:EI_VQK9(V:1&16*PDA2?N@G'&,_A6"GAJ\CT
M](XXHUG:SGBF(;[S,P*Y/>K7]@7"WDDT<42[KV";<" =BJ-WZY.*.2FK^\'/
M-V]TZ)8K=96D6.(2#[S #/XFA8[=7,ZI$'8<R #)'UKE(]#U"*PG@6PM&GV;
M'N&E)-SEP22.G3/WN_M1:>&[HM"EU!&T"27+;&<$ .%V\  =0>@P*7LX_P P
M_:2_E.GCDM!?2Q1^6+D*&D"KAL'ID_A1 UM'/+;PQ"-DPS83:IS[]">*QM%T
MBYL-1CGG@C8FRCB:4,"5=>"/?(QS[4FHZ)<WFK2R^6C6\DULQ!;JJ;MW'XCZ
MU+A'FMS:#4I<M[&Z(;8,S".++ EB%'.>I-)]GM?)\KR8?*4_<VC:#]*Y*[T&
M>SL)IDA1=L-XK[#R5;_5C'<#'3M3H?#]U<1)FTA@@=[8R0B3(<+G>Y]R#CUJ
M_9QM?F)]I*]N4ZTI \B.5C+J,H2!D#VH\F NSF.,LXPQVC+#W]17-OH-TNK;
MH[>'RQ<I+'=;\-%$H \H+Z<$>G-,/AJ]^RW\*S* L1@L?F^[&7W$$^_"_05/
MLX_S%<\OY3IO*M]WF^7%NX^? SQ[T?9[8 #RHL1G</E'RGU]JY>#P[<L]OY]
MN@@$LSM"[J0H:,!>% '49P/K41\,WZVHCB6-"UI$LP#C][(KDL#]1W/TZ4_9
MP_G%[27\IUQC@W^<4CWG!WX&?;FFB>VFNGM@Z/-"%=DZE<YP?YUS,?ANXD2
M7$"-&L=Q^Z=PP1GQM'  ['IP*N:)I%Q8:B9YX(R9+.&-I@P)#JN&'J<\<^U)
MP@DWS#4Y-KW39C>W:>2%8PK0XZI@?,,\'O[XI)1:6MG+,T<:P)&6?:@QM'/^
M-8E_HES=ZK-*8T:WDNK>0@MU1%8-Q^(X[U8M]+N(?#FH6 5 \GGB% > K9VC
MVZTN6-D^;L/FE=JW<5O$>D36TIE+[%17,<L# LI( (!'(R1TI[:OIHA21[>8
M'<8HXVM6WMQDA5QG&*S[CPN3HGEHTLM\T<49:68G8H92RJ>PXJUJ6CL+."&V
MMS=QI(799;AA*,C@I(3QCTJ[4MDR+U>J-*S:QO;-)K:.-H6.1^[Q@CCH1P14
MWDVS[#Y<1V'Y3M'RGV]*S[&TU"'P_);SLLET4<()'+ 9SM5FX)]S6#:>&[X$
M+-;QK"US;RM'O7&%#!^ ,=Q]1UJ5"+;][8ISDDO=.MD^S0H]PR1@#YRX49.!
MU_*J[7&FKI;7SK$MG(@E9F3 8'H2.YZ5STGA^]6)4^RPW$0^T(D+2;1%O;*.
M/H./6M6?2KF;PO;6*E%NH8XB QRI9,'!]N*'""M[W4%*3O[O0>FLZ0T$[L/*
M$*[G26 HVTG@A2,D$XZ=Z=I)L9[N\NH&N#<LP65;A2K1CJ% (&!S6?<:=J>I
MSSWEQ9VL3"V\A+>23>),L&8DC&.G'OS5S0+*]M#<FX5XH'*^3 \WFM'@<_-Z
M'CBG)1479Z^HHN3DKK3T-JBBBN8Z HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **;(2(G*YSM.,8_K6!X=O-0ET^YDN_,N)4<;%!3)&!P.>OUX]* .AH
MK+N-=@M=$N=4GAG2.WW"2/ +@JVTC@X//O7/?\+.T?\ Y\]0_P"^$_\ BJVI
MT*M76G%OT,:N(I4FE4DE?NSM:*XG_A9VC_\ /GJ'_?"?_%4O_"SM&_Y]-0_[
M]I_\56GU+$_\^W]QC]>PO_/Q?>=K17%_\+-T;_GTU#_OVG_Q5'_"S=&_Y]-0
M_P"_:?\ Q5/ZEB?^?;^X/KV%_P"?B^\[2BN+_P"%FZ-_SZ:A_P!^T_\ BJ/^
M%FZ-_P ^FH?]^T_^*H^I8G_GV_N#Z]A?^?B^\[2BL7P_XFLO$8N#:17$?D%0
MXF4#.<XQ@GT-:EW<I9V<]U*&,<,;2-M&3@#)Q^5<TH2A+EDK,ZH3C.*E%W3)
MJ*XH?$[1B ?LFH?]^T_^*I?^%FZ-_P ^FH?]^T_^*KI^I8G_ )]O[CE^O87_
M )^+[SM**XO_ (6;HW_/IJ'_ '[3_P"*H_X6;HW_ #Z:A_W[3_XJCZEB?^?;
M^X/KV%_Y^+[SM**XO_A9NC?\^FH?]^T_^*IK?%'0U^];WJ_54'_L]+ZGB/\
MGV_N#Z]AO^?B^\[:BN(_X6GH/_/&\_*/_P"+K1T/QSI&O7[65MYL<HC,@\[8
M 0"!@88\\BHGAJT%S2BTO0TABJ$Y<L9IOU.FHHHK Z HHHH **** "F/+'&A
M=W55'4L< 4YNE9$EGJ5Y:ZI;7WV:2&9_]%6-BA$>!PQQUR,Y&>N.U &LLB.
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M(JU5*>XG6YV+I[2H&4"3>O<C)Q[<_E5V@ HHHH **** "BBB@ HHHH ****
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M#_SVC_[[%'VB'_GM'_WV*/:0[K[T'LY]G]S_ ,CTCX6?=U;_ 'HOY-7::_\
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M''  XV*R,N <?=*,0PY(K3D1G[1G=>(+.#7=+^R"[$.)%??L+=,]JYA?!(0
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M /WM<D>M=?K/_(G:Q_UWE_\ 1M<@>M?%\2_Q*?H_S/H\F^"?JOR"BBBOE3W
MHHHH **** .H\#?\?.I_2'_V>NAU_P#Y%S4_^O27_P! -<]X'_X^=3^D/_L]
M=#K_ /R+FI_]>DO_ * :_3<I_P!SI>GZL^+Q_P#O$_7]#P9?N+]!2TB_<7Z"
MEK]>/Q]A1110 4444 %=A\-/^1HG_P"O-_\ T-*X^NP^&G_(T3_]>;_^AI7F
MYK_N<_E^:/4RC_?8?/\ )GK%%%%?"'Z"%%%% !1110 C?=K'N-&EN+V]F\Y
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M)LH/.>?5+=;FW'E 8C.<%LG(Z'CGI4NH>+M&TRZU"VN+@^;I]I]LN0L>0B9
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M $ U^@Y9"5/"TXS5FE^I\IC91E7G*+NCP9?N+]!2TB_<7Z"EK]</R!A1110
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M]L?_ &>NFU__ )%S4_\ KTE_] --;B>QX,OW%^@I:1?N+]!2U^F'Y6PHHHH
M**** "NP^&G_ "-$_P#UYO\ ^AI7'UV'PT_Y&B?_ *\W_P#0TKS<U_W.?R_-
M'J91_OL/G^3/6****^$/T$**** "BBB@!&^[2TC?=I: *P_Y"C_]<5_]"-6:
MK#_D*/\ ]<5_]"-6: *TEO(UW'/%(B8&UP4W%ESG .>/R--MVNDNF@N")5*[
MQ*L>P#G&WJ>>]6ZJ2)(FH),D<CJR>6V& 5><YP3G\J +=%5?M-SY>[[#)NW8
MV^8G3UZTK7%P/,Q9.VT@+\Z_/[CGC\: *ZV5]"T@@OHEC:1G"M;[B-QSC.X9
MZT[[/J?_ #_P?^ Q_P#BZLPW!EDEC,3HT>W.[H<C/!_2IJ *'V?4_P#G_@_\
M!C_\74MO%>))F>ZBE3'W5AV'/UW&K5% !2#O2T@[T 5=3_Y!EQ_N5;JIJ?\
MR#+C_<JW0 4444 (0""",@]159--LX_)V6Z+Y/\ J\?P_2K5% %"6PMX(XO)
MM@=LRN "1@Y )_*K]0W,)FAVJ0&5@ZYZ9!R,^U-7[9F/=Y&,?/C/7V_2@"Q6
M?82QK)>AI%!^TMP3[+4CRW4,<;RFW WA7QNZ$@#'ODU*]E:2N7DM87<]6:,$
MF@";.0"*6DP%    '  I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY/Q7^8?VCAOYOP9A5M^$/^1D_P"W63_T)*=_PAVK_P#/6Q_[[?\ ^)K3\/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#R=5'DZU)@;UO0%;'(^9^AJC:RR2(J.[,@U Q!6
M.0$ 8A?IDDX]Z**IE'HW@JXFNO"MI-<3232L7W/(Q9C\QZDUT%%%22%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>image_018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #& ;4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH KW%SY$UK'LW>?(8\Y^[\K-G_QVJ7]NP+<O \4I993'E%R!\P4$_BP
MJ[=V-M?Q"*ZA65 VX!NQ]?UIJ:;91C"6T8Z=O0@C]0#^%:)PMJ0U.^A2MO$$
M$\*,T$R2/M_=G'\2LPYSCHAH3Q'9M )6BN$4A6 = "0Q;!Z]#L/Z59;1M-<8
M:SB(P5^[V.>/U/YT?V/I_P F;2,[!A<C.!_DG\ZJ]+LR;5.Z*T?B*TD#?N;E
M2JD[60 G[O YZ_.I_&D@\0VLTK!T>.#Y=DS?=.4#X/H<9_*KCZ58."&M8B/I
M]/\ XE?R%+#IEE;S+-#:QI(J[0P'(&,?RXHO3MLPM4[HI#Q%:_;;FWQN$>T1
MF-@QE8D# ';DKU]:6;6+B.>2-;(;5A\P-),%V]/O\?*.3ZD[3Q5Q]+L9!A[6
M(\L?N\Y8Y/Z\U"VA:6Y<M91$NH5N.H&,#]!0G3["M4[D%GK;W.H+;2VIMPT(
MD!D)R6P"5'&#@$=\^U2?V[;"&&8Q3K',X6-BH^8'&&Z].1[^U6H-.L[:830V
MT:2!!&' YVCMFF?V/IW'^AQ<-N'R]#Q_@/RH;IWV&E4MN57\1V2*A*S8<(0=
MG #;L9.<#[II'\2V"ASB8JDGEE@G'<9SG&/E/6K7]CZ=\W^AQ?.=S?+UZ_XG
MCWIS:58NKJUK&5=M[#'!/^<T7I=F%JG=$-UK$=IJ*VLD3E&16\U>0"S%0#^(
M_6HI/$=G&%/ESME _P J9PI4-GKZ,*T)+.VED$DD*,X"C)']TY'Y'FH4TC3X
MU*I9Q '.0%]<?X#\J2=.VJ&U/HRK)XBLX@N])EW*[8VC(*[LJ>>ORGVI+O7X
M[:R2Y6WD(^TB"1'^5D]3WZ#FKCZ38/(7:TB+$$$[?7.?_0C^=226%K*C));Q
MLK.9"".K$8)_*G>GIH*U3N8:>*)91+)%8J8H1([DS8/EJ1R!CDD'.*F_X2)_
M/FA-EMDWJD"M)CS,MM!Z8 ]QGTZU?;1=,9T=K*$LARN5Z=/\!^5/.DZ>3.39
MPYG_ -;\@^;O_/FJYJ78GEJ]R&;53:V"33VY\]BRB&)@_*@D\^F%)_IFJ\7B
M:SD50(YFD.Q=J+G+-C@'V)[XK0;3;)[1+5K6+R$^['MX'^<G\ZAFT6PG7:8
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M\KM>Q/,KVOJ9L7B(R+*QTN]58XRY9DP"1V^OKZ4D>OSF)7ETR=&DWF., EB
M^T9XP"1SUZ5MQOYB!@K#/9A@TZD483>(I5A63^R;P_OBCJ$)*H!RW ^G'OUJ
M&;Q+.H?R;'>1T!9A_ &/\..,@>^>.AK>:1BYCC4%AU)Z+5:>Z$;FW-Y$)B.%
M"_,!Z@9H':Y<C?S(D?:5W*#AA@CZBG5G6NHJ'AM[AP)9%+)GJ5!QD_F/SK1H
M$%%%% !TJ%?W[!S_ *L<J/4^O^%!_?MM'^J!Y_VCZ?2IJK8GXO0*YG7;*X/B
M32+^#4_LL2R"*>%[ID6;G*C8.&/WO?IU Q735G7.B6EWJ\&I3^8\T";8UW?*
MISG=CU[?2I*)KS4([*2%9$D(DW<HN[&!GH.3^ K$\$3I<Z9J,\8<))JEVR[T
M*-CS3U! (^AKIJY[PA_QZ:K_ -A:\_\ 1IH UIM,L[B_AOI8=UQ",(VX^^,C
M.#C<<9Z9.*MT44 4KO5]/L+VSL[J[CBN;UBEO&QYD(&2!^8_.KM12VUO-+%+
M+!%))"28W9 2A/!(/;\*EJY<ME;?K_P/D! __'_#_P!<W_FM3U7?_C_A_P"N
M;_S6K%0 4444 9NAZ.-$L6M1?7EYNE>7S+N3>XW'.,^@J[<_\>LW^XW\JEJ*
MY_X])O\ <;^57.<IR<I;L%H2+]T?2EI%^Z/I49N(%N%MS-&)V7<L98;B/7'7
M%0!+5>YL+.\EMY;FUAFDMW\R%I$#&-O5<]#4KRQQ;?,=4W':NXXR?040S17$
M2RPR))&WW71@0?Q%--IW3 ?1112 **** "BBB@ HHHH **** "BBB@#+UO18
M-8M2KAA,BMY3J<$$CI],XKS>:":$_9[B&590<$L#@'Z>E>N4C(K8W*#CID4[
MEQERGF/A^\M)KB6VVN+I%W@R#&Y,XROMFNGMK6:Y;$*\=W/W1_C6Y%I.GPW4
MUU'90+/-_K) @RWXU;  &  !Z"KE.[T",HI/35C8D\N%$)R54#/K4-XMH%CF
MNQ'M@?S$:3^%L$9'O@FK-1/;PR2K*\2-(GW689(^E1=F=D4Q/?WG-O&MO#VD
MF&6;Z+V_&C^S[LN6;4Y<'J%0"M&LN[BOKVX\N/\ <11L,ECD2#OQ22&W;8SK
MN^U.QD@AL8#J$3R+$Q5@K(#U?'\0Z9Y'K[5H)9WID69_(\S;@Y8\9[#CVJFG
MB/2;2--HN"[G:W[H[@>V[T'IVJ<>*+$Q&3R[CARA&SG(4L3UZ?*?KQC.13=N
M@E?J/@TR22YD:\B0+G*F.5OF]B./_KUK@ # X%5+'4(]03S(8Y1'M#!W4 ')
M((Z]1CGZBK=(9SFI>!]"U;4);Z[MY6GEQO*S,H. !T!]!57_ (5KX9_Y])O_
M  (?_&NMHK98BJE929SO"T).[@ON.*O?AAH$]H\=JDMM,<8E\QGV\\\$X/&1
M6G:^$[+2-$DLM,9H7/S^?(VXAP.&P> 1],5N7%U';CYCEB,A1U-9%O;ZAJ=Y
M<'4XX/L".&MEC)'F*5_C!]#GV/'%$ZU6<.64G8(8>C"?-&*3*WAZ?6_[-\NY
M=;NY+DM.S#RT'3:I &[IG/O6MY&IL?FO(D]EBS_.KZJ%4*H  & !VI:YH048
MJ*Z'2V9+27]B,-"US'CEX5&]FSUQ5==+F&H->?9E+,V[YI "#^M;U<S!=7!^
M)5U:F>0VXTU7$18[0V_&<=,UK&GSW\M2)5G3M;KI_7W&A;6,TLKFY66)0V=J
MR@JP]..1QBM:BBI*"HG)D8Q(< ??8=O8>]+(Y+>7']\]3_='K3D01H%7H/UI
M[:DO7050%4*!@#@"EHHI%!1110!2OM.^VR0O]IEA,889C(SR,9&>A'^-847@
M^/3+>=H_$>N11%WN)3YZ'YB=S-]SUR:ZJD(# @@$'@@T <>=/B5RC>)O$08$
M*073@G'_ $S_ -I?SJ,Z3+-+#/:^+M7:UC)6YC\U#)N8#8H_=\')YSZUU@TZ
MR&<6D SC_EF.U2_9X?),/E)Y1&"FT8Q]* ..EM[2%T23Q9KZNY(1#(F6QG)_
MU?3Y3^57[?0!=QF2W\5ZW*@8H62XC(R#@C[GK6[_ &?9;<?9(,9SCRQUQBK"
MJJC"@ >@% '/?\(I*6#?\)+KNX# /GQ__$>U4KG3(K64QR>*/$&0VPXE0@';
MNQ_J_P"Z,UU]02V=K/('EMXI'&,,R D8H Y(VUFDBH_BW7DW!B"\BJ, D'),
M?'W31;Z//#9PF]\5ZU-,XW[[>1-I5FPF/W?<$#ZUUS6ELTBNUO$70DJQ09&<
MYQ^9_.B:TM[@ 301R8&!N4' H Y)+6R=V4>,-;&TX9FGC !XXR8^O(XK1/A6
M5@0?$NND'@_OX_\ XW6XMI;HX=8(E8<9" '_ #Q4U '/?\(M-_T,VN_]_P"/
M_P"-U0U'P="R^;=>)-?.[;&N)X\[CD#'[OK\[#\:["FR1I-&4D170]589!H
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M^0KFO#.D>(+-]1_X237TU!)KC=:)$=GEID_*< $]N/:NIBBBB0+$BJO;:.*
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<@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>image_019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "J DT# 2(  A$! Q$!_\0
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M* /0Z*X/P9XXU/Q!?V,&HV%I!'J&G/?0-;RLQ4)((RK9'?<",?2N\H ****
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M1D' QT^I ZD5935-.DCDD34+1DB<1R,LZD(Y. I.>"3QBBZ#4F^SK_STN/\
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M#_GZMO\ P';_ .+HMYA?R+=%5/+U#_GZMO\ P';_ .+H\O4/^?JV_P# =O\
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MMC/':V6II$UNC&ZNC<*Q7>,8+ G'4Y_2O5*Q];U]=%FM(19274MSO*JDT40
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M7-9,/@^]A1G34;6WE><2O#9VS00 !"GR@/N5CG)(89P >*=XGM=9UN&WT?\
MLVS:*:5I9]]P_E-$@X5F"9#%V4@ '[AYHDN_$*>$].G6"?\ M2"3[+=PHN?,
M.&B\T9'*AMDF?3-/0E7[D,?@AH+2R@&I(9[5;<0Y#H',,;H<[7#<B0G@\$=Q
M4=[X3N;?1[BWTZX62=XX8XC"F#!<)*SB3)8X4>8V0<GZYJI=Q>)+_2)8KM+M
MI1'=6GRQ ,YCMV7S5../,DY&.HP*T-'M]0MM3%S#)?FVN=3*R131X4P_9EQ(
MP*@@[U SQSQBD/7N=)I\?V"T>VD:".VM2(H-K8VQ!5"[\GANOZ5@6W@^Y@MT
MMFU"%H'2V2X(@.\B!]R;#N^4D8!SG!R1UJIJ&G7X\47NI36SW>CQ7L#R6*Q$
MM+^Y1?.'_/3RV ^3'9CU J!+WQ6D=]<7$TR26\4MQ-$8CL'ER!E56*A<,@8?
M*6R#DX(HOW%9]&7XO QBGC<WJ2(WE>>K*XSY<A<;0'"]\?,#@C(I;[P7<W6B
MPZ9%JBQ1K:S6TA$3#=YC;MWRL"?3:20>N*H11:W)?I<M<:E%-J,=DSM&N5BB
M:60NH^4A2JL@]>2:GNK_ ,1(#:VJ7[7$+WGF2&WR#'O7RBK$;6;825 ZD<^E
M&@]>Y9E\(3W4=W;OJ-OY#S3SH(X/G266(QX8[N0 Q., GCL*==^%A)+/&-3A
MCGN/.:)&7G+O"PXSD@&'G'][VK$FDUFU@U,Z:-9;S[J:6&=X2KR%8(A'N_=E
MC\P;&0H.TY/K!/H]_=:D+R]L[J6[FC4E$A?]\S!RI#_=CV;HP0<$;"1CN#L^
MYU^@Z3)::SK.H2HZ+<3X@C< ;%^](5Y/RM(68=^E4H_!TRV\$#ZA&8[2)8+8
MI!M;8)DE/F'/S-^[ XP.2>]7]9>_@MM,0SW:P[]M_<64>^48C."H )P7QD@9
M_6J_AO\ MNXNI)]8END*6T 6!E"H6*G<Q '+<+D9P#FGIL3=[G3$Y)-)115F
M85-HO_'G+_U\S?\ H9J&IM%_X\Y?^OF;_P!#-9U/A-Z'QC[?_D-WO_7*'^;U
M?JA;_P#(;O?^N4/\WJ_6$CKB%4-9TXZKICV:RB(L\;[BN<;75NG_  '%7ZR?
M$T]];Z#/)IKNEWOB5'2,2%09%#':>O!-2483>!YWCBB;48O+LMYLL6_.6F27
M][\WS@% .,9Y/7HW6/!6I:Q:O%+K$,?G1.LPCMBBAF<OD!6&X=L.6]>I-4KC
M4/%EFET]M-=7LJ7%W;PPRVJ@,J1EHWRJ@D[N,]&Z8S58:AK<D]G>RW-[-#;3
MSB$P0,QE)MR0K QQ[OG&!PHR<9S0!J:QX2N5LK^:UGDENY5F^S") #',]QYT
M;Y)QA&QGV!^E;%YX=E;0]-TZPNQ;?8F0Y*G]X I4C*D,I.<Y!![=":Y"/Q!X
ME>UN?])N%BCGB*3/;_,Z-$Q*AQ#@?.!SL(_ASR#4O]IZM;SWDN_5H9;V:V<H
M\ 'DJ;8=]C!<N"" &Y&.,YH T++P'<Z?9V]I%JD#1;[9IVDMB68P2^8NSYOE
MR.#G.#DCK4Z^";BVC;[+JFQOM9D4F-EVP!65(@RL& 7<3D$9R0>#6'87>NS7
M,%[/%<2WUQ'93-;S6^(T?R) VW*_(=X /.1GMFMVPN[W4/"FKB>>]NY?L9SY
M]GY)64QG?&N "V#[<9QD]@!NG^!OL.GPVK7Z.4-D?,$6TD6X ]>,_IGO2/X*
MNY+&RMY-2@+Z=Y2VGEPM$"D:.@\PJX8DAST( (R!R<\YJND:\=%MDO[G[?$^
M@W42PP6+1-&2L(VL0S9)&1V/!J74;"_2_P!0TS4H=1GMK73DBCO(83,9H?M"
MLNY?XRH&)%ZLH)'WJ -R+P/+;P"*VU"V6WE>WFN=UN6^:&7S/W9+_*#R.<XZ
MYR37:EE"[B0%]<UY5#!;FTMVN-(=O#46H,UPEI8S1Q3YB&R0VS98(K<$ %2V
M&QP:MRV^CB33YKK1-0_X11#<>7;RVLDB+*2A20PX++&1Y@4%< GH,B@#TNBL
MKPVL*:#;K;6=U:6PW"&&Z)\Q4W';D$D@8QA3R!@<8Q6K0 51UC_D#7?_ %R-
M7JHZQ_R!KO\ ZY&JA\2)E\++U%%%24%%%% !14<DR18#'YCT4#)/X4S$\WWC
MY*>@Y8_CVII$N71#I)TC;;RSGHBC)--V33?ZQO+3^XAY/U/^'YU)'$D0PB@9
MZ^I^I[T^G=+85F]QJ1I&FU%"KZ 54T?_ ) UG_UQ7^573R#7,C4+[0F:U>P>
MYMPQ,31M@J"<X.>OM36JL-Z-'345S7_"5S?] :Y_[[6C_A*YO^@-<_\ ?:TN
M5AS(@\?PZAJ&C6VCZ?8-=G4+I([A=QC00+\\@9P#L#!=F<?QUQNG/XFM;/2]
M.U2'7[2STZ&:T!TJ(N\D\<BB(D[?FC,1&"0%)#9[5W/_  E<W_0&N?\ OM:/
M^$KF_P"@-<_]]K1RL.9'"?V9KEAK>I&UM]69WUNZN [QLZ>6UD_ENC8P#OPO
M![*/2I+&W\90-;3/>Z](T?\ 9,I2495FE;%T&&WD*H&1GY>M=O\ \)7-_P!
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M$ZL560MD!&4=,=>:W-0\-:1JEKJ%M>V:S0Z@RM<JS'YRH 4CG@@*O3'2H_\
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MFUZ,JSBP\BW\D7#W(('.[&SJWKN[_C6,JMG:QPU,7R2<>79V/06N;1$A=IH
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MABRAE7)[X#,!]:2BT#DFK6.0URXUV;Q)J5MI,NL&6"*#[,ML81:H[ D^=O\
MF(..<=O>EL9M;EU35+Z:[O8[&VGNE29[J(VR;-P4-"$W[1CGYNV:[588DEDE
M6-5DDQO<#EL=,GOBB.&*%66*-$#,78*,98G))]S1RAS>1RWA6\O?MYL[_4+J
MYGEM%N%65X9HW^8 R1/&!A3D?*P]".]17WCB2TN;I([*&=$CN&A99' 9H652
M"Q7;R6_A)VD8-=+8Z3INEF4Z?I]K:&4YD,$*IO/O@<TTZ+I3323'3;0R29WO
MY*Y;/7)QW[^M.SL%U>]CG[_Q/J2+J%A':6L>H6L=PSR&X(C"QQHV5)7.[]ZO
M!&!M)Z58U'4+K^Q_#\8OS9_VBT4<]]A=R9B+X&X;0SL H)'&?7%;5SI6G7JL
MMU86TX9_,82Q*V6QMW'/?  ^@J::SM;BS-G/;0RVK*$,,B!D*CH,'C%%F%UV
M.*N+_4X[B[T:VUQ[@0W4*)<&6*.XD#1NSP+(5V>8NU6Y .TXZ\UTOAN\:]T<
M,]S/<21320N\Z(L@96(VML.UB.FY>#UJQ_8NE?V9_9O]F6?V#.?LWD+Y>?7;
MC&?>K-O;06=O';VT,<$$8PD<2A54>@ Z4)-,&TT2T4451 5-HO\ QYR_]?,W
M_H9J&IM%_P"/.7_KYF_]#-9U/A-Z'QC[?_D-WO\ URA_F]37]T]E9O/';2W+
M+C$40RQR<<5#;_\ (;O?^N4/\WJ_6-TFFSJLW%I.P@.0#@C/8UB>,+R]L/"U
MY<:=<+;W@\M8I60.$+.JY(/4<UN53U46ITYQ>6XG@+)NC.WD[AC[Q X.#U[5
M!9R-MXUNY-8DM&MU-VJ6]J]D7"+%=,\H8E\$["B!@<'(Q@9-;+^)Y!X?748]
M/WW)O!8M;&8 "7SO)/SXY ;)SCD=L\4S59_"WE7]W=+8W+GR8[LQLC/@2;4+
M<Y&UF/)Z<U6UQO#Q\.06A\K^R%>*8&V,;1D)/&,=>A9AD]N><XR 0W'C*Z>*
M^A33O+EM+6YEN9%N1^[,1V_N\H0Q/!&0 .X[5)=>-FLX)[EM-+VB-<PQ.)QO
MDEA1F8%<?*#L< Y/09 S5BZN?"NEZ;YSQV8TY[9XC-&4:-HVD563.<G+/SU[
MY/K9>R\+O>WTKKIIN3$1=Y=<A& !+#/ (P">XQ0 ^\UJ]M(=.B_L^)]1OF94
M@^TXC7:C.<OM]!_=ZGTYK%C\8W5M?WDUW:A],^T1QI(DRLT6ZV64@!1AQG/.
M[^+C(K3U_4_#AT^VCU,P74$ZR2VRKA_,\M"S;"#UVY'7G..]2P2^&9+ 7R/I
MR6PD20OO0*D@0*N3G 8+@8]* ,NS\;W-[]GA31I$NKHQ_9A*[QQL'5VY9D!R
M!&<[0P.1@GM5C\<SQ:YJ-M-;[U2T%XD?F*$C58=SHL@!$CENP/ R>@P=DZ;X
M2@@FLS'ID:.JSR1EU!"C[K=<A1GC& ,\=:9>67A:ZL!;K-IL NDVV\D;H#G8
M8E,?.#A6*C'TH KP^,+R6[MM..DQIJ5TL<D,9N\Q^6R.^6<+P1Y;# ![8..1
M#9^,I[ZXA%C8M,]XT21Q33JB1$Q2NQR%)_Y9$=\Y!%:EGX>\-KIT>FPVUG)$
M?GPI&YBGR%@1SQ]WCIG'M6E%I&G031RQ64$;Q;=A1 -NU2BX],*S#Z&@#'\-
M>(+O7K^[=X(XK+[-;30KNRZF126#<8/(]>WO72U3M-)L+"42VEI%"XB6'*#'
MR+G:OT&3^=7* "J.M9_L6\P<'RFP<5>JCK'_ "!KO_KD:J'Q(F?PL1HPJ.MT
MLFYE*F=&/&?0CE?P_.N6'A6_E\%/HPG8R"UV12I?/M+B1F7/&3P5R<G/0CBN
MXJ%K9-Q>,F)SU*=_J.AH;3W)2<=CDO$>B>*+R74)=)U1H&EDC^SC[2R"-!&<
MX&TC)DVD]<C-5+WPYXLF@NU756D2X+EHC=LG5YMH5@IV *T.0.NPCW/;^;-%
M_K8]Z_WXQ_,=?RS4L<B2KN1@P]0:3312DGH>?_\ ",^,/)6W76&BC50I:.Z8
M;@$(0*-OR;3@'D[NIIL_AKQ>  NHM*2T:M*MZT<JQAR[ -MY)!VC/ !]A7HE
M%(H\V'A7QE/JQNKK4U:/SMT<?VMRD8\R-B=NWYAA" IZ9ZU;C\/>,MD9DUE@
M\9W "Y8AG!BRQ.WE6VRG9T7<!].^HH **** *%_<W,$\:P)OW*<+M)W$=O;Z
MU6:ZU-H\^7M&1]V(DXR.>OUX]JV** ,5[C4,J_V<ABP+^7&<[1GOGGZ5)]KU
M)BJK".!EF,38/ZUK44 8JWFH-.K-#(JE@-GED9'.>?TJ[]ND[64YYQTJ[10!
M4-W*)&4VDA4=".]68W\R-7P1N .#3J* "FNBR(R. RL,$$9!%.HH S++P[I&
MG*@MM.MD*/YBD1*-KXQN''!P<<5SMZ]V=6;4$\/6MQ,CMY=PUIF10N0I+XSQ
MC/'I[UVM%4I6):N<1#-?X2-= M1Y,SSQ$V1"QGC#*.,,V6.<Y]:ET=IK[Q";
MJXT6VADE5EDF-GLD*@=W(R<D@8_V:[*BGS^0N7S#I1114%A1110 4444 %9V
MO?\ (#N_]S^M:-9VO?\ (#N_]S^M5#XD3/X60M]X_6O,_B5>S0>)-&MQJ2V<
M$EG<.PDU5["-G#(%)=0<D9.!]:],;[Q^M1200S8\Z"*3'3>@;'YUTM71Y\79
MW/*=+\9:G!8VTIN"6EL-.22]O@Q6 R22J\SKNQCY1@\9R"35FY\>>(/L\[6L
MNG,+2UO[@W/V=FCO%MV0*T8W?*&W$'DC()&:]/,49W9C0[EVME1R/0^WM1Y$
M; +Y,9 78!L& OI]/:ERON5SKL>;WGCG5K*WOK>YO=/AO(KJ-(9OLOR,KVWG
M["&D !&<9+<CH":S]2\8:[J_A;5[R.XAM8;;3=/N1';*5E:6?:2!)N^49!'3
MOBO5V@B.0T,9Y!.4'4=#]10((0I40Q;2 "-@P0.E'*^X*2['E]W\0O$$=M8B
M.*PCO)OM+7$<^R-(98Y OV4L\BC(!R6!).00N*N7WB_Q##9:K>QSZ;%'!JYT
M^.&1%5E4*&)#.ZJ[\XP2HP"<UZ&T$+?>AB;YM_* _-Z_7WI6AB9&1HHV1SEE
M* ACZD=Z.5]PYEV,+PWK;:U!8W1O[9OM&GI.;00F.7<6(,N"Q(0XP!SR,Y-=
M!30B!MP10V-N0!G'I]*=5(AA11BBF(***.M !1110 4444 %%%% !11C/2B@
M J;1?^/.7_KYF_\ 0S4-3:+_ ,><O_7S-_Z&:SJ?";T/C'V__(;O?^N4/\WJ
M_5"W_P"0W>_]<H?YO5FZNH+*W:>YF2*)<9=S@#/%8--M)'5=)-LFK/UO3GU7
M2I+-)%C9I(WW,,CY75O_ &6M $$ @Y!JO?7D.G:?<7MP<0V\;2N1Z*,FI+.3
MF\#-+:00^=;#8)A)F+A]]U'/SZ\(1]32:AX(N+H7GE7-JOG232(DD)9!OF@D
MPPSR/W)!]=U:MAXLM9M(BN]1B>PN6F:WDL\&5TE7)*X49;Y1NR!T.:DTKQ5I
MVI:7:WC2+"\ZP9BR6VM, 8USCG.1S0!BS>"[VX%S.US:)<W'FN8UC/E*[/ R
M@=\?N.3U)8FF7?@:[O(9[9[FT$&+HQL(CO<SMN82'NHR1[X4G&*T=-\<Z=>Q
M@SQSVS^7 P7RGDWM*A<(FU<N0 >@[$]JU[W6K>STV+4/*N;BUDP2]O"7**1G
M>5'./7 )]J *'B7P_-K,=LMM+#$8EFC(D4D;9(F3(QW&0:R+OP-.UW'=6MS#
M&T/DE(5+Q*Q2)HSED((X8$$>F.];*>*K2ZN]'33XI+RTU,MLO8\")<*[8R>2
MQV$8 X[X[U?#/C)?$>JWUBMF(3; G*SB1EP[)MD4 >6_RD[>>.] %*'P3<VF
MG7,%K=6RS2+:JK&(\"$Y(RVXKDYP>2M9:>"M52\EL2UK)#<6=S'+=RQ,VP33
MER$R<[P#WX) /;%=C_PE.B[$9;W?YBAD5(G9FRS* % R3E&&,9^4^AIP\3Z.
MS6X6\#"XV;&6-RH+L54,P&%)8%0&P<C% &;X:T5[/6]:OG618'G,=FDJX*(3
MOD(]FE9CGO@5U%8<?B_0Y0ACO&<.6V[8)#D*0K-]W[H) +=,\9K<H **** "
MJ.L?\@:[_P"N1J]5'6/^0-=_]<C50^)$R^%EZBBBI*"HI+=';?RC_P!]#@__
M %_QJ6BFG832>Y!NGA^^OG+_ 'DX;\N_X?E4D<T<N=C D=1T(^HI]1R01RD%
ME^8=&'!'XT[I[DV:V)**@_?Q=/WR^_#?X']*?'/'(=H.''5&&"/PI6&I+9DE
M45EN;PNUNZ0P*Q4.5W,Y!P2.< 9^N:O52TCG1[0^L2G]*:T5P>KL+]GO/^?[
M_P @BC[/>?\ /]_Y!%7**.9ARHI_9[S_ )_O_((H^SWG_/\ ?^015RBCF8<J
M*?V>\_Y_O_((H^SWG_/]_P"017"^(]9NY?%NK6,WBK_A&[73+&*Z@(CC;[06
MW[G8."61=H7:N,D]>E3OX^O(]6,:P6<MA!?6VG2DR%+F9YE0B5(\8"?.#@\D
M!CGBCF8<J.S^SWG_ #_?^011]GO/^?[_ ,@BO+[GXC^([CPM=W:6VGVDT^CW
M-_:2QLSF/R91&VX$8)(;([ CG-:LOCO6[2348Y;739%M+BTL$F$CJK3SK&=[
M'G;&N\^I/'2CF8<J.[^SWG_/]_Y!%'V>\_Y_O_((KA]+\7:GJOC32=/F:.$1
M2ZA:WBVS;H;AXEA974D9P/,(QV.1SBJ ^(%TGCZ^47#R:6PN;.V@:%EC$T$8
M??YF,-N99DP#GY11S,.5'H_V>\_Y_O\ R"*/L]Y_S_?^017FUS\2O$5IID%Z
M^F:6X;1X]8D02R+B-W51&#@_-ANO0>]=KX6UR\UA=5@U""WBNM.OFM'-NQ*/
MA$<$9Y'#@?A1S,.5&I]GO/\ G^_\@BC[/>?\_P!_Y!%7**.9ARHI_9[S_G^_
M\@BC[/>]K[\X15RBCF8<J*L,\JW'V:Y">85WHZ# <#@\=B,C\_RM50NSC6-/
M]Q+_ "%7Z)=&""BBBI*"L[7O^0'=_P"Y_6M&L[7O^0'=_P"Y_6JA\2)G\+(6
M^\?K5>7[7]K@\HP_9L-YV[.[VVU8;[Q^M)78G8\QJX5P_P 0$MGO=%%[+91V
MX%QEKVWDFBW83'RHRG/7!SZUW%9&K:CJ,6HV6EZ5]G2ZNDEE:>Y#,D<<>T'Y
M5(+,2Z\9&.342V+CN<_#JU[9);6FF^7+8BS^V12VMHQC$4:,)$52<Y,FS )S
MACSQFJ$>N:QJ#;@7GEM)C):N(A\Y:SF.#L&UAO &.>N"2:WWU#Q//JEOID+Z
M3;W0M7GF9XY)4<B38NW#*5R""0<D9QS4:>)]4GM=&U/RK6.QO)(X9HF$C.KE
MRCGS.$55(&-P^;IP<5!?R*%QXMNYC)]EN'$):!$F2W& S1,SC<XP/F '0\Y4
M#/2A!XAUP*+UYG1[R.R:970(ELK1/O9=RG;F0!3D$ MSVKIHO$-]8:EJ-OK9
MMPEO;BX1K>*4$ L1L^;/F8^7+*  3@@5)=>)7E\%3:]I2!YO(62**<,!O;;\
MK=#_ !=13^8?(K7>M:E!X &JR210WV(\RB$LH!E"[MA )RISC'?BL75/%>L6
M=C.UK.\YC\][6X%JH%VJ!=OUY++A!E@,@@58UOQ8]S;M'!:6\MO_ &8UZ_G[
MCMN%9&5.".%/)[]*T;G6O$>FSW5A-%9WU]]F6YMY+6)U!7S C[H]Q8E0P8!3
MEL$<&A@EY&#/J&L6>I7-S;WES<2QSWS16;QY1F,<;1KP,D8W$>NTX[UI:=K&
MMW]W:P"\3[.]PX-S'"'+JL6_;G8%^]QD#OCJ*GM_$FJW0MM/MI=.EU"XN)(Q
M.8I8TB1$#L7A8AP_( 7.".<]JO2>))=+:VL]:C5KZ9G -H1Y;JI ##>P(8[@
M=@+-UZBA _0C\+ZAJMU- FISB43Z=#>$^0(_+=F8,@QVP >>:Y[5-5U?4](O
M;1KB022PR?:H([;:UF5F553=CYMZENN<XR,"NQUO6HM%\F6X+&(K-(ZI'N9A
M'&7..1@\>^>G'6G6VJ2:I;WD=HDEI>6Y";;N/(1F4,I(5N001P"#U'%.W2XD
M^MC \:7=S8:=/I\%P;2U.F3>6Z6^\S2@;5B  ^7Y<GC!].AK.N?$VOVQU$*(
MHOLT5QMA=-Q1(XR8Y,!<G)"G);!W8'(JW)XC\1Z=HLVHW!TZZ*:@;010021D
MJDC*[9+GDJI('KZTW7_%5Q.=5L+>"":P MH8W:&28RB5RDGR(06 Z +SG-(:
M72Q7NM9U9Y([JS9M4^R&9[698#&)G-LQ9"HZ[6Q^>.HJ.75]6NA!++>>9;1R
M3HK1H&6<FV8A'PB@_,,#'K@\BNOT/4+FXTA[O4IE&QFR[6DEH%10#RLA)]>>
MGY51\(^);CQ!#<M=^3%,C#;$N4D P"V5))V@D8;C<"#@46"_D8Y\0ZQ#$5B8
M">-"JV(M>%A%MO$^[K]_ QT_AQFMO2+[5C'J,=TWVR:&UAGA/DB+>[QL2G'&
M-RCW&>:Z+<<8R:3-5RLER78\]DO-0UU+"UEO7N+9KFRDG=;0(%D8OO@8$<A<
M*>>1T)->A4I8GJ324)6$W<*FT7_CSE_Z^9O_ $,U#4VB_P#'G+_U\S?^AFIJ
M?":T/C'V_P#R&[W_ *Y0_P WJY-#%<1&*:-)(SU5U!!_ U3@(&N7@/5H(B/P
M+BIKZ^MM-M'NKN3RX4QN;!.,G Z5C9N24=SI;BHMRVUN6>E9VMZ1#KNFG3[E
MV%M)(C3(!_K45@Q0^S8P?;-: (8 CH>163XGU:70_#EWJ,/D>9"%P9R1&N6"
MY;'.!G/X5!H9D/@6RTZ[:XT:X?3B)!+''&BLB.4*.<'^\NW/N@/KEMMX&CM#
M9K%JESY%O]E9XRB'S7@X4DXXR ,@>G:LNS\9ZUJ12TL3HMS.]XENE]"TC6K
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MJMW_ ,AC3O\ MK_Z"*T*MM61"3N]2'SV_P"?>7_QW_&FO<ND;-]FEX!/\/\
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M3:+_ -!&#\Z/^$FT7_H(P?G1R2[!S1[FK165_P )-HO_ $$8/SI#XGT4#/\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9-&)87C89# @BGT4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNOP/048'H*/:R#V$#D/[7U#_ * [_P#?T_\ Q-']KZA_T!W_ ._I_P#B:Z_
M]!1@>@H]K(/80.0_M?4/^@.__?T__$T?VOJ'_0'?_OZ?_B:Z_ ]!1@>@H]K(
M/80.0_M?4/\ H#O_ -_3_P#$T?VOJ'_0'?\ [^G_ .)KK\#T%&!Z"CVL@]A
MY#^U]0_Z [_]_3_\31_:^H?] =_^_I_^)KK\#T%&!Z"CVL@]A Y$7.N71"P6
M$4 /\3DN1_(5=LO#CO.MUJ<[7$PZ ]%^@Z#\*Z*BI=23+C2C'5(155%"J  .
(@%+114&A_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>image_020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "T >\# 2(  A$! Q$!_\0
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M[_@'+*M6B[.;^]_YF[+J%X/#MK,+J<2M<R*S^8<D +@=?<UG?VMJ/_/]<_\
M?T_XU9F_Y%>S_P"OJ7_T%:RJSI4X6>BW?1&U>O53C:3V75]O4N?VMJ/_ #_7
M/_?T_P"-']K:C_S_ %S_ -_3_C5.NMT>QB;PPMW'HB:E<FZ,9!SD+@'/'O\
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MO'_Z$*M55O\ _50_]=X__0A0!:JGJ&F6^IBU%QO_ -&N$N8]K8^=>F?:KE%
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M-$T]+*S5Q&I9F:1BSNS'+,S'DDDDDU>HHH *JM_R%8_^N+?S6K556_Y"L?\
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MBDG"%)4/0JR,PS['!'I3L!H?V?'_ ,]KK_P(?_&C^SX_^>UU_P"!#_XU;HI
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MHW&[]W7MJ_S.J_L^/_GM=?\ @0_^-']GQ_\ /:Z_\"'_ ,:MT5H<A4_L^/\
MY[77_@0_^-']GQ_\]KK_ ,"'_P :MT4 5/[/C_Y[77_@0_\ C1_9\?\ SVNO
M_ A_\:R_$.I7\5[IND:4\,-YJ#2'[1,F\0QH 68+D;FR5 &<<Y/2LR_G\4>'
M]!UN:[O[:]2WL7GMKWR1&Z2 'Y6C'RD="#]0:=@.G_L^/_GM=?\ @0_^-']G
MQ_\ /:Z_\"'_ ,:\^T_Q3=?VMI<5EXRM/$375PL4UE%:(&2,@[I-T9^7;UYX
M/3K7IE#0%3^SX_\ GM=?^!#_ .-']GQ_\]KK_P "'_QJW12 J?V?'_SVNO\
MP(?_ !JK?6B0I$XDG8^9T>5F'W3V)K5JCJG^IB_ZZ?\ LIH ET[_ )!EI_UQ
M3_T$52O=(:[\1:;J1>/RK2&>-HV7)8OLP1]-I_.KNG?\@RT_ZXI_Z"*LT <@
MGA"ZM[FXL[6ZB70IKN*[%H5.Z(AMSHO;8S!3CMEO6M#_ (1BWN;S7CJ"0W%K
MJAC_ '97E0L80\^N1D$=*WZ*=P,OP]8ZAINCQ66HWBWDL!*)<8(:2,'Y2_\
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MRL!S@CG([@5N451B9'AW2)M'T^5;J=)[RZG>YN9$3:ID<\A1V   'TK7HHH
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M!&??FK- %3&H?W[;_OAO\:K,+[^TX_GMMWDM_ WJ/>M2JK?\A6/_ *XM_-:
M$QJ']^V_[X;_ !HQJ']^V_[X;_&K=% %3&H?W[;_ +X;_&C&H?W[;_OAO\:M
MUS>J^-++2M2FM7LKZ>*U"&]NH8P8K7?]W?D@GCD[0<#DT ;.-0_OVW_?#?XT
M8U#^_;?]\-_C5L$$ @Y!HH J@7^>9+;_ +X;_&N&^'>I:OJDFMO<WBSO#>-$
MIF!;:HZ <\"O0ZXKP%JL&K7&LO;Z9;6 AN3$RP# D8$_.>!R:SE\:U[G92_W
M>I[M_AUTTU?SU\OF=5C4/[]M_P!\-_C1C4/[]M_WPW^-6Z*T.,J8U#^_;?\
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M0^(=934TMY+D&6\>6$LI8[3&QV[3C&/RHL,]%^QVO_/M#_WP*/L=K_S[0_\
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M2YU"R=;O5]3UVPU$S[A?$F?2W0OP-J?*J%2 "0I!.<T["/3OL=K_ ,^T/_?
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MT_Y"LW_7%/YM5J@"'[':_P#/M#_WP*/L=K_S[0_]\"IJ* (?L=K_ ,^T/_?
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MQ6;K&FWWASPYK\EKKM]-;?V?(\,=S,9)X90#EDD)W8QC@YP>AIV ['[':_\
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M %,7_73_ -E- "QZ?Y421I>7(5%"J-R]!^%/^Q/_ ,_MS_WTO^%%% !]B?\
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M -]+_A1]B?\ Y_;G_OI?\*** &#3L2M(+RYWLH4G<O09]O<T_P"Q/_S^W/\
MWTO^%%% !]B?_G]N?^^E_P */L3_ //[<_\ ?2_X444 'V)_^?VY_P"^E_PH
M^Q/_ ,_MS_WTO^%%% !]B?\ Y_;G_OI?\*/L3_\ /[<_]]+_ (444 'V)_\
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5T\.5\RYN'"G(5F&,XQZ>]%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>image_021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "O CD# 2(  A$! Q$!_\0
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MN PR2E%V+^_:4=6!7 8Y.#G' S7=7>CQW=U]H:\OXSQ\D-TZ)Q_L@XI2=MI
MH1_E%_L6Q_N2_P#?^3_XJC^Q;'^Y+_W_ )/_ (JM"BL^>7<OV<.QG_V+8_W)
M?^_\G_Q5']BV/]R7_O\ R?\ Q5:%%'/+N'LX=C/_ +%L?[DO_?\ D_\ BJ#H
MUH!^[:YB;LR7#Y'YFM"BCGEW#V<.QF)/<Z=/'#>2>=;RMLCN,896[*X''/8B
MM.J]];I=V,\#_=="/H>QKSW_ (3;4?5?RK6%-U=8F%2O&@[2V>QV^DN+<2:8
M_$EL3L!_BB)^4CZ=#[BM.JMY8Q7@1F9XYHSF.:,X9#[>WL>*K[-9B&U9+.<#
M^-U9#^(&16;M+4U5X:6T-*BL[.M?\\[#_OM_\*,ZU_SSL/\ OM_\*7+YCY_)
M_<:-%9V=:_YYV'_?;_X49UK_ )YV'_?;_P"%'+YAS^3^XT:R]2\.:1J]S'<W
M]A%/+&,!FR,C.<''WAGL<BGYUK_GG8?]]O\ X49UK_GG8?\ ?;_X4TFMF'.G
MT?W$<GAO1Y;R6[>QC,TH(<Y.#E=I.,X!(XSC..].'AW20P8629!B8'<>L:E4
M[]@2*=G6O^>=A_WV_P#A1G6O^>=A_P!]O_A3U[_B',NS^XC7PWI"1JBV2!5C
MBC4;FX6-BR#KV8DT+X;TA/,VV:A9)%E*[VVA@VX$#.!\W/&*DSK7_/.P_P"^
MW_PHSK7_ #SL/^^W_P */>[_ (AS+L_N(I_#.C7,]S-+8HSW2LLWS, X8 -P
M#C) '/6HW\):%)+<2-IZ%K@.LOS-A@^-W&<#.!G%6<ZU_P \[#_OM_\ "C.M
M?\\[#_OM_P#"CWN_XBYEV?W#]3T;3]9MT@O[59D1MR9)!4],@@@C\#4"^&]&
M2&2%=.@$<D MF7''EC/RCT^\>GK4F=:_YYV'_?;_ .%&=:_YYV'_ 'V_^%&N
MU_Q'S+L_N&#P[I(MEMQ9KY:SK<J-S9$HQA@<YSP*N7=E;7RQ+<Q"012K,@)/
M#J<J?P-5LZU_SSL/^^W_ ,*,ZU_SSL/^^W_PI6?<.==G]Q:N+*WNIK>6:(/)
M;2>9$Q)^5MI7/Y$C\:KW>C:=?2S27-JLCS1+#(23\R!MP'!]>:;G6O\ GG8?
M]]O_ (49UK_GG8?]]O\ X46?<.==G]Q7'A/0Q+-*+!0\P8.0[#AF#''/'S '
MC'-.7PQHR"#99*I@)*,KL&R3N.2#ELGGG-39UK_GG8?]]O\ X49UK_GG8?\
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M7"X SVK>K.SK7_/.P_[[?_"C.M?\\[#_ +[?_"LFKN^A:G;H_N-&BL[.M?\
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M+EBKLSJU84HN=1V1U-%>;?\ "PM8_P"?"P_[^/\ X4?\+"UG_GPT_P#[^/\
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M]A^IJH0E.7+%79%2I&G%SF[)'0T5YK_PL'6C_P N>GCVRY_K2'X@ZWVM-/\
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M5'5HM/@M/+LG1CYRMPVY@"@R,^@;-9QKJ32LS6>%<(N7,K(QZ*Z6]ETF\O\
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M>2!'8^Y4$U:JCHHQH.G#_IVC_P#015ZOB7N?J2"BBBD,**** "BBB@ HHHH
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M%4$X Y)JA%I>ESW*WL=V6:2Z&IJ-XZ^5Y8..NW;S]:76[3S=0T^XM]3BL=0
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M;L&VU(?6PE_^)HM(+HUXXTBC6.-%1%X"J, ?A61XGYTRW4=3?6P ]?WJTO\
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M9D.Y&93ZJ<&GK<3(6*RN"XPQW'D5.=(U<9SHVH\>D&?Y&F_V7JW_ $!M2_\
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MOT50^P77_05NO^^(O_B*/L%U_P!!6Z_[XB_^(HL%R_15#[!=?]!6Z_[XB_\
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M(XK<TJZTB?4-0_L^Z66XED$DX#$C( 3([8^7''>N62P%KJ=I<VEM<^5;V\,
M26VE##82=PVN <Y[@\U8T2-](U.>Y,=X89%8>1#9LBLQ;.\J6(![?* #G-'+
M+L',CN**R/[?C_Z!^H_^ Y_QH_M^/_H'ZC_X#G_&CEEV#F1KUF6<B+JNJ!F
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M/[?C_P"@?J/_ (#G_&CEEV#F1KT5D?V_'_T#]1_\!S_C1_;\?_0/U'_P'/\
MC1RR[!S(UZ*R/[?C_P"@?J/_ (#G_&C^WX_^@?J/_@.?\:.678.9&O161_;\
M?_0/U'_P'/\ C1_;\?\ T#]1_P# <_XT<LNP<R->BLC^WX_^@?J/_@.?\:/[
M?C_Z!^H_^ Y_QHY9=@YD:]9A=4\1ON8#_1%Z_P"^:C_M^/\ Z!^H_P#@.?\
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M32[)(Y(Q "LB&-]Q)+@G)R3UY[T:AH00ZK(^I_9)+<0@DJN]B&; SD<;3W&
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M[#<2-''^ZB$@\MB0,@G8W'##'(]ZU:1D5D9" 58$$>N: .9/BJ80Q,+2&0R
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MT SG&<\#KQ[5+;:%9VCQ-$9AY;;@"_!.6.3Q_M-^=&H:$C7.EVMI"A,$=K.
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9HH <G#J?>M'!JM;VQ8AV^[5^LILTBC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>image_022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "# +\# 2(  A$! Q$!_\0
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M2M*NX)B6C&XC .X5I5S+#2AI-:^:.:.4XV$FW3E9)]&>[Z7_ ,@BQ_ZX1_\
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M/$.-KHPEXI93"JYJ,VFNB71ONSS/BGFWF6/S3#((^F\J<5ZM;Z586B!(;.(
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E[U9T[PSH_G)%]B&QLY7>W/Z_[(_*BBO.LCVE6J\OQ/[/5G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 28, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ACTINIUM
PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001388320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">74-2963609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226,015,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100
Park Ave., 23rd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New
York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">677-3870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,195,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorTable', window );"><strong>Auditor [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Marcum llp<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Houston,
Texas<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Actinium Pharmaceuticals, Inc. (the &#8220;Company&#8221;) as of December
31, 2024 and 2023, and the related consolidated statements of operations, changes in stockholders&#8217; equity and cash flows for each
of the two years in the period ended December 31, 2024 and the related notes (collectively referred to as the &#8220;financial statements&#8221;).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024,
in conformity with accounting principles generally accepted in the United States of America.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 72,904<span></span>
</td>
<td class="nump">$ 76,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,602<span></span>
</td>
<td class="nump">1,586<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">74,506<span></span>
</td>
<td class="nump">78,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $891 and $694</a></td>
<td class="nump">364<span></span>
</td>
<td class="nump">550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash &#8211; long term</a></td>
<td class="nump">324<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,685<span></span>
</td>
<td class="nump">2,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance leases right-of-use assets</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">76,899<span></span>
</td>
<td class="nump">81,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">7,568<span></span>
</td>
<td class="nump">7,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating leases current liability</a></td>
<td class="nump">569<span></span>
</td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance leases current liability</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">8,148<span></span>
</td>
<td class="nump">8,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term license revenue deferred</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease obligations</a></td>
<td class="nump">984<span></span>
</td>
<td class="nump">1,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term finance lease obligations</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">44,141<span></span>
</td>
<td class="nump">45,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 1,000,000,000 shares authorized; 31,195,891 and 27,634,213 shares issued and outstanding at December 31, 2024 and 2023, respectively</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">408,553<span></span>
</td>
<td class="nump">373,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(375,826)<span></span>
</td>
<td class="num">(337,583)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">32,758<span></span>
</td>
<td class="nump">36,379<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 76,899<span></span>
</td>
<td class="nump">$ 81,445<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, net of accumulated depreciation (in Dollars)</a></td>
<td class="nump">$ 891<span></span>
</td>
<td class="nump">$ 694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="nump">27,634,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="nump">27,634,213<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net of reimbursements</a></td>
<td class="nump">30,045<span></span>
</td>
<td class="nump">38,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">12,076<span></span>
</td>
<td class="nump">13,331<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">42,121<span></span>
</td>
<td class="nump">52,001<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(42,121)<span></span>
</td>
<td class="num">(51,920)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income &#8211; net</a></td>
<td class="nump">3,878<span></span>
</td>
<td class="nump">3,102<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">3,878<span></span>
</td>
<td class="nump">3,102<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (38,243)<span></span>
</td>
<td class="num">$ (48,818)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share &#8211; basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (1.27)<span></span>
</td>
<td class="num">$ (1.83)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share &#8211; diluted (in Dollars per share)</a></td>
<td class="num">$ (1.27)<span></span>
</td>
<td class="num">$ (1.83)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding &#8211; basic and diluted (in Shares)</a></td>
<td class="nump">30,070,028<span></span>
</td>
<td class="nump">26,604,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding &#8211; diluted (in Shares)</a></td>
<td class="nump">30,070,028<span></span>
</td>
<td class="nump">26,604,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=atnm_RevenueMember', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=atnm_OtherRevenueMember', window );">Other Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=atnm_RevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=atnm_RevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=atnm_OtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=atnm_OtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 355,220<span></span>
</td>
<td class="num">$ (288,765)<span></span>
</td>
<td class="nump">$ 66,481<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">25,674,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,842<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation (in Shares)</a></td>
<td class="nump">13,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of offering costs</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">14,610<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of offering costs (in Shares)</a></td>
<td class="nump">1,902,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options (in Shares)</a></td>
<td class="nump">44,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(48,818)<span></span>
</td>
<td class="num">$ (48,818)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">373,934<span></span>
</td>
<td class="num">(337,583)<span></span>
</td>
<td class="nump">$ 36,379<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">27,634,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,634,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,292<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation (in Shares)</a></td>
<td class="nump">13,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of offering costs</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">29,252<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">29,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of offering costs (in Shares)</a></td>
<td class="nump">3,538,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options (in Shares)</a></td>
<td class="nump">10,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(38,243)<span></span>
</td>
<td class="num">$ (38,243)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 408,553<span></span>
</td>
<td class="num">$ (375,826)<span></span>
</td>
<td class="nump">$ 32,758<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="nump">31,195,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,195,891<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (38,243)<span></span>
</td>
<td class="num">$ (48,818)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in/provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">5,292<span></span>
</td>
<td class="nump">3,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">614<span></span>
</td>
<td class="nump">583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(387)<span></span>
</td>
<td class="num">(2,177)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(527)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(530)<span></span>
</td>
<td class="num">(494)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used In Operating Activities</a></td>
<td class="num">(33,072)<span></span>
</td>
<td class="num">(47,335)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows Used in Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(153)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used In Investing Activities</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(153)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance leases</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sales of shares of common stock, net of offering costs</a></td>
<td class="nump">29,255<span></span>
</td>
<td class="nump">14,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By Financing Activities</a></td>
<td class="nump">29,321<span></span>
</td>
<td class="nump">14,870<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(3,762)<span></span>
</td>
<td class="num">(32,618)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">76,990<span></span>
</td>
<td class="nump">109,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of year</a></td>
<td class="nump">73,228<span></span>
</td>
<td class="nump">76,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities', window );">Right-of-use assets obtained in exchange for lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of right-of-use assets obtained in exchange for lease liabilities which includes both operating and finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Description of Business and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 - Description of Business and Summary of Significant Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nature
of Business - </b>Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing ARCs and other targeted radiotherapies to
deliver cancer-killing radiation with cellular level precision to treat patients with high unmet medical needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principles
of Consolidation -</b> The consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly
owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Estimates in Financial Statement Presentation -</b> The preparation of these consolidated financial statements in conformity with
accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses
during the reporting period. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Segment
Information </b>- The Company operates as a single operating and reportable segment for the purposes of assessing performance and allocating
resources. The Company&#8217;s chief operating decision maker is its Chief Executive Officer, who reviews total assets in the consolidated
balance sheets and net loss and its components in the consolidated statements of operations: research and development expenses, general and administrative expenses, and interest income, for the purposes of making operating decisions,
assessing financial performance, and allocating resources.&#160;All assets are in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
and Cash Equivalents and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months
or less to be cash equivalents. The Company holds most of its cash equivalents in a Money Market account comprised of U.S. Treasury notes.
Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
is a summary of cash, cash equivalents and restricted cash at December 31, 2024 and December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">72,904</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">76,677</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">324</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">313</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">73,228</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">76,990</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
cash relates to certificates of deposit held as collateral for letters of credit issued in connection with the Company&#8217;s leases
of corporate office spaces.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property
and Equipment -</b> Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives
of three to five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives
of seven years. When assets are retired, the cost and related accumulated depreciation are removed from the accounts, and any related
gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations when incurred. Capitalized lease
assets are recorded at the lesser of the present value of minimum lease payments or fair value and amortized over the estimated useful
life of the related property or term of the lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases
-</b> The Company has an operating lease for corporate office space and a finance lease for office equipment located at the corporate
office space. Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases
is recognized on a straight-line basis over the lease term.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
Value Measurement - </b>Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability,
in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the
highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue
Recognition </b>- The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, <i>Revenue From
Contracts With Customers</i> (&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of
promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods
or services. To determine revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps:
(i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction
price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue as the entity satisfies a performance obligation. The Company only applies the five-step model to contracts
when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers
to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods
or services promised within each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services
that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. In
determining whether goods or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can
benefit from the good or service either on its own or together with other resources that are readily available to the customer (capable
of being distinct) and (ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct
in the context of the contract).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company then determines the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange
for the promised goods or services for each performance obligation and recognizes the associated revenue as each performance obligation
is satisfied. The Company&#8217;s estimate of the transaction price for each contract includes all variable consideration to which it
expects to be entitled. Variable consideration includes payments in the form of collaboration milestone payments. If an arrangement includes
collaboration milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates
the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue
reversal would not occur, the associated milestone value is included in the transaction price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
606 requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance
obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should
be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised
good or service separately to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated
to the respective performance obligation as each performance obligation is satisfied, either at a point in time or over time, and if
over time, recognition is based on the use of an output or input method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Collaborative
Arrangements</b> - The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain
transactions between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or
net basis, depending on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships.
The Company evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the
nature of the underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators,
the Company follows the guidance of ASC 606<i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grant
Revenue - </b>The Company has a grant from a government-sponsored entity for research and development related activities that
provides for payments for reimbursed costs, which included overhead and general and administrative costs as well as an
administrative fee. The Company recognizes revenue from grants as it performed services under this arrangement. Associated expenses
are recognized when incurred as research and development expense. Revenue and related expenses are presented gross in the
consolidated statements of operations. There was no grant revenue for the year ended December 31, 2024.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
Revenue -</b> The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain
product in specified territories using the Company&#8217;s trademarks. The terms of this arrangement includes payment to the Company
for a combination of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments;
and royalties on net sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration
should be included in the transaction price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Upfront
license fees</i>: If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance
obligations identified in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when
the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled
with other promises, the Company determines whether the combined performance obligation is satisfied over time or at a point in time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Development,
regulatory or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement
of certain development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered
probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it
is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.
Milestone payments that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered
probable of being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate
the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#8217;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales-based
milestone payments and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the
volume of sales, the Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based
milestones relate and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii)
when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upfront
payments and fees may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements or when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when
the uncertainty associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts
receivable when the Company&#8217;s right to consideration is unconditional.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug
product, the costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to
facilities and equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share-Based
Payments -</b> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing
model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee
is required to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income
Taxes -</b> The Company accounts for income taxes in accordance with ASC 740 <i>Income Taxes</i>, which requires the asset and liability
method to calculate deferred taxes. Deferred taxes are recognized based on the differences between the financial reporting and income
tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to
reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred
tax asset will be fully realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
740 prescribes guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions. Tax positions
must meet a &#8220;more-likely-than-not&#8221; recognition threshold to be recognized. There were no tax positions for which it is considered
reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within the next year.
The Company recognizes interest related to unrecognized tax benefits in interest expense and penalties in operating expenses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
Loss Per Common Share</b> - Basic loss per common share is computed by dividing the net loss available to common stockholders by the
weighted average number of common shares outstanding during the reporting period. For periods of net loss, diluted loss per share is
calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2024 and 2023, the Company&#8217;s potentially dilutive shares, which include outstanding common stock options,
restricted stock units and warrants, have not been included in the computation of diluted net loss per share as the result would have
been anti-dilutive.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,137</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,445</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,442</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,444</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,192</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsequent
Events </b>- The Company&#8217;s management reviewed all material events through the date the consolidated financial statements were
issued for subsequent event disclosure consideration.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Adopted Accounting Pronouncements - </b>In November 2023, FASB issued ASU 2023-07, <i>Segment Reporting</i> (Topic 280), <i>Improvements
to Reportable Segment Disclosures</i>, which provides improvements to reportable segment disclosure requirements, primarily through enhanced
disclosures around segment expenses. ASU 2023-07 requires the Company to disclose significant segment expenses that are regularly provided
to the chief operating decision maker (&#8220;CODM&#8221;) and included within each reported measure of segment profit or loss. ASU 2023-07
also requires that the Company disclose an amount for other segment items by reportable segment, a description of their composition and
provide all annual disclosures about a reportable segment&#8217;s profit or loss and assets pursuant to Topic 280 during interim periods.
The Company must also disclose the CODM&#8217;s title and position, as well as certain information around the measures used by the CODM
and an explanation of how the CODM uses the reported measures in assessing segment performance and deciding how to allocate resources.
For public entities with a single reportable segment, the entity must provide all the disclosures required pursuant to ASU 2023-07 and
all existing segment disclosures under Topic 280. The amendments of ASU 2023-07 are effective for the Company for annual periods beginning
January 1, 2024, and effective for interim periods beginning January 1, 2025. The Company adopted this standard effective January 1,
2024 and reported on it in this Annual Report on Form 10-K for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued Accounting Pronouncements - </b>In November 2024, FASB issued ASU 2024-03, <i>Income Statement-Reporting Comprehensive Income-Expense
Disaggregation Disclosures</i> (Subtopic 220-40), to improve the disaggregation of expenses within the consolidated statement of operations.
The amendments in ASU 2024-03 require disclosures, in the notes to the consolidated financial statements, specified information about
certain costs and expenses. The amendments require that at each interim and annual reporting period an entity disclose (a) employee compensation,
(b) depreciation, and (c) intangible asset amortization included in each relevant expense caption; include certain amounts that are already
required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; and disclose a qualitative
description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively. The amendments
in ASU 2024-03 are effective January 1, 2027, and effective for interim periods beginning January 1, 2028. The Company will evaluate
the impact of ASU 2024-03 on its financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, FASB issued ASU 2023-09, <i>Income Taxes</i> (Topic 740): <i>Improvements to Income Tax Disclosures</i>, to enhance the
transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide improvements primarily related
to the rate reconciliation and income taxes paid information included in income tax disclosures. The Company will be required to disclose
additional information regarding reconciling items equal to or greater than five percent of the amount computed by multiplying pretax
income (loss) by the applicable statutory tax rate. Similarly, the Company will be required to disclose income taxes paid (net of refunds
received) equal to or greater than five percent of total income taxes paid (net of refunds received). The amendments in ASU 2023-09 are
effective January 1, 2025, including interim periods. The Company will evaluate the impact of ASU 2023-09 on its financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 - Prepaid Expenses and Other Current Assets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets consisted of the following at December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid&#160;insurance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">608</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">614</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid&#160;clinical trial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">637</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">746</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">357</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">226</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,602</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,586</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 - Property and Equipment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consisted of the following at December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Lives</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">5 years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">817</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">806</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment&#160;and furniture</td><td>&#160;</td>
    <td style="text-align: center">3 - 7 years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">438</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">438</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(891</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(694</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">364</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">550</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense consisted of the following for the years ended December 31, 2024 and 2023, respectively:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research&#160;and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">161</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">175</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">36</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">32</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total depreciation expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">197</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">207</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 - Leases </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys
to the Company the right to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying
asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic
benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company
has elected to account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components
are recognized when the obligation is probable. The Company made an accounting policy election to exclude from balance sheet reporting
those leases with initial terms of 12 months or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use
assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842
requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily
determined, its incremental borrowing rate. As an implicit interest rate was not readily determinable in the Company&#8217;s leases,
the incremental borrowing rate was used based on the information available at commencement date in determining the present value of lease
payments.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lease term for all of the Company&#8217;s leases includes the non-cancellable period of the lease plus any additional periods covered
by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option
to extend (or not to terminate) the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term
(and lease liability) for the Company&#8217;s leases as the reasonably certain threshold is not met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the Company has two leases which have been capitalized in accordance with ASC 842, one for corporate office space
and one for office equipment. The Company entered into a lease for corporate office space effective June 1, 2022. The lease has a term
of 5 years and 2 months, with an expiration date on July 30, 2027 and current annual rent of $0.6 million. The Company is also responsible
for certain other costs, such as insurance, utilities and maintenance. During the year ended December 31, 2023, the Company spent $0.5
million on improvements at its corporate office space, which were included in the value of the operating right-to-use asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of lease expense are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">691</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">691</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total finance lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">12</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
cash flow information related to leases are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cash flow information:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flow use from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;618</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;606</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">30</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
average remaining lease terms are as follows at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average remaining lease term:</td><td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 89%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right">2.6 years</td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Finance leases</td><td>&#160;</td> <td style="text-align: right">2.0 years</td> <td>&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the interest rate implicit in the leases was not readily determinable at the time that the leases were evaluated, the Company used its
incremental borrowing rate based on the information available in determining the present value of lease payments. The Company&#8217;s
incremental borrowing rate was based on the term of the lease, the economic environment of the lease and reflect the rate the Company
would have had to pay to borrow on a secured basis. Below is information on the weighted average discount rates used at the time that
the leases were evaluated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>Weighted average discount rates:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.8</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.2</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities
of lease liabilities are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating&#160;<br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance&#160;<br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">630</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">643</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">380</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,653</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(100</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,553</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Other Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_OtherRevenueTextBlock', window );">Other revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 - Other Revenue</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a grant from a government-sponsored entity for research and development related activities that provides for payments for
reimbursed costs, which includes overhead and general and administrative costs as well as an administrative fee. The Company recognized
revenue from grants as it performed services under this arrangement. Associated expenses are recognized when incurred as research and
development expense. Other revenue recognized from this grant during the year ended December 31, 2023 was $0.1 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 7, 2022, the Company entered into a license and supply agreement (the &#8220;License Agreement&#8221;) with Immedica Pharma AB
(&#8220;Immedica&#8221;), pursuant to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab)
in the European Economic Area, Middle East and North Africa (&#8220;EUMENA&#8221;), including Algeria, Andorra, Bahrain, Cyprus, Egypt,
Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria,
Tunisia, Turkey, the United Arab Emirates, the United Kingdom, the Vatican City and Yemen. Upon signing, the Company was entitled to
an upfront, non-refundable payment of $35 million from Immedica, which was received in May 2022. Under the terms of the License Agreement,
the Company is eligible to receive certain regulatory and commercial milestone payments and royalties on net sales of the product in
certain countries that may result from the License Agreement. The Company continues to retain commercialization rights in the U.S. and
rest of the world.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s contract liabilities are recorded within Other revenue deferred &#8211; current liability or Long-term license revenue
deferred in its condensed consolidated balance sheets, depending on the short-term or long-term nature of the payments to be recognized.
The Company&#8217;s contract liabilities primarily consist of advanced payments from licensees. Long-term license revenue deferred was
$35.0 million at December 31, 2024 and December 31, 2023; this deferred revenue will be recognized upon European Union&#8217;s regulatory
approval of Iomab-B or provision of definitive feedback that Iomab-B will not receive approval in the European Union.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_OtherRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_OtherRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 - Commitments and Contingencies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;)
to build upon previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase
2 clinical trial with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed
by FHCRC. A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug utilizing the licensed antibody.
Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Equity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 - Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the Company entered into the Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC, &#8220;JonesTrading&#8221;,
pursuant to which the Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of its common
stock. On June 28, 2022, the Company entered into an Amended and Restated Capital on Demand&#8482; Sales Agreement (the &#8220;A&amp;R
Sales Agreement&#8221;) with JonesTrading and B. Riley Securities, Inc. (&#8220;B. Riley&#8221;). The A&amp;R Sales Agreement modifies
the original Capital on Demand&#8482; Sales Agreement to include B. Riley Securities as an additional sales agent thereunder. Shares
of common stock were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-242322) filed with the SEC on August
7, 2020 (the &#8220;Prior Shelf Registration Statement&#8221;). On August 11, 2023, the Company filed a registration statement on Form
S-3 (File No. 333-273911), which registration statement was amended on February 2, 2024, and declared effective on February 5, 2024,
to replace the Prior Shelf Registration Statement, including a base prospectus which covers the offering, issuance and sale of up to
$500 million of common stock, preferred stock, warrants, units and/or subscription rights; and a sales agreement prospectus covering
the offering, issuance and sale of up to a maximum aggregate offering price of $200 million of common stock that may be issued and sold
under the Amended Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company sold 3.5 million shares of common stock, resulting in gross proceeds of $29.9 million and
net proceeds of $29.3 million. During the year ended December 31, 2023, the Company sold 1.9 million shares of common stock, resulting
in gross proceeds of $15.1 million and net proceeds of $14.6 million.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company presently has one equity compensation plan, the 2019 Amended and Restated Stock Plan, (the &#8220;2019 Plan&#8221;). The 2019
Plan has an expiration date of October&#160;18, 2029 and the number of shares of our common stock authorized under the plan for grant
to employees, directors and consultants is 9,333,333 shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had two equity compensation plans that expired on September 9, 2023; the Company&#8217;s Amended and Restated 2013 Stock Plan
and the Company&#8217;s 2013 Equity Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
is a summary of stock option activity for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-indent: -9pt; padding-left: 9pt">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,396</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.85</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">15,204</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -9pt; padding-left: 0.25in">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,402</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.28</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 0.25in">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(44</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.92</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(309</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">8.30</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Outstanding, December 31, 2023</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5,445</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6.80</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8.70</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">373</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -9pt; padding-left: 0.25in">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">154</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.47</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 0.25in">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(10</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7.39</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(452</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">10.04</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Outstanding, December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,137</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">6.48</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">7.04</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Exercisable, December 31, 2024</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,555</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10.63</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7.84</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2024, the Company granted newly hired employees options to purchase 0.2 million shares of common stock with an exercise price ranging
from $7.20 to $8.15 per share, a term of 10 years, and a vesting period of 4 years.&#160;The options have an aggregated fair value of
$0.6 million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model
include: (1) discount rate range from 4.19% to 4.45% (2) expected life of 6 years, (3) expected volatility range from 80.5% to 90.5%,
and (4) <span style="-sec-ix-hidden: hidden-fact-51">zero</span> expected dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2023, the Company granted its employees and members of the Board of Directors options to purchase 2.4 million shares of common stock
with an exercise price ranging from $5.00 to $11.60 per share, a term of 10 years, and a vesting period from 4 to 4.2 years.&#160;The
options have an aggregated fair value of $9.0 million that was calculated using the Black-Scholes option-pricing model. Variables used
in the Black-Scholes option-pricing model include: (1) discount rate range from 3.5% to 4.82% (2) expected life of 6 years, (3) expected
volatility range from 79.0% to 81.6%, and (4) zero expected dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, options to purchase 0.5 million and 0.3 million common shares were cancelled, respectively,
upon the termination of employment.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of all options
issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at December 31,
2024 was $9.1 million related to unvested options, which is expected to be expensed over a weighted average of 2.6 years. During 2024
and 2023, the Company recorded total option expense of $4.6 million and $3.2 million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
is a summary of restricted stock unit (&#8220;RSUs&#8221;) activity for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Grant Date Fair Value Per Share ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">325</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.96</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.31</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7.31</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.89</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">8.31</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">300</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">5.85</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
RSUs vest at the earliest of a change of control event, the termination of the recipient&#8217;s continuous service status for any reason
other than by the Company for cause and the third anniversary of the date of the grant. The fair value of the RSUs, $1.8 million, was
determined based on the stock prices on the dates of the grants and each RSU grant is being recognized over its respective three-year
period. The unrecognized compensation expense at December 31, 2024 of $0.4 million is expected to be expensed over a weighted average
of 0.6 years. During 2024 and 2023, the Company recorded compensation expense related to RSUs of $0.6 million and $0.6 million, respectively.<b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
is a summary of warrant activities for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-indent: -9pt; padding-left: 9pt">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,443</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16.58</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.33</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -9pt; padding-left: 0.25in">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8.77</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10.00</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 0.25in">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">106.80</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Outstanding, December 31, 2023</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,442</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">16.42</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.34</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -9pt; padding-left: 0.25in">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 0.25in">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,435</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">16.42</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Outstanding, December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">17.33</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">4.46</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Exercisable, December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">17.77</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">4.25</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 23, 2024, warrants to purchase an aggregate of 1.4 million shares of common stock expired. These warrants were issued on April
23, 2019, when the Company completed an underwritten offering of 1.4 million shares of common stock and warrants to purchase 1.4 million
shares of common stock at a price of $11.55 per share and related warrant. The warrants were exercisable for a period of 5 years at an
exercise price of $15.00 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, the Company recorded stock-based compensation expense related to warrants of $5 thousand
and $6 thousand, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 - Income Taxes </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets and
liabilities at December 31, 2024 and 2023 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Net operating losses carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">47,875</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">41,698</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,217</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,219</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,572</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,512</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Research and development/orphan drug credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,296</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,509</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Capitalized research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,664</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,684</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 0.25in">Others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(57</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(101,613</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(90,565</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Deferred tax assets, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has recorded a valuation allowance of $101.6 million and $90.6 million against its deferred tax assets at December 31, 2024 and
2023 respectively, because management determined that it is not more-likely-than not that those assets will be realized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
federal income tax purposes, the Company has $189.3 million of unused net operating losses (&#8220;NOLs&#8221;) at December 31, 2024
available for carry forward to future years. NOLs of $104.8 million generated prior to 2018 will begin to expire if unused beginning
in 2026 when approximately $3.9 million in NOLs are due to expire. The Company&#8217;s largest NOLs will begin to expire in 2034 - 2037,
with each year in excess of $15 million. NOLs generated in 2018 and later years of $84.6 million have an indefinite life, but will be
limited to 80% of their value if used in a tax year ending after January 1, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
state income tax purposes, the Company has $327.8 million of unused NOLs at December 31, 2024 available for carry forward to future years.
These NOLs will begin to expire in 2035 if unused.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has federal research and development tax credits of $6.7 million at December 31, 2024, which will begin to expire in 2033 if
unused and orphan drug credits of $16.5 million which will begin to expire in 2037 if unused.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
and state tax laws impose limitations on the utilization of net operating losses and credit carryforwards in the event of an ownership
change for tax purposes, as defined in Section 382 of the Internal Revenue Code. Accordingly, the Company&#8217;s ability to utilize
these carryforwards may be limited as a result of an ownership change which may have already happened or may happen in the future. Such
an ownership change could result in a limitation in the use of the net operating losses in future years and possibly a reduction of the
net operating losses available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tax Cuts and Jobs Act of 2017 (TCJA) has modified the IRC 174 expenses related to research and development for the tax years beginning
after December 31, 2021. Under the TCJA, the Company must now capitalize the expenditures related to research and development activities
and amortize them over five years for U.S. activities and 15 years for non-U.S. activities. Since this has been the Company's policy
since 2018, the current year capitalization of research and development costs in accordance with IRC 174 was $28.0 million for a total
accumulated gross amount of $87.9 million as of December 31, 2024.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
difference between the income tax provision and the amount that would result if the U.S. Federal statutory rates were applied to pre-tax
losses for the year ended December 31, 2024 and 2023 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Federal statutory income taxes</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(8,031</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(10,252</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,275</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.3</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,743</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.6</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred true-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">259</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">176</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development/orphan drug tax credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,787</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7.3</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,263</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6.7</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">788</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">608</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,046</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,474</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Provision for income tax</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-&#160;&#160;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-&#160;&#160;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-&#160;&#160;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-&#160;&#160;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Note 9  - Subsequent Events </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 27, 2025, a putative
class action complaint (the &#8220;Complaint&#8221;) was filed by alleged stockholder Nihil Kohil against the Company and executives Sandesh
Seth, Avinash Desai, Madhuri Vusirikala, and Sergio Giralt, styled&#160;<i>Kohil v. Actinium Pharmaceuticals, Inc., et al</i>., Case No.
1:25-cv-02553 in the Southern District of New York, wherein, the Complaint alleges that the defendants made material misrepresentations
and omissions concerning the Iomab-B Phase 3 Sierra Trial and the plaintiff asserts claims against all defendants pursuant to section
10(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and Rule 10b-5 promulgated thereunder, as well
as additional claims against the individual defendants pursuant to Section 20(a) of the Exchange Act.&#160; The Complaint purports to
assert class action claims on behalf of all persons and entities that purchased or otherwise acquired Actinium securities between October
31, 2022 and August 2, 2024.&#160; Plaintiff seeks unspecified damages.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The defendants have not yet
responded to the complaint, and they intend to vigorously defend themselves against the plaintiff&#8217;s allegations, however, there
can be no assurances as to the outcome.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 31, 2025, our Board
of Directors of approved the cancellation of certain stock options to purchase 5,149,944 shares of common stock held by certain current
employees and directors that were initially granted under the Company&#8217;s Amended and Restated 2013 Stock Plan and 2019 Amended and
Restated Stock Plan. FSuSuch cancellation is subject to the consent of the applicable holder of the stock options, which the Company is
expecting to receive shortly following the filing of this Annual Report on Form 10-K. Our Compensation Committee intends to conduct an
analysis of our equity compensation plan and develop an equity compensation strategy that satisfies the purpose of the 2019 Plan to attract
and retain the best available personnel who can make meaningful contributions towards achieving the business objectives of the Company.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (38,243)<span></span>
</td>
<td class="num">$ (48,818)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates in the biotechnology sector and is subject to various cybersecurity risks that could adversely affect the Company&#8217;s
business, financial condition or results of operations, including intellectual property theft, fraud, extortion, harm to employees, collaborators
or vendors, violation of privacy laws and other litigations, legal and reputational risk.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company acknowledges that an actual or perceived
breach of its information assets could damage its reputation, interfere with the progress of clinical trials, or interfere with efforts
to pursue regulatory approvals for its product candidates. The Company also recognizes that an actual or perceived breach of its information
assets could impact the Company&#8217;s business strategy, operations, or financial condition, as well as subject Actinium to third&#8211;party
lawsuits, regulatory fines or other actions or liabilities, any of which could adversely affect the Company. For further information,
see &#8220;Risk Factors&#8212;Our business is subject to cybersecurity risks&#8221; in Item 1A of this Annual Report on Form 10&#8211;K.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actinium&#8217;s
Risk Management Strategy:</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the critical importance of developing, implementing, and maintaining robust cybersecurity measures to safeguard its
information systems and protect the confidentiality, integrity, and availability of its data. With that objective, the Company undertook
a focused cybersecurity assessment conducted by an independent cybersecurity advisory firm to better understand the current cybersecurity
threats and risks necessary to establish the foundation of a cybersecurity risk assessment framework appropriate for its current business
operations and needs. The Company has also engaged well-known and established technology suppliers to support its key technology processes
and operating technical security management activities including threat, vulnerability, and network security management.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has established an Incident Response Policy and recovery plans to address its response to a cybersecurity incident, and such
plans are tested and evaluated on a regular basis. This includes continuous security operation centers monitoring of the Company&#8217;s
systems and accounts.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company proactively mitigates its financial exposure to cybersecurity incidents by maintaining a cyber liability insurance policy. However,
the Company&#8217;s cyber liability insurance may be inadequate or may not be available in the future on acceptable terms, or at all.
In addition, the Company&#8217;s cyber liability insurance policy may not cover all claims made against the Company. Defending a suit,
regardless of its merit, could be costly and divert management&#8217;s attention from the Company&#8217;s business and operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, Actinium has not experienced any material cybersecurity incident that affected the Company&#8217;s operations or financial condition.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Governance:</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on a multidisciplinary team including third-party service providers to assess how identified cybersecurity threats could impact
our business. The Company&#8217;s cybersecurity function is managed by the Company&#8217;s Chief Financial Officer, who assumes the overall
responsibility and accountability of the function and with select members of the Company&#8217;s management is collectively responsible
for the day&#8211;to&#8211;day assessment and management of cybersecurity risks, their prevention, mitigation, detection, and remediation.
Our Chief Financial Officer and other members of management have undergone various briefings from our cybersecurity advisory firm to
prepare them to effectively assess and manage material risks from cybersecurity threats. Additionally, members of the third-party service
providers have cybersecurity experience and/or certifications.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Board is involved in overseeing our risk management processes and policies that may be implemented from time to time.
The Audit Committee will coordinate these activities through regular interactions with the Company&#8217;s management including but not
limited to: presentations regarding recent developments, potential risks associated with third parties, emerging trends, any relevant
findings or any incident that rises to the level of established thresholds.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risk factors discussed in this document should be considered together with information included elsewhere in the Annual Report on Form
10&#8211;K and should not be considered as the only risks to which the Company is exposed.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the critical importance of developing, implementing, and maintaining robust cybersecurity measures to safeguard its
information systems and protect the confidentiality, integrity, and availability of its data. With that objective, the Company undertook
a focused cybersecurity assessment conducted by an independent cybersecurity advisory firm to better understand the current cybersecurity
threats and risks necessary to establish the foundation of a cybersecurity risk assessment framework appropriate for its current business
operations and needs. The Company has also engaged well-known and established technology suppliers to support its key technology processes
and operating technical security management activities including threat, vulnerability, and network security management.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has established an Incident Response Policy and recovery plans to address its response to a cybersecurity incident, and such
plans are tested and evaluated on a regular basis. This includes continuous security operation centers monitoring of the Company&#8217;s
systems and accounts.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, Actinium has not experienced any material cybersecurity incident that affected the Company&#8217;s operations or financial condition.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on a multidisciplinary team including third-party service providers to assess how identified cybersecurity threats could impact
our business. The Company&#8217;s cybersecurity function is managed by the Company&#8217;s Chief Financial Officer, who assumes the overall
responsibility and accountability of the function and with select members of the Company&#8217;s management is collectively responsible
for the day&#8211;to&#8211;day assessment and management of cybersecurity risks, their prevention, mitigation, detection, and remediation.
Our Chief Financial Officer and other members of management have undergone various briefings from our cybersecurity advisory firm to
prepare them to effectively assess and manage material risks from cybersecurity threats. Additionally, members of the third-party service
providers have cybersecurity experience and/or certifications.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Board is involved in overseeing our risk management processes and policies that may be implemented from time to time.
The Audit Committee will coordinate these activities through regular interactions with the Company&#8217;s management including but not
limited to: presentations regarding recent developments, potential risks associated with third parties, emerging trends, any relevant
findings or any incident that rises to the level of established thresholds.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">The Company&#8217;s cybersecurity function is managed by the Company&#8217;s Chief Financial Officer, who assumes the overall
responsibility and accountability of the function and with select members of the Company&#8217;s management is collectively responsible
for the day&#8211;to&#8211;day assessment and management of cybersecurity risks, their prevention, mitigation, detection, and remediation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">The Company&#8217;s cybersecurity function is managed by the Company&#8217;s Chief Financial Officer, who assumes the overall
responsibility and accountability of the function and with select members of the Company&#8217;s management is collectively responsible
for the day&#8211;to&#8211;day assessment and management of cybersecurity risks, their prevention, mitigation, detection, and remediation.
Our Chief Financial Officer and other members of management have undergone various briefings from our cybersecurity advisory firm to
prepare them to effectively assess and manage material risks from cybersecurity threats.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Audit Committee will coordinate these activities through regular interactions with the Company&#8217;s management including but not
limited to: presentations regarding recent developments, potential risks associated with third parties, emerging trends, any relevant
findings or any incident that rises to the level of established thresholds.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NatureOfBusinessPolicyPolicyTextBlock', window );">Nature of Business</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nature
of Business - </b>Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing ARCs and other targeted radiotherapies to
deliver cancer-killing radiation with cellular level precision to treat patients with high unmet medical needs.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principles
of Consolidation -</b> The consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly
owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates in Financial Statement Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Estimates in Financial Statement Presentation -</b> The preparation of these consolidated financial statements in conformity with
accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses
during the reporting period. Actual results could differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Segment
Information </b>- The Company operates as a single operating and reportable segment for the purposes of assessing performance and allocating
resources. The Company&#8217;s chief operating decision maker is its Chief Executive Officer, who reviews total assets in the consolidated
balance sheets and net loss and its components in the consolidated statements of operations: research and development expenses, general and administrative expenses, and interest income, for the purposes of making operating decisions,
assessing financial performance, and allocating resources.&#160;All assets are in the United States.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
and Cash Equivalents and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months
or less to be cash equivalents. The Company holds most of its cash equivalents in a Money Market account comprised of U.S. Treasury notes.
Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
is a summary of cash, cash equivalents and restricted cash at December 31, 2024 and December 31, 2023:</span></p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">72,904</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">76,677</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">324</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">313</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">73,228</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">76,990</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
cash relates to certificates of deposit held as collateral for letters of credit issued in connection with the Company&#8217;s leases
of corporate office spaces.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property
and Equipment -</b> Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives
of three to five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives
of seven years. When assets are retired, the cost and related accumulated depreciation are removed from the accounts, and any related
gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations when incurred. Capitalized lease
assets are recorded at the lesser of the present value of minimum lease payments or fair value and amortized over the estimated useful
life of the related property or term of the lease.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases
-</b> The Company has an operating lease for corporate office space and a finance lease for office equipment located at the corporate
office space. Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases
is recognized on a straight-line basis over the lease term.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
Value Measurement - </b>Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability,
in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the
highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue
Recognition </b>- The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, <i>Revenue From
Contracts With Customers</i> (&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of
promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods
or services. To determine revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps:
(i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction
price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue as the entity satisfies a performance obligation. The Company only applies the five-step model to contracts
when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers
to the customer.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods
or services promised within each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services
that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. In
determining whether goods or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can
benefit from the good or service either on its own or together with other resources that are readily available to the customer (capable
of being distinct) and (ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct
in the context of the contract).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company then determines the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange
for the promised goods or services for each performance obligation and recognizes the associated revenue as each performance obligation
is satisfied. The Company&#8217;s estimate of the transaction price for each contract includes all variable consideration to which it
expects to be entitled. Variable consideration includes payments in the form of collaboration milestone payments. If an arrangement includes
collaboration milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates
the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue
reversal would not occur, the associated milestone value is included in the transaction price.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
606 requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance
obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should
be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised
good or service separately to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated
to the respective performance obligation as each performance obligation is satisfied, either at a point in time or over time, and if
over time, recognition is based on the use of an output or input method.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Collaborative
Arrangements</b> - The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain
transactions between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or
net basis, depending on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships.
The Company evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the
nature of the underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators,
the Company follows the guidance of ASC 606<i>.</i></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistancePolicyTextBlock', window );">Grant Revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grant
Revenue - </b>The Company has a grant from a government-sponsored entity for research and development related activities that
provides for payments for reimbursed costs, which included overhead and general and administrative costs as well as an
administrative fee. The Company recognizes revenue from grants as it performed services under this arrangement. Associated expenses
are recognized when incurred as research and development expense. Revenue and related expenses are presented gross in the
consolidated statements of operations. There was no grant revenue for the year ended December 31, 2024.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LicenseRevenuePolicyTextBlock', window );">License Revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
Revenue -</b> The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain
product in specified territories using the Company&#8217;s trademarks. The terms of this arrangement includes payment to the Company
for a combination of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments;
and royalties on net sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration
should be included in the transaction price.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Upfront
license fees</i>: If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance
obligations identified in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when
the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled
with other promises, the Company determines whether the combined performance obligation is satisfied over time or at a point in time.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Development,
regulatory or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement
of certain development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered
probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it
is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.
Milestone payments that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered
probable of being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate
the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#8217;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales-based
milestone payments and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the
volume of sales, the Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based
milestones relate and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii)
when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upfront
payments and fees may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements or when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when
the uncertainty associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts
receivable when the Company&#8217;s right to consideration is unconditional.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug
product, the costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to
facilities and equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development
costs.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share-Based
Payments -</b> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing
model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee
is required to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income
Taxes -</b> The Company accounts for income taxes in accordance with ASC 740 <i>Income Taxes</i>, which requires the asset and liability
method to calculate deferred taxes. Deferred taxes are recognized based on the differences between the financial reporting and income
tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to
reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred
tax asset will be fully realized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
740 prescribes guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions. Tax positions
must meet a &#8220;more-likely-than-not&#8221; recognition threshold to be recognized. There were no tax positions for which it is considered
reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within the next year.
The Company recognizes interest related to unrecognized tax benefits in interest expense and penalties in operating expenses.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
Loss Per Common Share</b> - Basic loss per common share is computed by dividing the net loss available to common stockholders by the
weighted average number of common shares outstanding during the reporting period. For periods of net loss, diluted loss per share is
calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2024 and 2023, the Company&#8217;s potentially dilutive shares, which include outstanding common stock options,
restricted stock units and warrants, have not been included in the computation of diluted net loss per share as the result would have
been anti-dilutive.&#160;</span></p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,137</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,445</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,442</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,444</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,192</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsequent
Events </b>- The Company&#8217;s management reviewed all material events through the date the consolidated financial statements were
issued for subsequent event disclosure consideration.&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Adopted Accounting Pronouncements - </b>In November 2023, FASB issued ASU 2023-07, <i>Segment Reporting</i> (Topic 280), <i>Improvements
to Reportable Segment Disclosures</i>, which provides improvements to reportable segment disclosure requirements, primarily through enhanced
disclosures around segment expenses. ASU 2023-07 requires the Company to disclose significant segment expenses that are regularly provided
to the chief operating decision maker (&#8220;CODM&#8221;) and included within each reported measure of segment profit or loss. ASU 2023-07
also requires that the Company disclose an amount for other segment items by reportable segment, a description of their composition and
provide all annual disclosures about a reportable segment&#8217;s profit or loss and assets pursuant to Topic 280 during interim periods.
The Company must also disclose the CODM&#8217;s title and position, as well as certain information around the measures used by the CODM
and an explanation of how the CODM uses the reported measures in assessing segment performance and deciding how to allocate resources.
For public entities with a single reportable segment, the entity must provide all the disclosures required pursuant to ASU 2023-07 and
all existing segment disclosures under Topic 280. The amendments of ASU 2023-07 are effective for the Company for annual periods beginning
January 1, 2024, and effective for interim periods beginning January 1, 2025. The Company adopted this standard effective January 1,
2024 and reported on it in this Annual Report on Form 10-K for the year ended December 31, 2024.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued Accounting Pronouncements - </b>In November 2024, FASB issued ASU 2024-03, <i>Income Statement-Reporting Comprehensive Income-Expense
Disaggregation Disclosures</i> (Subtopic 220-40), to improve the disaggregation of expenses within the consolidated statement of operations.
The amendments in ASU 2024-03 require disclosures, in the notes to the consolidated financial statements, specified information about
certain costs and expenses. The amendments require that at each interim and annual reporting period an entity disclose (a) employee compensation,
(b) depreciation, and (c) intangible asset amortization included in each relevant expense caption; include certain amounts that are already
required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; and disclose a qualitative
description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively. The amendments
in ASU 2024-03 are effective January 1, 2027, and effective for interim periods beginning January 1, 2028. The Company will evaluate
the impact of ASU 2024-03 on its financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, FASB issued ASU 2023-09, <i>Income Taxes</i> (Topic 740): <i>Improvements to Income Tax Disclosures</i>, to enhance the
transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide improvements primarily related
to the rate reconciliation and income taxes paid information included in income tax disclosures. The Company will be required to disclose
additional information regarding reconciling items equal to or greater than five percent of the amount computed by multiplying pretax
income (loss) by the applicable statutory tax rate. Similarly, the Company will be required to disclose income taxes paid (net of refunds
received) equal to or greater than five percent of total income taxes paid (net of refunds received). The amendments in ASU 2023-09 are
effective January 1, 2025, including interim periods. The Company will evaluate the impact of ASU 2023-09 on its financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LicenseRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for license revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LicenseRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NatureOfBusinessPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for nature of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NatureOfBusinessPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
is a summary of cash, cash equivalents and restricted cash at December 31, 2024 and December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">72,904</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">76,677</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">324</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">313</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">73,228</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">76,990</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2024 and 2023, the Company&#8217;s potentially dilutive shares, which include outstanding common stock options,
restricted stock units and warrants, have not been included in the computation of diluted net loss per share as the result would have
been anti-dilutive.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,137</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,445</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,442</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,444</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,192</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets consisted of the following at December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid&#160;insurance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">608</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">614</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid&#160;clinical trial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">637</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">746</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">357</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">226</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,602</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,586</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consisted of the following at December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Lives</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">5 years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">817</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">806</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment&#160;and furniture</td><td>&#160;</td>
    <td style="text-align: center">3 - 7 years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">438</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">438</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(891</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(694</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">364</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">550</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ScheduleOfDepreciationExpenseTableTextBlock', window );">Schedule of Depreciation Expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense consisted of the following for the years ended December 31, 2024 and 2023, respectively:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research&#160;and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">161</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">175</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">36</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">32</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total depreciation expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">197</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">207</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfDepreciationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of depreciation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfDepreciationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of lease expense are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">691</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">691</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total finance lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">12</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
cash flow information related to leases are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cash flow information:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flow use from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;618</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;606</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">30</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
average remaining lease terms are as follows at December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average remaining lease term:</td><td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 89%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right">2.6 years</td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Finance leases</td><td>&#160;</td> <td style="text-align: right">2.0 years</td> <td>&#160;</td></tr> </table>Below is information on the weighted average discount rates used at the time that
the leases were evaluated:<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>Weighted average discount rates:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.8</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.2</td><td style="text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Lease Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturities
of lease liabilities are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating&#160;<br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance&#160;<br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">630</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">643</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">380</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,653</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(100</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,553</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">20</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
is a summary of stock option activity for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-indent: -9pt; padding-left: 9pt">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,396</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.85</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">15,204</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -9pt; padding-left: 0.25in">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,402</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.28</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 0.25in">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(44</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.92</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(309</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">8.30</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Outstanding, December 31, 2023</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5,445</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6.80</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8.70</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">373</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -9pt; padding-left: 0.25in">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">154</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5.47</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 0.25in">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(10</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7.39</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(452</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">10.04</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Outstanding, December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,137</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">6.48</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">7.04</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Exercisable, December 31, 2024</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,555</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10.63</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7.84</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Unit Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
is a summary of restricted stock unit (&#8220;RSUs&#8221;) activity for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Grant Date Fair Value Per Share ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">325</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.96</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.31</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">7.31</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.89</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">8.31</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">300</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">5.85</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
is a summary of warrant activities for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-indent: -9pt; padding-left: 9pt">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,443</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16.58</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.33</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -9pt; padding-left: 0.25in">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8.77</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10.00</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 0.25in">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">106.80</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Outstanding, December 31, 2023</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,442</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">16.42</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.34</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -9pt; padding-left: 0.25in">Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 0.25in">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,435</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">16.42</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Outstanding, December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">17.33</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">4.46</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Exercisable, December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">17.77</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">4.25</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of the Deferred Tax Assets and Liabilities</a></td>
<td class="text">Significant components of the Company&#8217;s deferred tax assets and
liabilities at December 31, 2024 and 2023 are as follows:<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Net operating losses carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">47,875</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">41,698</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,217</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,219</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,572</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,512</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Research and development/orphan drug credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,296</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,509</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Capitalized research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,664</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,684</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 0.25in">Others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(57</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(101,613</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(90,565</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Deferred tax assets, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of U.S. Federal Statutory Rates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
difference between the income tax provision and the amount that would result if the U.S. Federal statutory rates were applied to pre-tax
losses for the year ended December 31, 2024 and 2023 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Federal statutory income taxes</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(8,031</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(10,252</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,275</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.3</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,743</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.6</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred true-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">259</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">176</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development/orphan drug tax credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,787</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7.3</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,263</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6.7</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">788</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">608</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,046</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,474</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29.7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Provision for income tax</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-&#160;&#160;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-&#160;&#160;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-&#160;&#160;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-&#160;&#160;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-5<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-6<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 93: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 94: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 95: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 96: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 97: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 98: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-3<br><br>Reference 99: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 100: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Schedule of Cash, Cash Equivalents and Restricted Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 72,904<span></span>
</td>
<td class="nump">$ 76,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash &#8211; long-term</a></td>
<td class="nump">324<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 73,228<span></span>
</td>
<td class="nump">$ 76,990<span></span>
</td>
<td class="nump">$ 109,608<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">5,444<span></span>
</td>
<td class="nump">7,192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">5,137<span></span>
</td>
<td class="nump">5,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">1,442<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAbstract', window );"><strong>Schedule of Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 608<span></span>
</td>
<td class="nump">$ 614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid clinical trial expenses</a></td>
<td class="nump">637<span></span>
</td>
<td class="nump">746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other prepaid expenses and other current assets</a></td>
<td class="nump">357<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 1,602<span></span>
</td>
<td class="nump">$ 1,586<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">$ (891)<span></span>
</td>
<td class="num">$ (694)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 364<span></span>
</td>
<td class="nump">550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 817<span></span>
</td>
<td class="nump">806<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment and furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 438<span></span>
</td>
<td class="nump">$ 438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Office equipment and furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Office equipment and furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Depreciation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Schedule of Depreciation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total depreciation expense</a></td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">$ 207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Schedule of Depreciation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total depreciation expense</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Schedule of Depreciation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total depreciation expense</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedIncomeStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedIncomeStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease term</a></td>
<td class="text">5 years and 2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Expiration date</a></td>
<td class="text">Jul. 30,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Current annual rent</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateAndOtherMember', window );">Corporate Office Space [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandImprovements', window );">Spent amount on improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation and depletion of additions or improvements to real estate held for productive use. Examples include, but are not limited to, walkways, driveways, fences, and parking lots.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Schedule of Components of Lease Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 691<span></span>
</td>
<td class="nump">$ 691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityAbstract', window );"><strong>Finance lease cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-to-use assets</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract', window );"><strong>Cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flow use from operating leases</a></td>
<td class="nump">618<span></span>
</td>
<td class="nump">606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flow use from finance leases</a></td>
<td class="nump">11<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flow use from finance leases</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations, Operating leases</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations, Finance leases</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term, Operating leases</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term, Finance leases</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rates, Operating leases</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rates, Finance leases</a></td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Schedule of Maturities of Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Operating Leases, 2025</a></td>
<td class="nump">$ 630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Finance leases, 2025</a></td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Operating Leases, 2026</a></td>
<td class="nump">643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">Finance Leases, 2026</a></td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Operating Leases, 2027</a></td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">Finance Leases, 2027</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Operating leases payments</a></td>
<td class="nump">1,653<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Finance leases payments</a></td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Operating Leases, imputed interest</a></td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Finance Leases, imputed interest</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">1,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of finance lease liabilities</a></td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Other Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NonRefundablePaymentReceived', window );">Non-refundable payment received</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term license revenue deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NonRefundablePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of non-refundable payment received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NonRefundablePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 15, 2012 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_PaymentOfMilestone', window );">Milestone payment</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_RoyaltyPaymentsPercentage', window );">Royalty payments, percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PaymentOfMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of  milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_PaymentOfMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>percentage of royalty payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_RoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 23, 2024</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Apr. 23, 2019</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,255<span></span>
</td>
<td class="nump">$ 14,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Number of shares of common stock authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted options to purchase shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,000<span></span>
</td>
<td class="nump">2,402,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.47<span></span>
</td>
<td class="nump">$ 5.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 10 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 14 days<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Option fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.50%<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.50%<span></span>
</td>
<td class="nump">81.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Options to purchase common shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_WarrantExpiredTerm', window );">Warrant expired term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_WarrantExpiredPricePerShare', window );">Warrant expired price per share (in Dollars per share)</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.19%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.45%<span></span>
</td>
<td class="nump">4.82%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.15<span></span>
</td>
<td class="nump">$ 11.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember', window );">2019 Amended and Restated Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Number of shares of common stock authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Base prospectus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares of common stock sold (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,900<span></span>
</td>
<td class="nump">$ 15,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NetProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,300<span></span>
</td>
<td class="nump">$ 14,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ExpiredWarrant', window );">Expired warrant (in Shares)</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_WarrantExpiredUnderwrittenOfferingShares', window );">Warrant expired underwritten offering shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted options to purchase shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=atnm_CapitalOnDemandSalesAgreementMember', window );">Capital on Demand Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ExpiredWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares of expired warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ExpiredWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NetProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NetProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WarrantExpiredPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant expired price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WarrantExpiredPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WarrantExpiredTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant expired term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WarrantExpiredTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WarrantExpiredUnderwrittenOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant expired underwritten offering shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WarrantExpiredUnderwrittenOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the entity's equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=atnm_CapitalOnDemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=atnm_CapitalOnDemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Schedule of Stock Option Activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Ending balance</a></td>
<td class="nump">3,396<span></span>
</td>
<td class="nump">5,137<span></span>
</td>
<td class="nump">5,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending balance</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 6.48<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years) Outstanding, Ending balance</a></td>
<td class="text">8 years 10 months 6 days<span></span>
</td>
<td class="text">7 years 14 days<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, Ending balance</a></td>
<td class="nump">$ 15,204<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 10 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="nump">2,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.47<span></span>
</td>
<td class="nump">$ 5.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.39<span></span>
</td>
<td class="nump">$ 5.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(452)<span></span>
</td>
<td class="num">(309)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.04<span></span>
</td>
<td class="nump">$ 8.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Restricted Stock Unit Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs Outstanding, Beginning balance</a></td>
<td class="nump">305,000<span></span>
</td>
<td class="nump">325,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Outstanding Beginning balance</a></td>
<td class="nump">$ 5.89<span></span>
</td>
<td class="nump">$ 5.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs Outstanding, Ending balance</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">305,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Outstanding Ending balance</a></td>
<td class="nump">$ 5.85<span></span>
</td>
<td class="nump">$ 5.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs Outstanding, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs Outstanding, Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">RSUs Outstanding, Cancelled</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Cancelled</a></td>
<td class="nump">$ 8.31<span></span>
</td>
<td class="nump">$ 7.31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Warrant Activity (Details) - Warrant [Member] - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Warrant Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants Outstanding, Ending balance</a></td>
<td class="nump">1,443<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">1,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending balance</a></td>
<td class="nump">$ 16.58<span></span>
</td>
<td class="nump">$ 17.33<span></span>
</td>
<td class="nump">$ 16.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term (in years) Outstanding Ending balance</a></td>
<td class="text">1 year 3 months 29 days<span></span>
</td>
<td class="text">4 years 5 months 15 days<span></span>
</td>
<td class="text">4 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, Ending balance</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term (in years), Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Warrants, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Warrants, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,435)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.42<span></span>
</td>
<td class="nump">$ 106.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable', window );">Number of Warrants, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term (in years), Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share-based compensation arrangement by share-based payment award, non-options exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of non options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of non options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on non options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on non options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of non options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of non options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for portions of non options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of non-options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,613<span></span>
</td>
<td class="nump">$ 90,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Unused net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedContractualRights', window );">Indefinite life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Net operating loss percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Federal research and development tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,664<span></span>
</td>
<td class="nump">$ 18,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_AccumulatedGrossAmount', window );">Accumulated gross amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=atnm_FederalIncomeTaxMember', window );">Federal income tax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Unused net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=atnm_ExpireIn2026Member', window );">Net operating losses due to expire in 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2018Member', window );">Net operating losses expire in 2034 - 2037 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=atnm_TaxYearTwoThousandThirtyThreeMember', window );">Tax Year 2033 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Federal research and development tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=atnm_TaxYearTwoThousandThirtySevenMember', window );">Tax Year 2037 [Member] | Orphan Drug Credits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Federal research and development tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AccumulatedGrossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated gross amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AccumulatedGrossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedContractualRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date of rights with an indefinite period of benefit that arose from a contractual arrangement with a third party (not including franchise rights and license agreements).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedContractualRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of research and development costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=atnm_FederalIncomeTaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=atnm_FederalIncomeTaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=atnm_ExpireIn2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=atnm_ExpireIn2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=atnm_TaxYearTwoThousandThirtyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=atnm_TaxYearTwoThousandThirtyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=atnm_TaxYearTwoThousandThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=atnm_TaxYearTwoThousandThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=atnm_OrphanDrugCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=atnm_OrphanDrugCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of the Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses carry forward</a></td>
<td class="nump">$ 47,875<span></span>
</td>
<td class="nump">$ 41,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">8,217<span></span>
</td>
<td class="nump">8,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Share-based compensation</a></td>
<td class="nump">1,572<span></span>
</td>
<td class="nump">1,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development/orphan drug credits</a></td>
<td class="nump">23,296<span></span>
</td>
<td class="nump">20,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development expenses</a></td>
<td class="nump">20,664<span></span>
</td>
<td class="nump">18,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Others</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(101,613)<span></span>
</td>
<td class="num">(90,565)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of U.S. Federal Statutory Rates (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Schedule of U.S. Federal Statutory Rates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income taxes</a></td>
<td class="num">$ (8,031)<span></span>
</td>
<td class="num">$ (10,252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income taxes, percentage</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes</a></td>
<td class="num">$ (1,275)<span></span>
</td>
<td class="num">$ (1,743)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, percentage</a></td>
<td class="num">(3.30%)<span></span>
</td>
<td class="num">(3.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_IncomeTaxReconciliationDeferredTrueup', window );">Deferred true-up</a></td>
<td class="nump">$ 259<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps', window );">Deferred true-up, percentage</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development/orphan drug tax credit</a></td>
<td class="num">$ (2,787)<span></span>
</td>
<td class="num">$ (3,263)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development/orphan drug tax credit, percentage</a></td>
<td class="num">(7.30%)<span></span>
</td>
<td class="num">(6.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other</a></td>
<td class="nump">$ 788<span></span>
</td>
<td class="nump">$ 608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other, percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">$ 11,046<span></span>
</td>
<td class="nump">$ 14,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance, percentage</a></td>
<td class="nump">28.90%<span></span>
</td>
<td class="nump">29.70%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for income tax, percentage</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of deferred true-up.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_IncomeTaxReconciliationDeferredTrueup">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax reconciliation deferred true-up.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_IncomeTaxReconciliationDeferredTrueup</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled stock option</a></td>
<td class="nump">5,149,944<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !.(?UI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( !.(?UJ>!OZK\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( !.(?UH^!JY-NP<  *\S   8
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M2'YN,'(QC4\0QY\(X8>-^ +Y-SJC?P!02P,$%     @ $XA_6I?CX_JR P
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M$8#W:R'T\XTY8VW/U)?_ 5!+ P04    "  3B']:%<=[O#L#  #O"@  &
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M,I#7MXR)7P?J35[[;GCU'U!+ P04    "  3B']: #!JLC\&  !U&P  &
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MB&I>OISTPI?Q#*=*3E>P(E<N,"KH'M$K5&V]#F*ERD)(+T",--<AGTB6*%7
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M)1>X4J";JF+JSQ)+N9O[ W^_<,NWA;$+03JKV1;OT'RK5XJLH%?)>85"<RE
MX6;N+P;3Y=#B'> [QYT^F(/-9"WEO34^Y7,_M %AB9FQ"HR&![S$LK1"%,;O
M3M/O75KBX7RO_L'E3KFLF<9+6?[@N2GF_L2''#>L*<VMW'W$+I^1U<MDJ=T7
M=BUV%/N0-=K(JB-3!!47[<@>NSH<$";A,X2H(T0N[M:1B_**&9;.E-R!LFA2
MLQ.7JF-3<%S80[DSBG8Y\4RZ4E@SGL/U(QVS1@U,Y/#%%*C@LE$*A8&%UFCT
M+##DSI*"K)->MM+1,]*#"&ZD,(6&:Y%C_E0@H#C[8*-]L,OHI.(59A<0#\XA
M"J/A";VX3SYV>O%KDX>?B[4VBJ[0KV-U:+T,CWNQSVJJ:Y;AW*=WHU$]H)^^
M?3-(PO<G<ACV.0Q/J;_N $]*'P_\LS3H1? .7EZ\#NGA(5(Z9-8A68O,)+UV
M;9"V-T  V,B2V@876V &Z/BQ6A-K?P6<$$WBJ?=D[]#P'-""O'W$7.A&,9$A
MG$$23NQW,.QW,RH#SU@)1G'Z]D$G\1C&P\1K4ZP[]/]SBD=CB*+$^RH-R;V<
M=P:#\R2,W#B:)'#LK@0'#[]"M77MS9:Q$:;M ?UJWT$7;>/X!V_;[PU36RH,
ME+@A:G@Q'OF@VI;6&D;6KHVLI:&FY*8%_05060#M;R3=C,ZP#OK_2OH74$L#
M!!0    ( !.(?UH-,U+^  ,  !,'   9    >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;)55VT[C,!!]SU>,LF@%$DNNO=!M*P'+7B381;"7A]4^N,FDL4CL
M8#L4_G['3AN*!)5XJ&./9X[/C#O'TY54M[I$-/!05T+/_-*89A($.BNQ9OI(
M-BAHIY"J9H:6:AGH1B'+75!=!7$8#H.:<>'/I\YVI>93V9J*"[Q2H-NZ9NKQ
M%"NYFOF1OS%<\V5IK"&83QNVQ!LTOYHK1:N@1\EYC4)S*4!A,?-/HLEI:OV=
MPV^.*[TU!YO)0LI;N_B6S_S0$L(*,V,1&'WN\0RKR@(1C;LUIM\?:0.WYQOT
MSRYWRF7!-)[)Z@_/33GSQS[D6+"V,M=R]177^0PL7B8K[498=;Y)ZD/6:B/K
M=3 QJ+GHONQA78>M@''X2D"\#H@=[^X@Q_(3,VP^57(%RGH3FIVX5%TTD>/"
M7LJ-4;3+*<[,KQ3=KS*/P$0.YW<M;ZCB9AH8PK8>0;;&.>UPXE=PHA@NI3"E
MAG.18_X<("!2/;-XP^PTWHGX";,C2*)#B,,XW8&7])DF#B]Y4Z;P]V2AC:(_
MQ[^7DNX@TY<A;<-,=,,RG/G4$1K5/?KS]^^B8?AQ!^&T)YSN0G_#U>S$>9GE
M=VG02^ #O%*6C=FS9NS-F:1VU 9SD 68$J&0%?4U%TM@!NC*L%Z@ZJ_-@=(D
MF7C/]K87WCX7!"5;3<[Z "ZH2W47;2.]"[;8(C" 1V1*PQZ,HY$=PZ'WHRAX
MAEM.]M2B58*;5B'8+$?KL#09VY]W@5I/2!*RMFXK9O/)D8J3<>:T8G]\',$!
M[ ^/4SCPGI6H/^40!&GF'B3#E,;!(*2LGB \?"#=U+BK8B2ISM)10]LW.TIX
M2!JH&W0J5CV^H:!/I;RFVV<J*QUFCH0CNX+M032,[#@:>%]0H&*5\V$Y20ZW
M_6%/I50AB;V?TM#VLWIMDB6$8WLK<3B"ESH@V!*J&M72R;&F&K7"=)K56WO%
M/^F$[LF]>RXNF5IRH:'"@D+#H]' !]5)<+<PLG&RMY"&1-1-2WJU4%D'VB\D
MM<!Z80_HW\'Y?U!+ P04    "  3B']:'CQY8TD(  #I%0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q,2YX;6R-6%MOXS83?=>O(-QMD0".[_&F;A(@F_V*
MKT6W771[05'T@99HBZ@DJB05K_OK>V8HR9+C&'F((U&<X9G;F9%N=\;^[5*E
MO/B<9X6[&Z3>EZOQV,6IRJ4;F5(5>+(Q-I<>MW8[=J55,F&A/!O/)I/E.)>Z
M&-S?\MI'>W]K*I_I0GVTPE5Y+NW^G<K,[FXP'30+/^MMZFEA?'];RJWZI/RO
MY4>+NW&K)=&Y*IPVA;!J<S=XF*[>+6@_;_A-JYWK7 NR9&W,WW3S77(WF! @
ME:G8DP:)?T_J4649*0*,?VJ=@_9($NQ>-]J_9=MARUHZ]6BRWW7BT[O!S4 D
M:B.KS/]L=O]7M3W7I"\VF>-?L0M[I]@<5\Z;O!8&@EP7X;_\7/NA(W S>4%@
M5@O,&'<XB%&^EU[>WUJS$Y9V0QM=L*DL#7"ZH*!\\A9/->3\_0\*)KG;L8<N
M6AG'M=R[(#=[06XZ$Q],X5,G_E<D*NDK& -$BV36('DW.ZOQO8I'8CX=BMED
MMCBC;]Y:-F=]\[.6B3\?ULY;!/^O4T8&%8O3*J@@5JZ4L;H;(..=LD]J</_5
M%]/EY)LS !<MP,4Y[6=<?U;N-*H?C5?10ER)VNQ?4A4]FKR4Q1Y)ZI5%[F!9
M;X1$*5@KBZU";7FAG9 B(R$A<5?$JJ1R&4$#'C6BDDMHJPIE99:12K!"X@06
M=ZGRJ;("/SW%L2F>U-Y%WO"C!@Q=6RH5@0?8XRURGA8K(#" )S;ZLTJ$= Z4
M!-;!2JFL-@D]]2 $@!3J<YS22;P!6IQ.@"P ?ZR5&K:U0GK:;*^+;114PJH
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MTPN(CAW(OK1TG;83)MB_J;._ 5!+ P04    "  3B']:C*"/H^D*  !)'P
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6RU6=MRXS82?>=7H!PG95?)
M-*^ZC&=<Y;ED-ZDD,V7E\K"U#S0)2ZRA" 4 K7&^?D\W2(JR9<N9VCS,F(2
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M6UQ3]<";6^C\C U?QJFTOZAI8\=C!V6U5+SLP%I!25C[Q<]='8X _N0$(.@
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M!W _M]C\]H04]%]GG_\+4$L#!!0    ( !.(?UJ%M<.L?@L  '\D   9
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;)U:76\;MQ)]WU]!N!=% LBV)#MV
MG \#MA.W =)>PT[:AXO[0.U2$I'54B6YDM5??\\,N1^R5VOU JTC+<G#F>',
MF>&L/JR-_>'F2GGQN,@+]_%@[OWRW?&Q2^=J(=V16:H"(U-C%]+CJYT=NZ55
M,N-%B_QX/!R>'2^D+@XN/_"S.WOYP90^UX6ZL\*5BX6TFVN5F_7'@]%!]>!>
MS^:>'AQ??EC*F7I0_OORSN+;<8V2Z84JG#:%L&KZ\>!J].YZ/*8%/.,/K=:N
M]5F0*A-C?M"7+]G'@R%)I'*5>H*0^&>E;E2>$Q+D^"N"'M1[TL+VYPK]EI6'
M,A/IU(W)_]29GW\\>'L@,C659>[OS?I7%15Z0WBIR1W_%>LX=W@@TM)YLXB+
M(<%"%^%?^1@-L<^"<5S AC@.&[&4GZ27EQ^L60M+LX%&'UA57@WA=$&G\N M
M1C76^<NK-#5EX74Q$W<FUZE6;B FF_!E(UY5#U]_./;8CA8=IQ'Z.D"/=T"/
MQN(W4_BY$Y^+3&7; ,>0LQ9V7 E[/>Y%_*32(W$R&HCQ<'S:@W=2*W_">"<[
M\5QJ]9+=PTS%=>DPP3DABTP\!#>EYP]Z5NBI3F7A18>]Q'^N)LY;^-=_NXP4
M1#CM%H&"[IU;RE1]/$!4.657ZN#RYY]&9\/W/0J>U@J>]J%?_BY]:55;MRX)
M>S&Z)0S 2=MHAZ)'X#>UP&]Z!;ZSNDCU,H=5@7UC"@<C9Y).J$OR?<&2IV#B
ML$?8LUK8LU[\[XY-^]EY#7J R+H0M[J0V%3FXL'C&?C+BSLR6^%W:O'B+LD_
MW:57O?-:O?/>C1_4C(&_%('\=TC?"]+M/1$Y:2'W.<_;6N"WO0+?2#?GV.4/
MG_\J]4KFV"<$]+U"D.K4JS#>I<K+\,F^\ B'6Y,CYX$I$HTI5=XCCTDQ8<!_
MA7H"8QL8'I=>@/748J)LS7P\\>G3DW?)*WB&GYO28=R]WI[1_I+4AGHFPK_$
M^7AP,3RE#V>#L_/SY/Z)0#__]'8\&KT7N2EFAU[9A3B!1">C$T;=4RN@GPS&
MX[=AFXN+8<M\"<^P*F=G]T:DRGJF7Q]8(5-+X[07<Y5G0CJ!%$AS+:(![B1R
MY?&%9Z9699BHG2NQ,ZR3FJ*(Y<!:^SFLI< +BZ4L-JS7^7N']4CRS!BIL4MC
M 0TL[*\$.[([ZG'5B]I5+UZ@)M15UF_8.N1*2PJ(+I_<#R?9PND-_]&P*0V&
MO>!?V1*=B7^?A4FO%*T"9=0+=BNU%7_(O%3B-^ B[>PR53]0-Q41>O(,O3^9
MC<:-[.->V>_52A6 OE>I00VQBT+W0TE:**)"OK5FD2"U<?WAQ)_DU3=<-E(,
M7/DDC6-P_U1QJ3,0!A_9]YM!A["B:,;6&07=1'&$,*/ \5.X&474U<.-.!N>
M#=J1@QC$:>,_L9XK/+<\N(1@V@%L9DR&<,)- !9'%+EF*.Z@9#IO1)$H6#*-
M;%?0ER+CO5"J&ZL&H(5E2'-$J&HI.3H1 9Q'2"LSR?6,,\J1^(5VY@BKMD[\
M7,8=&FT+XZ/&S;:6;+.8\#@SA6'%MI7:@A94%>80JP:9E$66*S*MSB Q*$QE
M1\BF2;4W%9&5R0)@VTIM.VS;6X%:2V9#HD9)O&8U(+4<T"GG9=9&?J5?A[..
M7@$&+I*)*M04U#B%0CQ*^[>V%TKS8GB:AEN9=4&#WLP"9LLD. Y36A*XMBW=
M#G4.OUA)G<L); #S;HGP*I5+&B"6G2B2MM+T-1OUE8Y"/Q4+QJR.'1M4=N4]
M6!6SPYC1CVLG>U7ME[1&U*,G'V]/?'TDOLU54ED>0T7C.HZG8E[A9$@J2Z0P
M>.EZKN'1.HS+!5T8.!VA H7(-A0\L+YZ7"J*VN!]I(O/X5RLB6RL12'RF,YE
M,5,)9;CGX;6E*TWAD.J.BYB0F4K^CCH@@@W*2<K/-A(+$FL/")4T#I]<<.IO
M'7E4Q8*U,NDS.S6"MCD*WDO.G^=B)6TXV6V[P5C1OC[I-N 1TD7GTAI^*3<+
M+D[BZ9.&X8102DQ,G+[0N#IX4ZAZ/L)W"OO!RRV=!J>*"C1Y:?&N(&ZS9KW*
M10X*XN-<<. 35JD.&4NVPPB=9V5L8KC:Y8)5HGQ9I>OS<Z ;W"QL;YP7N?Y!
MP15!%A#.9*PXEU*-("'>A6O=CJ/S)/2O=2C(UJ;, \.:-"WMX*FW-59:<0XF
MLGQ)WB/*0@FR$+9#Q6.C#]<Q:LA[#)6+8;?666V[ \5"*#3U"CG.PY R)UF<
MRG,R23#/1#K='55).ZJF8 71IO9N8S\A&#Z]R&.;:E5WS+G&]8/IPP&Y.=D8
MC%ZK'0/R9<TXZT\YR45C5]$?EEBNKP/=T'QL&O9'"'"P;>(!$RQL69%2\I2V
M6YQ-QU-3VQ9S!'9M,1/VKN39)M)NR[)1M&O,D,2T P\AFB!3[*+$7K(3;;(;
M5*F1G7]I-%. 0/@ITMBL*)+Q91!.=IJTGMA6 0=,ZB9FY(4D9!F:";"L*?VR
M] 2F"_H0(["O(&T:7J/>=M/E3<-1L,95$QK=9?X_ $O:8*)7VJ9[->IO7_UB
MB51BJ=LIX/_1NF+0I*J?^PO]IFTUZF\U?84#%D[URKH70DNP[TL4 A UC]A3
MA9CXA.'<\"UO )J=E8AQ0UT%2P4K0HJ[0L^3CWC ==P=LLLE'<-<%)B-S#UU
M-*NMMX9Y_X7<5+1+W*$L7;OAMU6@MEV<0WU:<@L2D:7!":%(;M-U##D7ZLP6
MV:%Z#DD11I%MWX*J:V**_=(1IZ'(;JU2K%R4D1V?2/XW5_R@LSII51MR:BV+
M6'/[33N/<4%,ZNPH6HA!RHF#X:!"ON&J.5\14U^Q3%R2M$OE^FYE@V26,B)H
M2H;^L\/9ITJO> E;HZN58>F5!+=0G@H#-4R1\3')O#=8FV;HJ+]/>8^#DC:=
MQ^Y4[::0RNV@E_T DT[ _AY'T^,<O=#DG,/"A]?,Q'?1VSMEW1LFJ6#Z)6R:
MFJ/^MN,7'!5RRS?YN*,7L\_RA)>#5-IH7$>=GPX%D2.ND!,\FI4ZX_17732F
M=:O9U:WF5I /D)Z:M@F=%&Y6:6Y<?.]0QXOP\E%PXXZB^X@D:+XF"Q0$0%(4
MP>2^X^'[!2[\AZ$6/41L%X<(2!X:O=]FF3FDGYN\:ELT<<S5!<18TY_";$O
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MCB*>5G<('6 '/:8M=7R_TUTBNFH>$?N26K1IT#=9\?H#TG\3_8F8,IU7'K-
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M/'Q/05'^=N(G1K;N1K"4ANX7;EC1A0Z5%:#]4DKS-+$']%?$Q?]02P,$%
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MH0K^.E1DBX@.(^AFG.I:9#!U4/H:U'=P9N_?^0D_ZTDPZA*,^NBS6[QIBZ8
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M8;Q=!E+N.8PGVEY >S#^CQ)XY;G?\=ZR>U%,+$[@+/6#H4N6*.P'<'YJQ\+
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M[*GNFY6]1X%R ?9[*:5YZKBC/=S,\K]02P,$%     @ $XA_6AF5W[G* @
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M;GWCIC]B#V$O"%0!'W8C?VXT<(=>952+J%=%U&N-:"Y9=(]^FO^20'>7D"V
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M7Z!>MCM_.]&BMIOG0FC<BNVPP,,2I G ]:40^GEB]N/^^$W_ %!+ P04
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MI;Y,:]_N]P;F>EO-WS&.]1JS0[);D>PVDKQ!V90'D3X=(:SQJU><C_MK2.?
M:[>H$?*M6]02V(YZKU+OO:]9O38KT1+83B5Z525Z+9JUP/*VS>K9>V:MB>EU
MZ\UZ5I$\:R3Y#3+@2%-YE89X5\1"<JINR4:[-H*^=9-: MO1WZ_T]]_7KOTV
M*]$2V$XE;.OU5K=:-&P)MOWI=+T]P];%.'N&-;?ZD!3X4K=G@@1LE<GBRJY6
MBQ9PI%I U<?LK6-K>*$;(O,5IN@KKRE?QID@"2P0TCKM(2%>M&K%1+)<=SMS
M)K%WTL,(VUO@*@"?+QB3+Q/U@JIA]O\ 4$L#!!0    ( !.(?UH3F1]7X (
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MP+D%E=3U/2]R2TR8D\1V[%(D,:\5)0PN!9)U66)Q/P7*UQ-GY&P&KLBR4&;
M3>(*+^$:U$UU*73/[5AR4@*3A#,D8#%QSD:G:63B;< / FNYU49&R9SS6]/Y
MG$\<SRP(*&3*,&#]6L$,*#5$>AE_6DZG2VF V^T-^[G5KK7,L809IS])KHJ)
M\\Y!.2QP3=457W^"5L_8\&6<2OM$ZR8V?.^@K):*ERU8KZ DK'GCN]:'+8#F
MZ0?X+<!_"(@> 00M('@("!\!A"T@M,XT4JP/*58XB05?(V&B-9MI6#,M6LLG
MS&S[M1)ZEFB<2KZI @2Z@A6P&M!A"@H3*H_0,;JY3M'AP1$Z0(2A[P6O)6:Y
MC%VELQJLF[49IDT&_Y$,(W3!F2HD^LARR'OPLR?P_@"!J^5VFOV-YJD_R'B!
M[U$P>H-\S_?[UC.,3B$[V<"#'GCZ?'@X(";H-C"P?,&S-O#7V5PJH7^FWWT;
MU3"%_4SF@#F5%<Y@XN@31()8@9.\?C6*O ]]+NV3+-T3V8Z#8>=@.,3>.B@:
M!_ML&X2_U+:&;&S)S)F\2D:>%[NK;3?VE'#'C7'GQGC0C:^<'>NCMV8YGE-
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M:@0-U43[%=%^-Z+W6'X4)9^Y<!7Y5F0H!E\Q3<"E,*I7C*@PNH[\]34,"U0
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MYR3)3]<8A9C* '%_20C?7<@)JAW6Z7]02P,$%     @ $XA_6CZGF@1] P
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
M+AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*
M(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC
M)8QQ8K3^-8+)#^Q^ %!+ P04    "  3B']:R+.="1($  ")'@  #P   'AL
M+W=O<FMB;V]K+GAM;,696V_;-A2 _PJAIPSH8NN2M WJ JF=M0;:Q8BS]K&@
MJ>.:B$2J).7$_?4EI7FC4NU@+R=YLDE9]*?#RW=(O;G7YFZC]1U[J"ME9\G.
MN>9B,K%B!S6WI[H!Y:]LM:FY\T7S;6(; [RT.P!75Y-L.CV?U%RJY.V;8ULK
M,XD+VH%P4BM?&2H^2[BW_UX/1;:75FYD)=UAEG3?*TA8+96LY0\H9\DT87:G
M[S]H(W]HY7BU%D97U2Q)^PN?P3@I?JE>!\A;OK%=C>.;&^Y!9LGYU#>XE<:Z
M[A==^]PS[L'_N"^U3O\A*P=FP1V\-[IMI/H6FO%/,8D>HXO#\;,/XH7Y/V'4
MVZT4L-"BK4&Y/HX&J@"H[$XV-F&*US!+YGH/)CR/_X-EV3^;\U!1I,R%]!?,
MLNSPZ% NVU(ZME3]S?YJA)4A6!DMUMR7=25+_^\E>\<KK@2PKF=M!)@C@/FS
M ;*3%8\@"P2R>$+(=8 (-UBFM^RZ&8S ,P3R[-D@YSL>C\=S!/+\^2"YW460
M+Q'(E[20"[#"R";4![!WK94*K&5<>>:VCB!?(9"O:"%7!AHN2W;UX!NQT--=
MNQT8-F]-/"9?(Y"OJ2']W<8=.KBK[ZULP@WQBCW%ENPI+=U'X#YP,0TJ$&*#
M]'UW WM0+<10F#Y2<G_4M73]' U]Z.>O\[8')>0P<IA"4F*'A('E#C$-YHJ4
M6!9+)70-[)8_#".$J2$E=L.ZW5CXWOH?L:M]Z,P8#--!2NR#%3^PO64K,-WM
M0?X+:46E;6L&DP#304KL@Z6RLO1S\];PT@]^=FD,]W.@?AQ(S 8IL0X>,ZZ\
M9<,<[6;M:I D8SY(B84P/VS 6!"M\3.6W4A[QSYQQ?M@LCC=RS S9,1FN!1"
MM]U*]T\@7[#-H2\<6(R)*2,C5@::J'S-8DQT#T(L$315&6)B&LF(-3*>K+ 3
MO_&MP/X68V)^R8C]TF<MHUB88C)BQ?02'L7"!),1"R:V\2@<)I;L.3<:7_,8
M$W-+1NP6'+.(,3&W9,1NP3'/XO,.S"TYL5OPU3#N]!QS2T[LEO]8#7]G:]]X
MV<:8F%MR<K<@F .WY.@I%[%;CHOV AR7U6 %RC&9Y$\CDV.O5M"=Q.BZT>I1
M=IMC<LF)Y3**^8F[D$8.-Z(Y)IN<6#:#+?QX9V.ZR8EU@V[FV4F,B>DF)];-
M,9,8"Q_FEYS8+W]S#0?AVFEQQZZ]=>*C:LPO!;%?1C%OP#HCA8,RQL3\4A#[
M913S"P];:\<N18R)^:4@]LLP?QP9D@6FE8)8*P.Z7Q?Q&!-]??*$1V*/,/\Z
M79_&F)AEBJ<^)1OO<,PP16>8R?'59PE;GX.6?_KFK:\7O!(KP\)'?[);G(73
MF&U;57-?=ZT^:EX>WZ0>WP*__0E02P,$%     @ $XA_6OTLU:6N 0  P1L
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MDN,>) <?HP1!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M
M(:M (:M (:M (:M (:M (:M (:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$
M(:M$(6N"0M8$A:P)"ED3%+(F*&1-4,B:_"=9W[5>_?7_IG:-:U4V1W_6_=2;
M?P)02P$"% ,4    "  3B']:1L=-2)4   #-    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( !.(?UJ>!OZK\@   "L"
M   1              "  <,   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( !.(?UJ97)PC$ 8  )PG   3              "  >0!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ $XA_6CX&KDV[!P  KS,  !@
M         ("!)0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( !.(?UJ7X^/ZL@,  &8)   8              " @180  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  3B']:_9.^G[,%  !?%P
M&               @('^$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ $XA_6A7'>[P[ P  [PH  !@              ("!YQD  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( !.(?UJ9YIHSDP0
M .X4   8              " @5@=  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    "  3B']:!=;O0D8%   G'@  &               @($A
M(@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ $XA_6@ P
M:K(_!@  =1L  !@              ("!G2<  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( !.(?UIC^,#]+0H  (<:   8
M  " @1(N  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  3
MB']:4GNYWH\"  !C!@  &               @(%U.   >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ $XA_6@TS4OX  P  $P<  !D
M         ("!.CL  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    "  3B']:'CQY8TD(  #I%0  &0              @(%Q/@  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( !.(?UKRER\Y,P8  )P-
M   9              " @?%&  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ $XA_6AI;-)Q= P  7P<  !D              ("!6TT
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  3B']:C*"/
MH^D*  !)'P  &0              @('O4   >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( !.(?UILH%^3!0@  *43   9
M  " @0]<  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
M$XA_6EF,10"Y!   W@D  !D              ("!2V0  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    "  3B']:E):N<$T"  "D!0  &0
M            @($[:0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( !.(?UHL=6B^0P(  (H&   9              " @;]K  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ $XA_6L?&A)80 @
MW 0  !D              ("!.6X  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    "  3B']:0:UE,I$*  "I+0  &0              @(&
M<   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( !.(?UJ%
MM<.L?@L  '\D   9              " @4A[  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ $XA_6N&0V;>? P  QP@  !D
M     ("!_88  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !.(?UH4S!YI6P0  .H)   9              "
M@669  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ $XA_
M6M6]_#.3 @  I0D  !D              ("!]YT  'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    "  3B']:&97?N<H"  !X"   &0
M        @('!H   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( !.(?UJK3M2\5@,  -D-   9              " @<*C  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ $XA_6N\P2R": @  B@<
M !D              ("!3Z<  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    "  3B']:OX\M+84#   M$@  &0              @($@J@
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( !.(?UJV^^+Q
M" ,  #P+   9              " @=RM  !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ $XA_6A.9'U?@ @  $@H  !D
M ("!&[$  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  3
MB']:V NEE$($   P$@  &0              @($RM   >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( !.(?UKT8 E?]@(  "0*   9
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M970T,"YX;6Q02P$"% ,4    "  3B']:/J>:!'T#  "?#0  &0
M    @($FT@  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M !.(?UH #23)G 0  + 7   9              " @=K5  !X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ $XA_6G!Y_: )!0  )"$  !D
M             ("!K=H  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    "  3B']:UZOD)E4#   G"@  &0              @('MWP  >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( !.(?UIV]U7B! 0
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( !.(?UK(LYT)$@0  (D>   /
M      "  3SN  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  3B']:_2S5
MI:X!  #!&P  &@              @ %[\@  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    "  3B']:)OJ'I[4!  #<&P  $P
M    @ %A]   6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     -@ V +$.  !'
%]@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>88</ContextCount>
  <ElementCount>286</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>29</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995300 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995301 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995302 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995303 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995304 - Statement - Consolidated Statements of Changes in Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995305 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995306 - Disclosure - Description of Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995307 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/PrepaidExpensesandOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Other Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/OtherRevenue</Role>
      <ShortName>Other Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/PrepaidExpensesandOtherCurrentAssets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/PropertyandEquipment</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/Leases</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/Equity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/IncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Property and Equipment - Schedule of Depreciation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofDepreciationExpenseTable</Role>
      <ShortName>Property and Equipment - Schedule of Depreciation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/LeasesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable</Role>
      <ShortName>Leases - Schedule of Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable</Role>
      <ShortName>Leases - Schedule of Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Other Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/OtherRevenueDetails</Role>
      <ShortName>Other Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/OtherRevenue</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/EquityTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Equity - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable</Role>
      <ShortName>Equity - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Equity - Schedule of Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable</Role>
      <ShortName>Equity - Schedule of Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Equity - Schedule of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable</Role>
      <ShortName>Equity - Schedule of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Income Taxes - Schedule of Components of the Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable</Role>
      <ShortName>Income Taxes - Schedule of Components of the Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Income Taxes - Schedule of U.S. Federal Statutory Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable</Role>
      <ShortName>Income Taxes - Schedule of U.S. Federal Statutory Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ea0232395-10k_actinium.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.actiniumpharma.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.actiniumpharma.com/role/SubsequentEvents</ParentRole>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>atnm-20241231.xsd</File>
    <File>atnm-20241231_cal.xml</File>
    <File>atnm-20241231_def.xml</File>
    <File>atnm-20241231_lab.xml</File>
    <File>atnm-20241231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="ea0232395-10k_actinium.htm">ea0232395-10k_actinium.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_006a.jpg</File>
    <File>image_006b.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
    <File>image_009.jpg</File>
    <File>image_010.jpg</File>
    <File>image_011.jpg</File>
    <File>image_012.jpg</File>
    <File>image_013.jpg</File>
    <File>image_014.jpg</File>
    <File>image_015.jpg</File>
    <File>image_016.jpg</File>
    <File>image_017.jpg</File>
    <File>image_018.jpg</File>
    <File>image_019.jpg</File>
    <File>image_020.jpg</File>
    <File>image_021.jpg</File>
    <File>image_022.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="456">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="10">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>89
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0232395-10k_actinium.htm": {
   "nsprefix": "atnm",
   "nsuri": "http://www.actiniumpharma.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "atnm-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "atnm-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "atnm-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "atnm-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "atnm-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0232395-10k_actinium.htm"
     ]
    }
   },
   "keyStandard": 257,
   "keyCustom": 29,
   "axisStandard": 16,
   "axisCustom": 0,
   "memberStandard": 18,
   "memberCustom": 9,
   "hidden": {
    "total": 61,
    "http://fasb.org/us-gaap/2024": 50,
    "http://xbrl.sec.gov/dei/2024": 3,
    "http://www.actiniumpharma.com/20241231": 8
   },
   "contextCount": 88,
   "entityCount": 1,
   "segmentCount": 29,
   "elementCount": 629,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 456,
    "http://xbrl.sec.gov/dei/2024": 38,
    "http://xbrl.sec.gov/cyd/2024": 10,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/dei/role/document/AuditInformation",
     "longName": "995300 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement",
     "longName": "995303 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c9",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c9",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3",
     "longName": "995304 - Statement - Consolidated Statements of Changes in Stockholders\u2019 Equity",
     "shortName": "Consolidated Statements of Changes in Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c10",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c10",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.actiniumpharma.com/role/ConsolidatedCashFlow",
     "longName": "995305 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies",
     "longName": "995306 - Disclosure - Description of Business and Summary of Significant Accounting Policies",
     "shortName": "Description of Business and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.actiniumpharma.com/role/PrepaidExpensesandOtherCurrentAssets",
     "longName": "995307 - Disclosure - Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.actiniumpharma.com/role/PropertyandEquipment",
     "longName": "995308 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.actiniumpharma.com/role/Leases",
     "longName": "995309 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.actiniumpharma.com/role/OtherRevenue",
     "longName": "995310 - Disclosure - Other Revenue",
     "shortName": "Other Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "atnm:OtherRevenueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "atnm:OtherRevenueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.actiniumpharma.com/role/CommitmentsandContingencies",
     "longName": "995311 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.actiniumpharma.com/role/Equity",
     "longName": "995312 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.actiniumpharma.com/role/IncomeTaxes",
     "longName": "995313 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.actiniumpharma.com/role/SubsequentEvents",
     "longName": "995314 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R18": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c87",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c87",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c87",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c87",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "atnm:NatureOfBusinessPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "atnm:NatureOfBusinessPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables",
     "longName": "996001 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Description of Business and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.actiniumpharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables",
     "longName": "996002 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.actiniumpharma.com/role/PropertyandEquipmentTables",
     "longName": "996003 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.actiniumpharma.com/role/LeasesTables",
     "longName": "996004 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.actiniumpharma.com/role/EquityTables",
     "longName": "996005 - Disclosure - Equity (Tables)",
     "shortName": "Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.actiniumpharma.com/role/IncomeTaxesTables",
     "longName": "996006 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails",
     "longName": "996007 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)",
     "shortName": "Description of Business and Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c28",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c28",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable",
     "longName": "996008 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)",
     "shortName": "Description of Business and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable",
     "longName": "996009 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)",
     "shortName": "Description of Business and Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable",
     "longName": "996010 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable",
     "longName": "996011 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)",
     "shortName": "Property and Equipment - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c35",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofDepreciationExpenseTable",
     "longName": "996012 - Disclosure - Property and Equipment - Schedule of Depreciation Expense (Details)",
     "shortName": "Property and Equipment - Schedule of Depreciation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "atnm:ScheduleOfDepreciationExpenseTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "atnm:ScheduleOfDepreciationExpenseTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.actiniumpharma.com/role/LeasesDetails",
     "longName": "996013 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable",
     "longName": "996014 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)",
     "shortName": "Leases - Schedule of Components of Lease Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable",
     "longName": "996015 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)",
     "shortName": "Leases - Schedule of Maturities of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.actiniumpharma.com/role/OtherRevenueDetails",
     "longName": "996016 - Disclosure - Other Revenue (Details)",
     "shortName": "Other Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c9",
      "name": "us-gaap:OtherIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "atnm:OtherRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c9",
      "name": "us-gaap:OtherIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "atnm:OtherRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails",
     "longName": "996017 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c47",
      "name": "atnm:PaymentOfMilestone",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c47",
      "name": "atnm:PaymentOfMilestone",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.actiniumpharma.com/role/EquityDetails",
     "longName": "996018 - Disclosure - Equity (Details)",
     "shortName": "Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:EquityFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable",
     "longName": "996019 - Disclosure - Equity - Schedule of Stock Option Activity (Details)",
     "shortName": "Equity - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c73",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c73",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable",
     "longName": "996020 - Disclosure - Equity - Schedule of Restricted Stock Unit Activity (Details)",
     "shortName": "Equity - Schedule of Restricted Stock Unit Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c76",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c75",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable",
     "longName": "996021 - Disclosure - Equity - Schedule of Warrant Activity (Details)",
     "shortName": "Equity - Schedule of Warrant Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c77",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c77",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.actiniumpharma.com/role/IncomeTaxesDetails",
     "longName": "996022 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:OperatingLossCarryforwardsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable",
     "longName": "996023 - Disclosure - Income Taxes - Schedule of Components of the Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Components of the Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable",
     "longName": "996024 - Disclosure - Income Taxes - Schedule of U.S. Federal Statutory Rates (Details)",
     "shortName": "Income Taxes - Schedule of U.S. Federal Statutory Rates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.actiniumpharma.com/role/SubsequentEventsDetails",
     "longName": "996025 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c86",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c86",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0232395-10k_actinium.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business and Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net of accumulated depreciation (in Dollars)",
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r99",
      "r441"
     ]
    },
    "atnm_AccumulatedGrossAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "AccumulatedGrossAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated gross amount",
        "documentation": "Accumulated gross amount.",
        "label": "Accumulated Gross Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow information:",
        "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r592",
      "r878"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r762",
      "r763",
      "r764",
      "r765",
      "r821",
      "r879"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in/provided by operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r638",
      "r649",
      "r665",
      "r700"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r641",
      "r652",
      "r668",
      "r703"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r642",
      "r653",
      "r669",
      "r695",
      "r704",
      "r708",
      "r716"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r296"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Diluted Net Loss Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r74",
      "r100",
      "r119",
      "r150",
      "r154",
      "r178",
      "r181",
      "r191",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r350",
      "r352",
      "r382",
      "r434",
      "r517",
      "r575",
      "r576",
      "r592",
      "r609",
      "r780",
      "r781",
      "r838"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r105",
      "r119",
      "r191",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r350",
      "r352",
      "r382",
      "r592",
      "r780",
      "r781",
      "r838"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r625",
      "r645"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r625",
      "r645"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r625",
      "r645"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business and Summary of Significant Accounting Policies",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r625",
      "r645"
     ]
    },
    "atnm_CapitalOnDemandSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "CapitalOnDemandSalesAgreementMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital on Demand Sales Agreement [Member]",
        "label": "Capital On Demand Sales Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet",
      "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r97",
      "r566"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents and Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r66"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash, Cash Equivalents and Restricted Cash [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow",
      "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year",
        "totalLabel": "Cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r47",
      "r118"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r47"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r152",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r486",
      "r487",
      "r488",
      "r489",
      "r581",
      "r747",
      "r759"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share (in Dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Activity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangements",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r68",
      "r435",
      "r504"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r221",
      "r222",
      "r560",
      "r775",
      "r777"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r599",
      "r600",
      "r601",
      "r603",
      "r604",
      "r605",
      "r606",
      "r762",
      "r763",
      "r765",
      "r821",
      "r877",
      "r879"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "verboseLabel": "Number of shares of common stock authorized (in Shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r505"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r37",
      "r505",
      "r523",
      "r879",
      "r880"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value; 1,000,000,000 shares authorized; 31,195,891 and 27,634,213 shares issued and outstanding at December 31, 2024 and 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r437",
      "r592"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of the Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CondensedIncomeStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedIncomeStatementsCaptionsLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDepreciationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Depreciation Expense [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r121",
      "r748"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r569"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet",
      "http://www.actiniumpharma.com/role/OtherRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term license revenue deferred",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r255"
     ]
    },
    "us-gaap_CorporateAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateAndOtherMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Office Space [Member]",
        "label": "Corporate Segment and Other Operating Segment [Member]",
        "documentation": "Component of entity providing financial and operational oversight and administrative support considered to be operating segment and operating segment, classified as other. Excludes intersegment elimination and reconciling item."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]",
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r724"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Board of Directors Oversight [Text Block]",
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r724"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]",
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r632",
      "r726"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]",
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r634",
      "r728"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]",
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r632",
      "r726"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]",
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r722"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r721"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r721"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r721"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]",
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r723"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]",
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r723"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]",
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r633",
      "r727"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Role of Management [Text Block]",
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r725"
     ]
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxesDetails",
      "http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development expenses",
        "verboseLabel": "Federal research and development tax credits",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses carry forward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development/orphan drug credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxesDetails",
      "http://www.actiniumpharma.com/role/ScheduleofComponentsoftheDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance",
        "terseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r657",
      "r658",
      "r672"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDepreciationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r21"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r21"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r496",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r518",
      "r519",
      "r520",
      "r521",
      "r532",
      "r533",
      "r534",
      "r535",
      "r538",
      "r539",
      "r540",
      "r541",
      "r551",
      "r552",
      "r553",
      "r554",
      "r599",
      "r601",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r832",
      "r833"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r64",
      "r494",
      "r496",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r518",
      "r519",
      "r520",
      "r521",
      "r532",
      "r533",
      "r534",
      "r535",
      "r538",
      "r539",
      "r540",
      "r541",
      "r551",
      "r552",
      "r553",
      "r554",
      "r568",
      "r599",
      "r601",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r832",
      "r833"
     ]
    },
    "atnm_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business and Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r657",
      "r658",
      "r672"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r625",
      "r645"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r625",
      "r645",
      "r696"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r625",
      "r645",
      "r696"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per common share \u2013 basic and diluted (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r140",
      "r142",
      "r144",
      "r145",
      "r146",
      "r149",
      "r339",
      "r348",
      "r374",
      "r375",
      "r431",
      "r445",
      "r570"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per common share \u2013 diluted (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r142",
      "r144",
      "r145",
      "r146",
      "r149",
      "r339",
      "r348",
      "r374",
      "r375",
      "r431",
      "r445",
      "r570"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r148"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Provision for income tax, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r585"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of U.S. Federal Statutory Rates [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Federal statutory income taxes, percentage",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r304",
      "r326",
      "r585"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in valuation allowance, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r585",
      "r761",
      "r811"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development/orphan drug tax credit, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense."
       }
      }
     },
     "auth_ref": [
      "r761",
      "r811",
      "r813"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r761",
      "r811",
      "r812"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "State income taxes, percentage",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r585",
      "r761",
      "r811"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss percentage",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r309",
      "r761",
      "r811"
     ]
    },
    "atnm_EffectiveIncomeTaxReconciliationDeferredTrueUps": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "EffectiveIncomeTaxReconciliationDeferredTrueUps",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred true-up, percentage",
        "documentation": "Percentage of deferred true-up.",
        "label": "Effective Income Tax Reconciliation Deferred True Ups"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average term",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock Options [Member]",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment [Member]",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r89",
      "r109",
      "r110",
      "r111",
      "r122",
      "r123",
      "r124",
      "r127",
      "r134",
      "r136",
      "r138",
      "r151",
      "r195",
      "r201",
      "r213",
      "r244",
      "r321",
      "r322",
      "r335",
      "r336",
      "r337",
      "r340",
      "r347",
      "r348",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r373",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r393",
      "r396",
      "r420",
      "r444",
      "r472",
      "r473",
      "r474",
      "r492",
      "r544"
     ]
    },
    "atnm_EquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "EquityDetailsTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option fair value",
        "label": "Equity, Fair Value Disclosure",
        "documentation": "Fair value of the entity's equity."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823",
      "r831"
     ]
    },
    "atnm_EquityScheduleofRestrictedStockUnitActivityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "EquityScheduleofRestrictedStockUnitActivityDetailsTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity - Schedule of Restricted Stock Unit Activity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r638",
      "r649",
      "r665",
      "r700"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r635",
      "r646",
      "r662",
      "r697"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "atnm_ExpireIn2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "ExpireIn2026Member",
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses due to expire in 2026 [Member]",
        "label": "Expire In2026 Member"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ExpiredWarrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "ExpiredWarrant",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired warrant (in Shares)",
        "documentation": "Shares of expired warrant.",
        "label": "Expired Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "atnm_FederalIncomeTaxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "FederalIncomeTaxMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal income tax [Member]",
        "label": "Federal Income Tax Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on lease liabilities",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r407",
      "r591"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flow use from finance leases",
        "label": "Finance Lease, Interest Payment on Liability",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r408"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of finance lease liabilities",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r412"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease cost",
        "label": "Finance Lease, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases current liability",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term finance lease obligations",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Finance leases payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases, 2025",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases, 2027",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases, 2026",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance Leases, imputed interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow",
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on finance leases",
        "terseLabel": "Financing cash flow use from finance leases",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r408"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases right-of-use assets",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-to-use assets",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r407",
      "r591"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rates, Finance leases",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r591"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term, Finance leases",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r591"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r642",
      "r653",
      "r669",
      "r704"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r642",
      "r653",
      "r669",
      "r704"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r642",
      "r653",
      "r669",
      "r704"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r642",
      "r653",
      "r669",
      "r704"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r642",
      "r653",
      "r669",
      "r704"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r624",
      "r656"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and Fixtures [Member]",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r528"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDepreciationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative [Member]",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_GovernmentAssistancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistancePolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant Revenue",
        "label": "Government Assistance [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for government assistance."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r625",
      "r645"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDepreciationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r216",
      "r218",
      "r377",
      "r378",
      "r379",
      "r467",
      "r469",
      "r529",
      "r563",
      "r586",
      "r848"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDepreciationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r218",
      "r377",
      "r378",
      "r379",
      "r467",
      "r469",
      "r529",
      "r563",
      "r586",
      "r848"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r819"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r819"
     ]
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r300",
      "r304",
      "r310",
      "r311",
      "r312",
      "r314",
      "r318",
      "r327",
      "r329",
      "r330",
      "r331",
      "r491",
      "r585"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Provision for income tax",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r85",
      "r137",
      "r138",
      "r150",
      "r162",
      "r181",
      "r303",
      "r304",
      "r328",
      "r447",
      "r585"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r301",
      "r302",
      "r314",
      "r315",
      "r317",
      "r320",
      "r485"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r585",
      "r811"
     ]
    },
    "atnm_IncomeTaxReconciliationDeferredTrueup": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "IncomeTaxReconciliationDeferredTrueup",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred true-up",
        "documentation": "The amount of income tax reconciliation deferred true-up.",
        "label": "Income Tax Reconciliation Deferred Trueup"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal statutory income taxes",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r585"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r811",
      "r812"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income taxes",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r585",
      "r811"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofUSFederalStatutoryRatesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development/orphan drug tax credit",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r811",
      "r813"
     ]
    },
    "atnm_IncomeTaxesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "IncomeTaxesDetailsTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for taxes",
        "label": "Income Taxes Paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r49",
      "r757",
      "r817",
      "r818"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r749",
      "r755"
     ]
    },
    "atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "IncreaseDecreaseInOperatingLeaseRightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Increase Decrease In Operating Lease Rightofuse Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IndefiniteLivedContractualRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedContractualRights",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite life",
        "label": "Indefinite-Lived Contractual Rights",
        "documentation": "Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date of rights with an indefinite period of benefit that arose from a contractual arrangement with a third party (not including franchise rights and license agreements)."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r774"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r642",
      "r653",
      "r669",
      "r695",
      "r704",
      "r708",
      "r716"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r626",
      "r720"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r626",
      "r720"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r626",
      "r720"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r116",
      "r117"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r658",
      "r659",
      "r660",
      "r661"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income \u2013 net",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r157",
      "r181",
      "r575",
      "r754"
     ]
    },
    "us-gaap_LandImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LandImprovements",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Spent amount on improvements",
        "label": "Land Improvements",
        "documentation": "Amount before accumulated depreciation and depletion of additions or improvements to real estate held for productive use. Examples include, but are not limited to, walkways, driveways, fences, and parking lots."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total finance lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r591"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Lease Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Lease Expense",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration date",
        "label": "Lease Expiration Date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_LeasesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "LeasesDetailsTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Line Item]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r414"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating leases payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases, 2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases, 2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases, 2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating Leases, imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r119",
      "r191",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r351",
      "r352",
      "r353",
      "r382",
      "r503",
      "r571",
      "r609",
      "r780",
      "r838",
      "r839"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r69",
      "r439",
      "r592",
      "r760",
      "r772",
      "r834"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r96",
      "r119",
      "r191",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r351",
      "r352",
      "r353",
      "r382",
      "r592",
      "r780",
      "r838",
      "r839"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_LicenseRevenuePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "LicenseRevenuePolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Revenue",
        "documentation": "Disclosure of accounting policy for license revenue.",
        "label": "License Revenue Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery and Equipment [Member]",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r257",
      "r297",
      "r376",
      "r426",
      "r466",
      "r468",
      "r482",
      "r495",
      "r496",
      "r547",
      "r548",
      "r549",
      "r550",
      "r555",
      "r561",
      "r562",
      "r578",
      "r581",
      "r583",
      "r587",
      "r588",
      "r589",
      "r590",
      "r594",
      "r782",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r257",
      "r297",
      "r376",
      "r426",
      "r466",
      "r468",
      "r482",
      "r495",
      "r496",
      "r547",
      "r548",
      "r549",
      "r550",
      "r555",
      "r561",
      "r562",
      "r578",
      "r581",
      "r583",
      "r587",
      "r588",
      "r589",
      "r594",
      "r782",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "atnm_NatureOfBusinessPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "NatureOfBusinessPolicyPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Business",
        "documentation": "Disclosure of accounting policy for nature of business.",
        "label": "Nature Of Business Policy Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Provided By Financing Activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from Financing Activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Used In Investing Activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows Used in Investing Activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Used In Operating Activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r50"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from Operating Activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow",
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r50",
      "r70",
      "r94",
      "r106",
      "r107",
      "r111",
      "r119",
      "r126",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r137",
      "r138",
      "r143",
      "r191",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r339",
      "r348",
      "r375",
      "r382",
      "r443",
      "r525",
      "r542",
      "r543",
      "r607",
      "r780"
     ]
    },
    "atnm_NetProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "NetProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds",
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Net Proceeds From Issuance Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business and Summary of Significant Accounting Policies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r132",
      "r139",
      "r149",
      "r188",
      "r189",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r212",
      "r213",
      "r217",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r380",
      "r381",
      "r392",
      "r393",
      "r394",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r428",
      "r429",
      "r430",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r483"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r658",
      "r659",
      "r660",
      "r661"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r642",
      "r653",
      "r669",
      "r695",
      "r704"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "atnm_NonRefundablePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "NonRefundablePaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/OtherRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable payment received",
        "documentation": "Represents the amount of non-refundable payment received",
        "label": "Non Refundable Payment Received"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income:",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office equipment and furniture [Member]",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r572",
      "r766",
      "r768",
      "r769",
      "r770",
      "r771"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities of Lease Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofMaturitiesofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases current liability",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease obligations",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flow use from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r408"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rates, Operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r591"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term, Operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r591"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unused net operating losses",
        "label": "Operating Loss Carryforwards, Valuation Allowance",
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "atnm_OrphanDrugCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "OrphanDrugCreditsMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Orphan Drug Credits [Member]",
        "label": "Orphan Drug Credits Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other prepaid expenses and other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r592"
     ]
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/PrepaidExpensesandOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expenses and Other Current Assets",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/OtherRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenue",
        "label": "Other Income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r526",
      "r556",
      "r557",
      "r558"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid clinical trial expenses",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r752",
      "r773"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "atnm_OtherRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "OtherRevenueMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Revenue",
        "label": "Other Revenue Member"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_OtherRevenueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "OtherRevenueTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/OtherRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenue",
        "documentation": "The entire disclosure for other revenue.",
        "label": "Other Revenue Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r640",
      "r651",
      "r667",
      "r702"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r643",
      "r654",
      "r670",
      "r705"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r643",
      "r654",
      "r670",
      "r705"
     ]
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "atnm_PaymentOfMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "PaymentOfMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment",
        "documentation": "Amount of  milestone payment.",
        "label": "Payment Of Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current annual rent",
        "label": "Payments for Rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock par value (in Dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r236"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r505"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r236"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r505",
      "r523",
      "r879",
      "r880"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r436",
      "r592"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.actiniumpharma.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet",
      "http://www.actiniumpharma.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total prepaid expenses and other current assets",
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_PrepaidExpenseCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Prepaid Expenses and Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid insurance",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r579",
      "r773"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow",
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales of shares of common stock, net of offering costs",
        "verboseLabel": "Gross proceeds",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r11"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r185",
      "r427",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r565",
      "r582",
      "r593",
      "r594",
      "r595",
      "r597",
      "r598",
      "r778",
      "r779",
      "r783",
      "r847",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r185",
      "r427",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r565",
      "r582",
      "r593",
      "r594",
      "r595",
      "r597",
      "r598",
      "r778",
      "r779",
      "r783",
      "r847",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r413"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/PropertyandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r80",
      "r83",
      "r84"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r98",
      "r442"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet",
      "http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property and equipment, net",
        "terseLabel": "Property and equipment, net of accumulated depreciation of $891 and $694",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r413",
      "r433",
      "r442",
      "r592"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r80",
      "r83",
      "r440"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/PropertyandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r413"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful lives",
        "verboseLabel": "Estimated useful lives",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "atnm_PropertyandEquipmentScheduleofDepreciationExpenseDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "PropertyandEquipmentScheduleofDepreciationExpenseDetailsTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDepreciationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment - Schedule of Depreciation Expense (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r256",
      "r257",
      "r286",
      "r287",
      "r288",
      "r297",
      "r376",
      "r424",
      "r425",
      "r426",
      "r466",
      "r468",
      "r482",
      "r495",
      "r496",
      "r547",
      "r548",
      "r549",
      "r550",
      "r555",
      "r561",
      "r562",
      "r578",
      "r581",
      "r583",
      "r587",
      "r588",
      "r589",
      "r590",
      "r594",
      "r601",
      "r776",
      "r782",
      "r824",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r256",
      "r257",
      "r286",
      "r287",
      "r288",
      "r297",
      "r376",
      "r424",
      "r425",
      "r426",
      "r466",
      "r468",
      "r482",
      "r495",
      "r496",
      "r547",
      "r548",
      "r549",
      "r550",
      "r555",
      "r561",
      "r562",
      "r578",
      "r581",
      "r583",
      "r587",
      "r588",
      "r589",
      "r590",
      "r594",
      "r601",
      "r776",
      "r782",
      "r824",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845"
     ]
    },
    "atnm_RecentlyIssuedAccountingPronouncementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "RecentlyIssuedAccountingPronouncementsPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Issued Accounting Pronouncements Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r635",
      "r646",
      "r662",
      "r697"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development costs",
        "label": "Research and Development Arrangement with Federal Government, Costs Incurred, Net",
        "documentation": "The net amount of research and development costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development, net of reimbursements",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r563",
      "r575",
      "r846"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDepreciationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development [Member]",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r636",
      "r647",
      "r663",
      "r698"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r637",
      "r648",
      "r664",
      "r699"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r644",
      "r655",
      "r671",
      "r706"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet",
      "http://www.actiniumpharma.com/role/ScheduleofCashCashEquivalentsandRestrictedCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash \u2013 long term",
        "verboseLabel": "Restricted cash \u2013 long-term",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r751",
      "r758"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units [Member]",
        "verboseLabel": "Restricted Stock Units (RSUs) [Member]",
        "netLabel": "RSUs [Member]",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r57",
      "r438",
      "r476",
      "r481",
      "r490",
      "r506",
      "r592"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r122",
      "r123",
      "r124",
      "r127",
      "r134",
      "r136",
      "r138",
      "r195",
      "r201",
      "r213",
      "r321",
      "r322",
      "r335",
      "r336",
      "r337",
      "r340",
      "r347",
      "r348",
      "r357",
      "r360",
      "r361",
      "r364",
      "r373",
      "r393",
      "r396",
      "r472",
      "r474",
      "r492",
      "r879"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r564"
     ]
    },
    "atnm_RevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "RevenueMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r112",
      "r119",
      "r150",
      "r155",
      "r156",
      "r176",
      "r181",
      "r185",
      "r186",
      "r187",
      "r191",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r382",
      "r432",
      "r575",
      "r780"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Revenue [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations, Finance leases",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r591"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofComponentsofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations, Operating leases",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r591"
     ]
    },
    "atnm_RightofuseAssetObtainedInExchangeForLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "RightofuseAssetObtainedInExchangeForLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for lease liabilities",
        "documentation": "Represents the amount of right-of-use assets obtained in exchange for lease liabilities which includes both operating and finance lease.",
        "label": "Rightofuse Asset Obtained In Exchange For Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_RoyaltyPaymentsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "RoyaltyPaymentsPercentage",
     "presentation": [
      "http://www.actiniumpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty payments, percentage",
        "documentation": "percentage of royalty payments.",
        "label": "Royalty Payments Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate amount",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of common stock sold (in Shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash, Cash Equivalents and Restricted Cash",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of the Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "atnm_ScheduleOfDepreciationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "ScheduleOfDepreciationExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Depreciation Expense Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ScheduleOfDepreciationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "ScheduleOfDepreciationExpenseTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/PropertyandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Depreciation Expense",
        "documentation": "Tabular disclosure of depreciation expense.",
        "label": "Schedule Of Depreciation Expense Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ScheduleOfDilutedNetLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "ScheduleOfDilutedNetLossPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Diluted Net Loss Per Share Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of U.S. Federal Statutory Rates",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r585",
      "r811"
     ]
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ScheduleOfPropertyAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "ScheduleOfPropertyAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r413"
     ]
    },
    "atnm_ScheduleOfRestrictedStockUnitActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "ScheduleOfRestrictedStockUnitActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Restricted Stock Unit Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Unit Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r59"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrant Activity",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "atnm_ScheduleOfWarrantActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "ScheduleOfWarrantActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Warrant Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r74",
      "r150",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r187",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r219",
      "r220",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r574",
      "r575",
      "r576",
      "r580",
      "r596",
      "r847",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r184",
      "r186",
      "r573",
      "r574",
      "r577"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant date Fair Value Per Share, Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs Outstanding, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant date Fair Value Per Share, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "RSUs Outstanding, Beginning balance",
        "periodEndLabel": "RSUs Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant date Fair Value Per Share, Outstanding Beginning balance",
        "periodEndLabel": "Weighted Average Grant date Fair Value Per Share, Outstanding Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r274"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs Outstanding, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of RSUs",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant date Fair Value Per Share, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions",
        "documentation": "Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividends",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restricted Stock Unit Activity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289"
     ]
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Exercisable",
        "documentation": "The number of share-based compensation arrangement by share-based payment award, non-options exercisable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of non options outstanding and currently exercisable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of non options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on non options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Warrants, Expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations",
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Expired",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on non options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "documentation": "The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Granted",
        "documentation": "Weighted average remaining contractual term for vested portions of non options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value Outstanding, Ending balance",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of non options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Warrants Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61"
     ]
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years) Outstanding Ending balance",
        "documentation": "Weighted average remaining contractual term for portions of non options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Option Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofRestrictedStockUnitActivityTable",
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable",
      "http://www.actiniumpharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Cancelled",
        "negatedTerseLabel": "RSUs Outstanding, Cancelled",
        "terseLabel": "Cancelled stock option",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Granted",
        "verboseLabel": "Granted options to purchase shares (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Options Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r266"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r266"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Cancelled",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "verboseLabel": "Exercise price (in Dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payments",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r264",
      "r283",
      "r284",
      "r285",
      "r286",
      "r289",
      "r292",
      "r293",
      "r294",
      "r295"
     ]
    },
    "atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercisable",
        "documentation": "The weighted average grant-date fair value of non-options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.",
        "label": "Share Based Compensations Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Exercisable Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending balance",
        "documentation": "The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology.",
        "label": "Share Based Compensations Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years) Outstanding, Ending balance",
        "verboseLabel": "Options Term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r58"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r74",
      "r93",
      "r150",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r187",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r215",
      "r219",
      "r220",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r574",
      "r575",
      "r576",
      "r580",
      "r596",
      "r847",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r37",
      "r40",
      "r41",
      "r89",
      "r109",
      "r110",
      "r111",
      "r122",
      "r123",
      "r124",
      "r127",
      "r134",
      "r136",
      "r138",
      "r151",
      "r195",
      "r201",
      "r213",
      "r244",
      "r321",
      "r322",
      "r335",
      "r336",
      "r337",
      "r340",
      "r347",
      "r348",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r373",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r393",
      "r396",
      "r420",
      "r444",
      "r472",
      "r473",
      "r474",
      "r492",
      "r544"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r151",
      "r396",
      "r427",
      "r484",
      "r493",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r524",
      "r527",
      "r528",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r544",
      "r602"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r151",
      "r190",
      "r396",
      "r427",
      "r484",
      "r493",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r524",
      "r527",
      "r528",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r544",
      "r602"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r639",
      "r650",
      "r666",
      "r701"
     ]
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base prospectus",
        "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants",
        "documentation": "Value of preferred stock and warrants for common stock issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options to purchase common shares (in Shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r36",
      "r37",
      "r57"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock, net of offering costs (in Shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r36",
      "r37",
      "r57",
      "r486",
      "r544",
      "r559"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation (in Shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r36",
      "r37",
      "r57"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.actiniumpharma.com/role/ScheduleofStockOptionActivityTable",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock from exercise of stock options (in Shares)",
        "negatedLabel": "Number of Options, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r36",
      "r37",
      "r57",
      "r270"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock, net of offering costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r36",
      "r37",
      "r57",
      "r492",
      "r544",
      "r559",
      "r608"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock from exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r37",
      "r40",
      "r41",
      "r57"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options [Member]",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet",
      "http://www.actiniumpharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r40",
      "r41",
      "r52",
      "r507",
      "r523",
      "r545",
      "r546",
      "r592",
      "r609",
      "r760",
      "r772",
      "r834",
      "r879"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 Equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r422"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r422"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_SubsequentEventsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "SubsequentEventsDetailsLineItems",
     "presentation": [
      "http://www.actiniumpharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://www.actiniumpharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for reporting subsequent events."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.actiniumpharma.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r423"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosures of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_TaxYear2018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxYear2018Member",
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses expire in 2034 - 2037 [Member]",
        "label": "Tax Year 2018 [Member]",
        "documentation": "Identified as tax year 2018."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "atnm_TaxYearTwoThousandThirtySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "TaxYearTwoThousandThirtySevenMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Year 2037 [Member]",
        "label": "Tax Year Two Thousand Thirty Seven Member"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_TaxYearTwoThousandThirtyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "TaxYearTwoThousandThirtyThreeMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Year 2033 [Member]",
        "label": "Tax Year Two Thousand Thirty Three Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "atnm_TwoThousandNineteenAmendedAndRestatedStockPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "TwoThousandNineteenAmendedAndRestatedStockPlanMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Amended and Restated Stock Plan [Member]",
        "label": "Two Thousand Nineteen Amended And Restated Stock Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.actiniumpharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates in Financial Statement Presentation",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r77",
      "r78",
      "r81",
      "r82"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "atnm_WarrantExpiredPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "WarrantExpiredPricePerShare",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant expired price per share (in Dollars per share)",
        "documentation": "Warrant expired price per share.",
        "label": "Warrant Expired Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_WarrantExpiredTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "WarrantExpiredTerm",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant expired term",
        "documentation": "Warrant expired term.",
        "label": "Warrant Expired Term"
       }
      }
     },
     "auth_ref": []
    },
    "atnm_WarrantExpiredUnderwrittenOfferingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.actiniumpharma.com/20241231",
     "localname": "WarrantExpiredUnderwrittenOfferingShares",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant expired underwritten offering shares (in Shares)",
        "documentation": "Warrant expired underwritten offering shares.",
        "label": "Warrant Expired Underwritten Offering Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.actiniumpharma.com/role/EquityDetails",
      "http://www.actiniumpharma.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://www.actiniumpharma.com/role/ScheduleofWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants [Member]",
        "verboseLabel": "Warrant [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r599",
      "r600",
      "r603",
      "r604",
      "r605",
      "r606"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding \u2013 diluted (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r146"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.actiniumpharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding \u2013 basic and diluted (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r146"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-5"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-11"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>90
<FILENAME>0001213900-25-026371-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-026371-xbrl.zip
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M$&.^!Y@-=&+3K%I0/58+2@36HUT8\+/V]9,6RX37F2MF/5;1"6_K%]@\JS)
M0_Q3-$ 8(Y5.J+N)0&-%R?1Q'4K9^R;UU,/YJ:4$R@3PN6#-_6T1%O[*9IN%
MTB0IS6WW'*D(0YU]?.[8)IYWH)VN':E=L@T_5DI*T8+;K>X6\$8#B^$ 'Z\
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MI8,0XAYFS;$7%#"<DNHF?[R9._12^4RM_B9WO*0A-QLBZAA_Q8'Q+ [%Z)U
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MR6(7A!??--4>,,\+CEU\4E7KQYP2S[3Y%<S$M*F<;A335^V>&\IX7RPQS9>
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MP0$?1R72!G-UE.%4DRE*TYMF%CH#T6!&'"!B:"49S_Q<+.2<E7DMU6W),DW
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M\-$C]R32:>GUH+*B YU- 2P%R59_,[@7,9U'@RIUC,LWUO//_%J0K>3&@"N
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M_3%[\S_GYV]O_NOUX]/[DY_>//HWR=WOHO3V?\Z/'I[2BXMO;[+SM]$G[SS
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MY4(F&5P 1-W5Z+>H^KA_;[@(=)9QJ17>+,34_-(XCK+ #\(<$C9N\#I/@BS
MZ:6WQ;-(R^!R5K0.56A$!5X;PU ][@#!2*XJXD*L5#G;:NRL0A#3E\[Z ?MY
MB%<;_BIG3^LP]['/2A!L=SDK.KC:=*/Z9U%OI@7.]N4X*?0:4K\_0.7<Z.SJ
M!IUXX1KJ!T./\ZX>YN;>G47H6G?V]+0WON]'0C"7]C@96 NX'/2A%NFIA=Q
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MJ;>FT2ZSU-717=UN^IH><+I]I:G.U/PW+5J.,J@+UA[4O\I<)*^9"4HK1\V
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MK3D0%44%OR[&ON(>=&XZGPWAQ^.;(E$LE^@SM;6R-RTH)1L<0')[>A&QHM&
MQEO>?J61\W0BU%RLU<CE;H^:WQ4KHF,685\L>H :RT(6%5O89=N%&>C(W?MS
ML>N92-VY%R34.T54B7S+<#HKLBE/@\? QY%_330V:3&E<3(((" * VH <8!*
M,% )!P) GJ5,JE)Y4@G58ZU-=:51U4'J"&??(?KA 1.1 \1281W?5UT,1!IB
M'TO+BL,YRV9M97A6Z8:G.;XD:LWM%QP^XD]$A7T0ZNW%/(A.=("JJ0X@%?P.
MDST=D*W\$_82M(JP*^N8*=8\]IE1SNZQSZG*1S8T>XSD1"LJ"E&1C2_B:S4#
M:G1+@$E0NW39 2IR4YV^T=3QY7%4EUHVC\0S+P&?>5H:Q4^#,,_$]67*SX$K
M[&X]0,40EQ>D  LN,V0(V]E%"_/C'HG4*]17K]*6?O6^T*\01[]"!,Q"S4=%
M-Z4&I*@!*FK BJJXG +:\H_DI =X7[ 7\_D'!!S95C+J>H=QFC9;APBOG6H$
M@B&M)BJI:^5!C WO'!O"W1(KUGO_;R?[.YRD>)U#9Z#K(/WE.@:CUB<O\HJV
MID,6P-8,"*9 , <8!.M9T,_N_0YZZ#;Y9D(HY]>1C50<G>MGJMNG $WYMEG&
M5?-/E)]U9+$]@4&)<9[,\E\T[1K3Y50(YD)D,H<APPXJLQ_9=!)>8U9QJE3X
MZW[:_+I?12FOZH7S,QO@VD/!1X.G$<@0MOJDW.[">(_Q#4X>R7;F'R*7D!$+
M.5+TO$AOX\P+FW\_B=/L,LY^PE#<,[Z/@E_)"4/-W#1Z@OX*OCM2,1!75T-]
M<AV@"H+2'@Q+DM]F:(\S5*]Z4+;]9'$FU<INO8]VB<Q]2#M@L]5@F=H]R\?M
MFB!&[BN"'+6U?H9,;XKF,1R+Y-I3]'X/"6J]#K-((UCI )6K+-@Q/@G=Y)[S
M"5ECX6ZJ*R.N-I_+NOSBTHBKNS"X+Y[S _YV.BE:;1 $;Q7A1.7$1"%!Y=3@
M<&7&=-28'973.PTO'468GGXR 9DMOK\Z"C&4Q(5D3# 4#_*^]XHI1U.#.I^Y
MUN-4%?#KL5"=*';='Q]IYQ$J.ZHUCMF0 [;U4GDDI8,S6X(1[_P=)(!-?;/=
M]:3TE"E8 )E+L1S@]M+D(R$W_/71M4GVSN:\I 4XBPNY:4 FEW.P5CZZ+JLZ
MGFRBIJ/@ -&YW#)*"VT>_PSH9L\68M)3B&<,*>=!Y42@@W2V'JHG*S26?[Y^
M3);L7*V8GKMA@]Z=(.I,OYJ?TOM\;!!A ZR#ODVW @TU8$, G.-WDGUF"..\
M7,B$5<GG1M6<L.(F^K%'Q4"G*IL,(^6XHA8%+#YW!EN@\2Z58A J1J&>#NWT
M_IBX!YQU9_J<I2MGO 3(ZH="1U]U-;CK<&6#O,)C?59VVGQL]'6KJP3OO, O
MO4QE!D;DT[Y4\AZBE7;Z=3G?*YI\P*9$Q5PT#8G.YE@]'4<$GG",(:=%%QX5
MT(<X]'&2,FDD /6D-E4SL1?SL#90Y5D!+.8<+JD@UL35N:%! ^%9H$U'NS:U
MVF0/67#D$%K7J@E/&6AX16  O0C6"U#+1'CP/;8RG&UN-/"2L 2'4UJ*AOG@
M:/K )?Y"_R(\39E3BHU&;'CA,JUR)\@<[ /'5C8E/+D[2)U C6LQ;F-%_NUE
M<2+D@9?1BWFUH:NU]VO'1/Z0X TC24IH0NFQ\=([2I1B0D*<M[]]C<,L+7]S
M"+_YYBGU?Z.WIET3A0I(0&FN)!9CJ?VP,;I]Z'.R3YW(H@:_V[*H2B$+)P@W
MK/$3 3 )O##<'],@(>RODFNB9\21=Q?N/P:_X'!_&W>_NL;W 0 ?9>>A=Z\1
M*EI/A,KU$(W5*%=$;$E(&>I]B^IET<^P\%]=J7FSD7(P#'4Z?EEZLVHU;^9I
M#V0L*@<C&(W*X>!#;^;_.8L!G;6A]9%E[6[(-EX9I#2?;%V70C7/\MYJ H35
MGF=2:EDV%(&NVJE4T59DR>.B_8O&EZ*: DR'[Q;]: 4_L4_@Q=;Y97.$Z_S<
M,;3AB<($Q%Z:'3$=*&W ZK6750V,TP<&S(JIJG.)@5,7I^!XF!:1H^: _D9V
MQZG9;\,,R=6:WL<$:%:.*<-XE=SD=^OR7V1+[@@NP5T(468K GP*>)@D0M%E
M4+4.:+;-E5!C*1JB7"TFRI=RK=*.H=N@*CN>*2^@@,H/<4BF 04!0N4^>4_!
M-A>6&;512:4&B(8D'J "IA=75(5+^4G=,X9\MUW^HX3R$]%7\X1BQ)R<BO&2
M#9%J3*%6B=*%,UX57ZYG7H]8EEE9I7<5/J'W.,*;0!@TT4A^*_UH7Q=#7CEE
MD0 /P?M+C++E2BM$F]^!0,C3UZK/EI*VUH&;1V4N:E9MS40AP 0G>$.=XD<<
MQA2<@NE#^8)L*'V/-@970M_G@QMGU!"" K^4&EVL<JM**/6>F#_Z$@M/H3K1
MEIQ#[&OP0E'' !RUA883AO$7L(^Y]4KQ$..Q14P *WP0F([+V@74[DC @M*$
M %Z:0GE,G_PEV$"["B),]&/RX^U#@CT%OSW7UE^5@Z@6I,^>:LD#U%B4V8O*
M=5&Q\&(K24Q"305S_V0\,W5VLANV\F3-Y-X4K>)$@^J!(7!B%@I4[<OD%\MU
MIT()N=97H?@X6_8G<SWW+-UB5&P#FT(0W+"D\(8.KAKQ#5PJN<BU:_L_AF^.
M,MVNXQ\2GOS.4NY$B/&8I$(*JWN+",;QFJ9D@L0D<41^7#,CK]9C'W90/1%J
MSZ3TYG=1.EP3>1Y'S0AHVW4+%1P )G:F7T09)FM(# #E]T4A'**0%4,<O__Y
M>/!O+QG.M@H%+*9]IHL27<T"D48I72^@9M=+:L'J(M/1!.\^NA  ?_O@1?W*
M^QWTJ>?RE&B\E4%W1I\+;\O07(6,@,KMK\!Q7%.($8#<\.&X#W=WSK=)/38S
M2%1] RF]NME)4-7,(8H&T2%I$D!E@^6_P&$@?58?O?WVB#ZM=::R&0RH!I(H
M;KAL0+3:H'(X(N-1;5;GU%"Q?L%H,;"^ =0IHVO-Z<S/J;I4UELR%"^5&6T6
M2=4!3$'6N)6]ZL)>BY(Y#>9R1$^57C8[\_D^+2WGA=!#XB(Z\79!YH7"%GW5
MY[3G!,2#%2-<6WT$B/#N,"G.=I^5E1FC<"L-5KFJ33GEB 591H78\+@P@+I=
M/3G?[4*JOG@A1(^>A_&7BV@3)UNFW@PPI3F<Q>+"!*@QPX*8I(@K5_G3(9/%
M0XQ;U&&(::*Z%@MBE10O;@S-,"$LLJ7;9$1: XO74Z53Z&H!+56$]:PDN-I\
M / ;C_,L5V5C[[((?,ML9+TNHFE+=<OVE$N<P;E'GA#0P,U_O_^<0BG-ZBHK
MM+E@^!Z'* QZ4Y1S@:'C:YB.Z%2O&AZ;>DK^P>3$YJ]+!;[5WXR65ADNKZ#1
M*XCAK$TU5\UMEZNPZJXL[AY)*^K&)XX]D#4@7'=C%Q6;Q_GQ>IUO\] C+\8/
M29RFQUOPDHF.],;7B'Z.V/<N*][R,>B=[C)$K79+D(3\F09!+C?VD2?O"B2P
MY?EK7_DTV:E4KU2U&CJH5BD7HN"T4!G0=#AHVRZ)(BRM((K!AN* QUF6!'=Y
M1JOR9S&Z\A)A&)>K("&-8A-R,EB^7J^2(@:6PL7"DUC8DH@KU8BRG6]15[C;
MSM<!)\3(\#@QA+J#+'!R4@[E)G?^SN)9A/&^\"R NV0P#USPU4*S@\;0BB<*
MXVEOV<9XE^)_Y'"9/JK5:ZL&(#:"'[;GQ(0H0(5O-)3B;94'943&CT'V<)*G
M6;S%264G:U<>XW=$9\/1%S(>E1.T:N+RZJ^YN>$4<>7N+!TR6=1&>*&?%5R?
MO(S&]JOU&Q*$Q@I[JY>S2_L,+21^=H DW%>N*64MW[>SM=NBZD01B3)=,S4V
MH:2I6N>!_I):J#4IRK68VV.E??5\1QW+:9Z .T:BE--*N]6'CK-5NW +]&\.
M;K:+ZU01%9SVFUZ&VRTX%1O0E1$I\0;QFYA"?&"GD^G"+H,Q=.&J;J/I;$6[
M2Y/L;Y^"",H\R-.5BX_Z6<D6>=4#MDEX 28V#3YU3\&>S8,<M+@P3J6KA#9R
M47C%-/:5N!@I3'V RLEIW4HZO;RMH^.^CGH$DF\P(VK;K#W?*)W8:](D+&?7
MJ"!99PHV!KJU1T@PXK^*ABA@.R7)QQMR6&1$4W\$M:G*-F#"(DY-*L<=TH&M
M[!$VU*UM=@@Q'G/4B&%CPU ;_CDF&]D+J]M2?B\57S>U#3; :2L7/@X]=X4,
M5=M=$DP2$[@%]Z@3<DQA1?.ZBG3I!?3DFI:6W-MO+I8]D^)U@RDQU>N7M4><
M41X5\Z@J@ Z*%I6NE3%;I)]4?,WX;KDF%&L3788U-N(S3LD]NQ97/BM'HBJ@
M\^MF7$HQ^I5CP1G&CQ\;H485B]=>_1[OO,6?3A+L!]0?1N,YA/YZ15O' ?T#
MFY0Z(NFL/0NFTYIV0S3@*XY:!+1LZ3K%NP2O&4CB*E_U-ZZ=3DU8>-3NXV/S
M#2OU<I3]GTYS_!-A.%1Z$EIN=;U',"$MN^6XQIHV ;1]16(J6CP4!:'%K)Y%
M*[38,#R[FJD1GNWX1E/'F<=378K9W+7-5AY-W\Y@7\VJM0E0JL@M+<9R.F(Z
M<;@,8,;WP"B1XZ6\@:2%\)=8:T*A4\) P8F7]I;29*'=MY:1?-D\_E1<;[3"
MX''D?XS7#4N<^'I35_KIS#3.D,[=^!Y,^81HZP6$.HTA$3<T833)K3[6J\ZE
M\?&:B'N"RQ(75X3I6;/.A?"F+!N^$J6UF*,J 4*X#-.P&K+53&[U6'6,N3>H
M)KUL[O9F!J^HKA3](V1 'BGF-DLJA[&&8>V:8<YSG8<1Y['5A'2V&T(T0*1^
MJ=6&*-HT4>]X&R=9\*OTI=]A*YWA,-X<DCE8>6]JCJFF<=L+0@W5(48.4LFY
MBXGI$>34()< E(Q^Q'",#,3X#X02RF/WEZ,=2G%7U^,42+B #)OC/'N($X@P
MU,VRJ4>ZUI3D> D"_@8I857;*:N0@F5-TON@_*RPP)T]K<.<EM$LJOT ]%5)
MU@-NPKWK*(@6GGS;-8<4RZDKSM_LTB.QS$BKHX4&@ZZ]#2%"H\*C:Y>D/D6X
M!Z4I82T?E)^\]4,0X:153F\@"K,<TGY1<'OVN."@!"4>IP8I8-=6VC^M.V%J
M.A?74D+U!M!2O;=ZE+!=%@,T6IK733<L&):$3SCV,*L_IN9"QZE&?>CY_B$1
MEG:M(BQ3H:A<0#8GM?RQHB@G=0(;+Z"F3,PHNUC!.<5,O643I9-NCI^[= T9
M@H*-H487R]P2F& *O8;/II:%JGV=T$97CJU4$IP$GIT!&MAUZO0Z;5U$1:LD
M?I$0$9_Z;<B@&<)A,5<52]*MG^)8D=/%GA_N8$+!9^*Z*QPHC4N5O$>(JIH&
MZ[E=<96SK;$X;;#!EN\[U!9C,9F KI/ZQ]28Z#YV@]D$IXC=J&9:?.P&!V>-
MV TAQ6R\1V@B&^N\//08?%I&2EX3V":5!9BX"/%4["-5NVC52L$X#=E4: \E
MQ]\B(WH)8&T[*$_UX67 "<S!2\B DYN"!_&WEEY5W&"KS:<@Q&D61\*"<*7B
ML-J@ZEMG5>#Z8#?)+,7,;O1_V^FVNF-A[Q?1V=/Z 32*\S@1Q'\*TP)ZODI4
M3@NA4N7$M(EM)ZJV#JIUG31@3A;>=AI-98M'G_!I6F5="0(P90_T3J;;DE[H
MPIPU%4)8V:N2OF;I3(W-R@A36I)2MR->:J4E7@DB*_SI[*!WR)?>C>)<1JQ>
M78(#<[BVFRR5@U?4S65[%1%NO -+D2".VM[P@K5.@Y0V@X68RR+ 5)EIO0.A
MG(Q&MRXF8%47_V'&JM+0LFT1W@KDEBSKF/0=VM3(U/;5-;X7FA!I+@>H$U7)
M&'YW<CH]87O;O]D:Z;20YDCZ"",'1M/<>5B=POU4!>43_3G?,D-F*?A$=[Z*
MTZQ(7RJ+PJI6]S,T2]?)'*@!TD%]",'KI@$6:L+E^DRRS(9)K=AC),%V[;IV
M.5RY=;1; I@3(^.^_*\X-$:"JV6J%X=;#8&L><!2 I%:0//HR\'*[OU.50^H
MP2F-8F'U3UW>LQ6<PGB5&@F;S3>;]2/JQ'CR<XB+B.AFP+LT366H(4QS@0-4
M+4%5H>8B!\J)/RZ:'4U$,)X83,L,FT%_QR%M3(Q]_OTYT+YF,,"VU\;&#>N5
MD.0R5H,\MBOXK1,X?$XQ^V^C^UD1I3[4;:6< 7U=SO$*S.GUN[B81]#4THWG
M3Q%G@2]0BV(VMZ&Z'WYD<T!>!,-B&NOH4V%<3(.#YH#4K+I*=@]>=)KD]T6=
M(+DFSSY'\'U11"GMU7BT;:46H-"S($M1M=N.D=^Y6T[Z3L_RP[IG^6(T?2E>
MW#MMF!!6 R-"\IL8SN%'W- =B$H%+W P/,D['C7'MY6/>@JU6!9'<11J^/.#
M*G1H9W6W\0H]G>)TG00[62*7L#A68^SRRF U@.,_$A5H8=FH00/W6724\-JA
M60OL&\>*7P-:KCNCBXQMNYQ7E6$_B:,T\#%+7[G&:PP5I5?1+=F;J;>6YC!Z
MC4+W8/9H3(3*F1#YN3&7X[QN';2Y-CY]NC4/L;B-)GVIQ4F'1^N]_[>3/;G9
M4KRFG8BN@_273U[DL:/RABB &;Z'!+P/\2-.:/6 KG;YD. -(UE*:$;I16;[
MYCY^?$VF)W1[^UOXX1!^^.8I]7\S:E$[[\@Q( (K>%=Q<SH$\Z%Z0B@'Q*9D
M1J%Z5N?/CRE$!,1Z-$EM=BM6""!KUM*8-$BO58N$'Z*WU!@]+DU,(_0D!+9I
M?.AE&I$7])"9H9^7E=*LN>48BV18\1@V3 6[!CZUMDEEI>%I2S3W0UT66IFM
M)@"/I28DM*V'EZ\"!N)'241L_28J6/DU?/W*+9,X\$L#CKIHVHX5N1N.$+A3
MB1  RS\T"I:64ILQ+*1<OU=^S5GXQRR4%49ZS,A'JW82]>+)(PW_O++3SC5O
M<RIH&/X':6FWZM%TV;9UAP^KJ=+=[BW/*=Y,1,1)(\KDG+)MFS+%0AS!7]=G
MF3,@DJQ_*,SD.&A4MW&=@3TOA2>53 V>6E3,--,!Q=D6KO4@C02^H>0\BR=$
M[^%;/8E.O"39;^*$]L\>:@;$M0C4CTK4FJSN N16\=#$7<ENH$(^5V6AKY*
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M@N-C2,!_I'DS%)GT-LZ\L/EWB$V\C+.?<%:$S_V*_7HF-JB;B*-BV^-&1U;
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M#<?M7#DLJBDL+=_Y,T]<F8;JD[Z#3!AN.35.N?+O0'%?)P\AI2*^RZC56]D
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M,CV$C8FGU/[M(C51ZSKM5"S^"NZ[I5G]=9QX(^AI]VXA*FQ<0LF.A@'#47-
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M*6+#!*V1%R(Y9'+?!!,]YI4L<<!IS86$G6TNX<RID3Y+=0N!81LK1CG$DN]
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MY2TQ>^JUH-@/ZRJH%?0PR>0XHVZBSY4!9H.\UWG@<NYU?1S:6"%3=OA 8>8
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M$EU[D*?CGIX!-2J TA^*E(+=(CLJ D>7QI<$;O(\*<E"L06=#*&'<FW/C_8
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MCY;OQ(C17;4?SZFYA(9L_YJ20'IQ;3.AHB5BXS"@@<4LBS>_#C4\I8?'S^@
M@BY$-C=C IZ]ZDDKIAPQ<<Z\ECWG /=4R*V?/2'?QE&-+OC4MZZP-NW-#%G$
MZ\5!/1E7(O@M1/^^>:_WTGO=EI6=$"\B=6BYO+CL2,<QZ'@'IB<.&#D174L)
M6$;2L$FX8!O#'L7V)\L%#TSJP]-H=FO(.K_(;_6L:JF6-R+.B>'B-ZY>.N7[
M^+TXY>W8"_="R+"\#L@C%\7ZQ2/7)0Z R6TC[GCU1JL<+>B',R9V\.*.=R E
M8*_!#)^+O'O68_$O(OHBY7 \-_J\K2TE/[(/!O3"NXFN!SIFZNC \,5I@6 S
MX)L\/;)+I7;5)^<<$'.SU6#]DW1(H8!-7<L? )Z(OJ T1,YIR(S*/,8YVA[-
M9*E3\X,<:#F61^"[\QP4>)3F8@"*UXSIUG0[@U2O<LA_=R+=L6RDQ\'0B,&V
M]#TG_@SA@%,UW6_/7.0R#%]<9 @VIZ(+,<'0C!XOV=:0-+DL^B_>LF;Q2$\$
M1$?8CNH])X@1$-ML2Y&_=N?A0*SN4_+,[L;PU4!4G <ILJ+\182/D@DV0I22
M'@FING;+^B.5TW<I,RNR"[M^F9TG:7"<I(0<<ZVD+$X@\P:5.I1S:M^R#VH8
M(IE?VY0_UO*(YSJ*YXEE;DADR1[H9'JG:PQA#2RS#8'+A+<P_JZ.3NJUTLPS
MN"=F!Z(!RC6$W8 8D]:IS8OI=^$QJH61HS@.%LB_75A>XAE>$V_-:(J<?A5I
M2>,]U.C.GE,"(K+R;&_[HF(:6'[0ZK5>!YLMW'FB',(IN[Z?6]CO5:DMY)8&
M>E<V?3 $9*7M8XS\F>FY9?CSS? .QY +>TW+_X[KZD[/?C5Z3T6\\; /4?H%
M3<.+<= D+["O./IU<O+E%X,Y&P6TA_E@R9#P%UD..!"FS[+]?.X,LOMZN3AH
ME1JPAR/].CV?(@,Y.,M00/O%,K1@N>$I0%UM]/E8!ME]O5@&K5(SZ*<F+W5T
MST"F!8KE9-Z3Y&OE;KMY5J)\7C.[?CXJ7FI3+]Z/-G$97!O%SQ:GD6@IG5HA
M70&&8O%<U2HME,R):U&Z77GL1_-12XKC6A_\&D"*4?/2%765P#4 ,Y2<%Q:P
MK**H8SE,+10<.S64LU7#,5QAT7P4&[D(6="FQ,0$'2T5;/FU3?NSC>*:95:!
M+) %:SVC@)R\ A>>=>UH7Y/$1=IWH?K:L%<&Y3[*EQX76(J1H*UYY?S)TOU1
MJ V*OZ>J\E0-XM=+>U JK4:Y"-M>M[WP:MIU5<^F%F+<-:9#%^C..0LXK;,_
M<EW7*->(^)9TQ'V14MT-;GOBU4;A/OCF+?H0??%@,TPS5,ZD;TN:_%7MJ'W7
M.E.(=X;FJ>K:;C%MTC?O5 [)%_$5Y^=0"X6J":"MA9M.5,V6\_3"#=AOZ]:Z
M^L:P:MWNJ(]^@!AR@_%/S;'/Y'A-+;M>83\.^ U!@>Z0-5HQTQ,-FF&=0I4+
M4&=,73OKJQYM1NV[=DB%>*?2R!6D1;8^NR'<OTLS"D;THED=H-<AR!4B]41@
MP9)S2C.8S&1;908OO1P 8X*BGM#MLV;O><!, 5-33DI?3TKGDO)\TL.50WQZ
M<!QZDAY^[E(/EVXV].B"$X5X?%=D%BS0:8+RK?4THA0%E%G!2VS=8Q<'&-&F
M]L9*]>9;#,:S/?"C'/CRYQKM*]$5,%",9.TM?XT"3;NJ!67\JJ[.]&QTJ9Z<
M<'<7$%:/5XB'K;SY):'TQ/+]S8SX7-- 1R!E()L6!)$#4<OQ.JJ:NKQ6(IO^
MXL)CJACZ95<3-)/-Z5JSN4@YN.L6"&/9#^GOF'_"O R4\S8\YQAY:(8#[4==
M')'!GWP)F@/>.<#DY83]&P<YC35A3& $7'0@)'70S6;I(>2BEK:P/GI[6;CP
M;GQB([I%D8GN*5HCEZSX=4.W,#2!'[R>:*0O8$$FD*?('_YK=PHC( ,_ZPFE
M#-4I5J+%HP$Q'5V7/%H>^!PL$8B&BUI:\[:,B IU?-7I?J@+? <7]\$S,R)3
MBX(W$EANKMU4![&QN^DY8@A;[I2M%C*9V$R8"#4&P=0$ZVPV0[QI!(IO.(QP
M'!B/GF,O9-?;Y)Y+/)K\:8)LXMG8Q;$<Z DB06&E&"[;0<TMN_UUXO<GCOXH
M*/(KAS4P:6!Q,VN'@84OJPF 60@6TH$[HP5:="J$$!@]6]$#89="H G6XZ@X
M0!Q?Q"/E[,ON]C,(.L D"_W9"I,T&\!B3KHT54<2U H5PVZO8>74*%PR,:PJ
MK20C7A6'8.OM^R$*5T+5#V(K/3MM(DA A8A4!7NEIO?N[[<2R[L5%>*S[)K/
MCN/21%6(90'POL',;6/JNG(4XG!-IC&[]R_*" \9!-/E7%P3'@\)V<?N793<
M\3K);P C9SK[8=@#D6&C0G0/Z"E6PQF*D@3;7WES'7UII4 ;?</7O0ZKH#_4
MBU*-6BS"?.1\#6D057X:T%5[*#P[#ZD=0T ?@ (JG9,%+S"^\+K/#0(@]'WY
M6%*L@GO"J4MIF9,\:.R>JYT$YV(JE!!1ZE8Z,)_-T:78"E">L8]>2=B4XRKA
MY7PN77>ZVEA&^GOSE,J)GPJ*>JCXMB@OK<LO(E@4V3_,R?K0WC@QN)/-/3>0
M=NCC8#/!].'*\JSXC1:[:DX9-0(TWYQB:KN$AGYM"8:,2#,$_JR!G0)F.'PD
M:^1[7.4*E%MD]Q?)-?MA)\ZM@,H?6Q5P3=-GX#>X'4.C?W.7 O-IX#=XF1U4
MT[EF@A!TKH9:"!/H2)2>DVYO!$=+.06@'>"I2FJJ$9]*QAU32GEDQV%_P;,-
M^Y'M(OHP^_&6G2TKH+=,11\S6 ^ZCEP;E PEFD%4EX!LM>(6X#.ZU@(X(7S*
MUFYCFH2J&LQ0%+>XE-20U%13DXH-LT6QY;J;4>3_(F?L3Y!%B<<4[>82/R!W
M<TN*GYJ@.>8F3)NHP*%E)-RA6P.!\0SN#9]Q23QWK7F_A##"Z$7^*C@%]V*P
MM>@=$SXT>7:*?88G\>F8T81& ]_T:#<!>,_2=1*ALZ%!#J7X)@X><^\NO!GQ
ME\R1V]%B[)^0Y1(' 4*\C&1%/,KS^9I$IATJ9H)V>H6I)7.@7C="WOX(Q5&
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MSAS?EH7H+[Q8WUUB<:JD7&L?E(=[7INKC]O^D29_I=#7*34<!N-7*)(X%0R
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M2N508W_Z*5:T<]ZT\J-K]@YJ1"SG6/=^3>Y]@U3QZ/PU_5N+]@UNU(UW9#H
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MP@SUZR@B;*HS[L\AQ1 46635@3JHDQSTWHJ[V>JP9BS6^^N=[5=KV&(,7J"
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MB5''4$Z[0,>^^-5N<?K5G018O?L";- .MWVW?S9Q0C'+A7>1X4-<H S>/UZ
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M_]0Z;A$'_U"?)U=IV2PD:E:58 IKV:SO<?:4V]':E_<"MYO%G#,FZ0Q%J?J
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M1_RQ!#9J\FI>"G68?4_^GHCP7:B\3CH-GH-#/_W=EX+$%H)/KRC@O(]U33;
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MQNM5D4F_?&!$/L:8'3@,UK61A98549X\7YOB*F\6IBFSZ:N)#"PC@6OJ'[-
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MD[,WY?S-S 6)4W<>YCO)Z.4S-C,MW51I?A*(%V0#W-%ZG6MO;*L .K<'KJ[
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M9I!ABWD:B&Q,V>GRW:(4RC:POULE*9;&C%HQI?B#.I4O),D8 O:15/X8P?G
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MEC#-SN-&+=9-%P3!>4_GN2[SZUKZ@)P-VG FL/QP.E7,:/'/YY-GP9^:'K)
M_<80BJK>7:T0>[@ ="T+##]#HDH^TN4FGCGX_J1/"5.F"3;ET,DG5[5[FC.W
M&MW$8(&XX C/T2B;%7FD($(NUYKGE9=$*3?;O&Q"'5KCI(F(JOBLR+JMY4JJ
MT(ZCF_YC,3!ADR,3]CD<RW?WB5[769-C;T<Q@JY.OY231)=;>DM(486OMZL<
M>]_H+%R(65>ZK'PG;B1T[]8KR\<SQL4(4N YRI;':F)NHG\EYASFX&'K)!AF
MC)$FZY+=M@[C&AA#*0M4_LX'8HH 60LR8"'MD_'W&G"W$Y!K2DP%3I\"B&>Q
M\9(:T!_)384D:[;7V,=D@L)_3K;./5[E!%??.LPLFOB(&:LIKU8=,M5,3S5"
MKZS.=PPL&3??23^1!.NZK&T;"HNKNA18R\X@MZI?9>?& 3<+-P"7!EEAU_G>
MG;QSI)YFN>Q#)4?LBEL;"C)V).C1[=-M;>>.$OPE\&P'=X1;$V:"QT7/?=$$
MA#[,JN$1ES<--KLH;+$JQ<;O&8!<V"N9'%C)UX1EQP.SR%CGAN?^T*YL.\ M
M49!!WX?QF3*S&,&I$9\.;P!^78G47K@T$B59U+3A;W2<;AR)$QW%)O\;K$4!
MKJ^M>R8]9L.4+27IY]_<VIF1JI57%&&,,9'X'O.4I6GJ1 W!SH1(W,V:6QMI
M!V+ T<.*]2#&6/.3[E;.6EX;#8/OZ1#(FDP\ZHDIYU[V6VID*2'":(=.^HE>
MKXHLWZ $*_I+ZB:K6:&;+/!Y]A%M<'1Z^;NP.31'?M60S:Z#N9&T>SMW*Z%/
M/AWG$8T-[X?L;:]1]&W3 ,M(^P.'1.]<F*K;+E7].TY?I4.YY;>V=0?K#T+6
MRD*2$+S2DFD)72BZTA_\$/O9/,Y9#H=_E(G3KF%@L)0N\IJJP;!)$@<B*M(W
MA7!N.D.V;7^0[[ =M^FJ"'>*7Y0256'_EP>J#&X4TA>1YGX/=:1[FA'COC^Q
M\H"5R@T$DHM<+8)7*-RJ>Z''E A]*)Q9')7)0;"@UL('"ST'8.$<F)K=AU4O
M7ARK 7?BB=YMQ< OXPJAQW<^>3WP'5YN5A18$\Z2+\JYU.)]8FC.,R%O!9\?
M>Z<"<6+K; _D%,Q?VIX5,$'X!F[H:__A(\M1P1?J)7A*!G^2>4$%U<.2LM[8
M$NQ=64138<\O96/CK]*,B_>>=++",6P_$ST>C^**QPH>!0MYY5[ULG/S&AW6
MU\XSQ%?4\T5P.BOVM1X$/(SJ-:$,N;INOY5$LP(B^2Z9^+$6MNL"&:*=Q FX
MV7IM<"L6J$.)L=UM-L0)1)>+W'V6L&TJ^&"+>$1I,8G,EG@8=<GAKCA'V=VW
M%TL9_".D;6M",8IM%ZQ2-/84^Q5[.CWW7+WV=CKL_ XZR_XLMH+K8G+M6[ M
MG6%]U> @Z[&1Q2#I>V!E[LG9^A[EX_\'JO''%>,_"9KW0Z^93PUD_-#/]^>Z
M*GPE'H2)L::9F%0]?^A_&6&9_@WP'HWVYT4)--) F',^>9*WDK#G$M6SR1UE
MW<YG=&VI9;%>D#L78]0'NN/<"7%-KG\!E=5)DO@@7E,Q-W4KVZ)XDW('XZQ+
MGWHT>!_BB=[SK2</WN'F:";Q=J[WMK.;O-7%LI ZV8N56ZN31WTN4=86-W5%
MNYAOQ:;ZEOL;7F./4[MDKLQ9VQGRH.S'1.[1J$+Q8Q83#07/)R@6&;^%[0'-
M0)[<X7#GV=P6^68-LZTC_.JQ#LUJ!['Z!EA/ZP8>W9.?+Q190]?O-^"'F3T^
M?AW):,B=#M%^6F_6FRVNU<M2OUTN]GCP8CT/&"; GT!9^I+<1,'+7._%GT]>
MEP4,U8Z@4K#B[#;8/<([T\8O]:%_#+8H5+4S89/+BY=GK_7% '2Z*M=2!RU1
M6\[7F7E;2D_C)EJO4K#2.G<CSZ]H&W\#3^D%1.1Z'$4X=#W[3710Z]APN\Q=
MX"^O7_T5!J\MYV^4)C6X>IQV6:K=Y+)>N_DH<__&A!/M&M;-=N+]LVIO UMZ
M/,*6CL&6'C\884LC;$F@F?"-Q#8](4 &ZA!SY]<U4YR$()PMZUW+3$4[!QAW
M,17TO6!YA>!F6U[7R"W8,?#JV8\O7UZHE?KB%4Y,\BN$^_R(>K*[*EI!M^ZB
M@,>\+)8-RP#[R<7SG[_DB0,L$+;#(CJ<S*ZZR_Q4S)H=,NC:$J$12U,$;8K;
MSLATH)NBTX*!\R"((UILZU*R)XO+EV+'X<NB,D[?TQ/GNLWSQ?8,<)?B7]?=
M#P_.'SQX\/!+%^QW;MZD&LB\ B[?%C#ER0UP=#&R8N(BB^X!=R"BYRTW!.5O
ME#ZHIH.,.*^Y+J\% "0G6J?9#.*;W*&P5;6L\\DOU>1B=^76U^0;:<N8QI)T
MB^ @P#U9%,ABL+CG^Q:2.<O7+JJ 3R+=;YH@.3+G EIH-:$K?XB=>G>$+NH-
M6@F@BK1PMN0,_YOU/+2^4.G /,R*JEB*@Y97MTZ']DE,O4?FQL?*\Y%!9@L
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M&90'HT61M&$%P0EF%14^QT&S9VNDZ[Y[D.P[/-1Q29WF4.^.6<LGZ_J&Y "
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MHI;UU])'R=>F@YGRH-MT5%-JM 8DX^GCIY]=.&0&Z *ZT.D!X@40P%L@HGD
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M6.NP%,:?T<G3?DFY,U#S<D]M-;:ULU3VC##6?=,QPGX*6HWE3OI<!I[EA6*
ML.7FFGA.)/A6Z"R0U& C.P.=_J4W^NV!3L]IKP0;+.7_ZK FFB/L=,7'T@Y6
MFKW4!DO,%\JJQ!#XSE\EX,<2;L!@1L0TA ]R"VRS<XOUZ%U,^)PQ4 _BC>@T
M2A0F"F-=MO6Q^7W;'(BY<1,Y&UI&69=[66<9^"28&+"< W9-J4,< 35U?&CM
M7[$';B-+?35=ZH15CRN;EF^BIR'31_!6\]CA8/JVN27@ Z,[Y*M,MQC>L*J5
M-VWYEF@$"!;==AYMZ#MMHE)GH+CLLB*GW2PR6$6\C^S9Q!U% U,1+HR0$:DS
M01#&=L,Q_6=\&).A+3L&71F,&:%*+H(7*J-$I"M7Z22+%TFO0M=FDC":JS@4
M6V(2<QCPMA^7:M&1'Y[C.T#(^)1OQM,:OGEJJ"5./U7(OZIP.EW[$-)=YRT[
M[559"]++.DEVI? EI0L>3#_AK6BF^MX?CCWW\@%%1&/)-\$#,A=0>&38-OH<
MUG2V#.#!4*<&O6Z^#.60!W::.C2VA64PPF)+0&U<E%D:FQLB]2^WP3D@J'=X
M?%Q.L,R=-POWQXBM0O]EECQ'8LT^3^Q:23.W;3PSM(&B55C,!-!L&(]67_[U
M,M$7Q/8O\"G$EAET1X8E,(0M3+N;G(\PIM?AE7>$9:)K6%"5B]!$6<5W[.CI
MN\/3D9-I2JY$$U\3+BGZ..2N7;6>_Q'FI>=C*KBVU8:Z1B*G!7=CR)]7_&=R
MB:CUA!R]EAM5!>&%#Y'[5_L]P^ 4CH8MM-L1=BWW8F79C)>\,VL04T?M<Y'*
M M<P2Q,^7CQQX9X/Q%%'W:K$T"O6DW9(+1=YC?7&6+D#$06:2W:Y\0E>(-0I
MU $F,!UM:WGP@Q"9I19$&8%S$]T'= J_C<O&Q= ("'B"&ZX.P1Z&J*G+.&,B
M(UH(U+BC"7S/6)+8$MRK%';#H=Q >LNP,H<E4W'K16[M"]XTMR%>"^8P,2/O
M_!;TUR:ZDZ/CYXL?+^RJ[TY=,-GB<&);E[%5*T%GYXC/)#245<TN:'TJQ$]F
M*C3:#Y8\K(JS_W&YIV%5?)PO%LZ41=8@K):U]T1"F/B_[7[@I1"#Z@JFE%NK
M=\T&%*8$1&DB?Z*E&4J+%(> NR2[MX4#^IQ6+@B==LAKE$215XS<7<X@L#MQ
M2V=66O15)_W>[,;!!4FGB? +ADUYPR2+M%O;;O$I] 6Z;!S@='2)E)IW6'4X
MEJ.=Q"Y6W"6%:-%7Q%S4U'Q4RG%NV0GX<$NG-!U+_N[P868FPZ9E-UT]#_0\
M&*+#]&!TA5MB,+R-.2<AE$,C'+)/%ZNY\1D/!>XS-2D*;\_ R5AME'GA^8$+
MD(ALJSJ:NC2]U)47/*<# .[6Y9&<4OCU0#Y&HG4ED[QI*TXDH3\M,LX-(!,3
M-SG%+?[7>#'_:]ALEAKW#W]\_.5*GJ%PV9\[&O;H?J_2@X)4@ ,Z9;P'4'T0
MYZ;U:_JF:84*XQ(>)6QT4@$X&5S_.%.&N76[MARVG+5<4[3F"1F_P2?(YZ6<
M0R0Z/NDRC?&*<;7,-DJ/'^Q/L$>2-Y.^1VS. WDY_&NI+_$!D:'19WNS@XFR
MUU>X?3S\K \?UBAP_C0SQLC$\*;WF^N:NKQ/U$T<EAH/#)XDO"J%8A$W@_@J
M-N"$> %!:QI:.3#1"NG]=DUU$7G0>Y"[>S?I^K<B__MI=#A0&SBX9$-,__<P
MB1MFJ<U2R+2+_&;@?]+0VE/$'AOH[0KQ^DD2Y[3%C_N2TK1PDH\>V5@_:X>Z
M"@ND[QP2\KSVO[$GB+"L7..  %6!;P^\D(,5>!E6;(4$RD_M<#B&8Z0;M,,C
MW/9K?875]Q2&V=AY&S;CAM^ ^^+A$[K$;%L=!+L5G35#K*#&4^S+W*MIX$^>
MX&I3M9OA@'8GHB./#,?CWC/>'2Y9-49VI]S&S)TN5L_#H:1VOZ"?KLBAA4!6
M&!QB[;/5 B/((+/#\T1SQB3IG-IPRR]WL?H%5-WQ5M?"@7ZDS<PM2JV_EMXJ
MN8MYAB+.T+K:$^=QI-&;CKQ;&N"TGOFNHX5#7_NI_'7U?! NW?]NUAW/S&[U
M]/&3SU=^7['DQ'9Q$N-4"V\[]VXE"D=F9@UVNO-R7E<VP1*C_4*+(U3!>OKX
M6;J&SG"!OSQY1A.-&$1'PQ"L<KG_1'[&/WS;%.'M@SVH11DGO-,7Z./ZRH=3
MA'R>\)L_%TQWB3X%" + O/\4ABG,FM]O$U7$])DDF1>643@_!LEH<F!?]HX7
M<-??M0DJ=4TY_U?5P4VJPDQ]C[Y^#\8ERMA5NS!8SVF3A&#_.9Z2"$;Q$2R/
MJCW(-!%:.ND$N)FG)G[;L*E*CO/(?Z7IP;$@IPEG0G@T1..'SJ"8@J5WO&YN
MN5M3;ZBDGG0!O(:D3NDI7C,.TL1JWS+6/+=^4[$S4B]- Y%U\' EB09$C3\.
M1[(>/&(7+HSJ?P_!Y7SR>1'F_ND3'MSL0Z,Y#YN>B%EVNV[U"39MA0B 7X1=
MH_ #5DO6C1B<ZK  ";$J/8"1\E6,I)F7CC@6MC /V+(4$&PU'WD=#(X/3H[$
M&7:EI>&=&](X?C/CQ5G(#?6%(@E:N)MR$_?Y:Z:!7;ZP88:-?F.T?\)SA]]0
M2C*NKN!ECY*><\_L:%6")[JJ-8(G225>5/4C98.FP^T9+4 .!&XG%>5;$)ZF
M6G<<QLY4BT>LSZ!O&/H-J6%@2S:[PF"-RHT1*5'MGE0\K;.X0+BP$K7/"2?
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M)_I2'?)PTOU%5-FR2.6Q.(=&*:#8Q"H9TN<_7'YUF=S*L)*2@&6.P8O*K(K
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M#A55RK:#CVQ_Z;@OM[!F\MK&;V_Z9M/LQT^<22<1!MXHSI$!H7(FAL\_>ET
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MVE9[<=NH;FYPULX"N)=ZV7)BG=*NQ@E97L0YK4I@!Y@F,IG;<0<AR8$0%&%
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MB<FM-D[IMNJ. YA.@T/ 9':-E"HH*Y)$9H;.,#A'M!_9NXX#OBTAO,,7'QU
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M,0([$J3%N44:P$ZYV">:Y<I"[>A6KO)84SOU^5//$W@C,5))$$/]Q(:.-0[
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M-"G&U3Z@93UO^2!2\(AKTGQ_)CC$[649ZF*YW!/C_J6[L0-&9Q0A=@@4 RS
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MJ6872%+*'94U^P)\OTACBHFD=.<*ZL:.^[M]#-SY55TE"P#K,4@3!6H"=-Y
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M3O#1 PI@E;TU=/TVBZ&0H%5>AUI::GJ5'8W#K R_TZ=NBXI[E!A$4)GGT:_
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M'065(E$(KX.S@4.]4OX/C'-SS!UK\2>.C7?+-QINN%KJ@&[1OE7"P,<.K\!
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M,E[!W0WWR\'OO2]X$>\?''PZ//K]]=S$3SVCS_70PBRMN$W_:-."VVZZK3G
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M9,-MO^MLK0\NUV&UMKI:[D^3 B4Q=C]I]D20_-)<)<<TM""M0O%)RR,!04H
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MX:^BGH@Q-E/R-'@L<_/Z:1X2XVXR'&8@[?"*,-9K/$Z5B;28X:#%:6GY9Z1
M7)(C\"PS.HP=,NHOPC1P_UO -G/+>)9ZC&\AZR5&XRZ4'Y!9+5X"F-Q\O.CZ
M^@G"G"N0C_P*!GJ-O'8#=@?0L_)AGG\EU.N/;9*,B';!K"X[RSM]9:YU:E.O
M)0KE'846D\MCL#%Z&"$4:]X\+4#N:#1Z,G;X?F*,GIX#(\F2.%:6:&H[J'D*
MSB]=ZWC#G0QKL:4])/ D\+OE*<"TG<0U80U1[E-].L&!9-[1(*'[7@95'S .
MA\A+<94P!HF6 +'Q.DG,6U!222*YKQB8\#7U4PV*7-D?0@+LE]8F_:58$E*@
M1H9$KU*@9FR)E='P6$;#].I Q[Y"+;.AO=&MF UP"[<?8C:TN]8#)[_O3+@[
MZ$_AE6W&)SSYVG!@[T<K0K[>+<L W \.GT3J'+GGE=S*;<L<HC_+%\N&K7I%
M)-1??KQB29@;P6NT#R["<W29,2 U\+.+:D=8^P7MC<[*2E@D/<6)U$.!TJX4
MTF+/B'=+BAG"C,Y9&A*#^9 \T[!6\  F33\A3G5,DY+%P"S$&ZY=A<,QXXV]
M.ZD\I_0*R)*#!]Q)9W8G_2+1([ZT4C.S2:F;QQ(?LQ=ATQRIW/E" ,R5GECL
M&>%.(52V;N6TZM&1W?(^OH^9L[F[L7NGZ$C5JDAO"^YX\L'SJ09=:3#1W[0&
MB?!AQ)YN:;FE52!+;V5\"?];A. \7Y,_M.^/0RSC.5$9>+.#E2>T^#/ZA^EK
M%5U[SI62%BS4$PBMCVKDPG9;TJ0XORB3N!3N248CS'-3+V&=%3:_4" JE_!Q
MBJA02ZMJ;X7,:J[@9"I2U)B8W(XA-5&SVGU-;;VP:J50A;6O6BDL32N%56.!
M.^W,JK' JR/9?]SZ1U&+.]L-7-YK'_;Q'J*>8@CW,'%ZR<*%DXQ&AE]X5K;D
M&6J5+!KDQCJTKM?:F:BVO?$5$P?^&8:]N>-UNQ/%5+,,^PDJ&VL['\:7*INR
M\X_%^->>(%BZ81\?;1!;$_KG4;9E;FPBLG&$ZPG83Y96ES<>VZ4K+N_L>=T5
M$5E[T]N=Y.A\;K:,Q:T)7ZC!/+>^V)30&H]I<.''%*,FW]-C#]1R7@U.&-QF
M[:$N;2%SU]O9OI6?XP46<'<[WO;#*]=7!=R/-*.)5]]0H[736M5H3:W1VEG5
M:*T.UF-EH@:W^<0SI9ZDFL!*,GNN7^)L"5VR::>S*">]N5,"<1P!W5.A[3J]
MBP/#GA6Q]JN00U\R4+&0S_![6E;:B_-.9APA5RU9T\PH7DWH&ZOJ I_3J:!A
M7LZFOP(Q;G+P64+;;1,GI4W_!5SB\C>S4U T5\08/@K/F4!/D&P7*1BF?![0
M&!U+G_N4,B]2&(_U+1B??]J,Z$KJ[H'8[A7G\"[<_]9D>2MNN$ZF@B;ZI."A
MP?_[_W8W=SM@^5#*K5;W^L\D5ME9ZE-EF29G8$@S#.(R',!7OGS9)RH$^[,@
M;1-ULE+]Z7/EIYNI*/*D5 NF10()_^^9'""3&U2>ZA9C*6KUSV&@2)[ BK%5
MUD!4DH8.Y0@WW./8_6<1*[>S.[7T-W9[,.^ YH[GZ4117_5@YA6C1< EIN?
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M(B?+Q%.T1NWTKY'M5-\[?+$JC@:3#ZOYQ<!M1K\RIW,%?U11IJ[PS:*.2SZ
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MI3$G*&A'@RPQ;J;W)X,5LTUH7X#F9/#5),@VK]_KU+N8B]B;( IA(U&2)RU
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M#5IKIN0\Z.6_K?VG5P18IW(\AM5*XC/XX,<(Y&)]T/H/?O _[35790-_C+T
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M,I^Z=_-S: 5(6/@'D?+1\-D->+Q#?[-X=[V)-=Z=%+;**<5:<KTC+4)1;:<
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MQM/-9OP8._:0Q4X?-S^%>!B) I*UDBZLYZ *+T;A2@ZW0.:K*NY5J1M])=[
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M!V21:;B]/),;]((]"N%!8V-B C@EB!.$JDBRC<"(7<F%,E]EP$# H_VK_6;
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M?E&P8H+'A2/+.N3^U7QA"ZY!KF\(SO<A>;T/:3<3(\E?C4&D[7:+U<^'JJ6
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M$UC=EHZP"XX,FD(.+]O!A!9&5>[R)\Y</4_<DR+=22]#9U"PZO*1U?XC ;R
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M-OCC#>>J?8?3[N&7WP/W+_;&.>4'2 #8 'Q.OYF:E/D=^^8?L-Z1,^6?_=-
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M! F!]3V6@\#*B8&H[NZ!J'W$G-IZ65<611P?6U;6,:BS7D[R$G\+P.RKM5#
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MKZ[0JO2%,3,QX1!$SQ<&HX] #3:[]4_Z$YWQ?ERO_@92V/ON&N2+WMFP'#]
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MO*0,22?P8$-A0NSG$)0!+[S#&4T(K)4  Q:0%[8"K=P[8.4W:;-QL,I0Z.4
ML'/O:P\;)_"U"_1U\=?-3TQ*\N2?#W3=<?D?Z0 U3ILT84<C\;?,QPX,2WR"
M78[$/_'$D&Q\)Y3KRZLROOP[++"Q/7/(_Z103G9LM*\^6T(PM^J_S*F3I1A"
M]X$/)J[-\TI^,VRZ4!;QZ*V[I!T(@[2S"T)$LJW4CRJ7/[\M1"[ZKX8[$J)6
M(1R7Q8GH$DG>9>/B"CS+WF)4=6]0L7G9HG1IG7O8H;E&'5)'D')(C H$WNB!
MN4F[U[RXZE920#T5:O,2W8Y.,W4;/=J'P?JM&FR\5:'.4I05:JEZ?%=:N"O=
MUL(=1)$W)=]"+U20I!I30>O4VWA+5@+UE2U,<V9-1%/C9OW**P\V:5N9)8CP
M+DV:=V6!7WGFE<WSK7[%N]K4F@\3 $K-ZJX@C4<F>,9:S-N(X!EJLN[%5:M2
M7]\_[ B;L?Z'.9[(7IOHII%.DBGV*9]6PSON)* P7+>8V<DO<]189KC,U/*G
M=W'57*][5J!QOB>Y(\F[!]'3J*+HZ>52#[Q3T9-@#6V+32S%$%6B6E8DAE8.
MO-2\SC6.[3$ML5O''3,343#"(YI6$C9J%U>-ZF*BWB'QBM.RVK;X_YN[5L>4
MM@F;F:&\K:-[G*(YT=[[,!QET[=^_GVO]6AV[&)@>B%5^E@&63,?P9?-(L[8
M1:15:C87:PYR8.:D)_<)1(\;3>SSG*(ASO$V(C$4W"M,)+A!D>!.=5TD.-><
M7JBH;@/KF3J[]JMYEW'<:C'CN ULM=C:)I!RW#-6/<$H;H.BN,U.'C?CG892
M3B:*NY-XVEL4MX%%AMM84$>+XAY3[NPQBHN9PIU*8WT4J2 G/C<3.4=Q#QS%
M/:8=MD,4MUF[N&JVLF]<EOL@5VZE[5ZCN,TZ*KY*BNR9<VCSO-:]&[+;=1Y<
M']MMKEOU?#.['1O9;:!ECM7-[FB1XR9%CFN-]>[EGAL6KF*\W5^UXVZ>0&"Z
M28'IYOIDL)/=YV65EP6)>S=;Z(Q%ML&RN/<)[I\""X([5#9_EB?F"%301YW_
MMSP&JI7Q[J4L<#"R(,IA(]:]V0*A<N*MGB>2VXD<]P9?J".L,5YAY1TZ&'=,
M.TRAR(9V&#8E+K5:Q;O!/Z*AI% [0T.I0TYX>]?[SH-?X1_.E%E.]V6F3"U.
MXBZ:,MVUILPQ")S6UF@MM3722&RU/[A"@-,!GBC@,@0\[2($K>Q"8[-7!/\B
MM*$0!4O CE!+FEG@#JGWS4J!V=H)KW:/20%KL#^;/>Q8O!B,7H/]*7K](&J9
MP&W@ -4X8Z0W=498#939JIW@O7Z++M?J"8C7P$EKZ%$_17K4,*^KE@";/ .C
MDAXHZ8;.^T2&O882-6&K41BOOE57[[JE'N"X'"4!'?]"38F?D0Y \:P7OXTP
MH?_[)Y\6YX.X@H<Y7"UH=[ZH"M<6B&LH)>?$P$Z'2J^3D3XV3%=_(4@.9[S'
MSIH<R.T6WD;I<%'_OU3HN:TF2L3EX+D<H X;0,!8PX"W)PL\B11-(>?RTW#B
M6*$>*:-PQ!],G1&S*OH_#==$4\&#YWBKU71/:J(1R$?]LO9!'\&Z$/I(Q^[3
M)'D9[TBS6LS$4A:;A]%3X5[T/2^8<@[Y(J9_Z[@/CN>+\X#0?;!D^D7*5F M
ML-J:E=IB0L,O*'17$Z-U<L1H(S$2<L9_T2_K'Q!7D0V182USS-8)G0/X'DFT
MN!%S7'0Q6N#%M9>)U<N&LKP7!\XE;W><]F#$#+@#!1A6+?^?X1(>X7S_#EIG
M&DS3<@'X8MUJ0K>"]4<BYV3@'5+2D@&,VUXB&4H$!7K9_*#'7(U5SB&:,O]F
MKB-<HHC7P%TTX5>CO6#+IO&6I*M6?!^MD>RC83.>R#?#G9M25-*3W2L_.\!%
M^,>7$+QX<P^N74P/K@TN1[VRF%VRQH/35GMP>AH/;HOFG[GW6-HUS,Q.ZEFT
MWH/KGB(]T)>I5=H)!-G<A2M.05*[L;$+IYH8R<OO'-^):S>3G+C(*$B>>#<'
M$R<KO[[._]32^I_K^FX>S?]L@P7?JZSHF9:U_ZFE]C_U#/S/=EX,S,Q<KG8G
MN3/8>EN[73LU][/=Q5/:3>K,O;'[>0!EL9G[V>ZE=#^U+=S/7DZ.11;N9P>C
MX$DR;/V1R#D9-G(_.QC\KB6$$G_A%@2YG]LBFXS-GVQ41H?T('3X(IQ<I$+:
MY=>EPSROR?+C.I_O2U>W\US?8J&TN:>]TU7IJ@+%&Q$CH!\]B+E@%Y?4SG2G
M@<'_%5T^<=D;0$OE:W%TL[&\XV48'^ ! ^H,/I1U9-3M<<;;6%MO)2V8.=QL
M1,?/M'D'']#H/$ZSV(ZWF/$PO;K!>_'Z*_(Q*.)B6)8\'YK2S]B)O%,=:*T/
M&/UKZK@^M>K"WM%(7!@KHOJ<O^GQ/F*![;*A\VS3<[%V2BAE;3B+X"VHQY=R
M(<A_6.T!M>N[N$"269G[8@Y9LDKZYMBX),9]/^^[XQN6^OTUF*+?'/^_&<Q(
M+E&M04[E3G5:Z$ZM:/'I,NY"@?@*Q'SDELDF\*87J2SXV8!)VHJ=,O17V<#!
M$*T;LKO/W1LIN7 !DU]\A+^+&[P=S%^L+#%YP_ZXR$]:I [4 "ZRICLBJL&$
M9#,?R9AKG?#6+K? ?<MRAKBSR12[X9-(QT,=]&I67 GCZM<L91>]D.52NNBL
M+L_WB8OY2G$-F0/98QGW0I,N-_B0O&W=#]C(S)NB':6W_?XZI45$(YH1R7A,
M<4W;M%ZM5S^UMFEN2 R1J8>B0+\4S4@?GWYXL@_IN:E:ZJ9J&S=+6]M^+;FI
MFJ:G::O&NQQO JV0T-?HT*W5PDDG=(/:8@%)_:(NKI"]4U9?[[?OU4%6N[)K
M&-T'ZE\P-(]Q'=$*"VP^G81HMDVQTO!MNGJE>=X6AZ;3_B6+IE=+1C]4#YA8
MMMG=M]O#A#?Y==2=#7HAH)OD>Y#U[O>)80L_*G0>-JMNZO3 E*ROKVW*K'M/
MGG;O0#51Z?=N[I:;CC^>_C"HN]FU?Y=C_6?8[6P7.2%*;^<9(*%Z<04TY/S3
M^ZJ=:^?TF,<S1-*>\B[FPV1:-7><?<C+@5V9I[/SJ>6(\8O1KLW+V?:GTA-.
M[3])A.V;6=)6 ;:WK (\_LP[.]0O[DDVSQF3"9N_ U3=YI[03D!"N\'5'4DO
M[ Y8UVU<7*6P\_:)5Y>2N[8%*=D2LRZ?&D;9Z:S52Y.@0]>KEZT1S[+7.EMT
MI#B4@=)IY]-0W-(?[+:P.U$Q;<7X5N3E)._-N6NC<]?=%0+XI#RZM"96M[#&
M8>\(QF'QO0&$RR[FAB/.\-D;R*TWT"BJ-]!)$Q!ZA\[ ,3"SCND,=%/&FG+D
M#"R;4C-[>.-4PB@7$,?MYFFY(7@ME5"_N6X#,X947<=RQX _;A^C,=_1O)P>
M76%U-]=5J7%D44 M 7VCOY'XIAT8_*UHB&F:,,A.(6M&K.B$E_2_RF7]UF36
MZ*/^ !SY"0;Z5\# 0/VH=UN?>$X%C*67R^)).O3\6<5*Y\LL^\X,?ES'M8I/
M),>U\;-U1N9BIIJ-Q]=*1>G%_)%P$C2M:L*L>*996:6"7/\G_?O;#);>=XV!
M.?RD?P-9P6GTS4%JU!KJ4W^3CQ&AD,PAB9:1;. RXZ_R@(&$@H%G1'QUONV$
M^2)I52(IW'6QZK7J3'$)T79FP]J'X%@QT3FA0^+P3Y++$\<"[O*X-.[;HP5A
M[84)DN5A]4\<Y<^")D=B&3AF@E'!!)8_8&XC,US+Q+^Q*D,?3J@LDS Q;-]U
M+)V]P&1*214M^)$+2G%FPB\P>;+6^>3I@LQ.X.D>S\R'N1L^_(DY=#SYW? <
M6W-0W6'1MJT/WF+9\?C#H1%@B88]XF^>F"Y6B-@FJ$!/9'3B%R/,XQ+_)E04
M7OP1KVC'+W'=I765';NDU>_/#N!A'^F.4@G#HN9?E=O>JUU<U2J+S1"BW/97
MP]-&C.\O&^E4#ZR+.B:>+4L@*)[\#,GNQ>C.X6>8,9P@J?EG6!_"*WB44APJ
M#$'@&J6 QY^XC)4QRU;C-3Q;EO#P?-RUY1/MG4 ,]E;!$X[$'YIG@W1;7<=2
MMA6@-YN7[&AK2G;:A2C9Z35BZ(4K2G;T-24[B8RH%$N1A%W/@SDIX>FM0W5<
M7\(3O^T]XE):JY<R7\(S"(V&0?&K2'(^Y?\RK_XP7%(4YZ(=6;2#BC5F?H)8
M8Y),]^XCRN'(^E3*<QJ-1C$MT.7E.:]\V;+V!BS28U;?'+6H)FVIS,;%-W-%
M-6E*:M1(74+UQ7K7/'TYC9=-/<VRZI)4M2-I5L2CKL"SO)XD$FLY**_9^^)7
MEM9(-#WQ)X'JG<FBA\!ZXF\%7T]\@I!*XI]P7OC$2>IE5(J4=_+U)1:=(,(=
M$,BT/="L_&]R=;.KRMI'#RDAF5OU7^9T:+JNH5M5;1VQYB>&<'JHME/@&7)?
M>#%DLFU'T%[[XJI6:C;7]S_*K%HK+[N6[IK+\.WIDAWSLMJR[$!9>]C.JEUI
MK6_\6:CM3/0S.NO!1U=LWI[V;AF(;'R7NAB/;#06[P:+N$?\F4W_/WOQ>H#-
M#O5R//;<6!64Z:7)BMJH6/)P74JKE3HYP"M2;0^2A%W/E[85Y$BI8QM5!&+/
M<7_!-$3?65EF0?#,]&2C2NVG.NO[H!]O5Y)U7OUH.H_7IVZA[AI5ZGJE0.?G
MJ -DH=KP2G$L&7^O CEM,GD]DS3X0\^ZD:=9;\.$N9E(IA;)JI3@="=CA@T[
M-T\=+TQY0-YL(:*X$;^@7V</P>%;'V_89Z% _HH$\F1MB4.4H;751 .@7>EN
MGGR=Q6X<?^NW?OY]K_5HAM9B?#I5??A!W+)>ON3_MI'G1K7%(\\%](Q7M5\X
MA3!RH]JF,'*N]R9O_O%N,>%&M4,8_ LMN/) \+1.57.'NN*3#&JF)5PK3]YH
MZEEG X=U]J'/$:4X7VT+5G;<66>#_W$^#>>(TJ$C2K5\>13;1)2ZY$LTC@L_
MD<.H4NV4HTJ]M$[*.=!R7NO>;:WE0 R[19HV!A@I!KA(MYHOK;-U'*N&/4V/
M#2J2-T"1^.Z>8HBLAC7%'26)[_UM?7($KE;4"%RMCLW<F@LELN]@/]/ZN,N1
M(K>&RCE<W*\W6R!43AS>\T1R.Y$<6HM":6$%Y=E:/(XG&VY :B.Q<382"V,D
M*ON;H;W8)'LQ1<KQR7)!WNS%Y?N<SEYLH;T8];\XVXOS]F)K.43V#O;B$F#%
M@C:2/PH,Q;VM]6>N:>D(\H-60TGB3WB(X#,+W.'$(/@QW0A+DR,8I"4P..TM
M8'#H;,O0,)]"(M9-DD3%))554$_\&8[E-IWB!X3DQ?C;"&(+UA@N_)6Y3#<]
M+^#07T0@C1.HUL..[\R. 2(A#I+%""C*AHF"P?/JFK[/$!MNS A.:2W).MN2
M3-!*4.Z'\O9[\?(G0;&4Q.QL1TQ$'TEDG3VM>TM6Z:Y>G;9L=;YN<.2W%(!6
MW>TQ=*\MP_/NQV)5 ODF9FR$7X:X.+4-[0^\+:E56HM79 A$H@L@$MA-B>0E
M=I4CT<4/"8L4)P<UU#EJG;X.*:V73M?'F7M!\=:K2DEE',B,=LS6F 3B2+EW
MG6TMT?A,::> _'3T-MN>.H836Y4$>.IH>RHGV5^[@,O@8'E:>FRF)4AZ)&3*
M'&QR':I>> +7,_,N]_D;PM&MJ'QNU.M)E<\A&)*V'EAOIUJ7+%<"WGL"K)Y<
MR3RNGH+!FQ>P[\A@78 %7@'C)F8.;A&0_,\[&WB4?3=^?C&]H>5X@<N^LWED
MX-IJ\+=58RCX;BUL+KLS=19C<J\\;)PAK-_@"C'KM*Y>UOG:=%@<#)$]IN(!
M5G,JXIF!!0SJ6#/YCOBT(RX;6W!&21+;S,=/=0:V\I#+5)]-9XZ+$$0C$RUH
M1"5']%[_E0F[?P@2^ VM>@'71H#1GL<$]*]E&@/3BI#[QJ9MV$/3L#27P<@^
M/@G6\<SQF!?B.LNA E0!^%0TY?#'E94VU<(QC? 5)1V (_LTS[X]^AK-\CO:
M;QN?X"V'C\O3YL75$W"$.3:'B'F(NL^QF:"IHBI#4.V1>!<1)B*ZIA(]$0M9
M:F"=S%O<&01@]#XN!FT*SO1)9S<9]'UG_KA:#=^X,2SC6J#'9/C&-%V %CO\
MK$^@3 !0BX$X9@/3&,XK 5=NBSDF(<]=7*6Y$#H(@MZA5KL '+<]2-YF[!4J
M'45"?4RZRUQ%B;5WEBO^S&[<_7;8$@>[TTZ .MH@+?L;:' '/&.#]"I8DJA5
M24.C&L6X_SPG)"-C+9E>,A#3?RP9<QLLNL8.KLV"X+Z7E/@*A+A&*@@B)&=0
M+_@W>)/1*74[&0)5Y9;PS3P1O@V$KY7:O0SQ^O;0I'.'<QJ*11?[J$0@IJM8
M89=JG8,=.?D!]_K2[7;GX@K$8BU;U*E#42_3<[,-];J<>L=L3KU>O>UP5"A.
ME1 -/)DC@V$?\9F(OL6N\NW19V:SL>FGE)UXH5%J=;*M42_D:<J6L(TJ$;:V
M*V'SI8@>F<<,=SBAB, (E)'ES# +Y&^..\,67",W>-:'0$$S@K(_A1-W34N*
MF2:2%.FX ?S]>J-4[RT&P-_C.=N9G'7T4TNMZLFJL6MC9OKPZ+_)Z$L^=/*"
MZW1.VIW]X#I#YH7< %+W2[3@=+S1(-YHMQ<3%=[=4<N$GIARV2VUN[O2<U^:
M+,UQHBYX^SXGJPO$LPU5X'K4[?-@(C#LJGU$I*CU[>07U__AJ&3+-M"P!=G:
M%U>M;7S-#\?1,-LB-5!1Q%<0%1^IXRF_ZC#PFL>P4_;?61F9RC5X0Z9G\Y^2
M?'U)O71R%G,'J[52NW9<5,]";5RFTF';C>M>7/7 &&UGCYMQ$.=O)XF1<&%3
MPL2 X_#=0H1[*Y9+G9B_'+1[[_@1!:36<K#PK1$H\&RHA0RQ)+'3R4 HX#*P
M2;S,U)P87I2M:229%^O3,7?I<[R)H%_1&;C1Z)&&WJW-\2Y-P[-:2+.*&FOE
M.IX-T_9\ZK">F#6T)$M(HRPA-9&SI _8T @\!BQI&[S(3%>:Q/L3 U^#'<5M
MQ]>GCLO*EOD7/%GV,:*('])O_(F#M33\_:\P3^PZ[C(>(UE(%U63DHZ3++I'
MD1!?T?\JE_5;DUFCC_H#$/@3C/.O !/O/NK=]B?>]1"&TLME\2"I#OZL(KOY
M*LN^,X,?UW&IXA,IE=N4/[FV"^,\A6WD;RL5H1?34<))T+2J";/B#8'+*A7D
M^C_IW]]FL/2^:PS,X2?]&QPF3J-O#E*CUE2?^IM\C A%?"1)M(QD V"_O\H#
M!D<8!IX1\=7YMA/FBZ15B11O%[S\M>I,<0G1=IXN9R=FWJ5,H"XD/6X=5QLS
M.&!P8!)R6.,%$*A65^N:;FT'9;,\*6-;K8/%.=U>9=&]#=4.F &!35F\=E)F
MTB5FLM:KG[[=?_7HG[5/'Q)5D6:\&*855E;%,IJP#&0<^, VO.RDHN-P^[5
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MGTW388*VP4GM=->C5.?1V-FS_":B]D=XQ4]=93<V>L!/K:>(09Z *;XW]NR
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MS#/,? *7(?ABJWM\>+ M->W$2F-XR)S??O4QF T_.]K=[KBON="= Z,<T7&
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MYC'1EH\/#5]?;LXK,K>-]VQQU&75B7=HN;5XI$5AE]X<)ZS'%86LTK _4J9
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MNK07><N-KSFXY34MGUSI%<$1=O3^TZ:;K<8 N\KQ-(#$[BLJ*9V*:Q7V'DR
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MH28Y.YQZ8,5Z%KL$UO'&X&>1FU(I6F3J6B+ $]7$(1(1"AN2T\-O_*LP<#\
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MVFE_%<$E^\71588H0#)3"#F8D3<EYV:XV/8C\.#C;,+@(WC^RA]P35?3T+Q
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MLDAC+)O8.F_ #"CX).(]/HG]:)J%:ZU'/MD^/4;!D.8.Q-I*;,AU1+V3Z]&
M[(!;+K7E3,T$#"1()F19D>.*^>+ ?ME0>@J7E?2T7.FX;YF?<_+MO"F2'TEQ
M4J9=NL0\2[$.=3FU"UI4'I@(;_*8H^!\'9CM9>J/19P-R.V"(QLY!]*$2V7U
M=GL]+1#><^T%)-6%73.1BVQ9GU!5(-*<,9J!6:KHW>K[<$<HQ,'4<F:H!0,C
M=PT:K/6.^Y'E&@Z=N0/,$[# PWX_H](2&C7<3Y-OBALKT@_ $C@\[NS]!#(6
MK'KZ=8C(H0F*.%VH"7:[B')3C+%*1:88U3&(L'H)R]F0X#)NM:E1.?NF(>A,
M8-D3FBC7G4CF']) #;C=(IX]2LW!5VB HSX2>FS6%SPQ=CCIU\6/0B CRD!<
MKU4"RTQ5UVUP)MC[!'T<D=121%)(2C&J-D0!4D$H?'_CZ;T.Z;1BX>1"N58Y
MG@7(A,E(AM#D8Z23'::#8IQ191HI:V%5@QHJ%6!:\ H8://ZO#QN7E'EU3>E
M81ZU:9ASTS"/=MLTS%60Y)MG*W]5CB3*(0*49"_!RV?%W\_N5G?;O0"&I[(1
MC)>/A/$NT@AX"TM57"LNK42UJ6(V]!91:G5%B-.SCUS<;ZL'$\D5CB\RXUU2
M7(ZB,-93PEF\-3@"F<4*\.3V*-[DM@FSJ@HR[SQD*L^DO*A/ 9'"V.1SU=\/
MI-7-G$S&"G\X^UCQ?SCU84D#&86@E"3P?[ LJN<63;6^U?Q*&-44J"K]-Z:H
M\P:>Q[5WY7XD%Q*7,AQ2J;G*B?S$FN$ZF]F;R#C4'-/%N'3-W47$@_K&-B!.
M4CR%NKJL7/6L:ELV^V$16#RMV[H.R;9 UZ?6!1,IOZRT8*0O"_MZ0?"*244U
MD[!RKA\)CDRJ5H.U2/4)T;Z\PA3U*=5J-E7A&\;!XXN18ZS:B"5*I=1F8L[W
M33:FJ^(15][$$GO&]= FPS\(>FR01)$_R6 F^J\66-8"RY9%3S_/4W^02[B'
MW#>F!*S J0(W)RB5"BS>E?V"W[2PT/9BMQ=[)2\V==0(T*;VL2>-5.GE*VV5
MYS9J@X[XDC:@&U/D2MS!_2*,.$2<Q)<[&%F0"MN2<VZUI2%_,S>P]S.I.@D3
MQBQW>B+%N7 R>F*A]+,0UNFG\N:L!4RNU8K.8P?9)6-K*S6B^V+^8D&&*\$=
M<.Q;=AP4TRS,"\I:L9,VI)@Y-T1B]527[<8\C+(#XF3D@]X\4 7Q/@P=!<4@
MUV&6D/WR.;57,-_!Q(!DWQ2%[GWK5$L7!U-9/"ERF)3BROF<F>>.X4H5=(SI
M;F2*8AQ<<X$FFI(G%4NB2N((T@%OT,SUT<X ;060QHX8@XJ)P7I\.19<KA#]
M6_C+LHJ%T=UI!_HJHF>H] .6Q\;V)T:;5]5"C573A1,EK4VC%CI^F.I[3$$Y
M6"0VPLE,*2VSAK*$+.;;4!UM_;"#P98T[$O6CJ9+ V?90/?')JWHJW)@#R/X
MA-,25'I%?8HH])HJ##Y_G8)RR6ZY'%%5[]Z=6D7]FPS+C.O":TEA&($Y]QGE
M2&F(CK&JRX >/*T#WXW.MPC91E;QP5603<.RN8RY#M6N:YW:^HA_F.84@6/5
M<:9H8A'EV@N@+[@AU@"N*#95RD<I>JB!U]",_Q53<MH%9L^M0MW4=;X'#^P
M/.,$RAO=?[3'7T=3]ROV_$"Q@_WS6J?@*AW$7\/?WH.M.^,8G"28EIEQKX#-
M6>[F;2"BIH2G[ERCG=,D3VS(497E8T<M1.!@SX_KF%LQ 1?&;I0^9<7JD_ S
MHH*4^%P]VTO+;M=^$F-O5^J&6G:/*769RK3JCEQ4\MQD8C*8T<N<<A5#_JX
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MD='=RY53R6*)/1#=.&:D;2DBJNC+?KZ#\ES;*U8X@:,Z57NE&B(;^!BO-R8
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MT+H"AZ3OXAI>Z#)7\G=BI9\0!H-E=)<H-M=F6Y_&8QA%3C6-4=3_QCJ6&8O
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M%0]HEON_N'_Z40%_'^ZZ.SOR4[*[^-?PGZK"QFI4M]>@1[W"ST1UTI^]CL!
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MH;DJ^$9;*%D*0=9QOXJ^[T<@-TB8D(<&SG0-L>">:,Z0L4\()NKPZ6:N)$O
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M(,SH;B.BA+Q?''"#$97]O8.3 RJ\VF5=?>92>^0 PS@;&AM%#C:>CDT'%KN
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M"J)!.,Y+ C2I!CV$+&\CRY=L[T!E6L)"O2C36&21(- D2=?U'2.(]P<1O:F
M[25%4ZET@.':%L*YR5DP,COO' *''"#@![/((5,NAZG+6FTA,4C6S)A6T,$Y
MC^3LE&92LJ/3V08Z.-<\:Y/3UJ70)HE@LF/=N6S,"" @BT=HF)W\XH,;#WT"
M+26>D-")@YU8/#G@LDS2?@WS[ D?QD_$J426,*IAG:FRDJ/]F*EVXJZ2T/,
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MH:W&;&,2,"<'P(+D%8PO:H5-.HP<:O%L5X00IF23% W]*2G*=:_X4]851='
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M72CZ(I1#X8F9-R1^F2JW6_WW*\$?_@^OLGCNG"H/+G>^_0102P,$%     @
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MX4H@=+VVG$E_QDQ&OS8#+(46Q2BTA%B:2/! )E,\K'2&)9JY\*V'-/ <OJD
M"\43P[9,5M6-N'R#_L\!_;/?"7T*A FP13#=0,D![F&.VP#;QD FB)Y M<1
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M$Q%E\,N!M4@2$1Z<TMA<VM/)=*S;4VM>K5@36"RG\_%TH<]@,IWK>(E7^MP
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MRCS?!_$HB\,M;/NT6LFW""\-@BUJ/XP"I<12G9)^39FD(7;#6!5[7!9WG30
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M7M$F^V@34'U+?2K;?3M3G]C^ %!+ P04    "  4B']:0Z<]L?KU 0 $#@(
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M6=F8#_-E9<O]UDC:"_"_=7!FTX_GK-#*EX'8!R#RQQF)C\N ALI/I,K<#'2
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M'D-S!P^^M23T(#<WXD'RC#B!V52?P'3]#D2P(,8;]\&ARB$69,<@ W""\8"
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MM[[71<B0\ ,R(7D4'Q#>[^+1JP(T:<S_#N+]:FJ,I,@0D:J:6U_&[G+%$$(
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MC7^J$EF@IRR0,/&R!W"?_.J]]@(1=AI7.*038 %>^O+$_QDE@)2D$(,X C1
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MN,A]H/E!\JCY&>$]18MSTXD5=5>T.#<[TCZJ$#X)RTHZ.!]-N_G]U:%5PL_
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M?3$-]K%Y<5[8)J><:[B4^^^D8MA].2["A*V ENV/0(8F8:K -9,H=^>J?>S
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MD$ J@261,=]\#Y1C]^ \2*>CA1:PVAW&G0JO!J'LBHGJV9VU0SB[U?S/!\7
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M]<=3$ @DOQB46AGA08>0YNB1SD^@_KGH@:&5AMR@)_NPVT0,[M PPO=P?O@
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M\T?R\V 2\]X!3!^Z8GO PHR1Z%3.L%D8#,>YJ'X%;-"V(KQVQXK5X&]RQ!<
M84J3?MW&=FK.@0]DGT*8,ECF&$;C][JP,VS0@W*]XH8FH&6+#1J"B2$@>&8=
MCG.0EULDP( ,?"V2D';5@O%79/?Q7.61+*T>%Q3"=//7Y"JOD "M32ZC*_<A
M9*(9>_AJQ$#ZB9K!V?.],LNO.!HH"/9Y%0+(\:TUN3=\RJ)!^D>QT3OU/U&#
M>GJM.D$#@7M@ND72MRE+I?L9/5R/KRWZAG@\ZSGZ"^<2M%OY14E9LY-X$Q*G
MU4-RZF>#TB1Z7J)TP'R\GOP['226M\&5JJ.(ME.(0W2,GM.MO3#8G4='6)H9
M5&?M$>D?OTAA4%@V$)&T.;-<<57'_RA9OV6O\OW[LD+\DC50<\=CMX3TRY&(
M@D:^H_\0^R?LZB8;E%'SD7:4C9'N !F6HAL/1Q$%<X'@+9[-U4E).X#U!TKX
M"E+G[<>/<CMK$;FD+=XC'?OZ84?BDGKZKRC%@S$X\R41!<=YT']\/355)TS:
M5_QAQ12D_P-_XB,56I^-6DU\-NMV5&HV236)1'J:6JE^S3])EI#C#3^K:>0A
M&9-K#/PP/2^97QKIOOSLGO7G;3%E<XEHQ&Q(SCZ%9ULST3"YG7"FADO"::*0
M,N"]HC[L/>HZ.JY%B]62213UN)WW^WI!PJT"[Q=*>0H@I9(7H&,@[N1895R8
M6_FN_C_)IK*_']6FWLEFO?_SUNR30EXLZ/_MN<T&Q8G;-F]V#,6$R$J#1_2<
M-:KH;%"WDZV!$.-D)12W Q8T?X\*MJY-(A_,M")9*7D(\?[/:NOF]@U'K"RO
M /4?<&*D[Z^-W^<N@;^8^D>5;9< O67P*3U]?5Q'CG^EWC&Z1"?K%- _AX_D
M,)P.<RI6_N]Q%J2+@$JAV256E=]"KV+/ 'B:FL9^:=&TBQ&UR3*[08,TW!/-
MU,\#6LB4_4@]4T)[*1#<>:!13%W'FC7/[B%A1A-E7J.!K@;S?:@?6Y!'C[WJ
M,_K?@/O3ZG7J1=$QA]HL,I87Z@D& X1.TG$]BWG\64"PVT#L"U&WE"DYONOL
M=QY0_GV.2\\".1=7>7HE9"%G,IZI[4=-N'QX;[A\QYMI^KS S1%>.NVD/IY0
MP#BZ;)=)I;_5",T8SS&ROUIH>C><H&V53>T5&;JGOF[FGW0CDAZPE_#47.16
MUK.EA?FK@<H>U<P[,B)GU'ZLF&<J^<<W92Y$$)YWM2AB6'HD@7QK4S.HCSVC
M]_=Z&FSO HJ+-3#?/GN 1UM7KCTF_0&=JYBE<WAF(KB.U#G[!]H3$#TXV52,
M<..J!<)HL-.K(>,$W,;]^I&ZZ5"7D=U6U>V[6[6'C45^ G"G%8U1UZGO4UG.
MVLA\HGD,J_?GD[-0K@Q_N3/&NOSF/+<<[B#!2">7U'SK<B7,X(V<S/ 4@D*Q
MV?!B-3+@,EHDWM'8*X=N .%*G:L2BU(52[>)/:@0EI[DU]%"6P0[V2XK&MM)
M:4V\RK[X?"O [%J&[!MF&?,28#@/26A336F?X785YLF2.N;*"(X.W#SOJ\&2
MHF=$,,'4N!M8&E@850EO=KPX\DSE\I07_LG%QL9,6JBOKJYS5LN_][%V\&_D
MO:3A.C9(% 6FVD41&#Y#]H 7P9<%&6>#O"R>;M+ X40+>FGGT_+UVI C3M9-
M_O[=>S_CP.$0'HDV)SBN&%J-VL+RWMZ/+.6DVCDP4Z"4Q7V";M*%D1N'&'"C
M>'IR^8"7]-6NV=-MLJC+^[39J!UA!N0%TY<W;V7""1O]"%+AIP<MH[@A*(]+
M"U;HE!FYNMU7Y@&>P;ZR7Z!COVMH/8!.\5##!@L+4(9[%P'?/+1.'4.S?2AZ
MAI=>CSNTZ,D#DF=IA/93>D8B47I^#(F>>V];@$3U/8;^(8ILR.JECZ<72M5G
M2+W*]'!\*W>$E>I"*=PK^? VW3PVK]CJF;N-6+CMDO5^R<I83DC@N%.@A\5P
MH65&59KN9!IJ/%\\@.7;1]0=4*)^&+KV"2C](S9=1E#2SD?;S6?5.O^QB][5
M'82[$E7N5NOIB8.)2_4RJU<K^R,)$<6XSK%R<X9,!_8L:>X=/\KDS@3Z-!5.
M:88< Y(^\@.A)FWT8L:.-'@"(XI(=ZJH0O[W34IG0Q?!!'MY^%>X?D5<%&X7
M"+NGJQL@VV"E"2]!BQ^UJ2D:G/76=+L =,\( /GOT&HC;6*H?#,&K-/5ETIS
M0BU]/!C?C]#C%]I(\@H+0)8@9O@8?#&UCDR5(N_]H2)GG]Q+PU<>-#4TCG&(
MU)-:\ LHW;I5WH8>51E\J 5<VMHD9PY]= VP#B?OO:2S$HI\@^$G5#&79[Y/
M]11-40:0A0ZH[GW:WS6F7J(M<7^+ZS=?&#<8;:/,)!WJLF9SI8G \W)O4C4T
MG,H0B>);V_:85SXRW,L9V56!=!M('V4_JG-@*A.\,5*9[<]F__0)F<@O-7U>
MX9LN8Y=I[ONL.G&LM6MAH2?#)O;^(@6M,!HX\^_W\X6*H3HE$<76^19FUQ>.
M?KAK#5C:+G'[X_4A(4FXW32%;O-.-=J'JMKJLHEL#S[D+8?W(_F&F:K9U,]I
M8K:%.JJIOC:E3L_"<F5^;45TL$$-49$$%*1;PREX79O@S5*>0.OF,_48^@F3
MB>ZC3).R[X#/? ?K7"U]G*EIIDIHHKNF3;S\3^G1,;)&AOB=/W4E',OS=GGY
MJ&#F>=_N3+Z$==7=RJ1,+"[03Q*0I_9TNLIWLC095/'9: .%GQ,$LK5OF^C(
MXD2=G]!/2GTDX6?0Z,I$B&7=F0E!%&90B!A[^T'<'L3P*)D-\IN2D)(P8HBL
MY=-7NPTD1]7\7HBK#.%V\4EM4F%*>Y"7=X$MA8V1WG7YFJC5S@ 4M7)".<YW
MBO?Z]NT7<$<@?&1K9:(EFA.VI*DEED".3*<]MMK^5:4[?2B&]! N##S^Q!K)
M/3M:6#\!?3C+A\KJT,#9(L$=%$Q*J,<\Y"PJ=T-W6A<VK!:G<LRNH;YUY+]0
MK;S1!X&->1&D&C;(KFDT.]^.1A=LCK17XH_WT:JSHEQ/S;I+L KU,5M]G0T!
M/1AQFV)=.H/HM7E%7U495'2R4U!"E22G"6F9Q1*IW#ZJA4Z0E?'IPG78XJ0E
M #VTZ:'B(Y-_DO@,U/E.K)+X$V;;M9\-@#NK4 $V0'&PC".Y%*U[>T(9A?8J
MQO/]NJ=3@1<J*G]?E"C3D O_L!832/I&VB.,$>&T.*@ 6@1H#YU_K_*.@8\;
M=:4OELI'R^$Z%]D@VP;&R5+_]V"H53.#Q\FG@6%6X^HCGD7QL2E[VEHWG'1P
ME3ZT-LL&G3A''\SG8''G!TP?ZP]\MQMXC/4'G_3*^J'1,O9KKCJ=M#9U.9\-
MXEXUHD^^*DJ<-P,"RZ:-GONT*3&,(E9%Q,OJK?M]W0D)E@>: W3H&L=D)[CH
MW2E45\%.: TX@AB0A_*E$J+0?V"I2"Q'C+S<Y3L)K&!Y@$H:-/;*;J48$ JG
M3[3)I9&H#UP0Z0V9)_8B:.O",QU>PTRX=W-YY]4=@ZNO7!:XB=K8F<)'(^'%
M&JL!D.>VL3X^>@.#IK;%"I/9" 6SMSU@7A]+M>5Q,J,+/SY%XGNP8)SLX.<E
MM[9@'+!8J+AEK$:;YCZ_XJXX=&[E5A6S GOKYNYQR7,F#TY=B/AT(6+@?U=6
MA\GB$,7C1D>DHL9,*_IF>]"R?X!:GFB;# #[5&^Z^/SX-:[Q@HRUO16: IF8
M_,NJ8C&X'[P2S#J]?'@=E;)G<I2N=YKNU^TTF%4&-'>LNG!RTN7A^&J$L XA
M>E=1_;1:@LX*BIK)XKU^[$1!9L345%Q_06.NZ*67-"<&VFCH.AIC:,(3_OD#
MZO/?-9+J<,^H2O&M!!W;*H.1@!\)^>=7;BGV5B!TC71UPV#A:/G.)I@(S?]7
MA<G;A4:M?_Y=@TY< QRI%W6^Q@)RQCE07U6?E.1WULA;D&3^Q:R$$<PJ@S3_
MN^SEMTFR."2N3=E7I^U- 2JEBP)]P80*OYSCH".PZ31!=*V<6M%TLHPI^GWV
MCB^:>?-Y8#"R8.4&%^Z.]Z7$">-<[Y>NE%Q>8)3>WQ.$$6\<UK/S0F!IZTH6
MOK?H#;'W6^FP)%6U3]:+CA6/,6"@8\J0491Y*7QP<=%A5X5[Q&']DB_!J*$3
MQSD49-(W;>@C2%0;-_T8BF1$#P4@M-E7!LID?QK\CX9.[-E5&Y0EN5.#A[KN
M1^9'D3YN?W> 5[1MZP^0HI%%#>F#EZH^5WQ$<UP+D*O/HO%>F9YEFHT@F8Y^
M[YAJP^N[?"#F]7H H[(S%(4_B]%"0Z6EZ#D+0_%$QU) TY3A6MDMVT@"4R@4
MAP'J)];PR4KA@E[W7QA!GC?W/GY)5[Y6&=EC67]9?<R[KU7GV;R258>ZA76L
M?V::Z42VOZIO\M7X"S]^D C*=I\O1K\O=B^>('?GR%LTE3Q-I6259?^:LE2Y
M=36NL.]7=G9.&1MT*VOO%7!)/>R&,2S6@+L1?V\D<-UGA#4$']W4,TB7%F_Y
M<D4]JHVA4K:-PEHT-30S#'#G[^E$%2+#4'X1CL[?935Y1=RY$MJD?32;8=^(
MKG/]ZR9WZ;M#,3L0&?B7C4H_M(*9RE+T,[SJ^E(3G7&MNT&G+O=(4R'<.;YD
MGA$PM\\4P'>+'S&E=8&%2A3/QX,Q RWZX(=97B(/)R'\-8:6*_YIP,L&13WP
MM1W+KQU?5\O2+<? OXWGCUUH:!BWRF/<'-OPU+Q',)-ZR2'F:H".;\M\ &.V
MJVJY&4^N% ($G)'R'?1E$8KR:B:V2T7D=A,=^4-:,9U,=CJ9E,>$-8=SF'J/
M\5C^1.6SN-!&=5?AD:WY.VY]W_QXK=\O5URH*#Q5ISWZD6BA:+G"(%C'$<0*
M"C85H%X&)J*F9A8]IQ[4F';!#G5R"C9%^_G7BO(KJN/'OKN.C-Q+7FRQ4,':
MJ! ]Z$I]?T\^8MK0TT?@0MZ4] ;I*F0%2N>TGBEUU;@IPWY\]&[LLH3#<+G;
MX(:%V='#QJK(\L=N*W97S>PU.V=%,,> &XZ ,[(":&@7;N9D20N8"1W7@7J4
MD%Y>ZOL452*17VA$K1VFMA$CR,W93K8KE+$'LV0?%5KB"NOZ%V66/P7;?DE/
M-I>/88_S8ZD.J%;2L%&^<^Z5"!+?_=%)HW$:L.W.&/,5UR^<C*]S-1LB-R<L
MIA  ^T[I<[A._OZRGYLE=]#F"(.\*DI@[BF.F5V7<X\SACJ@H@BL2%XSCCH9
MW<8/M#A7C6'$*#,^F=T-]/0E6EI7>5(XT\1_7MO/0!* =B(9,*LP+[(RDD;P
MS;G<L1#X$%%IC<X5Q&7HD1K\TUSL/$7UA,PPDQF\=L-FI8':,DHE"6**-[=-
MWLI9"L874\K?AI8>&KQ2G9NRFU<U'\?I/JE]/*:]F)F>.+"M50>I9%UB#<_6
MP#NPL13P"R*RP@'!!IU'.^EI7DTRHX-CF+#G!.?5D.P9"7H81VMPC.]WQE<'
M&_[LR..>>8X$.3,IH<Y58' +M?'N0TY>%#6?JJ=^^ 3SR4UY@NE:^%-:H:6)
MP16QCK8OGZ;TTG$TSZAWM-M$/EH-%2\\S=35G#E1AXT5T>&*?YAD,69#704R
M-WBMMV9LQ$2L+ ]8RD>9;1?YDD*6NG^7T)6^#%CB^=<,Q!%0,:9*('V(3#H'
MB]_9C,QH[O?FI;H&N(X_PKVH4U[GZQ0GX=2S&H:9=@C][(G]/9W'^#*G\D,
M^A)['Q)C<&:B%ND&HSP@V\51PP@]WA@00H4.,<99T*6&UH_-8P%SM"\T:;Z%
ML5&LV842M+B.LN[KNDQ7N[;<8)\QE6$;ZIREF&]R(5WZ>GEBIS%I7*$-CHR.
M.^@/V*LMM-0.=+B5??F=&;=6[)N#6D*\]1[=0:QIZ)J=4Y1T%F&]1'G+&ML\
MFNP#$SQM9IVDMA!BA1E7$MY[BHK<@4>0$)O?_+HH)#(':6'PT<>J!E<0.FEL
M$#G:_J.T_*@:KWM^EMM8G=_9BII0:BCL[$^6JB-1@N9J8D6W+,42@/^@477*
M+3D7]',/IH#90T/TGT=OISKD::_V*2I+\44,WJ'(,J(<G=S-@HY70JF\(U$$
MFH7-H29U\A71XCUB+^3LF_=9<=/W#F9&)GA"F\ZY",I&8Q[3)YF"*_M_UP'\
MU%Z6]LH'%&1.GY3P&*V"G)L]1D&!>T)4JQA_]O?H8&/4AOY &W]@Z+,*Y_RB
MGE)09(OZ*CK/<JYLZRB2R377J*+G+AGR3]Z\X5[UT8MR-@B1<VQ.XQ5>X(K*
MY-SCK'F52XJL:P#WX7PQH[PA7D^Y$'!"PCJK29T07$@V2[XZSEP\=G74IP$9
M&A88(#>=)3)]*Y^\"8YZ52,)'[O,@#JEE88ZO"?:= S8H4+E[RGSBH]-B->\
M6M(NJ<A>OQ-X0PA7,B&>-"&SUAI[-"O37%#2U6[;<O=QZ:L<AP YT2U%XZWE
M0#B@H+FFXB<2HZYO2-N/?)SW97<HW$!P$I)/Q\6I7U,M/31#G)M%2]2&^V)Y
M7.IK$/-A,GV>K:,#&SD%-\'?F"8!!?_&FX\"(GMM1^FLRZ@,6O KM*9_97T3
M'6XRH6?$4 (+H,\ I50>Z.EER@,VR'?6/+ $:*&R$@I=7*>=-?<6\>X$M^D5
M\>D(7@_S^M8ZOUI\! 0[%V<@.A9XJ!_$!NU%,S"%<H6X%U14'>P$8M*O>&66
MEWF#'DQVXV.<K%)")5-TCTS^BJ#BHPN&^YT[F]'P<W4\J/ZV%*G!P@,#-J@&
M[5>&F<AL8%[.^(LU=F"94-C_^-GMM^C31TGT3+[(.'_O)1LV*.978^*)"8IV
MBBG_)^-<J7FK9T'=UM006]H'A[5^06O;^>=C:697\Z%E<\5]!D,K&27IP@XK
M;)"46B&WVOCL]>+S\EF6]I6XCI'8E!$E=3FM0Z4M6-94:!*E3%^_L( @[^DE
M+4.=78\Y%$1;-@X3M>>28L!\JO,,^78)".72H)0A>3]7],ODW&8\^B:2BD+;
ME*U(RWZI#>,S#//J/#EIV4K?: ETIWF]E>&($6,'#T>3&@1<&//G]]5FUALO
M&@FT?#"30<N1,!U+/W!5-@RSZ=+!X6JE/ QUC!;STN\">1NN7)V9IZK&U+1W
MU>W&5': #>$Y]6J,$^#!.C50",B8CC]"*QX:K09EA'3_JZ<>IEI*G[0<?[;,
M/->\1)X.@?ZI'N]V=;1R74]3:C-B]]LE<>.Z0I^]452]Z:-=9[N1>)VB#!P;
M-)<H+3*BYCRMR@;-VZPV6*.X9]LSC8NQ]!KST)P_]T;)8 [UCD*BK8J.\KLF
MGY)+G-OITA2:#.]G$7[-F(>QRC^[4\YG'-K_OC7=Q!#Z64AC7M2X2*#<+&%;
M4RGE\7G:/.*6TMDMGP2S6)==Q=%XF\KLIUVV_?1!Y][N6H_S9<GQ]FHY&P53
M4[.OD-Y]L)VL#FGMHTS,!2B.>7,.+\14F/2L8?AU*J*U ]ZM2H,3O1CX5V!;
M>D9G5C^/^?.YY$.'+W^'%.70>'8;&M,GABF+IEV%G9H"(6>@0BSA[X[??*ZB
MS>C'#S"%%9 HM54 [4']=F63:<8H**:N*A>,.?&4^].2M45,7_X@>4]+.J=Y
MRF\+^P&R2[@E!BME7A/H]1=*3RH!6'NCAM5 F' NG8*J[&&#! UDO(O]L%[S
MMY$7QG?*O6@8 @&5Y:!SY0TP]->(FJL>(E<J4[EEJL(/S@'7FXA]UODZN@G.
M0(]#392I?QF(#A0#F!ZJ=*I:RSJ<FM&QB<.??:1G@91^.V\AL UC""T,O1#I
MA 3NK9:K9[FVC>XFR+OE#MT9+W^^$$[M2PE_SE(QF@(:N=/T4YVSLK73OB^V
M=C>YGS)S80ZX"3@I_<JV)5%UXGS8H).7KBTAY,0<ET69IMN:LDU(['-PF0K#
MA)KL!"3NLBX!_%>(DE\JXRJFNF; SG#NNJ[.]->0Z(VS_UWZ0@E][UG_RL?/
MYY_&V-MWU:+[-*^@[:E(&_NF+VJS C_%$UL]"0ZK(IERB34$UY6]3.,B341S
MX6"67X#<#_&@_XA?9\VYG5T3D0NO[1>Z9ID"I)L6]X8Z=<!=*DK]3J.;E743
MM>,L?H3.9@31CN:<E$3B;].@N#'-Z7E @SD<C @2)O%O,L$GT\)*'%W>C:JQ
M0><H/GM/%4?L.6*2#6HWV,&^)-6JEC)^&<@.T'0'3,B4J"R1J'*T$ &XU6,Y
MKCY[%G6,'#*Y%_(SY-N71WI")QK(AZ>)BG,6FAT3PC.BOKT/7#UL8D<^&_7;
M<[TQ3D ,#RJ/E8H+YHA;?^PS&"&&)2>(F2).#>YZK3>5Y;WC.F&M+J?O#K\:
M\,HKG""J\R9^L>KTUBAZ/].Y0>+F4Z?U!CE5>R$P'CO7@MURS\PX2L/CX ?"
M=?#^V0[2U)_;<QEK;% >P/516I!#I[O*(;3@+H@( G\.;5?@ZH/[V&S"01(*
M^"5E_V.;<8V7)SCV<GW=>/FFY^2S!+<^"L59<2W//"VH<MUF;^,H->^H!NH%
M/8\^#Q-(.K6RGYD>1X/S^M8XMTY'5D;KZ3_=_D8N=?[[S!8B^,M H$?07E-3
MO7,:,5S[1X/P-E:3P[]/,C$3-__EBX:?X(ZZ"-MC@V*C; 5KYP#-<./34C'=
MEC?@>4^,_<FIJ+"%;X.Z?+AB<_7RN(.VBQ.O?+J?+9=8-#];$J_-6>DNU%0H
M&DFXW<>7CAUD*=.')&B-O5XNUU+G_5/]):&1_6XWCDFJ.*7*6Y9CRXR4QI>'
M^-PTR(.1J-'4O*P<\=05(S/\T.IA &8HH)=1KHX-]_<-RI7_PI3*1ZO5D>A)
MN.0^/KZ?6*[+=(V:.8NG0R9C:C<*EBE)G<IO#2[ASY$-2I\'H./"_!]1ZHHR
MZ?0#TGH@_:%Y@M/2S2]ZC@2$TV0[5 BM-4+DX7N)D?Z9J4F.R\%VL/X83L05
MH;+^]B8:S>MS;SK1V^HJ76> EY.?= J>]B!4"<^+/\\Z<Y@Y%%R'/SH/#L<#
M4(8]&W2M%ON_--7MGOL,"/,V+J4&_K PEXC/#OMD'5XK'YG]8+;J5:'"^T'K
M0(BJ64H$(/Y6),[N0;Z!8)?WBKK"@B-2)Z/4GO^>?;'Y58)VEYZ=PRTA.>OL
MB^)ZM>-FYTMZ%J'1\/J,C[."O?/K,H8 0C\I NTELLX?0G$=>DD4E-IGRH+/
MZ7E08>?0%\<D;!*UU75EZ>J),<6WAAU\SI&+!M#+'F<8KM^7"L:ACX:^P5T9
M[R94,5*HGK_HYF@7!BZ^C@WZTQM\EB4,YXL6%E^*WYD5 $PZ#TC1N^-X&_I@
MU9SKY7X6?QU](ISD21JE\3O"G7J*?<3VDP#<_!X'%O(BZ!P@YF(IL4&+&O_;
M1L*A^4M;6P^\3=*5YWZ2F.N;WW\\15+_R;%TEK/J&E2]EBKI)70IUY0V1E <
M>N4[T.>3'U\=7]?E1*BSI>7_V]Z=!+WQ[/Q1ZKS.ZU+QU"4%:"R6HP H67.;
M796X-G4ZEHP]M>HFT<(!"'RX&[3Q.5&_  @V;VH!GM,CX$ H;?W68H_EV*Z@
M=#&-U\^J=AR9/1"H/UZ)-R $3=(,Y9?2,(S_CW/\<ZXQ(X)^/BP*K-\1:A"L
M.UX97:JI:)PM$9 NO#E=>#S#'/$-]8WP)Y"116MKBJ=>Z9\*U1HQBQ+DPA6\
M$T];D2TF7_6'X?GMZLLQ2+N-V;D%H4,.CISC!"%VYRZ&&SO'!G7!F=W#_YNV
M2?C!0L?LCOY'[%P@Z5?J-HDFAN)(CK\3_3G8\F&628=R*53.0/\_STK2;G\D
MZ6?H"S;HXRIV6P';>9W!Q8J1G&>#3KB3?LUASMJ/XD\T'E[<\3O*)%FQ031P
M$F6(%<O7#F."@5(VZ%_*'A@W2S=,HOAUY,+V<(D8?HN%W4/5%MJ]3?PO!%64
M#3J8V4W 7*4^M_'17ORCK2^0R :M"$DY0'FU#H3R%>FY?J++I851]<MLT)=0
M+;_P:17,&S;H<N48_ACVD\[DT3CK09,?CD2WX(O'G#_':]B9>SRK?ZIEK;FM
M K,1\CQ7$@Z'];4-TQO6*FGKEWE\0]?-#3O_.2TM<=B4>O;JC./(?UZ@K9]R
M,6^?EEZZ=L9 ]RI-,I&@6?.97@/@6Y22AF#?\W?6,L*!"IQ2^>OY99\,$K>B
M2GKY@YR,X&'XA\THEL08T?"],_E!8JG$Z7\:?Z5KR=RZF6ER')G@S/UGSA9I
MX\&O?CUL &(/?[^ZON9&[Q,DC?_7R)SN7,J^/8^X:E"7 +/*N%B<6:(,[F@3
M'F'*%!H5(=XD_JD^/JH4L^EE>^KAOY4@D :9F[5QZN/?X.=9!95] >C^PULM
M>_X+Y-&4/=/"(<V:8GW*(OR,8*W'8]_>!O!/ \E/Z1:1;A-F*,J7I ;_E&?+
MA0@EM3WKNU@AXTKMV93TS-@W1N?MD\-$?_]WS__?I[T*#7*FGW8:^4]29YO\
MEQ/U^,JOHDS]]\[?C)Y2-G*OR)":'=<J/F<<2/ U_+11-DX/>7G#0NHSMJFB
MB)1+ E0RUBL/_\(,N<D!)O2&.4*"'T;*"84GZ^#CB>8TJ1,7DCJ=4M^L3(IK
MY!3>+!Z0'%EN#OROMIG8Z/S'B:[=@:[&S#EGBJC\P> I:MEH'"KEV)M_@'A5
M08D80EQ)E=;X0-0[0UY<($-=GJ^45FA5XG,M4NMNZH)VH9A-;1%)CV&3>)WO
M;*.,&JU-KGU^^TSE,6?(NRMG'>7//(:()';W\(3GFU5.7CV7EX.P#/2UZ[J5
MIF/[8XE[DF &;V:@A%$5<\ULT*NEGN1H=141J\,KE*XLI\^9FKC"+V#+W&N%
MI08Y9;T*D[OOCY5.H\*U*MW3*4(:Y?=FJ0M=1.$G'&K7 21HU];0R]]ESKM\
M2/:MH2:X(>\YM]2+ZUQIR)4WC4JCQ5AY6!B:1DGXHM8*#'6QI\%T3@::(K 2
M(VB3K/.38*;%14Y0O\9,@P2P/N"XOT"F\IV3QXX5:T]]!!=B=MD@ 4:/!+8\
M6[V.],,U;LKO0)!#A+:AG.BA!>@IM7(V4HS63>PO*<_#WZ7IK*:PRL_J:J$M
M"):4BX5OP".#BTR35]\1E*,733C7*N>LH,E H.[KYOH/'5TE'W$!XV<JW ]-
MS/5/FEY9BEUY*')KO.>E?"YM90ZUVO.!)VM38";ZPL2CY)EO:)-\PP(3ST<)
MA2TFGM1)W"&<['^CY:NOP$" 7L8;K0;X'(!MOXU]' 2J7#=D(%[^-(G9.*6U
M?XSK8#^?)6UT&.!U;"\/J$F^W<.4W5Z2D8BZ-N;_9HK#Z#J)_D-'0MGJ'-6Q
MQLF\VET<LOV6:G\DT:;)!I%GCHVR8F';4*(R]D_8B8'R=L90DKPP!8?S&R >
M#*1,?:_$[2C6FEYYG.^J>"9=^L)S;#W1\$\U9&AY%^]W <?.J&_%[?05FH2O
M;P!#D*;7/06CC[]LS'+]$)J53E]LT6B0V^U/D+IGS@;QR^;_S9#LB\XXD+Q+
M,10JZWN<!7":<4FL:?#.,[ PB5[4>, &!3-WEBTXS:\QWW]-L4&\1@S?($TD
MQXERY[4DO40';W2'"$YF0FEN6DNLV$%QSA""E-F@;.K_8U03')$P?/'HNPM:
MMS%W9N,/!@]-[>1*3Y?P+93ZU/G<,2##&>>8N#<^^+I#=Y.W0-Z$_OES128F
M06TBI>NY,D]D'?2E5^8B[0=JJ>=U7(()?.P$4:<KV=FYHN4_HW>7\7YB(U^+
M<M[U\D\^$Q6;,=</,?6[G+ER4CB.*=W /(_;6X2W'EJA'5VR>6?DL__))<M4
M%FD3L.1/T,?X QV^.#A@_1W+4/M?9H;,DK_147F@B?;CC+^,Q $9P\.V>KKD
MWKYP"EX:=3#GY(9R6VOW+_M*%#&GYEP.4W+6K765.U./D7L>54I##>>'&=I%
M2<0AKG@8'KN'HXYW:KQVPD=C^1>O(IJ%LQ\733X27PD:UC."1(.M<F_FEQ@4
MEIM<H+,:=+K?3 ,A6FON491 32_ #$RWYILJ.(>EOC=0>6*(_33@/W;.V'C&
M1#(1]X[K,JD$"LCLKYLR[/>*CMX&3H?.GRP%1Q,=Y_ABQ#->I'3Q'A<^2(I6
M:T1K4_'\WZ97%7V%6LLR$VI0X4C]"O=PC>:ZNOKTU0&BIH@@.E@2L.N6//VF
M[4+WTEM5CPA"? =5V:;=74AIAQ"?<_ON^_RXWGGNVFDG2\&[F=G:^0:.-WM-
M=BJY#5Y+2Z!JNOSGF#616OC+GTL]&YD]/,YJGSVC.^P)Z:/Y]B(WQ_H;$P.]
M[1Q"&*5F=HB^'#?349M(.R[(L&XE+D/DZLPM@XMHHWK-H%S56L?RNO[CF0-$
M^Y*;Q5W!#X?R/U5-H^SNZWB]^A'XYMGT=<3ZAO6!B:!*$YI7KR%@FD\2M7%1
M@U"Z<FM"Y4$O\KZK,]D?"%3[*J/C?!W1;,O)'1V&!5,UQ/09F>>0@LS0(&&/
MUB7H4BX1*^/FRJB<%WE)\MJ,E-8'QAG76=MWZ'QDO[,SJ/PN^X.@K.=E<&>$
ML*[>+Q6U<@/M2K^-&Y>NW*NO,E4K:[<ZK579@UC4SO%)_3E2O.XSGJTP0CAS
M^:1-L75!OF6.EI'G9.J28C>_Z72?J7S0VZ-K>G&77WE:HQ#&5RT+EJY@'N4+
M20Q:I[ HU?&V+CGCR3!S;[=Z^HFNVGIK/!A]LU$XV("_T;M"O53L$E'Z_"AA
M=*&!:%50G#S;9:$UIN<0/5Q?^/[F\8G*^['#ZJ@VR>\F"-YW0!SCLHWPV\+E
MH@V+D(_3?12O&'@GLMC\PG!X?6&Q,1M$3UP)B.X,EI:PK;K]H!%>CT\-] ,4
M3=;:O6BNP>W-)_,Y:0,21X26H76^/-:[02=3<?'HYQ4^XH0N/I O7)!YP_?=
M,N5D5H!_62V&F\XJ+UV-:K\L+D#1;\O_,738O%P+!11$UKIH22+,&W1X)-&9
M!A7T 0NI@<^@XOX>>P;&S6B-[4C]V=/=7%'Y'\H2"O;9HPA. 6>WG1A<N-WI
M$T@T["CWP*V\ $[Q)9AYW_0SODOS[K)T<+'UZ%7Z/J3RL:"X@YM8HK;U8_Z$
M13%!J^-Z8NJX<8YZ7W6%1'!X@F8)P3/SX<:&Q8@5[! Y8T^$7\G.VTU)&)L=
MSH#S>34G[EUC<-'D*J=4F)Z@4->GW=I7AN(VRS?=<WNS;F.5L*?*3O:W;W3<
M+'*$^0N-S-;$",^CI(-:DC=9@E@IA12[MC%67W/KO[4)$+1JF[CX/QR*ZIGN
M>KW/CI,2D[OYKO;SQ;RMI#Q7&?J*2V6*'96VG6.&,J0;J$,X013EU[-6G7FG
M$2*LC*G)&(HB\LR7_SGDD$*>G+D !,PC0V]^H$\FU/I:/)4?+2!^V95XJ7N"
M6&U>?OWV)CX&0!ZB,(.S@GKFI<"#?A>&2<3BZ Y)TI?BUL+0;)>6 X+G9L51
M6"H^&A;9=F%UYA@#'WOEBMX-VH!R.X4:-0K'FX\MA)YO"E^YG5"<[,UX.C39
M$)$?W2:>HSV)&WMB^:QXW,(F(/:C3MS;R\E6V?/]!BB;)UE1<4K4O>4!FZ1-
M+X@79%V2,IHM6ZAZ;SN2"^&XZJU;D#VO4!QV&CEW>IW2E934=N%[6"SLY*=^
M__*OS1QX[KB(U*\M#A$QA6E 1<2ZAN+M]"K7S?^]D#RVW!>?9(>1^*Z21\%V
M] #I7<]:7&^L6U0N+S(R)SN7.@G6"&Q5>([EH@;'KH]7YHQE4L@7G^V^5.6:
M\LUE@-=EZ#(=!X_?O5^!"NN=T/V* ML B9G&&;0<03O&V=*Y:67#,::I?_E/
M'=ZT'4I1 T(C(=\GHQY6-.6BLA:D>?E;P9:<8E(Y:YP-JFF(8FJ[T\)":9,1
MM:T&;) M\/S=42[RWNFZ,*@S4#)A.J<B[S3\B+)D,PQ!WSJ(_%#O:DT944CM
M5_G\@7Q\1-9$,+<__2XA.B5U7=JEYLPO0MF(^2$8'@6[O758H1GTQ+!7*TQ>
MS"K<3#AX(,#.V]&&\Z-^T]XC)$V-$OL6&_V3J]2=?64T5Q+KXE18G=ZC%U.^
MZ0J/AN*+ZM-%JF<+>A<T(XR:XMHCF>V%1OY/&CRL9@JOX(\-^O'.,B^S=-K'
M"\8-/JF'0JI>I73,TN,Y[AA-JM[G;$P@3-OAJ;=GXFC8G6WM>C;H5H4)&5\+
M:X<+>#=CZO@ZL:=_SOK154B=36I805\*#(<V*@"$%_EU@"S7+W7F4V$FQB,7
M8R*^S\Z2>0NK7X_>*;FIGX/K',+I$%XM,A;?S@]Q^1B<JD]'J>JY>]!<I3?)
M&MM3<-[KBV*[7R&RHQ>3IZPN=5-EF^Y%_?PE$)FR4$:(&UB>$;1S?UBL?N6D
M6.B(]:O[A4=I7HH*%D;&3U-__3.W.)HYHJUJ>ID@KMC2W."8_G OU4?[*1OT
MV#G-M*NEW<C5V"H>+D- TEFA'@]@26T778[B6.=:.Y:<JUZ[<=Q-4O5O$I*G
MX$(&2_#84[YX)DGYT'9J*BSE4$N&BZ/KN&?FU_#_L$&120P(])N7Q2%\CX7?
M^]#3R4F+R6P0XCGI:PNVMA/+L(B+$(MC\2<!&;_ W@/K_J1S;) /[ 6)9^U1
M'5B(:4[O#-K/O3:NQ[U:L)(>,CV.BT;KJST!JF=MJD>6FH@U2>U(-:YNB.P)
MII:J2H9-[&G5^Z8*3/!1.=:K,DFG:^,EO8$6C$.;EE&6#\Y6(8M4* X^3H-Q
M-!BW-TMM5#V'Y\X8;WUAR3+^J\XB7G]]O#Q?->?)MN,L3VC6\WR+"7F#/>LN
M)522N_ "1^]^^Q?FR0FN!D5B?K*BI?_C92-%Y0KC?[8LI9_:2BD$F"EQX_>*
MD(.TN;ED<X,E9+M:9DIZPG; 84^!*]J@L>DP2 _+.#NU3J)G(0]5&SS 7TG4
MZ^;_X-:<:W%;N C,(+S=G3FT1FALTL12;OTE,,2\,!K7U2*MQ9@1N8>SU< Y
M5&L\>H-R .XO(T7V.+.P5NP)I:>8/Y85:(CEVGN1@R1]\?UA 6=QFQ]>^RD^
MVXGD<R$":86F]!ELK(:F>/EF1Y*D$75(;&7VI+HY$DQ[&$F?ZH1_D[_-&&RB
M.J_V>V_6E@MO./<(*CN;:(A"&IE7C]YC^-$V=+\DM"_!)W,IHHQUWFT6P08)
MJ4%B#80G6>( B5HW'A6'I"&XXID0VJK4C7O#Y1MZZJ&>-!Z>Y?NA4H:FS;$K
M@XOWJ\L"[8_<WQG9EAOR6\;9_D>X<I(K[1!EK&;M_]'2CZ+8P8_0'-*Z91WY
MW%C@21^ "<0&GS(K25UQ?*A=-U8\,);E_[PC,E^AST*]OU],_;2U=<-_%+1!
M[O@C6^9? "YP3X%Y/GXR9"$^*00MH=XYJK]L<>G:#:#3Y13ZX5UC=0?D^L07
M1!>/&B]]AEHN_@5M J06UK:T7G55;24<E3NM=LYWQA5?(1@IJ>LZ]#!E@AI.
MWA!'_9/%%6X>#C%)7YZMEU]C@XK1%P X8Q$L'H:GFG0=N=?"3Z!:K$9VI:[W
MT6RK&6X%^Y2"8+KS]Y^93@@6S^2F+&F,6A^KH))__;AO=.H61N"(2/+""_=3
M/Y%JB8%S;!!@CK;PHY)XAQ@0:E(B2]S1]ZJ/]"D&I-,5W)6N@TO8T3_;C3WA
MZW:.GMY2BF#)FD=X54]H04X4=HW76M?91.-K,_-C,'WEM^VPW[Z"G]:)I^Q]
M2<76&.C8*0[8$<0#GGUWRK[(HVC8"P2DJTUK/1W,?FZ_E^NW:9VCU<%KZI6Q
MD*-M9/RXP*6B4#PQ./- >NFCX'?]U20.)6HX?)1[_;5<6\.#F(=Z<%\_W_-!
M-VMQUTRH@G\TTY\VO5X.MOEN^HP2J].=0GBY:-ZXP091-1FC92$5^.(LDXDK
M P5Q[E0<?121;*SV8;UP]M,L/1D^%?-W"NJMS=U$[_*>KXF;47IV5+SXSWJ,
M+!T;_0Q^'L#>%<B2\B,?Y.16%4Z+RJ'D'2!EEW,IIBH;,LDS-/77O2<ZG]Z\
M7E#5K'KTQ/SZ9YF0@-(^6H[V+8<[YSTE3+XU]IJKQ,_+5HJ$6N@[6^\GUKU>
M.&M6\*0:V6MK[< <)ZAB?0J2![/%E_;+\N8F6_JH&]+^OO2M4.^U?.@YS*7O
M6<K8DU.U&4X+\<EN^%-P%[=^_575U^&.3)<&\ -&7%ZGNKFH"JW.57_^NMY3
MIE9C^HBS%4.$=L?8 F(W>F(L9/=%2T(=3% ^1M ZT3#_>D5QD3&.G.G:GI#?
M0!]M??7:XHG1SYUFUAD2@@]0T%R/F(<D0/D#W0]OHJWI03E\<8'KNK?IDR^)
M@33X2<#O[Y%'=>998;H6U2,[O#!8';9ZRD02%OHT!3YSN]P_V%]M1!<_@M:>
M&Y1E@,7>CGSTTL8XGBE*E!",[O1X<EYY>ZR+IM01J6-[M>E!:E8.=YV\HM;(
M*X__@Y;WCFIR[;Y%8V4C0D"EEX@(*-6&%(%L"R @1$%ZB8I($T*5*"%1I-<M
M56E1*:%'I0D$(EU@TYN$$I(HU4B"$%X@)"=^YW?/&&?<[_YY_\W+>,BSYEIK
MSKEX61+KYGE7T1 :+&[F^'RQRS^3_8"/[J!W@)"";$3KO77"M&A4\-*/;[?T
MF39,"4*[@7]\DKZM7)**?](M(X>!(%;Z7GI9WVY" ^/HUK&Y7OTPYF$R/4M.
M_;-]96VY!+5:3F7T[2BUOMIXQ+D;0;%]3@8L9+X&SUY[NM@8?E7FQJ?.>8?W
M31%+ .W/7,1 VNKRI]7+OCYZRW+2:>UX'$QB9!QK,?[]'V2,_7.]GA"J#JTE
M/BS,__'@-A<$GH:SB*=?[%JCAQ[BYP[0-#LNF(R!1;ZC+V':?3B3VPH<J1S6
MRZ]=)FP->.Q324E)"./5]X?[C9\E^VS"@"Q+M1\_N""7"W*NKN:8^]06.5=S
M^ J*+)2UL+#K/#.W#?"Q+;-B4)Q1CGR,V._?NSR#7NF Z1ZD(_KV<#W,W1E"
M+M8C+6W+8VO-]T_.J%&@PBT*SM)78/R.DE4AT_S*38:BX[AQ]T9"R/"0>2@U
M(]<+K?K*5FNLIN1D79TYOPCN"8RQ0O5Q2KC/$_XWE,(ONHX:_:OW*[_^W.4&
MJ@3AJES1P1AC=POS&S>YH ^7='LO/<F72S67O-^0%S7/.<!'Q^_"7WU&CQ%K
M))T]_($^)EAB<Y!]&MG=?( UL8?_.@/UAI..)GHH\"*C[S8)9;RBR6W"F1IL
M>/\@I_&[_LS,%J>M ^7,WJH?>XI6]^WK8SU]:M &I081=+ZS,$P!H"DM;6IZ
M[W$K2FYPRBEGUPD+H->TH09[OS!>N^V[NW\PUQ8/2I%C_UTO;M=REB#LY&-[
MOM6[16EX?L2MNL9XQ*6@FC':%H(X>H.NX+5#&'6>,0T_KB9P6NY@OD".3QH-
M+S>@O@D!KQR>"W_44UDE?G5(<:CPP^>DX$*/T=K)=)]L]I&EK>R- ->K6H4J
MOK!M3LJT#XN :-J]BQY2_D<'&&3^M?Y,2-]DC"5K8<H%"9;OWN."AD?00UC@
MJ>$IS&\C:R[HV'(G@8!=+;[>U]>#^*EOU][3X[,'RZ&,L&?(/CDY9$V.LGE[
MRY_AOW![0L/V7A$7-%%!I+'R)]A$$@K;L=7P5%?]UWH8=!9++B*V-\6JTT]"
MA3D*EKZ/41<?>&!=/H0E%%":_7P?F4_C7&3%S-=$NL\-$RPN%'IAWG<*5A)L
MK>4;'F(IXQT3D[8T*J0#:=$?$U=AU*%'CW!VTH[=_!I2@J\LU+NB%CHG>],R
M@=+S1E8MV/113;YJPVL738;D?[O7G\ORX(\XP>'!+^'V%<)H0,M_?S'V@@OB
ME[-4(5)= &).SE[(UZ<-#6M[4;% P_8:HF2=[3B=E873U/QLPK8,C9')Q?X?
MD'W^#\CYG,'9A<5%8O,@'8K$O#W(.90?EE/^@H:5NZ81 A%>V3\G^*!'O3(+
M/O1N:*2-=+'HH@EN25-D@@W=%QJF'NA5M9CZ2\SIH3OQ^6)]_D@0C0AQ%G B
M'W65T-#*48Y80B),<DPS!Y;%S8Q3^SJ2SHT3S(\T&G#P1[5MUZ<ZBF>)S\&
M+Y[T^\D@X)U"XGL24,\1AW:H3VU,_[E:$#UQ-.9/XJ?^O5>*\;Q@)_FG[O43
MUR] *0I?OW[WJ(2QS;%B@>M<4-4;<4U-=>(')@:LJ8C?-$3$F/\."EE8V$J"
M4H/95Q996.91G28LE@3?\^KC0+W^U'71_Z[KS*VGNM G&+0_6R]?U2D, =AC
MCRE>WGGR$I?SIG95O"&O!BK<AV]Y%W!R>/SA6,C7[YS620^1PM!\2++J&?F:
M-Q93X=WM?7&4IDC4-2!A7U,UT_UM-MGYHVDE+#[$4^MF%5VR)D;$!7"1UX-'
M%;J'C-:4%M=_-I]R\(#/GT:3R+7; _^IW?EY&N]V%R/T7J:(,$S>+61QI.U8
MK5Q00>'>.RAC'76#"UJ(+^<H3B<T-! GG6-R<O*YH&_V*0DY^:R=%,W.RH:G
MSP+7=Z,Q3-TYF<! 3(<F]9<KS .QB3_$"(.Z^R'H?HB7?\#>=69S003HT'[$
M@7[UF:WK79PKL;#25;V4J?L3:A,3HN/L*Y"84<N(BT752GF%IA 6)X4'-ERX
M1W%C9*:M;?Q!'>,$:V2J%_64MIORR1EI27G?,%%1&/\3Z62)A67.T0^G%YMC
M3ERBW69:*1CO9!8</3[=XR8EX00<Y(*BQ_<^8):6H9XPMCY6!+K]ON"_71/'
M41Q,T'V*F;P5DY652O[V&A^3E3JY@]-N+]IN:/P=%-:%9>JA91M^<T$=YZB_
M_#!>F$V<!L"KYVU,30,:&I:5EO9S/1#]D\,N $("9 LOXZC*'7%2ZMKFHTEC
MV9LO&C-J!D6(L4YW,KJ22TC).&F>J8&662K8_]+7BW.3.6=)?'S!F<U3[<GK
M?\88LO73)YFH_>:^?FVZON $S3]CC/Z<FP$G."?L!;,B\R)?6GS,1_K9[LVZ
MP^:5_]N-4@!?^#0?)SF-%<D%M??\>7\[6P4/9/EI+"SPB"E0^G<0?%= A!D4
M-$>^4___@%G\W\ ,#+L2A/$)0LGQVC.4M+BX1^$\UYQ_FO_+' ]8L(,3E$HQ
MI0)W)]2B*KS"*1D,ZO+'KN!/[18?7\%B*TYZ>,DS%;38:1:'U0]>GMN?/_7S
M-?"[>POBEM:Z?F%FU=9*<9Z14=M9,SP7-9+6G]")]10WU+A[_G)1" *A7FVO
M<LF7O1_3[LWY!MT(QM8H<^1@L5CV\)W_[W:<2R#^IQWW(7[>LITA9!+'MEMD
M-?O1A)DY)H:IYRK[.^A_0/0+XY&N+J9SD*Z)H!O"4^;JE36GOG_? J_UH&5F
MU-\[\C#J /[IO-3DHDVWJ/HF7><#/U8?2ZS)OUH0Z6NY<)$+^HL^P[%/A@N6
M?5,3&1"DY/]1M(HK_UO1/D"VVE1N-IWPN4B=>INM7*U>^#F.H/Q=@G#2^>:E
MKQYY&M%O71R@SZ/V:C&/]_=A23RD=MLY/LH=4/BN1/D(X<KN0\Y$T/8C# E.
M&R.'[GETDF/!V-?)H<A(CI:688J^$XR,\GJEW=]?;!+KNJ6M1=^4@R<X.?UI
MP8TVFL7P&"WQ3ZX2 =XIFHI8T7EL(^4G'4-W1;SD=:KP*C0&Q:'#7BQJ/_K/
M .S>2JHWYJ%4\S\U_,K1)C'0ZH-NYG.7OG[GJ9INQ(*D>$<A^0V)O"=43@+V
MA[FY_QEC-NQ"V/)3XHZSZ1&_.2*0&G[T=+UI8A^OD2+RP0FLUUQ0S;_"X3D_
M]TG"@78&%T1WWX4-N/TF>L*3 A=U?QN>!7[LG..P")@>?. 0QFN0I/*@);0;
MFE#MGBZBV9$BV6),6:WDB"[:,"#Q7AIVG=L*IH%3#[]%%36HAT80VXO6_@,I
M?6C'R5_PZ5F\D,[["X&+3=3'TEL\5G)_L\Y^]C]TA+'WH(QW3QGV<$$"QZG&
MF&IIBUT[UF8*:4L[#D-1D(K+VH5XC4U  9Q1UZ F1V1P8Q\H=^]3A3-P."SM
MF4F*X4FG\(\$UU[UVG*=3BQ;,6[_#;5V+]@/?-310^S3D'\Y_4\7M978.@+L
M422&%0VLZN'SF#'48!Q/ 3K0UL0:='6@8?;0[Y,-0"@MIDMRZB#Y..>D^>H"
M<K1C+=_$A53:_W03)45]9E'?^50_&S4P96!4N5V'%$!45OIEUC<^ S"%W?OM
M4M10AM2;W1G71JB.L-F [[43OOV,9;0?HK:_?PW2W-YZ7*#VSQ\!I[M/:Y0>
M+F)9ET^%O\H$"T*$9+7><_IF@GL*>2H-AEAXFD(]I]G1!]J5M:D%, :?IDJ9
M6QVJV(_=\\!454B3I!0#,*-2J0Z:1Y;/+A 3#E+!XB=XE%=#GW^AWO+E=C7:
M&(FA3G;TF#V=,V2F$X/V$/&HO_<LP7-C*=X;R!8EU-_W&IA9\8$FRIQC!KQB
MRY384^TOI\".63D35Y7L%/M\+Y2JZ_HBP@Z%9^##-ILW#58@-^4$JL8F#RPR
MT[*TR,)7=V=F)C_UJS.O3&?.ZCX-']UXPY%U-JC()#,^&BJ4AE_8LM@U\ZD[
MM2SUNR.!*E)2&&.BHJ5Z<Y(CLGHE(EJ'H.?8T?8;6SN>@ 4-^F]5Z?.((^"I
M=H+2W?J)B@+S\]1R'?53\?]>3E\X@U(;DL8?47@CE!-R:=TY9],_8;M;O ,K
M)Y)&Y8*.R^U;[-";6M%=+;$E8$0(@?8'J(/'1-;PJR:?-XE5ND! AW\HZFIF
M7=Y&+Z5Y=/5YW2]6;:,C27:#\'B^M]3(_]'3$Y/J^1AEG*9Z57486\]U:Q6-
M0.X=@1VPS IPP;0%T.KM-PVN6%W&5SCD.(C#&#1D>,VR@I3]H]$0?FG.,<%K
M,WJ$.7F;YF3[>Y"'6G0.!(80S?7X\_K%+\$B8N3\A1F?3)CZ%*.6O34RB.PK
M?-\'C1<+<*-FV21Z7SYW5;!Q2J\FA9$(%49Y!V!/ +%[<XVL3\_V$*NNHU1P
MXLA-,N>82TAO+CW<QR[$S_^Z*ESXZL&4.V/"_C[QN'W,0Y<F60NN&UZ*6=9V
MGS[9(<5]BGPV9NM^#5IF)1 4;&;]DP/S?DT/*FT&+OCU738/:W+0R#0W8A5B
MA7[)D7P"F&#JI4<NVO:C4;T^F?L7E,8)?V>O>Y_7'>ZM*B@Z)2M@EEM@XOOV
MRI3^Q5M&0]70%\KY/@TQR:@P4&,34VLH7O!1OWPM_)B7__)'$DE^9*;;A](=
MN>(JE928=+_4XM(6.$Q:3760?1YXXTN=OKFQ9VP4XQRUW[WWY-C^LVHK9:)&
M0S8>J9>,DA_:YA]RR1)CM1#A^8]$JRNJQ>WX$[.+7-.)2^(@FD[=C/=H%LO;
M&F= 4UP4*SCS&3\5Z"BCB?TQ=E'M4PX^"B_MM+K=6'ZMT$W4&AR+VZO[8=8L
MMNU]S9)'03<MB_3^*=4X CE@(?JON#)/V*1?+_&L7YAS>3!<6>P"N99V(TR2
M)O6@^IL/6)DU40T*":L,U/E%S9P3O=Q5 0%[1 C8PSH@L6E[V8/MMM$^28&=
MBPV&,N,+XP^;&D)&A$U#J:=?>[DJ9-B(<4&F\=*>"C491^E+&W;BK"HH!\/+
M _X/$/8O _@FY@QY)6V."UJ;:MDB[@DU\3@_6'\!$5-_W,EY.B46*B*O+28G
M_U%<>#53-<"/Q*D5JY:E-^7)9UZA'U+0,WQQWMA<7<K4]W0RU59<X!%F_Z!!
M9_\7YF"*O+@X:6_MU>&/CS)9JU5+'SV7W1_'F+O)9D8R,8\]SXL]J9YPSUQY
MJD&[[]=,1UGLHM'?GF ^:GZ17DN ,Y*4$_6O8_!><R*,F)@JC>\?1JMJZ59S
M.QLNWEO_=*MW.#[*PRW7UP=U/HZ@LCSI/T]E3]*-U\DXOKA^)D P%.#7LCL>
M7W[DDM<>7#-%R[3^X0^U9N/SIF96Z=F);I*F2Q5 M3Y8Z.$V^N*E?\^:@U_T
M,3;/VY<-2N8.3@T79EV\'1V@DI86&"G_E_+9 ?_X"3NXQ=5Y4\KGNL^&>LR?
M;:2M]JQH_MH<[?H&.-CKN-<%AYFN2[47'( 7"YQQYHFKK]9J/=\U1)C?_.?+
M. 5X&B!:V]P 1#'%K ]%1SWP4YQ\[+A J;%XYA*P5G7:1=X&OUGXCV?VS-?8
MK&<R 5.=HH0R/]AZ%6:>@B4%*4/X# _N2WL>3(X]_>+;,4-YD*5>[M$=H0P9
M+,-_C7[QV%K:/!?TY>:DSLQ.:,<AY_R7RE0)27P-%V0%K'!!0ONY()9(&A?T
MNWP#JLX%Q>(H*G-/.XD_^>*@._+0LKZ4F'IQX=DVPY-LH^>S)&3QF#FBRKYP
M M=!JM#+M;--)%V/_46X]"'O8ON%"U\;T5F7)GXKSB0K.5D!4D\U'C7(Z3)G
M'OB:VXVA^\7P#^N&-2HI&T/6L&B>^^()\J_8Z<9;AZ;HM8MA/>Z?HUIZH>GI
M7-#+&(S7FWWGV2<!_I,2!XNQS'T?;G[E@P@/" GYA_&4&%4>2PKEQ"Y^P;#%
M4%>YH,4H\SUS6F6#ORQQ[@)Z@@MZ9\/BX$MX/W@6,&_,#VA>VY0[/;?%!;V/
MF&;S>BAD/+S^.:X^=>3Z'X\7GDEK&ZT)E>K/?34+/KK\V][\T$B2.JH/<_P2
M&<'4DT^J%0#>9<_^?'74PL%0UEFQPO8_3-&08#&RL5;3TO3 K]#W8@>,YZK4
M7IH<(247\?3W/>^@V'$-?</RAZ^NZVA[;#OP AN-\2+O*&#W<4$,!R8?%Y0O
M"F$*#]*O<$$W@N:A' '#DSP0VG"<XH#9M;[GS6L<9MH:3T4.E4UO.Q55OB52
MSP"F/D$>8K7$F<]9/H%KG ]D7\T_%,<#"1_S>Z8;F4#C_1K;KG6P^+73=1,_
M7]'!\6LGFZ+#+I#,8XL9;Y^3D!:O=48KE?)5,UH\A.K@7WXWSV3Q+)/>WSM%
MOW LF_&?G67JB]&3[046-P<R[;TR \\R!?,: IG(N.SMXM2CCN ?IS&M[9B:
MZ7#R2_(^)]D '.IOG8& 42H$!?FZ8\73OM>A-6M[(H//N2! #7C)!0T>R=K)
MZ+:M5]H_4;\[<*>VDLAR8:W^^=:JG%.XR,F%Q0%-M,^>2>S6PD(S<4( Y4B:
M6/:#!W/**U$'#*H=/C(7.P2P'XF1,I4#M8]60WFR./=XNXKK(9Z@AXF^Z9A3
MY_^19X8\&1;TH.1.PR@C>BD50_%#/9 \34%9%T5)ZG[A:^]XK@<RI37@%^S:
MX Q_<K<-4R.)U]UP7WB"AI02Y72[SB)PM*V?)BC=<<%K3:6R=41+T*G3D94C
MN&[L0)_8NI4]YW6M4RUSJ5\/8^LJP13"4LF"R+#.9Z:OEUV5AS:PPLO15*C2
M_/+.>%1+T4./F*"GUM(^K]G?MBYWSS0E7W35"(BD5DD%*[XVBQ)-9+TJLLK0
M+Q#E[TVS+CT\8:W(WTTZ.YVJG5B3%O\]9<Q_PIVR)=,M>C1;HN+6IT$WE8T
MK<]I^VQSSXMDJ-BX208<E76T9ETH^K=L,+-0_<Q9<Q(LL.4N(X6>P8!UPV4U
MB![$HZY EA5S HN@%I3"E:/7CK<]>U1*48??'<&CM#%4O@#!^MA:B1J#(.>A
MC:F3?-8,5EI(N<F%JXJO&W>JB.)$=^+QP2+T+%&,K2R[%E'%EJ>2XS"0D!2P
MJPFC@"*;TM&T)@D\\Y4:[/('"CH-Y8"84K;#Z*4]I:F*#5^!#HXAPS@/DE C
MJ&P\>LS%<  AV!U.=7^MHD,P]+6M4+%$JH$GSIRQ8=VQ#I%1/,M9P-=^CUB\
MBS#/.UMOJR(('0JP632N$A(.N(./904%QESY\:/QSA:EY]_97)Z1"IWU<T0/
M3:[[<D%\ IB>IX H%_0P=9<+LI;U)E9D<X(Q\Y\QG\#=:\ER:H !TV1^K7U0
M&&4V@H)2?,U;\^5'4+(XY]5\A1$$W!%K-[J6<^U#<KC5;XN6^!VDXWK7!%65
MOR*'3O?+NCRHO,0Y[,;01<1)&BN<Z[KOK_/T7G6N7H>;ZDC[;9OR'P,GO'J;
MGZ67M-EX\%^3&ZG4Z?4RR3.[8\5![]C]D*P*F<\2N;>.JI?-IIU=(%Q,S 2K
MMSTX_ZT^JLU#!5DVU$8Y0SVO=3\&9RNJ4J;S;#3J\HJ>GW!.S'HYW ;=F0\!
MPBO00QR1"8[J:HL$S^"T8Z(;,;$MJLBJQ<YVNI06V_# B(:6K_BU'+-$@\58
MH09JP'NOD25'W^:Y@I*I_N#,B6IZ2#F9P<OQNOH]*7SW&OL21X<+^B$KO_>"
MZ&N=R.G%0BS_4H#R$_S]3:Y=?,<P>: KNM?S>E$&FM+'_"P18&OZ,O.B@)/
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MJ%1<2F<C+E[C^V3EI5FHL=BY_O GX<9P0%F\B_86Y3JLZ<N1! K:N"!!]$D
M9KR79BCEX\@I%X\F>.R>6R9*\]'Y:-B71%%-R[02I>?Z(>6SRSQ742B\[#B7
MGB\!^,P/EY)<O;2UG]PN6XE<-LNS5+>V*3*U3;IYK]SF;NZY;_;61;$Q-7>7
M^J:&2M4N>=]Y=UWPK_$.8YU<@^!XO\)'13(Y&:VFK5TV%#XME5KWLZ-9JNF3
M6C?+JBZ66E7DGM4VJ[SXLPGS+92BW0&9\IE?^[D-[;BR)LW68&C'UPZ*@466
M1KPN8.6\\N7K@3?%*XXWQX)S<A)4KSQ*H!H6G=#+S[KT^_KEC,>M#ODA,H-Q
MO/[$.05D\#+N"/(B#4;7I&(3&J'/-^/<&>@L*B**%X4* M2=4@38T%*BSGD^
MFTAZ_\T><LQ;NS$TJ6B<8$*5O;8'MR&./#Y^:Q0%%7^#O;,7:W@(29['17,T
MR<CNMGP!P)JO$Y\H5=^!/\KF WS+DT*_8 \'F^,% 8_VRK>>.X52FC'!/9N\
M0UTA+<SZ.+>A8(,K?[]T9AX:<WQLM4^K@^PW.4@->HP&BSOFBY_?Z=1#EGW.
MMD]QCTK/5#@N,=8Q5F1U"2=Q-\.L]HQM:62IE%9STK+Y-SW;C=)[C,V2T3QG
MS4_II=?22W]/Q <O:TO=SG6F_C@D85PH[ZCAO[@U6;.H+\#R!*2X(!X1^"I0
M?)"_.S#"M)$0B[#;M1.$FR5IWT@^CI5=1;Z468W+^3L[!@?^C@\9W0B>T H/
MM1?[>'9,*V?9<G.+= 8OUNS].7L\0+1HT+'6U*;<T+X[.R@TO>&^Q%675<\N
MU5YZ_:RE2-%?UA$_(D\52,PV&:OTN%I:3(7Z;M,?$%^F3+EU$04YLN@95TTF
MKC.6(!LR/WO 8N\M0ND#<TS/MSMFT^4^ZB+UZMMEI6E;4[5?6A;FUN<</8<>
M^\2%2)YT@I/3%7:[\93CK*@_2A ]-2<)##,A%M5[6$-E8-0"([::M0.+8PO.
MSV(Z6Z0G-LKWS%96+<<>A[B 8<UUUD'>S#[UI/;V$ON;77,L$O\_I9RX'>A$
MS\H(;2;G<C^CP8SG<*H%+8M0:''-2CUST<1D%:3C9X+MD9QR8RVOV6N-Y8<<
M[B8^;BA@VVVTM0>H'^&(,#6%& O0V*)V9Z-\-]4[;>XZ;)J@^7%](2?K?4?;
MP5GNVWGV0QV641[B=OPJHN[1P1Y7>D:QXY :<!3F 83'?PQL&S0&*F(HW%?*
MEF<@.O:T*8OQ%2BOM\ASR+Z.5(!&$:K+QB=NKM9%J)MJZ&M2(3S)(5,WB:<Y
M13,VAKPTM68+GP0RY^1'B0_HXKRR/F8(0;JN4B")"HRJN%W+:93,A!8^5NR5
M-],"P8RA!,\=&:,R;X4^"W:<J\?,GV:ZXN:7-]/4LBOKLI[B/%DC>==6)GC<
M1'F!\;7$,GHQD(!N"*.4$#"-8W_9?5+ D1!GC7%!!=; [C3'2SOY"D\YO88\
MS@WWV1$ IS^4>';"?["CR#'IZ(V/KY)<Y2D_SCY8H8HIBSB&G/486Y@X55!1
M=B>QP-3D>%SD@]*Q)!5,M_V< I7]2/5X4LJ+08'8SGN4+,N[.MJ)[G^YCYU#
M'(AH&RF(HZALI'\(+HC.D+FU/(97>2TCZIB:X7T1[[0&2X <XH(>JJNOM6AH
MQP;KT@G6-'P\^C3#KL.)&)]]MY3:QP4=0 4QL-%LZ8(EN)!:\+2@0 ='F,D7
MA6,>S%=CBKVY+YK\3QW$+]-"W4UX1<YD]RX@S5*M'?%K.<56!EZ\]YDS9/)U
M^5A84:>-F;99 07-=7BF0-<Q9/MUQ$&GF7/#!%&*[_[!]BPY*:9H<<Y]]Q*2
MBZHZYZ/0^U?+9+T9=#N\WNA'9D[Q+.=?<HW[1%Z!XM@S0VP0H[O[MX/7>?(@
MJ_S[J._#X6SI$\V-7)!ID]/#)#_EO8UWA=ME*>QSVO02/70O%F(BP06E6M"2
M\['K!Y:_4&N_W O,5726]9Y3LL*KR2R"'WY^&4.[?CS"0D7GU@V/7$OG>.$B
MO8\%/Y=VW:%NEGF&UX^2M:AJ[> W]S]P#MNVM9\O,L--*+:RW?5=!2YZ6W4\
MDC =I33>7@Q1F2B*R528?B F.;K3[SW^Y\7'ZRU:G%'(I]!$M#P[B%&$B];7
MILF*MZ*%]@H]&(,)FTW0J+F_AE%V<O4^%%GH%XR X7$?Z-&:<H/KUHS-VH6<
M4A^T[.1F3CE6ZBM"\]V'_&^$U,E_7%#[]UZX,;"=LPZ&*IX77!U\2L,9*P*:
M27K(\9\U)0BT6#\TLO!C\PNLO7GSQ0Y#J#GDV-7WR/Q; .;?EJ91S8WNT1!H
M.I3R@NCKRL>^@.N>$?J;"XKBA0A<P@7%04Y@V@^@26_X.)+6M%\FUWD,D-,M
M"8$!K\8H@<E2?4MWVG^@3ZD=T@OXHM(R&/=):E"888;5+R[WN!"E')_KW5OA
M:8W[JUO$*C[)S,O,+H6JH3,08)_[*&R^O;]L(M]7#5HW[Z?97G$B2-O!&F=I
M[R<5Y7S#_P3NFH37@U6;4KW79CIQEE$^;1 _9_0@F6'12B.?:".*7?K*OIQ_
MA/&#DT79 )H?IGI:#U8A6[H[LWN1N%WKN\,AY&/+),L\BLOU&XPJ+%7S&!?D
MV5[65^*,#"0Y?:30-2GXH\AZRBZGFPN28@N&%+ -/S#'B9TID3N#483K!I^4
M.R'B2X'$I'>3)Y-7?JUXV?V9H%F<G%DFR59FU-A)13BO5(;J9PZ*I@#WX-/6
MG"08;<V9"^I18G;#X=O[-G'_&2<U8R@9:.C#8.B?RN]ZQ@7]*]0L(ZJ? +:X
M+DD5E9F<HGY"N4BZ?4Z(63,NOF-5:6YT>\#K;+=4V?J#YOK:A40W[2.U=U6L
MF4%F!*>D<I6&T)?(?(B-O[YI%O5^AC]<PNGX]=B2^TOU=ZB A_#RH"HRQ$YS
MYU/[KNY ,,T:')-AIL5Y"4"8F#;7<X D S'?W066!J3-&,D?=\V^ 0)4-7 A
M6Y=!3'P,]0A#'%ZVZ_T-].B?T[]3X/D1R-=M0S;4'BC)H6G5[*0/BT4TI41B
MP5S0 T1\MEV;&U.Y"WV"81)3LZ=--5MI 34 1(_WWFC1!'M@32BI<'9ZM;',
MZUDFSC!O_J)F0E$M4SOVE\::N@=G=#@XR;'KP'O-KQZLPWNU,/B4-6WY:^M@
M&T(F>(,+^@=B!OXS+)0C?L)UCVX"%K277-!GO<7.>TCOPH]I7P+F!)3S-47C
MN^ :@\@GN9Z3G8TM$T4ZYKK^(4]55/SQI\O:A._$J'DX:EWQE\3+#.$RK?H)
M2O\"J?E.S[^X]WCHG^W*\(AK<Y_KI"S9EL.B;8QB%M^OW&WK)!B89<BLG!W(
ME LV'/H 8';!J+\9N.A+@W+L:XQ'K_!(398/H^M%H0\)WB%XO'WB"5KMPT3+
M>5A8.+7RHGE8.*S#5?$5G2VV92=V&:TY=BCC1U0.<(U*MJX?WUCK=A\8;CJ8
M&/'W29ECVB#_OQ\_W+\/-/\<B:_"_*D\V(X6+*4YB LZG=,M&X[YSC>1Q9&
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M!Q>6=51D%"W4NQ5+S*G>_.E>'P\MT1\$Y,%[O.[LA=UE$]G5!?_RS*LPK[M
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M+HH5AVC'G2^)K?]U2B/"U.Q=")\_^]E>6BUXZC<-0H<7HH?@/&KQTGPN-5=
M@QY%3G8U(MK ^[3CWP%-F&+VU9&-<*-*CK+#"L_A$>Y3OM5J'G:D;,8&@T&>
M@8ZKT9YN69;53@E.*<][K),/0$M50IHS;C6MK#3K:96UB:9S/DII*9HEV5AJ
MW3^DK/*IP$(E(*?T5R!^R3D()I)E9";#[-B%>9QM.^;_@^478%W*I\QO6OBV
MS'PNX,Y6%<]LJOZ^PCFBS04=$N<IYGMTOE8Q%OHP)M85"L22.G:$DD+*S-\M
M.:+3WK9@Q8I*5TCI8GI1':E:73B?0]%YO@<100FEA4WUYO>J.:\GUWE'\(EP
M05^9NQ>XH&^E3)Z8M>1(XXL863&?JL[09G*4!DK,13,G<&\>G)?P'"\ULD.J
M-;8H9>AEG.D5M3EKDRA[<S1/U_+\]\7X]!QVUO+Q+@<N:!_2I&/&O%WB\[V+
M!*W':7PON\W!UT753OW[.U>#3\0U0^:6"N6'J\[3L;N*CAGVUGDPKY^X,U?5
ML$#L2VH5]/LT&N+!Z<:(T*"PG_A1:!*$*<+7"=^Y3(XA TY "A>48<->L:M$
M'09@Y:@08)31/L^*6ZS\L[11TI,C&Y;@V5$O)N7;^27+<?Q4;&'\6K$G@PP_
MU7CI,>/4U\OG\3]S[5YR1.\QON4^4H[Z<.G#MUL&*-M3%1^?XM7U)+RU?"9*
M>(H>YFE58&4[.Z58\8KC,8].A=Q4ZY.-Z/,W//GH6Z+?_<2V^7-(I/N,P2!<
M/*GC=MO]DFZ.,%HE@WGB;<YPD"[TR87Z7RGL&U>93IRD>LH:1XQSFHU9$.6"
M5K8*.*=._MF8:#S-V.6"!#"\\*^7M6CQ'-D#S-3N%Z@X1Q,0[PXEUJ0A[=JY
MH.KF1?IU!LZFKIX!B]2WJ$3ICZ"NB++**41I3_091G/?-V2;IG Q[MV;G_>J
M1^F6V72MW.B[_ZS!N:#6R^Q]88QI(Z"? H8@R;<90J4,\3:BB%:>'IU]/H"*
M![&-F-A$?04$!7,$J/Z9??>R!67M&'"\8Y)4'%-*FC92G&NF]-M^<W[M=KF<
MN1:M+Q#1;H83Z,U0>^B/%X@M-=>[JSHH&6U?=D+>5G+VX<=CQ65M=\N,L1H*
MX-AVE;1*R_.5.WHT?%'DW.4\.8-D!9$L<\@F6_:HB8"Y9&1!IIOK ?&$\IC2
MMM=>^C*J>J)NKHGE0?>8KV_Y%)@+.H:<(]IB.FY 1#%+O(S 4!!4*,?F&2:E
M5OF_QQ6?R^'U[E8-MCACLAU>*Q['-J -QLHIUP$8ODAIEO\')QBXOP1EV9#C
M/$PXRY2;[& Z>L6NFU/@XMX,I'>O^GY9/?,DX[ 0;,#1E!]0?IZX?(TYKN_
M\('_60A:#I%C:S'S)CO T?G'&-J1FFSYIS*WD3X=V&,U6!!RNANMG?EK,"0I
M,YJ4T=&H\>K0> 9]D&7#*4<SEZC\RF<8Y.<V#,USR18O<#$[$P)\HJY5 ==%
MK%JT!4S$#YD+6&O;Q__3/E)1D%Q^)! 746E9)U>3Y^TMZJJ:A,[ZYCS\<)V*
M(M5=7)',=]>]?\9_0)7/G#^#QG0(<9CL'J'4OWQG+1G;UOO4YDCM.Z=+;1/M
M;N=J)J2JRZ__@OZI*OR>-*)]C:W.-N&">LN@U%/@>.*&+Q%,9-0S(5R02OD/
M)TU >>V+].XLM)/)-@;ZQ-M@(MYS<D# 6U)=SOQ3P]/3*(O)%@,?\GXA7,6A
MJ$O\^H<\0M]IQXL)F'N&])4@#C_7H#;5^EY#]((E +_%UOQSS-"7"(U[! (C
M)AYUE>)3WO=X+_L7K7VG=BY-:[S%])1T3(U7P<%4D2^G:<J3/01]!L*PW#49
MWE8SZZRE8U-YU(0U)]J>75"@AR'T/RIR CNE9BKE.K&LRXW.3B3.++/)QX"^
MC=<4/8E;E@%40>10MUWY=0&[0YQRMP*[J:%DE3R?.Q128+*T9#0K@V&#$]V,
M1Z+,@S^,%)9.<"(P?T+0 &$F$<$?7V&!2K9)7H,DB*>]<X]=?!G!YX*3@#9A
M/J30LRB#TYCY-T!I >"]VDKJ2J!>&3P,=+<?G\-X32^C3WT<K>FWS].TW55/
M\.:QZYL*KZTGOTW=??0OF&OE#E=//_V-P?9C7+@@!B*+G5W?R07MZLA:<T$V
MQ/8R "&%NC"?+SW_;'O"*-6Z[Z+,9:^,VTG>$A7!-*OD"\W/1)=MB^(Z'W@-
M:)R+G!^)I%AI6P6DO^6"['?.(9>I6&ED>10E69U:-L6R2/ZJ$R-J+9CXQ?TN
MSD0T\_XY)$$=98 2@K^HM/0.4;$NES2K5*GQZ%,)2+]_![W!:_L3@Z-8GG(V
MZ+5<7(+FV*WOX_R38'3B-E\O49;XF!@!K<Z*KR'RHRR;F+6U]+7(*GU,N3=:
M$@BAP:20F%;7 ]63OOI:3VEPN557L>%:)^A?R >C]LT1$XMV$U)S)!E"<IO.
M;$SE-,H7T'JJ'BE&%#.4GK$H UX0E(N-P$D$[=/9*?%6ES+8V@\32L4:)PM,
M%2YX"<<0C3-/AX4\=;-E0A,@'^&MF&2L'$&!V4==>'F?1IO'Q%P$Q-OG#C,%
M8TCL_\77FX:SM;[QO_;N;A551=&:TDG-U#S+KA9%2<VS[%8-H:BB@I!=\YS6
MV)I2-400:4M,-908=BE*D(HQ4=1424VK1)ST=Z[_FW/.=5[D3:ZLE?7<X^>;
M]:S<&@%(K8S0K8O2J8%O7)MI$TIO\JW2K%C]$[5;.RG_>.H_5Z_^X]>A&YN:
M/.&"#B2$5J4KPGABY^4C C2-C_8)IR]!=0YD6E"WTL 2.YVHUMS*W.#@,UEP
MO=Y6<'*H@?S?)$14A5B&$_"$LRF/O&F]2A8-;[="\=F7QF?<]0#SIMK9]MG9
M>4+YY,;@B51S8?LK6+G0*Y1 (0G_ZT5>-I*(E5<F%3ZBVI$-+912R7"K-[%[
M_@5//J2M/*D::U*WUVL@I7OM.=0?WHT9H9S"4F=%[  BG65@V^NA@TPLD"IN
M2MXY,C%CADEFU,!C(;SNC86*,Y'VS$B3I.HY\%[]UX^QHZ6PA)[GO5(.1]A.
M'Q4\$$Z49=10/Q_@4YDZB\HBOJ"'#,/"\,IY>!!UYR"L*7TWI(XRI)3D'T!=
MW?4_O=6[7!9T8WN*EGIG\X<'*'6G$[@NF?]ZL&:(BL\HV$K(@J:&@P69TN4
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M1?G,TC*1+^&1H<<E7'MBI\<!/Q,YAF&*+1Z:]+TO1XH;GNW)/WVE^4Y=6Y2
MV^T+-U*I5^FQM8Q38O$AG']'\!2PEH81-O1]E8\6O,\8(HH#[Y0Z!!K8DK7
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M8-X,QZ_J6KVC'7. */#,?@>&:5S;"<Y$IDD^ZRSR+_\FT<8R@T+<_%X2)<Q
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M[TLF+12-%%U-Z>2D#67%H,T?B@]1)J1O/V]/KEYB53'QP&7.WZ/'.IFG)Y#
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MI=.A?0Y(.!<0V>+8TB<M<]__\MV-3P$5;"#[>*E]>72YE2N_,RWAOGL^K8_
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M?RJ]^-/ >)]MG;VS+/\W.3V32K_"_0.J;6>KTT2&V!\/3S]]#O^2'$F;?BT
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MV>8RBV AJ1:XU&I_<3!GF_P4.X"_4+Q:?/"?MW=G$U5OD,]WV]M[V)U_\/V
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MQ@"O]NY8 .DA[X#@:?'.IC#^$0V'']<Y__;SY8"V.^A]*_6>!<NR2?$L>_)
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M_KV?@?_)S_^?!C.$'G _Y$?T(Q^H0VM"V4(X16"[HGJ9S.9+8IZP8D+8@^+
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M8O"&KNUAK9%=-UU=/FTHL!PAJD]SD/BS]&YD"D%=PLH^1U:06M84:,TW-D&
M-T98;@B!L8:[AQP(E[ \ <! ;23;DXN^<4%$-/F %\O/95;/RSB0;>A/;4_:
M!Q:XC1_!#5 0U7:<>[LVGPWMXT*P$P>27_B!V\.*SBT]V86X5G8SR!63)E A
M@#X<SX%\[0>H=X/@^PPN/1'  .PPZ$.@4Y_<L,E5A:S_LL+E+=E,'%=T<B ?
MB2R]#"X!NK1#YW:!I[-/<!MFEH$<2$SF IH#,;2 4UA$N@-P8."*9VF1CP+[
MTS;_W2J7GGTEL144KW 7)\*E5)-<GK;T<H_G/TT,F2P@V>>LN#-_?0"GGMN<
MV6,_A?["[4?U);)Z)KE4A\Y&@BK$0VGU'K8D^@F1M:'$@<1N<7FE P>RO!(
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M],*F]S2 FGE^)9$#Z2H#+S3N, D"L0%PCU9A&B#-U32R4*&VVS#543;N-+S
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M<&(;3;1HEH"3-O3=9K&ZHO--$[^]?=%'.OCF]+'Z).[+8^ =SP:I$*22:&_
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M)H3P^Q$$K_J?/,B<4J2< *%=O8_:1!@0VCF?2=;)Y"=L_,=/BD>/RF7=RT"
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ML#\'K>CL/B]IB-L(T-H4DD++H/IUZH/G8"/3[C#Z+*I:K%R0RW__1#XEG.1
M_/!3NJ1Y#>CID,UH#N14BR:#277JA,;")=2,X%R..%!>P!)@(%X8*7I2JG]%
M007E:Q.ZYV49ZS#I4:S#PB!?Q>Y[S(N(YDA!R^=J]_T2\#USFB28\;"VL:[+
M2(L^5<K8SFQ,K<[]\D:PU-])1?G%".G^U']BO@WXH1*%25+[3A?[T4I(#9^"
MI+^EAM@J8 ]MKWO#Z<8$3@GH0%#]B$(KZ#PP?,Y(U3_7APT=*1JKUBXO5Q?Z
MG;[[LM"GZ:93TT!N9#DY4XK78\^V.>?[XM?49SQJ-3K^-AR(LY>1^DT-C224
MN4VT;XCJG;D35]Z4UI+?)SO<4;Y[7D5#O&AU+.MUFN:OZ?#=!YZ.VB4#?$&]
M9Q)55)*3S RKPS2NIRH4%8REW'T%M\,ILKN(?"QAYF-6,.@?FHL1%(IJ4SM,
MA2E@74##.V_\G";3<*=:W 5'S>C?JQ\WE:'*\[!_C(;TJ9MUNE3_R];*!$%_
M7%F"Y]^??+GR=>(!X6WH^LQ",S[1(":9(=65<Y%.>-JBS70&#5WQ5)EL^C;[
MC#+V*M,0^P=X)5=(C 5K'=JL#.9 !#Y1YX[V3"=FR!263F.>;EYO'D4KQ),=
MWS>^5(>?(U*.,QZ>Y4"B$)UGU9SQZ_XF:49I\&76?[SA6#$#SGT<"F68<U/F
M*%MNDG5L8)@#D3E\'^APKOA<KH5F7'G$ZP<R,M5JRO(>SO84E2V[SO$4E<FB
MTFT+43L'3Y61$"^;;F7:P^]VZ;O^QKZ3Y?R]_NV.>ZE:XTK*U[)F,ZP%Z;X9
M7VV:#]?'@(77Y%^P88Q'FY3NZ#*01(DE;0C10C>$"U1=\;Q^4%$XY1C]12']
MB@G=X]UA8ZGV7$]BBU0P\;1FBUWAISL+:\QF38$9=]\KY'H"K+!J!88N97\D
M0H+QQXJ>%X)I2Z;CR1_)9[':-"")>$IN2)M\%.A +2!GO#O(1S9V.! AEVGW
M%>^/TU6I"Y8TZEJ?\X[TG<%H#1*"O_#']!@R : _!1O8T?!3P=-"N[#<O]Z(
M3@N]_*O9W.UHXIE++Y2X+A3O^M##NH#[K2=WN+KW<"Y;H VVV3?ZG3&2)P'S
MEC'54*A4LDLR-)FR"2T5:5P=2WFGX5"HD[*O\FGTV\2MQQ8.:H]/;VNGVMDF
MIRX.&E_8[.,MM!BRL2IO#W(UU2"_;8IE";ON1M#GR'&:+"\&FN;QI'"9 5[H
MQT%G9U@*]6"#?R@-.OV*O/MHU.AVA=;33=(MC%!7D_97N!A6<+<>7^8&/N(O
MC^C++%=6VYGB0!39E\%?H-'0LS@UK%K]A%/G8Z( 3AY#^ZC3=N%&WI.0-30O
MF&X[Y+_S\M<SLU>%=K-T^#!W8\)R$S_;*M_[O2JL^B=1R>) ?C*5 P[$TU>"
MV0P9G-K^%U%).OW)DRX]C&(W!&*D2CT%@1S)7ST+><C#BMBM1AR)Z:+X6F-:
MOMV.\K:^F*3R%VDD2;_;!C<B*&SGSX6)I4=!WVQ3LV1Q-TU]M3W/#K>K&=H^
M"DHL,^]5U^X==2M%IEFFRDMI515L?!YVA[/.PRYQ(+E.G7!0<0R^+X,'KV$]
M.9!KU7$ '5$";!F'MXT06*QB#N29,@>R17HUPKX-+%SF0+Y:WXU?X4 H? S\
MX8FV\QQ(.RR7 _GG!] A3(,>B&)-N%@5R?WQ<GDWA0-96H2S)+@"..U8(>L]
M!_+1B]LUJRN<)X:X2* XD^E18 \[&GGJYTD9M[ACAV^R=!>(XGA-V-G)'NLF
M*SK[X8ET/;_-T1DVSNX[<862A.F;(CYVY4#46HA-X0VQP'@QL_Q0=9ZE/PPC
MC+002&U"#.>D(_3Y^HOY^J.:QR^]:(QS:@$C.F!*)_ZF[[Z%;;K#OH;*O!MK
M[-@DQR(;$/OP-<K6A^6^^3WOR77N1/\R]B,1M@8/:1S(^\E6,.B[XB0'<K]:
MEKX9;62AXWUM_#B?HH[="[T=A.]>M2"([+0H$4PJ>6'FBN)QI&7=S<\1P[$,
M(C^$<2!8D/5 L;K1>'%7D;MHF68*N9E;,.[AHHG=K7ND.=F#ZBUMVKPT?:)%
MS&A%-W^QY^+;)<6J\!!IOWFL,67C0=CMT8#8JEN"KW=DBU!!I'T*!_*$Q/4D
M5/I%L6'?7H@!!]+7E$T^-#1.)D5>X$:2:748?=.9 QED2#+(@CX&'7'/G&\6
MZW]]PU[^SFYQ:@8C_A@_@M<)@%6?8LMR(%8JD85:,R'*A?[[E+G_F&Z(05KZ
M]]4'',CBN,<@.UO:"HU"AL$'?<L/$TJYP^8#Y'\ <#'80".ZK%_K8L_]3;D7
M[_)4KW\?Z%0IRS.\L?[Y6MF%*\VG2BH^'_G61552$0ZHDWOEWV K9JXP@\[\
M@_MKWKOV].$*QD6+I/M?J:_L_71F4FS-5=3K9\SE,OT+DOT55]L@$W65PB[O
MFH;E_@Z(BL_3>Q*HTES@+]QYE,_VSP[%J-+M3W_\KGC* (=?<1)O</%/&LB_
MK\5<V<A[]?T?"P6QT::C<M=^A_@7S\A^K[^AT.)$$>IP;I%'':^KNO9^;?LW
MC#_9LRHEL=55PI'H)6>H:O0X_N;%*S>\/V3.^^TC\5<^-^M]SC]Y3-+.V3K<
M[K-GP3N-#8/@Z?<Y,EE5%%L+ZZ#F@G%-*A"),>GX>U+@:U!E)E5U*"RC,*[P
ME=7\6='>C$ZGQ&H5Y_4_SCFXB,S*6J>@>DZ5W4W>/29B@^3%-?T\%^B_7R9!
M06AO=&!8J)%.?=K;OJ"0H$ 5$S0:_8M6#<)HY'*/R,7N2KGW__2^S*NY<NS7
MR:_P]4W_4@_<5#U2^#R8M&"%;"=+8XT9:"J"Y!_0USWBZTV#DQ2;Z)]Q4@UT
MQ8ZUZI@F$4#H>YN$:<D7;L&Y34U 2JU.QR;]-@;4WI2L2ZN)#,EC-ZPV>1"J
M4.%IS\M=3(%"/S'Q#(]B3ST%_CGXK897([LC?Q8Z=P7Z:_WUS]%?;/[Y5<:/
M5OV4 WF'B,6=QO1]S%$>@ZECG<#\8NQ9>D[= OQ?L#.,PZ5HN6&<$,:D4\S%
M.K44=> P&&ND_L8/ISKF='7HQZ  ZF OJ<XXPOXM_<=E9],KED&!(8HU:=2W
M7QXH>$O6>9WXDJ7UEEZ\ SPHZ[!?5%()T4A5>=FE8IU?[@LX+F7#'MQ4_H/2
M95ON6'^ZX\2M0@?[E-9BV:B45\DIH5GNBAH.0A'34Q9CA3J1I1XVC'1'4"H?
MHV-9/2UL!]H48HW90[5G9K%>K?1H_#.@SNFSWQ&Y>=TT=6'F[W<]?23:1BZ=
MCP7+Q]? K)__UL2RHO+!C'"?84+^'AP(^W2"9E2;'$.Z/D;COKN.<:@=(WH^
M,Z)<ZG<J3UL&R>)M#=/RNM>+>2$57?M7MPYGH7]Q(!6-;"'E@[F;)\I/6H7=
M+37)J=.C^!CTV^)K"UH+,A,]E>T3/</,YS\97:GH86IJ5";N7NK4LTC5MGBT
M&)7MFY60O=6_5>EJH=YZ9G7R![?4\JNR^;BEVV2/)<P5@B>JI\HYD.1E#B0Z
ME0/Y]36WIC/9?%R8BG9:'^= /NVP_\PD,_M_?HV=D1_!@801-_/9VDQOUM55
M^ _')2*HD<Z!&/T\=<;=FUO^'Q YD%^X=ZY 5_;^]TW=<VJ38.AD+AQJ4@5S
M\WT?>QR;8%TMQ]C=8(2,79?FL67H1'L7KQH,/$/AUB^DVXVJ:?M?WMH:P]+;
M =^E"S9N-;XZ<5TR[*ESQ^0E5^7_E H8L?]'4"K<GY;=E_A=PH8."!E^"'P<
M)B]A(= M<B]E823+]86GJH5 H5*SA7JAO-B(/Z/RQO2^SA%WA:IO50758M4Q
M3E:^&<.5=MX'SX".WI^GJ@%#A]S)KW/3H7S7EPLY!W"*%]"N %_&<9\^!B@.
M3&U@*Q+X6R@:JTM%GEMU>8%?F).U8< J\Y<--N.U_0U-$?7N*VU2].Y,6 U5
M_=&NR,.)@X#G!=.SJ_^CLN^*:FKMNH['AJ BO0GQJ/0209 6R!$$! Y$0A,0
M<A21)B ]0"32I2M5:3D0('24*C72%42D2Q!"$JE2$H&X@9#\^(W_\AW?^-Z+
M?;.O]GK67'/-.<9^UM)*_I2+F!\[(^63:?88K0($TD]3X8D!F&/,J[2L#KI8
M?\&E2-:/6[21Z(V4\DJ/K%;'Z/V:$G_7/VY72G;$OO;TQP2KOWK;XWFBKNVD
MO@6,XTW&I+$5]>(2#^XDH@&_BY*S^N8BJ55CEV&MH=&/L"PC"PD/FI@9-%#[
M XLIN+1_BI>^_8/;N+I\=<PW\J[-XE6BF8%QZ5@C$7ZH3/A/48)I=82%=/ .
M#-.E#:-5'.80]G0)PWP4G^[:!/#)=FM(!$L)Q=>'/ ]%GDLN*)T7/_)ENIEE
MG:_+Y!M32KS3EN2'==>-+C5W-&2%N4O(.MNA/Q0;;!]N'2ZQ09VIP#B>?%ZP
MZ@HB6]C5VOVSW)URL_MKEGE.8]'DU^9\B:LR@\8[83.F26O=YM<_7KN6X8!(
MZBAV$6Q&)+UYF^99X:YVQ%GP+KHTZ\RUV\<'2#3S,6/0,0IVIBP-#@)!?AKK
MG'PZLS"$/34/6/[5 H3XDA,)QX=+'<!<WU JCG(83E/<B5FW@#,!-Y[^N?,^
ML>GKZB<OO;,&[_LP+SI_L;8Q)".FY^]_L*+^0<,IXOX,4:"ZV%.TO[#<O8#W
ML+C=N!AXU/]SR7AC1T?E@+S<DQRTV6.6HF=07=)?7^%A7_S&Z#EQG[5)=4L+
M$>DT2H%JIIY_Z',#CWTDDH!+[/Y2 !8WE[O19U(BB<@@)]0.:9APO38Y<P35
MJV/PF0\:KY=0NU%9R+CN[=%*"^M"Z;!1B]PDRLIX^\/B]8F:XD8S'5AQCDP1
M05SWJTQ1 NA_>^27Q8,9?8<OVR&53BNZ4H='K=H5?/Y'SN,MK[(5XE8_&Q1K
M;UA]WU^,/VW^E_D$%.X3X@E]S-ENV7/Q^?O8.S<%:"2FD#15.C6< ]-UHU,3
ME4ON;WE*KN5%12YW8;A)3F.;-0J!CMKZ]-J$@ VQ7J._.QO3Q'*UV^8$'>:N
M.=Z\;'96O1ZJE!8=R 9ID6(PIUF*Z$#ZK<ZS@/8"6 !M2@^P=YQO\_T7A?BP
MII6GI9/TPNAIQ8B8*:>!LY?B9+O_-^/+%<90$V,E^=WSG+1?W+U[-A"-@67>
MH6NOT%:T-XR )]O!./-,D\G*R;XIG&'RU1_CT0*;)-42F9J[0]^WYZ^69SY8
M67@#2"96(S(\AG("K] '?:-ENY.D-8</-(U7'U:E>6]@RD\SU:77+=D@HZ@#
M13:(\A=3B@U::DH%O.%?\:S4T[^',?5&_-X5.>R%R1I(9?&AK0'$Y2-RRU_@
M%D+#K@/XWG"."*AC\9Q;FAF5FT._]!L*U^-K$'HER\Q6KWDJ(#%9;^["7M!^
M?M+*F+ZO&%:%-=K \=FGNOMJIRF!6/0U'3,BY078H6!M5]4;GW; 3JKDO+&6
M]972K9*D?<[B5BP_8S_=L$J1%FHEP@/GD%W9XLZ7OKEFDLF2[:Y( 1'(W<$\
M^YG-EZP:+.T;]BW\4()[O9D-BC].RV6#<H@P<@OL 78?"I[Q88-X3Y/5V2"U
M1I8%9?/*E5ZE.T.B<6E_JKSF$=NL[Q=NK7SH=17DIYRS2Q!EG@-F:21;FDT$
M_3C9J!=YZ@>!5W5.W19X6O1[(%DGM@(8-Y]2^K-A;!.J?E^RI672B;%&(<[+
MF[H1=UU;FA(<W.8I B_A78^+\@HY\TQ3HM=D6Y\4\"E$EY8/%."B7>.32LM[
M2&54$1G]^=SHI^0:K7YC$XO!%1-E7T2&YX/BHJ6]!\634ND9'5]+Q]/'9#NX
M=P6.$/O], &S0L.X$)BWP=$DYM3H;T-^P,\&C2ZPAC# "]@9PEYU[?:UEL-$
M@N</&/_ 0BYAIHTJWISX2$+<354LE0/9$^;7J=@^T4 ZIU;^HKIQ[(=H5G+E
MZM2P%[0B)S8;X^SW3VMCEN37QL,H-LC+X?>*0R>>MX>O=2'S +8GYU%RU0^B
M>&W<&(4-,AYC&BB5G(\(";EH6_4\YQ-1MU(PE[?MGJ,Q?D[A23I/C2U9^IQD
M<#_"N(<H-668C@\$NV,VN/S\3927"1#5M*4VX_5W0ZJA"B_5AX<>TG\MU:.;
M]COVJG(7&]=S&S-'=IK_[Q&#HQ@&AQ4UX> C9__O(39<<8A&[=F@&$RCG3IY
M)S#UJE$+<X9;1G3?B<N7/ 2'R%Z([OV>7F[)%V:7*8,K2%7Y$S6=#A1L+($7
MRDW&'$/-]CMQTN$Q3# =;MA)%^I!\OT(=9R,3:16<_W=*J@56TU.W/LKSNIM
M?9M+I/N"I+Z6RF;RY.<)YL4/'D-IV0(4N1&B%K1AQ45 <@-G-IFI=-=9&N(I
M:CR1J>U?X3[QY(ZYIZ9OT_V3(=]W%EJLMF2IEULNMO!OR?'<2X%GFC!KG-;0
M\ZNL4N3_'=(/YN4.CXRE._8X6B&*&I?4R?%[=$C7;*7B%8LF(+MRU9<(&(:)
M/]W@,VA)M%)_G"I1/,W0^R8G AO;^%0NG&E,%T?>GE(]!^G1FF]VU<TN1HV8
MY=K1"G A5Y6)J#B3Y@GOAOBMG8^W/DDWIUJ^;7_[0 ^&]9*+ECLN9-J5E];:
M<5ZF;]JD>*79Z%RFM4FCVC B/8!NS5MI+MN:,<MX8=S2+7\'*T9=7;64+3'[
MV1^4?^\>^&H^3ML\X^E'=;<A<OJH,7:M]C\E%\<22V<<F6U<UV$6&T2_%,Z'
MV79 +D[^-GY'E6I'A7 RM6D#W5OB0-1 N 9M'DN%<*#@M[_4^C02+J!@UF_3
M+<>9UO<]_R P+9OM'R-(-?5/:'<-W)*AV[VOI-/HOR*9[K3*OGW\D8V,[Q29
M9AZCYO.B-AI].(#6[F5]^LGH\9OB$W\\O;'W(&_ WU-5W::^M\YACC@L,-Q0
MUR5W^[/NV8?UY>N%O<#'R8##BI*S-ZSE:K*AA1O6&I02B['EI,(-?ATLU$4B
MW*TAG9H4X#RB4)KT3\G'$;EWC>?#9/W\M>2@WZI-LW-SAG4=5$G[A9@>O_ ^
MV X*5D=B7>7N]F%YNOV'2IC>.ZJ^1^O6D(W\9W[6WD6/_E#[]CWB3PV#/>Q!
MY<?W2ZW)?#U.DG1(7+LCA<3MMI_52,: B*OJG>KT4[E@8D,MI]T/8I%;CN3G
MMF"Q5^OW)P/C^?ZN"]'(H4_Q1/K;FW8IU'!N4Q3Z.>G)BQ%#12UX20[#G[4"
MPYJ#RI$=B[(R?29FTERIRHB@%(=8[^&9!\J*1-E!\\%S,U=GPXYLZU4B&V1%
M^D]]!/R?4,T&R99=;FL9V]P=<O.N4373I8R-L4%VD;*E8X^]=T^V/M4=VT8D
MVP].K1TJU#H-SH=0<U85-HDG7GHMR;Y=^'W?+Y<BV.%,]OG#;3\[L=VXW,YC
M/R6_<(7GD(#H>/-%M:W#YUY[8W/R+S.?XA6&$#%_Y[E)EZL[=+A;5'*AP%KX
M,X("[58NS<TKB1S""<L4?U^6=I2Q4R5I)Z>;S:C.W@M.])+,NC^;V8*HC?>V
M#;I7;NEMZU[R<'/'?@53X?-?--&,G$$[_:KHRG-=41<%KER**HCV+WA5:S_=
M>8+I0ZOM$>>BVL:'\S-O?CGRD05A83[<3.-)M&;9# "SSMGU%GWO\(.W_U**
MHIF7TJS)NY:?BKLNC2U>-QP*3\0\"N=ZN#.G,4&YYZ5IG5-BHG;M]4-)&YRY
M2;XD]&]QDQ3E]#NE^!OIZ":S%&A@<DYZBK6>"<]R;O)CJXS+.??&?8LGG(.R
M5?.<@S)W81.F_ZGJC/YCG(1!-1^O;[,53GK#05U>>M_^5#][5^G2,38H-/B"
MLL2ZQ+E0P6K:"$4WHA;8[FY=CFJ_B0-RR4&O K'/]\_CO)MR:B,#2I[>N(ZA
MB!D_LE.H_O5#%!&IWW+PM.V$S*?!Q852RU,90#KXU'@:HLOEK;?<D]+O&96E
ME HK_*FQNOS;-SM#NE5,4^AIMBEV<1Z,UMIX#V9=9DUY8_C=09N./6=9^U$O
M3'G<?Y,B6T9F87*I$*-?,C"YY,#*R;[M;,7UO5S]-XM6+VY_/^XX$L<\224(
MK 1+2-%&8AHW,#U-G;(T?,1F8(?<Z.;.5Z@S%=^6VE4@DK9TXZM:*K].S)I;
M4U[C:B/VOM@9/.S$SPK/'#S/$C\U4,)]H6[%Z/7\:/N//G]M;?FYF1GM:ZGB
ME.\;%^NYI1]MB *OM17G,F^LU]0P;">Q:R'_!4.R00N$F1Y&#/"2"A%F0@$,
MS95BFPP-I/T,^P$7!^ ]!:*$2;5:CGGWYFUWVRS1C>K6YJ^-'+NFGLDWQ'7R
MYN=)78HE24+7KURBMI^AC5.,^K@ONK-!9SO% 4@O2P6(K_BV9A,:'!F@HQ7"
M- X,QLW..:XQADI-OX]<W'=L3%[?C[9\7O!9VS1*0Y\O(IMYLRKU%Y:>02'X
MFZM58NH782TXC>WN:B2#,(?(X\N3L_J.UP@;S<-M";':J(<CP.V2@X\:^K]>
MC83[9BL4<G\[V$[JF!;>-C8UXM^!30S\%P =@E!<>[#/,2>9]_UI!Y3E**81
MC30@^,1N#DY&"G\UPWE>'K>(\ [X\=7+^_:!8_)AF\*4;9./3O6GAPW7=:<&
M1'A'='-#JMZG#^/<?P5-B<;6\AI+93IC0M.'7)S#ROZ]$=3<_-)^SM3='3HZ
MXBO>V/NB?_5$24!<Y&NSVWK5NE<')DHL#*W6]$]G?<Z_/;+PI/SLK4(U6!U9
M4_9IMG11O.^4BDJ&9":9JM%4(F+;9VCA.V>BE)-AOU:<V7ID]FPP_PFE=^&S
MKHSK+XZ#-WP/E#]PZV$E6 +78&:=\IJU/Z.%&)_>ONMX5C4F7'3?7\3.Q3+J
MXD-=B;]0,L5OH#Q.;32?GG!%()N2ZW.<J3O:B!1%X:S2K,:8VN257(N)S9+Z
MAM8)"+/L,MI(/"O?)1#S5&&87S KJ%DH6,7@A,KMFO SBP%DV9'G]1QZ/'YY
MRQ%#A1R&LBTFB$Q4OW("/ >1@5@;Y:5^>^"T9!N;EVML\$#9'.$U(U,VGN[5
M5)7FM?,W&X0(.*QC@YSW=)<W[ YNP) M]!%R5,"/\3YI?&@=MI$-6L^6_G98
M1G"U'3'#BNF*WL! ^$39(.4YK56O1RW-[]H29-<?I1'IHFN7O6JN9!:A2EPR
M7UP+=#GM:WLIXY&PVFYJ-R$"?+%3!D#>HS?W^,2PM.@CT>V*5Z=8?])/Q^PD
MYMO"Q[P5&W8G-Q4W1>=R7-_%F;I,/(PDBBPZ7%]>_]EU16O^[,.OH>%3!#YG
M-TMO'FOY^WZMJM\J["Q3=>Z9:?B;-0H;87.\2OAGC7*8)I]*I#DUI40;QC):
M9*<')K *?'[9DEI\V0H(;WC6J*U7<>J.%IPXPK!-WPP?!]=O+Y>.)!'..\"R
MX\_9P8FYC ='[T<)QTB'(XDD[MP]5/3TWO*]U:. HQOYQZ!PES(W49R[J&&K
M@IK95+.KP?2ZXJX7MY6R]J:@?4UVH!?&6?N^5%.!IE!L7["](NU!A,]QU02G
M"\TB[GP>S-%G>R[O82K?GX10RE'RF8-R=R@7^WW=35123D,R'N;O(I+=#:HE
M*LS<=NO&!VLIF\YZB,0/;^0LLN63Z*]6/NJH^@98PJUQQFL-D^ 5$+9A>GWN
M*#7_=G+ #K "S%.D(:2:"\R--+,&W\5(Z)XE'&#YH1=(^^??>0*NM%,O*7!1
MSU#;V/8_\6OSTO13]8$,<7F#+Y1W$XV*>EMG-WR\/+V6C*\46[37T02%G=/<
M7U].G@M/HY&Z4I.#B8>_8A188L!/:F^K3:%49KF;K]OT1MG7-1YWW-TPA]PG
MU\4P+EX3O'KH>*^'D7=+ M]%?>JNC6J1/"TS14FR%C'$-F9XWAET-U%MR=.I
MPMF*F)M@M;XS4N0NK@Y@<^<TCCA"V37=Q$K#@>MY4D68S& FFECE8IN-G3&T
M>A-X12ZO@ VJ3PS4]%(R1Z)8/>.,"(!+>I^03.# 'H[$ZY[S6:P6K2.(ZYZ!
M?0,&:-5LT!P00Y9BV;?44F=-XVR:#X*)?T[\R_KPPF&-%1!LD:Q$KM']\,;#
MX+V@I=J$GX-"L)2T9S3*2D0@([0F7[#2L]2=.-S5&F<\N=B>:#KAA+8G&>-O
MOR 9^5S*V/2T<TG1C."*#3P>K#'-NM1DNSG[O)X[I&S@,%$)/>:[;)%<V>FN
MH10H$$3>*B9O2:CY2/@GW&.0DQI_&A684;=OX4["'BU"&(%# HB);_E%%6JG
M)@Y[]CO@R>#3#]D@6[HS&<<&M5 )7.JLJ(J<.JR0+O_'7[K2:!WTS@P5?J[Y
MYT0R1B4H*&<I]U1Z(.8\SM6K>D;<TJC 7\'7P_[)NX(/\S,MC\V\E3:\O9A]
M"Z9GXR?-0G53@P-CCJSBNP,V:)L(OX<)&T\P[4+7F.9 ]5\9.U8.G,PV=E*R
M2&OW;$0-\B9E;I:(&!13K[8?Z<';26M1&2[=KQ%I%NCZ3_YN)F-)KH+C/5(9
MA1KF2E,9+B(&[P95LG?N$?A8HD?''[?@R@8%][4>QRC^M9]01[C !+%!_@.Z
MW#Z_T&9%S3\[U !-W+PCD[!J*WZ:V9P]BB'66HQ[;S)QK'1?-@A3S&"#/+#,
MF_=:B:Y[,4R:!C^!L[K VJ?X<Z Y@ZSP>K;3,Q<R=#Y\$-/]G@8^/#_/PP9U
MIQO^7M%N0=WZ0WV.7AN=.MX;JLFRS03V&&V$O;UW;!!A#$.W#O^\^4/Z4(I:
MS@9EC85R,RHU <BSZ'N$YK>?YW1+CGSV8FQ 9WK+G'$_=[2?2W#KL#]F^GQX
MAW0R4^C//V!"J/L?5_B08Z\*SBPHSD@_@W\17<W,G'045GESMJI8I>[-!Y<K
MER(Y+D7>/'V9<.4QQ.>8GM+FS1,O;OV,Y"!%<H3CFO$>^UL+6WTXMQ<HG][L
M$S-G)9-WJGIG7(63/W/O<U]]<U7QV4GJ'P.A=F@,#\K+0;;;5""+\N.14J)?
MK5X)9\#:P=6:90.+C([BPD>+9C7NAIM":8O9*]^$J#%GV2"5V..Z0]=:%*$F
MT=?>?=.%\#SO&>"3M5=]FRI@GEMH7CWA3KD\IQ6H*,K,6*H8WZ<D&+BXV-B<
MK3HN+WO2[O;___:H2$W^QKV0 YJ% 3_(EL8^2MUI<\S'8=8PAJ&WBSR$![:R
M%N3WAMB@J&>P!>R\V&$QDX=&8L0AGVNE1J(=:%7J/7L[N[1UW2MC[69D$I^'
MBD=0X61CQ_FGTA:CC6IM.=KOOG?&,J;V'>PVKJ"\-A\<$,[5GU6RZQ?QOB)B
M,89#9*ESEA9J954G=+<&6.%.?,?)O5ST,RZ;TU1R:-QF6L16)WSTM5HQ,/?-
MY/RL9)%,-JQ5,\S+L;4(-EEM4VVLPW2)"^P?B:/SJ\(C3"6^<=A/^$ I9B4(
MQQ(?NP8_>M./6<*FS+!!Y;-$0AD;-'41QXID@W[&7F&#,L$OV2!7"ANT/,V"
MP]F@- CK$Z;)MLLG!E9?&D]S[M_G3GK,]"]!_P5\I(+/,^^.0D\NP..Y:)T^
MSVW IQ36U6JY@.L#6L,IJ11%?^NQ<'&@MJOUYYI\:5,B#BA5A-\FM+\3L@G<
MM8V#+> )=1)Q8:5$=T+]PP(1FAQ0>7L*TL[C2L,N_'I.:1S=#-=%WZ)C4U1G
MS5QMT\1--MH-:&%]6K#(,:F<SU/$AX0O 72\NZ"6][^DRVQ03VL<F(Z":_\.
M;N]W<$VR&/+<E2->C>D..U(I,/&W;)!E<P>:(15WAE(Q7>T@D+34.UGN5!3S
M^*F&7*9:1B$'PD30FV:REM>"/RDR42E7D"FWURAL&2UKT:AAR..'C\MHN>\B
M(/5]EC@6JBEO:-9_+2G\#0W#Y'=@J-)LH\*YW73Y@3"Z=E?G)1IW1*<DH.4C
MO H[T\GOA$KM&:++,P*F6$)K?TQMH*U+5CNUQQ7#I4GVJ)_RXJY&HS&?,]H"
M-=5@/'V^Y<@0< ]VMIEA1(O;\,'0BZ@,_\DJ547]'@D96FDU'?9WXW@MU(*2
MB.$-__R+P-&XH>]XF'-YJ@$2%2^4BO8)\:62!%:;G)2>S3H@'5=MFH7$OH=
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M3KQM=)>M>!*CJ0V(_Q?P?*_+H<NECN37%4!KT+C75[T6,,!MR%9@+;<]6I9
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M I/W^]Z9N7?=>]?<.[/6S.RSGC]5M<XZ3U7MJKVKGO/\_7D#@*^FI*H$0$!
M %C\>0#/RX"7 '145#14%'0T-#0,#'1,;&(<;"PL; I"(CQB&DHZ6AI*:FIZ
M9EXV>D9N)FIJ=E$.;CY^(2$A.C9Q:3$!*5Y!(8&_7H* CH&!C85-CH-#+L!
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M-15KY1H2?1G>:3H%'O>WCQ5D+(&0<?OJ?X?U,<%\ EGC::"8B/$[GF&EL\^
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MYV:F$]$,_+UBW242HJ73=:[YL6S5E''"Q\]A_6#CLX$C&=="[OW#@N/.P%Y
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M'2[ R[%S^/+T._O2_@=<GPNB.7AX297XSTMB?5"[1##M7%*P^!743G@:)/W
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M;\LX>O+@68YL.2L[X#+2:@(%%&9M6X5?R9R'^>;)3UY]]STV\]Z6TF21DLF
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MLV")%*1'12%DC!EQ^Y#&[1Y4LQ'X(9&DC[=N"^.$>R!G.C<H*G:% J;TG5F
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M*NF:7['(0]+T4&3JK16F5=55+/_D:?1%?]P;Y9_GE*@\?XLOT)S83Q4!?^;
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M=\AU/PYOBJ>%I74?CD#OW]LVUS+A*VW?585UAJ!RLF@LCN7W4$(>NY2<);!
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M*'^B!$))24E+3<MVZA2;O "W@/Q_?.$_ '1D0"&D@1#"!1#000CI(/@6@ ,
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MYQX:U>1N6EPXD);81.UJ%N \[/[*7=H9?WSJ,(0Y3-9,(<X\1*4L"257._]
M?#A)7C;5-9ZM+(T)-)B^IDGZP%07I%<5Z;?,27A3H\]A!OFA_R65E=  'V2
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M87]#AR!B*7X(/HVH][(K*V5+6'>/UHX44*L_<1[?[_0(P#C92G]>K-]0$+>
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MG $RUM>0C0U+,#!PX[X!:F-%J2/UVZ)[:Z$ K*SQ;)] ;(M+^5>_5)M@\'B
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M_S*R/J'-H'9\HUCI>##9S,].9:UDLI?J1.U)5LK]OIG/7S"/DL1*LN_AQ_;
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MV$OOY2W_UNOFQLOK0JN_=6GJHCS8C!UQ=",8RT)2I Y%?JA\+W5JD<6+#5)
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M58?ZA)"(.\\'7WC)]A5\JC[56/0;O$$J\!-8P8 +'$5^*)D_2/)D^?2[#\?
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M\U]2*JIJJWY$WF7[U(M6%OTI7=N+U4F_@74@$M&["XMSAP6E?Z(F($RBXN6
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MZ;.!Q6S@O-[1%-(W_V6S+G(AG%A>$SVP&O#2D,XTSKA *.</11YOR-L(.C!
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M<NQY=O;?UU/(/? F0>]R+18\_<.M/]7%X7GL2=!_L3_CW.J' ?Z:W[,T&8F
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M95\P,#4N:G!G[7EE5!S;MF[A$$CP!'>"NP<GP8,'U^ 2W+618!W<(4 3)%B
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MKY/J?S]K7Y[2:OKY<5[Q75-RU'1-7;!'DPVM8F&LD'MR@(DV%5:,7?;D1:H
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M&#T\)"L\^K@N1!OCM3963#J71R)[F1Y,PPV0Q2;'R%TA9V9<OJ&W'WDZ9=9
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M"]GX)*;EW#9;O3:YGY<M9U9#LRB(YW_RV45G#4%B%X%8[*+"U9Y\H;F=\[G
M+D*OWZ1;-MEX?G3BH#O*!PN#X"?W,&#HP4 5U;W[,DBPOB'AJ5<2!@U.WAH1
MJR(CT9J#]ZA"S2+U6*!YDPHC[R@ZGFQG*-53&.!)IYG6(E[8B=<5W_HSJH>'
M6IP)&?2<EQRQ:Z!J575@(XQ.]"3Y%@^A=VHRD)9D,6W1+5<(\Q4__J5KBD%\
M+UGYFSMG)25/&6K^J%>1FW39DM/<S<=/7AQLD=O:0$4+1\!?$AXWS&I)H6_$
MGIE)>8&4%:7K<(4B?9"HQ=NK*^[:UB0P&")JIHT6GB>O>L<@RA.KMQS<!.V,
M$I;J0J:U LRYJY7'I*'V/$^=,U=BG3/&_^//2,BSS?4F#CT\,<Z*?WQ5>-I<
M//QYE\0MV"0E9,@W1Z)=LL9JCK3Z6NM EJV%)TH)R^5Q08 [6LB$Z_1W-#H_
M^:)9W7F%[<37="F.;#TB#<EJP2>!7"U8B5.5I=BKF$6'YM;+H:O1'X3E>CW&
MJ0S8T5J]S\O#]#&%3C9G)9\3U8\2B:P1WRX_,JZ<78ZM?MG7?H,FLG7S'8T/
M!F \S7-D2/@NZ[)[VER%]3A82P)5&8%HU_^KJP8V[D+)Z]-VQS!M3A1+NGB!
M)"1G>#VE5/%9L!?KGQ?6G:M&XT8T)<;RJ5=N>6(S;&&[K7;PR9RJ6(.(*MA%
M=M4[YXG+>-?4%#?.Y.1N7%_\:(IPI,UK$",Q4N4Z1"$9*NM69VR-\ZW'AI J
MFJCZLT[%2%NX ]1W<M^#/YY)Y\!$PCFN,BB3++;O3')\/R*-5 X]<U-M(W81
M]'7O^CNRC^%\ZJR;-K[TAMP,5OHH5?P]CS9393<9UQ=GFGQ;SI(\ /NM\G_^
MI>__D6'#9OX74$L#!!0    ( !2(?UJIH22BT#0  #TW   -    :6UA9V5?
M,# V+FIP9ZV;=5 =49NG[\6=X!#<G>"N27!W3T@N[NY.(#CAXN[N>G%W=X)<
MW-TEV.:;G=G9VIV9_79KWZZG_SFGNOK7_=8KIT^__7[; +R3DY*5 @"!0(#1
MWP/PM@+X!$!"0$!$@$="1$1$1D9"0<-%1T-%12/"QL'$)7U/3D;ZGH2$@H:-
MGH**A9J$A(&/D86=@YN;FYQ>0(2?4YB-BYOS'Q<!(B$CHZ&B$:*C$W)2DE!R
M_E_;6Q< "PF("%2 !5(!8+" L%C MSX .0  A ?^BP'^U8 PL'#P"(A(R"BH
M?R<TO /  &%A8>!@X>'AX/Z.^OP=!\!AP6-3<D@@X*A^0Z1RP.4,B,U!HOY8
MTXVG-GU!P_7=,1 9!9^ D.@]+1T] R,3-P\O'[^ X*?/DE+2,K)RZAJ:6MHZ
MNGH@8Q-3,W,+2R=G%U<W=P_/H!_!(3]#P\+!<?$)B4G)*:FY>?D%A47%):6U
M=?4-C9"FYI:>WK[^@<&AX9&9V;GYA<7?2\N;6]L[NWO[!X='EU?7-[=W]P^/
M?_ZA"PB !?Z;_8>ZL/[J@H&#@X5#_(<N((S;/R9@P<%3<B!@2Z@B?G/ H>(,
M0,+]&)M3TXU,S:5V@??=<1H%GX9[D_;R']+^1=D_)RSP_TG9_Q#V[[J6 6BP
MP+\O#Q8+( :X_\.0ZX_R7U)*P'?UR8T;%3LC<<"H[U: FO"9L1B22Z>FJFTR
M$(=9SPB*3'?%>[^*CXC%<=[]!A!>\-DKV+&@NV!<O4"DE.#?IFNNX.N/ZZ@!
MP<KC3D-[9H#D&K"D/LW/_79HPD4$M%.[99%%2OD6HQXV.= 2M)R?'[GD9?)0
M$+,+*IVJ&7+# ?\TE:;'@WJ*2>'2/_?E"YHXI0DRJCTDH&X,] ([;@.(%09O
M@!^0WCUY8T.]^:C>%BG-J_S<,^O8KI[K<8"-JJ[81;SYUX,WP"5?';DY_T\N
M8-L9ZN"6^)]8S4IO4)[$9K/+02'X:)B& [-N0!?:>[)<UDW/#>R4-!NLM'!<
MU=<O>&G./.)@X; CSD :HO"*S.KZH\G<B;N\9!E3)&M2S#,PX/Y1(JO>9J5)
M>D*)KXH>MDKX/0":V]PN-K"L55*\K+-</B[29T-'_/W1B(L2D17L1HV9Y*9P
MLU<.?8!(UJ5_O)\6#G2!Q(*,%%@^D72*,3U'338 ;*8-GCMX+V[4EAGG3I>%
M\BAD%\1!:@&R:$L;FP%X)7:EA_=N=4OZ:Q*L\QW"OU6[C2>+LU'C524!N'_!
M^[C'NMCW!O"$27D^>C$S' ,ML( F1YEDD/X +(ILPL#*#J 0OMF\QOAM+'\Q
M#&;$C]/.QT+'S=3A_&..O'C:B&"G/W<5I_C;IWH::G%@>=@'#EPH-V;CUPNQ
MA3> NGZ/HRKX%2)@V>TEYR<V-*7P:-5:B6 QIVJP;Z0JB0OXIY 9PY/G (H/
MTS>HU\_7/]V:-K2&B]=Q$R$2N3R-<"V2S0'#1&*"J>=NHSY>'?6MK@:'[.XE
MP'[D]?@F<=1,M"V<NG]6;P??:V3<M$CFSMOFM%HQ9@WW<;5P8%G0PX>=*]-)
MJU*8?-.'2\/PHX]XWWUJH"+95CX17WVK4TR+#M^7Y %+!F_$S>:^1 Y+I[.&
M,&M2Q])/'FAY#QXVX+/M97\"Y2EA I[..*MRZLWQ/+Q4[G7Z-)(^(P;XVE!^
M4I&CFV7,8-LV,5P"04A:ONZ785'?WUCX4BRN=968(Q/V7.G; L4-F##FBEYW
M4&DUFZF1^VA:\WEQ6E0P1Q?K^_2['<W=B[O8-P#2:72*7>F)OGR BYU]%3&[
MJZF1#+4%HA<:ECCN29O(I@]WA,;"<+"-*FTC^!0)_(X(!!TXS3%>1J*FMG52
M[0QN$[M;&6)]_B12OSCE$TP5LB=R,9!.F$N#KX(D +BE%[YAZR [6-1>=.,\
M6D10!X9-'%R_6PX2<_-'DQ,_P'#?JSUS?@,@ZZ"B?]G_VFK'>;83MO4C*>-Y
MP$(C>58(UG;H,&;"G\]H5E@ QD+!Y6!Y>4!2WKSM0(V+RLP.!9%"3%S*?8@G
MQF53#*TCIUR<1W=S3KCK!U0F1W@)#PK@AW\#+)+M;,,V:-=?5 6])W1N17?H
MNS3HK=6!><P>?L<1;-]FRCVQN8@H&B2UW_.*=QDUOM>1&I^$-2C$LLNNJF!9
M?!S8$8KAQU8/E!J4NW"9ZU5,,@1O_?&RL-E)&]?$QBZQ'6H#-GE8 H[7TQ<6
M8DPVVPGZI;Q8Y?3+3B5W&I9I=&'8H1QHXD/"O'PX _"\BSVIZ,_,7@BE5RM0
MW@<D8T)T>P@_B9E0NT=W/UO,A@VYS +KK4Z#;$&\DJ[PH(+,$XT"-H+.UJ?S
M7PRPC;DE^I;+/M"JY6^MH;W@UN&5H>\_JY[DI#>US0&YX0R <E;;K_0&4RMU
M"I?[1YTOELNI&H$$B5(HH9RR-Y6RQ*H+/,1\39I MOXYU=/N\'=(CS%E9.)O
M #(VYA).;F^*OH.K/#3"L\*OS^Y9Q]KUYP^OG>0W4WYZ7>Q'+2:7^EK\^F'T
M5PY7JWF@R#N3;@JW<1L+'.2S*A--H_(1;6K$G KN^M37!H%]7T_?JBO3!EQ5
M'=+/?+Y^O_>?V*8==B$)G87/#EG66VVM[ZNGOE]37":E0WC7EW5C(SAZ'SND
M9EMM'3*:#$"DQ_-'T75.7A:Y:ZN'"SU'5PRZFS_> ,3 KFP,_'GOS^ #R3A#
M,UV::\V5BA+.$VQ>U\=L#^,S(GI"@7&=!CNL_DW4NX:_SFHHQ]MH%1H9E_;]
M\IR8G/47ZNV$#(V]>"$DU-L(M X?DX(K 37V0L:JC)?%#JA.'Y#Q$-QY3AE@
MEN]+S0JK:&".8!4<G&CPDF7#WJ4&U1G;)-=BKIM=W6W7V,D!1F=OJXC7CA'6
MK!AM;,@N$5/OO ?Q:5>YTLG4Q-*R.M=J;;PMMDFE%K:?1'%;4C]0C-<NBGZJ
M3G)D@#LW'(IHG=J/W+&0+7=?^AZR^\T^IU)%'Q7_^R[5F'YR^O-XICMIB:VP
M^I;.7N3A,DGNFOSVJ,45VX/3.YI[K<<= 0JT#XU(\&51GP9X6[Y444FP+ :I
M1'[N-!OIMQT*CG0G;^M>%4HM*'E(&O#TYM/&60JMV)QIN_ZPY%CFMAL(>EIW
MZO!K3YC$DY98%/YF9,-J]_EJM'AUT(I@!22T+82UK."0@$([^:1S6Q%#:.5+
M'Z'9-NO<+KI9@9[OKTA:5V?'(<1,'1D9@M(DO'-S+HZ5\750$:]W9:FNG'=V
M&#'-8K>A%QE/W7YRQ#5)R.N4K(&VL&%;N='BXU;_,F-L7PXK4O?JYI>/]@2[
M2'+/1;_W 599.'X]+5>@GZIQNJUMB5 =0&T_4<JK=R/,%L=5W""TTO/N:3#I
MXP<J=*TUK5G)X)Z3+:&H*U-[:;C3* \2WPL5A'J]-T!,ZD0?6^*>NOVP<*U>
M OH]KW^[)L;7/0J0^<ZMX!I)\R7I>B3;NE;T$;-&8RR<%/8OZK!H:$56>GPW
M]/P!MMMS(MN6K7[\.ZD&M#Y7)C]S09E!>F? 80]DM[8^X+G7JO>_50,3B_4)
MB\Y"[1Q[YEI;(IG?([?3;\[X=]R(\$8&+Y;PIE?4#!XGF4-//\)#F4:?<EKO
MS9BC5G>TW20!'H\/IOV;H+)!"HCY<WSBL"%OWDBW@>UCY]\$\I2;]S48_\BF
M<\O!<126LO>#2@GVW;=KWP.C:__?@T15GW/]!=#-NF*MWD/WLNW:@MOJO73S
M=& )$#C]P4K\$^Z RT6\C&)O]N@W@'SJV)$LCK*0(O.@.<"ZK\8?8!W5ZB@P
M*(+N"8\+[!F_6%C3I4VPZQEE'J6&+'5C$V0*^#MD94C$V&*J#!;HQ'03)+J^
M-]!SK4]<Y,4Q&*%[>F=LQU]#0;=!0-RT<U,Y$@ZX?GC%7UDV[/8H.JK3AXIK
MT(10+&D&C0!#I$[X)C"_RYSK=9!??/8E;>QL@,RS5;*>4\B$K\*;2FDP-F%%
ME]6#R'L76EH88 -F7PE6EGV2)N:$)REY@7BU?6)S'I1=P[W7K6Y.T<FEHQ>9
M/+,5Y8NZ<=9<'GW)R/ _DQI^3OX2CYD+:KJ<)8OY^T1OLE"_\;I52Y?RVE9V
M+'R1X4O>';WJ9-^VVK88VDAWE'1S_=70D/Z.NU KFN<3I0KJ+XYT# 2?4DN&
MOS$S6G8[*I [O%(:D KH:Y_K[^\=*-8CS+\*Q'IM^7KV@JBN=^>ZAQ3FU&+V
MF&^G;E 5*OQM\Q16->Q<3S[JFTJ^JY;_*+59>C )VI]T[0_%[M<#D#J\FAE6
M;G>'7XMCQK]>8?U]2O<9EO0_,;$7[\S./Y*5.< 8? ;Y=45G_PG? [6TU<_O
MA]'@&-B1-].;Q[MUG_16[1L8-MR'5]4/?[!M\R#-R\^E@T0HQ0@,D1COW+XP
MIL[OASK7!UHI6DY<[9&.<R_B_WZ2($4)?FHB<5BHC,^-3UM4GIO$4LHO("RK
M\)//[%\.OQK_L#6_@W_,%WI#1-4 ;:@J5TYYGW7WZ[GWMO))\9(LK4*O8"#6
M'C+-=_G1_>M]9XM/U/>G#&:O]_7_5LGU6Y%QSCF??M(.)!44Z.@GXI ($U[R
MU1"U%5_9W0T5WM\5DSLUS\:D\R-ZB#:T7#X_4?VA_XFJ9_KU-'HT^G.:/%--
M--<@I-)J2IBU?+3*G'U=^5VTEJD4$*52,W1HPE&DF^*.KM$\&R:<X?^.DJ_K
M/K]RF<YBK\-;=98?C,,%Q$=B$II*$DYS[&5'QD)\;$W4"CX;7\:^,(^WJ6X+
M0=5>;J 8-E& )9=B8-:'EQ^W?KMJ[K,&J<0ZW*U$-7Z^*ZJ3SS61/H<BU?SE
M95:?9\7J3KB'C QH:EE:?@SPKYNB<C AL\AC9N\WF*XSM:X>1'Z'-LJ7/D=!
M83_73K&2*1;8[JH99RJG2D_>)U_Y!H7;',CGU.):DQ@5OR9\W._7%EONDS4K
M:DAND9=H=&4CS<-L+21R=,A2LJQ?XV_5YTTZ28RMY_MJELGC2JBF@0"(1AQ/
MSY(X'F1ISC];@LH6?W"E:_M5D= J;$D=7[OW^6C_J3 [<8^N 7*=MQP)?I?M
M;-1+,L_8X/[M$OL0+&$_\T@GP?B16LFA^W"]"C2HUVE?S+WB[ S%T!<0H,YD
MM\J-NZ?W72\5N,1=%V%VCGL#S.@F^9'V/@80CT4R,&D$3Y9F?6'*QR?0@SLM
M/8#0*\T3P.ECWO*A0HWQZFRG]$<6]=T2# 8*6H#S-<>W-Z6"Z=/R3/A.U':<
M?/PT) "1%AQU(NY3[%5*AM?KG9;G&,4+[:CL2YOZZ?;F^KD*C)4R+>MX.]4C
MS H7EXVDR]$")6'=S2M0YO!0K.S?D)[<M$J\T%[U>;[B%HH]J]%@,[4Z0.K3
M+CU'QES(*FM(YKRQR:9E_K>*'_JO.\S_G/<G6$23DD3\Y?K'!U6G<_HC*TJ?
MZ-B=5GA*W!P7IDMDOFB#_,M>K*+F"IH:ZEO:?IP[1^UB[1<B>!3''5@AE1FF
M*\6@"0Z&-[2K;NEN1W^MT4MZ"@\;A6Q99'*V)%[]Z56.4*QK'Q&N&;3_.  #
MHL_9C_VSU_P&0'.OG%6>865A^Y%8Z293-Y(2K?5=R6FEDKF\==::AW K3B5\
M^6AU8X"H-C_V=_3\I&Z#B*O016SDX<'M&X K)4YCVOK#GE44J[[JTM-@^+L5
M"124,@QD8+SK5AK\0HS(B/[*P0RC?UWCL9'O9 B3;KN ^O%,X]G&#.MM4EU$
M;Y0+9REJRK:)YD]W..^B2I@2_A-$O>[Y9^E<&F3>+#AM]?*81O&FY;ZSX4F5
M,=GG(_QV],>=AMFSU?8BR^4O%<7=I*U?A"9DX+=@S0$<WV6?FB@6=7W0&.^\
M="3 O#;A([]AYQ:9=_O-;"'X>HZ2=0XL$>"4S3G/=P@<!VU:&;\SZH54HAW[
MPQ(\ECLZU9<A!>2NOEFE''TC:@GXT'7>M9JD9_:#3.DV4^- Q5*0)M1?B@/,
M&&=1PWU.XC$QR<F27BF^^_>N>,<<4']K=KIVZPM?KO" %)LUYR6P;1H==7)$
M6L/[>9WE4JT,IV79B"UA=()'DB^O7ASTLU!NW69=2)5[:\&L6TFG^,<O<W'I
MF$9^&:9*=S6KD^]"DZ^OX@5@#RR_HBF47(K)KK^+8BNG^Q'YLE'DN%"_5D'B
M'BIFFO_'MZ@A*#96$F!DI&J(F([[KQ'R_P@VHGIXY55;+>$F/^RY6-%,KF0=
M>#.;C38%08=C+[Z <$EV^0FF=8E 8E*.J;D^RB,T>;(T56?O&WT"+^S?YHB4
M4%._NFHU,YQAG#(8;L-X#MO WW6@4/J$X-DB<$UVPO8K]:M'%>SE;9'M5N=W
MH;*33_1+5V.(; @?%ZDKE2;SCU ($AM_X0O')?!,67WQ%I+[E>CO,[_M<,,S
M"JT5^47)/DXA170K(L;TD]4Z.E3"<4TZ8UGR;^L4("QF1\7\"!Z$I48+^FDJ
MEILU 285/5:8IQ4E6V%M4RV?.:R330 E3B;Z_=@PNRRFC'BB[HO*D7/E2;B9
M'8SK#LNC5=Z;JSEJY-7K[TOBF^Z+0(EN9@4_H_GBI<>UGMC(=G?SGLPGK3;0
M@8]&O\YEJ2!_2"?Z/$U$A)+PE#-'PBN$HYCT>3H0#SQ7CGSMP C$X)C+1&PP
M?FG95[TRF64Q)N"(^7 Z\QRJ0@9\O1C@/U5X$LOPI5H\(RV08BL]P8=VO6Z0
M*E=ZE-SYI,S4\,E=:I_7"F*56<PJ-XZ?L>EIP4C >?WBV""%,MTU()QC?"Z4
MA1DXCVLK,W;NQE-"O-J.QO_*DK7.KO&4C<;PHKQC.5#&C(DVR,S%&<3X'4%V
M8SM\!BR?"NW4^!:VY_"3[]KOM)9!DF<^M]Y!P=:(9<2HR3J!QKN O*IXG[I
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M3,M&36.76%\_]J4$A9&<BQW1/'^)IO-8:?YUZPV@)X,K"0, V.31976T6ZV
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M1I'%76+^VX<&!7_;]5OB,-QN'S-\V\3=G7<)KO;4\"T7?JZ]T>.+T:9DR*E
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MU!QRKW=;<;H 3DU]Q#^*NIND/U$K,Y7J.DZ/UJ;?'90[HK_$#T-.&IO+_LH
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MD8%2WZ=Y4D>":[DQ(73XE60? :@S_'I0K!>A3?_D0B\X>2W=0VIYV -N]#1
M(48Q#E/?Q&E.F(R_HO3?S$KYNUGS\'VB6:H:VD293BZ^R[J?A'NQQT%1V4J]
M^$HBMH32&#FT%!^AE:!UW:R!_W+)2,$Q@^ZS!$N74(&6!MH/Y$2VJ2B1TM9
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MB3Q-V@3C@(G->M=R@QT"G;!)2I(8D<X@:Q3>Y(54*=R=\"@!,J$_A=R84Y!
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MFB8"$3@[=VV%3-F3P[K\L=5:VSA=R;0@<U='J*OEZ&X_WG]]2P2=8GP^]!8
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M] .D@4-Q4K)HB#6:XRL%8W8N</XD$CYQ;*CQ"&>,[&2]=<+)\[2?-^'RQ4#
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M<NE '"TU''1!SYF-2U8*IJ:R0DTBP4IB=C-_2-P/Z\BV?*-C9,WG1OPJ^;K
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M#UUP>G^6AU,Y:2KQOL=2.R^E&4E"RW:M]Y9_#7PW]*'N?EVO\D"3[L&T!Z*
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M -/\E&?:7H4N(X3*G1K>B[<SY[[Z9O\5@=(_I2;]WR'K\@#XG[15)L7>FWX
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MQ*VTS/>%;U!@"L)B8I6KO1)^>4Z>HY!GI9Y8A"EG^<HEQ))A'25'1BJ\^G/
M-B@C*R4T"N&7-@^ RH%UX,F@VU;^62'6GVNIC %P%-;OSFK%!5T9Q51_Q07\
M,U"T"UA.9>OB?\N"S%"]T;SQ@[/ITF6O?NZ[N2]^#P#5EB)/]*$0U]@BR]F-
M)+V=>(<%'?IPC%BV6L=SHAO/T8LPGN</@-\M59@>=P<;C:V.4[5$\_'$_)">
M?53.#7MP.1L@M2;@?H[MRH1I,;:[)1,"I6I!Z=TPJG?!-T,-SWF_GL]#\ME+
M0E!,ZV^@D:KO65&-G./K[&J?!_=)4?AD]#[3\H]5M/>,&LT;J^:3TYXHH5]G
M(I Y:MF@51L)J8CT@,.0Y,,E0_\=7?&(PN/P\*O:Y$-FC=A-N^SQ7O2<%[*O
M/P T6Y6D!Z:]/S:*8VFP#*LFW3OY8O=:Q'EFD_!-N2"GO/YNY(6%A-+B#806
MVO,H.G+9]MP[Z(D/M%&V?Y6@,(GT*6"J?ESW\R^=8C>$6N+5TZ6:"/DW25+$
M;[P*MTUE$),&760D'3.3(?;L-K*V>@7.=6M#BHL8O7F6)ZJ'B\BCH83VQO[2
M9<4LL [F)D,_I/E/KR:[9]<>0V_W6.!3I'>GH!]*/9V#$;A0C+TK02SW #G.
M>*2"A>\.[!"*CX<N?"5;1F61,$*O2=ZK67IS@0IW$0PJ:I$W>W,4S%[%FW03
MH"^AD#:X)C_W/"L5O=4%G0X\ %@D9]>$'N_*E\-94> 4HHF\H!)V]9;&0(92
MTV@J,7_$12IC*2@-E=E:J? ]75S#D<:G4BC)3H-!O"5J5UJ>K/4%SY)]M#J,
M6,'NG#!R'>H"%\'9X4\1L'Q*A*XW'P!?LJ)"4XBZ E#[O84G2LSD"I\FF%FR
M949&OT5N! XIPJ(/5MY1K@C(BDVRS_5F:#X 1@Z5K^. BR;\*RL]0]RZ:V,Y
M;J36X%OP \#GF<(OXX[,6Y(P)/XWT>YI\M$=TMX-:T,H8VQDV4X2K4T]Y)X?
MYI\Y<W\OX*T)+=5TMU8=R47E*)Y8?[YS-7LPRM%CQQY+&-P#RP):1<##*Y6_
MU77O>C3;$DAJ'>8L^<<_1&'>VPDMQS>CJD+68*A'ZV,*_=1+(?8"EY4J,^-?
M]/LS0#P&AIMBXW_69,$#X,]N- \ 2W#O0OEQ([%D#E$13^3-%K^E$:A@FW7G
M@EFOSUQ2@G,JU%9"]3VIVZ)HZINMZ<G#WP*NN#KM1!XYOE^R3WY$N) I?8$\
MO=)P2V_>KVY!P&&((([RYF* ,=2\N/3CN0](:X3">L?HA$&),8,EIZ%&G?*Z
MLCY"L]+0/(*N]%;7)%/H_HSFIUWE=:,?$9)M-;X4H_SD>1:0W$Z@8Z[[1IW7
M9X>G;KQ2V+X/@!_?L'OX-1B\5N2L18]:0Q@8,6=7.)"]^/@D:M29V&=F=?VE
M$9QP*"XWFPT@#H_C#M==)]/L&C'& ^ P0Y*<E)<"4!!(30% .L_)]_V9O1>/
M<\VM)*AQ&MT^HZDFJ,6RJM?61$L3RU'X'&OH5VA?-\)&\V28%Y1V?')1V ^X
M3W9>*O_4= 5]AXG/!1RT]W0:]/G:\F*LVMI:P!<9PC_=##GOG&CT..[MR )X
M9R^'^?"4I/T"1/HS#H[,FY(PV98:-TM^=_C9/LGM>3J?>2MZ7#F!-^)5)Z)2
MZ3'; CNOCFJ:$<"4DW&3G&$&0\XP]0:554"<B3E2M>1(6*'<Q[(1YG)(S?^C
M6K+_BO\C4>Y[%>DI%U21=L7RLIBW$SDX2U:-8.4?KT-FW!-9H)4P7]!X!AUI
M+P/(G9@^,7G71B WO[-\B5+75U" TYUA9J*'^ROF*F[XN_](<QZ\^BB&/Y^9
M%;3^N@J:-3EQL_&V[5;:48@-9B45%_TE)_BOJFCY_N-3_M_DCM"8YHD:D+0L
MR.NP;E;=0;@5.%NQJ+C/%$J)G3FMY6DW1?,Z7\TZJDDHG-N^N<^!^)7'G9SL
MKLY?[U!C;EE<2W\G,C\KR?M/FL)G[[C-'@;<O<B]3V[/F:-WM+)^-3NWC*=9
M0R+%BI)F=IE?[,VPBJQ )%?,D"V?>;*[3E.O9+M]#)&+.I?^] S_?J[$03_(
M=DU Z8^LD?X+L(2@LR-!1%2)@=4D06!X6.*[/)H:KEJ'79X/$L%,+QYKE($E
M3M%AB0?;[3M+/=B@B:7)7M^:Z\6;DD9IX6HND^'8_Z6JV.B_59C*AD] P@N5
MF'OC>W&-O\H\8I>-%@"._N:"Q5VV*1&+I:2[N2EP>.<K?4[:H\'HK8!5ZF6H
M5 71GF5C\;^@<MAXVOVE18MO:MMIB+LD\Y+L1(3W..P>WE';(-AVO[-#/M$E
MVPVNEZ$K>8RA7] 1*:IW2"#"?;5A8K_(D4]O/JV-=QWZ:H3D9,40D_)'V=/@
ME[Q9AIR3UY%I!ZGB=FJHU!)5(\"<H&&9MZ<<':,_-M;C)'9_**A\NRNXUYY3
MUK^!QU)Z*RR.I0CS^ZX,ZJ^]0[]1=?FU^*)BE]0D89YD.D.%.2=$!.:P2/DK
MV0^T509>O]GU.)!<TSE/*-E67R0;@W[WX)AWW0C@G>NO]$5\^2+@VTL"DMDG
M2\K$7JIU9:TC]$!.)!?D8V2V$D@Y+5L][!2RWWG![+ORPL7=Q5=CV37E6F<7
M'W7@HR[*HF11(6$7Q A7$\4*8M'G59;&#61K;QNE)Z6[3FDAKW<[3.+4^6_&
M@$TL=I;Y5ES#NP3I=>-82,GSL&'V.;[ZSR(0JN5K2>)PVSR;!YM7K!F4-U]'
MKYHY[N&(/"&.#UN_*,+WUB@272G%L&+[;AK/R_  ^'S<7A^U:D!?UV]X,+N5
MC)9"9R=[E!,196=F!W3)QRO*]G@IS2@-Z_[2'T 83/'>\T5BAMNR>YKD^-FM
MGL0I078OY=J"[.8!X>=Z14 [:[[N6?9UD0"CBP?<DU;G,' .<?Y:V;=]@=<"
M=")(C$)K*]!J8NG'TB!%/\_?80BZ9&E2^:JWO4C:.%[\KB)TO[PJPG8B00=V
M0ZDJ0OK;G2?!5Z]2@^Y<=X>X&:#=N=<7LF@:B<.7K/&1/F^4$>J+4>W:+Q+O
M7+^Z,8P;3QKQ^XHE"3H,)_NC\7FJ:N<&4YZW?'[5"*K:J8W2D^3H'C2=B_S^
ML4N6CGFHA%:OJT@I0'N2\CCPPA]7X8NX*:/82*&?S?ZTYL96M,;F&D)$K- '
ME\8!+X66U$T^5YS+Z#E1)UL\<<=/W5_2H]\,2JJ,A4AY$QK9X>1@:<RFARJQ
M<O3=%QZRG=M !AV^;?FITS>Q61L!S>RP-S-'M 1O7:PCG@-I<0$ #01N@>L,
M)]CR(7WW4IWJX,YG.&VN(V0A($'$:8GN0VDD%(4?6"3"CZN&QH_K6L;2*@>\
MP;HW&%&Z12WP0>@H!A:>[[(\B+C2L].L8@:>X;=+M;^7+>OII2YVL2KXF!^
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M*#'H-!X6=+<#;!(J%"W<BQ_5VW$LR27OD+/:+S A5&5F.'W"EN8;.WO],XW
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M5^?/Z3I(OE%QP@Q@R_^;NNQ.H5&?7_^'T\'DW),C''ZK_<U6A'MP6C8MW5A
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MTM]-'/R:I5OS *C0U9-Z5^>T*=5J82H>YB:.[.^%"<\YUS%;Y5;K*]+MQ/$
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ME?EPP:,%L4,08OWV.:OT7H0YYB> 72TVK8[3;2OA7;*0N'!LX42_B[JO@4)
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M[+2M()Q9K]L#O<O(Y%ENM=P_*RZMC-)0&Q>)25/6UOI]#SQYM"G/ZXWHC-X
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M_?O^*LGRA.J4@Y;:Z\]43-F]W1A\J''B-G!DR@R) PS<RQ8J)][$+*QD('&
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M8+0P7-L!J^N3,+ H1$(HX#YF6=)NZ"_7^3ZF'J-')<K7DFHR$%V)9#Z<_9%
MAY]3D69E?$?W13Q>M8KM=%UX453@L00K[U.%K39'.R=JC+;&HX_;8L//W=%4
MTZ?8)E#/7DKP^B4FU6MLB_XLW?O A-G+@XK99X/T=^$#;[;N.EH5&)G0L ?D
MO8#1&'JX$Q<77[0"D;(SLLR8.714O/NT>L#7<S21FZ$.#5PJ3%.E^FU+/+A)
M.8WIH7:\AT-8Q5DS5>_'+DLA(05GF>GBA'"QWDKW^':)"&[],?GS YP&3;<?
MD,]W5>*-\I.\8O+5O01<V@@/I"\AN+.0'*E=QX?3 S:*/[8&I++:@5U(-Y1"
MF)&_1?& @5^?-]-F,<N\MNF!/AC&6#")'!P?!Y8>7V8@*9:_UO^,'M\QU$_"
M_(-17'Y0\V%6O^ <&!!'@DZCQL* CMHL_Q"-1(] _IP:0])Z5VDL_>*R_?W%
M"F.Z1G#.XJX6/?YE;!TK'^[PORIB=^<'(&TKXLIG\(M$N=$P)(P@E5N"RJ,8
M+%:N]J)1,'"%F$-%ISNC9RT8F!,(9"^Q>_\:3Z!.MKH('<E3C7$M>C%MO%<@
MPE!S2I^0^0%'L;V1?,!LQ)#V_(%2.9CBXI_8/5#3N20:LB:7.47T<'L' V'$
MFH%E!=V_58^Z(S! %23-A(*G1I]/>G9;FT8Z[YSM\H7.5XUXK;@ZGC?EW&=&
M=8*P]LBUQ5PG?;&^#@.B2">&&9*97V-LW@H#(Z2AT^'\I/:G5V!@T(S^ 3.C
MP4A#<DH]_0X)V@;R@!]S>:"#$!]8;38T1]LA_JW@+>64I<7OQM YD$87=.V:
M0=/9,.3+,# ?2PF PF^ "P/S:1LF\R-E]0\'->NF)&0C!_? @&3.3W#0&^9G
MZQ"TTHV;88 )'$/W7%['P@ JBBH*TJ4@,82H'=%(%RG[TWQO/MR*G!U(V0X#
MRE!;3@^&P@4V3,' 1K#8C0;DHY&L;KX$ Z^)U.NKR<$MR.B_CQ9?D%$B$6)!
MBGE,P=1J%,2,7M2  8HA71,YBK48RAP%]Y,!LFS:I 72)<S+0&<8&?8%X+P
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M'QV13HC=3?:"?O['@R@NR&EML0TC>UE@3J*3E@V"=JHL.6*$M_8=OF[#"R2
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M6818V;EY^/GY:9A%Q(5YQ3CY^'E_(4'"N'\?&PN;],$#4MY'E(]X_]L/O G
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M\OS5@]/\D*=BU!)FS5W97!]X(,8/^B+EW_6_0U:@M/?=R4PS'@FW164FWKN
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M_4PQ%T^/ZA5/:XM)9<+>] #NTQ(!YJ+U?))4#P[]\OEW60NY$.J%P9&B<J+
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M_BJ*<S?88IPL3<TGK4]*U065(X&RXGYG!DBWMFX<M2$-/8#+N+)BW)KA5&)
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M\E#]'M?]<\47"KF&=-%FP49TQ>@1M8;T4T&[_Y-7_A$%!)_^OP!02P,$%
M  @ %(A_6DWH]LV^-@  ^SD   T   !I;6%G95\P,3$N:G!GG;L%4%S/MB^\
M"3(0+%AP'R2XNX:@"1 ([J[!@R9AD #!+;@&=W<)[A;<+;B[#S,?_R/WG%/?
M>^^^^WIJ5TU5=Z^]UF_UTJX-GX.O 2\49.1E  0$!,#HZ0? %P$I !4%!82"
MC H"@=#04)]CX&-BH*-C$./B8>.3DU!2D).0D5&!V1BH:%AHR<@8^5^Q<'#R
M\/!0,@B*"G")L''S</U%! $5#0T#'8,($Y.(BYJ,FNM_/.#M  XJ $%81$2@
M 9[A("#B(,"[ 4H 0$!&^-L _C$0GB$B(:. 4-&>HS\MJ'T!/$- 1'R&A(B,
MC(3T-/OU:1Y PD'&I>:41,%3,0;1..%S^4;_1*5]7=E!H#I^"N8V<?9#>_Z2
MD(B8A(Z>@?$5$P\O'[^ H)#4&VD963EYA0]JZAJ:6MHZIF;F%I96UC8NGUS=
MW#T\O?R_!00&?0\.B8G]$1>?D)B4G)6=DYN77U!85%5=4UM7W]#8U-G5W=/;
MUS\P.#$Y-3TS.S>_L/YG8W-K>V=W;__L_.+RZOKF]N[^+[D0 $2$?X[_I5PX
M3W(]0T)"1 +])1?",_>_%N @(5-SHN!*JH",G?!HN'Q1\5]'_ZSL0*/E5CTE
M,'$>?_X2S+-.=_:7:'^3[/].,+__)\G^2[!_R;4 8" B/"D/$0<0!VYT4X*1
MLA;FI92ZG%AO5+XJ7Y+O^;\+:.>7+LMH3(B#$F9""R91'DP_R8XY?UF" U7>
MNW#@E]/]]$+=W:<W="/%3!!SZ]6+=5LXX*T)980-3K;M=,["H.6WZDVO7-XV
MW-'.%3[&Y4/& LH?[PQ/LQ^8E>! !KKAPWG;NL9N=K)^5XQH2,:\CCOT5@<.
MK,;!@>?B534G=Z>U<*"-&49@'R*8NR3X/R<BE:>;IUC!5WZ MB!.L MA:I0F
M.S\FBSY4JV^(4KS6S42:&Q0*8_&?\L)94F\J+*3F"V>"E/K?%'SM<^@V\^8U
M4@C$X?-6;*X^"OM]-?UL4D;2R8DZY7"FG?C[$#=&B>W^5^7,O'"NY5-[R4:(
M=L3Z+;ODG>I>OW1F4M^)I9CMH[+D+09V9^FD0\(;<&.MN?)AJSCL"ROD9! .
M!%#.>T'^Q6B]-)NU.R7X,X%XU24<^*?<^!#S/3CP3UB9/(ZID^5-(Z0M@^OZ
M,\_S@348$@F%1W:R0+JT-GBTAR&^3T]EA&U]@*+[/XG_!TT"^ZR0;;2E$M7L
MJ)\1D^EH5)2_86I/*G*6K<2^-LB  V(OVVZV()V1_\ZL;E:$M3N6W#73?S#T
M*E\Q@,ONK4Z; _,QC'FB;%R6ISGH28;2,OT<V\\!:$)AT#;7V8<NJ+!Z<GY!
M)!M^$QEO,VCL093(6UO<I_B'V"ZA!;Z*M+RD-/Y[)$U"-+N7-T@QKXL*!DR\
M$-2O;;C9WOU>]&+*.Q?+B886VDOP7PL>CLH^GMML&0S@-)M35NU37N)0WJQ!
MPBG-I\1W:<1/VN$ 2:MZ+<CC<C$_+.H /8ZV0$ @.PT.R'TI"#UL"GI$DGV\
MI=R0G7?%OD>-?#@5[VVY[E.?K=%U;4IC(X](K);%GU5TK&<;]JEG:GZ.&-.X
MR:^',7,"!7N5W"-5#>77)\8R?<T#&;(&)8>.:T4Y*K^+$!H?A0,Y9 5[WD,%
MD-]O(*N^,)ZO">_A0.;W)[@1H;8QD3TZ:WR%CO$JZ T;T9:<8D-&/1W8%RXW
M$F01.ID3+<8%DMFO8XN6#5Y&#B'Q[8W[XW8MTCZ+<'^DVI*UOM:7@OG1PJ#8
M9]G_8E]/\>3[E2=55:JACA"7@OE;JS3G%:6KL!@/(Y?)\V+F/\O&"P+K(=.Y
M:=!*G/ A'1/U2"Z74<G^O3N5O[-Z\+]AU4;T^?7^@^(%.\'+=;H8!LY"=;LR
M32H*&:?DB;]A**@B)UE +]<:(C5O0(8]3!*_L#MX@E%Y]R&?):F?MA+44$R@
MY,VK^UHXQ^=13(=]I*'4+O2'BK2D\9-Z$:35/D]86-G]Y&Y*%1R=DCI>^=5%
MG]*L)G[>._S9LP1RK5.FH<S%-JY6;Y-Q,3H&@_'# 3R9HP\PS_FG0]P+!_Y8
M;5T0\L?^-RNP'.CULPKMI\5WTC(>H0XP^O"%?.AYM?CU>-MMLN"7OI'-H1IU
MSB_C0KF;8I*F 8Z+41GOSB*[GS?*YP4FFRLRPR1?&EYUBC\B/7F#7$@_Q1"L
M=0,._)9FL;C<QPO&Q;$@^)*GZAY_$CV)OW/&97)$\/B)546=]_6&7"MG/"XJ
MI?U*XX)3I-<ZR]%5&D@V5(TK\<W,:==F,#ACQP0M^B:5NE<V7V0JWHN78,LM
MG>:,]BZAG*R>4!:3("D@SEMKAS1HJFCGX+(4'?+B-GV/WBR>D@W5+,U,UP3F
M9,B^>0A:,>X3\?*7H B6]IPN:RO3,93&2, 6L2MX5R5C-Q"%R(>/<?4^AP)+
M8B>SS+_'*Z\Z[VNB-=^!\%)@L&18A3P*$5[$HE1D&2-B;E9+YXW6++O?"DI#
M=8C;4G2)8DPX1C-!X]HF^Q_97%<88</4"G.*G8*A8.;Y-^<[77248"W_,0%P
MV&_0WXR5,.-LPPD.Z"W>J:O  9HU.%"N_!A3:@#I"^][=''84I>%AOK#6L6O
M%2:$V3\(?E'^W6@'!R@JX$!#VV!N06G;Q@SE#>B\T(9BJ]0OA)FYVZMPO(8Y
MI09IQ">J0+\GQS0 <-_<H9@*=";IR4\K-0P&1QM[YL7:>/JS;M)0"\M:?K@\
MT.:6@K#VIR5KMH:;.=0F1'DFJ2WX.O7R1:>G/<PJYMXV[>O*V9'3)+SW>7O=
MR$9Z>/"]_ZY"%MF?&>,4H:"T1;\@)3=@+= V6#N&1W.1B.++=S2!40FEKU:(
MG&SV>5,&Q]<KGEDQ[AYVT#V\P^X*Z@&5,40BXE[1_;3<ECIC6@YYUF^ZZH<;
MEH8UQGG"OGUD37QH.Q33XPP1VU8?ABM"B/.#Z0,P<L])AY&,-<&1+.G"9-<\
M(X1]>"L6QW_F2$E#?<E>\ZVR> 88D@*;EB)7VSZO;NT7CD4U1FV+!RQ;^)'D
M-@?\L:.*"*,C?^7 6@_&;8.;S[X%_TDQ_S[8I$JTUHAIWX7[=C"F^TNS]WM)
M.)#NU_Q>DA@)YT@"_4E!R**&,(G9U:L..'")]]ZVJ6DW^<,*T?"W%T5)O?(W
MA5>0.T1#R&PS'-BEKX!^?=)@%V36#%8[&>27)B>CR^=D:J,01Q)'W10<  ?0
M:4Y@OJ=/-F:1V7CK^]FQTM>63!JL.5BY0]Y&LG@JDV'NLGX&OHY2@-EBCA$Q
MU)?JS?0%U-RQ4DU93!Y2R"/V4MH0\T5'7PX0ERODZI$SE6&EKU@&O<5.G,TL
M8H(#N*TEGS@4&/P$7U<%O5_4,@J+N*(SE_RCC[NA$JL<I%[SN;_>(<"<-'"E
MY?.'V6XAX78+1:7I+"Q3%C 1!J&W6+/GO>;WL0)=&^6G\TAY#=%\,E>;KA%\
M9UG2_I!S7)RW@"Y9*M95I&69M<[R<O6>5T#M0N\PY4 4WU)AKRUIMY=,8\%!
MVX*&RFO"=VJ?I:/2)GZYR]>#$)G/7?9MTOO?NKF9^X7% #<%_7[G<X6O6+A>
M@4#4 8[U.F[EG@X,"W:NFFGV$YZ<SD@?BP7,<0KLL\1:062;X[8_;_TD K<W
MWD?>_'PNZUK[QN"MI0]D)V_%"T9<R+BW>7H<0/8YMZ)>366Z ;%6P,/TC1IJ
MTT<$D#0BX$W0N>\%"77(.C>8N:I^$?&> =E,WS\ZMH9O/3UIS&NW=+;;T3JA
MU!J/:*BAUN_L1BFS*&#(+ RTY G^X\.+U_6+LN%[XB&K>=B6TFJBHR>E+SZD
M4WA]_16E40WNF\SH9<)[+$QS#T/EJ2_L+,EV4Z]MY1?X G6-%++CNHX'QNC<
M+?-'-+Z\S374,^@12Z'0.:8U=FOWK:)Q!M\L7F! ZB4(/W0)(46_BE2LM1H;
MS961''."\9S<RO!P:+=5VW5\M!?8W,BSC?57.&/\]=:!ZYK4O 'M58A$Y1T"
M['V0FPQ>!'"2FFZME/8GUJ-"GF[/AY(-1=OEVP49?Z([1BS%,"[:/0EP7'+$
M^K&T6\,)[!C;@+0WYI78[R<=UA1D)*=W+K'O=!LYVO)G5>E,^E>2I9TYP26A
MBJYNG_W$.PQ.Y'<*8&)!$\F.COT&FI+6B!H">SL65]:SA9$7#XJ_N8Y-L112
M8T"#.\1'O0*9V!)%+G"@7W7L<5X\UTE#(_T5[KP#X9 =P=!CKH%QDQQ&4AB;
M5FI$/@.=,Y=M;0;L=3SD>."1*;N1BTU%FH .6;TM;J-N$<\N7@/GYR7X"HJB
MO*Y!\288O;]#S16\]CR_ %+VY/#*HY\"+*^:1H[\KHX?T=&Z5I9^03:@]D-%
MU:#C;X'Q[P^B63A]>':T%"T&5_J?QKTOTA2QS%I++#'R:+VP1H/BC"\X^N2>
M.\%MF\9-<, 'LONLR?'T0VQ8G6 E]Z<_N>2C&PIP($HTX?%SW]/K0NK5><KO
M$.<ALRV0>]1BUV\P>@?L )PE9?+2FGH\OKFLU\=SN\! "?>&(H;D-F]W<0P@
MX]M5P=S H<JE2;:3:Z>_2+>5>EV%2YO,%UXYBV0$!X2VK[#1K1+"KY/8IL'?
M<YYIF!D%:%HL<=""*<N<5%6L6RQ_?LT8";DR8T5<DBG*9ROJ\-B8\KT-J<SU
MB.C[X/<[&S]](Y(!*<[.MU_D4P?9I2!!XA?R]:NIT"0M/<]"]G@+,F,^A/K?
M1Y@1AYG7Q5[*@;&*L^"V_KGX:.WVG\'":LY'BTZ=$<*,F4C34'WS//W'))6M
M:*V2\LIO3M'$L<BG,DX10A?*$"*K,SU23_HHQ; B5+V[("IC@;L(N3UYR+JP
MXNMM3W!CHUR^*3B*%@B4HHS7S7.I/^T?L5B^Q4*./8K_T.]@8G)*G$(J;]2W
MC>C4^Q0-]L+>H_SPYAZGB^'1WAYZ@77@_HQ+*W-%[L[;2)9G]JPLB*30-MC7
MY:&6[R0)),X5]F7H/%TV5W,"2HY/\C':!J_E!J^JY9#4[TV>A"!%/NA>=63-
M]M7Z^69+DV,!=:BG!D[/6#\"T<G4.8?@'Q]V/8]ZZ=J6S]HG2,XT6Z'4"_GV
MCSD;)W8[Y#:*I/JA.LE7U'Y6,S/2[P8#B*M^_MH#(FHS&'QKDMC,XKZET$E4
M47>PO$;"; F?7P!Y9_,6YNRAYZ8$\6L2<NMQU<2\DV1 M.H%VMLST=W_WV.W
M>-Q;%5U(7XGX,?:6ZI3HD"Y!?IO?ROW,Z.M.W5*82A]2P0#Q5:_RFDT.25EL
M80]9H!:Q>ECTW1QH"^P 7*^MC9=;LQ?O_6%D\QYR(?.3LT1O-L7")B97B[Z=
MY?YZNBV<M(5C@%3K^(VVD.YY+^U>%*K P'VRE)#\;->-KSV#OI#11)C<.BD;
M"D@L\P,KP^EESK($BWI.6O;%<Z9JN1(IU\W4G8N;$M&W[33GY[K?V2;H8IT3
M7Q-(E))0K\OM;#XZ*:R 4G4'',BW&L/_Q*^R(]#1>J(?&WC?@L-NVB\S,4/S
M3O=B2#V-*I-:IGUH>L,K?YD@7")N0T?>6F,'_4PYXG.RKNS/S(RGDZ9"Z.^_
M?F2F6.V8Y9!TL*^?.2 O'&9C]8W^!0?8NJ%]._<4REX_GTJO8\_2K9"=#S(7
M%,3<FS%2,CGLX,<)9=K)K4RLP?5/<W9@VX#:MYXI7P(Z Z(C! 77TD%;[ZI3
MWM:$LQS9LTX!9EHSDK_3NJ_V1FW*&K.7;1:^UK;P6R/VT#1'!6$&T"*"F&=%
MOC*GAZX/TH?487_)4^9H5HI:_WZNP]H*60"=]@"N,T*EZ;FL@SKOZ!Z$O[E]
MB!MXWP5J0U(?[/M]&5PSX+"==C2<$%,28/?G?-PQ)(W+Y<8E>2[SN5<;U+>\
M[6#YK_1!RUL,#D0;MQU40726IN' )N93PF!P\N1FDKO.;J"AF'! /_9^U@+[
M]O>5R.'0XTSYK52[^#EKY/W^ZD3V&8,_[1E?FZ6+NQ.35H\U"VX/1@")_F$0
M*$+SN3.3,O#D@.O$#XHA"OM,3ADG>%?,K'# )7<WDL\AB+#N9NRSI2N.>_P!
MCL*A:8 Y$DMTQ"@(5(F2V7)K[.5 E]Y[CFJ:_.>/O-''.'.K9 'E:D83[()[
MS0(5O7S/KEO#3JY;0VW5R=#$G4!>W/[#B9]R_:]BI[EC1+EL&XKJH_IA:K]]
M)CH7_?!\VL-P[BA'HWF9/W0-4CM-T]^A0O</%S1H]OB=EYW%&,\^W;_,JI#$
MQ\UBL>.JDS*>*^CH)V]]4N\>I(:E;><8^^&6"<UL@B'./*DD)UJ&8-6:RNN9
MM?.OKNU(EWA#POT5\]::<>O3$5=\EYSA89I@;3-AP\?RY;6OUC<DO3_9?3^9
MU:>[%.T[=6=9J7&7#S4N(?8!E,.:RN#D=^.)6[8,KP&F'KGVO;Y:4?N:Z?/K
M$1N1RF]=[(.BH%RR\@H7V<;V58_XZ_V%F8NCB86:E]^6%Z29>IC>E:@G@E3!
MQ$3ST?<A"T\Y,KY!DFNIC##=I$GS\W-DK:&:GQ%\9S[9$7.E=UCAW,QOKPG-
MO^[K&G=Y14*\XHYKYM$)TZ?KV6:&7O5?BBTE"QH:_27-Z:_6 KV6?-4'O<F"
M" %JN==W493-SI+B/:L/#;V"12/"<SW%!DL>H:JZ^$VZ<NII)/+DWJ=2-4;Q
MPE_],DK=(!\GH1T,"ZSU 0ND7IO8[^[55']%.Q'&<6O+4QPM4EH37W6<R#(?
MDHT?NVAP[KL+]8;C)X\,)-G!)CVB%<+1J>C4O4_ Z3F4:V*U"]-$EA-'TQK$
M=K3/FR5>9R.6"1RIP@$K;<C8$N7-J<K@ XCG<[QMVIE2BFM1;5QK6E\T%=OB
M#4XOB$RCRT9#@?NZ(+*J;N/N>3'O6"S9?>VP WEM"=;@MR^;"/$?W=8<F154
MXUZYE 7R[G6VD M^?( D#4(Z"<LAOPV?O&8KY6G P>HEX=/Q+5=N.9LI-LV4
M+M*WFJFD&Y*P"UH8@L9<LA&X/T-!:Z=-QP13XE@T3/ \%%Q&S?+WF7$&5X2-
M,$;P+6E2DVY_C$YE5]B'C9=OW=".P7HZX<!G./#,_',YBFW6@O)M8M(M'-#<
MYER^.]-7K$WK"0B,M7-UM(QC !KA@%/#38\+!=5M<,&MQZ*4:\X">GZ(;#3R
M)%=,65%16(&G71=IW<;/LI!)+=@<9^6WSNN%8-_QID*<EU0/T.4BAM!";<;1
M5=<F4I6AW?6<':4;+YO%_4^\.\E3R;EM(;5.MF"8QD]\-_E 8>.O*=_\?YMZ
M@-V9#8+TAH52$R8'O'A"929F+(./P5%HP#M_:E7.>JJ;4<'K,MH)@?4_HA8+
M@Q.=N.?=46 N62YS.##]C"@]/YU+;J"_QZ!YQO6F,D2^/,P:7$SKZ8C,4:1?
MM"$J]VI@[.-UZ?69;)"F38K\EUGD"6JSQ7F^^!44L6.$G85<Y1>W]C*-Y^/$
M=E/<0HN;9!N TX!P N(O*\2TBC/*X),K(CNSY)5Y\PRSX<H36X>V\W-@MW@J
MHW^2_BRPI33_<'&;1^7NC$AB5,K<YR#,=PGPV*Z+#.$QK$_$S.&4(D%D5L31
MD!G:4CA:\TFZ&7D*?-DL[M5Z>U62F"W%1,LV4F2]8'"9 )%X.&"1!M&K]_C9
M,H4K0"&0&W.IX[_%34N>\AG:CG%UM%)JO4(U<RRB4_<!56/JET@5JEOH(.:V
M*=D7J//<T4R)KD>&=-JVJ5EE%[&KJA%=;A>3GS_99@5BJY8RWJVW\/=QZD\)
M5&*L<ARX#V+>8H8I$5:(>>4B9_S0,'[#4^Q'0//G;+I'"DR&M/P6!/-AKD8[
M:Y.*)(;R[KN3:$)]#]L.5O[__0O=,FWHN_V@SN\.=/'HK[;\\'@&2'F<$,,/
M08AGO-L7'OQ:#QA-^IVY/;^R?H^)5(3_4EL_/W;V2MVA;0JYW&=2$!FV%EJ;
MI9H]^=1HL-7B[T1&IQ7)NDE$=M'Q%"*>E<O4IBXM]'$&:KT-NW,.XWJ45I0&
M\%7^]4AZ/B40_)17(VUQZI3G;-CWEW!@GFEZ!^JQ!)GE@ZFK0?H;Q \FX8!9
M*6W5%7="]R-Z_.K9 ?:#_YU:+4$]U*L+M@939Y5:JJU05U0ZW;O7'UGHGJA1
MB=>:PM5OQA)58EK&#_0,$:NTRQ[)LV7UM*-*9XY+?CT)#FD_D;6Z4UO!5DH)
MLFG$C)JZ/,+2#+DT5>$0U U^7B-L)HBT]J.?B(6[O?QUEH^ 1OP]]DOQF(0)
MJU!.-269@_86-F4:=I=>.&!3ZVE+=]UFZR+BWN09.'U<%N;"#<@.%O!!\YN=
M=IDKLGQ$9E![B[/U2.79VYL:0TCETK9P=8^1>,J4!&E9(WQ\EY(O;3TT%A88
M"9+B>5#1Z[1\. >.;108@:P0QF?IY7" RO;D_@;RB#1#&=FVJ>5P?Y@Q4\_[
M;W5Z3DMEW10K-+1!0ZL*:^:J+(2 0+#7(5N04TW?YD,N^4+EV--QD*Y\"L:Z
M]YHJZH>'=C6W(J%R&HS5:<4'&DRV4^I,@[;%S&C2XS^?JRXS(^.K:*51RPV6
M<+3C'+^RRD3Q?$H&QWC@P"]I"C7(Q8CX2;1R5JC/&)/XW7;&37_V8"3,,__Q
M_-6EBB/QEBP<$)F$W>'_:X]8"!NB2 $<V$F&K-)$_F-3_KATNV4<)?1"^6%3
MY;\VW3,V8*JI/Q2!?JM6%?^4?3_8A803)<V*C^!OOC:"J&0WT^0E\Z:0*>W0
M[0<XDUB$$;R&)9B/C6I%,W.\^" J$IJ%$=RP01T:W@)ML& (<[9U#@&Z0SM)
M,/C";9*_6!#Z'BUKA]K+&HW$*,F#$=-KLM]63X3G:#AYVK*>)-Z9]*0,T8(S
MS EJU6JQKV8HK\[%+U&* C>538Z<8SR4UH_-3#_EC6]9A\=K2;=6QT:T#O0Z
MI3OIZQ/0I0:T^><%;K$9[#&DT7#0#FK%A17JM[@!&1"=4-@+"RX'VV\F-#A]
M4T1G]4@X U19T:F^BZ5N/]Z#B.$ *M\=.-[3)%T[PL*3WT+JPMEI\B0]<?=5
MM0?)YV_&HG=QRZ$BD3%:1-T>?<I-((%^D>UF'4;$\,@.;!*NTD%32NHA"^XX
MX8151FQ>%@/L>$Y.ZS_1QWQ)FW:+.=0WQZ+5&5W/FA88@?^QE_B0W9!VA7:T
M,!Z#I/Y*T$@J=LJTH(?_/RM)O>K;I$G\)8VVZ>_'#"$S"[K!2V 5:G?3WXS$
M] V8S+TZ,<$_6X-GMH_EMFOYHXE4&3?!! R(3(D&LJJ=K<CC9C*R[_N[D+7,
M<-1YR=EF/]2=,ZB" "['=LM,L=1/A2R;-7" ?-E ;['[XU'[Q4O!D(&NX[AL
M3&)1B<78@XE:7DR;8VR\GKQ%>?SHH1J%F#^T+VB+!,4YKSON0Z8K?]<LBZTL
M$+'2P $9I#?'/].<Y<&<FV8Q$)*&F=\B61J!?%&?G#.C;W^#4"9MMD>U[5R3
M,/ ,$W\^J'>^Z17H0F%Z0!WB$&U"T*WVB/LHPIUGRXZ?-Z@F):P \22I.E42
M2IL#'>A6S2TH.UQ[EAK%D.T,>73HW:^=J1CNQ=_'M;C=(+3\B#8[GZXHK=E\
M)ASFVU<+. UM'/1H\&MH7!]J=>*DA<HR,HD9"5+%MP-N%"UT]1&N;YL_#YA4
M5?<DHE%SX?R2HLU<X)[<'.6.3=6TID\Q9HD9H(NK;LG^&#;^BDT4K8\V1"5?
MJP0;J*I_T= E0Z-?(K069O0;B80^A_<KQ<K#YG"(.Q(2($EU!5P1_'P7PK@6
M;!+(&\%+I";I ZK OP?\+F B]N('*1"F(O%-/<JK/3A0I5X\=GO6  ?*[*!%
M3R8;[0B9S8<-Z,B:[UNR!]\3LOZC.9N?(+$?\(/[V>O8@3X=\W\ZX>@_NKIY
M?HLJDYD7)X=FJ_A&/F8:I/K.7R.\BY@HMDK#<UT=%3B,L-! (A-!&A;J1@JI
M'*"?!R.>I=L)?U+08F;?/NB4V"#*DT)C7K[6[Q, #8NB,K0IU#OEW?I-Z.;(
M3N76"9Z3$ <E3WIR(EN*3CK&"IY$3 5Z(1/L3)2'TM7P33PV"69IM^RM=V"]
MZX@UZ@<C;83A3);:%]DJKCFF6$2JG9_*)B6A+L]'GA'LI7_[#9(I*T\KP<+"
MPI;:>VO@@))6OL@Z4!>I+K>=KLV*\,/A AV#9^F\618"L5&O/W->4":5_S*T
MTSLQV'T7X&W7@<^OW#P8A7HTXR-*D/:!-!&S#Y&A\#)?DQ9B7*9W:RJC-IR<
M@UL2=N[#5Q'>SCIPK"DRHQZ7'_9R\9636Z^FKIMN!(;D#_L?YL'"6M[Y^ B[
M[_9S4(SXR3#2\^);1EG9>V*5B9MBCF4"92S!&,S0=1VN8<FU"!\L6:\#$:KD
M5"^IO (&KI)\T]'NZK+Q :28EF.B@;WT0!_>?X\,*44V\?>B"0ME]7>?_:#^
M#/1IQ4]I*<D#K'45#DCR!FV<W+TDA34S7)6EBA#(]^+.5T<2:ZA9C>:X*VS/
MQ!4M'KR$V-2N;ATS7X21A;3JM?E -G4IKZ;;<ET)!$)LTK1?"]-K8)44&Z^K
M?JYUS IA1BQ@S&LNL=&>8XK(27T>>A3?=G&!_7C-B&=M/["?GENL977=N:/2
M'+* VR$E-S<@&E18Z#UO"P?$.># JDE%B[39?=B]W75*@;;TU_S!B3=LWE89
MSOC4/E016)+X>GKCQ]H.1!ZN%H%X)3H.22K9I+=&T%=C2I_50S-PK*X=B<M<
MF3VR$863X,#"(ASXB:&)Y[HFZ5D0KK2A51USS6FC#CI>B^H=UA,Q6O./CLC!
M28X3H19A)I_2Z?&=8K5_<_W+7D?$XK5ZH.3.\+[0"\:&I_II2CRL19 RNDV[
MAL(+C5;XEDD)8<PX7; 4>;KFNCYYW8&:\W6/N>,&JF0'Z.Q/ [EL>[Y&T\/7
M[4JSV6('DJ*^Q#5+;>UY P['?DG$U/1'FVX*3#E7GF:2N)B26'FZA6)(J48:
M'?J)3XXWCYY@]M*^;"@/(CY7N,&DV0G8J3Y1S"(,=^US&-G4[ K-!,^BK6YH
MZVNBK"9BWV XH-WKT6<@6,X?NAX<81YU$&]&[?;FL&1WB)K2, H&FJF=[4P0
MRA&BJ__.RRK0D6O^X4',FL:2PJ C?M0E.ET@:WV$8L?4[@\KQ8D*;*Q^RBCF
MPOZ$3G>[%P'VANSS3)KCS"^2SX9D:7:\NN!:EN$!8NJM03N$WJ-\<G??AC5$
M_81%5LC.-N7#H8KC=J2S%Q..YT<EY&Y!\:.09-^\]+_:EQQ%.D'W!]CW=Y3W
MB.H+N?_1\N2G^4QHZQ?4O= ^Y6!)KUU2RFY/FRY>>10A[''SI=/PCSV(?*"/
M8&4*1WM1"K]2]AF+<[-(: 1QXE;P_79.=<IDBSE?=H&.-GTXC_/812PX1=UT
ML=E-83/5K6]#U0;&\E7H^'[Y8W#$' UO7Z) C#2=F%*.&>!YHF$2U-5$=^FX
MV(7A;BFLP:'=)^&RA"6-F;7K4+1BRX^"EAMK(RRW5F*N5B;*/7!P($'LEB[(
MJ=5]GQOL"_UAZ1I%P#+NH#+I-T=+'B&T'75[L!FU-/_6[/<0Q>V\O^!K.=,:
MWSYR&=E66QL2L4A'&MEX5&H_.?-X#C70^=AQEV4F$O:6HM]DE^7[1BVC.NON
MW'S:J(@&^\_L*R. :D9/M2ZZMGU)0-,(Z>!W^Q=!^IEENK?*8AGOIOA@HMS]
M!X^Q5"^/7^ZUK#^T]-/>.2/8RXDVE)K];N'?+&&VM5#]^(/4ES4:RB!XU"MD
M&E(-"JH)-8NFK@C04$4_2^LF[Q)K"?N-DO8??>)6K):+[M5SCF5(N_@E@GZB
M<O@]F<?8>OF'AHFV3>RGRLS@[,F)T.2^'?)DVZJ5CRZC>3]&)%(@BE90\V\M
M9'2,M]S#E9EQ[1CK,EI82;Q#XL%IG&U,]5>90\V^UN:B _J=C N*V;]0G/2.
M@B)8V%D_'M,%'\5;I6UK8X\@%JI4^$[%=!$=1!_H$RQQ+FF/8936"=*:N:0:
MX?CK06'/)_(;(\[,T@55YZFP8C#( [3)PHPJ%@0O"UG:C/\(DRMKQ"K7LIV0
M4=@*JCY+ZU%(/2?"F5PI,K@=>EO/%/6NNM]L/BR.""G02&X3L:-':P+*CY)0
M*.^=P#W@Q,4UJA>FT%-O3X6%NM=G,T*)??E]>8[G>Y+%^Y\R(]W57^8&-F]X
M$%RAAKE,3*7#%FYDKY9>1/NUBW'(83"A?K'+'W% #S"/VSY?X!\\TM]"WPQ[
M@7JD77G+I%U+%%VFL/<B(89'WIV0!20J((B4+K<3,@X'OE$J1ZNSL;'EAW!]
MR7$CDM"J1O =E8<6()HJSGSD=> ^_!",8?P6,^<%D;FRZ/==6[:^7CZ\/MIE
MRFILP0D.*;Q*78OKC2WDAD(1X>P]+Y(E67-7LOQ7I.<^F2H!("NR1Z])NM.
M%+]"%Q>2?F++YUTW!7J_)OO(8B<K>1"*\VSJO'H*&RM^# $FOM<$2!$-_<04
M&R'-ZCRM0N0,[^HGCX:(['[3V L*$-C[4+7 @4C2R/OMU<&BR#M"T*,7Y##.
MYG^1,VA$SWLE#?WQ#AARN+T*>NR %NF$+,)$C>& (X0I*BHS1@*QD!?;>:;7
MK;28+WGF=Y<UW?+($%<?+H=>@.JPO @6Z$#KGCTD'3:D/7V<C6-=E\^!@=GS
M#,7$<U]^#WJ@\T>4P:#&4"!G'!Q&X/^#.H&Z0A(T1>:6MZAEE2!D&6M'T*RM
M=Q1K0AEWO0&BR&"$%F)TCK=8.KD;12M:U0LU*YF>4XGIQ+W:1AFZ1/"X8;(2
MXVT(.59OF,R1UC:+8/Q1:,U!W:ODK8I1V_HYQ^K^VXCH,"=/22;QR]>E :."
M2*;$XFEODNG]["DDK7%;S-B4U"4[-Q#SI972_7RX0>&=A1>7A>LF8%02LRXA
MH>RPG4JG,>]I0^6SDT4V\Z1#L+X@AMSYI@6AA:L@N9;YY^>[;#R8% <?G1=D
MM(ES]#@Q<A,YC23[A>.4OA;%U86NI^@;#OBM$)T8&PKD7:]9"G]G "%?Q$[R
M($AIGW7S)2Q YC;##\=.',@WC-Y(UV'^^L8Y,'9:6"J.XQ%00URR7 I=E$<J
M%PXDC5;A=Q3>KJ&OFC0\<N!QK%^D01<TA54"M*!%))BK5D?6P<NZ]7CA4 _U
M=W3!"U)L*-AGS_)7?.@F7"VF#/:)2REF]J>GS8,3^?@9C23)*#"MU<G%^I0G
MULVJU<+-OE03LN@W.7?'> #>!"8SQ^AS2-?G:+1@GW9W$.@*'P'K_Z)D_?>K
MY7E_&(^HLC 7'' MAKTXQ8:&FL*:ZB_+LAHA_[L>L%_R,6UX:E@ TIE67R\%
M.9H''%CD"_C83XAL-CJ<EIW?1N9>[)9<&EB=.^2>KR_M@D+LWNN,@!CU%=,Y
M;<Q$CE7#3#<T>EMAPXTTRN<:\7Y:6/G%7H+[D#40BZ5MDMC]1C7NH4/W9R_V
M5H_-&R?[("2HO^]EV4MA<B<>AT,Z/ZO+W74/TVCJ#\R%2(P.&8C$FQ&_YG."
MP]0CIO3G\64)7V[I'7UH,8Y\]]RIH9;"WB+HQO! S/C\ZU?FT=4NS01^DH#I
MWL2S 5>KW](8'.4)B%& Z]"5P(!89_HG<D4'-HN(02?2=]5@3)*J_C<IIZM\
M$F))M"(/'YCZCR8U*F+NCG#JA0!MGSL)Y@:RR]Y7,_=E:9_*QI>D:NDY[,'
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M&6;&XZ,#C+Y<17UD*=V@A_R^''KV=/[;2N% ]WB;.AQ(YX/<7+7=)K=*BSF
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MR+[)A[E8NWX!V*CLG,.QU=@&?,R9=WO3BKN6;B[LY9*7@DC=3%I0X?]+6_/
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ME-="?W/0+7-&;SA-39V,&F4]?,";>G#ATE<Z>#:-=)*54QZA?I"NSR1*M/@
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MX&,87?:;?P7 3Q*I_]?B*N;>?>CP3HHU)\@CE^CQ?B8!=]+:D"NUAI\D*T2
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MR^)$LY^C!E?NE"Q".;N)Y7JC[>])M2,7+"#X_BG3B2MF1N-E[/P,N$?]UST
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MN:4?$P3_ .?HP.],+LA^(E8A+BCF5H)($8KZV=9K X ;49+8 Z^+8"Z<_M@
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M'G=)LR-S"G;A6W-<G"&$ Z&9"G"@X#T<>,BWR;=@$A+(T@S25A@Z#_3*E_E
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M>>X<IY>0/9A$!6MLY1<'I;%46IK0TEOA23(VD4D'[6(LLI]]K3'OT9"?W3H
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MHY.,([D\H@I-Z6+_\SQ!T2/)E68X("*Y9-[.!JH*<1 )8HC>]O*W^;$PM3L
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M$XEC_\$!YV0-:<\O9Y/OFB#8C_LA;@P(O'[SE5C:UIZVA:3,H2N'A-B(/3
M^-4M[6ALY<XN[V@/C@XH2:)I$RL"B=.36U5_[3.02S3EH6%1B@CP<OX)OF;'
M-Z32-M2^SIU@CNOR,^UM.^J1NYAYK+57_W(8IH.<826XCR*E<>-B$S94^8B>
MER8SQJF3:HWO_OIW5P^/)4C GT+:IG.HJE']0E%XYOUX,7,6]BIP[^1NF%A;
M;F8A<4F&_8C1 $>_%R0L1.O+/G(JGI;$,H"N$URW,JSMF.D]EJ58C5B9E;>+
M>0A=?><8BW;51I.-1^G''+2UFN-ME<.F#ZYZ03%N!VL7OG!P1B$DR*:'4=0,
M&<N!&NMN:*+9/WJ>$JL\/]S5Y=ITH]RY_T (8I1IH %<^++YPE0\,6+,04(;
MSTT"8+> O0Y4<Y<7J21Z"U@\,QZ^!90E)+HTA%OT3*T]/3&_.LO4]6(]::X'
M![:!C_1^\5?96V$BI82^V1(89BHO.:EL*Z6IU*33"TRS]K.NJ8TO2_3YJ:,]
M\TA6-(][._2^QY"[LE>H5[DE.$9*[$W3^: ,_/W8\^@5X!,H^&1S++JVF"79
MF!M+48CZW<]XZM]3((E8T $Y+6?[!^Z:@,H--X);(-,2Q"^J\U%LW %-_!6I
M=I?,\).+4%5A\'CR/%-T?Y9M0==6R/B%-EQ'1@X_/>N30M.T9N88O-P<+4Y9
M(]*4X1:(?4@O5XEP3U74GIL1AO-.TM _#0<*?11-DKZ/":7Q!DGUTCCE@XD=
MOP7A7+&W?.%#$5/I0"T3*BX$B$O*Y A'5.5Z*:KK*,/?1]@2:_<08U"K[:J7
MM0@73(F-==N4V6GS95H,M0V36V33B'I_0]<]#^\XNM*50M'@VP[*J).]@]!L
MG]%GG2I9:VJ$AKK,B>PIIGG()<Y^T:E!QLK2!:"W^;=8:P;@%91.]WKGS[;#
M9O-MWE;5QN7%!@Y3),<J<W?K%U54G0I7[P4/VF=@Z7ALB6V 0!U$B^MU*4@8
M#4=*$']OABW4B==HX;'08-R(<TQ/D\*BWX.V?L+9F?M"^=$DU#@44$!P7VZ^
MU]O,;ECD7LNDZQ-P9NEBAN;>UIJBF($VI57D>UTM%G VC=I8T#VJC]"3(I=6
M_.U3*:7I0_G[3,5L7^<-O^+H?VH'T'D\UYK9V4")YTX5F;AU\M!C6CO.8/%9
M.PG+>%90H2^LY&\X7TV_NN\1>;/XHQ"I!9:I07L3.3PJ>V%64'CG05O"IL/F
M:9R^3IHI_0RT:;!&/K*)\*NR%^T<E\<I4+"D>!;?96V'T@NTHX16(9B&?.*-
MS?!^ $8$CNE&Z^$[=N:4FJ0*<>B5/7)/W"+1QJ8K[4U"%29^]>5^1@RJR!5Z
MFFBA<Y%ALT+$ACW7"M0DWM/8<T*2.%AXZ/!MC/?>KSR.'IQE]?N("N"Y8D3[
MW&#UD3&WQI-N7M3A$ZRYAMZ'2VV#=UN_W.D+Y;BMK2@__]!WVSS%T@S4\V;G
MWQ=<V,6TW.>:H6G%V]B4B[^VX<>\1<>K]#O%OX/GJGU#=5'DLY,"@ZTGK7V9
M9J<P@6+S6P"?5$QP%_]T9.>[_Z,OHNV7!\IBL+Q/G/7?7"+L(T;Q?5FTFJ+)
M'NNG39IFHKGUGT'H3C:+15_('>87#:?SE*)K;3W6; C[EORHTO8';$Y/W^V(
MMT!-^72C*W4-WXC@6)98%'V'2B)# 0<"B=/8-Y6'%]X+;X.0-%C4\BK>?15*
M6=<.*M<86MQ5=G_UMO\..2VJIUHXVFR64Z3*P/)DK9*. 61LGU^)5$])?'UG
MD@-J4^,Z13$1UNN'MG!@"8H_?SU(GIH1I&+JE-0/Z)2U%,I@"&+&4<&YAYT\
M1_Q\L:KY8+!F1I'9;5C12E2.[7+$H.CZGNM(:X'U-S1IXW/$+: YME@?KU!+
M]5RGOH,D)2L:@(2L%[-^5+:&*4Y>J4A\L'-A<:K<DTM\SO*T 9A)7S C=<N4
M^>D%U/QE76XT#(7O+Z19('@?U':/FK$^5IF&]O5MAV\5_8]3C,)!IJ=D@XP=
M3$FF&YA.7^ 3CSCL%I3$]N7K5&H-F>N3N.V/":*6DY@]0-59;VK$<\RJIV>W
M2!]$A F,F)J2VB6**WM@KXEF?5@@LD.BL93;\9>SRS0VI@ZT>3IWPGFH5Z$^
MG6Y:J^OVM![KJ!HDK<)/)93I.US.$UN35>FN0SM"EB/@8B9$FKIM6,0QM:J8
ML]R_<%#L,$:E!C_>,CH*<MQS\6#5,/<6^*DA&$P'62RRHWH3)OMA_:LF$(N[
M*K^Y/P3;-M8WZ!4N&;ISQKBN;[U"$H;@70(<QH](V6,=&^(:COO;+K6TRK=V
M[0E.-8G3/LOG,AO+8YAPR1+L7X&^G8B%>/Z,%#4G\WDRRN&R72[)=(&P+E)+
M 4RP3%\9-SEYTK_2RM'3CK/@R,C(?C?_ZJ)FSF>$6\+S_9;\B8EXXHQF1*<,
M;RFM647R+< \,R:[8;+U!N5N074PC-KJ5,Q<[HI.IGKHS%";,'NQSCSCH4[3
M/D^]XN2L?S,X]/3:REK1]!: C]\<]C;2NV\(GY4]"KVDR(S/:>[*6?-.F2@P
M/C8V-P<=44QJ"C4.UUH)%] S5]\T<V J\R9H(<<&KWZ$4;0(S,/?"9FJ2X]-
M 7DWJ1ROCD9=N\RE";[O([!9UPQJY9%],>&(_5U!/XM8Y1'1G9[%GOD/IZ6[
MMP!C0^OVW"WPB[DX/1NEME%^[;M665=,=O=7[]VF]&2H-5&ZX!;H8QF\:6"]
M"7IXQAEE):3YPJ=NPS?J95WXGCY+YTX][!Y'S^[HWO#+F+[C?=5:]K4""@,4
MK"BQ>Z+CJ_Q 8HP=%C;=U<H-O\F[,MS9.SOY]&\= '[RC=GYG?%UX,M+LR)H
M--%S9TW88_WQQ5'DX\]2;BFF(3RZU)%EC0O$>16X0X"C!)Y]JL>GW?NH:9 M
M&*#>?4$#Q> B^*U?K<P[+/)[,F\R\PKNG5)^ @NS-VL,U]*4,>J5\%Z;G5V)
M)/R,-6H0\N?>#MS:N7]!MG@+?"IMO69#-(6OBN+R:=[@A\L7R.51:7E:&&7[
MY\O/3JI'5S.X& UT,@3'6J)9EETKZJ.0WIXLX_P/],PB ^9M2EHR@^/'3RDB
MZ*,PW#7=SIHT9NU]B;*L3U7M%%G!#6I'=%KCSI/!3V@U-))?5 ;M<K!\KHM>
M/:RF2GQ:YV4LWU^&<])*]@8O=["3WI2(C%[P19/&T<K( ![+DHRP:(S"<NVH
M@X^JRYS"?-=64V =]Y;F01;/I!6XNQFZ$.052>J<FB(OJ]F7OHSI^9BNP-\M
MZ;YO]VP(^M,'<HIUHVTCK+5.I_."Q[LL>J600L-[D'?KSD=^>^I KSL4$R.=
M+E%/_^ ZS4KPSB5-5MC-'0O&<W0Y%L<2$#88)F_ Z-LRF6[&K.>D;2I<]=7"
M.VJ,_=1?715*4:B:Q?>R"K>7!CF[A;>N?#887!OE1)(W/BI6Z1%,*BV:_E)*
M.%>C7R7WMI[:BCPS,B= _<)O<Z25Y3/EM!A59Y*?L0<'1K#SH&BP=Y;F:V'^
MM582']A2%NF;)I<A<G/&=?-TYI:J^+/T2KAO *TURB6&T.K^*[G3:1\K;B %
M.MB?[N]9[:^[4RR5(>*0AK"=WQ0KG[^^"J$9ZB^U=)[G/=0H/9=5]5;$W^[S
M*;L8M'T?V-?+R=4IM$%H>B4PIO+^BL:68W6[H$3NJ78[<9ABI'^9T.!A<'1F
MXR?Y<0Z#TP%%CSVS.@MJTMZSY$V-7_H<2%\Q^-#LI$(Z1'&<DPL;5:"9=Y^3
M.^*EO?=GBKJZ\!NWUI1[B5O."OLJR6NF<Y;V5&'(Y@@-I$:@V92YK,4*FX3
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M][J:Y=:'](J_H8^=F8:9C@32ZYCZ";,F<Y::R[6Z='U/X[VM[ _940_70N+
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M@$] ^?@QI< SVF<"_\?'_4\ T4/ /<8T%@8C ),( XL(X[X/  0 ,+ Q_N,
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MWH+B?&_\<<OLJ]8\R,6Q?"&V$)115#)HV578?B)##7J^;"A['2.I<R+]3EL
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M QP ?:K-_7JE#[T@97<A>RJ/D!?6>@SP>-3L/(1N\S'C^87>=(UEN'&%A$O
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M&TQS*J.S ;ZEX#/($Z& E\#U:Q'H;IH8A$ZNZ30Z#36T,4AM)-<?%!YX2,8
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M5)^NA6K\:WZ>-7?-\DUU)*"U5NA5 OPD'_[8#;[;@U_%L!_E7#4JLU!CV1B
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M[B2X/[>2I4U+(7!MYT)J<37!OL;6\); DGH;KFS;'O)]@1M._[4KN@J7',Q
MKO@SD=!%V3KC7/G8A1BK$V[UGW^&J."Z5<9]>7X'XC:)Z(E#*$Q)K3=$ 1\]
MT-AA37TSLFLBAIB%*^1#J5>UH./7;XAN&]6SM5\V)XO)/>U.KQ8]-$6Z=9*=
M;7DEOZCQ)'4L4^\2ZL:L(_!T5I!"I?IK0TG);TY+9-<<".G?KTBK[9Z$!.Y+
M$9N^<EC<<T\)4&Q"M^:#5<5P?N'R98)57N;H=X$2U1(0L(G^IW;QG:NK43VA
M%$V+>A5H6"+]>NW^A+]>::2D&GD\9I^E+Q;@UHGD,#X\>Y)E1L2Q*NH*2/1G
MWR^R?D;&G>:UE7+V22VP]^JZRH[5<$TY1<)4CB"65O_1>LT34P>1'P=^6_EV
M-NE!@U3:_@0> -<0\>@C873+/;J3VO_^>^EUW$\WL<6KXDNC\%-9Y08NI8:'
ME2RI>KZ)K5S@IW0.?=J#0JK,O#4T'M9B..U3A 0F/H.&Z9JSI:GO":B92,C.
M(7<51[[#A_U^)*.618:]M,F*SI@;HMVB0)5 X253CS^C4(WH#PB^KQTSFV-)
M+D%CL2(_MC!?GL;.584=-Q98/EXNJNCF/)%MV,UC/0N[!\0@#+Z>OTQKW*+T
M.JMZ=!A.>S+NE,O5&<7M0<?"].L5"#-L> U/=;V-!E89V;#LL"H[S=*642%>
M;K>^A*6B*&JNH_"Q:MXG5#%4JU:F-56.C F;L("^80#6VPM!\<^NU0N638=4
M-I[D>]P#?$YHP^G:W$W#DTK^P$"O50UD^Q]PI+\/E$B1G6\D]$AR0\%7U1M
M,5':PK2/CTA)_MC.S)F'!6A8;^3R':>530Q5ZMD!3YD(S:'5X($TD3R>Z*E?
MOZP".=>5>7-"&21QI%Y>#OJMGM6$.TKR%/-4,E"(V5NQL20$J0G7?0"^CLN.
MB73D6?&/TF;7M,X= ]#O?&\7V5@D)%HR[\:CK'9DM9NG@<UX>$IU5]X#**0&
MNHH5024:M&DZ0Q9M5AB1N,$/4?M2@=\&0]JI'-<EV+ (/?E64YBA>X*O_9:
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M1RW&)#WSU[=L23)>/8>[&Z*HSWZ;,;0X>NO\_E'?-B4?<,(4:]L*'9R!% $
M !=L;9/.0B>XQ[,V0_HQS\C4Q('NAT>N_2XK!).>^,.0MY JZQ X;L\+KRCH
M3R^ST<6E]VUP#AZZ@2L]*G9W_,BA)V^/V6J/S3S7CYG>SC:TX$8>%QL>63UI
M(FHDUZ9< VHAY*:%]TDUZ[UQO]5B;V^1D^N8+G4.66B?K 3KY]N](-S '\F_
M-!C(9!G1D!CM.]+@C.T,K;VL+G3DTS9_JNK!:IS[XNCA3GU0)']<[^I<0R4W
MS^6(?%.C:>V7G^,F7E0%WI;.A:BN*F6J@KH&YB1:?M:@:&S?S)G5/OCQI::A
M W'@E[[$-@)Y L/M\8*3Q_:F9N:@UB,1.',"XRN1^6J>^<9;'QE^ABMM<7W[
M4OO&!=.6\#FII#1NW*_^A Z@VXR\K&<3BD_2OWZ3"(M^<)L3ZR*>8N:_$6-J
MWA?$] ,U;-TZ91TKDATWV=?+D!]$J'%6_>VTK]72U,R>XJX@G9%%_:NGDT!G
MA^]EE2.?6L.4T-Z'#],C39$6%!/:RQ?/%U^S9G_PZ&#$]RT5\"5:+W9:T\?>
M-/1T?+\Q>^FE>LSZ1J&'*?='B#@\%CC5NJS:UTCMB6BD_OB<2:Y53'E#O5_Q
MSE3T5%_(E'=095I[52.RWVGP]UNI5TYJ4JN"V(7;KX/HIDHFZ^TJ=_/'/+E5
M,8(%W(,E\'80[I[>%7L5A!%6%,E50^$;#V^Q-1Z(E*HW3#@$,==-7E%6U8RG
MD-:F*?]!M$6<Y<OM'VK;93GEVQ(T>1$)\%P$%MP0D%LNQ<_D=U1@GWQN!Q8N
MVRU8QK2$*DL\(K!P81(%)!PXY,?6G/)ZM&6;8NYP\'UY5LV NTMT<P^X\JZJ
M,C=IFK1NN#-*;<J,%KJ]?2\5XP\TBE&LG]IM:X9\(,WDPX%\CO7]Z// 7Q-Y
M_,K_JTBP!U>'P-#R4DNLB4*!X_5:&1V^7]9166&V-['>7^\T_=/+D%_2QA9
MD=4L35$[,=(FL5]^( D=\OY9PW%41Q_HS@CD]5GIE'W!TUS\8S?WX\?#XR]+
MIE&BFAKFI5/-CMX&75":SA2KE=?O7UKC!7F9_;P'_%#'8)IKD'0N-U9Z-MF3
MR6LX92*^\RR<TI#PW6#T]-E)'$]YBM:,Q4=ACN$E1C&#Z5@&J9_]C\SU'B_*
MMTA'%1G;Z1&H=POR[G]]AR%Z)?7SIAK49\;4/O-F03V5/?(7SGSB]KS$YR/W
MP;7'()]IW?J&J;%<_L\C/L7L4>X-BGK.UWY85U]]G%]_'LI**P'9D]:6J1H<
MQVL+#6H&[L'RVG![020PX][$O;D*H0*S_72:<19T!2:(GHY7:4'YHJVCV1JF
MK")_K7U)]_*5M/:W<H?K0:*$51T%7^<I_RX=Q2$U4##-# >8@\^JG7O\N%:-
MC9;,C8UB)'QZ%KE-TM^IFP[:2 V6E4*EO C#?-,EGZU_M"3UOBD>]U#0*J9B
MDNE/F4B:\:CH9("^]E,G)B$9HGST2.S1D>O$7&=)V>*^4<!-$_=KS>J=0;9]
M$][0$M6J<2:I=B;5Y/7=U.(-+_<A1;K&O(BIB%,)3&6N'V "'X>=Z_TK*2<Y
MUV>)G?,XKYR6/# T9,6C3\O+8J@Y&?"^/0<<<<S\?S._X+T;(P& \$P3PSM.
M%WVE3DKW&!F<4'[IOZA!DL<P^M"$PU+'I7BT% XPWPA^@3KAJ'5\>91SS?6-
M!U9:JT\[LUA2\KSIV8KFH_D\;:=],V9%ABPI>G?B_K_S.<W';+.SCTCMW39Q
MZ9[-G3$G:K9XN,7.^";W]4Q%L..D3]:1[Q6V6-5N2KM^ZK7VM/,S#F\N4VK9
MN>6%]>V@^\U_#+]Y3/KWM_?H.4^W*:F-MM'S6KXS=^U^)"^R;EJ8=C+/I'<W
MSIS]M%CP@,6+XN8O;-M,??WN>UQ>MG>G^JF.DL!)_@[L.VW"!1=D&F7[^4R[
MP*MR[K+'^2.?[%,F5/5\7?[1ND3\T#K_A_$\YPN+;LW;K!QSZORSI, )\1N/
M._;=>)-='?]1IBK$9\(6_P)VM_RI_ DW7L[+CJM\L&%S94K"A$.MLV\ZK+<%
M-H(^RBTMN1A]9%?*=Z5'Y7.2RF)J5KA_]V>1,B]SW+9F_N$JGE]7O]S:ME%Q
MKDKMOYAFY;]3C_LP-O''9:^]5KJZ5HDGS]G,2-B^I+ZB;\=:CL==EUA[&3PN
M5L@UA,_3V50Q^<CTY=YMQCP/DZ=53VR/.'C0\-?*X\\]7_T,R-DY8U;<S-I'
M9[-\W8.GF_V\I10\)43^$+L3?U'E>:\O&8OZ)"9I3 PRD0X-26 ,C(R,?OEM
M96ZV1)^*!)?64;-?BJ78$P(Z7I4UK2A+*O;LDN M_":I8J&O6OH6K;WHH,LC
MJ^TV.W?/KDU+MF^;V:G'_F>;W]'VUU_7[IQPDGO1W*53&FHMEE]TOEX0)7-N
MZL/?4SIS32M9']WR?!85._GSA.*I^<O]JZY=*XVNY?:8]>]AS$$.2<%U'BR-
M!_YD.\WZN*0CR"4L^(K!B86[FS99Y+*[[]NU<\_V_?G;,LV9SWJ>F<EW=-.:
MQ3\\7M1-O;G;/3'IG?B35FX!=G5F^[FZ<Z?N;=W1=,M0QF$:EQ63GZ^/@T*3
M$7^R\ZT38M_3Y]_@WEL=X^MU==9KMROBWT\J)[CM+@B<?D7.\?NZ5^<N:4M'
MO'THX1*PV-;/-G/;-;%M16=5]VA+^SC;W6-42%X:N?S2":L[P.+0 ==N/G1<
M+/9/?L_OT+?+%IK?+KD]4^J167+[]IHG6K^KPKUELD6RP!.FP2L6+VU>>ZXH
M5NS/ZW)]G=/E2^/7G7R[Y/') P^G_[KV=.N6LK#5/,I/'!M?955IO$QX77PV
M:>?UTGXAU0/;IJD'*<V[YG9H3:6R2KU XL^DO<S^E]=^.9V8GS,[.>9!%<]S
MT>0D=OVMY1.;;CP7>55^Z<#7<IO'T7NOE\H+<.0JS.)\&_.3(SKKS$QY^WV6
M++7:NRYO.9UKF6+@LG%F=+7&"\[7_3F?PTXIEA:MBBQN4Y[HMV1+&/OJ'>B[
M5@<0,_Z_"0!02P,$%     @ %(A_6O4>ER'Z-0  OS@   T   !I;6%G95\P
M,38N:G!GI;<%5-S-LB\Z2/! <)?@[J[!W6'P$#RXNTP@'S:!P2%X<!W<);B[
M.P1W=[]\>YU]SM[WW;?6?O?UK%GK7UW2]:NN[JYZG7_] _B@(",O X"!@0%\
M>?L!7I< D@ D! 1$A'=(B(B(R,A(*&@X[]%04=$(L; Q<$B)R,E(B4A(**A9
MZ2@HF:E(2.CY&)C9.;BYN<GI!$3X.859N;@Y_S8"@X2,C(:*1O#^/0'G1Y*/
MG/^?QVL[ !,)!@!##P=#"8#%A('#A'GM!I # ##O8/XQ /\U8&#AX-\A("(A
MHZ"^"=1^ ,#"P,'!PL.]>P</_\;U?^,#X#'?87WD$$? 5C=!I'3&X0R,R4*B
MDJCLP-68.*/F,G4)0D;!PR<@)**AI:-G8.3FX>7C%Q"4E)*6D9635]#4T@;J
MZ.KIFYE;6%I]M;9Q=7/W\/3R]OG^5W!(:%@X.#8N/B$QZ6=R2G9.;EY^06%1
M<55U36U=?4-C4V=7=T]O7__ X.34],SLW/S"XOK&YM;VSN[>_L'YQ>75]<WM
MW?W#W[A@ ' P_QS_1UR8;[A@X>'AX!'_Q@4#Z_FW ";\NX\<"%CBZH@FSMB4
MG(%(.!(Q694=R%1<&F>XIBX3*'C4W.LTYW]#^P>R_PQ8T/\5LO\&]C^X%@%H
M<#!OFP>'"1 #W(K(\RT&OLQ=\8!9[O>-W@V>1I'O9A5+8-A,<E8)'$A<-&90
M%,$3BC#>A:11PI;\5$C^)'ZLN.6K_0I@5M]^U+K$[5>_$"GJQ+!IWGY$,6:%
MF,:CB,K6DLG6?KYX+O)K2HV*'WL4JV5;:"WY)'NLN$W$JAVQ5NVKX9\J4J(Z
ME#-TD^<\/_1(5TMN<5-2'[1#7Z_?&5OO;KG45VO"%SY2FB_TB!<>:B&V*3_
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M:>SY-B.$H($>VG ?V)>__$6;2<A>4\, F=IW'?%D*V;+B42T#TWKYC.PB%-
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MG0!=RA@?ZH[=RJ49_TVILJ9QXU0Y*P+5XUNYJ L! E<B'DG,#J/T:TZLZ)>
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MZ8R:[M^5]!:4.667Z=UYVY'[+V I"<#=Z3S9TA"RC#:,)O -;Z4>@2OT/MN
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M#'<C0*Q,0%N^!W(?<WTM2!<US)&K<A%?%HK6Y#34(G^10W=V5B1GVJI!;#Q
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M),F-!_[!>"^CX4TPT+'L<G\S9C/<<A9YO*R,'Q\C-0@V4PRLWY9([DN":+W
MFYNFK>*T6>_^E"9JJ2@U9FDG6*H)X5?]N2V[.BI0LAWEXKWFV%[O*A9B.C>:
M1S,<Y8G=!Q,LR2[CUUO@(.@B6_#Y.J!/[>RZO[XVB$G+>J*E03CKUL6%GX"0
M445H<[$2N]/G+T]-P^+R=.9PVDT79*"><,<K@/E^5\2UC[1X-/6739-VMXM^
M,2-C(#7(^MZ"R@/5+WG3>1\2%$JP!.H6>&J#G3P4)<I0G,Y8)8@W(K"P/F['
MEFL8<MM">]YL'U%T+;W3(Z@=3@0U)R2Y=D63 A#30$A](B6<FUWZP1WQ]PR$
MR3N<\4V/^ZRH?8-N0K(BTMA>IC>VQM6I7X$<-]]X5\C@^UB>2)O5A]Z:BK#[
M-ZSS2<"SXZXE0V6:TBBJGUDQ&P-HZ"A;$ &1\]D26:B7S<62JR3&PK#-YD@]
M'+\9T;=<\[0@1%)!H'U?,%L9*] 5QP;HD?FUL9_9R+C)>1 BR[\1N&XOK2!(
MR5QIUA]M>(E'FF:VU?&XY;J8Q.P;6N/?!I?S_?/$Z@8JDV^_4BSCO=SW()3M
M3YND,.TW4(5->S\^7_/QG_8?81G,XN'<5/1PDS+C?F^HMCK</^P^W>F] OXH
M@LYY.(/V>HL]54]XK D3<*H_%"/(TP%0AB^ONUX!K+R2:\?O7P'=4\1*S=,$
M()OEG$\"CRP-'XF?-[Q-CMN+MD_Z1E<'7L3S0 4K1@<18N[\F)\PO)+$^#;D
MQ934L^5O+.+DXS=L)2^L[C;HMDV>HAJ@7V + 0!$ /J,QBM &?Q$A>=5$/6S
M(&)]_!6@?N15,)P19>I-HF$+&MT>_'[$FVQVH^O21WUO%I>^-I8)52=?JGC?
M4-4,EQ,[P?$0@7FOOGN8>;EN]0H(9'ES<W+[DFGQ#0KK<]!8U)4N__YC91_U
M*X!3=5.>+-4,Q0X\N(+M<5R"%9AF)B*X&96G>7D]=G]6_59R);X"-K[^.[7M
M_PKXL&N4N6SH+]@K%4XVNA)+1@D,EU,M( G @9I8#H74?(LP0^ X;+Z_O"[^
M'-#X"A#% ]UAK3TID_TK05+>MD%R6/WX8V=RX=<'8J\(BBT9-7M$@5'1EFGK
M_/G<2$H]@Y)J!TM,>NK+ ?[#@:>#@LPRT%APY@M\_2L 6_;?"*;3NU#!HY>-
MS?U93BE37R&/B.-!@OBHI *"X\7<1VYB:E5:D:I70*E1#D:OP/4F>.P_0FCT
M^"Y3;"_:->WER),B<QJC7^,'DYH+2U:_P%L#*^()$@VHE1V;$]OM''L%P!J\
M L)S_IU*N'V23/< .;N("/;BLY$F-''8]R32P&=X[\_%W:?(3MDMBOQPQ#$W
MLZ4$J 5^T]H,0E15*/JWG9OX=VKP\>7C:+-80V/!O,&^CQ\OL!!(H&,3Y!*0
M^Q WHLH<CJ;*7(;%_2[YYQ^80[W? 0U>C[C1MWS_R%1059FCN<Y,&9;N]+:]
MB4:EU4SU4("PK[J](RVK9XU:$V=KUXJ-0U[ ;-<@D("2AL!X+.YN0K]&:V!E
MN:$O0?=UX7\!4$L#!!0    ( !2(?UK:VX7PKC,  !\X   -    :6UA9V5?
M,#$W+FIP9[6Z!50<W;8M7+A#L. 2(+B[-Q"< ,$]$"1HT.#22 @)&B! <(([
M(;B[NVMP=W>Z_\XGYYSOCGO?>/][XQ5C#;I'5:V]UNZUYYQK5T%GH2O $T59
M!5D #@X.,('] = %X 6 BHR,@HR$BH*"@H:&BHY)@(6)@8%)@H>/0T!!2D5)
M04I.3DW'SD!-PTI+3LXHP,3*R<7+RTO%("0FR"W*SL/+_=L)'"H:&B8&)C$6
M%C'W,_)GW/^_#V@K@(L*M,,3(,#1 /"X< BX<-!.@ H X)#@_CB OPXX> 1$
M)&045#1T#-@%54\ >#@$!'A$!"0D1$3865_8>0 1%PGO&9<D,K[:&Q0:)P+N
M@.COJ+12Y6V$ZF,G=#RFSH%HZ$^)B$E(G],S,#(Q\_+Q"P@*";^0EI&5DU=0
MU-#4TM;1U=,W,[=X:VEE;>/RWM7-W</3*^A#\,>03Y]#8V*_QL4G?$M,RLS*
MSLG-RR\H_%E1655=4UM7W][1V=7=T]O7/SXQ.34],SLWO[JVOK&YM;VSNW=Z
M=GYQ>75]<WOW.R\X  'N[^._S0L7EA<\(B("(LKOO.#@W7]?@(N(](P+&4]2
M#>6-$SX-=P J@53T]_(V-%H>]1-"4^<Q]*=TO*O/3W^G]D=F_WN)!?X?9?:O
MQ/Z=USR B0 '^_$0< $0<'V7S\?"0^!\N_]3P>>KZ-EM-XA+>_]+F$2S?/$&
MFZ,1'Q7?"C='?$%C:JO7.DJ9UW2*&<NY"/CEL'/,G/&=G [BZ6)[A=1"EGT(
M(EA8OO1-ZJ9\"H_T CG.JN P2'_%87JK>XBFV5( OJ^QZEYE.N*Z9BC\80X1
MFV?7 "W[-1L46,!C>JH!QC_",^,\@/O) P5F2HQ0<_S,GNLKS_?(\5U6-4WR
MCP\6\,Z=34*!I\P-MDDV+^B&W-(,G3U59D5!>8H#IY0)GMY@6Q>K1&^KQ'6[
M2#K,;)P>Y(K5T>,#N]"<(L4^7Z3N*5>D]GQV6=7K"FEK#2?E)BDM^NQQ?0J&
MJZWD*U!56.V@R$-3!]T1Y$AX>X&@K,1Z;.[YNE%>]+/Y<&XE*@GA[?D?>1,.
MEK8-N[RW.B.I%&]"32JD"?F/U;&Y72;&XY<&M&OX!<[UJSH,^@2.W*D3S-9M
M\=OCU]-+*/M3:QY>>2LL.PSNOK//:*I1"K/6UDT_^IF&I6P87_2FP&C!0(DB
M(%)MBXJ&@0R.(6+VS<B]1(IV;IF9"_A=;E?5#W;<4FEGW+-W(A]=8GCTZIWJ
M)ZO4]K]7R#@S9>^%%1H]O9<=MT"C<P9(N6ME^NQ1UV\\:(7R#WD?7R^-H58E
MV DX*1)YZ-&]0K6+Z/*.7.=[W0T:Y+"! E_WMIJJ:Q(&DBQD9\=]%GVR"H:$
M#;YE?%"B7>.60$&\%*0:KF.J?"=[-/6A^G"+F-T?BUKPK6,O3[K-;'U5'1AG
M0=(6,UJQ!-N,XYP14\!\>T)LY_U*23YSC/OH?&9=,AO[%9;Z_&[\*^6AMF^)
MSJ(5J2F6Q,/,U>584TM-WEC%&GV<@;08V0M/B>@>.BW3TD(NLPL86%P0"L>;
M(IM#-XF4IUJJPI/-]2#C1PZ8=>'MFJO\EC,4#99\&O<,.OP\V9R&+YAJT)AL
M(Y;>-[0M-9ZVBI[.$$P10P%N%&WC?C<79<)&9=9Q5J?\ 1YR.-5B(P>%\T8>
M_G1+7%. Z[M+S O+ M#K*LD2/E"UI]/\X ^^#?P0[G"Z-Q(6HMNT%,QF*MPZ
M=>K)*M/"22QA1O /\^PWVSQD>M>0AW/VXU_7%P_,?1-5LI,QLJ%FH&3\YR/I
M'R(YD2]8TE27#H=MFL+!W])M.3:%ZUD8.NY\XH7]]H.=7&FY8GV":Q?=KEM7
M(N-*=/OH#A*+#6P.&#-#8P)#63@Z(T]OG!_7W^K@XI&HH!:&>V8G.)O?:KS-
M(0SR+>V.CV_O/AL+C\E6?SE,\081/[[M.!PS6F_\)E;3P"J<\P5O['$DLI:(
MT=B)0=DO9F>Q+EM2_+?VE;@S8[K525_GXX.\O61[9Q4V3)ZXP86G^P09Y@1O
M7D3E&(B>'5:GT;NQ@CV>,VMZG^BG6 F]/GZC6*\]X3)F54HJM*ZWD436AYWW
MF#]63./L3O_P1$-P(?P\U#5BX$51D<Q[^YRX+71U-VP5[*>ZR1F4612%S:6'
M=>*_W$2\6*+&+2OD#^TU7B5>RGV42^*/2]0+W+@-2O6G3&51[:COO$M/2V C
MB>&,N*\B[L#NY$+T>L^'G[GN/EL[I?[SR'[,,.!4;,'0L)C#[O13CD=81(#B
M#P00/Y@3Q$S56;-LHJ,3-(@OK%"GR0DG24QV5=-,EF<#UOG6U(@-*Q_Z4[Y1
MY].J6LU(%%TC5.]TGM)ACYYUY?H9=OJ:R1<C-OPE[6SYF,^-@@+EQ>ZN]MN^
MO]FB7$(QD'&.*C/"DF61IPLQPT5#$I(]N[:,[]M>H+PMU(;035*7_Y")04LL
M^3!$]P'KP)B,6]=9)$U%?BTX)%GJKA-[+73#?*K4_C),?LDC4W-2GZ."73I9
M2Y5MA/I1C$7U]90#;Y^)@4>\I".F4V!VN@"MO>>.['%_SEC<^%[_57F%;T0]
M2VBL8>.D:/*G]G9*D0"X#GLD&L042Y2M8<%U@MY+9:EYAJ;(/:;&$G$T.FPT
M;*4G<J]Q"BX)P=H)SG[E^+69/ZL6[L,PB#>KN5 \M7"^2:QL'VWXJY;S?:R_
M;*N//#W&I19VZ2O/?*84TM:^+;1^]K#W3%9=1Z:_V/1@N#MTW6SZ^*CT'>%1
MYF?U&^D# *Y-JI6<BS*KS-!+T_$F=&]\N#<(O54K\:X!"I18[!BX<>VFV4!*
MN,7+\:LS:V^J,'(::?3\1OL*^D,3G\5)<2$$C:[[RRA1?=H6]D@\MIO7DY91
M%_S,101R;;;S,_<>]_!\3UI&F:<CXRC@535U&+LHFBMPC]AZJQP0EZC)V2:Z
M?CLCZ5#TNJ\4;/%3KEZ(8L,Q#YDBXSOYY7-_T OI? 7J"(]J!S49PF%[ C49
MX'\ROJR(_@09TSQF^6'QKWN,&?"A?QIJ::E9157\EJFT&I,;M66 7EYGDO.G
M@<0O@ECGTAVFL?Y#.VB[.L<E>'?=WG)O-1/1\9HD: G3W5<7;(OR2S%+PZ.+
M7_(7.6@)44BV71,6BZ4VG3.=/\9(KF' VSM:,-F5FCN1+)P]'H&'K8O6Q$2[
MZ#X,YKB](:7'OH<<C4UN%1I[O+$0J,%5.7;BY<YD05)+(+[]1&(B8IDC#L*B
ME2!=.W*OAV>+]:D+LV1&(1:-G2FQMN%OZFTRF._Z>$H1F/WN_LJ=O5F_O6LR
M5P!>!#?)Q^LQO.;50N>X_'BA( L)-?)]W04D=4_0!X3(W<.5II/XLOAH=C""
M&HCMR2#N>@$%4)N:[[GMG[/8Y!>BE_J]_F9G;EF+')=_&WFI5*T_%?<X((E0
M;H*F_LI_A1POKQG+>![A:6O?GBV+\BC;14-\/ E) B(-H?%7_-A>$M#G7?VI
MK[<.1W;6V+;>"\$$:J]TU60(@/\T=>ZB NU7_5Z!W%AL!'#J%A75U:GAN+<V
M==%XG I4DM-Y&&AHP9*5%LCBQQ/C=;2KC]+\F>4=I-DG_0&)4Y]9G3EG42@;
M"M%,6=:(5[A8:ZCF<96V'A:FX,-+N:YEA;>I(ER]Z:ZBAP[UEQC,6'\8Z#<0
M4FK:*&@:GAX@:9#&IU]U5\O/9<O*F/Z((4BO1^LA'EG595HMZKVXB!3,TIL?
M]LA]UGS. U\GMC=SA=2^I,#K)-U09I+L2$T1FN6^'QLJQ%1TWS8BX/!^)Y[%
M-2Y;=PT/I[$5$T(?'/G+<+C@B1MY+]!'I;]).WJ)6LP08,=&ZIM,N9I#M[C9
M1A>9RG/=<*]FO=J0.9HSB5N)]GS SA(16'4[ 2@D=SB9O 6A .=C=LO7W?68
M46,E C_=.G12B:*/;;NQ-VH(!G*BU2>=M.8=_/@V*?<7#*'=8^_#DK%DA;8#
M^>G[!9->M<:YKD3YA+L<*N3O) @D5?Z\M9H^4[;K?+I7T.!.]>ENLE8N:7$>
M2]&PIKS^637F(&T8*YHI@4M:]KAOVDS?6>,WGQR0B]4\SG@=2Q.RMPA:KKR:
M6X='V8\SK9:I<'<$"A&-[R>/4YT*R?(F 4NS?:BQS]JWO=.=L<5L'E/>^9GZ
M9I?9:Y0P(?1&:G/O<7\(^"*6?V;"/FP67A'.-<_=L3RIPW^'-;ZWD%43,D#$
MQ.IN<#(FG8'#R)&'Z.7R4IRTZ9[M@87;OYR8U<^A@<2W$_^X_1%)M2+JG' $
MQI\.S,ONR9M=#5'I"*+>8U?>)L!99J>EXZU<OZ]O44)01PWK%<2W'A6Q0D3J
M*)O1JO4U =RD)<*^&A7F<DE^Y/,(#'WI"F#]^B=+3.NCG,O%KNI<QVW7X?.'
M/$.S('"*NM@VBA^R;UWNY\/<>F^3G7,IPCGAN&%'<*H+UXW]FK2_H40$:8_3
M?9YC&\EII2-PX.7(O/4YVU#7AMYS)3R1=34B%Q,-N^@C99XH;/;;T00&^83X
MFR;>"M18;P2;H8^N%YKX=(A20FZRO^KKSPWPR)&V1L?[YG-5ND#X/H,S#7_M
M52B:R=;$["U)8;A*:V/UK D>:\,6UR<?H7Q=)(DSSS4"%/^2U*R%$G;=.7'[
MCJVX^1HG@TXOZ>GQ1*4#31VN 03X?GG 7XZ6[GU>=5GN)W6YFF\4W8SKMMI+
MB^;!AI;$Q?=1&+&9GE;C SYC7236;QE,/ZKWY_U8*['1%\$0?%9=(^"4'3QG
M4?N&L7<E^\-IE&*#^APWATXA;_%\]]40?74D?W"DW-%IH.".'*+FDG+%@;BA
MW)M;E;&S= ?%D?+*R6<G#_'G/_O>J[6CD?\@&9YZNY+NHLN?1M:,R#I]6LSF
MXL BU^04C$GES[7H*Z<?AUK]>!CJ$J/T2WA.? A=K(/.!">E5BTV8.:L\- I
MMS1^9KB<+>73\[?FK29>>")I<2,*J_=3GS4.?BQ*BX]^QE"HE&GZ&2D>%*4_
ME:Y8E]Q^-<VL9O\]D@:!O,"\K>UJ+025Q?N7I*(*Y%ARMW@7"_&HH_])Z;:"
M">."PDHP+1U^9.KNO$)YVM'9'G*M &N;A4$P\UCD=PEJ$Q>]:U*WO((1L<VN
MU.*7;(T?:F*4UU[^>$L7;I9'^3 U!-]_-;J8'.R1X=S\$D<@:6S%Y=R+4C#O
M.2&195E^YL9&:>4%?WYFZ);PW]SRWYO=AT\II2Z5Z\20JH#5A2$I(_$MI1;N
M-4VG<LF7T0&MVV4S48K CE5Q0X0;AA'>MF8:R;B(;[O\"49@264D-H[XY0BX
M?7@,"FR/O(("S?A0(+2D8+1(1]_)8;2[E":./D[AN=_!H54I ^2I6Q04$/<*
M>3Q)?]#B>& ])(/X\N'<7\&^65^RJC[<@YVB9GZTG)_Z;MO*.(%/*MX[W%Y,
M@H[GP:>:X/:AL9;M"=@0+=90H$OC+IX!XMM2*]X4# 72PXY%%%G"H$!P<A9X
M)/<[%/";@(61!7EJ'P$;,"GD\5X5PAQ58 K>7K@/VI\UOKUI/J_,+/<!K=ER
MX(8%61-V^DF^6K- $!KF"O3%LC%:S$E-N5;_R-5!)K\@JP+T]6P:CG_XSJ['
MPE.('[Z60_2^+[^4T4=E[!/*P5_.$_XY5KU?SF=87 Y'0G[_%P'6MMSHU0L\
MW-E071^";@IM?=1&9XX-ELJF7H$/+IKS/OTQ D[9FY;MM?OA^= UT*KU#NB\
M^_P,-LUA)10X/<*R37[3VDMVSI\&@X9GX8" @(^B9\P,'TN0AA@KF[">A7X7
M<NZV;M'(S0QE0<B 27[@MS%%L3I]=W?5HE BAU.QCXM^GI;C:5MH8.R;)/\6
M?*$5$8I+B8+I-$,K1+(?.0E7_)/67VTJ@ 21?,-K?,-KFD6_JES^Z>9W&D;:
M1;*,Y4"X'HWQLET'NOKWRG3AQ^?P/04=N".;$D_/Q*QZ+[,HM\*]DP#N__HY
M(U(X*?_,&,4D_LO/[4!+ZNB+A;_N* Q4>@B?:T4!7P1!@<[QQ0%WLK6EL;>O
MA;@/CT=V)9[^%+-:%)-!R+'<X]IS<#)_?_LF\GD*V7?J/JO37G+7#(S,-;SA
M3*L!AB6XCSK[NZJ]E\4B33Q]D*EZ!,MY^)3B#_$]^;11T[E5GBU5_54+BC&>
MG;E^6O/] +DKD#**7"U70D)9:;8X%N4B@?Q?/A.8+4Z0>;BB9Q2 N-@"Q8/(
M1Y$TBF;A)>L,(X6I3G*4M;M^J=EK5I##!?4]Y-\;;7\UN.>[1IDG&E*1NZZ?
MZ.KJBY?A?XDKCPXQ?5@73;$,=\V ?R<[O.3 ;!NLP(T\L2>/<$E3HL5TQ&"0
M&I97F4\B$>MU3<M N0C1<O-'9\S\7QI";UM^R>&[0]JSPXQ0 LB!%8&?5$ZF
MOQ 5+K@WK!0*S"BT7%AX,NV_KEKCN,5U7;[;%8"$EST7L]W[217H5W0F_N)3
MRV?5,<@;&0*=L73NOT6L%T/[2$,1N(GHS.:0#PK<$O&![BX2H( $7]<#ZWU]
MS?T8F+YTQ!@*1+MH0($R!? %@C'2-RC0-#+S$#7&O7S-[)>^Y2'\V'6G/LZQ
M:)S#YKL'$H&-\0K.J*9C,JI_YBW_9U>Z5]U]9-2FG6C8*!3[GTN75T_A!SJE
MATVH+%\.PCTNX_DLNO3HG_&D7\OMM?#,]8&6B;(>(J/D)NE;1H^/[1_X*$JZ
MFGWR2?$P6]@]%C,NUW/01!;9-HCT^:J*H^G=:<P+R.2%NH46G0+]=O,?!*B-
ML?<BZQ<,"1%OAW_FQ9YA@SUCC]6L$_"5L-84BF6\I*6_ZNE%G9@%(G,-JVK4
M6A*>,ALN7;,U-E!Y#O27>-]>BWC]Q[SC-A^RT?K.ZP,#DV3F%0/?Y.+0%1(#
MYOGKA-;3INBCFZC3EI2SVT2H+2#4CJV/?@[CR7ZEQQ[EF?);$W!T]]F;M>*3
M]>:AY\N'0LB.*W<%$9Q6"+)_ 3=P4?C.UE'[%1]&,/N<.JZXY(ZX\792G0R@
M=2^Z9%:S8-G!".>62W#:>PN3^@E/:_ &7XOLOE$G0-1"Q"1/:VYB/B0 L+\&
M-;%1[UG!E^9! >J!J&OF +V,R<[\=Z'90V0T'U'PXJCO['OOJ&Q:"J! +_?Z
M8W^!VV -=T:(RW&HA6[/X%Z.)"@8L%73;*E4?;A9 B^70WC!5NFWIXTPF#9[
ML((_)%2ZEX8"(Q';C_=4ZQH&1FSC=;A])++S S0K0?[@: (X,4E1;D4-B\XO
MAT(B\*D=HQM4XWF9_DQ5V9OF\)!5)7[-#ZI?O' 2\F;$F,X,^D_DPUR919YH
MM9?JY#KU^% V5[T-!<H<,+^$X V?/[4+;,7*0H@$C?"9?AD?A?M=1S*6^\*-
MPL]#YK?EWB_AH\W0UT&!&]TDRX=[([\7#[:9:4^K=,^E!.0H[-Q(/]0Q#S$\
M>E($$_9 @?;."=#V_/X9U;K< ZLR#\2WM.49A"]OT@G4"ZODQ*BK:@R('T?/
M0V1[Z#H46#6U3C\_=+W%.2W B;I8M6.X%QL>W^0*2/''*6NB4NL$TT*:32H,
MR:! 0M@I%* MSJS]SSBL8,P0E@L>J1K9 '5'Y:^!HZ& ,2=DN@T\TG4#6SVS
M:H;@?T?!"_Z/X/X*Z!O8U@1& P_@W@/&0B_MG*<E>3V>Z/7=MZU^C>1JAC_#
MPIR\LYIAY)5']'[@JYJ,@IGYN^@*I[- 3\%B7S)C9?5N[]Q/S%*MN/@D:"N4
M_I8/ME;AX:2A9!YL7XN?].#%QN!*!8+1@8VJ/FUPR-UB/C&+:*>]>MZCI:,G
MX29#B=?(IT_&</N=7U 2N>A@<*)X1NN$#9Z1@P*^H7<IH0I2[KXZ&SX)3V3J
MOQ[4@P9C0J,.G\#* I;W<;G<_#,HD 83$,NFS2'S+^KOQ\Y?#_NF+\(J[G^Z
M+LH:>_]8\F![[G'DX3-C/F0,Y^$J"G)/X)M)=7M(]7C%>/7EJ/F"\B\O%U'!
MZ>[:4,"+8V-JWA8*G+';@"]W.2#^MJ$WFCN[15]=34@YZEWFBJIFH,"&X204
MV!\W?@1FVM]BW]15+3]$C3I/3F,G^;8,GEC<AUWD9!O7MBCJWV_XN;7_7HLU
M#UQK+.\0;;A^S0ZX$FY8?9#M%R0+0*%SQ=(ET!&GQ<&4 5F*18;STWO8A.:(
M#:\M="<AI89?N4&H&N39D9^K"JFLAKNRI<5]S]KW\JO)-S38]<)?,%)"XY8?
MIRD=S-_!L>?DVG_M8!32H7I+2@_[K06@P.AX([F;EM1'2JUGWF4@GIT?),TT
MS32\>;8@#@Z-:1B)WP;MM?\%%(@.#5JN0CE!RDFZE(*;6K>O-8+)+_FLFP]I
M:>H)73'S\FFI1Y$MLL=5GUG"]56\:(DH5?'%>I%GM+"P^(MUPJ"S4UKJUA_G
MTBQ/C$6&@#V[/P.@?@4<]N4?E)C:HHHNR$<'PE4 AU=#@#P?"STU1H.S0BN\
M%A0@K8C=L64QK*HQPCLH:93X-(PJJ3\))(I_#$]_H20#T*M^SV(8'1^30(O=
ML>J[X*U\!3"A>.E++OESVML?&=]K,U$*J7,B.LGJ..-H;U4I./PF&)V:/E&G
M%I&0W9>363(31ZEJ+[A].K%5I].YX?+U>T5_='+C^9T:6B*< A ".$N&T;'8
M'6NK#,2^"SZ584V!A+&/&M1?\>I($$S/0QOT#@I%7Y AP444;:S'GK,!QK @
MS.](]1GAN'VQ2,0_QH<"+R_6XO\"$A2V4P2(#$RX&4W<S210QNV!GH V]*DN
M?X%*G)- (0=E!ZRE])Z2G@8CZ+.W/)5FRTX(IV59 WO=\61)1G.G>MV4KJ>+
M/Y;C<!6LW]!GQHI6OT,P8(SDXGQE@1M)19X_[.SK5R7JYD?JP%NY\LZY4+2C
MUSA9?"4\ _3BI2_Z1/_\LWKM)]FY)G.8+Y,5X2)K=T?T#2*0QQEBK%9K8PB"
M4VETGFT^:[]@1E\7$J6R^37,H>+^Z#.LI6)S/-?U" 4VQY<W71(9Z+YPXC@H
M5BZ?H45!FF%8)*G?XO+]H+*^/GR *J:'_PPP0I9;@JFZ281CO4,8(<"8>G^U
MY8*PM$MP>+%IA&L\E7]R1NXVUJK$OGZHPLCN#('B_C3<Y&YZJEB?;\/M1]17
M7OD&#(1G#EP_T1 FJ"15C+%UJV(6XY.1>SS)0NX.DWL<&JJC*UD(&D'UC<'/
M:L\^(Y9_L6.K-3$WB71*PW+6+%*QWZUZY!G/"BE19!+LREO>W!#W%J.?(AW>
M(C;UA!>BM!ZT,S7[HDIGW]JVGK01HKB;,T:C9QYW>'24N!GQ5#!G ,EB^$QQ
M>P>5\C+!.SM969BLZVMO:9ON.X0WU"F4+FEBG-[:7QD(\_@6A$[?%RII(<8<
M+HS(W/BA9'NP0&1LC8O /#*4Z##$U9_96QX<,^8*A8@^ZEU_P[G6!Z\:1X]J
MZA!QZDM,& Y&2S<9+0!^?&PN2WS/?/AXXJFSLC I56D?KDM=?BS+Z>$:$7/_
MZ*4^D1$NTON29(<52""51]RW^\KZKJLTQX'NE$A^7=",^;"'9/\&5JIA)28W
M KJ]ZR,P[20[0VX6!7("'4<;?2S>9PB\=)?%S/5TE.P%-95*7Y:%KQFO:5R
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M.V.'PT<AM*)4X[D9Z%26L!9Y&X+S@ QZ,%)R(%Q32#S*C..ZUJ8( 1EUE\
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MH1&$JM>]Q0U/[!GJ(^7+:'!;^L=?SK[I75\(A_"]>_?=*2Y)72S/X30#0XC
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M^P\O$( ,^K?RO^5%\,0+"04%&07]'UX@)(]_*A"@H+[@0B.45$4W=B*BXP[
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MF))JKB!6A_S'[Y'S F1]ASJ<'ZY;#YEC=66O>'B0Y "[7JI=@1Y<I]18KF[
M9H_?$;JI4E^OK1.[MR8"VTT<NS11/M2[3,M]\XG*@_N 0)+X?,AL'B5?6K5.
MPZ=;6]QCHM8*R'5;@>7"X;"HVEH5=')P9Z2HJ6;"U8&6SA?K+7]MG)C.)5=P
M=)G;3&5=6RXG;QFK3'B(#$#:WJ,DL)/WW[MU_O\;XHCY_P%02P,$%     @
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MC 9HG%134IL^TX?["&:FP"$US')W8NNFV0>:RDMVACU\W)JG8MOHPL,\'0"
MO7$>?)+\ECZC;Q_DY6R?4[#\OKEK/-O[7,W%."/Q%=)KSH0;+R\ +O=0?ZK_
M8_&^%U^AX54F*H(Y.A*-S1*#%Q43->%")KQZOIW9;!2H2C23(;,\<I\Q&^$T
M%'ZZ)PY<T_DT\M!A1S51ZSRL2= ]/0ISS-_S&N*8/I4D^4B,.>!D/(]#O<_
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M_77!R*P_K%8>O+XNWYRU/"['7CKG?*_^RW-]TMWY2UT>IVR".U*Q_G$_T-*
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M9-GZY654K%,L^\.!"QYE.SHN=X?S0]&+,CR@Q\=!SJ]Y7-< >%%/29<X$<H
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M>6O[QI*'KTP7W<6T:K@_% ]ZD\S5D,)7>F=J7WY3(S=]X7F24S,&J5=K=46
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M1YBB<M[X:M6_<QZ,]WSA3COK]GH;I/IS!-.@8/EOY02)4?!_L^I$:5U=8-?
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M\*SJ2$"XX6$&?E=;<4OO/\KY4G$HSE@X^,V]UL69Y45S7PL--D55D(KS14-
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MEX0_;Y+[95/X_G?N$XO:Z7.N>(AC!_IDSL2VDGG4/JAV\!]02P,$%     @
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M[X.?,KPN+_,.KN^VXIM,$%)_)LTOH6#,43 -;N5NC*S-7&1.MI22E-<<6D.
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MBQZ_A]+0&N/&1%D;H)O\[8J\H/ +#9]CMTZ,8K9%]XAM/^DSO.VV7^4N61"
MQ=/]:A"J_&>* ^\2*(H/H >KJGL1K(>VF!V0U2H4Z%^@34^=/Y\ONSV?A  \
M64\O,* 9**P)>KRX )FM_PN,3^3G3Y@/43*9S5.?1*>]9O=VGA OH)MJHFY_
M05.X+>H)UUL,*C;Z3ZGG$(!JPKR,"^J!H&((,!H('4)!Y ^,1N].#]7J'#3V
M53,G--29'+-.(KY=P*_BT=6"^$-6#WX(3D0&5E>1,&O0BUH>'N9GAFX*_#N6
M_USP1C6RGNC3K '/,='5^W]NR_-+'(]L5N'<),W%/BI!@$8KJA^+[FK0L"HS
M?E+1,]:1\Z0O/G+7Y@FJP:L^%QZS613?>CR:Y>UMH2E"-!_7%IS1I6.KMD%K
M?C\2FHE-""M-H,J$\4&Y;4O%H.U4O*3Y<'Q9SAY'/Z8D9'[Y4VHC5IT=!1ER
MT=5G8Z=;L@!QCPTK8=:PH42;'+-OHO=$/T,[O[UE8!ME-R:7N2 8_!9=C[KU
M5E^ [)(]ZI5"7*\J:X@R35S)1+B<G1><Q')R"A5FMWKH?+$=KE,6/03(:[)[
M)/DJ:1_?LX2G*T%9W[MUHI$46#[-HWJU9[<CRTN-ODH/CP[&O>8$UR]4U(GK
M8V*K8T6?G;F3B3D=\VYZ31)W31?1RX'C>ND&;_W-B%TW^$:0-N3C@MCY&1A3
MR1@FKC.Y.JG:*'5?YA&,2%%E((56F)6(@1P-?&EOE;PX?GS$L$<2&M7+85'%
ME_CI[C1POK@X2DDK;18SF[8)S>T#U*MOLPF$O7HRIYR[*Y=0SKN@TFU5;/-@
M%=MQ#V@S0MBYP\B,7&_4"J[68$G].<9GJC](BVOP%:8NCZ)N2W=SWU$HZFN.
MY#SMI,S2B&7H7DZ0="(>UFHXV\?A;9CZVXB4TUZ"O0-E%_/J&V;!)CH)8<>Z
M9PT^].P<N\1<*58%G,7#9@'V80GLE6R[I?%7.K1G$. PC @A(C'^;2V77>P7
M= &<Q4DB1@)]]\/L2GW2AW-'L>?<X0A"'S#68A9195I#3XW<Y71RD_2F>P7>
M)!YM^ZUSU$J91KZCJD 7R97<$&?7:VP[R7OZPJA9>+&U.V0_7#AFU?@P?@QE
MU$\:=_8*XKC [TN5/ @POV3T'XJUQ#FVW62T5KA!@*UCQ.G4.]UP];8[!EU8
MJ3!_2]N=RS:JD;X@S"DF$%0QX*S#TNYT,BP?8)X[]BNL_@+[W"#R S(GV$[?
MYB4QB&@O=JZ7"C_4+6SH+%$]@ 8M@ 61733V1JFDV<C(B4-RZ[TO6I"IQ(XA
M56H6^>O;WK8=%>'>U9OBI6>+C.B.#-QF@NP] TB/9UH/H1K.HRA]MG!+O;Z$
M'FS.]J$#H5IEA*CI>246YE>F;@G.FF3<X^^_G>><-<?0)PS89">\JLIULT4*
M7:QN]+N;8"RR4%6G^;A[,.:O[3'Y\-*U8Z<.7,[YPX"/'BDU9>>^H[]W:OI"
MLS4@9T[2-BF@L1N=^.>[C&_?=>9(1TDFOJJ]@]:P9+S8]>!X>;3]=Y>1B(G(
M^Z7^CC''R'@9%B[/CE)X5(_)"*.EP@7\V!D20GA_M99  %U'"+"+F"N0N=P3
MT1RH99YM6^P;M<X@DX/":(;(=HU?5U[HF99'\^7CMU6.0:9D/$#X2VP[G8_0
M*\U#UHPJ<:>57S$+&:\XG9C".FW"&*3V84XB=V8G:4X%L2JC:+5!!,[S [Q4
MD;=(5'OR<6&)I#1XPSRAAU0,E25=UKTPFACRU#@7\"135W<7:FXQ"QWHFZTG
MJ5GS&6]$>,8V8"-5A8WMU")O_"22N_FK&OKQB9$J"WV0;B_+-"1I@N0'FJ.@
MS5!,K!J4=6J?1%N8RFY&QWY5[3P-M*CM*V:&[B*/;P=B\F6=HTM]*8J;"^ZG
M@RM8\KV9&?OP*7YBIU<QYXBU4/78Z3:ST>+#UZOC%U)X WWHR:U&<7+-1KEN
MSA>%=^&:*BT1/S3Z<:3V4Y"6^IQ2R'.?F1%=NVZ9GOUPS+V-#\00QQMK64Z@
MJ8D++WQ]VKD]5/C]'2@LFB-V;#N52'TA2(N/*:N1EGW=#5LB[-P6M<OI@?KZ
M(FMAP;W\KM!.NNP@[V+$,:M>9WHB/.8,&_G0H:,@NS?IWC6F?L.\_4&H\%7;
MQK+>-?&MZHFRHZ0THYM0V?O$8^=DODT^#PI)HV-E'-7"R%"V[WN=3ZG0NC,F
MKEL6XI5>0)$9^@J=/C,4^-_+>&6?&@(X0P"&@5]M#Z&-:H^>>6<ETC=U"8^=
M#T4<G>1GC!9ZEP?D3WX,C6@%6EW7L?,TP?CL<W.R?%I-^6K,1(<T7B0F/H3=
MQCQAK(?+RTN45C5G6#^W [*25E\;:M,3P+B&[\S4X;6L,TMX<P\LE6Q&ODC;
M%G!-$Q_X0<QG*(+NU"-5ZJ9P&M>3PKD9N3]_@VAA9^;W@L$ LRK<F-&%;T18
M3%-<Q]J,SJQ^[I-9R4*[L3?WS_YY7+K$ZR2::+-(?U?,%N:5"*XPTD'N5-O>
M(3#;2_S99&IZC:K95:.TBT:],*Y7-3VR46E=R?$$_@E2"W ##-(QC<;Z#L/6
M%G7S<3,AI=^]JKG9.DCV"&MG;V)=<<'N/2LR-C2-V#:'0]>GMKG,6_56C%;N
MJE*&*QQ\6 GA?&84WN.IS6XOBY9N)LZZ^M81OE8/X!';(PA6&Y6ONAG-I-O)
M)G@N%^0>\/L-4KNY3F_#D#:^P_HVU*V,3U>+Q+L=[3ZFM=1KXV37*LU*M.17
M/R3F_L9AT?AR/<P#X6$X'5-G47<OBGGR1;3.!Y^XWH'*<KTQU+!N#2+VYVCD
M-0OZ&- &72:]<^;<,@DA[K+]+=/XL8T_'-_1QYOTI[=LF'?>M1!@O%_C,?.I
MWV/9E.^>>B7)$P*TJ)A51&X[IVFA#.5S%R%]=$C9"+HLU&6:KF$FM-DLKST?
MZ^5X#_M"'T]B@FU7BMJ-L$2RN4EV05UUJEF1@ET&Y@<1TY'#DK4JOS-Z<9[L
M)_9#P;RE#;@3+\R!&.<F8X#EZP;I:Z5)\N5"GOFE0_P$!4G!SXJO'T_ 4N%K
MK:(<4]%9IQLUTB[K(<RF:735"&L1&CY&<33*9VSM@T9\^Z_F0G<KYW6JI$BK
M\YA@" ><!4&>N:$_#>*VPN3CJ&-/RE^-\CU=-Q1'W<BR3,\=:W8RB,:%8W,C
M*O,Y2I)4*9_=A-YJ$%CL!^N1"P91 XO.[7QPI.(DE1C&TL7[2?$)SZIK^9F[
M+\ ?*JK??GV>39+BYS#9AK?UD<V\CCW.<$@F-N53;^A5"</-OJ8QCRD55C1)
MQN';WHV)9DV6C^E7T E4E.O 1(\D(6'_T\YS$"KFZ 6YN'9E=>3VJ\V8@>#:
M#23"$="/'!TR-ZE9:?(3@![#8\0AC7?7<Z9V7UR ^U.Q^8@T9ZEN=45-K(2?
M!G/F[.F020.+F,3 YP\W.[ELPS++9#6A= B;'DG8*FZL QU?<78EB*J()6)H
M5<#F/DSXCEL-HT)(UFXY3]W1_+9)%.$>5-2^T4CD$8XMQ[ENS,5[NO,@O4GJ
MG]7?JA]N;9C\#6L_O,YS@"<?#.TO<M#(6I0C[ELS@C]16?5*@0"Q2JGL7'3.
ME08J==P=/A)\=XY"!^ZC<9H?#K=3>7B&D><\$ZO[^5D?G>4?T546!E5JSP;X
M7 RN6WH50G,AP-GH4V,O!,@HX:O>JVUB4PB+<*=;^FQ^+4.?V?KZ\?7OQ/+'
M@M9>L2>::^'K&9$[KB+;"D%VD74-D<?/B]"Z,EVHQ28T;J?X\[#Z:_A27WN?
MU+M(;E=K=##>6UXXL.473=T$H8'E7E>-[$:BI(B-LK@M_\@FU_/+G.DCP24Q
M^?JZJ?6**0!,(-B%08V.N(I/16V#)/PSV6O5R5NH"[Q/TWPAD&V.E*3>N452
M+N)$SKWH4JA:NRFP8N#?Z4D;2[RO1I0]$OID)$U59/S%Y9#] [7P ^IH_:_E
MZ+%AA,@BAB5IZ_A!'!]>](IC$[3X+5ZZ6^4$8=Q)EC+;PZ-++^J$'59K(]4S
MY6(/A@9B=8*[.[;\GHC, JW3=5+!MSMKN0,[;BFFJ,2")-@BZ-,AM]$S,25T
M7ZR)1[[M5X6D1J6R;!(GNSO%A+O"D7T=!*'L[L%IA/57P$F$:UFFQ[_T,2-Y
MJ#2+O$S[Q)RS-[8@G[]_]7*J\G Y-&8$MAY]CM=,X$RKE4&JF=!"*%OK4HJ%
M*HV*!/WC\R%]]4Y6P9@J%\;;R&5) P-4C;FWQG3GFLC30L,^73 ^4GAJ76UG
MC)8KESNL3SY6:>/. BTB/1(:7:(TD:O9X8/;HRU9._Y@1 '?<-]A9S)::/W4
M4H763VG0!8[&_(3X\JEQ>?.P%2+3UAK2*=UW"&"9V5@I^U.\<1*] T/-0_[K
MO9."%8]G7'R,X9VVJ,;0.".E]O%[DZ#:-SW>%LQ<SU1U<&0;7C3MI.+EJ<GE
M<$3.$7!JY>ME\%:I,$A\@_GXAN\#S(C7??I(EAP[\ABUYSO+K.^W(J.>KB5.
M^6^I5\SBL$6JCE798BOJ?*0I2'[)$QPICP:SK')7<!5)'=EL]Z%61)])O%'I
MX1WE7;T81N%^EKE@,=Z@>*?\7OE84>:7-TC34^/;EH;1I)$&K@TZZ5LX@MX]
M#3;W*%4P%=]D/PR*NH+Z"XKZ$:F]'^FZEDJE!]A:3$5&N/H!_0+)*>$I,).$
M>0.=B3@':DD]Z;E"/:DY:$TYSFB8B:GMY4AY'P1FDO3Z!>=[LFB&R,T22]6;
MM3H/>4F,7<HTQFM0+HDM=-<7.Z@=*XV0X#&^X$PWEZGO=&G6/7X6N2B397KB
MT-7;=->XOJ_\;'7Y:ERU^EZY*75"@E*1_<&M1RBJY$/C.S!=4B5">#R 1_W+
M8=8KZHQQQ>5E:N+I:18?8S?F^'>-^(LP\U):J:_=)'E^;CY>D7,EK(<Z7)M)
M#MR4&NVHE;!-;O0&:2VC?+N,##8OS-^R2Y/#T=EJI0D)MUA,[()I-4S"<]VI
M239('1X9D^2DES[,".CG$.0/I!X]@C3C79B)EJ=_6&6;J6D$JP\B$KMA+=2W
M/QQ@E(',,O?U3(8BD9RUR5(]=AD,<KJZN?LY_#P8?(R??Y#P OB&K5#R&:47
M>W)X%-6^V$Q^SM61%'GPDH, V@NW1&.-59%HYEN1$M%LG=BOD;0=+O#2'2
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M5ND6-V/.87E[A*"6[OUW_TK^!W@:/YUS+"YH\X)E/6!O?5U/$,1@)<MX'Z#
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M,2YX<V102P$"% ,4    "  4B']:%8UZ"-<,   9G0  %0
M@ '[#@  871N;2TR,#(T,3(S,5]C86PN>&UL4$L! A0#%     @ %(A_6HR'
MQ'I]+P  ^04# !4              ( !!1P  &%T;FTM,C R-#$R,S%?9&5F
M+GAM;%!+ 0(4 Q0    ( !2(?UHXG']]!GL  &&&!@ 5              "
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MY@, 96$P,C,R,SDU,#%E>#,Q+3)?86-T:6YI=6TN:'1M4$L! A0#%     @
M%(A_6H2#E0A&!   3Q,  !X              ( !U>X# &5A,#(S,C,Y-3 Q
M97@S,BTQ7V%C=&EN:75M+FAT;5!+ 0(4 Q0    ( !2(?UHX,+5L5P0  &D3
M   >              "  5?S P!E83 R,S(S.34P,65X,S(M,E]A8W1I;FEU
M;2YH=&U02P$"% ,4    "  4B']:0Z<]L?KU 0 $#@( #0
M@ 'J]P, :6UA9V5?,# Q+FIP9U!+ 0(4 Q0    ( !2(?UHSTKFS83,  %HW
M   -              "  0_N!0!I;6%G95\P,#(N:G!G4$L! A0#%     @
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M2P$"% ,4    "  4B']:R'U@F"8P  "V-P  #@              @ 'QUP8
M:6UA9V5?,# V82YJ<&=02P$"% ,4    "  4B']:B^)XKCA*  !V5   #@
M            @ %#" < :6UA9V5?,# V8BYJ<&=02P$"% ,4    "  4B']:
M0Q\;Y*Q.   >60  #0              @ &G4@< :6UA9V5?,# W+FIP9U!+
M 0(4 Q0    ( !2(?UH?&FQ2VQ4  %,>   -              "  7ZA!P!I
M;6%G95\P,#@N:G!G4$L! A0#%     @ %(A_6B/PJFJ)*0  &#$   T
M         ( !A+<' &EM86=E7S P.2YJ<&=02P$"% ,4    "  4B']:OYO-
M<YX[  !Q1@  #0              @ $XX0< :6UA9V5?,#$P+FIP9U!+ 0(4
M Q0    ( !2(?UI-Z/;-OC8  /LY   -              "  0$=" !I;6%G
M95\P,3$N:G!G4$L! A0#%     @ %(A_6I4M8!KH3   W5(   T
M     ( !ZE,( &EM86=E7S Q,BYJ<&=02P$"% ,4    "  4B']:Q[;@B\TO
M  #S.   #0              @ ']H @ :6UA9V5?,#$S+FIP9U!+ 0(4 Q0
M   ( !2(?UJX'R I#"(  #TF   -              "  ?70" !I;6%G95\P
M,30N:G!G4$L! A0#%     @ %(A_6C]/B/C)10  7DH   T
M ( !+/,( &EM86=E7S Q-2YJ<&=02P$"% ,4    "  4B']:]1Z7(?HU  "_
M.   #0              @ $@.0D :6UA9V5?,#$V+FIP9U!+ 0(4 Q0    (
M !2(?UK:VX7PKC,  !\X   -              "  45O"0!I;6%G95\P,3<N
M:G!G4$L! A0#%     @ %(A_6L_$KD6&+@  @3$   T              ( !
M'J,) &EM86=E7S Q."YJ<&=02P$"% ,4    "  4B']:,Z67555+  !K40
M#0              @ '/T0D :6UA9V5?,#$Y+FIP9U!+ 0(4 Q0    ( !2(
M?UJT+)NQT$<  )13   -              "  4\="@!I;6%G95\P,C N:G!G
M4$L! A0#%     @ %(A_6L8UR/HN2@   U(   T              ( !2F4*
M &EM86=E7S R,2YJ<&=02P$"% ,4    "  4B']:=LUL, ,-   U#@  #0
M            @ &CKPH :6UA9V5?,#(R+FIP9U!+!08     (P C )D(  #1
%O H    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>ea0232395-10k_actinium_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:atnm="http://www.actiniumpharma.com/20241231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="atnm-20241231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2025-03-28</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:RevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:RevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">atnm:OtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2012-06-15</startDate>
            <endDate>2012-06-15</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atnm:TwoThousandNineteenAmendedAndRestatedStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-23</startDate>
            <endDate>2024-04-23</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-23</startDate>
            <endDate>2019-04-23</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2019-04-23</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-23</startDate>
            <endDate>2024-04-23</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-23</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">atnm:FederalIncomeTaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">atnm:ExpireIn2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">atnm:TaxYearTwoThousandThirtyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">atnm:OrphanDrugCreditsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">atnm:TaxYearTwoThousandThirtySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-14944">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-14945">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-14946">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-14947">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-14948">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-14949">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-14950">001-36374</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-82">ACTINIUM PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-95">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0" id="ixv-101">74-2963609</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-122">100 Park Ave., 23rd Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-14951">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0" id="ixv-14952">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-14953">10017</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0" id="ixv-14954">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-14955">677-3870</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-171">Common stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-177">ATNM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-14956">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-14957">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-14958">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-14959">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-14960">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-238">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-245">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-255">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-14961">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-14962">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c0" id="ixv-14963">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c1" decimals="0" id="ixv-14964" unitRef="usd">226015477</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-14965"
      unitRef="shares">31195891</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c0" id="ixv-5382">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates in the biotechnology sector and is subject to various cybersecurity risks that could adversely affect the Company&#x2019;s
business, financial condition or results of operations, including intellectual property theft, fraud, extortion, harm to employees, collaborators
or vendors, violation of privacy laws and other litigations, legal and reputational risk.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company acknowledges that an actual or perceived
breach of its information assets could damage its reputation, interfere with the progress of clinical trials, or interfere with efforts
to pursue regulatory approvals for its product candidates. The Company also recognizes that an actual or perceived breach of its information
assets could impact the Company&#x2019;s business strategy, operations, or financial condition, as well as subject Actinium to third&#x2013;party
lawsuits, regulatory fines or other actions or liabilities, any of which could adversely affect the Company. For further information,
see &#x201c;Risk Factors&#x2014;Our business is subject to cybersecurity risks&#x201d; in Item 1A of this Annual Report on Form 10&#x2013;K.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Actinium&#x2019;s
Risk Management Strategy:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the critical importance of developing, implementing, and maintaining robust cybersecurity measures to safeguard its
information systems and protect the confidentiality, integrity, and availability of its data. With that objective, the Company undertook
a focused cybersecurity assessment conducted by an independent cybersecurity advisory firm to better understand the current cybersecurity
threats and risks necessary to establish the foundation of a cybersecurity risk assessment framework appropriate for its current business
operations and needs. The Company has also engaged well-known and established technology suppliers to support its key technology processes
and operating technical security management activities including threat, vulnerability, and network security management.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has established an Incident Response Policy and recovery plans to address its response to a cybersecurity incident, and such
plans are tested and evaluated on a regular basis. This includes continuous security operation centers monitoring of the Company&#x2019;s
systems and accounts.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company proactively mitigates its financial exposure to cybersecurity incidents by maintaining a cyber liability insurance policy. However,
the Company&#x2019;s cyber liability insurance may be inadequate or may not be available in the future on acceptable terms, or at all.
In addition, the Company&#x2019;s cyber liability insurance policy may not cover all claims made against the Company. Defending a suit,
regardless of its merit, could be costly and divert management&#x2019;s attention from the Company&#x2019;s business and operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
date, Actinium has not experienced any material cybersecurity incident that affected the Company&#x2019;s operations or financial condition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Governance:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
rely on a multidisciplinary team including third-party service providers to assess how identified cybersecurity threats could impact
our business. The Company&#x2019;s cybersecurity function is managed by the Company&#x2019;s Chief Financial Officer, who assumes the overall
responsibility and accountability of the function and with select members of the Company&#x2019;s management is collectively responsible
for the day&#x2013;to&#x2013;day assessment and management of cybersecurity risks, their prevention, mitigation, detection, and remediation.
Our Chief Financial Officer and other members of management have undergone various briefings from our cybersecurity advisory firm to
prepare them to effectively assess and manage material risks from cybersecurity threats. Additionally, members of the third-party service
providers have cybersecurity experience and/or certifications.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Board is involved in overseeing our risk management processes and policies that may be implemented from time to time.
The Audit Committee will coordinate these activities through regular interactions with the Company&#x2019;s management including but not
limited to: presentations regarding recent developments, potential risks associated with third parties, emerging trends, any relevant
findings or any incident that rises to the level of established thresholds.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
risk factors discussed in this document should be considered together with information included elsewhere in the Annual Report on Form
10&#x2013;K and should not be considered as the only risks to which the Company is exposed.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c0" id="ixv-5407">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes the critical importance of developing, implementing, and maintaining robust cybersecurity measures to safeguard its
information systems and protect the confidentiality, integrity, and availability of its data. With that objective, the Company undertook
a focused cybersecurity assessment conducted by an independent cybersecurity advisory firm to better understand the current cybersecurity
threats and risks necessary to establish the foundation of a cybersecurity risk assessment framework appropriate for its current business
operations and needs. The Company has also engaged well-known and established technology suppliers to support its key technology processes
and operating technical security management activities including threat, vulnerability, and network security management.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has established an Incident Response Policy and recovery plans to address its response to a cybersecurity incident, and such
plans are tested and evaluated on a regular basis. This includes continuous security operation centers monitoring of the Company&#x2019;s
systems and accounts.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="c0" id="ixv-5430">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
date, Actinium has not experienced any material cybersecurity incident that affected the Company&#x2019;s operations or financial condition.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c0" id="ixv-14966">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c0" id="ixv-5459">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
rely on a multidisciplinary team including third-party service providers to assess how identified cybersecurity threats could impact
our business. The Company&#x2019;s cybersecurity function is managed by the Company&#x2019;s Chief Financial Officer, who assumes the overall
responsibility and accountability of the function and with select members of the Company&#x2019;s management is collectively responsible
for the day&#x2013;to&#x2013;day assessment and management of cybersecurity risks, their prevention, mitigation, detection, and remediation.
Our Chief Financial Officer and other members of management have undergone various briefings from our cybersecurity advisory firm to
prepare them to effectively assess and manage material risks from cybersecurity threats. Additionally, members of the third-party service
providers have cybersecurity experience and/or certifications.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Board is involved in overseeing our risk management processes and policies that may be implemented from time to time.
The Audit Committee will coordinate these activities through regular interactions with the Company&#x2019;s management including but not
limited to: presentations regarding recent developments, potential risks associated with third parties, emerging trends, any relevant
findings or any incident that rises to the level of established thresholds.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c0" id="ixv-14967">The Company&#x2019;s cybersecurity function is managed by the Company&#x2019;s Chief Financial Officer, who assumes the overall
responsibility and accountability of the function and with select members of the Company&#x2019;s management is collectively responsible
for the day&#x2013;to&#x2013;day assessment and management of cybersecurity risks, their prevention, mitigation, detection, and remediation.
Our Chief Financial Officer and other members of management have undergone various briefings from our cybersecurity advisory firm to
prepare them to effectively assess and manage material risks from cybersecurity threats.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c0" id="ixv-14968">The Company&#x2019;s cybersecurity function is managed by the Company&#x2019;s Chief Financial Officer, who assumes the overall
responsibility and accountability of the function and with select members of the Company&#x2019;s management is collectively responsible
for the day&#x2013;to&#x2013;day assessment and management of cybersecurity risks, their prevention, mitigation, detection, and remediation.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c0" id="ixv-14969">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c0" id="ixv-14970">The Audit Committee will coordinate these activities through regular interactions with the Company&#x2019;s management including but not
limited to: presentations regarding recent developments, potential risks associated with third parties, emerging trends, any relevant
findings or any incident that rises to the level of established thresholds.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c0" id="ixv-14971">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <dei:AuditorOpinionTextBlock contextRef="c0" id="ixv-6423">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Opinion
on the Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have audited the accompanying consolidated balance sheets of Actinium Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) as of December
31, 2024 and 2023, and the related consolidated statements of operations, changes in stockholders&#x2019; equity and cash flows for each
of the two years in the period ended December 31, 2024 and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024,
in conformity with accounting principles generally accepted in the United States of America.&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="c0" id="ixv-6480">Marcum llp</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0" id="ixv-6502">Houston, Texas</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" id="ixv-14972" unitRef="usd">72904000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="-3" id="ixv-14973" unitRef="usd">76677000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" id="ixv-14974" unitRef="usd">1602000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c4" decimals="-3" id="ixv-14975" unitRef="usd">1586000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" id="ixv-14976" unitRef="usd">74506000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c4" decimals="-3" id="ixv-14977" unitRef="usd">78263000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="-3" id="ixv-14978" unitRef="usd">891000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c4" decimals="-3" id="ixv-14979" unitRef="usd">694000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" id="ixv-14980" unitRef="usd">364000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="-3" id="ixv-14981" unitRef="usd">550000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent contextRef="c3" decimals="-3" id="ixv-14982" unitRef="usd">324000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c4" decimals="-3" id="ixv-14983" unitRef="usd">313000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" id="ixv-14984" unitRef="usd">1685000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="-3" id="ixv-14985" unitRef="usd">2289000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c3" decimals="-3" id="ixv-14986" unitRef="usd">20000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c4" decimals="-3" id="ixv-14987" unitRef="usd">30000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="c3" decimals="-3" id="ixv-14988" unitRef="usd">76899000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c4" decimals="-3" id="ixv-14989" unitRef="usd">81445000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-14990" unitRef="usd">7568000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-14991" unitRef="usd">7953000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" id="ixv-14992" unitRef="usd">569000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c4" decimals="-3" id="ixv-14993" unitRef="usd">530000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c3" decimals="-3" id="ixv-14994" unitRef="usd">11000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c4" decimals="-3" id="ixv-14995" unitRef="usd">11000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-14996" unitRef="usd">8148000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-14997" unitRef="usd">8494000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-14998" unitRef="usd">35000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c4" decimals="-3" id="ixv-14999" unitRef="usd">35000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-15000" unitRef="usd">984000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c4" decimals="-3" id="ixv-15001" unitRef="usd">1553000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-15002" unitRef="usd">9000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c4" decimals="-3" id="ixv-15003" unitRef="usd">19000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c3" decimals="-3" id="ixv-15004" unitRef="usd">44141000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c4" decimals="-3" id="ixv-15005" unitRef="usd">45066000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="ixv-15006"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c4"
      decimals="3"
      id="ixv-15007"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c3"
      decimals="0"
      id="ixv-15008"
      unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c4"
      decimals="0"
      id="ixv-15009"
      unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c3"
      decimals="0"
      id="ixv-15010"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c4"
      decimals="0"
      id="ixv-15011"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c3"
      decimals="0"
      id="ixv-15012"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c4"
      decimals="0"
      id="ixv-15013"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="ixv-15014"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c4"
      decimals="3"
      id="ixv-15015"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c3"
      decimals="0"
      id="ixv-15016"
      unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c4"
      decimals="0"
      id="ixv-15017"
      unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="0"
      id="ixv-15018"
      unitRef="shares">31195891</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c3"
      decimals="0"
      id="ixv-15019"
      unitRef="shares">31195891</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c4"
      decimals="0"
      id="ixv-15020"
      unitRef="shares">27634213</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c4"
      decimals="0"
      id="ixv-15021"
      unitRef="shares">27634213</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c3" decimals="-3" id="ixv-15022" unitRef="usd">31000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c4" decimals="-3" id="ixv-15023" unitRef="usd">28000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="-3" id="ixv-15024" unitRef="usd">408553000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c4" decimals="-3" id="ixv-15025" unitRef="usd">373934000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" id="ixv-15026" unitRef="usd">-375826000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c4" decimals="-3" id="ixv-15027" unitRef="usd">-337583000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-15028" unitRef="usd">32758000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="-3" id="ixv-15029" unitRef="usd">36379000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" id="ixv-15030" unitRef="usd">76899000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="-3" id="ixv-15031" unitRef="usd">81445000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c8" decimals="-3" id="ixv-15032" unitRef="usd">81000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c9" decimals="-3" id="ixv-15033" unitRef="usd">81000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-15034" unitRef="usd">30045000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c9" decimals="-3" id="ixv-15035" unitRef="usd">38670000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-15036" unitRef="usd">12076000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c9" decimals="-3" id="ixv-15037" unitRef="usd">13331000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="-3" id="ixv-15038" unitRef="usd">42121000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c9" decimals="-3" id="ixv-15039" unitRef="usd">52001000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" id="ixv-15040" unitRef="usd">-42121000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c9" decimals="-3" id="ixv-15041" unitRef="usd">-51920000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c0" decimals="-3" id="ixv-15042" unitRef="usd">3878000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c9" decimals="-3" id="ixv-15043" unitRef="usd">3102000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" id="ixv-15044" unitRef="usd">3878000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c9" decimals="-3" id="ixv-15045" unitRef="usd">3102000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-15046" unitRef="usd">-38243000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c9" decimals="-3" id="ixv-15047" unitRef="usd">-48818000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-15048"
      unitRef="usdPershares">-1.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-15049"
      unitRef="usdPershares">-1.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c9"
      decimals="2"
      id="ixv-15050"
      unitRef="usdPershares">-1.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c9"
      decimals="2"
      id="ixv-15051"
      unitRef="usdPershares">-1.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="INF"
      id="ixv-15052"
      unitRef="shares">30070028</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ixv-15053"
      unitRef="shares">30070028</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c9"
      decimals="INF"
      id="ixv-15054"
      unitRef="shares">26604045</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c9"
      decimals="INF"
      id="ixv-15055"
      unitRef="shares">26604045</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c10"
      decimals="0"
      id="ixv-15056"
      unitRef="shares">25674823</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="-3" id="ixv-15057" unitRef="usd">26000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c11" decimals="-3" id="ixv-15058" unitRef="usd">355220000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c12" decimals="-3" id="ixv-15059" unitRef="usd">-288765000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c13" decimals="-3" id="ixv-15060" unitRef="usd">66481000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c14"
      decimals="0"
      id="ixv-15061"
      unitRef="shares">13144</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c15" decimals="-3" id="ixv-15062" unitRef="usd">3842000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c9" decimals="-3" id="ixv-15063" unitRef="usd">3842000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c14"
      decimals="0"
      id="ixv-15064"
      unitRef="shares">1902005</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c14" decimals="-3" id="ixv-15065" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c15" decimals="-3" id="ixv-15066" unitRef="usd">14610000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c9" decimals="-3" id="ixv-15067" unitRef="usd">14612000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c14"
      decimals="0"
      id="ixv-15068"
      unitRef="shares">44241</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c15" decimals="-3" id="ixv-15069" unitRef="usd">262000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c9" decimals="-3" id="ixv-15070" unitRef="usd">262000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss contextRef="c16" decimals="-3" id="ixv-15071" unitRef="usd">-48818000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c9" decimals="-3" id="ixv-15072" unitRef="usd">-48818000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c17"
      decimals="0"
      id="ixv-15073"
      unitRef="shares">27634213</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="-3" id="ixv-15074" unitRef="usd">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="-3" id="ixv-15075" unitRef="usd">373934000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="-3" id="ixv-15076" unitRef="usd">-337583000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="-3" id="ixv-15077" unitRef="usd">36379000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c20"
      decimals="0"
      id="ixv-15078"
      unitRef="shares">13394</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c21" decimals="-3" id="ixv-15079" unitRef="usd">5292000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c0" decimals="-3" id="ixv-15080" unitRef="usd">5292000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20"
      decimals="0"
      id="ixv-15081"
      unitRef="shares">3538136</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c20" decimals="-3" id="ixv-15082" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c21" decimals="-3" id="ixv-15083" unitRef="usd">29252000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c0" decimals="-3" id="ixv-15084" unitRef="usd">29255000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20"
      decimals="0"
      id="ixv-15085"
      unitRef="shares">10148</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c21" decimals="-3" id="ixv-15086" unitRef="usd">75000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c0" decimals="-3" id="ixv-15087" unitRef="usd">75000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss contextRef="c22" decimals="-3" id="ixv-15088" unitRef="usd">-38243000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-15089" unitRef="usd">-38243000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c23"
      decimals="0"
      id="ixv-15090"
      unitRef="shares">31195891</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c23" decimals="-3" id="ixv-15091" unitRef="usd">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c24" decimals="-3" id="ixv-15092" unitRef="usd">408553000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c25" decimals="-3" id="ixv-15093" unitRef="usd">-375826000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-15094" unitRef="usd">32758000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-15095" unitRef="usd">-38243000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c9" decimals="-3" id="ixv-15096" unitRef="usd">-48818000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-15097" unitRef="usd">5292000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c9" decimals="-3" id="ixv-15098" unitRef="usd">3842000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="-3" id="ixv-15099" unitRef="usd">197000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c9" decimals="-3" id="ixv-15100" unitRef="usd">207000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c0" decimals="-3" id="ixv-15101" unitRef="usd">614000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c9" decimals="-3" id="ixv-15102" unitRef="usd">583000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="-3" id="ixv-15103" unitRef="usd">15000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c9" decimals="-3" id="ixv-15104" unitRef="usd">-49000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="-3" id="ixv-15105" unitRef="usd">-387000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c9" decimals="-3" id="ixv-15106" unitRef="usd">-2177000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <atnm:IncreaseDecreaseInOperatingLeaseRightofuseAssets contextRef="c9" decimals="-3" id="ixv-15107" unitRef="usd">-527000</atnm:IncreaseDecreaseInOperatingLeaseRightofuseAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-15108" unitRef="usd">-530000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c9" decimals="-3" id="ixv-15109" unitRef="usd">-494000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-15110" unitRef="usd">-33072000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c9" decimals="-3" id="ixv-15111" unitRef="usd">-47335000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" id="ixv-15112" unitRef="usd">11000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c9" decimals="-3" id="ixv-15113" unitRef="usd">153000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" id="ixv-15114" unitRef="usd">-11000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c9" decimals="-3" id="ixv-15115" unitRef="usd">-153000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c0" decimals="-3" id="ixv-15116" unitRef="usd">9000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c9" decimals="-3" id="ixv-15117" unitRef="usd">4000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c0" decimals="-3" id="ixv-15118" unitRef="usd">29255000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c9" decimals="-3" id="ixv-15119" unitRef="usd">14612000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c0" decimals="-3" id="ixv-15120" unitRef="usd">75000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c9" decimals="-3" id="ixv-15121" unitRef="usd">262000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" id="ixv-15122" unitRef="usd">29321000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c9" decimals="-3" id="ixv-15123" unitRef="usd">14870000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="-3" id="ixv-15124" unitRef="usd">-3762000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c9" decimals="-3" id="ixv-15125" unitRef="usd">-32618000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="-3" id="ixv-15126" unitRef="usd">76990000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c13" decimals="-3" id="ixv-15127" unitRef="usd">109608000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" id="ixv-15128" unitRef="usd">73228000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="-3" id="ixv-15129" unitRef="usd">76990000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <atnm:RightofuseAssetObtainedInExchangeForLeaseLiabilities contextRef="c9" decimals="-3" id="ixv-15130" unitRef="usd">30000</atnm:RightofuseAssetObtainedInExchangeForLeaseLiabilities>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-7917">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1 - Description of Business and Summary of Significant Accounting Policies&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nature
of Business - &lt;/b&gt;Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing ARCs and other targeted radiotherapies to
deliver cancer-killing radiation with cellular level precision to treat patients with high unmet medical needs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principles
of Consolidation -&lt;/b&gt; The consolidated financial statements include the Company&#x2019;s accounts and those of the Company&#x2019;s wholly
owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Use
of Estimates in Financial Statement Presentation -&lt;/b&gt; The preparation of these consolidated financial statements in conformity with
accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses
during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Segment
Information &lt;/b&gt;- The Company operates as a single operating and reportable segment for the purposes of assessing performance and allocating
resources. The Company&#x2019;s chief operating decision maker is its Chief Executive Officer, who reviews total assets in the consolidated
balance sheets and net loss and its components in the consolidated statements of operations: research and development expenses, general and administrative expenses, and interest income, for the purposes of making operating decisions,
assessing financial performance, and allocating resources.&#160;All assets are in the United States.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cash
and Cash Equivalents and Restricted Cash -&lt;/b&gt; The Company considers all highly liquid accounts with original maturities of three months
or less to be cash equivalents. The Company holds most of its cash equivalents in a Money Market account comprised of U.S. Treasury notes.
Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
is a summary of cash, cash equivalents and restricted cash at December 31, 2024 and December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;72,904&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;76,677&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &#x2013; long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;324&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;313&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;73,228&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;76,990&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
cash relates to certificates of deposit held as collateral for letters of credit issued in connection with the Company&#x2019;s leases
of corporate office spaces.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Property
and Equipment -&lt;/b&gt; Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives
of three to five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives
of seven years. When assets are retired, the cost and related accumulated depreciation are removed from the accounts, and any related
gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations when incurred. Capitalized lease
assets are recorded at the lesser of the present value of minimum lease payments or fair value and amortized over the estimated useful
life of the related property or term of the lease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Leases
-&lt;/b&gt; The Company has an operating lease for corporate office space and a finance lease for office equipment located at the corporate
office space. Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases
is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair
Value Measurement - &lt;/b&gt;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability,
in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the
highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Revenue
Recognition &lt;/b&gt;- The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, &lt;i&gt;Revenue From
Contracts With Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;). Under ASC 606, an entity recognizes revenue when its customer obtains control of
promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods
or services. To determine revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps:
(i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction
price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue as the entity satisfies a performance obligation. The Company only applies the five-step model to contracts
when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers
to the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods
or services promised within each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services
that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. In
determining whether goods or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can
benefit from the good or service either on its own or together with other resources that are readily available to the customer (capable
of being distinct) and (ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct
in the context of the contract).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company then determines the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange
for the promised goods or services for each performance obligation and recognizes the associated revenue as each performance obligation
is satisfied. The Company&#x2019;s estimate of the transaction price for each contract includes all variable consideration to which it
expects to be entitled. Variable consideration includes payments in the form of collaboration milestone payments. If an arrangement includes
collaboration milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates
the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue
reversal would not occur, the associated milestone value is included in the transaction price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
606 requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance
obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should
be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised
good or service separately to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated
to the respective performance obligation as each performance obligation is satisfied, either at a point in time or over time, and if
over time, recognition is based on the use of an output or input method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Collaborative
Arrangements&lt;/b&gt; - The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain
transactions between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or
net basis, depending on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships.
The Company evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the
nature of the underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators,
the Company follows the guidance of ASC 606&lt;i&gt;.&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Grant
Revenue - &lt;/b&gt;The Company has a grant from a government-sponsored entity for research and development related activities that
provides for payments for reimbursed costs, which included overhead and general and administrative costs as well as an
administrative fee. The Company recognizes revenue from grants as it performed services under this arrangement. Associated expenses
are recognized when incurred as research and development expense. Revenue and related expenses are presented gross in the
consolidated statements of operations. There was no grant revenue for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;License
Revenue -&lt;/b&gt; The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain
product in specified territories using the Company&#x2019;s trademarks. The terms of this arrangement includes payment to the Company
for a combination of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments;
and royalties on net sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration
should be included in the transaction price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Upfront
license fees&lt;/i&gt;: If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance
obligations identified in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when
the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled
with other promises, the Company determines whether the combined performance obligation is satisfied over time or at a point in time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Development,
regulatory or commercial milestone payments&lt;/i&gt;: At the inception of each arrangement that includes payments based on the achievement
of certain development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered
probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it
is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.
Milestone payments that are not within the Company&#x2019;s or the licensee&#x2019;s control, such as regulatory approvals, are not considered
probable of being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate
the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#x2019;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Sales-based
milestone payments and royalties&lt;/i&gt;: For arrangements that include sales-based royalties, including milestone payments based on the
volume of sales, the Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based
milestones relate and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii)
when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upfront
payments and fees may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements or when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when
the uncertainty associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts
receivable when the Company&#x2019;s right to consideration is unconditional.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Research
and Development Costs -&lt;/b&gt; Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug
product, the costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to
facilities and equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development
costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Share-Based
Payments -&lt;/b&gt; The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing
model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee
is required to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Income
Taxes -&lt;/b&gt; The Company accounts for income taxes in accordance with ASC 740 &lt;i&gt;Income Taxes&lt;/i&gt;, which requires the asset and liability
method to calculate deferred taxes. Deferred taxes are recognized based on the differences between the financial reporting and income
tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to
reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred
tax asset will be fully realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
740 prescribes guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions. Tax positions
must meet a &#x201c;more-likely-than-not&#x201d; recognition threshold to be recognized. There were no tax positions for which it is considered
reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within the next year.
The Company recognizes interest related to unrecognized tax benefits in interest expense and penalties in operating expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net
Loss Per Common Share&lt;/b&gt; - Basic loss per common share is computed by dividing the net loss available to common stockholders by the
weighted average number of common shares outstanding during the reporting period. For periods of net loss, diluted loss per share is
calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2024 and 2023, the Company&#x2019;s potentially dilutive shares, which include outstanding common stock options,
restricted stock units and warrants, have not been included in the computation of diluted net loss per share as the result would have
been anti-dilutive.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,445&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;305&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,442&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,444&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,192&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Subsequent
Events &lt;/b&gt;- The Company&#x2019;s management reviewed all material events through the date the consolidated financial statements were
issued for subsequent event disclosure consideration.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Recently
Adopted Accounting Pronouncements - &lt;/b&gt;In November 2023, FASB issued ASU 2023-07, &lt;i&gt;Segment Reporting&lt;/i&gt; (Topic 280), &lt;i&gt;Improvements
to Reportable Segment Disclosures&lt;/i&gt;, which provides improvements to reportable segment disclosure requirements, primarily through enhanced
disclosures around segment expenses. ASU 2023-07 requires the Company to disclose significant segment expenses that are regularly provided
to the chief operating decision maker (&#x201c;CODM&#x201d;) and included within each reported measure of segment profit or loss. ASU 2023-07
also requires that the Company disclose an amount for other segment items by reportable segment, a description of their composition and
provide all annual disclosures about a reportable segment&#x2019;s profit or loss and assets pursuant to Topic 280 during interim periods.
The Company must also disclose the CODM&#x2019;s title and position, as well as certain information around the measures used by the CODM
and an explanation of how the CODM uses the reported measures in assessing segment performance and deciding how to allocate resources.
For public entities with a single reportable segment, the entity must provide all the disclosures required pursuant to ASU 2023-07 and
all existing segment disclosures under Topic 280. The amendments of ASU 2023-07 are effective for the Company for annual periods beginning
January 1, 2024, and effective for interim periods beginning January 1, 2025. The Company adopted this standard effective January 1,
2024 and reported on it in this Annual Report on Form 10-K for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Recently
Issued Accounting Pronouncements - &lt;/b&gt;In November 2024, FASB issued ASU 2024-03, &lt;i&gt;Income Statement-Reporting Comprehensive Income-Expense
Disaggregation Disclosures&lt;/i&gt; (Subtopic 220-40), to improve the disaggregation of expenses within the consolidated statement of operations.
The amendments in ASU 2024-03 require disclosures, in the notes to the consolidated financial statements, specified information about
certain costs and expenses. The amendments require that at each interim and annual reporting period an entity disclose (a) employee compensation,
(b) depreciation, and (c) intangible asset amortization included in each relevant expense caption; include certain amounts that are already
required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; and disclose a qualitative
description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively. The amendments
in ASU 2024-03 are effective January 1, 2027, and effective for interim periods beginning January 1, 2028. The Company will evaluate
the impact of ASU 2024-03 on its financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, FASB issued ASU 2023-09, &lt;i&gt;Income Taxes&lt;/i&gt; (Topic 740): &lt;i&gt;Improvements to Income Tax Disclosures&lt;/i&gt;, to enhance the
transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide improvements primarily related
to the rate reconciliation and income taxes paid information included in income tax disclosures. The Company will be required to disclose
additional information regarding reconciling items equal to or greater than five percent of the amount computed by multiplying pretax
income (loss) by the applicable statutory tax rate. Similarly, the Company will be required to disclose income taxes paid (net of refunds
received) equal to or greater than five percent of total income taxes paid (net of refunds received). The amendments in ASU 2023-09 are
effective January 1, 2025, including interim periods. The Company will evaluate the impact of ASU 2023-09 on its financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <atnm:NatureOfBusinessPolicyPolicyTextBlock contextRef="c0" id="ixv-7923">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nature
of Business - &lt;/b&gt;Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing ARCs and other targeted radiotherapies to
deliver cancer-killing radiation with cellular level precision to treat patients with high unmet medical needs.&lt;/span&gt;&lt;/p&gt;</atnm:NatureOfBusinessPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0" id="ixv-7930">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principles
of Consolidation -&lt;/b&gt; The consolidated financial statements include the Company&#x2019;s accounts and those of the Company&#x2019;s wholly
owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-7936">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Use
of Estimates in Financial Statement Presentation -&lt;/b&gt; The preparation of these consolidated financial statements in conformity with
accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses
during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0" id="ixv-7942">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Segment
Information &lt;/b&gt;- The Company operates as a single operating and reportable segment for the purposes of assessing performance and allocating
resources. The Company&#x2019;s chief operating decision maker is its Chief Executive Officer, who reviews total assets in the consolidated
balance sheets and net loss and its components in the consolidated statements of operations: research and development expenses, general and administrative expenses, and interest income, for the purposes of making operating decisions,
assessing financial performance, and allocating resources.&#160;All assets are in the United States.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c0" id="ixv-7948">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cash
and Cash Equivalents and Restricted Cash -&lt;/b&gt; The Company considers all highly liquid accounts with original maturities of three months
or less to be cash equivalents. The Company holds most of its cash equivalents in a Money Market account comprised of U.S. Treasury notes.
Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
is a summary of cash, cash equivalents and restricted cash at December 31, 2024 and December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;72,904&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;76,677&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &#x2013; long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;324&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;313&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;73,228&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;76,990&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
cash relates to certificates of deposit held as collateral for letters of credit issued in connection with the Company&#x2019;s leases
of corporate office spaces.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c0" id="ixv-7954">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
is a summary of cash, cash equivalents and restricted cash at December 31, 2024 and December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;72,904&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;76,677&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &#x2013; long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;324&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;313&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;73,228&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;76,990&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" id="ixv-15131" unitRef="usd">72904000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="-3" id="ixv-15132" unitRef="usd">76677000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent contextRef="c3" decimals="-3" id="ixv-15133" unitRef="usd">324000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c4" decimals="-3" id="ixv-15134" unitRef="usd">313000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" id="ixv-15135" unitRef="usd">73228000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="-3" id="ixv-15136" unitRef="usd">76990000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0" id="ixv-8009">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Property
and Equipment -&lt;/b&gt; Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives
of three to five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives
of seven years. When assets are retired, the cost and related accumulated depreciation are removed from the accounts, and any related
gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations when incurred. Capitalized lease
assets are recorded at the lesser of the present value of minimum lease payments or fair value and amortized over the estimated useful
life of the related property or term of the lease.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c26" id="ixv-15137">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c27" id="ixv-15138">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c28" id="ixv-15140">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-8015">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Leases
-&lt;/b&gt; The Company has an operating lease for corporate office space and a finance lease for office equipment located at the corporate
office space. Leases with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases
is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0" id="ixv-8035">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair
Value Measurement - &lt;/b&gt;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability,
in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the
highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c0" id="ixv-8041">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Revenue
Recognition &lt;/b&gt;- The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, &lt;i&gt;Revenue From
Contracts With Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;). Under ASC 606, an entity recognizes revenue when its customer obtains control of
promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods
or services. To determine revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps:
(i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction
price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue as the entity satisfies a performance obligation. The Company only applies the five-step model to contracts
when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers
to the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods
or services promised within each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services
that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. In
determining whether goods or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can
benefit from the good or service either on its own or together with other resources that are readily available to the customer (capable
of being distinct) and (ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct
in the context of the contract).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company then determines the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange
for the promised goods or services for each performance obligation and recognizes the associated revenue as each performance obligation
is satisfied. The Company&#x2019;s estimate of the transaction price for each contract includes all variable consideration to which it
expects to be entitled. Variable consideration includes payments in the form of collaboration milestone payments. If an arrangement includes
collaboration milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates
the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue
reversal would not occur, the associated milestone value is included in the transaction price.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
606 requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance
obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should
be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised
good or service separately to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated
to the respective performance obligation as each performance obligation is satisfied, either at a point in time or over time, and if
over time, recognition is based on the use of an output or input method.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c0" id="ixv-8063">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Collaborative
Arrangements&lt;/b&gt; - The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain
transactions between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or
net basis, depending on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships.
The Company evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the
nature of the underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators,
the Company follows the guidance of ASC 606&lt;i&gt;.&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:GovernmentAssistancePolicyTextBlock contextRef="c0" id="ixv-8070">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Grant
Revenue - &lt;/b&gt;The Company has a grant from a government-sponsored entity for research and development related activities that
provides for payments for reimbursed costs, which included overhead and general and administrative costs as well as an
administrative fee. The Company recognizes revenue from grants as it performed services under this arrangement. Associated expenses
are recognized when incurred as research and development expense. Revenue and related expenses are presented gross in the
consolidated statements of operations. There was no grant revenue for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:GovernmentAssistancePolicyTextBlock>
    <atnm:LicenseRevenuePolicyTextBlock contextRef="c0" id="ixv-8089">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;License
Revenue -&lt;/b&gt; The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain
product in specified territories using the Company&#x2019;s trademarks. The terms of this arrangement includes payment to the Company
for a combination of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments;
and royalties on net sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration
should be included in the transaction price.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Upfront
license fees&lt;/i&gt;: If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance
obligations identified in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when
the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled
with other promises, the Company determines whether the combined performance obligation is satisfied over time or at a point in time.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Development,
regulatory or commercial milestone payments&lt;/i&gt;: At the inception of each arrangement that includes payments based on the achievement
of certain development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered
probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it
is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.
Milestone payments that are not within the Company&#x2019;s or the licensee&#x2019;s control, such as regulatory approvals, are not considered
probable of being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate
the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#x2019;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Sales-based
milestone payments and royalties&lt;/i&gt;: For arrangements that include sales-based royalties, including milestone payments based on the
volume of sales, the Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based
milestones relate and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii)
when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upfront
payments and fees may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements or when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when
the uncertainty associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts
receivable when the Company&#x2019;s right to consideration is unconditional.&lt;/span&gt;&lt;/p&gt;</atnm:LicenseRevenuePolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0" id="ixv-8119">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Research
and Development Costs -&lt;/b&gt; Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug
product, the costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to
facilities and equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development
costs.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-8125">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Share-Based
Payments -&lt;/b&gt; The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing
model. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee
is required to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-8131">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Income
Taxes -&lt;/b&gt; The Company accounts for income taxes in accordance with ASC 740 &lt;i&gt;Income Taxes&lt;/i&gt;, which requires the asset and liability
method to calculate deferred taxes. Deferred taxes are recognized based on the differences between the financial reporting and income
tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to
reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred
tax asset will be fully realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
740 prescribes guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions. Tax positions
must meet a &#x201c;more-likely-than-not&#x201d; recognition threshold to be recognized. There were no tax positions for which it is considered
reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within the next year.
The Company recognizes interest related to unrecognized tax benefits in interest expense and penalties in operating expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-8159">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net
Loss Per Common Share&lt;/b&gt; - Basic loss per common share is computed by dividing the net loss available to common stockholders by the
weighted average number of common shares outstanding during the reporting period. For periods of net loss, diluted loss per share is
calculated similarly to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2024 and 2023, the Company&#x2019;s potentially dilutive shares, which include outstanding common stock options,
restricted stock units and warrants, have not been included in the computation of diluted net loss per share as the result would have
been anti-dilutive.&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,445&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;305&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,442&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,444&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,192&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0" id="ixv-8165">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2024 and 2023, the Company&#x2019;s potentially dilutive shares, which include outstanding common stock options,
restricted stock units and warrants, have not been included in the computation of diluted net loss per share as the result would have
been anti-dilutive.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,137&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,445&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;305&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,442&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,444&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,192&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c29"
      decimals="-3"
      id="ixv-15141"
      unitRef="shares">5137000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c30"
      decimals="-3"
      id="ixv-15142"
      unitRef="shares">5445000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c31"
      decimals="-3"
      id="ixv-15143"
      unitRef="shares">300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c32"
      decimals="-3"
      id="ixv-15144"
      unitRef="shares">305000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c33"
      decimals="-3"
      id="ixv-15145"
      unitRef="shares">7000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c34"
      decimals="-3"
      id="ixv-15146"
      unitRef="shares">1442000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c0"
      decimals="-3"
      id="ixv-15147"
      unitRef="shares">5444000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c9"
      decimals="-3"
      id="ixv-15148"
      unitRef="shares">7192000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="c0" id="ixv-8225">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Subsequent
Events &lt;/b&gt;- The Company&#x2019;s management reviewed all material events through the date the consolidated financial statements were
issued for subsequent event disclosure consideration.&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-8231">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Recently
Adopted Accounting Pronouncements - &lt;/b&gt;In November 2023, FASB issued ASU 2023-07, &lt;i&gt;Segment Reporting&lt;/i&gt; (Topic 280), &lt;i&gt;Improvements
to Reportable Segment Disclosures&lt;/i&gt;, which provides improvements to reportable segment disclosure requirements, primarily through enhanced
disclosures around segment expenses. ASU 2023-07 requires the Company to disclose significant segment expenses that are regularly provided
to the chief operating decision maker (&#x201c;CODM&#x201d;) and included within each reported measure of segment profit or loss. ASU 2023-07
also requires that the Company disclose an amount for other segment items by reportable segment, a description of their composition and
provide all annual disclosures about a reportable segment&#x2019;s profit or loss and assets pursuant to Topic 280 during interim periods.
The Company must also disclose the CODM&#x2019;s title and position, as well as certain information around the measures used by the CODM
and an explanation of how the CODM uses the reported measures in assessing segment performance and deciding how to allocate resources.
For public entities with a single reportable segment, the entity must provide all the disclosures required pursuant to ASU 2023-07 and
all existing segment disclosures under Topic 280. The amendments of ASU 2023-07 are effective for the Company for annual periods beginning
January 1, 2024, and effective for interim periods beginning January 1, 2025. The Company adopted this standard effective January 1,
2024 and reported on it in this Annual Report on Form 10-K for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <atnm:RecentlyIssuedAccountingPronouncementsPolicyTextBlock contextRef="c0" id="ixv-8239">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Recently
Issued Accounting Pronouncements - &lt;/b&gt;In November 2024, FASB issued ASU 2024-03, &lt;i&gt;Income Statement-Reporting Comprehensive Income-Expense
Disaggregation Disclosures&lt;/i&gt; (Subtopic 220-40), to improve the disaggregation of expenses within the consolidated statement of operations.
The amendments in ASU 2024-03 require disclosures, in the notes to the consolidated financial statements, specified information about
certain costs and expenses. The amendments require that at each interim and annual reporting period an entity disclose (a) employee compensation,
(b) depreciation, and (c) intangible asset amortization included in each relevant expense caption; include certain amounts that are already
required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; and disclose a qualitative
description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively. The amendments
in ASU 2024-03 are effective January 1, 2027, and effective for interim periods beginning January 1, 2028. The Company will evaluate
the impact of ASU 2024-03 on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, FASB issued ASU 2023-09, &lt;i&gt;Income Taxes&lt;/i&gt; (Topic 740): &lt;i&gt;Improvements to Income Tax Disclosures&lt;/i&gt;, to enhance the
transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide improvements primarily related
to the rate reconciliation and income taxes paid information included in income tax disclosures. The Company will be required to disclose
additional information regarding reconciling items equal to or greater than five percent of the amount computed by multiplying pretax
income (loss) by the applicable statutory tax rate. Similarly, the Company will be required to disclose income taxes paid (net of refunds
received) equal to or greater than five percent of total income taxes paid (net of refunds received). The amendments in ASU 2023-09 are
effective January 1, 2025, including interim periods. The Company will evaluate the impact of ASU 2023-09 on its financial statements.&lt;/span&gt;&lt;/p&gt;</atnm:RecentlyIssuedAccountingPronouncementsPolicyTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c0" id="ixv-8266">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 - Prepaid Expenses and Other Current Assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses and other current assets consisted of the following at December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Prepaid&#160;insurance&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;608&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;614&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid&#160;clinical trial expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;637&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;746&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;357&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;226&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,602&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,586&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="c0" id="ixv-8272">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses and other current assets consisted of the following at December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Prepaid&#160;insurance&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;608&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;614&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid&#160;clinical trial expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;637&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;746&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;357&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;226&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,602&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,586&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidInsurance contextRef="c3" decimals="-3" id="ixv-15149" unitRef="usd">608000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="c4" decimals="-3" id="ixv-15150" unitRef="usd">614000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c3" decimals="-3" id="ixv-15151" unitRef="usd">637000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c4" decimals="-3" id="ixv-15152" unitRef="usd">746000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c3" decimals="-3" id="ixv-15153" unitRef="usd">357000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c4" decimals="-3" id="ixv-15154" unitRef="usd">226000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" id="ixv-15155" unitRef="usd">1602000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c4" decimals="-3" id="ixv-15156" unitRef="usd">1586000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0" id="ixv-8338">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3 - Property and Equipment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consisted of the following at December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Lives&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;5 years&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;817&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;806&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office equipment&#160;and furniture&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3 - 7 years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;438&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;438&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(891&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(694&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;364&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;550&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense consisted of the following for the years ended December 31, 2024 and 2023, respectively:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Research&#160;and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;161&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;175&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;36&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;32&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total depreciation expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;197&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;207&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-8344">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consisted of the following at December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Lives&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;5 years&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;817&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;806&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office equipment&#160;and furniture&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3 - 7 years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;438&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;438&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(891&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(694&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;364&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;550&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c35" id="ixv-15157">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c35" decimals="-3" id="ixv-15158" unitRef="usd">817000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c36" decimals="-3" id="ixv-15159" unitRef="usd">806000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c37" id="ixv-15160">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c38" id="ixv-15161">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c39" decimals="-3" id="ixv-15162" unitRef="usd">438000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c40" decimals="-3" id="ixv-15163" unitRef="usd">438000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="-3" id="ixv-15164" unitRef="usd">891000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c4" decimals="-3" id="ixv-15165" unitRef="usd">694000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" id="ixv-15166" unitRef="usd">364000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="-3" id="ixv-15167" unitRef="usd">550000</us-gaap:PropertyPlantAndEquipmentNet>
    <atnm:ScheduleOfDepreciationExpenseTableTextBlock contextRef="c0" id="ixv-8420">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense consisted of the following for the years ended December 31, 2024 and 2023, respectively:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Research&#160;and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;161&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;175&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;36&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;32&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total depreciation expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;197&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;207&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</atnm:ScheduleOfDepreciationExpenseTableTextBlock>
    <us-gaap:Depreciation contextRef="c41" decimals="-3" id="ixv-15168" unitRef="usd">161000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c42" decimals="-3" id="ixv-15169" unitRef="usd">175000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c43" decimals="-3" id="ixv-15170" unitRef="usd">36000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c44" decimals="-3" id="ixv-15171" unitRef="usd">32000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c0" decimals="-3" id="ixv-15172" unitRef="usd">197000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c9" decimals="-3" id="ixv-15173" unitRef="usd">207000</us-gaap:Depreciation>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0" id="ixv-8476">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4 - Leases &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys
to the Company the right to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying
asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic
benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company
has elected to account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components
are recognized when the obligation is probable. The Company made an accounting policy election to exclude from balance sheet reporting
those leases with initial terms of 12 months or less.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Right-of-use
assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842
requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily
determined, its incremental borrowing rate. As an implicit interest rate was not readily determinable in the Company&#x2019;s leases,
the incremental borrowing rate was used based on the information available at commencement date in determining the present value of lease
payments.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
lease term for all of the Company&#x2019;s leases includes the non-cancellable period of the lease plus any additional periods covered
by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option
to extend (or not to terminate) the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term
(and lease liability) for the Company&#x2019;s leases as the reasonably certain threshold is not met.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the Company has two leases which have been capitalized in accordance with ASC 842, one for corporate office space
and one for office equipment. The Company entered into a lease for corporate office space effective June 1, 2022. The lease has a term
of 5 years and 2 months, with an expiration date on July 30, 2027 and current annual rent of $0.6 million. The Company is also responsible
for certain other costs, such as insurance, utilities and maintenance. During the year ended December 31, 2023, the Company spent $0.5
million on improvements at its corporate office space, which were included in the value of the operating right-to-use asset.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of lease expense are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;Operating lease expense&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;691&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;691&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Amortization of right-to-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-28"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total finance lease cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Supplemental
cash flow information related to leases are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Cash flow information:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating cash flow use from operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;618&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;606&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-29"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financing cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Non-cash activity:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-30"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-31"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-32"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
average remaining lease terms are as follows at December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Weighted average remaining lease term:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 89%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;2.6 years&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;2.0 years&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
the interest rate implicit in the leases was not readily determinable at the time that the leases were evaluated, the Company used its
incremental borrowing rate based on the information available in determining the present value of lease payments. The Company&#x2019;s
incremental borrowing rate was based on the term of the lease, the economic environment of the lease and reflect the rate the Company
would have had to pay to borrow on a secured basis. Below is information on the weighted average discount rates used at the time that
the leases were evaluated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Weighted average discount rates:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Maturities
of lease liabilities are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Year ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Operating&#160;&lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Finance&#160;&lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;630&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;643&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;380&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-33"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,653&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,553&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="c0" id="ixv-15174">5 years and 2 months</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LeaseExpirationDate1 contextRef="c0" id="ixv-15175">2027-07-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:PaymentsForRent contextRef="c0" decimals="-5" id="ixv-15176" unitRef="usd">600000</us-gaap:PaymentsForRent>
    <us-gaap:LandImprovements contextRef="c45" decimals="-5" id="ixv-15177" unitRef="usd">500000</us-gaap:LandImprovements>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0" id="ixv-8512">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of lease expense are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;Operating lease expense&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;691&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;691&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Amortization of right-to-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-28"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total finance lease cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Supplemental
cash flow information related to leases are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Cash flow information:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating cash flow use from operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;618&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;606&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-29"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financing cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Non-cash activity:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-30"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-31"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-32"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
average remaining lease terms are as follows at December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Weighted average remaining lease term:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 89%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;2.6 years&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;2.0 years&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;Below is information on the weighted average discount rates used at the time that
the leases were evaluated:&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Weighted average discount rates:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense contextRef="c0" decimals="-3" id="ixv-15178" unitRef="usd">691000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c9" decimals="-3" id="ixv-15179" unitRef="usd">691000</us-gaap:OperatingLeaseExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c0" decimals="-3" id="ixv-15180" unitRef="usd">10000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c9" decimals="-3" id="ixv-15181" unitRef="usd">3000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c0" decimals="-3" id="ixv-15182" unitRef="usd">2000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost contextRef="c0" decimals="-3" id="ixv-15183" unitRef="usd">12000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c9" decimals="-3" id="ixv-15184" unitRef="usd">3000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="-3" id="ixv-15185" unitRef="usd">618000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c9" decimals="-3" id="ixv-15186" unitRef="usd">606000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c0" decimals="-3" id="ixv-15187" unitRef="usd">11000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c0" decimals="-3" id="ixv-15188" unitRef="usd">9000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c9" decimals="-3" id="ixv-15189" unitRef="usd">4000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c9" decimals="-3" id="ixv-15190" unitRef="usd">30000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3" id="ixv-15191">P2Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3" id="ixv-15192">P2Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c3" decimals="3" id="ixv-15194" unitRef="pure">0.048</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c3" decimals="3" id="ixv-15195" unitRef="pure">0.062</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-8786">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Maturities
of lease liabilities are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Year ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Operating&#160;&lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Finance&#160;&lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;630&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;643&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;380&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-33"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,653&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,553&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c3" decimals="-3" id="ixv-15196" unitRef="usd">630000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c3" decimals="-3" id="ixv-15197" unitRef="usd">11000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c3" decimals="-3" id="ixv-15198" unitRef="usd">643000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo contextRef="c3" decimals="-3" id="ixv-15199" unitRef="usd">11000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c3" decimals="-3" id="ixv-15200" unitRef="usd">380000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c3" decimals="-3" id="ixv-15201" unitRef="usd">1653000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="c3" decimals="-3" id="ixv-15202" unitRef="usd">22000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c3" decimals="-3" id="ixv-15203" unitRef="usd">100000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="c3" decimals="-3" id="ixv-15204" unitRef="usd">2000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c3" decimals="-3" id="ixv-15205" unitRef="usd">1553000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c3" decimals="-3" id="ixv-15206" unitRef="usd">20000</us-gaap:FinanceLeaseLiability>
    <atnm:OtherRevenueTextBlock contextRef="c0" id="ixv-8868">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5 - Other Revenue&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has a grant from a government-sponsored entity for research and development related activities that provides for payments for
reimbursed costs, which includes overhead and general and administrative costs as well as an administrative fee. The Company recognized
revenue from grants as it performed services under this arrangement. Associated expenses are recognized when incurred as research and
development expense. Other revenue recognized from this grant during the year ended December 31, 2023 was $0.1 million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 7, 2022, the Company entered into a license and supply agreement (the &#x201c;License Agreement&#x201d;) with Immedica Pharma AB
(&#x201c;Immedica&#x201d;), pursuant to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab)
in the European Economic Area, Middle East and North Africa (&#x201c;EUMENA&#x201d;), including Algeria, Andorra, Bahrain, Cyprus, Egypt,
Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria,
Tunisia, Turkey, the United Arab Emirates, the United Kingdom, the Vatican City and Yemen. Upon signing, the Company was entitled to
an upfront, non-refundable payment of $35 million from Immedica, which was received in May 2022. Under the terms of the License Agreement,
the Company is eligible to receive certain regulatory and commercial milestone payments and royalties on net sales of the product in
certain countries that may result from the License Agreement. The Company continues to retain commercialization rights in the U.S. and
rest of the world.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s contract liabilities are recorded within Other revenue deferred &#x2013; current liability or Long-term license revenue
deferred in its condensed consolidated balance sheets, depending on the short-term or long-term nature of the payments to be recognized.
The Company&#x2019;s contract liabilities primarily consist of advanced payments from licensees. Long-term license revenue deferred was
$35.0 million at December 31, 2024 and December 31, 2023; this deferred revenue will be recognized upon European Union&#x2019;s regulatory
approval of Iomab-B or provision of definitive feedback that Iomab-B will not receive approval in the European Union.&lt;/span&gt;&lt;/p&gt;</atnm:OtherRevenueTextBlock>
    <us-gaap:OtherIncome contextRef="c9" decimals="-5" id="ixv-15207" unitRef="usd">100000</us-gaap:OtherIncome>
    <atnm:NonRefundablePaymentReceived contextRef="c46" decimals="-6" id="ixv-15208" unitRef="usd">35000000</atnm:NonRefundablePaymentReceived>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c3" decimals="-5" id="ixv-15209" unitRef="usd">35000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c4" decimals="-5" id="ixv-15210" unitRef="usd">35000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-8888">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6 - Commitments and Contingencies&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&#x201c;FHCRC&#x201d;)
to build upon previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase
2 clinical trial with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed
by FHCRC. A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug utilizing the licensed antibody.
Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <atnm:PaymentOfMilestone contextRef="c47" decimals="-6" id="ixv-15211" unitRef="usd">1000000</atnm:PaymentOfMilestone>
    <atnm:RoyaltyPaymentsPercentage contextRef="c47" decimals="2" id="ixv-15212" unitRef="pure">0.02</atnm:RoyaltyPaymentsPercentage>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="c0" id="ixv-8900">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7 - Equity&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the Company entered into the Capital on Demand&#x2122; Sales Agreement with JonesTrading Institutional Services LLC, &#x201c;JonesTrading&#x201d;,
pursuant to which the Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of its common
stock. On June 28, 2022, the Company entered into an Amended and Restated Capital on Demand&#x2122; Sales Agreement (the &#x201c;A&amp;amp;R
Sales Agreement&#x201d;) with JonesTrading and B. Riley Securities, Inc. (&#x201c;B. Riley&#x201d;). The A&amp;amp;R Sales Agreement modifies
the original Capital on Demand&#x2122; Sales Agreement to include B. Riley Securities as an additional sales agent thereunder. Shares
of common stock were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-242322) filed with the SEC on August
7, 2020 (the &#x201c;Prior Shelf Registration Statement&#x201d;). On August 11, 2023, the Company filed a registration statement on Form
S-3 (File No. 333-273911), which registration statement was amended on February 2, 2024, and declared effective on February 5, 2024,
to replace the Prior Shelf Registration Statement, including a base prospectus which covers the offering, issuance and sale of up to
$500 million of common stock, preferred stock, warrants, units and/or subscription rights; and a sales agreement prospectus covering
the offering, issuance and sale of up to a maximum aggregate offering price of $200 million of common stock that may be issued and sold
under the Amended Sales Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, the Company sold 3.5 million shares of common stock, resulting in gross proceeds of $29.9 million and
net proceeds of $29.3 million. During the year ended December 31, 2023, the Company sold 1.9 million shares of common stock, resulting
in gross proceeds of $15.1 million and net proceeds of $14.6 million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company presently has one equity compensation plan, the 2019 Amended and Restated Stock Plan, (the &#x201c;2019 Plan&#x201d;). The 2019
Plan has an expiration date of October&#160;18, 2029 and the number of shares of our common stock authorized under the plan for grant
to employees, directors and consultants is 9,333,333 shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had two equity compensation plans that expired on September 9, 2023; the Company&#x2019;s Amended and Restated 2013 Stock Plan
and the Company&#x2019;s 2013 Equity Incentive Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
is a summary of stock option activity for the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amount)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; text-indent: -9pt; padding-left: 9pt"&gt;Outstanding, January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,396&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.85&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15,204&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,402&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(44&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(309&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;8.30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Outstanding, December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,445&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;373&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;154&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(452&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;10.04&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Outstanding, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,137&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.48&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;7.04&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-34"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Exercisable, December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,555&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.63&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-35"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2024, the Company granted newly hired employees options to purchase 0.2 million shares of common stock with an exercise price ranging
from $7.20 to $8.15 per share, a term of 10 years, and a vesting period of 4 years.&#160;The options have an aggregated fair value of
$0.6 million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model
include: (1) discount rate range from 4.19% to 4.45% (2) expected life of 6 years, (3) expected volatility range from 80.5% to 90.5%,
and (4) &lt;span style="-sec-ix-hidden: hidden-fact-51"&gt;zero&lt;/span&gt; expected dividends.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2023, the Company granted its employees and members of the Board of Directors options to purchase 2.4 million shares of common stock
with an exercise price ranging from $5.00 to $11.60 per share, a term of 10 years, and a vesting period from 4 to 4.2 years.&#160;The
options have an aggregated fair value of $9.0 million that was calculated using the Black-Scholes option-pricing model. Variables used
in the Black-Scholes option-pricing model include: (1) discount rate range from 3.5% to 4.82% (2) expected life of 6 years, (3) expected
volatility range from 79.0% to 81.6%, and (4) zero expected dividends.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2024 and 2023, options to purchase 0.5 million and 0.3 million common shares were cancelled, respectively,
upon the termination of employment.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair values of all options
issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at December 31,
2024 was $9.1 million related to unvested options, which is expected to be expensed over a weighted average of 2.6 years. During 2024
and 2023, the Company recorded total option expense of $4.6 million and $3.2 million, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Restricted
Stock Units&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
is a summary of restricted stock unit (&#x201c;RSUs&#x201d;) activity for the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;(in thousands, except for per-share amount)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Grant Date Fair Value Per Share ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Outstanding, January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;325&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-36"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-37"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;7.31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding, December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;305&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-38"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-39"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-40"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-41"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;8.31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;300&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.85&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
RSUs vest at the earliest of a change of control event, the termination of the recipient&#x2019;s continuous service status for any reason
other than by the Company for cause and the third anniversary of the date of the grant. The fair value of the RSUs, $1.8 million, was
determined based on the stock prices on the dates of the grants and each RSU grant is being recognized over its respective three-year
period. The unrecognized compensation expense at December 31, 2024 of $0.4 million is expected to be expensed over a weighted average
of 0.6 years. During 2024 and 2023, the Company recorded compensation expense related to RSUs of $0.6 million and $0.6 million, respectively.&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
is a summary of warrant activities for the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in&#160;years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; text-indent: -9pt; padding-left: 9pt"&gt;Outstanding, January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,443&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16.58&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-42"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-43"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;106.80&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Outstanding, December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,442&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-44"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-45"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-46"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-47"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-48"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,435&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;16.42&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Outstanding, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;17.33&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.46&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-49"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Exercisable, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;17.77&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.25&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-50"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 23, 2024, warrants to purchase an aggregate of 1.4 million shares of common stock expired. These warrants were issued on April
23, 2019, when the Company completed an underwritten offering of 1.4 million shares of common stock and warrants to purchase 1.4 million
shares of common stock at a price of $11.55 per share and related warrant. The warrants were exercisable for a period of 5 years at an
exercise price of $15.00 per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2024 and 2023, the Company recorded stock-based compensation expense related to warrants of $5 thousand
and $6 thousand, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c48" decimals="-6" id="ixv-15213" unitRef="usd">200000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c20" decimals="-6" id="ixv-15214" unitRef="usd">500000000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c20" decimals="-6" id="ixv-15215" unitRef="usd">200000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c20"
      decimals="-5"
      id="ixv-15216"
      unitRef="shares">3500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c20" decimals="-5" id="ixv-15217" unitRef="usd">29900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <atnm:NetProceedsFromIssuanceOfCommonStock contextRef="c20" decimals="-5" id="ixv-15218" unitRef="usd">29300000</atnm:NetProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c14"
      decimals="-5"
      id="ixv-15219"
      unitRef="shares">1900000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c14" decimals="-5" id="ixv-15220" unitRef="usd">15100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <atnm:NetProceedsFromIssuanceOfCommonStock contextRef="c14" decimals="-5" id="ixv-15221" unitRef="usd">14600000</atnm:NetProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c49"
      decimals="0"
      id="ixv-15222"
      unitRef="shares">9333333</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-8940">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
is a summary of stock option activity for the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amount)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; text-indent: -9pt; padding-left: 9pt"&gt;Outstanding, January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,396&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.85&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15,204&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,402&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(44&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(309&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;8.30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Outstanding, December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,445&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;373&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;154&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(452&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;10.04&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Outstanding, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,137&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.48&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;7.04&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-34"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Exercisable, December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,555&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.63&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-35"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c73"
      decimals="-3"
      id="ixv-15223"
      unitRef="shares">3396000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c73"
      decimals="2"
      id="ixv-15224"
      unitRef="usdPershares">8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c74" id="ixv-15225">P8Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c73" decimals="-3" id="ixv-15226" unitRef="usd">15204000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c9"
      decimals="-3"
      id="ixv-15227"
      unitRef="shares">2402000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c9"
      decimals="2"
      id="ixv-15228"
      unitRef="usdPershares">5.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c9"
      decimals="-3"
      id="ixv-15229"
      unitRef="shares">44000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c9"
      decimals="2"
      id="ixv-15230"
      unitRef="usdPershares">5.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c9"
      decimals="-3"
      id="ixv-15231"
      unitRef="shares">309000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c9"
      decimals="2"
      id="ixv-15232"
      unitRef="usdPershares">8.3</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c4"
      decimals="-3"
      id="ixv-15233"
      unitRef="shares">5445000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c4"
      decimals="2"
      id="ixv-15234"
      unitRef="usdPershares">6.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c9" id="ixv-15235">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c4" decimals="-3" id="ixv-15236" unitRef="usd">373000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c0"
      decimals="-3"
      id="ixv-15237"
      unitRef="shares">154000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-15238"
      unitRef="usdPershares">5.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c0"
      decimals="-3"
      id="ixv-15239"
      unitRef="shares">10000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-15240"
      unitRef="usdPershares">7.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c0"
      decimals="-3"
      id="ixv-15241"
      unitRef="shares">452000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-15242"
      unitRef="usdPershares">10.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c3"
      decimals="-3"
      id="ixv-15243"
      unitRef="shares">5137000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c3"
      decimals="2"
      id="ixv-15244"
      unitRef="usdPershares">6.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c0" id="ixv-15245">P7Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c3"
      decimals="-3"
      id="ixv-15246"
      unitRef="shares">2555000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c3"
      decimals="2"
      id="ixv-15247"
      unitRef="usdPershares">10.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0" id="ixv-15248">P7Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c50"
      decimals="-5"
      id="ixv-15249"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c51"
      decimals="2"
      id="ixv-15250"
      unitRef="usdPershares">7.2</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c52"
      decimals="2"
      id="ixv-15251"
      unitRef="usdPershares">8.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c53" id="ixv-15252">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c53" id="ixv-15253">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EquityFairValueDisclosure contextRef="c3" decimals="-5" id="ixv-15254" unitRef="usd">600000</us-gaap:EquityFairValueDisclosure>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="c54" decimals="4" id="ixv-15255" unitRef="pure">0.0419</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="c55" decimals="4" id="ixv-15256" unitRef="pure">0.0445</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0" id="ixv-15257">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c0" decimals="3" id="ixv-15258" unitRef="pure">0.805</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c0" decimals="3" id="ixv-15259" unitRef="pure">0.905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c56"
      decimals="-5"
      id="ixv-15260"
      unitRef="shares">2400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c57"
      decimals="2"
      id="ixv-15261"
      unitRef="usdPershares">5</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c58"
      decimals="2"
      id="ixv-15262"
      unitRef="usdPershares">11.6</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c59" id="ixv-15263">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c57" id="ixv-15264">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c58" id="ixv-15265">P4Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EquityFairValueDisclosure contextRef="c4" decimals="-5" id="ixv-15266" unitRef="usd">9000000</us-gaap:EquityFairValueDisclosure>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="c60" decimals="3" id="ixv-15267" unitRef="pure">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="c61" decimals="4" id="ixv-15268" unitRef="pure">0.0482</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c9" id="ixv-15269">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c9" decimals="3" id="ixv-15270" unitRef="pure">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c9" decimals="3" id="ixv-15271" unitRef="pure">0.816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c9" decimals="2" id="ixv-15272" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c0"
      decimals="-5"
      id="ixv-15273"
      unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c9"
      decimals="-5"
      id="ixv-15274"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c62" decimals="-5" id="ixv-15275" unitRef="usd">9100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c53" id="ixv-15276">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c53" decimals="-5" id="ixv-15277" unitRef="usd">4600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c59" decimals="-5" id="ixv-15278" unitRef="usd">3200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c0" id="ixv-9192">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
is a summary of restricted stock unit (&#x201c;RSUs&#x201d;) activity for the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;(in thousands, except for per-share amount)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Grant Date Fair Value Per Share ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Outstanding, January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;325&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-36"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-37"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;7.31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding, December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;305&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-38"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-39"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-40"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-41"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;8.31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;300&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.85&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c75"
      decimals="INF"
      id="ixv-15279"
      unitRef="shares">325000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c75"
      decimals="2"
      id="ixv-15280"
      unitRef="usdPershares">5.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c65"
      decimals="INF"
      id="ixv-15281"
      unitRef="shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c65"
      decimals="2"
      id="ixv-15282"
      unitRef="usdPershares">8.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c65"
      decimals="INF"
      id="ixv-15283"
      unitRef="shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c65"
      decimals="2"
      id="ixv-15284"
      unitRef="usdPershares">7.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c76"
      decimals="INF"
      id="ixv-15285"
      unitRef="shares">305000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c76"
      decimals="2"
      id="ixv-15286"
      unitRef="usdPershares">5.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c63"
      decimals="INF"
      id="ixv-15287"
      unitRef="shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c63"
      decimals="2"
      id="ixv-15288"
      unitRef="usdPershares">8.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c64"
      decimals="INF"
      id="ixv-15289"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c64"
      decimals="2"
      id="ixv-15290"
      unitRef="usdPershares">5.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c63" decimals="-5" id="ixv-15291" unitRef="usd">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c64" decimals="-5" id="ixv-15292" unitRef="usd">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c63" id="ixv-15293">P0Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c63" decimals="-5" id="ixv-15294" unitRef="usd">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c65" decimals="-5" id="ixv-15295" unitRef="usd">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c0" id="ixv-9333">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
is a summary of warrant activities for the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in&#160;years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; text-indent: -9pt; padding-left: 9pt"&gt;Outstanding, January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,443&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16.58&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-42"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-43"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;106.80&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Outstanding, December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,442&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-44"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-45"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-46"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-47"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-48"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,435&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;16.42&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Outstanding, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;17.33&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.46&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-49"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Exercisable, December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;17.77&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.25&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-50"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="c77"
      decimals="-3"
      id="ixv-15296"
      unitRef="shares">1443000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="c77"
      decimals="2"
      id="ixv-15297"
      unitRef="usdPershares">16.58</atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm contextRef="c78" id="ixv-15298">P1Y3M29D</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue contextRef="c77" decimals="-3" id="ixv-15299" unitRef="usd">5000</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="c72"
      decimals="-3"
      id="ixv-15300"
      unitRef="shares">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice
      contextRef="c72"
      decimals="2"
      id="ixv-15301"
      unitRef="usdPershares">8.77</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm contextRef="c72" id="ixv-15302">P10Y</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="c72"
      decimals="-3"
      id="ixv-15303"
      unitRef="shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice
      contextRef="c72"
      decimals="2"
      id="ixv-15304"
      unitRef="usdPershares">106.8</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="c79"
      decimals="-3"
      id="ixv-15305"
      unitRef="shares">1442000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="c79"
      decimals="2"
      id="ixv-15306"
      unitRef="usdPershares">16.42</atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm contextRef="c72" id="ixv-15307">P0Y4M2D</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="c71"
      decimals="-3"
      id="ixv-15308"
      unitRef="shares">1435000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice
      contextRef="c71"
      decimals="2"
      id="ixv-15309"
      unitRef="usdPershares">16.42</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="c80"
      decimals="-3"
      id="ixv-15310"
      unitRef="shares">7000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="c80"
      decimals="2"
      id="ixv-15311"
      unitRef="usdPershares">17.33</atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm contextRef="c71" id="ixv-15312">P4Y5M15D</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable
      contextRef="c80"
      decimals="-3"
      id="ixv-15313"
      unitRef="shares">7000</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable>
    <atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice
      contextRef="c80"
      decimals="2"
      id="ixv-15314"
      unitRef="usdPershares">17.77</atnm:ShareBasedCompensationsArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAverageExercisePrice>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm contextRef="c71" id="ixv-15315">P4Y3M</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm>
    <atnm:ExpiredWarrant
      contextRef="c66"
      decimals="-5"
      id="ixv-15316"
      unitRef="shares">1400000</atnm:ExpiredWarrant>
    <atnm:WarrantExpiredUnderwrittenOfferingShares
      contextRef="c67"
      decimals="-5"
      id="ixv-15317"
      unitRef="shares">1400000</atnm:WarrantExpiredUnderwrittenOfferingShares>
    <atnm:ExpiredWarrant
      contextRef="c67"
      decimals="-5"
      id="ixv-15318"
      unitRef="shares">1400000</atnm:ExpiredWarrant>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c68"
      decimals="2"
      id="ixv-15319"
      unitRef="usdPershares">11.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <atnm:WarrantExpiredTerm contextRef="c69" id="ixv-15320">P5Y</atnm:WarrantExpiredTerm>
    <atnm:WarrantExpiredPricePerShare
      contextRef="c70"
      decimals="2"
      id="ixv-15321"
      unitRef="usdPershares">15</atnm:WarrantExpiredPricePerShare>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c71" decimals="-3" id="ixv-15322" unitRef="usd">5000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c72" decimals="-3" id="ixv-15323" unitRef="usd">6000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-9581">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8 - Income Taxes &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#x2019;s deferred tax assets and
liabilities at December 31, 2024 and 2023 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Net operating losses carry forward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;47,875&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;41,698&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Deferred revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,217&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,219&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,572&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,512&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Research and development/orphan drug credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,296&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,509&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Capitalized research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,664&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,684&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(57&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(101,613&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(90,565&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-52"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has recorded a valuation allowance of $101.6 million and $90.6 million against its deferred tax assets at December 31, 2024 and
2023 respectively, because management determined that it is not more-likely-than not that those assets will be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
federal income tax purposes, the Company has $189.3 million of unused net operating losses (&#x201c;NOLs&#x201d;) at December 31, 2024
available for carry forward to future years. NOLs of $104.8 million generated prior to 2018 will begin to expire if unused beginning
in 2026 when approximately $3.9 million in NOLs are due to expire. The Company&#x2019;s largest NOLs will begin to expire in 2034 - 2037,
with each year in excess of $15 million. NOLs generated in 2018 and later years of $84.6 million have an indefinite life, but will be
limited to 80% of their value if used in a tax year ending after January 1, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
state income tax purposes, the Company has $327.8 million of unused NOLs at December 31, 2024 available for carry forward to future years.
These NOLs will begin to expire in 2035 if unused.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has federal research and development tax credits of $6.7 million at December 31, 2024, which will begin to expire in 2033 if
unused and orphan drug credits of $16.5 million which will begin to expire in 2037 if unused.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Federal
and state tax laws impose limitations on the utilization of net operating losses and credit carryforwards in the event of an ownership
change for tax purposes, as defined in Section 382 of the Internal Revenue Code. Accordingly, the Company&#x2019;s ability to utilize
these carryforwards may be limited as a result of an ownership change which may have already happened or may happen in the future. Such
an ownership change could result in a limitation in the use of the net operating losses in future years and possibly a reduction of the
net operating losses available.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Tax Cuts and Jobs Act of 2017 (TCJA) has modified the IRC 174 expenses related to research and development for the tax years beginning
after December 31, 2021. Under the TCJA, the Company must now capitalize the expenditures related to research and development activities
and amortize them over five years for U.S. activities and 15 years for non-U.S. activities. Since this has been the Company's policy
since 2018, the current year capitalization of research and development costs in accordance with IRC 174 was $28.0 million for a total
accumulated gross amount of $87.9 million as of December 31, 2024.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
difference between the income tax provision and the amount that would result if the U.S. Federal statutory rates were applied to pre-tax
losses for the year ended December 31, 2024 and 2023 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Federal statutory income taxes&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(8,031&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(10,252&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,275&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,743&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred true-up&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;259&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.7&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;176&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development/orphan drug tax credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,787&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,263&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6.7&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;788&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;608&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,046&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28.9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,474&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29.7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Provision for income tax&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;-&#160;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;-&#160;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;-&#160;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;-&#160;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0" id="ixv-15324">Significant components of the Company&#x2019;s deferred tax assets and
liabilities at December 31, 2024 and 2023 are as follows:&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Net operating losses carry forward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;47,875&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;41,698&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Deferred revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,217&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,219&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,572&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,512&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Research and development/orphan drug credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,296&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,509&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Capitalized research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,664&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,684&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;Others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(57&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(101,613&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(90,565&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-52"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="-3" id="ixv-15325" unitRef="usd">47875000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c4" decimals="-3" id="ixv-15326" unitRef="usd">41698000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c3" decimals="-3" id="ixv-15327" unitRef="usd">8217000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c4" decimals="-3" id="ixv-15328" unitRef="usd">8219000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c3" decimals="-3" id="ixv-15329" unitRef="usd">1572000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c4" decimals="-3" id="ixv-15330" unitRef="usd">1512000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c3" decimals="-3" id="ixv-15331" unitRef="usd">23296000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c4" decimals="-3" id="ixv-15332" unitRef="usd">20509000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c3" decimals="-3" id="ixv-15333" unitRef="usd">20664000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c4" decimals="-3" id="ixv-15334" unitRef="usd">18684000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther contextRef="c3" decimals="-3" id="ixv-15335" unitRef="usd">-11000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c4" decimals="-3" id="ixv-15336" unitRef="usd">-57000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="-3" id="ixv-15337" unitRef="usd">101613000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c4" decimals="-3" id="ixv-15338" unitRef="usd">90565000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="-5" id="ixv-15339" unitRef="usd">101600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c4" decimals="-5" id="ixv-15340" unitRef="usd">90600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance contextRef="c81" decimals="-5" id="ixv-15341" unitRef="usd">189300000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards contextRef="c3" decimals="-5" id="ixv-15342" unitRef="usd">104800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c82" decimals="-5" id="ixv-15343" unitRef="usd">3900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c83" decimals="-6" id="ixv-15344" unitRef="usd">15000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:IndefiniteLivedContractualRights contextRef="c3" decimals="-5" id="ixv-15345" unitRef="usd">84600000</us-gaap:IndefiniteLivedContractualRights>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c74" decimals="2" id="ixv-15346" unitRef="pure">0.80</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance contextRef="c3" decimals="-5" id="ixv-15347" unitRef="usd">327800000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c84" decimals="-5" id="ixv-15348" unitRef="usd">6700000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c85" decimals="-5" id="ixv-15349" unitRef="usd">16500000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet contextRef="c0" decimals="-5" id="ixv-15350" unitRef="usd">28000000</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet>
    <atnm:AccumulatedGrossAmount contextRef="c0" decimals="-5" id="ixv-15351" unitRef="usd">87900000</atnm:AccumulatedGrossAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0" id="ixv-9731">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
difference between the income tax provision and the amount that would result if the U.S. Federal statutory rates were applied to pre-tax
losses for the year ended December 31, 2024 and 2023 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Federal statutory income taxes&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(8,031&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(10,252&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,275&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,743&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred true-up&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;259&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.7&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;176&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development/orphan drug tax credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,787&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,263&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6.7&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;788&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;608&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,046&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28.9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,474&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29.7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Provision for income tax&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;-&#160;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;-&#160;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;-&#160;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;-&#160;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="-3" id="ixv-15352" unitRef="usd">-8031000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="3" id="ixv-15353" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c9" decimals="-3" id="ixv-15354" unitRef="usd">-10252000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c9" decimals="3" id="ixv-15355" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c0" decimals="-3" id="ixv-15356" unitRef="usd">-1275000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c0" decimals="3" id="ixv-15357" unitRef="pure">0.033</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c9" decimals="-3" id="ixv-15358" unitRef="usd">-1743000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c9" decimals="3" id="ixv-15359" unitRef="pure">0.036</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <atnm:IncomeTaxReconciliationDeferredTrueup contextRef="c0" decimals="-3" id="ixv-15360" unitRef="usd">-259000</atnm:IncomeTaxReconciliationDeferredTrueup>
    <atnm:EffectiveIncomeTaxReconciliationDeferredTrueUps contextRef="c0" decimals="3" id="ixv-15361" unitRef="pure">-0.007</atnm:EffectiveIncomeTaxReconciliationDeferredTrueUps>
    <atnm:IncomeTaxReconciliationDeferredTrueup contextRef="c9" decimals="-3" id="ixv-15362" unitRef="usd">-176000</atnm:IncomeTaxReconciliationDeferredTrueup>
    <atnm:EffectiveIncomeTaxReconciliationDeferredTrueUps contextRef="c9" decimals="3" id="ixv-15363" unitRef="pure">-0.004</atnm:EffectiveIncomeTaxReconciliationDeferredTrueUps>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c0" decimals="-3" id="ixv-15364" unitRef="usd">2787000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment contextRef="c0" decimals="3" id="ixv-15365" unitRef="pure">0.073</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c9" decimals="-3" id="ixv-15366" unitRef="usd">3263000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment contextRef="c9" decimals="3" id="ixv-15367" unitRef="pure">0.067</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c0" decimals="-3" id="ixv-15368" unitRef="usd">788000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c0" decimals="3" id="ixv-15369" unitRef="pure">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c9" decimals="-3" id="ixv-15370" unitRef="usd">608000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c9" decimals="3" id="ixv-15371" unitRef="pure">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="-3" id="ixv-15372" unitRef="usd">11046000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="3" id="ixv-15373" unitRef="pure">-0.289</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c9" decimals="-3" id="ixv-15374" unitRef="usd">14474000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c9" decimals="3" id="ixv-15375" unitRef="pure">-0.297</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-9896">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Note 9  - Subsequent Events &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On March 27, 2025, a putative
class action complaint (the &#x201c;Complaint&#x201d;) was filed by alleged stockholder Nihil Kohil against the Company and executives Sandesh
Seth, Avinash Desai, Madhuri Vusirikala, and Sergio Giralt, styled&#160;&lt;i&gt;Kohil v. Actinium Pharmaceuticals, Inc., et al&lt;/i&gt;., Case No.
1:25-cv-02553 in the Southern District of New York, wherein, the Complaint alleges that the defendants made material misrepresentations
and omissions concerning the Iomab-B Phase 3 Sierra Trial and the plaintiff asserts claims against all defendants pursuant to section
10(b) of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;) and Rule 10b-5 promulgated thereunder, as well
as additional claims against the individual defendants pursuant to Section 20(a) of the Exchange Act.&#160; The Complaint purports to
assert class action claims on behalf of all persons and entities that purchased or otherwise acquired Actinium securities between October
31, 2022 and August 2, 2024.&#160; Plaintiff seeks unspecified damages.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The defendants have not yet
responded to the complaint, and they intend to vigorously defend themselves against the plaintiff&#x2019;s allegations, however, there
can be no assurances as to the outcome.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On March 31, 2025, our Board
of Directors of approved the cancellation of certain stock options to purchase 5,149,944 shares of common stock held by certain current
employees and directors that were initially granted under the Company&#x2019;s Amended and Restated 2013 Stock Plan and 2019 Amended and
Restated Stock Plan. FSuSuch cancellation is subject to the consent of the applicable holder of the stock options, which the Company is
expecting to receive shortly following the filing of this Annual Report on Form 10-K. Our Compensation Committee intends to conduct an
analysis of our equity compensation plan and develop an equity compensation strategy that satisfies the purpose of the 2019 Plan to attract
and retain the best available personnel who can make meaningful contributions towards achieving the business objectives of the Company.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c86"
      decimals="0"
      id="ixv-15376"
      unitRef="shares">5149944</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c87" id="ixv-15377">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c87" id="ixv-15378">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c87" id="ixv-15379">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c87" id="ixv-15380">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c87" id="ixv-15381">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorFirmId contextRef="c0" id="ixv-15382">688</dei:AuditorFirmId>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c4"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c4"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c5"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c6"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c7"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c0"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c14"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c16"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c16"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c14"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c16"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c14"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c15"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c22"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c22"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c22"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c20"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c21"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <atnm:IncreaseDecreaseInOperatingLeaseRightofuseAssets
      contextRef="c0"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c0"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c9"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c0"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c9"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <atnm:RightofuseAssetObtainedInExchangeForLeaseLiabilities
      contextRef="c0"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="c9"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="c9"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c0"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c9"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="c0"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="c3"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c3"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c3"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c65"
      id="hidden-fact-36"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c65"
      id="hidden-fact-37"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c63"
      id="hidden-fact-38"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c63"
      id="hidden-fact-39"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c63"
      id="hidden-fact-40"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c63"
      id="hidden-fact-41"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="c72"
      id="hidden-fact-42"
      unitRef="shares"
      xsi:nil="true"/>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice
      contextRef="c72"
      id="hidden-fact-43"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue
      contextRef="c79"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="c71"
      id="hidden-fact-45"
      unitRef="shares"
      xsi:nil="true"/>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice
      contextRef="c71"
      id="hidden-fact-46"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="c71"
      id="hidden-fact-47"
      unitRef="shares"
      xsi:nil="true"/>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice
      contextRef="c71"
      id="hidden-fact-48"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue
      contextRef="c80"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue
      contextRef="c80"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c0"
      id="hidden-fact-51"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c3"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c4"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c0"
      id="hidden-fact-55"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c9"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c9"
      id="hidden-fact-57"
      unitRef="pure"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-15443">0001388320</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-15444">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-15445">FY</dei:DocumentFiscalPeriodFocus>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
